Identifier,StructureData,,,,,,,,,,,,,,,Polymer EntityData,,,,,,
Entry ID,EM Resolution (Å),Experimental Method,Matthews Coefficient,Percent Solvent Content,Crystallization Method,pH,Crystal Growth Procedure,Temp (K),DOI,Ligand,PDB ID,Molecular Weight per Deposited Model,Resolution (Å),High Resolution Limit,Structure Title,Sequence,Source Organism,Gene Name,Macromolecule Name,Entity ID,Entry Id (Polymer Entity Identifiers),
"5J9Z",,"X-RAY DIFFRACTION",3.39,63.75,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES,
900 mM - 1100 mM Na/K-tartrate",293,"10.1002/anie.201605011","6HJ","5J9Z",37.55,"2.5","2.5","EGFR-T790M in complex with pyrazolopyrimidine inhibitor 1a","GEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5J9Z"
"5JA0",,"X-RAY DIFFRACTION",2.76,55.44,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.08 M TrisHCl, 1.6 M ammonium phosphate, 20% glycerol",295.15,"10.1038/ncomms14132","FPP","5JA0",43.62,"1.9","1.9","Crystal structure of human FPPS with allosterically bound FPP","MGSSHHHHHHSSGRENLYFQGHMNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK","Homo sapiens","FDPS, FPS, KIAA1293","Farnesyl pyrophosphate synthase","1","5JA0"
"5JA7",,"X-RAY DIFFRACTION",2.12,41.99,"VAPOR DIFFUSION, SITTING DROP",6,"0.2 M ammonium sulfate, 30% (w/v) PEG-8000",293,"10.1002/1873-3468.12495",,"5JA7",49.96,"1.61","1.61","Human cathepsin K mutant C25S in complex with the allosteric effector NSC94914","YIPEWEGRAPDSVDYRKKGYVTPVKNQGQCGSSWAFSSVGALEGQLKKKTGKLLNLSPQNLVDCVSENDGCGGGYMTNAFQYVQKNRGIDSEDAYPYVGQEESCMYNPTGKAAKCRGYREIPEGNEKALKRAVARVGPVSVAIDASLTSFQFYSKGVYYDESCNSDNLNHAVLAVGYGIQKGNKHWIIKNSWGENWGNKGYILMARNKNNACGIANLASFPKM","Homo sapiens","CTSK, CTSO, CTSO2","Cathepsin K","1","5JA7"
"5JAD",,"X-RAY DIFFRACTION",2.42,49.12,"VAPOR DIFFUSION, SITTING DROP",7.4,"1.2M NaCl, 0.1M HEPES/NaOHpH=7.4, 28.8%w/v PEG 3350",297,"10.1021/acs.jmedchem.6b00212","FB2","5JAD",44.5,"2.05","2.05","Compound binding to Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)discovered through fragment screening","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5JAD"
"5JAH",,"X-RAY DIFFRACTION",2.46,49.96,"VAPOR DIFFUSION, SITTING DROP",7.4,"1.4M NaCl, 28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4",297,"10.1021/acs.jmedchem.6b00212",,"5JAH",44.38,"2.06","2.06","Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5JAH"
"5JAL",,"X-RAY DIFFRACTION",2.46,49.96,"VAPOR DIFFUSION, SITTING DROP",7.4,"1.0M NaCl, 0.1M HEPES/NaOHpH=7.4, 28.8%w/v PEG 3350",297,"10.1021/acs.jmedchem.6b00212","6HO","5JAL",44.57,"2.06","2.06","Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5JAL"
"5JAN",,"X-RAY DIFFRACTION",2.33,47.2,"VAPOR DIFFUSION, SITTING DROP",7.4,"1.0M NaCl, 0.1M HEPES/NaOHpH=7.4, 28.8%w/v PEG 3350",297,"10.1021/acs.jmedchem.6b00212","6HP","5JAN",44.53,"2.12","2.12","Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5JAN"
"5JAO",,"X-RAY DIFFRACTION",2.43,49.47,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",297,"10.1021/acs.jmedchem.6b00212","6HX","5JAO",44.57,"2.06","2.06","Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5JAO"
"5JAP",,"X-RAY DIFFRACTION",2.44,49.69,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293,"10.1021/acs.jmedchem.6b00212","6HZ","5JAP",44.63,"2.46","2.46","Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5JAP"
"5JAR",,"X-RAY DIFFRACTION",2.44,49.66,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293,"10.1021/acs.jmedchem.6b00212","6HV","5JAR",44.65,"2.11","2.11","Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5JAR"
"5JAS",,"X-RAY DIFFRACTION",2.43,49.4,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293,"10.1021/acs.jmedchem.6b00212","6HW","5JAS",44.63,"2.06","2.06","Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5JAS"
"5JAT",,"X-RAY DIFFRACTION",2.46,50.06,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293,"10.1021/acs.jmedchem.6b00212","6HR","5JAT",44.66,"2.04","2.04","Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5JAT"
"5JAU",,"X-RAY DIFFRACTION",2.44,49.64,"VAPOR DIFFUSION, SITTING DROP",7.4,"1.4M NaCl, 28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4",293,"10.1021/acs.jmedchem.6b00212","6HU","5JAU",44.76,"1.95","1.95","Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA<sub>2</sub>) Discovered Through X-Ray Fragment Screening","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5JAU"
"5JAX",,"X-RAY DIFFRACTION",1.94,36.76,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 400, 200 mM CaAc, 0.1M NaAc pH 4.5-4.8",301,"10.1021/acschembio.7b00369","6J7","5JAX",15.51,"1.486","1.486","PKG I's Carboyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with 8-Br-cGMP","GSTGLIKHTEYMEFLKSVPTFQSLPEEILSKLADVLEETHYENGEYIIRQGARGDTFFIISKGTVNVTREDSPSEDPVFLRTLGKGDWFGEKALQGEDVRTANVIAAEAVTCLVIDRDSFKHLIGGLDDVSNKAY","Homo sapiens","PRKG1, PRKG1B, PRKGR1A, PRKGR1B","cGMP-dependent protein kinase 1","1","5JAX"
"5JB8",,"X-RAY DIFFRACTION",2.21,44.29,"VAPOR DIFFUSION, SITTING DROP",6.5,"6 mg/mL protein-inhibitor complex, 
0.1M MES pH 6.5, 
18-20% PEG6000",293,"10.1042/BCJ20160336",,"5JB8",33.07,"1.45","1.45","Crystal structure of factor IXa variant K98T in complex with EGR-chloromethylketone","CNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTR","Homo sapiens","F9","Coagulation factor IX","1","5JB8"
,,,,,,,,,,,,,,,,"VVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINTYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT","Homo sapiens","F9","Coagulation factor IX","2","5JB8"
"5JB9",,"X-RAY DIFFRACTION",2.27,45.78,"VAPOR DIFFUSION, SITTING DROP",6.5,"6 mg/mL protein/inhibitor complex
0.1 M MES pH 6.5
18% PEG6000",293,"10.1042/BCJ20160336",,"5JB9",33.13,"1.3","1.3","Crystal structure of factor IXa K98T variant in complex with PPACK","CNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTR","Homo sapiens","F9","Coagulation factor IX","1","5JB9"
,,,,,,,,,,,,,,,,"VVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINTYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT","Homo sapiens","F9","Coagulation factor IX","2","5JB9"
"5JBA",,"X-RAY DIFFRACTION",2.15,42.91,"VAPOR DIFFUSION, SITTING DROP",6.5,"6 mg/mL protein-inhibitor complex, 
0.1M MES pH 6.5, 
18% PEG6000",293,"10.1042/BCJ20160336",,"5JBA",33.07,"1.4","1.4","Crystal structure of factor IXa variant V16I K98T Y177T I212V in complex with PPACK","CNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTR","Homo sapiens","F9","Coagulation factor IX","1","5JBA"
,,,,,,,,,,,,,,,,"IVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINTYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTITNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGVISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT","Homo sapiens","F9","Coagulation factor IX","2","5JBA"
"5JBB",,"X-RAY DIFFRACTION",2.2,44.18,"VAPOR DIFFUSION, SITTING DROP",6.5,"6 mg/mL protein-inhibitor complex, 
0.1M MES pH 6.5, 
20% PEG6000",293,"10.1042/BCJ20160336",,"5JBB",33.01,"1.56","1.56","Crystal structure of factor IXa variant V16I K98T Y177T I213V in complex with EGR-chloromethylketone","CNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTR","Homo sapiens","F9","Coagulation factor IX","1","5JBB"
,,,,,,,,,,,,,,,,"IVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINTYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTITNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIVSWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT","Homo sapiens","F9","Coagulation factor IX","2","5JBB"
"5JBC",,"X-RAY DIFFRACTION",2.18,43.69,"VAPOR DIFFUSION, SITTING DROP",6.5,"6 mg/mL protein-inhibitor complex, 
0.1M MES pH 6.5, 
20% PEG6000",293,"10.1042/BCJ20160336",,"5JBC",32.99,"1.9","1.9","Crystal structure of factor IXa variant V16I K98T Y177T I213V in complex with PPACK","CNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTR","Homo sapiens","F9","Coagulation factor IX","1","5JBC"
,,,,,,,,,,,,,,,,"IVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINTYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTITNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIVSWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT","Homo sapiens","F9","Coagulation factor IX","2","5JBC"
"5JBV",,"X-RAY DIFFRACTION",1.92,40.83,"VAPOR DIFFUSION, SITTING DROP",5.9,"20% (w/v) PEG 3350, 4mM CdCl2, pH 5.9, 200mM Mg(NO3)2",291,,,"5JBV",17.27,"2.104","2.104","Lys27-linked triubiquitin","MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBA52, UBCEP2","Ubiquitin","1","5JBV"
,,,,,,,,,,,,,,,,"LQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGA","Homo sapiens","UBA52, UBCEP2","D-ubiquitin","2","5JBV"
"5JCG",,"X-RAY DIFFRACTION",3.21,61.69,"VAPOR DIFFUSION, SITTING DROP",8.5,"12.5% PEG1000, 12.5% PEG3350. 12.5% MPD, 0.02 M alcohol additives at pH 8.5 (Gorrec, 2009)",293,"10.1016/j.str.2016.04.013",,"5JCG",199.75,"2.8","2.8","Structure of Human Peroxiredoxin 3 as three stacked rings","GIDPFTAPAVTQHAPYFKGTAVVNGEFKDLSLDDFKGKYLVLFFYPLDFTFVCPTEIVAFSDKANEFHDVNCEVVAVSVDSHFSHLAWINTPRKNGGLGHMNIALLSDLTKQISRDYGVLLEGSGLALRGLFIIDPNGVIKHLSVNDLPVGRSVEETLRLVKAFQYVETHGEVCPANWTPDSPTIKPSPAASKEYFQKVNQ","Homo sapiens","PRDX3, AOP1","Thioredoxin-dependent peroxide reductase, mitochondrial","1","5JCG"
"5JCT",,"X-RAY DIFFRACTION",2.22,44.48,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M HEPES (pH7.5), 8% (v/v) Eythylene Glycol, 20% (w/v) PEG 8000",277,"10.1021/acs.jmedchem.6b01055",,"5JCT",35.19,"1.73","1.73","Crystal Structure of Human Pirin in complex with a Chemical Probe pyrrolidine 24","MGSSHHHHHHSSGLVPRGSHMGSSKKVTLSVLSREQSEGVGARVRRSIGRPELKNLDPFLLFDEFKGGRPGGFPDHPHRGFETVSYLLEGGSMAHEDFCGHTGKMNPGDLQWMTAGRGILHAEMPCSEEPAHGLQLWVNLRSSEKMVEPQYQELKSEEIPKPSKDGVTVAVISGEALGIKSKVYTRTPTLYLDFKLDPGAKHSQPIPKGWTSFIYTISGDVYIGPDDAQQKIEPHHTAVLGEGDSVQVENKDPKRSHFVLIAGEPLREPVIQHGPFVMNTNEEISQAILDFRNAKNGFERAKTWKSKIGN","Homo sapiens","PIR","Pirin","1","5JCT"
"5JCU",,"X-RAY DIFFRACTION",2.36,47.92,"VAPOR DIFFUSION, SITTING DROP",7.4,"PEG 3350 20% (w/v), Sodium acetate 0.2 M",293,"10.1371/journal.pone.0163821",,"5JCU",105.06,"1.93","1.93","Crystal Structure of hGSTA1-1 with Glutathione Adduct of Phenethyl Isothiocyanate and Cystein Adduct of Phenethyl Isothiocyanate","AEKPKLHYFNARGRMESTRWLLAAAGVEFEEKFIKSAEDLDKLRNDGYLMFQQVPMVEIDGMKLVQTRAILNYIASKYNLYGKDIKERALIDMYIEGIADLGEMILLLPVXPPEEKDAKLALIKEKIKNRYFPAFEKVLKSHGQDYLVGNKLSRADIHLVELLYYVEELDSSLISSFPLLKALKTRISNLPTVKKFLQPGSPRKPPMDEKSLEEARKIFRF","Homo sapiens","GSTA1","Glutathione S-transferase A1","1","5JCU"
"5JCW",,"X-RAY DIFFRACTION",2.58,52.32,"VAPOR DIFFUSION, SITTING DROP",6,"PEG 8000, MES, Ca(OAC)2",293,"10.1371/journal.pone.0163821",,"5JCW",48.68,"1.945","1.945","Crystal Structure of hGSTP1-1 with Glutathione Adduct of Phenethyl Isothiocyanate","MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ","Homo sapiens","GSTP1, FAEES3, GST3","Glutathione S-transferase P","1","5JCW"
"5JD0",,"X-RAY DIFFRACTION",3.04,59.59,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM HEPES, 10% PEG8000",293,"10.1074/jbc.M116.736140",,"5JD0",48.37,"2.3","2.3","crystal structure of ARAP3 RhoGAP domain","MGHHHHHHMGTGLQEQQMSRGDIPIIVDACISFVTQHGLRLEGVYRKGGARARSLRLLAEFRRDARSVKLRPGEHFVEDVTDTLKRFFRELDDPVTSARLLPRWREAAELPQKNQRLEKYKDVIGCLPRVNRRTLATLIGHLYRVQKCAALNQMCTRNLALLFAPSVFQTDGRGEHEVRVLQELIDGYISVFDIDSDQVAQIDLEVSLITT","Homo sapiens","ARAP3, CENTD3","Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 3","1","5JD0"
"5JD7",,"X-RAY DIFFRACTION",1.72,32.83,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 400, 200 mM CaAc, 0.1M NaAc pH 4.5-4.8.",277,"10.1021/acschembio.7b00369","6JR","5JD7",15.43,"1.749","1.749","PKG I's Carboxyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with PET-cGMP","GSTGLIKHTEYMEFLKSVPTFQSLPEEILSKLADVLEETHYENGEYIIRQGARGDTFFIISKGTVNVTREDSPSEDPVFLRTLGKGDWFGEKALQGEDVRTANVIAAEAVTCLVIDRDSFKHLIGGLDDVSNKAY","Homo sapiens","PRKG1, PRKG1B, PRKGR1A, PRKGR1B","cGMP-dependent protein kinase 1","1","5JD7"
"5JDD",,"X-RAY DIFFRACTION",2.54,51.6,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bis-Tris Propane pH 8.5, 20% [w/v] PEG 3350, 0.2 M sodium acetate",292,"10.1098/rsob.160114",,"5JDD",29.71,"1.53","1.53","Crystal structure of I9-I11 tandem from titin (P212121)","GAMVKIIKKPKDVTALENATVAFEVSVSHDTVPVKWFHKSVEIKPSDKHRLVSERKVHKLMLQNISPSDAGEYTAVVGQLECKAKLFVETLHITKTMKNIEVPETKTASFECEVSHFNVPSMWLKNGVEIEMSEKFKIVVQGKLHQLIIMNTSTEDSAEYTFVCGNDQVSATLTVTPIMITSMLKDINAEEKDTITFEVTVNYEGISYKWLKNGVEIKSTDKCQMRTKKLTHSLNIRNVHFGDAADYTFVAGKATSTATLYVVEA","Homo sapiens","TTN","Titin","1","5JDD"
"5JDE",,"X-RAY DIFFRACTION",2.2,44.18,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris HCl pH 8.5, 30% [w/v] PEG 4000, 0.2 M MgCl2",292,"10.1098/rsob.160114",,"5JDE",59.41,"1.9","1.9","Crystal structure of I9-I11 tandem from titin (P1)","GAMVKIIKKPKDVTALENATVAFEVSVSHDTVPVKWFHKSVEIKPSDKHRLVSERKVHKLMLQNISPSDAGEYTAVVGQLECKAKLFVETLHITKTMKNIEVPETKTASFECEVSHFNVPSMWLKNGVEIEMSEKFKIVVQGKLHQLIIMNTSTEDSAEYTFVCGNDQVSATLTVTPIMITSMLKDINAEEKDTITFEVTVNYEGISYKWLKNGVEIKSTDKCQMRTKKLTHSLNIRNVHFGDAADYTFVAGKATSTATLYVVEA","Homo sapiens","TTN","Titin","1","5JDE"
"5JDJ",,"X-RAY DIFFRACTION",2.19,43.75,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M CaCl2, 0.1 M Tris pH 7.5, 25% [w/v] PEG 8000",292,"10.1098/rsob.160114",,"5JDJ",163.1,"1.738","1.738","Crystal structure of domain I10 from titin in space group P212121","GAMETLHITKTMKNIEVPETKTASFECEVSHFNVPSMWLKNGVEIEMSEKFKIVVQGKLHQLIIMNTSTEDSAEYTFVCGNDQVSATLTVT","Homo sapiens","TTN","Titin","1","5JDJ"
"5JDP",,"SOLUTION NMR",,,,,,,"10.1002/anie.201602639",,"5JDP",30.98,,,"E73V mutant of the human voltage-dependent anion channel","SAVPPTYADLGKSARDVFTKGYGFGLIKLDLKTKSENGLEFTSSGSANTETTKVTGSLETKYRWTEYGLTFTVKWNTDNTLGTEITVEDQLARGLKLTFDSSFSPNTGKKNAKIKTGYKREHINLGCDMDFDIAGPSIRGALVLGYEGWLAGYQMNFETAKSRVTQSNFAVGYKTDEFQLHTNVNDGTEFGGSIYQKVNKKLETAVNLAWTAGNSNTRFGIAAKYQIDPDACFSAKVNNSSLIGLGYTQTLKPGIKLTLSALLDGKNVNAGGHKLGLGLEFQARS","Homo sapiens","VDAC1, VDAC","Voltage-dependent anion-selective channel protein 1","1","5JDP"
"5JDR",,"X-RAY DIFFRACTION",2.16,42.97,"LIQUID DIFFUSION",,"0.2 M Ammonium Acetate, 20% PEG 3350",295,"10.1038/celldisc.2017.4",,"5JDR",54.34,"2.7","2.7","Structure of PD-L1","MAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTDKLAAALEHHHHHH","Homo sapiens","CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1","Programmed cell death 1 ligand 1","1","5JDR"
"5JDU",,"X-RAY DIFFRACTION",2.29,46.3,"VAPOR DIFFUSION, HANGING DROP",6.9,"200 mM KCl and 20% PEG 3350",295,"10.1021/acs.biochem.6b00385",,"5JDU",68.03,"1.7","1.7","Crystal structure for human thrombin mutant D189A","SGEADCGLRPLFEKKSLEDKTERELLESYIDGR","Homo sapiens","F2","Thrombin light chain","1","5JDU"
,,,,,,,,,,,,,,,,"IVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGAACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE","Homo sapiens","F2","Thrombin heavy chain","2","5JDU"
"5JDV",,"X-RAY DIFFRACTION",2.12,41.85,"VAPOR DIFFUSION, HANGING DROP",,"We soaked these crystals with BTA and TA by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,"10.1002/anie.201609409","EVF","5JDV",29.39,"1.34","1.34","Human carbonic anhydrase II (F131W) complexed with benzo[d]thiazole-2-sulfonamide","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDWGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5JDV"
"5JDW",,"X-RAY DIFFRACTION",3.83,68,,7,"pH 7.0",,"10.1074/jbc.274.5.3026",,"5JDW",44.42,"2.6","2.6","CRYSTAL STRUCTURE OF HUMAN L-ARGININE:GLYCINE AMIDINOTRANSFERASE IN COMPLEX WITH GLYCINE","STQAATASSRNSCAADDKATEPLPKDCPVSSYNEWDPLEEVIVGRAENACVPPFTIEVKANTYEKYWPFYQKQGGHYFPKDHLKKAVAEIEEMCNILKTEGVTVRRPDPIDWSLKYKTPDFESTGLYSAMPRDILIVVGNEIIEAPMAWRSRFFEYRAYRSIIKDYFHRGAKWTTAPKPTMADELYNQDYPIHSVEDRHKLAAQGKFVTTEFEPCFDAADFIRAGRDIFAQRSQVTNYLGIEWMRRHLAPDYRVHIISFKDPNPMHIDATFNIIGPGIVLSNPDRPCHQIDLFKKAGWTIITPPTPIIPDDHPLWMSSKWLSMNVLMLDEKRVMVDANEVPIQKMFEKLGITTIKVNIRNANSLGGGFHCWTCDVRRRGTLQSYLD","Homo sapiens","AT38H, GATM, AGAT","PROTEIN (L-ARGININE:GLYCINE AMIDINOTRANSFERASE)","1","5JDW"
"5JE7",,"X-RAY DIFFRACTION",2.12,41.85,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,"10.1002/anie.201609409","EVF","5JE7",29.44,"1.15","1.15","Human carbonic anhydrase II (F131Y) complexed with benzo[d]thiazole-2-sulfonamide","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDYGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5JE7"
"5JEB",,"X-RAY DIFFRACTION",3.46,68.33,"VAPOR DIFFUSION, HANGING DROP",5.5,"1.34M Ammonium sulfate, 1.34% (v/v) PEG 400, and 0.1M sodium acetate/acetic acid",294.15,"10.1038/nchembio.2171",,"5JEB",39.12,"3.298","3.298","Crystal structure of EGFR tyrosine kinase domain with novel inhibitor of active state of HER2","MKKGHHHHHGGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMRKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5JEB"
"5JEG",,"X-RAY DIFFRACTION",2.09,41.07,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA (EVF) by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,"10.1002/anie.201609409","EVF","5JEG",29.65,"1.19","1.19","Human carbonic anhydrase II (V121I) complexed with benzo[d]thiazole-2-sulfonamide","AHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLIHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5JEG"
"5JEH",,"X-RAY DIFFRACTION",2.06,40.41,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII in BTA by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,"10.1002/anie.201609409","EVF","5JEH",29.38,"1.13","1.13","Human carbonic anhydrase II (L198A) complexed with benzo[d]thiazole-2-sulfonamide","AHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSATTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5JEH"
"5JEP",,"X-RAY DIFFRACTION",2.1,41.33,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA (EVF) by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,"10.1002/anie.201609409","EVF","5JEP",29.55,"1.19","1.19","Human carbonic anhydrase II (T199S) complexed with benzo[d]thiazole-2-sulfonamide","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLSTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5JEP"
"5JES",,"X-RAY DIFFRACTION",2.05,40.03,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA (EVF) by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,"10.1002/anie.201609409","EVF","5JES",29.57,"1.205","1.205","Human carbonic anhydrase II (V121T) complexed with benzo[d]thiazole-2-sulfonamide","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLTHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5JES"
"5JFR",,"X-RAY DIFFRACTION",2.72,54.72,"VAPOR DIFFUSION, HANGING DROP",7,"40% MPD, 0.1M Hepes pH 7.0",277,"10.1016/j.bmcl.2016.04.072","6KP","5JFR",41.91,"1.6","1.6","Potent, Reversible MetAP2 Inhibitors via Fragment Based Drug Discovery","KVQTDPPSVPICDLYPNGVFPKGQECEYPPTQDGRTAAWRTTSEEKKALDQASEEIWNDFREAAEAHRQVRKYVMSWIKPGMTMIEICEKLEDCSRKLIKENGLNAGLAFPTGCSLNNCAAHYTPNAGDTTVLQYDDICKIDFGTHISGRIIDCAFTVTFNPKYDTLLKAVKDATNTGIKCAGIDVRLCDVGEAIQEVMESYEVEIDGKTYQVKPIRNLNGHSIGQYRIHAGKTVPIVKGGEATRMEEGEVYAIETFGSTGKGVVHDDMECSHYMKNFDVGHVPIRLPRTKHLLNVINENFGTLAFCRRWLDRLGESKYLMALKNLCDLGIVDPYPPLCDIKGSYTAQFEHTILLRPTCKEVVSRGDDY","Homo sapiens","METAP2, MNPEP, P67EIF2","Methionine aminopeptidase 2","1","5JFR"
"5JFS",,"X-RAY DIFFRACTION",3,62.95,"VAPOR DIFFUSION",,"protein was concentrated to 10mg/ml. Crystals of complexes were grown using the hanging drop vapour diffusion method from 0.1M HEPES pH7.5, 0.1M MgCl2 and 10% EtOH at 4C",277,"10.1021/acs.jmedchem.6b00850","6K0","5JFS",35.55,"2.07","2.07","Crystal structure of TrkA in complex with PF-00593174","MHHHHHHLVPRGSVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLG","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","5JFS"
"5JFV",,"X-RAY DIFFRACTION",2.96,62.47,"VAPOR DIFFUSION",,"protein was concentrated to 10mg/ml. Crystals of complexes were grown using the hanging drop vapour diffusion method from 0.1M HEPES pH7.5, 0.1M MgCl2 and 10% EtOH at 4C",277,"10.1021/acs.jmedchem.6b00850","6K1","5JFV",35.55,"1.59","1.59","Crystal structure of TrkA in complex with PF-05206283","MHHHHHHLVPRGSVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLG","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","5JFV"
"5JFW",,"X-RAY DIFFRACTION",2.94,62.16,"VAPOR DIFFUSION",,"protein was concentrated to 10mg/ml. Crystals of complexes were grown using the hanging drop vapour diffusion method from 0.1M HEPES pH7.5, 0.1M MgCl2 and 10% EtOH at 4C",277,"10.1021/acs.jmedchem.6b00850","6K2","5JFW",35.53,"1.52","1.52","Crystal structure of TrkA in complex with PF-05247452","MHHHHHHLVPRGSVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLG","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","5JFW"
"5JFX",,"X-RAY DIFFRACTION",2.97,62.59,"VAPOR DIFFUSION",,"protein was concentrated to 10mg/ml. Crystals of complexes were grown using the hanging drop vapour diffusion method from 0.1M HEPES pH7.5, 0.1M MgCl2 and 10% EtOH at 4C",277,"10.1021/acs.jmedchem.6b00850","6K4","5JFX",35.58,"1.63","1.63","Crystal structure of TrkA in complex with PF-06273340","MHHHHHHLVPRGSVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLG","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","5JFX"
"5JG3",,"X-RAY DIFFRACTION",2.13,42.25,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA and TA by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,"10.1002/anie.201609409","EVF","5JG3",29.65,"1.21","1.21","Human carbonic anhydrase II (121T/N67Q) complexed with benzo[d]thiazole-2-sulfonamide","AHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFQVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLTHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5JG3"
"5JG5",,"X-RAY DIFFRACTION",2.11,41.59,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA (EVF) by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,"10.1002/anie.201609409","EVF","5JG5",29.65,"1.19","1.19","Human carbonic anhydrase II (V121T/F131Y) complexed with benzo[d]thiazole-2-sulfonamide","AHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLTHWNTKYGDYGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5JG5"
"5JG8",,"X-RAY DIFFRACTION",3.7,70,"VAPOR DIFFUSION, HANGING DROP",6,"PEG8000, sodium potassium tartrate, sodium acetate, sodium cacodylate, MES, pH 6",293,"10.1016/j.jmb.2016.06.012",,"5JG8",135.43,"2.8","2.8","Crystal structure of human acid sphingomyelinase","GAPLSDSRVLWAPAEAHPLSPQGHPARLHRIVPRLRDVFGWGNLTCPICKGLFTAINLGLKKEPNVARVGSVAIKLCNLLKIAPPAVCQSIVHLFEDDMVEVWRRSVLSPSEACGLLLGSTCGHWDIFSSWNISLPTVPKPPPKPPSPPAPGAPVSRILFLTDLHWDHDYLEGTDPDCADPLCCRRGSGLPPASRPGAGYWGEYSKCDLPLRTLESLLSGLGPAGPFDMVYWTGDIPAHDVWHQTRQDQLRALTTVTALVRKFLGPVPVYPAVGNHESTPVNSFPPPFIEGNHSSRWLYEAMAKAWEPWLPAEALRTLRIGGFYALSPYPGLRLISLNMNFCSRENFWLLINSTDPAGQLQWLVGELQAAEDRGDKVHIIGHIPPGHCLKSWSWNYYRIVARYENTLAAQFFGHTHVDEFEVFYDEETLSRPLAVAFLAPSATTYIGLNPGYRVYQIDGNYSGSSHVVLDHETYILNLTQANIPGAIPHWQLLYRARETYGLPNTLPTAWHNLVYRMRGDMQLFQTFWFLYHKGHPPSEPCGTPCRLATLCAQLSARADSPALCRHLMPDGSLPEAQSLWPRPLFS","Homo sapiens","SMPD1, ASM","Sphingomyelin phosphodiesterase","1","5JG8"
"5JGI",,"X-RAY DIFFRACTION",2.11,41.59,"VAPOR DIFFUSION, HANGING DROP",7.9,"20% PEG3350+0.2 M NH4Cl",289,"10.1111/febs.14405",,"5JGI",35.66,"1.38","1.38","X-ray structure of neuropilin-1 b1 domain complexed with M45 compound","MFKCMEALGMESGEIHSDQITASSQYSTNWSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKIDVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFPKPLITRFVRIKPATWETGISMRFEVYGCKIT","Homo sapiens","NRP1, NRP, VEGF165R","Neuropilin-1","1","5JGI"
"5JGQ",,"X-RAY DIFFRACTION",2.09,41.04,"VAPOR DIFFUSION, HANGING DROP",7.9,"18%PEG3350+0.2M NH4Cl",289,"10.1111/febs.14405",,"5JGQ",36.19,"1.6","1.6","X-ray structure of neuropilin-1 b1 domain complexed with Arg-7 ligand.","GHMFKCMEALGMESGEIHSDQITASSQYSTNWSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKIDVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFPKPLITRFVRIKPATWETGISMRFEVYGCKIT","Homo sapiens","NRP1, NRP, VEGF165R","Neuropilin-1","1","5JGQ"
"5JGS",,"X-RAY DIFFRACTION",2.12,42.07,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA (EVF) by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,"10.1002/anie.201609409","EVF","5JGS",29.4,"1.11","1.11","Human carbonic anhydrase II (F131Y/L198A) complexed with benzo[d]thiazole-2-sulfonamide","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDYGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSATTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5JGS"
"5JGT",,"X-RAY DIFFRACTION",2.12,41.86,"VAPOR DIFFUSION, HANGING DROP",,"We soaked monoclinic crystals of HCAII with BTA by carrying out the following steps: (i) We prepared soaking solutions containing 1.32 M sodium citrate, 1 mM ZnSO4, 100 mM Tris-HCl (pH 7.8), and 5 mM ligand. (ii) We combined 4 uL of soaking solution and 1-2 crystals of HCAII within a drop on the surface of a reservoir cover (EasyXtal CrystalSupport, Qiagen). (iii) To a clear plastic reservoir in a 15-reservoir plate (EasyXtal, Qiagen), we added 1 mL of soaking solution (without ligand present). We attached the reservoir cover to the reservoir and left the entire setup at 4 deg C for 1 week.",277.15,"10.1002/anie.201609409",,"5JGT",29.51,"1.1","1.1","Human carbonic anhydrase II (F131Y/L198A) complexed with 1,3-thiazole-2-sulfonamide","AHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDYGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSATTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5JGT"
"5JH3",,"X-RAY DIFFRACTION",2.24,45.15,"VAPOR DIFFUSION, SITTING DROP",5,"0.2 M ammonium sulfate, 30% (w/v) PEG-8000",293,"10.1002/1873-3468.12495",,"5JH3",24.83,"1.75","1.75","Human cathepsin K mutant C25S","YIPEWEGRAPDSVDYRKKGYVTPVKNQGQCGSSWAFSSVGALEGQLKKKTGKLLNLSPQNLVDCVSENDGCGGGYMTNAFQYVQKNRGIDSEDAYPYVGQEESCMYNPTGKAAKCRGYREIPEGNEKALKRAVARVGPVSVAIDASLTSFQFYSKGVYYDESCNSDNLNHAVLAVGYGIQKGNKHWIIKNSWGENWGNKGYILMARNKNNACGIANLASFPKM","Homo sapiens","CTSK, CTSO, CTSO2","Cathepsin K","1","5JH3"
"5JHA",,"X-RAY DIFFRACTION",2.38,48.27,"VAPOR DIFFUSION, SITTING DROP",7.5,"17%  PEG  4000,  250  mM  (NH4)2SO4, and  100mM  Tris  pH-7.5",293,"10.1038/ncomms14683",,"5JHA",110.74,"2.51","2.51","Structure of Phosphoinositide 3-kinase gamma (PI3K) bound to the potent inhibitor PIKin2","MSEESQAFQRQLTALIGYDVTDVSNVHDDELEFTRRGLVTPRMAEVASRDPKLYAMHPWVTSKPLPEYLWKKIANNCIFIVIHRSTTSQTIKVSPDDTPGAILQSFFTKMAKKKSLMDIPESQSEQDFVLRVCGRDEYLVGETPIKNFQWVRHCLKNGEEIHVVLDTPPDPALDEVRKEEWPLVDDCTGVTGYHEQLTIHGKDHESVFTVSLWDCDRKFRVKIRGIDIPVLPRNTDLTVFVEANIQHGQQVLCQRRTSPKPFTEEVLWNVWLEFSIKIKDLPKGALLNLQIYCGKAPALSSKASAESPSSESKGKVQLLYYVNLLLIDHRFLLRRGEYVLHMWQISGKGEDQGSFNADKLTSATNPDKENSMSISILLDNYCHPIALPKHQPTPDPEGDRVRAEMPNQLRKQLEAIIATDPLNPLTAEDKELLWHFRYESLKHPKAYPKLFSSVKWGQQEIVAKTYQLLARREVWDQSALDVGLTMQLLDCNFSDENVRAIAVQKLESLEDDDVLHYLLQLVQAVKFEPYHDSALARFLLKRGLRNKRIGHFLFWFLRSEIAQSRHYQQRFAVILEAYLRGCGTAMLHDFTQQVQVIEMLQKVTLDIKSLSAEKYDVSSQVISQLKQKLENLQNSQLPESFRVPYDPGLKAGALAIEKCKVMASKKKPLWLEFKCADPTALSNETIGIIFKHGDDLRQDMLILQILRIMESIWETESLDLCLLPYGCISTGDKIGMIEIVKDATTIAKIQQSTVGNTGAFKDEVLNHWLKEKSPTEEKFQAAVERFVYSCAGYCVATFVLGIGDRHNDNIMITETGNLFHIDFGHILGNYKSFLGINKERVPFVLTPDFLFVMGTSGKKTSPHFQKFQDICVKAYLALRHHTNLLIILFSMMLMTGMPQLTSKEDIEYIRDALTVGKNEEDAKKYFLDQIEVCRDKGWTVQFNWFLHLVLGIKQGEKHSA","Homo sapiens","PIK3CG","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform","1","5JHA"
"5JHB",,"X-RAY DIFFRACTION",2.32,47.02,"VAPOR DIFFUSION, SITTING DROP",7.5,"17%  PEG  4000,  250  mM  (NH4)2SO4 and  100mM  Tris  pH-7.5",293,"10.1038/ncomms14683","6K5","5JHB",110.45,"2.48","2.48","Structure of Phosphoinositide 3-kinase gamma (PI3K) bound to the potent inhibitor PIKin3","MSEESQAFQRQLTALIGYDVTDVSNVHDDELEFTRRGLVTPRMAEVASRDPKLYAMHPWVTSKPLPEYLWKKIANNCIFIVIHRSTTSQTIKVSPDDTPGAILQSFFTKMAKKKSLMDIPESQSEQDFVLRVCGRDEYLVGETPIKNFQWVRHCLKNGEEIHVVLDTPPDPALDEVRKEEWPLVDDCTGVTGYHEQLTIHGKDHESVFTVSLWDCDRKFRVKIRGIDIPVLPRNTDLTVFVEANIQHGQQVLCQRRTSPKPFTEEVLWNVWLEFSIKIKDLPKGALLNLQIYCGKAPALSSKASAESPSSESKGKVQLLYYVNLLLIDHRFLLRRGEYVLHMWQISGKGEDQGSFNADKLTSATNPDKENSMSISILLDNYCHPIALPKHQPTPDPEGDRVRAEMPNQLRKQLEAIIATDPLNPLTAEDKELLWHFRYESLKHPKAYPKLFSSVKWGQQEIVAKTYQLLARREVWDQSALDVGLTMQLLDCNFSDENVRAIAVQKLESLEDDDVLHYLLQLVQAVKFEPYHDSALARFLLKRGLRNKRIGHFLFWFLRSEIAQSRHYQQRFAVILEAYLRGCGTAMLHDFTQQVQVIEMLQKVTLDIKSLSAEKYDVSSQVISQLKQKLENLQNSQLPESFRVPYDPGLKAGALAIEKCKVMASKKKPLWLEFKCADPTALSNETIGIIFKHGDDLRQDMLILQILRIMESIWETESLDLCLLPYGCISTGDKIGMIEIVKDATTIAKIQQSTVGNTGAFKDEVLNHWLKEKSPTEEKFQAAVERFVYSCAGYCVATFVLGIGDRHNDNIMITETGNLFHIDFGHILGNYKSFLGINKERVPFVLTPDFLFVMGTSGKKTSPHFQKFQDICVKAYLALRHHTNLLIILFSMMLMTGMPQLTSKEDIEYIRDALTVGKNEEDAKKYFLDQIEVCRDKGWTVQFNWFLHLVLGIKQGEKHSA","Homo sapiens","PIK3CG","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform","1","5JHB"
"5JHK",,"X-RAY DIFFRACTION",2.07,40.69,"VAPOR DIFFUSION, HANGING DROP",7.9,"30%PEG3350+0,2M NH4Cl",293,"10.1111/febs.14405",,"5JHK",36.17,"1.8","1.8","X-ray structure of neuropilin-1 b1 domain complexed with Arg-6 ligand.","GHMFKCMEALGMESGEIHSDQITASSQYSTNWSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKIDVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFPKPLITRFVRIKPATWETGISMRFEVYGCKIT","Homo sapiens","NRP1, NRP, VEGF165R","Neuropilin-1","1","5JHK"
"5JHO",,"X-RAY DIFFRACTION",3.29,62.58,"VAPOR DIFFUSION, SITTING DROP",4.4,"40 mg/ml protein, 100 mM Formic Acid , pH 4.4, 9 % PEG 8000",277,"10.1038/s41598-017-12409-0",,"5JHO",77.81,"2.801","2.801","Crystal structure of the regulatory domain of the sodium driven chloride bicarbonate exchanger.","MPLGRQSHRHHRTHGQKHRRRGRGKGASQGEEGLEALAHDTPSQRVQFILGTEEDEEHVPHELFTELDEICMKEGEDAEWKETARWLKFEEDVEDGGERWSKPYVATLSLHSLFELRSCLINGTVLLDMHANSIEEISDLILDQQELSSDLNDSMRVKVREALLKKHHHQNEKKRNNLIPIVRSFAEVGKKQSDPHLMDKHGQTVSPQSVPTTNLEVKNGVNCEHSPVDLSKVDLHFMKKIPTGAEASNVLVGEVDILDRPIVAFVRLSPAVLLSGLTEVPIPTRFLFILLGPVGKGQQYHEIGRSMATIMTDEIFHDVAYKAKERDDLLAGIDEFLDQVTVLP","Homo sapiens","SLC4A8, KIAA0739, NBC, NBC3, NDCBE1","Electroneutral sodium bicarbonate exchanger 1","1","5JHO"
"5JHU",,"X-RAY DIFFRACTION",2.76,55.36,"VAPOR DIFFUSION, HANGING DROP",5.9,"30% MPD, 0.05M MES pH 5.9",277,"10.1016/j.bmcl.2016.04.073",,"5JHU",41.99,"1.8","1.8","Potent, Reversible MetAP2 Inhibitors via FBDD","KVQTDPPSVPICDLYPNGVFPKGQECEYPPTQDGRTAAWRTTSEEKKALDQASEEIWNDFREAAEAHRQVRKYVMSWIKPGMTMIEICEKLEDCSRKLIKENGLNAGLAFPTGCSLNNCAAHYTPNAGDTTVLQYDDICKIDFGTHISGRIIDCAFTVTFNPKYDTLLKAVKDATNTGIKCAGIDVRLCDVGEAIQEVMESYEVEIDGKTYQVKPIRNLNGHSIGQYRIHAGKTVPIVKGGEATRMEEGEVYAIETFGSTGKGVVHDDMECSHYMKNFDVGHVPIRLPRTKHLLNVINENFGTLAFCRRWLDRLGESKYLMALKNLCDLGIVDPYPPLCDIKGSYTAQFEHTILLRPTCKEVVSRGDDY","Homo sapiens","METAP2, MNPEP, P67EIF2","Methionine aminopeptidase 2","1","5JHU"
"5JI6",,"X-RAY DIFFRACTION",2.68,54.06,"VAPOR DIFFUSION, SITTING DROP",5.9,"24.% PEG MME 2000, 0.05M MES pH 5.9, 0.0175M Ammonium Sulfate",293,"10.1016/j.bmcl.2016.04.073","6KN","5JI6",41.84,"2.15","2.15","Potent, Reversible MetAP2 Inhibitors via FBDD","KVQTDPPSVPICDLYPNGVFPKGQECEYPPTQDGRTAAWRTTSEEKKALDQASEEIWNDFREAAEAHRQVRKYVMSWIKPGMTMIEICEKLEDCSRKLIKENGLNAGLAFPTGCSLNNCAAHYTPNAGDTTVLQYDDICKIDFGTHISGRIIDCAFTVTFNPKYDTLLKAVKDATNTGIKCAGIDVRLCDVGEAIQEVMESYEVEIDGKTYQVKPIRNLNGHSIGQYRIHAGKTVPIVKGGEATRMEEGEVYAIETFGSTGKGVVHDDMECSHYMKNFDVGHVPIRLPRTKHLLNVINENFGTLAFCRRWLDRLGESKYLMALKNLCDLGIVDPYPPLCDIKGSYTAQFEHTILLRPTCKEVVSRGDDY","Homo sapiens","METAP2, MNPEP, P67EIF2","Methionine aminopeptidase 2","1","5JI6"
"5JI7",,"X-RAY DIFFRACTION",1.77,30.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M NA-CACODYLATE, PH 6.5, 6% PEG
 4000, 0.2M KCL, 0.02M MGCL2, VAPOR DIFFUSION, HANGING DROP,
 TEMPERATURE 295K",295,"10.1016/j.jmb.2016.09.004",,"5JI7",26.34,"1.51","1.51","The Crystal Structure Of IUS-SPRY Domain From RanBPM/9","LAAGPGPAGGAPTPALVAGSSAAAPFPHGDSALNEQEKELQRRLKRLYPAVDEQETPLPRSWSPKDKFSYIGLSQNNLRVHYKGHGKTPKDAASVRATHPIPAACGIYYFEVKIVSKGRDGYMGIGLSAQGVNMNRLPGWDKHSYGYHGDDGHSFCSSGTGQPYGPTFTTGDVIGCCVNLINNTCFYTKNGHSLGIAFTDLPPNLYPTVGLQTPGEVVDANFGQHPFVFDIEDYMREWRTKIQ","Homo sapiens","RANBP9, RANBPM","Ran-binding protein 9","1","5JI7"
"5JI8",,"X-RAY DIFFRACTION",2.24,45.12,"VAPOR DIFFUSION, HANGING DROP",6.4,"0.1M Bis-Tris PH6.4, 27% PEG 3350",293,"10.1002/cbic.201600184","6KT","5JI8",13.25,"1.42","1.42","Crystal structure of the BRD9 bromodomain and hit 1","ESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSKLEHHHHHH","Homo sapiens","BRD9, UNQ3040/PRO9856","Bromodomain-containing protein 9","1","5JI8"
"5JI9",,"X-RAY DIFFRACTION",2.85,62.49,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M NA-CACODYLATE, PH 6.5, 6% PEG
 4000, 0.2M KCL, 0.02M MGCL2, VAPOR DIFFUSION, HANGING DROP,
 TEMPERATURE 295K",295,"10.1016/j.jmb.2016.09.004",,"5JI9",26.34,"2.5","2.5","The Crystal Structure Of IUS-SPRY Domain From RanBPM/9","LAAGPGPAGGAPTPALVAGSSAAAPFPHGDSALNEQEKELQRRLKRLYPAVDEQETPLPRSWSPKDKFSYIGLSQNNLRVHYKGHGKTPKDAASVRATHPIPAACGIYYFEVKIVSKGRDGYMGIGLSAQGVNMNRLPGWDKHSYGYHGDDGHSFCSSGTGQPYGPTFTTGDVIGCCVNLINNTCFYTKNGHSLGIAFTDLPPNLYPTVGLQTPGEVVDANFGQHPFVFDIEDYMREWRTKIQ","Homo sapiens","RANBP9, RANBPM","Ran-binding protein 9","1","5JI9"
"5JID",,"X-RAY DIFFRACTION",2.1,41.5,"VAPOR DIFFUSION, HANGING DROP",,"Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. PFOA was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter.",291,"10.1021/acs.est.6b02771",,"5JID",28.41,"1.2","1.2","Crystal Structure of Human Transthyretin in Complex with Perfluorooctanoic acid (PFOA)","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5JID"
"5JIH",,"X-RAY DIFFRACTION",2.7,54.5,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.05 M TRIS,
22% (w/v) PEG 3350",295,"10.1016/j.str.2017.04.014",,"5JIH",53.71,"1.663","1.663","Crystal structure of HER2 binding IgG1-Fc (Fcab STAB19)","TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEYLSDSVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVPRHSETMRRWAHGNVFSCSVMHEALHNHYTQKSLSLSPG","Homo sapiens","IGHG1","Ig gamma-1 chain C region","1","5JIH"
"5JII",,"X-RAY DIFFRACTION",2.76,55.5,"VAPOR DIFFUSION, SITTING DROP",7,"0.05 M Sodium phosphate, 
16% (w/v) PEG 3350",295,"10.1016/j.str.2017.04.014",,"5JII",52.94,"1.79","1.79","Crystal structure of human IgG1-Fc","TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG","Homo sapiens","IGHG1","Ig gamma-1 chain C region","1","5JII"
"5JIK",,"X-RAY DIFFRACTION",2.73,54.9,"VAPOR DIFFUSION, SITTING DROP",7,"0.05 M HEPES,
24% (w/v) PEG 3350",295,"10.1016/j.str.2017.04.014",,"5JIK",53.31,"1.82","1.82","Crystal structure of HER2 binding IgG1-Fc (Fcab H10-03-6)","TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEYLYGDVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVPRHSARMWRWAHGNVFSCSVMHEALHNHYTQKSLSLSPG","Homo sapiens","IGHG1","Ig gamma-1 chain C region","1","5JIK"
"5JIM",,"X-RAY DIFFRACTION",2.14,42.63,"VAPOR DIFFUSION, HANGING DROP",7.6,"Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. PFOS was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter.",291,"10.1021/acs.est.6b02771",,"5JIM",28.58,"1.26","1.26","Crystal Structure of Human Transthyretin in Complex with Perfluoroktansulfonsyra (PFOS)","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5JIM"
"5JIQ",,"X-RAY DIFFRACTION",2.14,42.48,"VAPOR DIFFUSION, HANGING DROP",7.6,"Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. BP2 was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent 
glycerol at pH 5.5. Drop size 3 plus 3 microliter.",291,"10.1021/acs.est.6b02771",,"5JIQ",28.16,"1.45","1.45","Crystal Structure of Human Transthyretin in Complex with 2,2',4,4'-tetrahydroxybenzophenone (BP2)","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5JIQ"
"5JIX",,"X-RAY DIFFRACTION",2.14,42.49,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 400, 200 mM CaAc, 0.1M NaAc pH 4.5-4.8",277,"10.1021/acschembio.7b00369","6J7","5JIX",18.71,"1.47","1.47","PKG II's Carboxyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with 8-Br-cGMP","GSTAQARDEQYRNFLRSVSLLKNLPEDKLTKIIDCLEVEYYDKGDYIIREGEEGSTFFILAKGKVKVTQSTEGHDQPQLIKTLQKGEYFGEKALISDDVRSANIIAEENDVACLVIDRETFNQTVGTFEELQKYLEGYVANLNRDDEKRHAK","Homo sapiens","PRKG2, PRKGR2","cGMP-dependent protein kinase 2","1","5JIX"
"5JIZ",,"X-RAY DIFFRACTION",1.99,38.34,"VAPOR DIFFUSION, HANGING DROP",4.6,"20 mM CaCl2, 100 mM NaOAc, 30% MPD, pH 4.6, at 4oC",277,,"6FW","5JIZ",18.65,"1.5","1.5","PKG II's Carboxyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with 8-pCPT-cGMP","GSTAQARDEQYRNFLRSVSLLKNLPEDKLTKIIDCLEVEYYDKGDYIIREGEEGSTFFILAKGKVKVTQSTEGHDQPQLIKTLQKGEYFGEKALISDDVRSANIIAEENDVACLVIDRETFNQTVGTFEELQKYLEGYVANLNRDDEKRHAK","Homo sapiens","PRKG2, PRKGR2","cGMP-dependent protein kinase 2","1","5JIZ"
"5JJ2",,"X-RAY DIFFRACTION",2.29,46.37,"VAPOR DIFFUSION, SITTING DROP",7,"2.5 M Sodium malonate",293,"10.1107/S2053230X16010189",,"5JJ2",24.83,"1.25","1.25","Crystal structure of the central domain of human AKAP18 gamma/delta in complex with malonate","RKKKRKDYQPNYFLSIPITNKEIIKGIKILQNAIIQQDERLAKAMVSDGSFHITLLVMQLLNEDEVNIGIDALLELKPFIEELLQGKHLTLPFQGIGTFGNQVGFVKLAEGDHVNSLLEIAETANRTFQEKGILVGESRSFKPHLTFMKLSKSPWLRKNGVKKIDPDLYEKFISHRFGEEILYRIDLCSMLKKKQSNGYYHCESSIVIGEK","Homo sapiens","AKAP7, AKAP18","A-kinase anchor protein 7 isoform gamma","1","5JJ2"
"5JJD",,"X-RAY DIFFRACTION",2.16,43.03,"VAPOR DIFFUSION, HANGING DROP",6,"0.1 M MES bis-tris (pH 6.0), 6% (w/v) polyethylene glycol 10,000, and 10 micro molar calcium chloride",293,"10.1074/jbc.M117.780007",,"5JJD",40.85,"2.403","2.403","crystal structure of the ceramide transfer protein PH and START domain complex","GEFSGPPVERCGVLSKWTNYIHGWQDRWVVLKNNALSYYKSEDETEYGCRGSICLSKAVITPHDFDECRFDISVNDSVWYLRAQDPDHRQQWIDAIEQHKTESGYG","Homo sapiens","COL4A3BP, CERT, STARD11, CERT1","Collagen type IV alpha-3-binding protein","1","5JJD"
,,,,,,,,,,,,,,,,"GHMAMEFSSVGTHRFVQKVEEMVQNHMTYSLQDVGGDANWQLVVEEGEMKVYRREVEENGIVLDPLKATHAVKGVTGHEVCNYFWNVDVRNDWETTIENFHVVETLADNAIIIYQTHKRVWPASQRDVLYLSVIRKIPALTENDPETWIVCNFSVDHDSAPLNNRCVRAKINVAMICQTLVSPPEGNQEISRDNILCKITYVANVNPGGWAPASVLRAVAKREYPKFLKRFTSYVQEKTAGKPILF","Homo sapiens","COL4A3BP, CERT, STARD11, CERT1","Collagen type IV alpha-3-binding protein","2","5JJD"
"5JJX",,"X-RAY DIFFRACTION",3.06,59.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"30% PEG 3350, 0.2 M NaCl, 0.1 M HEPES pH7.5",298,,,"5JJX",37.25,"2","2","Crystal structure of the HAT domain of sart3","GGEYEWEYDEEEEKNQLEIERLEEQLSINVYDYNCHVDLIRLLRLEGELTKVRMARQKMSEIFPLTEELWLEWLHDEISMAQDGLDREHVYDLFEKAVKDYICPNIWLEYGQYSVGGIGQKGGLEKVRSVFERALSSVGLHMTKGLALWEAYREFESAIVEAARLEKVHSLFRRQLAIPLYDMEATFAEYEEWSEDPIPESVIQNYNKALQQLEKYKPYEEALLQAEAPRLAEYQAYIDFEMKIGDPARIQLIFERALVENCLVPDLWIRYSQYLDRQLKVKDLVLSVHNRAIRNCPWTVALWSRYLLAMERHG","Homo sapiens","SART3, KIAA0156, TIP110","Squamous cell carcinoma antigen recognized by T-cells 3","1","5JJX"
"5JK9",,"X-RAY DIFFRACTION",2.87,57.16,"VAPOR DIFFUSION, SITTING DROP",,"12-15% (w/v) PEG6000, 0.1 M sodium citrate pH 5.6",293,"10.1038/nature18596",,"5JK9",170.31,"2.1","2.1","Crystal structure of human IZUMO1","RSPWCVICDPSVVLALKSLEKDYLPGHLDAKHHKAMMERVENAVKDFQELSLNEDAYMGVVDEATLQKGSWSLLKDLKRITDSDVKGDLFVKELFWMLHLQKETFATYVARFQKEAYCPNKCGVMLQTLIWCKNCKKEVHACRKSYDCGERNVEVPQMEDMILDCELNWHQASEGLTDYSFYRVWGNNTETLVSKGKEATLTKPMVGPEDAGSYRCELGSVNSSPATIINFHVTVLPKEFLEVLFQ","Homo sapiens","IZUMO1","Izumo sperm-egg fusion protein 1","1","5JK9"
"5JKA",,"X-RAY DIFFRACTION",2.43,49.41,"VAPOR DIFFUSION, SITTING DROP",,"20% (w/v) PEG3350, 0.24 M malonate pH 7.0",293,"10.1038/nature18596",,"5JKA",51.71,"2","2","Crystal structure of human JUNO (crystal form 1)","RSPWGDELLNICMNAKHHKRVPSPEDKLYEECIPWKDNACCTLTTSWEAHLDVSPLYNFSLFHCGLLMPGCRKHFIQAICFYECSPNLGPWIQPVGSLGWEVAPSGQGERVVNVPLCQEDCEEWWEDCRMSYTCKSNWRGGWDWSQGKNRCPKGAQCLPFSHYFPTPADLCEKTWSNSFKASPERRNSGRCLQKWFEPAQGNPNVAVARLFASEFLEVLFQ","Homo sapiens","IZUMO1R, FOLR4, JUNO","Sperm-egg fusion protein Juno","1","5JKA"
"5JKB",,"X-RAY DIFFRACTION",2.26,45.62,"VAPOR DIFFUSION, SITTING DROP",,"3% (w/v) PEG4000, 5% 2-propanol, 0.1 M HEPES-NaOH pH 7.5",293,"10.1038/nature18596",,"5JKB",101.86,"3.23","3.23","Crystal structure of human JUNO (crystal form 2)","RSPWGDELLNICMNAKHHKRVPSPEDKLYEECIPWKDNACCTLTTSWEAHLDVSPLYNFSLFHCGLLMPGCRKHFIQAICFYECSPNLGPWIQPVGSLGWEVAPSGQGERVVNVPLCQEDCEEWWEDCRMSYTCKSNWRGGWDWSQGKNRCPKGAQCLPFSHYFPTPADLCEKTWSNSFKASPERRNSGRCLQKWFEPAQGNPNVAVARLFASEFLEVLFQ","Homo sapiens","IZUMO1R, FOLR4, JUNO","Sperm-egg fusion protein Juno","1","5JKB"
"5JKG",,"X-RAY DIFFRACTION",2.57,52.1,"VAPOR DIFFUSION, HANGING DROP",,"0.65M NH4H2PO4",277,"10.1371/journal.pone.0162491","6LF","5JKG",35.14,"2.352","2.352","The crystal structure of FGFR4 kinase domain in complex with LY2874455","GPLLAGLVSLDLPLDPLWEFPRDRLVLGKPLGEGAFGQVVRAEAFGMDPARPDQASTVAVKMLKDNASDKDLADLVSEMEVMKLIGRHKNIINLLGVCTQEGPLYVIVECAAKGNLREFLRARRPPGPDLSPDGPRSSEGPLSFPVLVSCAYQVARGMQYLESRKCIHRDLAARNVLVTEDNVMKIADFGLARGVHHIDYYKKTSNGRLPVKWMAPEALFDRVYTHQSDVWSFGILLWEIFTLGGSPYPGIPVEELFSLLREGHRMDRPPHCPPELYGLMRECWHAAPSQRPTFKQLVEALDKVLLAVSEE","Homo sapiens","FGFR4, JTK2, TKF","Fibroblast growth factor receptor 4","1","5JKG"
"5JKK",,"X-RAY DIFFRACTION",2.89,57.46,"VAPOR DIFFUSION, HANGING DROP",,"0.52 M magnesium acetate, 100 mM Tris, pH 8.5, 8 mg/mL Ftn(neg)",293,"10.1021/acs.inorgchem.8b01995",,"5JKK",171.89,"1.6","1.6","Crystal structure of the negatively supercharged variant Ftn(neg) of human heavy chain ferritin","MTTASTSQVRQNYHQDSEEAINRQINLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIQKPDEDDWESGLNAMEEALELEKNVNQSLLELHKLATDKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSDNES","Homo sapiens","FTH1, FTH, FTHL6, OK/SW-cl.84, PIG15","Ferritin heavy chain","1","5JKK"
"5JKL",,"X-RAY DIFFRACTION",2.8,56.07,"VAPOR DIFFUSION, HANGING DROP",,"0.19 M magnesium formate, 4 mg/mL Ftn(pos) and 4 mg/mL Ftn(neg)",293,"10.1021/jacs.6b07260",,"5JKL",258.96,"1.8","1.8","Binary crystal structure of positively and negatively supercharged variants Ftn(pos) and Ftn(neg) from human heavy chain ferritin (Mg formate condition)","MTTASTSQVRQNYHQDSEKAINRQIRLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIQKPDKDDWESGLRAMEKALKLEKKVNQSLLELHKLATKKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMGAPRSGLAEYLFDKHTLGDSDNES","Homo sapiens","FTH1, FTH, FTHL6, OK/SW-cl.84, PIG15","Ferritin heavy chain","1","5JKL"
,,,,,,,,,,,,,,,,"MTTASTSQVRQNYHQDSEEAINRQINLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIQKPDEDDWESGLNAMEEALELEKNVNQSLLELHKLATDKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSDNES","Homo sapiens","FTH1, FTH, FTHL6, OK/SW-cl.84, PIG15","Ferritin heavy chain","2","5JKL"
"5JKM",,"X-RAY DIFFRACTION",2.81,56.27,"VAPOR DIFFUSION, HANGING DROP",,"0.20 M magnesium acetate, 100 mM Tris, pH 8.5, 8 mg/mL Ftn(pos) and 8 mg/mL Ftn(neg)",293,"10.1021/jacs.6b07260",,"5JKM",258.4,"1.8","1.8","Binary crystal structure of positively and negatively supercharged variants Ftn(pos) and Ftn(neg) from human heavy chain ferritin (Mg acetate condition)","MTTASTSQVRQNYHQDSEKAINRQIRLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIQKPDKDDWESGLRAMEKALKLEKKVNQSLLELHKLATKKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMGAPRSGLAEYLFDKHTLGDSDNES","Homo sapiens","FTH1, FTH, FTHL6, OK/SW-cl.84, PIG15","Ferritin heavy chain","1","5JKM"
,,,,,,,,,,,,,,,,"MTTASTSQVRQNYHQDSEEAINRQINLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIQKPDEDDWESGLNAMEEALELEKNVNQSLLELHKLATDKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSDNES","Homo sapiens","FTH1, FTH, FTHL6, OK/SW-cl.84, PIG15","Ferritin heavy chain","2","5JKM"
"5JKN",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM Hepes-Na pH 7.5, 200mM NaCl and 25% PEG4000",293.15,"10.1016/j.molcel.2016.05.009",,"5JKN",32.44,"3","3","Crystal structure of deubiquitinase MINDY-1","GPLGSPEFPGRLEMEPDFYCVKWIPWKGEQTPIITQSTNGPCPLLAIMNILFLQWKVKLPPQKEVITSDELMAHLGNCLLSIKPQEKSEGLQLNFQQNVDDAMTVLPKLATGLDVNVRFTGVSDFEYTPECSVFDLLGIPLYHGWLVDPQSPEAVRAVGKLSYNQLVERIITCKHSSDTNLVTEGLIAEQFLETTAAQLTYHGLCELTAAAKEGELSVFFRNNHFSTMTKHKSHLYLLVTDQGFLQEEQVVWESLHNVDGDSCFCDSDFHLSHSLGKGPGAEGGSGSPE","Homo sapiens","FAM63A, KIAA1390, MINDY1","Protein FAM63A","1","5JKN"
"5JKV",,"X-RAY DIFFRACTION",5.84,78.94,"VAPOR DIFFUSION, SITTING DROP",7.4,"20-30% PEG 4000, PHOSPHATE BUFFER, PH 7.4",277,"10.1016/j.jsbmb.2018.02.009","ASD","5JKV",59.48,"2.75","2.75","HUMAN PLACENTAL AROMATASE CYTOCHROME P450 (CYP19A1) AT 2.75 ANGSTROM WITH BOUND POLYETHYLENE GLYCOL","MVLEMLNPIHYNITSIVPEAMPAATMPVLLLTGLFLLVWNYEGTSSIPGPGYCMGIGPLISHGRFLWMGIGSACNYYNRVYGEFMRVWISGEETLIISKSSSMFHIMKHNHYSSRFGSKLGLQCIGMHEKGIIFNNNPELWKTTRPFFMKALSGPGLVRMVTVCAESLKTHLDRLEEVTNESGYVDVLTLLRRVMLDTSNTLFLRIPLDESAIVVKIQGYFDAWQALLIKPDIFFKISWLYKKYEKSVKDLKDAIEVLIAEKRRRISTEEKLEECMDFATELILAEKRGDLTRENVNQCILEMLIAAPDTMSVSLFFMLFLIAKHPNVEEAIIKEIQTVIGERDIKIDDIQKLKVMENFIYESMRYQPVVDLVMRKALEDDVIDGYPVKKGTNIILNIGRMHRLEFFPKPNEFTLENFAKNVPYRYFQPFGFGPRGCAGKYIAMVMMKAILVTLLRRFHVKTLQGQCVESIQKIHDLSLHPDETKNMLEMIFTPRNSDRCLEH","Homo sapiens","CYP19A1, ARO1, CYAR, CYP19","Aromatase","1","5JKV"
"5JKW",,"X-RAY DIFFRACTION",5.83,78.89,"VAPOR DIFFUSION, SITTING DROP",7.4,"20-30% PEG 4000, PHOSPHATE BUFFER, PH 7.4",277,"10.1016/j.jsbmb.2018.02.009","TES","5JKW",58.86,"3","3","HUMAN PLACENTAL AROMATASE CYTOCHROME P450 (CYP19A1) COMPLEXED WITH TESTOSTERONE","MVLEMLNPIHYNITSIVPEAMPAATMPVLLLTGLFLLVWNYEGTSSIPGPGYCMGIGPLISHGRFLWMGIGSACNYYNRVYGEFMRVWISGEETLIISKSSSMFHIMKHNHYSSRFGSKLGLQCIGMHEKGIIFNNNPELWKTTRPFFMKALSGPGLVRMVTVCAESLKTHLDRLEEVTNESGYVDVLTLLRRVMLDTSNTLFLRIPLDESAIVVKIQGYFDAWQALLIKPDIFFKISWLYKKYEKSVKDLKDAIEVLIAEKRRRISTEEKLEECMDFATELILAEKRGDLTRENVNQCILEMLIAAPDTMSVSLFFMLFLIAKHPNVEEAIIKEIQTVIGERDIKIDDIQKLKVMENFIYESMRYQPVVDLVMRKALEDDVIDGYPVKKGTNIILNIGRMHRLEFFPKPNEFTLENFAKNVPYRYFQPFGFGPRGCAGKYIAMVMMKAILVTLLRRFHVKTLQGQCVESIQKIHDLSLHPDETKNMLEMIFTPRNSDRCLEH","Homo sapiens","CYP19A1, ARO1, CYAR, CYP19","Aromatase","1","5JKW"
"5JL6",,"X-RAY DIFFRACTION",5.81,78.81,"VAPOR DIFFUSION, SITTING DROP",7.4,"20-30% PEG 4000, PHOSPHATE BUFFER, PH 7.4",277,"10.1016/j.jsbmb.2018.02.009","ASD","5JL6",58.86,"3","3","HUMAN PLACENTAL AROMATASE CYTOCHROME P450 (CYP19A1): ANDROSTENEDIONE COMPLEX #2","MVLEMLNPIHYNITSIVPEAMPAATMPVLLLTGLFLLVWNYEGTSSIPGPGYCMGIGPLISHGRFLWMGIGSACNYYNRVYGEFMRVWISGEETLIISKSSSMFHIMKHNHYSSRFGSKLGLQCIGMHEKGIIFNNNPELWKTTRPFFMKALSGPGLVRMVTVCAESLKTHLDRLEEVTNESGYVDVLTLLRRVMLDTSNTLFLRIPLDESAIVVKIQGYFDAWQALLIKPDIFFKISWLYKKYEKSVKDLKDAIEVLIAEKRRRISTEEKLEECMDFATELILAEKRGDLTRENVNQCILEMLIAAPDTMSVSLFFMLFLIAKHPNVEEAIIKEIQTVIGERDIKIDDIQKLKVMENFIYESMRYQPVVDLVMRKALEDDVIDGYPVKKGTNIILNIGRMHRLEFFPKPNEFTLENFAKNVPYRYFQPFGFGPRGCAGKYIAMVMMKAILVTLLRRFHVKTLQGQCVESIQKIHDLSLHPDETKNMLEMIFTPRNSDRCLEH","Homo sapiens","CYP19A1, ARO1, CYAR, CYP19","Aromatase","1","5JL6"
"5JL7",,"X-RAY DIFFRACTION",5.81,78.81,"VAPOR DIFFUSION, SITTING DROP",7.4,"20-30% PEG 4000, PHOSPHATE BUFFER, PH 7.4",277,"10.1016/j.jsbmb.2018.02.009","ASD","5JL7",58.86,"3.1","3.1","HUMAN PLACENTAL AROMATASE CYTOCHROME P450 (CYP19A1): ANDROSTENEDIONE COMPLEX #3","MVLEMLNPIHYNITSIVPEAMPAATMPVLLLTGLFLLVWNYEGTSSIPGPGYCMGIGPLISHGRFLWMGIGSACNYYNRVYGEFMRVWISGEETLIISKSSSMFHIMKHNHYSSRFGSKLGLQCIGMHEKGIIFNNNPELWKTTRPFFMKALSGPGLVRMVTVCAESLKTHLDRLEEVTNESGYVDVLTLLRRVMLDTSNTLFLRIPLDESAIVVKIQGYFDAWQALLIKPDIFFKISWLYKKYEKSVKDLKDAIEVLIAEKRRRISTEEKLEECMDFATELILAEKRGDLTRENVNQCILEMLIAAPDTMSVSLFFMLFLIAKHPNVEEAIIKEIQTVIGERDIKIDDIQKLKVMENFIYESMRYQPVVDLVMRKALEDDVIDGYPVKKGTNIILNIGRMHRLEFFPKPNEFTLENFAKNVPYRYFQPFGFGPRGCAGKYIAMVMMKAILVTLLRRFHVKTLQGQCVESIQKIHDLSLHPDETKNMLEMIFTPRNSDRCLEH","Homo sapiens","CYP19A1, ARO1, CYAR, CYP19","Aromatase","1","5JL7"
"5JL9",,"X-RAY DIFFRACTION",5.83,78.9,"VAPOR DIFFUSION, SITTING DROP",7.4,"20-30% PEG 4000, PHOSPHATE BUFFER, PH 7.4",277,"10.1016/j.jsbmb.2018.02.009","ASD","5JL9",58.86,"3.1","3.1","HUMAN PLACENTAL AROMATASE CYTOCHROME P450 (CYP19A1): ANDROSTENEDIONE COMPLEX #4","MVLEMLNPIHYNITSIVPEAMPAATMPVLLLTGLFLLVWNYEGTSSIPGPGYCMGIGPLISHGRFLWMGIGSACNYYNRVYGEFMRVWISGEETLIISKSSSMFHIMKHNHYSSRFGSKLGLQCIGMHEKGIIFNNNPELWKTTRPFFMKALSGPGLVRMVTVCAESLKTHLDRLEEVTNESGYVDVLTLLRRVMLDTSNTLFLRIPLDESAIVVKIQGYFDAWQALLIKPDIFFKISWLYKKYEKSVKDLKDAIEVLIAEKRRRISTEEKLEECMDFATELILAEKRGDLTRENVNQCILEMLIAAPDTMSVSLFFMLFLIAKHPNVEEAIIKEIQTVIGERDIKIDDIQKLKVMENFIYESMRYQPVVDLVMRKALEDDVIDGYPVKKGTNIILNIGRMHRLEFFPKPNEFTLENFAKNVPYRYFQPFGFGPRGCAGKYIAMVMMKAILVTLLRRFHVKTLQGQCVESIQKIHDLSLHPDETKNMLEMIFTPRNSDRCLEH","Homo sapiens","CYP19A1, ARO1, CYAR, CYP19","Aromatase","1","5JL9"
"5JLE",,"X-RAY DIFFRACTION",2.44,49.62,"VAPOR DIFFUSION, HANGING DROP",8,"0.1 M KSCN, 30% PEG2000mme",291,"10.1101/gad.284323.116",,"5JLE",32.62,"2.4","2.4","Crystal structure of SETD2 bound to SAH","SGETSVPPGSALVGPSCVMDDFRDPQRWKECAKQGKMPCYFDLIEENVYLTERKKNKSHRDIKRMQCECTPLSKDERAQGEIACGEDCLNRLLMIECSSRCPNGDYCSNRRFQRKQHADVEVILTEKKGWGLRAAKDLPSNTFVLEYCGEVLDHKEFKARVKEYARNKNIHYYFMALKNDEIIDATQKGNCSRFMNHSCEPNCETQKWTVNGQLRVGFFTTKLVPSGSELTFDYQFQRYGKEAQKCFCGSANCRGYLGGENRVSIRAAGGKMKKERSRK","Homo sapiens","SETD2, HIF1, HYPB, KIAA1732, KMT3A, SET2, HSPC069","Histone-lysine N-methyltransferase SETD2","1","5JLE"
"5JMY",,"X-RAY DIFFRACTION",2.53,51.46,"VAPOR DIFFUSION, HANGING DROP",,"6.5, 25% W/V PEG 3350.
                      2 MM MGCL2
                      AND PROTEIN SOLUTION WERE MIXED",293,"10.1038/srep27909","6LD","5JMY",162.59,"2","2","NEPRILYSIN COMPLEXED WITH LBQ657","DDGICKSSDCIKSAARLIQNMDATTEPCTDFFKYACGGWLKRNVIPETSSRYGNFDILRDELEVVLKDVLQEPKTEDIVAVQKAKALYRSCINESAIDSRGGEPLLKLLPDIYGWPVATENWEQKYGASWTAEKAIAQLNSKYGKKVLINLFVGTDDKNSVNHVIHIDQPRLGLPSRDYYECTGIYKEACTAYVDFMISVARLIRQEERLPIDENQLALEMNKVMELEKEIANATAKPEDRNDPMLLYNKMTLAQIQNNFSLEINGKPFSWLNFTNEIMSTVNISITNEEDVVVYAPEYLTKLKPILTKYSARDLQNLMSWRFIMDLVSSLSRTYKESRNAFRKALYGTTSETATWRRCANYVNGNMENAVGRLYVEAAFAGESKHVVEDLIAQIREVFIQTLDDLTWMDAETKKRAEEKALAIKERIGYPDDIVSNDNKLNNEYLELNYKEDEYFENIIQNLKFSQSKQLKKLREKVDKDEWISGAAVVNAFYSSGRNQIVFPAGILQPPFFSAQQSNSLNYGGIGMVIGHEITHGFDDNGRNFNKDGDLVDWWTQQSASNFKEQSQCMVYQYGNFSWDLAGGQHLNGINTLGENIADNGGLGQAYRAYQNYIKKNGEEKLLPGLDLNHKQLFFLNFAQVWCGTYRPEYAVNSIKTDVHSPGNFRIIGTLQNSAEFSEAFHCRKNSYMNPEKKCRVW","Homo sapiens","MME, EPN","Neprilysin","1","5JMY"
"5JMZ",,"X-RAY DIFFRACTION",2.11,41.75,"VAPOR DIFFUSION, HANGING DROP",,"1.6 M Na-Citrate, 50 mM Tris, pH 7.8",293,,"AYX","5JMZ",29.32,"1.9","1.9","Carbonic Anhydrase IX-mimic IN Complex WITH U-NO2","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHSFQVTFDDSQDKAVLKGGPLDGTYRLLQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDVGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTEGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLAECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5JMZ"
"5JN0",,"X-RAY DIFFRACTION",2.13,42.26,"VAPOR DIFFUSION, SITTING DROP",,"100 mM MES pH 6.5, 12% PEG 20,000",297,,,"5JN0",11.4,"1.677","1.677","CRK-II SH2 domain","DSEERSSWYWGRLSRQEAVALLQGQRHGVFLVRDSSTSPGDYVLSVSENSRVSHYIINSSGPRRLRIGDQEFDSLPALLEFYKIHYLDTTTLIEPVARS","Homo sapiens",,"CRK-II SH2 domain","1","5JN0"
"5JN3",,"X-RAY DIFFRACTION",2.11,41.83,"VAPOR DIFFUSION, HANGING DROP",,"1.6 M Na-Citrate, 50 mM Tris, pH 7.8",293,,"WWZ","5JN3",29.38,"1.6","1.6","Carbonic Anhydrase IX-mimic IN Complex WITH U-F","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHSFQVTFDDSQDKAVLKGGPLDGTYRLLQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDVGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTEGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLAECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5JN3"
"5JN5",,"X-RAY DIFFRACTION",3.04,59.52,"VAPOR DIFFUSION, HANGING DROP",7.5,"LITHIUM OR AMMONIUM SULFATE (1.4 -
1.55 M) WITH 0.1 M TRIS, PH 7.5 OR MES PH 6.0",293,"10.1111/febs.14025",,"5JN5",129.39,"1.75","1.75","Crystal structure of the D263Y missense variant of human PGM1","MHHHHHHSSGVDLGTENLYFQSNMVKIVTVKTQAYQDQKPGTSGLRKRVKVFQSSANYAENFIQSIISTVEPAQRQEATLVVGGDGRFYMKEAIQLIARIAAANGIGRLVIGQNGILSTPAVSCIIRKIKAIGGIILTASHNPGGPNGDFGIKFNISNGGPAPEAITDKIFQISKTIEEYAVCPDLKVDLGVLGKQQFDLENKFKPFTVEIVDSVEAYATMLRSIFDFSALKELLSGPNRLKIRIDAMHGVVGPYVKKILCEELGAPANSAVNCVPLEDFGGHHPYPNLTYAADLVETMKSGEHDFGAAFDGDGDRNMILGKHGFFVNPSDSVAVIAANIFSIPYFQQTGVRGFARSMPTSGALDRVASATKIALYETPTGWKFFGNLMDASKLSLCGEESFGTGSDHIREKDGLWAVLAWLSILATRKQSVEDILKDHWQKYGRNFFTRYDYEEVEAEGANKMMKDLEALMFDRSFVGKQFSANDKVYTVEKADNFEYSDPVDGSISRNQGLRLIFTDGSRIVFRLSGTGSAGATIRLYIDSYEKDVAKINQDPQVMLAPLISIALKVSQLQERTGRTAPTVIT","Homo sapiens","PGM1","Phosphoglucomutase-1","1","5JN5"
"5JN7",,"X-RAY DIFFRACTION",2.11,41.8,"VAPOR DIFFUSION, HANGING DROP",,"1.6 M Na-Citrate, 50 mM Tris, pH 7.8",293,,"6LU","5JN7",29.64,"1.517","1.517","Carbonic Anhydrase II In Complex WITH U-CH3","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5JN7"
"5JN8",,"X-RAY DIFFRACTION",2.5,51.3,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 mM Na acetate, 200 mM AmSO4 and 21% PEG 4000",277,"10.1007/s00249-017-1256-0","AZM, SO4, ACT","5JN8",124.52,"1.85","1.85","Crystal Structure for the complex of human carbonic anhydrase IV and acetazolamide","AESHWCYEVQAESSNYPCLVPVKWGGNCQKDRQSPINIVTTKAKVDKKLGRFFFSGYDKKQTWTVQNNGHSVMMLLENKASISGGGLPAPYQAKQLHLHWSDLPYKGSEHSLDGEHFAMEMHIVHEKEKGTSRNVKEAQDPEDEIAVLAFLVEAGTQVNEGFQPLVEALSNIPKPEMSTTMAESSLLDLLPKEEKLRHYFRYLGSLTTPTCDEKVVWTVFREPIQLHREQILAFSQKLYYDKEQTVSMKDNVRPLQQLGQRTVIKS","Homo sapiens","CA4","Carbonic anhydrase 4","1","5JN8"
"5JN9",,"X-RAY DIFFRACTION",2.5,51.3,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 mM Na acetate, 200 mM AmSO4 and 16% PEG 3350",277,"10.1007/s00249-017-1256-0","ACT, EZL, SO4","5JN9",124.01,"2.1","2.1","Crystal structure for the complex of human carbonic anhydrase IV and ethoxyzolamide","AESHWCYEVQAESSNYPCLVPVKWGGNCQKDRQSPINIVTTKAKVDKKLGRFFFSGYDKKQTWTVQNNGHSVMMLLENKASISGGGLPAPYQAKQLHLHWSDLPYKGSEHSLDGEHFAMEMHIVHEKEKGTSRNVKEAQDPEDEIAVLAFLVEAGTQVNEGFQPLVEALSNIPKPEMSTTMAESSLLDLLPKEEKLRHYFRYLGSLTTPTCDEKVVWTVFREPIQLHREQILAFSQKLYYDKEQTVSMKDNVRPLQQLGQRTVIKS","Homo sapiens","CA4","Carbonic anhydrase 4","1","5JN9"
"5JNA",,"X-RAY DIFFRACTION",2.5,51.3,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 mM Na acetate, 200 mM AmSO4 and 21% PEG 4000",277,"10.1007/s00249-017-1256-0","SO4, ACT, TOR","5JNA",124.3,"2","2","Crystal structure for the complex of human carbonic anhydrase IV and topiramate","AESHWCYEVQAESSNYPCLVPVKWGGNCQKDRQSPINIVTTKAKVDKKLGRFFFSGYDKKQTWTVQNNGHSVMMLLENKASISGGGLPAPYQAKQLHLHWSDLPYKGSEHSLDGEHFAMEMHIVHEKEKGTSRNVKEAQDPEDEIAVLAFLVEAGTQVNEGFQPLVEALSNIPKPEMSTTMAESSLLDLLPKEEKLRHYFRYLGSLTTPTCDEKVVWTVFREPIQLHREQILAFSQKLYYDKEQTVSMKDNVRPLQQLGQRTVIKS","Homo sapiens","CA4","Carbonic anhydrase 4","1","5JNA"
"5JNC",,"X-RAY DIFFRACTION",2.5,51.3,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 mM Na acetate, 200 mM AMSO4 and 16% PEG 3350",277,"10.1007/s00249-017-1256-0","SO4, 6LH, ACT","5JNC",123.93,"2","2","Crystal structure for the complex of human carbonic anhydrase IV and 4-aminomethylbenzene sulfonamide","AESHWCYEVQAESSNYPCLVPVKWGGNCQKDRQSPINIVTTKAKVDKKLGRFFFSGYDKKQTWTVQNNGHSVMMLLENKASISGGGLPAPYQAKQLHLHWSDLPYKGSEHSLDGEHFAMEMHIVHEKEKGTSRNVKEAQDPEDEIAVLAFLVEAGTQVNEGFQPLVEALSNIPKPEMSTTMAESSLLDLLPKEEKLRHYFRYLGSLTTPTCDEKVVWTVFREPIQLHREQILAFSQKLYYDKEQTVSMKDNVRPLQQLGQRTVIKS","Homo sapiens","CA4","Carbonic anhydrase 4","1","5JNC"
"5JNR",,"X-RAY DIFFRACTION",2.4,48.69,"EVAPORATION",5.5,"7% PEG 10K, Bis Tris, Ammonium Acetate",293,"10.1038/nchembio.2344",,"5JNR",18.21,"2","2","Crystal structure of human low molecular weight protein tyrosine phosphatase (LMPTP) type A","GSMAEQATKSVLFVCLGNICRSPIAEAVFRKLVTDQNISENWRVDSAATSGYEIGNPPDYRGQSCMKRHGIPMSHVARQITKEDFATFDYILCMDESNLRDLNRKSNQVKTCKAKIELLGSYDPQKQLIIEDPYYGNDSDFETVYQQCVRCCRAFLEKAH","Homo sapiens","ACP1","Low molecular weight phosphotyrosine protein phosphatase","1","5JNR"
"5JNS",,"X-RAY DIFFRACTION",2.32,46.96,"EVAPORATION",8,"25% PEG 3350K, 200 mM NaCl",293,"10.1038/nchembio.2344",,"5JNS",18.38,"1.8","1.8","Crystal structure of human low molecular weight protein tyrosine phosphatase (LMPTP) type A complexed with phosphate","GSMAEQATKSVLFVCLGNICRSPIAEAVFRKLVTDQNISENWRVDSAATSGYEIGNPPDYRGQSCMKRHGIPMSHVARQITKEDFATFDYILCMDESNLRDLNRKSNQVKTCKAKIELLGSYDPQKQLIIEDPYYGNDSDFETVYQQCVRCCRAFLEKAH","Homo sapiens","ACP1","Low molecular weight phosphotyrosine protein phosphatase","1","5JNS"
"5JNT",,"X-RAY DIFFRACTION",2.47,50.11,"EVAPORATION",6.5,"20% PEG 3350, 200 mM NaCl, 40 mM MES",293,"10.1038/nchembio.2344",,"5JNT",18.64,"1.45","1.45","Crystal structure of human low molecular weight protein tyrosine phosphatase (LMPTP) type A complexed with MES","GSMAEQVTKSVLFVCLGNICRSPIAEAVFRKLVTDQNISENWRVDSAATSGYEIGNPPDYRGQSCMKRHGIPMSHVARQITKEDFATFDYILCMDESNLRDLNRKSNQVKTCKAKIELLGSYDPQKQLIIEDPYYGNDSDFETVYQQCVRCCRAFLEKAH","Homo sapiens","ACP1","Low molecular weight phosphotyrosine protein phosphatase","1","5JNT"
"5JNY",,"X-RAY DIFFRACTION",5.02,75.5,"VAPOR DIFFUSION, HANGING DROP",6.5,"6% PEG 8000, 25% Isopropanol, 0.1 M Imidazole pH 6.5",293,"10.1371/journal.pone.0157409",,"5JNY",96.6,"3.041","3.041","Crystal Structure of 10E8 Fab","EVQLVESGGGLVKPGGSLRLSCSASGFDFDNAWMTWVRQPPGKGLEWVGRITGPGEGWSVDYAAPVEGRFTISRLNSINFLYLEMNNLRMEDSGLYFCARTGKYYDFWSGYPPGEEYFQDWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCD","Homo sapiens",,"10E8 Heavy Chain","1","5JNY"
,,,,,,,,,,,,,,,,"SYELTQETGVSVALGRTVTITCRGDSLRSHYASWYQKKPGQAPILLFYGKNNRPSGVPDRFSGSASGNRASLTISGAQAEDDAEYYCSSRDKSGSRLSVFGGGTKLTVLSQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC","Homo sapiens",,"10E8 Light Chain","2","5JNY"
"5JO3",,"X-RAY DIFFRACTION",2.23,44.87,"VAPOR DIFFUSION",7.4,"20% PEG 4K
10% Isopropanol
0.1M Hepes pH 7.4",293,,,"5JO3",38.14,"1.49","1.49","PDE5A for NaV1.7","EEETRELQSLAAAVVPSAQTLKITDFSFSDFELSDLETALCTIRMFTDLNLVQNFQMKHEVLCRWILSVKKNYRKNVAYHNWRHAFNTAQCMFAALKAGKIQNKLTDLEILALLIAALSHDLDHPGVSNQFLINTNSELALMYNDESVLEHHHFDQCLMILNSPGNQILSGLSIEEYKTTLKIIKQAILATDLALYIKRRGEFFELIRKNQFNLEDPHEKELFLAMLMTACDLSAITKPWPIQQRIAELVATEFFDQGDRERKELNIEPTDLMNREKKNKIPSMQVGFIDAICLQLYEALTHVSEDCFPLLDGCRKNRQKWQALAE","Homo sapiens","PDE5A, PDE5","cGMP-specific 3',5'-cyclic phosphodiesterase","1","5JO3"
"5JO4",,"X-RAY DIFFRACTION",2.69,54.35,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M NH4SO4, 12% PEG 3350",293,,,"5JO4",94.34,"2.53","2.53","Antibody Fab Fragment Complex","QVQLVQSGAEVKKPGSSVKVSCRASGGTGGTFSAYAFTWVRQAPGQGLEWMGGITGMFGTANYAQKFQGRVTITADELTSTAYMELSSLTSEDTALYYCARGLYYYESSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK","Homo sapiens",,"D80 Fab Heavy Chain","1","5JO4"
,,,,,,,,,,,,,,,,"EIVLTQSPGTLSLSPGERATLSCRASQSLSSKYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYSCQQYDGVPRTFGQGTTVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"D80 Fab Light Chain","2","5JO4"
,,,,,,,,,,,,,,,,"QLVQSGAEVVKPGASVKVSCKASGYTFTSYWMHWVKQAPGQGLEWIGAVSPGNSDTSYNEKFKGKATLTVDKSASTAYMELSSLRSEDTAVYYCTRSRYGNNALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK","Homo sapiens",,"G6 Fab Heavy Chain","3","5JO4"
,,,,,,,,,,,,,,,,"DIQLTQSPSSLSASVGDRVTITCRASQGISSNIVWLQQKPGKAPKGLIYHGTNLESGVPSRFSGSGSGTDYTLTISSLEPEDFATYYCVQYSQFPPTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"G6 Fab Light Chain","4","5JO4"
"5JO5",,"X-RAY DIFFRACTION",2.49,50.59,"VAPOR DIFFUSION, HANGING DROP",,"15% peg8000, 10% Isopropanol, imidazole, pH 6.5",293,"10.1371/journal.pone.0157409",,"5JO5",189.67,"1.7","1.7","Crystal structure of 10E8 gHV-gLV antigen-binding fragment.","EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCARTGKYYDFWSGYPPGEEYFQDWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPK","Homo sapiens",,"10E8 gHV","1","5JO5"
,,,,,,,,,,,,,,,,"SELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDKSGSRLSVFGGGTKLTVLSQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTE","Homo sapiens",,"10E8 gLV","2","5JO5"
"5JOE",,"X-RAY DIFFRACTION",4.77,74.19,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris pH 8.5; 30% w/v PEG 4000",292.15,"10.1002/1873-3468.12362",,"5JOE",10.64,"2","2","Crystal structure of I81 from titin","MGPVTLIKDIENQTVLKDNDAVFEIDIKINYPEIKLSWYKGTEKLEPSDKFEISIDGDRHTLRVKNCQLKDQGNYRLVCGPHIASAKLTVIE","Homo sapiens","TTN","Titin","1","5JOE"
"5JOF",,"X-RAY DIFFRACTION",3.02,59.26,"VAPOR DIFFUSION, HANGING DROP",9,"0.1 M Tris pH 9, 17% PEG 8K, 0.33 M ammonium sulfate",293,"10.1016/j.str.2016.06.012",,"5JOF",188.77,"3.208","3.208","Crystal structure of VRC03 gHVgLV antigen-binding fragment.","QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARRGSCDYCGDFPWQYWGQGTVVVVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPK","Homo sapiens",,"VRC03 gHV heavy chain","1","5JOF"
,,,,,,,,,,,,,,,,"EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFEFFGLGSELEVHRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"VRC03 gLV light chain","2","5JOF"
"5JOG",,"X-RAY DIFFRACTION",3.04,59.58,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 18.9 mg/ml protein in 50mM NaCl, 50mM Mes/NaOH pH 6.0, 10uM ZnCl2, 0.5 mM TCEP with 1mM compound
Crystallization solution: 35% MPD, 0.1M MES/NaOH pH 6.0, 0.2 M Li2SO4",277,"10.1038/ncomms13166","6LT","5JOG",29.52,"2.46","2.46","CRYSTAL STRUCTURE OF CSN5(2-257) IN COMPLEX WITH CNS5i-3","GAASGSGMAQKTWELANNMQEAQSIDEIYKYDKKQQQEILAAKPWTKDHHYFKYCKISALALLKMVMHARSGGNLEVMGLMLGKVDGETMIIMDSFALPVEGTETRVNAQAAAYEYMAAYIENAKQVGRLENAIGWYHSHPGYGCWLSGIDVSTQMLNQQFQEPFVAVVIDPTRTISAGKVNLGAFRTYPKGYKPPDEGPSEYQTIPLNKIEDFGVHCKQYYALEVSYFKSSLDRKLLELLWNKYWVNTLSSSSLLT","Homo sapiens","COPS5, CSN5, JAB1","COP9 signalosome complex subunit 5","1","5JOG"
"5JOH",,"X-RAY DIFFRACTION",3.09,60.21,"VAPOR DIFFUSION, SITTING DROP",6,"Protein solution: 15 mg/ml CSN5 in 50mM NaCl, 50mM Mes/NaOH pH 6.0, 10uM ZnCl2, 0.5 mM TCEP with 1mM ligand
Crystallization solution: 35% MPD, 0.2M LiSO4, 0.1 M MES/NaOH pH 6.0",277,"10.1038/ncomms13166","6M3","5JOH",29.5,"1.99","1.99","CRYSTAL STRUCTURE OF CSN5(2-257) IN COMPLEX WITH CNS5i-1b","GAASGSGMAQKTWELANNMQEAQSIDEIYKYDKKQQQEILAAKPWTKDHHYFKYCKISALALLKMVMHARSGGNLEVMGLMLGKVDGETMIIMDSFALPVEGTETRVNAQAAAYEYMAAYIENAKQVGRLENAIGWYHSHPGYGCWLSGIDVSTQMLNQQFQEPFVAVVIDPTRTISAGKVNLGAFRTYPKGYKPPDEGPSEYQTIPLNKIEDFGVHCKQYYALEVSYFKSSLDRKLLELLWNKYWVNTLSSSSLLT","Homo sapiens","COPS5, CSN5, JAB1","COP9 signalosome complex subunit 5","1","5JOH"
"5JOJ",,"SOLUTION NMR",,,,,,,"10.1038/srep40662",,"5JOJ",11.05,,,"Calcium-loaded EF-hand domain of L-plastin","MARGSVSDEEMMELREAFAKVDTDGNGYISFNELNDLFKAACLPLPGYRVREITENLMATGDLDQDGRISFDEFIKIFHGLKSTDVAKTFRKAINKK","Homo sapiens","LCP1, PLS2","Plastin-2","1","5JOJ"
"5JOL",,"SOLUTION NMR",,,,,,,"10.1038/srep40662",,"5JOL",9.27,,,"Calcium-free EF-hand domain of L-plastin","MARGSVSDEEMMELREAFAKVDTDGNGYISFNELNDLFKAACLPLPGYRVREITENLMATGDLDQDGRISFDEFIKIFHGLK","Homo sapiens","LCP1, PLS2","Plastin-2","1","5JOL"
"5JPJ",,"X-RAY DIFFRACTION",2.68,54.05,"VAPOR DIFFUSION, SITTING DROP",7.5,"1 M sodium/potassium tartrate, 100 mM Tris-HCl, pH 7.0, 200 mM lithium sulfate",277,"10.1016/j.bbrep.2019.100682",,"5JPJ",23.72,"2","2","Crystal structure of 6aJL2-R24G","NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNHVVFGGGTKLTVL","Homo sapiens",,"6aJL2 protein","1","5JPJ"
"5JPN",,"X-RAY DIFFRACTION",2.99,58.85,"VAPOR DIFFUSION, SITTING DROP",6.4,"0.9 M sodium citrate pH 6.4, 0.25 M potassium chloride, 1% v/v ethanol, 3 % v/v acetonitrile, 6 % v/v ethylene glycol and 10 mM spermidine",293,"10.1107/S2059798316012201",,"5JPN",193.08,"3.6","3.6","Structure of human complement C4 rebuilt using iMDFF","KPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAGLAFSDGDQWTLSRKRLSCPKEKTT","Homo sapiens","C4A, CO4, CPAMD2","Complement C4-A","1","5JPN"
,,,,,,,,,,,,,,,,"NVNFQKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRAARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKANSFLGEKASAGLLGAHAAAITAYALSLTKAPVDLLGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQASAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEG","Homo sapiens","C4A, CO4, CPAMD2","Complement C4-A","2","5JPN"
,,,,,,,,,,,,,,,,"APKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYYPRVEYGFQVKVLREDSRAAFRLFETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPGKEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQRAACAQLNDFLQEYGTQGCQV","Homo sapiens","C4A, CO4, CPAMD2","Complement C4-A","3","5JPN"
"5JPV",,"X-RAY DIFFRACTION",2.48,50.42,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Na Cacodylate, pH=6.8-7.4, 0.1-0.2M (NH4)2SO4,14-20% PEG 8000, 2% MPD",293,"10.1021/jacs.6b12964",,"5JPV",34.98,"1.9","1.9","Efficient targeting of the asialoglycoprotein receptor by polyvalent display of a compact galactoseamine mimic","MGSERTCCPVNWVEHERSCYWFSRSGKAWADADNYCRLEDAHLVVVTSWEEQKFVQHHIGPVNTWMGLHDQNGPWKWVDGTDYETGFKNWRPEQPDDWYGHGLGGGEDCAHFTDDGRWNDDVCQRPYRWVCETELDKASQEPPLL","Homo sapiens","ASGR1, CLEC4H1","Asialoglycoprotein receptor 1","1","5JPV"
"5JPX",,"SOLUTION NMR",,,,,,,"10.1371/journal.pone.0181551",,"5JPX",5.21,,,"Solution structure of the TRIM21 B-box2 (B2)","GTQGERCAVHGERLHLFCEKDGKALCWVCAQSRKHRDHAMVPLEE","Homo sapiens","TRIM21, RNF81, RO52, SSA1","E3 ubiquitin-protein ligase TRIM21","1","5JPX"
"5JPZ",,"X-RAY DIFFRACTION",3.65,66.28,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Monosaccharides; 0.1M Tris/Bicine (pH 7.3), 32%PEG550MME_PEG20K",283.15,,,"5JPZ",120.2,"3.045","3.045","Crystal structure of HAT domain of human Squamous Cell Carcinoma Antigen Recognized By T Cells 3, SART3 (TIP110)","MSYYHHHHHHDYDIPTTENLYFQGAMGSGILEIERLEEQLSINVYDYNCHVDLIRLLRLEGELTKVRMARQKMSEIFPLTEELWLEWLHDEISMAQDGLDREHVYDLFEKAVKDYICPNIWLEYGQYSVGGIGQKGGLEKVRSVFERALSSVGLHMTKGLALWEAYREFESAIVEAARLEKVHSLFRRQLAIPLYDMEATFAEYEEWSEDPIPESVIQNYNKALQQLEKYKPYEEALLQAEAPRLAEYQAYIDFEMKIGDPARIQLIFERALVENCLVPDLWIRYSQYLDRQLKVKDLVLSVHNRAIRNCPWTVALWSRYLLAMERHGVDHQVISVTFEKALNAGFIQATDYVEIWQAYLDYLRRRVDFKQDSSKELEELRAAFTRALEYLKQEVEERFNESGDPSCVIMQNWARIEARLCNNMQKARELWDSIMTRGNAKYANMWLEYYNLERAHGDTQHCRKALHRAVQCTSDYPEHVCEVLLTMERTEGSLEDWDIAVQKTETRLA","Homo sapiens","SART3, KIAA0156, TIP110","Squamous cell carcinoma antigen recognized by T-cells 3","1","5JPZ"
"5JQ0",,"X-RAY DIFFRACTION",2.1,41.52,"VAPOR DIFFUSION, HANGING DROP",8.7,"SODIUM CITRATE 1.3M, TRIS-HCL 0.1M",298,"10.1039/c6cc06399c",,"5JQ0",29.69,"1.4","1.4","Crystal structure of human carbonic anhydrase II in complex with Benzoxaborole at pH=8.7","MGMSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5JQ0"
"5JQ1",,"X-RAY DIFFRACTION",2.46,50.04,"VAPOR DIFFUSION, HANGING DROP",7,"0.1 M cacodylate, pH 6.8-7.4, 0.1-0.2M (NH4)2SO4, 14-20% PEG 8000",293,"10.1021/jacs.6b12964","ZPF","5JQ1",34.77,"1.83","1.83","Efficient targeting of the asialoglycoprotein receptor by polyvalent display of a compact galactosamine mimic","MGSERTCCPVNWVEHERSCYWFSRSGKAWADADNYCRLEDAHLVVVTSWEEQKFVQHHIGPVNTWMGLHDQNGPWKWVDGTDYETGFKNWRPEQPDDWYGHGLGGGEDCAHFTDDGRWNDDVCQRPYRWVCETELDKASQEPPLL","Homo sapiens","ASGR1, CLEC4H1","Asialoglycoprotein receptor 1","1","5JQ1"
"5JQ5",,"X-RAY DIFFRACTION",2.02,39.08,"VAPOR DIFFUSION, HANGING DROP",7.8,"0.1M AMMONIUM ACETATE, PH 7.8, 6% PEG 3350",277,"10.1002/cmdc.201600535","I74","5JQ5",34.43,"1.94","1.94","Crystal structure of CDK2 in complex with inhibitor ICEC0942","MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","Cyclin-dependent kinase 2","1","5JQ5"
"5JQ8",,"X-RAY DIFFRACTION",2.04,39.62,"VAPOR DIFFUSION, HANGING DROP",7.8,"0.1M AMMONIUM ACETATE, PH 7.8, 6% PEG 3350",277,"10.1002/cmdc.201600535",,"5JQ8",34.37,"1.94","1.94","Crystal structure of CDK2 in complex with inhibitor ICEC0943","MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","Cyclin-dependent kinase 2","1","5JQ8"
"5JQD",,"X-RAY DIFFRACTION",2.29,46.38,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 4000, 0.2 M CaCl2, 0.1 M Tris pH 8.4",293,,,"5JQD",94.9,"2.591","2.591","Antibody Fab Fragment","EIVLTQSPGTLSLSPGERATLSCRASQSLSSKYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYSCQQYDGVPRTFGQGTTVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"D80 Fab Fragment Light Chain","1","5JQD"
,,,,,,,,,,,,,,,,"QVQLVQSGAEVKKPGSSVKVSCRASGGTGGTFSAYAFTWVRQAPGQGLEWMGGITGMFGTANYAQKFQGRVTITADELTSTAYMELSSLTSEDTALYYCARGLYYYESSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK","Homo sapiens",,"D80 Fab Fragment Heavy Chain","2","5JQD"
"5JQT",,"X-RAY DIFFRACTION",2.07,40.47,"VAPOR DIFFUSION, HANGING DROP",7.4,"2.4 M SODIUM MALONATE",298,"10.1039/c6cc06399c","6M9","5JQT",30.9,"1.36","1.36","Crystal structure of human carbonic anhydrase II in complex with Benzoxaborole at pH 7.4","MGMSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5JQT"
"5JR1",,"X-RAY DIFFRACTION",2.36,47.84,"VAPOR DIFFUSION, HANGING DROP",6,"21% PEG 8000, 0.17M ZnAc, MES, pH6.0",293,"10.1371/journal.pone.0157409",,"5JR1",48.39,"1.601","1.601","Crystal structure of 10E8 gHV-matureL antigen-binding fragment.","EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCARTGKYYDFWSGYPPGEEYFQDWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK","Homo sapiens",,"10E8 heavy chain","1","5JR1"
,,,,,,,,,,,,,,,,"SYELTQETGVSVALGRTVTITCRGDSLRSHYASWYQKKPGQAPILLFYGKNNRPSGVPDRFSGSASGNRASLTISGAQAEDDAEYYCSSRDKSGSRLSVFGGGTKLTVLSQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"10E8 mature light chain","2","5JR1"
"5JR8",,"X-RAY DIFFRACTION",3.84,67.98,"VAPOR DIFFUSION, HANGING DROP",,"1M Na2H/KH2 Phosphate pH 8.2",298,"10.1038/ncomms12973",,"5JR8",41.14,"2.65","2.65","Disposal of Iron by a Mutant form of Siderocalin NGAL","QDSTSDLIPAPPLSSVPLQQNFQDNQFQGKWYVVGLAGNAILREDEDPQKMYATIYELKEDKSYNVTSVLFRDDGCDYWIRTFVPGCQPGEFTLGNIQSYPGLTSYLVRVVSTNYNQFAMVFFKKVSQNQEYFKITLYGRTKELTSELQENFIRFSKSLGLPENNIVFPVPIDQCIDG","Homo sapiens","LCN2, HNL, NGAL","Neutrophil gelatinase-associated lipocalin","1","5JR8"
"5JRB",,"X-RAY DIFFRACTION",2.45,49.77,"VAPOR DIFFUSION, HANGING DROP",,"0.05M Sodium malonate pH6.0, 5% PEG 3350",293,"10.1107/S2053230X1601027X",,"5JRB",258.94,"2.405","2.405","Rad52(1-212) K102A/K133A/E202A mutant","GSHMSGTEEAILGGRDSHPAAGGGSVLCFGQCQYTAEEYQAIQKALRQRLGPEYISSRMAGGGQKVCYIEGHRVINLANEMFGYNGWAHSITQQNVDFVDLNNGAFYVGVCAFVRVQLKDGSYHEDVGYGVSEGLASKALSLEKARKEAVTDGLKRALRSFGNALGNCILDKDYLRSLNKLPRQLPLEVDLTKAKRQDLEPSVEAARYNSCRPNM","Homo sapiens","RAD52","DNA repair protein RAD52 homolog","1","5JRB"
"5JRP",,"X-RAY DIFFRACTION",3.88,68.28,"VAPOR DIFFUSION, HANGING DROP",,"4.5 M NaCl, 0.1 M Tris-HCl, pH7.5",301,"10.1016/j.str.2017.10.005",,"5JRP",47.26,"2","2","crystal structure of monoclonal antibody MR78 Fab","DIQMTQSPSSLSASVGDRVTITCQASQVISNYLNWYQQKPGKAPKLLIYDTSNLKTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYENLQFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLRSPVTKSFNRG","Homo sapiens",,"marberg virus monoclonal antibody MR78 Fab light chain","1","5JRP"
,,,,,,,,,,,,,,,,"QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSVYYSGGASYNPSLKSRATISVDTSKNQFSLNLDSVSAADTAIYYCASIYGSGTFYYYFYMDVWGKGSTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPK","Homo sapiens",,"marberg virus monoclonal antibody MR78 Fab heavy chain","2","5JRP"
"5JRQ",,"X-RAY DIFFRACTION",2.05,40.05,"VAPOR DIFFUSION, HANGING DROP",8.5,"100mM Tris pH 8.5, 14% PEG Monomethyl Ether 2000, and 200mM Trimethyl Amine N-oxide Dihydrate",277,"10.1021/acschembio.6b00529",,"5JRQ",65.13,"2.287","2.287","BRAFV600E Kinase Domain In Complex with Chemically Linked Vemurafenib Inhibitor VEM-6-VEM","GSEFDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHASETKFEMKKLIDIARQTARGMDYLHAKSIIHRDLKSNNIFLHEDNTVKIGDFGLATEKSRWSGSHQFEQLSGSILWMAPEVIRMQDSNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIEMVGRGSLSPDLSKVRSNCPKRMKRLMAECLKKKRDERPSFPRILAEIEELARELSG","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","5JRQ"
"5JRS",,"X-RAY DIFFRACTION",2.27,45.79,"VAPOR DIFFUSION",8.5,"PEG 5000, PEG 8000",298,"10.1021/acs.jmedchem.6b00722","6MV","5JRS",63.42,"1.97","1.97","CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -3,4-DIHYDROQUINAZOLIN-3-YL)PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE","GHMEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","5JRS"
"5JRT",,"X-RAY DIFFRACTION",2.86,57,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350 20%
0.1 MTris-HCl pH 8.5
0.2 M Ammonium Acetate",285.15,"10.1016/j.molcel.2016.06.019",,"5JRT",8.8,"1.53","1.53","Crystal structure of the human Tankyrase 2 (TNKS2) SAM domain (DH902/924RE)","SNAEKKEVPGVDFSITQFVRNLGLEHLMDIFEREQITLRVLVEMGHKELKEIGINAYGHREKLIKGVERLISGQQGL","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5JRT"
"5JS6",,"X-RAY DIFFRACTION",3.21,61.7,"VAPOR DIFFUSION, SITTING DROP",7,"HEPES 0.1 M pH 7.00, sodium formate 3.3 M",291,"10.1021/acs.jmedchem.6b00293",,"5JS6",29.73,"2.002","2.002","Crystal structure of 17beta-hydroxysteroid dehydrogenase 14 T205 variant in complex with NAD.","GHMATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRATIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPSGS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5JS6"
"5JS7",,"SOLUTION NMR",,,,,,,"10.1073/pnas.1604125113",,"5JS7",37.25,,,"Structural model of a apo G-protein alpha subunit determined with NMR residual dipolar couplings and SAXS","GASREVKLLLLGAGESGKSTIVKQMKIIHEAGYSEEECKQYKAVVYSNTIQSIIAIIRAMGRLKIDFGDSARADDARQLFVLAGAAEEGFMTAELAGVIKRLWKDSGVQACFNRSREYQLNDSAAYYLNDLDRIAQPNYIPTQQDVLRTRVKTTGIVETHFTFKDLHFKMFDVGGQRSERKKWIHCFEGVAAIIFCVALSDYDLVLAEDEEMNRMHESMKLFDSICNNKWFTDTSIILFLNKKDLFEEKIKKSPLTICYQEYAGSNTYEEAAAYIQCQFEDLNKRKDTKEIYTHFTCATDTKNVQFVFDAVTDVIIKNNLKDCGLF","Homo sapiens","GNAI1","Guanine nucleotide-binding protein G(i) subunit alpha-1","1","5JS7"
"5JS8",,"SOLUTION NMR",,,,,,,"10.1073/pnas.1604125113",,"5JS8",37.25,,,"Structural Model of a Protein alpha subunit in complex with GDP obtained with SAXS and NMR residual couplings","GASREVKLLLLGAGESGKSTIVKQMKIIHEAGYSEEECKQYKAVVYSNTIQSIIAIIRAMGRLKIDFGDSARADDARQLFVLAGAAEEGFMTAELAGVIKRLWKDSGVQACFNRSREYQLNDSAAYYLNDLDRIAQPNYIPTQQDVLRTRVKTTGIVETHFTFKDLHFKMFDVGGQRSERKKWIHCFEGVAAIIFCVALSDYDLVLAEDEEMNRMHESMKLFDSICNNKWFTDTSIILFLNKKDLFEEKIKKSPLTICYQEYAGSNTYEEAAAYIQCQFEDLNKRKDTKEIYTHFTCATDTKNVQFVFDAVTDVIIKNNLKDCGLF","Homo sapiens","GNAI1","Guanine nucleotide-binding protein G(i) subunit alpha-1","1","5JS8"
"5JSF",,"X-RAY DIFFRACTION",3.22,61.77,"VAPOR DIFFUSION, SITTING DROP",7,"HEPES 0.1 M pH 7.00, sodium formate 3.3 M",291,"10.1021/acs.jmedchem.6b00293",,"5JSF",29.54,"1.842","1.842","Crystal structure of 17beta-hydroxysteroid dehydrogenase 14 S205 variant in complex with NAD.","GHMATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRASIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPSGS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5JSF"
"5JSG",,"X-RAY DIFFRACTION",2.6,52.71,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2M MgCl2, 0.1M HepesNa, 20% PEG 10000",298,"10.1038/nchembio.2377","6P9","5JSG",52.29,"2.5","2.5","Crystal structure of Spindlin1 bound to compound EML405","MHHHHHHGSRRNIVGCRIQHGWKEGNGPVTQWKGTVLDQVPVNPSLYLIKYDGFDCVYGLELNKDERVSALEVLPDRVATSRISDAHLADTMIGKAVEHMFETEDGSKDEWRGMVLARAPVMNTWFYITYEKDPVLYMYQLLDDYKEGDLRIMPDSNDSPPAEREPGEVVDSLVGKQVEYAKEDGSKRTGMVIHQVEAKPSVYFIKFDDDFHIYVYDLVKTS","Homo sapiens","SPIN1, OCR, SPIN","Spindlin-1","1","5JSG"
"5JSJ",,"X-RAY DIFFRACTION",2.58,52.27,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2M MgCl2, 0.1M HepesNa, 25% PEG 3350",298,"10.1038/nchembio.2377","6PD","5JSJ",52.48,"2.348","2.348","Crystal structure of Spindlin1 bound to compound EML631","MHHHHHHGSRRNIVGCRIQHGWKEGNGPVTQWKGTVLDQVPVNPSLYLIKYDGFDCVYGLELNKDERVSALEVLPDRVATSRISDAHLADTMIGKAVEHMFETEDGSKDEWRGMVLARAPVMNTWFYITYEKDPVLYMYQLLDDYKEGDLRIMPDSNDSPPAEREPGEVVDSLVGKQVEYAKEDGSKRTGMVIHQVEAKPSVYFIKFDDDFHIYVYDLVKTS","Homo sapiens","SPIN1, OCR, SPIN","Spindlin-1","1","5JSJ"
"5JSM",,"X-RAY DIFFRACTION",2.39,48.46,"VAPOR DIFFUSION, HANGING DROP",8.5,"100mM Tris pH 8.5, 5% Ethanol, 2% Benzamidine HCl",277,"10.1021/acschembio.6b00529","6NB","5JSM",130.68,"2.19","2.19","BRAFV600E Kinase Domain In Complex with Chemically Linked Vemurafenib Inhibitor VEM-3-VEM","GSEFDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHASETKFEMKKLIDIARQTARGMDYLHAKSIIHRDLKSNNIFLHEDNTVKIGDFGLATEKSRWSGSHQFEQLSGSILWMAPEVIRMQDSNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIEMVGRGSLSPDLSKVRSNCPKRMKRLMAECLKKKRDERPSFPRILAEIEELARELSG","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","5JSM"
"5JT2",,"X-RAY DIFFRACTION",2.41,48.91,"VAPOR DIFFUSION, HANGING DROP",8.5,"100mM Tris pH 8.5
5% Ethanol
2% Benzamidine HCl",277,"10.1021/acschembio.6b00529",,"5JT2",129.89,"2.702","2.702","BRAFV600E Kinase Domain In Complex with Chemically Linked Vemurafenib Inhibitor VEM-BISAMIDE","GSEFDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHASETKFEMKKLIDIARQTARGMDYLHAKSIIHRDLKSNNIFLHEDNTVKIGDFGLATEKSRWSGSHQFEQLSGSILWMAPEVIRMQDSNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIEMVGRGSLSPDLSKVRSNCPKRMKRLMAECLKKKRDERPSFPRILAEIEELARELSG","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","5JT2"
"5JTI",,"X-RAY DIFFRACTION",3.61,65.9,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris pH 5.5
0.2 M Magnesium Chloride
25%  PEG 3350",285.15,"10.1016/j.molcel.2016.06.019",,"5JTI",53.12,"2.9","2.9","Crystal structure of the human Tankyrase 1 (TNKS) SAM domain (D1055R), crystal form 2","SNAERKEGEVAGLDMNISQFLKSLGLEHLRDIFETEQITLRVLADMGHEELKEIGINAYGHRHKLIKGVERLLGGQQGT","Homo sapiens","TNKS, PARP5A, PARPL, TIN1, TINF1, TNKS1","Tankyrase-1","1","5JTI"
"5JTW",,"X-RAY DIFFRACTION",3.41,63.92,"VAPOR DIFFUSION, SITTING DROP",7,"the crystals appeared after mixing C4b at 4 mg/ml in 20 mM HEPES pH 7.5, 100 mM sodium chloride with 100 mM HEPES pH 7.0, 400 mM magnesium chloride, 7.5% PEG8000 and a microseeding stock at the volume ration 1:1:0.5. The crystals appeared in 1-2 weeks and reached the final size in 1 month",292,"10.1107/S2059798316012201",,"5JTW",361.66,"3.5","3.5","Crystal structure of complement C4b re-refined using iMDFF","KPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLRNPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDSLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPNFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLESQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSWYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDSRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPSFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVALGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAGLAFSDGDQWTLSRKRLSCPKEKTT","Homo sapiens","C4A, CO4, CPAMD2","Complement C4-A","1","5JTW"
,,,,,,,,,,,,,,,,"ALEILQEEDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEIPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKANSFLGEKASAGLLGAHAAAITAYALSLTKAPVDLLGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAEMADQASAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASHTTEERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQFSLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTPLQLFEG","Homo sapiens","C4A, CO4, CPAMD2","Complement C4-A","2","5JTW"
,,,,,,,,,,,,,,,,"EAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYYPRVEYGFQVKVLREDSRAAFRLFETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPGKEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQRAACAQLNDFLQEYGTQGCQV","Homo sapiens","C4A, CO4, CPAMD2","Complement C4-A","3","5JTW"
"5JU5",,"X-RAY DIFFRACTION",3.63,66.1,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Bis-Tris pH 5.5
0.2 M Magnesium chloride
PEG 3350 25%",285.15,"10.1016/j.molcel.2016.06.019",,"5JU5",53.12,"2.5","2.5","Crystal structure of the human Tankyrase 1 (TNKS) SAM domain (D1055R), crystal form 1","SNAERKEGEVAGLDMNISQFLKSLGLEHLRDIFETEQITLRVLADMGHEELKEIGINAYGHRHKLIKGVERLLGGQQGT","Homo sapiens","TNKS, PARP5A, PARPL, TIN1, TINF1, TNKS1","Tankyrase-1","1","5JU5"
"5JUW",,"X-RAY DIFFRACTION",3.58,65.68,"VAPOR DIFFUSION, SITTING DROP",4.6,"1.5 M ammonium sulfate, 0.1 M ammonium acetate",291,,,"5JUW",48.39,"2.28","2.28","complex of Dot1l with SS148","GMGEKLELRLKSPVGAEPAVYPWPLPVYDKHHDAAHEIIETIRWVCEEIPDLKLAMENYVLIDYDTKSFESMQRLCDKYNRAIDSIHQLWKGTTQPMKLNTRPSTGLLRHILQQVYNHSVTDPEKLNNYEPFSPEVYGETSFDLVAQMIDEIKMTDDDLFVDLGSGVGQVVLQVAAATNCKHHYGVEKADIPAKYAETMDREFRKWMKWYGKKHAEYTLERGDFLSEEWRERIANTSVIFVNNFAFGPEVDHQLKERFANMKEGGRIVSSKPFAPLNFRINSRNLSDIGTIMRVVELSPLKGSVSWTGKPVSYYLHTIDRTILENYFSSLKNPKLREEQEAARRRQQRESKSNAATPTKGPEGKVAGPADAPMDSGAEEEKAGAATVKKPSPSKARKKKLNKKGRKMAGRKRGRPKKMNTA","Homo sapiens","DOT1L, KIAA1814, KMT4","Histone-lysine N-methyltransferase, H3 lysine-79 specific","1","5JUW"
"5JUZ",,"X-RAY DIFFRACTION",2.74,55.17,"VAPOR DIFFUSION, SITTING DROP",,"0.6 M sodium phosphate, 0.6 M potassium phosphate, 25% glycerol, 0.075 M HEPES, pH 7.5",295,"10.1021/acs.jmedchem.6b01888","YL4","5JUZ",43.67,"2.4","2.4","Crystal structure of human FPPS in complex with an allosteric inhibitor CL-06-057","MGSSHHHHHHSSGRENLYFQGHMNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK","Homo sapiens","FDPS, FPS, KIAA1293","Farnesyl pyrophosphate synthase","1","5JUZ"
"5JV0",,"X-RAY DIFFRACTION",2.74,55.09,"VAPOR DIFFUSION, SITTING DROP",,"0.85 M lithium sulfate, 0.425 M ammonium sulfate, 15% glycerol, 0.085 M tri-sodium citrate, pH 5.6",295,"10.1021/acs.jmedchem.6b01888","YL5","5JV0",44.67,"2.4","2.4","Crystal structure of human FPPS in complex with an allosteric inhibitor CL-08-038","MGSSHHHHHHSSGRENLYFQGHMNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK","Homo sapiens","FDPS, FPS, KIAA1293","Farnesyl pyrophosphate synthase","1","5JV0"
"5JV1",,"X-RAY DIFFRACTION",2.72,54.82,"VAPOR DIFFUSION, SITTING DROP",,"25.5% PEG 8000, 0.17 M sodium acetate, 15% glycerol, 0.085 M sodium cacodylate, pH 6.5",295,"10.1021/acs.jmedchem.6b01888","YL6","5JV1",44.29,"2.3","2.3","Crystal structure of human FPPS in complex with an allosteric inhibitor CL-08-066","MGSSHHHHHHSSGRENLYFQGHMNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK","Homo sapiens","FDPS, FPS, KIAA1293","Farnesyl pyrophosphate synthase","1","5JV1"
"5JV2",,"X-RAY DIFFRACTION",2.69,54.34,"VAPOR DIFFUSION, SITTING DROP",,"1.6 M ammonium phosphate, 20% glycerol, 0.08 M TrisHCl, pH 8.5",295,"10.1021/acs.jmedchem.6b01888","6O3","5JV2",43.95,"2.3","2.3","Crystal structure of human FPPS in complex with an allosteric inhibitor MIT-01-055","MGSSHHHHHHSSGRENLYFQGHMNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK","Homo sapiens","FDPS, FPS, KIAA1293","Farnesyl pyrophosphate synthase","1","5JV2"
"5JW5",,"X-RAY DIFFRACTION",2.65,53.63,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.2 M Ammonium Dihydrogen Phosphate, seeded from crystals obtained from 18% PEG8000, 0.1 M Sodium Cacodylate pH 6.5 and 0.2 M Calcium Acetate",293,"10.1016/j.cell.2016.05.073",,"5JW5",95.02,"1.9","1.9","Structure of MEDI8852 Fab Fragment","QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSYNAVWNWIRQSPSRGLEWLGRTYYRSGWYNDYAESVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARSGHITVFGVNVDAFDMWGQGTMVTVSSASTKGPSVFPLAPSSKSTGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPK","Homo sapiens",,"MEDI8852 Heavy chain","1","5JW5"
,,,,,,,,,,,,,,,,"DIQMTQSPSSLSASVGDRVTITCRTSQSLSSYTHWYQQKPGKAPKLLIYAASSRGSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"MEDI8852 Light chain","2","5JW5"
"5JWK",,"X-RAY DIFFRACTION",3.41,63.9,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes, 1.6mM ammonium sulfate, 3% PEG 400",293,,,"5JWK",41.12,"2.3","2.3","Factor Inhibiting HIF D201E in Complex with Fe, and Alpha-Ketoglutarate","GSHMAATAAEAVASGSGEPREEAGALGPAWDESQLRSYSFPTRPIPRLSQSDPRAEELIENEEPVVLTDTNLVYPALKWDLEYLQENIGNGDFSVYSASTHKFLYYDEKKMANFQNFKPRSNREEMKFHEFVEKLQDIQQRGGEERLYLQQTLNDTVGRKIVMDFLGFNWNWINKQQGKRGWGQLTSNLLLIGMEGNVTPAHYEEQQNFFAQIKGYKRCILFPPDQFECLYPYPVHHPCDRQSQVDFDNPDYERFPNFQNVVGYETVVGPGDVLYIPMYWWHHIESLLNGGITITVNFWYKGAPTPKRIEYPLKAHQKVAIMRNIEKMLGEALGNPQEVGPLLNTMIKGRYN","Homo sapiens","HIF1AN, FIH1","Hypoxia-inducible factor 1-alpha inhibitor","1","5JWK"
"5JWL",,"X-RAY DIFFRACTION",3.41,63.9,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes, 1.6mM ammonium sulfate, 3% PEG 400",293,,,"5JWL",41.13,"2.4","2.4","Factor Inhibiting HIF D201E in Complex with Zn, and Alpha-Ketoglutarate","GSHMAATAAEAVASGSGEPREEAGALGPAWDESQLRSYSFPTRPIPRLSQSDPRAEELIENEEPVVLTDTNLVYPALKWDLEYLQENIGNGDFSVYSASTHKFLYYDEKKMANFQNFKPRSNREEMKFHEFVEKLQDIQQRGGEERLYLQQTLNDTVGRKIVMDFLGFNWNWINKQQGKRGWGQLTSNLLLIGMEGNVTPAHYEEQQNFFAQIKGYKRCILFPPDQFECLYPYPVHHPCDRQSQVDFDNPDYERFPNFQNVVGYETVVGPGDVLYIPMYWWHHIESLLNGGITITVNFWYKGAPTPKRIEYPLKAHQKVAIMRNIEKMLGEALGNPQEVGPLLNTMIKGRYN","Homo sapiens","HIF1AN, FIH1","Hypoxia-inducible factor 1-alpha inhibitor","1","5JWL"
"5JWM",,"X-RAY DIFFRACTION",2.52,51.15,"VAPOR DIFFUSION, SITTING DROP",5.5,"2M ammonium sulfate, 0.1M BisTris (pH 5.5)",293,"10.1038/nchembio.2209","6ON","5JWM",31.25,"1.71","1.71","Bivalent BET Bromodomain Inhibition","SMKDVPDSQQHPAPEKSSKVSEQLKCCSGILKEMFAKKHAAYAWPFYKPVDVEALGLHDYCDIIKHPMDMSTIKSKLEAREYRDAQEFGADVRLMFSNCYKYNPPDHEVVAMARKLQDVFEMRFAKMPDE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5JWM"
"5JXA",,"X-RAY DIFFRACTION",2.89,57.44,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES pH 7.5, 13% PEG 4,000,
10 mM CuCl2, 350 mM NaCl",293,"10.1016/j.str.2016.06.012",,"5JXA",49.26,"1.6","1.6","Crystal structure of ligand-free VRC03 antigen-binding fragment.","QVQLVQSGAVIKTPGSSVKISCRASGYNFRDYSIHWVRLIPDKGFEWIGWIKPLWGAVSYARQLQGRVSMTRQLSQDPDDPDWGVAYMEFSGLTPADTAEYFCVRRGSCDYCGDFPWQYWGQGTVVVVSSASTKGPSVFPLAPSSKSTSSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD","Homo sapiens",,"VRC03 Heavy chain","1","5JXA"
,,,,,,,,,,,,,,,,"EIVLTQSPGILSLSPGETATLFCKASQGGNAMTWYQKRRGQVPRLLIYDTSRRASGVPDRFVGSGSGTDFFLTINKLDREDFAVYYCQQFEFFGLGSELEVHRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"VRC03 Light chain","2","5JXA"
"5JXG",,"X-RAY DIFFRACTION",3.73,67.05,"VAPOR DIFFUSION, SITTING DROP",,"crystallization solution: 100 mM MES, 200 mM K/NaH2PO4, pH 5.5-6.0, 3-4 M NaCl, 3% DMSO; reservoir solution: 3-4 M NaCl",293.15,"10.1073/pnas.1613630113",,"5JXG",52.73,"1.8","1.8","Structure of the unliganded form of the proprotein convertase furin.","DVYQEPTDPKFPQQWYLSGVTQRDLNVKAAWAQGYTGHGIVVSILDDGIEKNHPDLAGNYDPGASFDVNDQDPDPQPRYTQMNDNRHGTRCAGEVAAVANNGVCGVGVAYNARIGGVRMLDGEVTDAVEARSLGLNPNHIHIYSASWGPEDDGKTVDGPARLAEEAFFRGVSQGRGGLGSIFVWASGNGGREHDSCNCDGYTNSIYTLSISSATQFGNVPWYSEACSSTLATTYSSGNQNEKQIVTTDLRQKCTESHTGTSASAPLAAGIIALTLEANKNLTWRDMQHLVVQTSKPAHLNANDWATNGVGRKVSHSYGYGLLDAGAMVALAQNWTTVAPQRKCIIDILTEPKDIGKRLEVRKTVTACLGEPNHITRLEHAQARLTLSYNRRGDLAIHLVSPMGTRSTLLAARPHDYSADGFNDWAFMTTHSWDEDPSGEWVLEIENTSEANNYGTLTKFTLVLYGTASGSLVPRGSHHHHHH","Homo sapiens","FURIN, FUR, PACE, PCSK3","Furin","1","5JXG"
"5JXI",,"X-RAY DIFFRACTION",3.76,67.3,"VAPOR DIFFUSION, SITTING DROP",,"crystallization solution: 100 mM MES, 200 mM K/NaH2PO4, pH 5.5-6.0, 3-4 M NaCl, 3% DMSO; reservoir solution: 3-4 M NaCl",293.15,"10.1073/pnas.1613630113",,"5JXI",52.63,"2","2","Structure of the unliganded form of the proprotein convertase furin in presence of EDTA.","DVYQEPTDPKFPQQWYLSGVTQRDLNVKAAWAQGYTGHGIVVSILDDGIEKNHPDLAGNYDPGASFDVNDQDPDPQPRYTQMNDNRHGTRCAGEVAAVANNGVCGVGVAYNARIGGVRMLDGEVTDAVEARSLGLNPNHIHIYSASWGPEDDGKTVDGPARLAEEAFFRGVSQGRGGLGSIFVWASGNGGREHDSCNCDGYTNSIYTLSISSATQFGNVPWYSEACSSTLATTYSSGNQNEKQIVTTDLRQKCTESHTGTSASAPLAAGIIALTLEANKNLTWRDMQHLVVQTSKPAHLNANDWATNGVGRKVSHSYGYGLLDAGAMVALAQNWTTVAPQRKCIIDILTEPKDIGKRLEVRKTVTACLGEPNHITRLEHAQARLTLSYNRRGDLAIHLVSPMGTRSTLLAARPHDYSADGFNDWAFMTTHSWDEDPSGEWVLEIENTSEANNYGTLTKFTLVLYGTASGSLVPRGSHHHHHH","Homo sapiens","FURIN, FUR, PACE, PCSK3","Furin","1","5JXI"
"5JY3",,"X-RAY DIFFRACTION",2.4,48.83,"VAPOR DIFFUSION",,,298,"10.1021/acsmedchemlett.6b00234","6OX","5JY3",124.79,"2.4","2.4","CRYSTAL STRUCTURE OF LXRbeta (NUCLEAR RECEPTOR SUBFAMILY 1, GROUP H, MEMBER 2) COMPLEXED WITH BMS-852927","MHHHHHHGENLYFQGSEGEGVQLTAAQELMIQQLVAAQLQCNKRSFSDQPKVTPWPLGADPQSRDARQQRFAHFTELAIISVQEIVDFAKQVPGFLQLGREDQIALLKASTIEIMLLETARRYNHETECITFLKDFTYSKDDFHRAGLQVEFINPIFEFSRAMRRLGLDDAEYALLIAINIFSADRPNVQEPGRVEALQQPYVEALLSYTRIKRPQDQLRFPRMLMKLVSLRTLSSVHSEQVFALRLQDKKLPPLLSEIWDVHE","Homo sapiens","NR1H2, LXRB, NER, UNR","Oxysterols receptor LXR-beta","1","5JY3"
"5JYO",,"X-RAY DIFFRACTION",5.27,76.65,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris propane (pH 7), 3% DMSO, 1.8 M LiSO4",293,"10.18632/oncotarget.10791","63J","5JYO",295.36,"2.098","2.098","Allosteric inhibition of Kidney Isoform of Glutaminase","MGSSHHHHHHSSGLVPRGSMIPDFMSFTSHIDELYESAKKQSGGKVADYIPQLAKFSPDLWGVSVCTVDGQRHSTGDTKVPFCLQSCVKPLKYAIAVNDLGTEYVHRYVGKEPSGLRFNKLFLNEDDKPHNPMVNAGAIVVTSLIKQGVNNAEKFDYVMQFLNKMAGNEYVGFSNATFQSERESGDRNFAIGYYLKEKKCFPEGTDMVGILDFYFQLCSIEVTCESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSGVAGGILLVVPNVMGMMCWSPPLDKMGNSVKGIHFCHDLVSLCNFHNYDNL","Homo sapiens","GLS, GLS1, KIAA0838","Glutaminase kidney isoform, mitochondrial","1","5JYO"
"5JYP",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, HANGING DROP",7,"0.1 M Bis-Tris propane (pH 7), 4% DMSO, 2 M LiSO4",293,"10.18632/oncotarget.10791",,"5JYP",37.15,"2.74","2.74","Allosteric inhibition of Kidney Isoform of Glutaminase","MGSSHHHHHHSSGLVPRGSMIPDFMSFTSHIDELYESAKKQSGGKVADYIPQLAKFSPDLWGVSVCTVDGQRHSTGDTKVPFCLQSCVKPLKYAIAVNDLGTEYVHRYVGKEPSGLRFNKLFLNEDDKPHNPMVNAGAIVVTSLIKQGVNNAEKFDYVMQFLNKMAGNEYVGFSNATFQSERESGDRNFAIGYYLKEKKCFPEGTDMVGILDFYFQLCSIEVTCESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSGVAGGILLVVPNVMGMMCWSPPLDKMGNSVKGIHFCHDLVSLCNFHNYDNL","Homo sapiens","GLS, GLS1, KIAA0838","Glutaminase kidney isoform, mitochondrial","1","5JYP"
"5JZ6",,"X-RAY DIFFRACTION",3.02,59.32,"VAPOR DIFFUSION, SITTING DROP",7,"1mM MMT buffer (DL-Malic acid, MES, Tris base), 25% PEG1500, 1 mM MnCl2, 2 mM N-oxalylglycine, 18 mg/ml protein",277,"10.1038/s41467-019-12711-7",,"5JZ6",49.96,"2.354","2.354","Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese and L-malate","KPKLLNKFDKTIKAELDAAEKLRKRGKIEEAVNAFKELVRKYPQSPRARYGKAQCEDDLAEKRRSNEVLRGAIETYQEVASLPDVPADLLKLSLKRRSDRQQFLGHMRGSLLTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKKVYEEVLSVTPNDGFAKVHYGFILKAQNKIAESIPYLKEGIESGDPGTDDGRFYFHLGDAMQRVGNKEAYKWYELGHKRGHFASVWQRSLYNVNGLKAQPWWTPKETGYTELVKSLERNWKLIRDEGLAVMDKAKGLFLPEDENLREKGDWSQFTLWQQGRRNENACKGAPKTCTLLEKFPETTGCRRGQIKYSIMHPGTHVWPHTGPTNCRLRMHLGLVIPKEGCKIRCANETKTWEEGKVLIFDDSFEHEVWQDASSFRLIFIVDVWHPELTPQQRRSLPAI","Homo sapiens","ASPH, BAH","Aspartyl/asparaginyl beta-hydroxylase","1","5JZ6"
"5JZA",,"X-RAY DIFFRACTION",2.95,58.33,"VAPOR DIFFUSION, SITTING DROP",9,"100 mM bicine, 100 mM sodium chloride, 27% PEG 550 MME, 1 mM manganese chloride, 2 mM N-oxalylglycine, 18 mg/ml protein",277,"10.1038/s41467-019-12711-7",,"5JZA",49.98,"2.14","2.14","Aspartyl/Asparaginyl beta-hydroxylase (AspH)oxygenase and TPR domains in complex with manganese and N-oxalylglycine","KPKLLNKFDKTIKAELDAAEKLRKRGKIEEAVNAFKELVRKYPQSPRARYGKAQCEDDLAEKRRSNEVLRGAIETYQEVASLPDVPADLLKLSLKRRSDRQQFLGHMRGSLLTLQRLVQLFPNDTSLKNDLGVGYLLIGDNDNAKKVYEEVLSVTPNDGFAKVHYGFILKAQNKIAESIPYLKEGIESGDPGTDDGRFYFHLGDAMQRVGNKEAYKWYELGHKRGHFASVWQRSLYNVNGLKAQPWWTPKETGYTELVKSLERNWKLIRDEGLAVMDKAKGLFLPEDENLREKGDWSQFTLWQQGRRNENACKGAPKTCTLLEKFPETTGCRRGQIKYSIMHPGTHVWPHTGPTNCRLRMHLGLVIPKEGCKIRCANETKTWEEGKVLIFDDSFEHEVWQDASSFRLIFIVDVWHPELTPQQRRSLPAI","Homo sapiens","ASPH, BAH","Aspartyl/asparaginyl beta-hydroxylase","1","5JZA"
"5JZC","4.2","ELECTRON MICROSCOPY",,,,,,,"10.1093/nar/gkw783",,"5JZC",259.06,"4.2, 4.2",,"helical filament","MAMQMQLEANADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGFHTVEAVAYAPKKELINIKGISEAKADKILAEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKLLQGGIETGSITEMFGEFRTGKTQICHTLAVTCQLPIDRGGGEGKAMYIDTEGTFRPERLLAVAERYGLSGSDVLDNVAYARAFNTDHQTQLLYQASAMMVESRYALLIVDSATALYRTDYSGRGELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAADPKKPIGGNIIAHASTTRLYLRKGRGETRICKIYDSPCLPEAEAMFAINADGVGDAKD","Homo sapiens","RAD51, RAD51A, RECA","DNA repair protein RAD51 homolog 1","1","5JZC"
"5JZJ",,"X-RAY DIFFRACTION",2.04,39.56,"EVAPORATION",6.5,"PEG MME 5000, ammonium sulphate",298,"10.1016/j.str.2016.07.008",,"5JZJ",67.95,"1.71","1.71","Crystal structure of DCLK1-KD in complex with AMPPN","MHHHHHHHHGSENLYFQGSGEEVSEEGFQIPATITERYKVGRTIGDGNFAVVKECVERSTAREYALKIIKKSKCRGKEHMIQNEVSILRRVKHPNIVLLIEEMDVPTELYLVMELVKGGDLFDAITSTNKYTERDASGMLYNLASAIKYLHSLNIVHRDIKPENLLVYEHQDGSKSLKLGDFGLATIVDGPLYTVCGTPTYVAPEIIAETGYGLKVDIWAAGVITYILLCGFPPFRGSGDDQEVLFDQILMGQVDFPSPYWDNVSDSAKELITMMLLVDVDQRFSAVQVLEHPWVND","Homo sapiens","DCLK1, DCAMKL1, DCDC3A, KIAA0369","Serine/threonine-protein kinase DCLK1","1","5JZJ"
"5JZN",,"X-RAY DIFFRACTION",3.83,67.89,"EVAPORATION",7.5,"PEG400, Hepes",298,"10.1016/j.str.2016.07.008",,"5JZN",63.92,"2.85","2.85","Crystal structure of DCLK1-KD in complex with NVP-TAE684","GSGEEVSEEGFQIPATITERYKVGRTIGDGNFAVVKECVERSTAREYALKIIKKSKCRGKEHMIQNEVSILRRVKHPNIVLLIEEMDVPTELYLVMELVKGGDLFDAITSTNKYTERDASGMLYNLASAIKYLHSLNIVHRDIKPENLLVYEHQDGSKSLKLGDFGLATIVDGPLYTVCGTPTYVAPEIIAETGYGLKVDIWAAGVITYILLCGFPPFRGSGDDQEVLFDQILMGQVDFPSPYWDNVSDSAKELITMMLLVDVDQRFSAVQVLEHPWVND","Homo sapiens","DCLK1, DCAMKL1, DCDC3A, KIAA0369","Serine/threonine-protein kinase DCLK1","1","5JZN"
"5JZV",,"X-RAY DIFFRACTION",3.73,67.03,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.01M MAGNESIUM CHLORIDE HEXAHYDRATE,
 0.05M MES MONOHYDRATE PH 5.6, 1.8M LITHIUM SULFATE MONOHYDRATE,
 VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293,"10.1038/ncomms12310",,"5JZV",24,"2.07","2.07","The structure of D77G hCINAP-ADP","MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSMLLPNILLTGTPGVGKTTLGKELASKSGLKYINVGDLAREEQLYDGYDEEYDCPILDEDRVVDELDNQMREGGVIVGYHGCDFFPERWFHIVFVLRTDTNVLYERLETRGYNEKKLTDNIQCEIFQVLYEEATASYKEEIVHQLPSNKPEELENNVDQILKWIEQWIKDHNS","Homo sapiens","AK6, CINAP, AD-004, CGI-137","Adenylate kinase isoenzyme 6","1","5JZV"
"5K00",,"X-RAY DIFFRACTION",2.6,52.71,"VAPOR DIFFUSION, SITTING DROP",,"100mM Hepes pH 7.6, 0.2M NaCl, 13.3% PEG 3350",294,"10.1021/acs.jmedchem.7b00033","6PV","5K00",39.53,"1.77","1.77","MELK in complex with NVS-MELK5","MDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKIMDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQMLQVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCVTELSVHHRNNRQTMEDLISLWQYDHLTATYLLLLAKKARGKPVHHHHHH","Homo sapiens","MELK, KIAA0175","Maternal embryonic leucine zipper kinase","1","5K00"
"5K02",,"X-RAY DIFFRACTION",4.29,71.3,"VAPOR DIFFUSION, HANGING DROP",6.5,"T2D was crystallized in a buffer of 2 M (NH4)2SO4, 0.1 M Sodium Cacodylate, 20% MPD and 10 mM ZnCl2 (pH 6.5) after a period of approximately 5 months.",298,"10.1016/j.str.2016.08.011",,"5K02",383.29,"1.99","1.99","Structure of human SOD1 with T2D mutation","ADKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTSAGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVVHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ","Homo sapiens","SOD1","Superoxide dismutase [Cu-Zn]","1","5K02"
"5K0H",,"X-RAY DIFFRACTION",2.46,50.05,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, 12-18 % PEG6000, 5 mM CaCl2",293,"10.2174/157340606777724040","6PK","5K0H",32.52,"2.2","2.2","Human factor Xa in complex with synthetic inhibitor benzylsulfonyl-dSer(Benzyl)-Gly-4-amidinobenzylamide","IVGGQECKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGEAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGIVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSGGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKT","Homo sapiens","F10","Coagulation factor X","1","5K0H"
,,,,,,,,,,,,,,,,"LCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLE","Homo sapiens","F10","Coagulation factor X","2","5K0H"
"5K0I",,"X-RAY DIFFRACTION",4.12,70.12,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M tris pH 9.4, 36% PEG 1K",294,"10.1016/j.bmcl.2016.08.023","6PW","5K0I",19.02,"1.3","1.3","mpges1 bound to an inhibitor","MALPAHSLVMSSPALPAFLLCSTLLVIKMYVVAIITGQVRLRKKAFANPEDALRHGGPQYCRSDPDVERCLRAHRNDMETIYPFLFLGFVYSFLGPNPFVAWMHFLVFLVGRVAHTVAYLGKLRAPIRSVTYTLAQLPCASMALQILWEAARHL","Homo sapiens","PTGES, MGST1L1, MPGES1, PGES, PIG12","Prostaglandin E synthase","1","5K0I"
"5K0K",,"X-RAY DIFFRACTION",2.21,44.37,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein at 32.5 mg/mL (in 20 mM Tris pH 8.0, 500 mM NaCl, 2mM BME) was incubated overnight with inhibitor at 2.5 mM final concentration, and then was mixed 1:1 with crystallization solution (27-33% (v/v) Peg 400, 200 mM MgCl2, 100 mM Tris pH 8.5).",285.2,"10.1021/acsmedchemlett.6b00221",,"5K0K",72.94,"2.545","2.545","Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC2434","MGSSHHHHHHSSGLVPRGSEELQNKLEDVVIDRNLLILGKILGEGEFGSVMEGNLKQEDGTSLKVAVKTMKLDNSSQREIEEFLSEAACMKDFSHPNVIRLLGVCIEMSSQGIPKPMVILPFMKYGDLHTYLLYSRLETGPKHIPLQTLLKFMVDIALGMEYLSNRNFLHRDLAARNCMLRDDMTVCVADFGLSKKIYSGDYYRQGRIAKMPVKWIAIESLADRVYTSKSDVWAFGVTMWEIATRGMTPYPGVQNHEMYDYLLHGHRLKQPEDCLDELYEIMYSCWRTDPLDRPTFSVLRLQLEKLLESLPDV","Homo sapiens","MERTK, MER","Tyrosine-protein kinase Mer","1","5K0K"
"5K0M",,"X-RAY DIFFRACTION",2.62,53.06,"VAPOR DIFFUSION",8.5,"3.08M Sodium Formate, 20% Glycerol, 0.1M Tris pH8.5",290,"10.1038/nchembio.2306",,"5K0M",43.42,"1.83","1.83","Targeting the PRC2 complex through a novel protein-protein interaction inhibitor of EED","VPRGSHMKCKYSFKCVNSLKEDHNQPLFGVQFNWHSKEGDPLVFATVGSNRVTLYECHSQGEIRLLQSYVDADADENFYTCAWTYDSNTSHPLLAVAGSRGIIRIINPITMQCIKHYVGHGNAINELKFHPRDPNLLLSVSKDHALRLWNIQTDTLVAIFGGVEGHRDEVLSADYDLLGEKIMSCGMDHSLKLWRINSKRMMNAIKESYDYNPNKTNRPFISQKIHFPDFSTRDIHRNYVDCVRWLGDLILSKSCENAIVCWKPGKMEDDIDKIKPSESNVTILGRFDYSQCDIWYMRFSMDFWQKMLALGNQVGKLYVWDLEVEDPHKAKCTTLTHHKCGAAIRQTSFSRDSSILIAVCDDASIWRWDRLR","Homo sapiens","EED","Polycomb protein EED","1","5K0M"
"5K0X",,"X-RAY DIFFRACTION",2.25,45.26,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein at 32.5 mg/mL (in 20 mM Tris pH 8.0, 500 mM NaCl, 2mM BME) was incubated overnight with inhibitor at 2.5 mM final concentration, and then was mixed 1:1 with crystallization solution (27-33% (v/v) Peg 400, 200 mM MgCl2, 100 mM Tris pH 8.5).",286,"10.1002/cmdc.201600589","K0X","5K0X",72.9,"2.231","2.231","Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase MER in complex with inhibitor UNC2541","MGSSHHHHHHSSGLVPRGSEELQNKLEDVVIDRNLLILGKILGEGEFGSVMEGNLKQEDGTSLKVAVKTMKLDNSSQREIEEFLSEAACMKDFSHPNVIRLLGVCIEMSSQGIPKPMVILPFMKYGDLHTYLLYSRLETGPKHIPLQTLLKFMVDIALGMEYLSNRNFLHRDLAARNCMLRDDMTVCVADFGLSKKIYSGDYYRQGRIAKMPVKWIAIESLADRVYTSKSDVWAFGVTMWEIATRGMTPYPGVQNHEMYDYLLHGHRLKQPEDCLDELYEIMYSCWRTDPLDRPTFSVLRLQLEKLLESLPDV","Homo sapiens","MERTK, MER","Tyrosine-protein kinase Mer","1","5K0X"
"5K10","3.8","ELECTRON MICROSCOPY",,,,,,,"10.1016/j.cell.2016.05.040",,"5K10",94.16,"3.8, 3.8",,"Cryo-EM structure of isocitrate dehydrogenase (IDH1)","KKISGGSVVEMQGDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDAAEAIKKHNVGVKCATITPDEKRVEEFKLKQMWKSPNGTIRNILGGTVFREAIICKNIPRLVSGWVKPIIIGCHAYGDQYRATDFVVPGPGKVEITYTPSDGTQKVTYLVHNFEEGGGVAMGMYNQDKSIEDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFEAQKIWYEHRLIDDMVAQAMKSEGGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVLVCPDGKTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRAKLDNNKELAFFANALEEVSIETIEAGFMTKDLAACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAK","Homo sapiens","IDH1, PICD","Isocitrate dehydrogenase [NADP] cytoplasmic","1","5K10"
"5K11","3.8","ELECTRON MICROSCOPY",,,,,,,"10.1016/j.cell.2016.05.040",,"5K11",94.16,"3.8, 3.8",,"Cryo-EM structure of isocitrate dehydrogenase (IDH1) in inhibitor-bound state","KKISGGSVVEMQGDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDAAEAIKKHNVGVKCATITPDEKRVEEFKLKQMWKSPNGTIRNILGGTVFREAIICKNIPRLVSGWVKPIIIGCHAYGDQYRATDFVVPGPGKVEITYTPSDGTQKVTYLVHNFEEGGGVAMGMYNQDKSIEDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFEAQKIWYEHRLIDDMVAQAMKSEGGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVLVCPDGKTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRAKLDNNKELAFFANALEEVSIETIEAGFMTKDLAACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAK","Homo sapiens","IDH1, PICD","Isocitrate dehydrogenase [NADP] cytoplasmic","1","5K11"
"5K13",,"X-RAY DIFFRACTION",2.37,48.1,"VAPOR DIFFUSION",,"10-20% PEG 3350, 0.2M di-ammonium citrate",298,"10.1016/j.bmcl.2016.05.056","6Q7","5K13",28.16,"1.85","1.85","Crystal structure of the RAR alpha ligand-binding domain in complex with an antagonist","TPEVGELIEKVRKAHQETFPALCQLGKYTTNNSSEQRVSLDIDLWDKFSELSTKCIIKTVEFAKQLPGFTTLTIADQITLLKAACLDILILRICTRYTPEQDTMTFSDGLTLNRTQMHNAGFGPLTDLVFAFANQLLPLEMDDAETGLLSAICLICGDRQDLEQPDRVDMLQEPLLEALKVYVRKRRPSRPHMFPKMLMKITDLRSISAKGAERVITLKMEIPGSMPPLIQEMLENSEGLDTLSGQ","Homo sapiens","RARA, NR1B1","Retinoic acid receptor alpha","1","5K13"
"5K16",,"X-RAY DIFFRACTION",2.52,51.24,"VAPOR DIFFUSION, HANGING DROP",7,"0.1 M Tris-HCl, 18% PEG 3350, 0.2 M Lithium Sulfate",277,"10.1016/j.molcel.2016.05.031",,"5K16",82.83,"2.599","2.599","Crystal structure of free Ubiquitin-specific protease 12","MGANASALEKEIGPEQFPVNEHYFGLVNFGNTCYCNSVLQALYFCRPFREKVLAYKSQPRKKESLLTCLADLFHSIATQKKKVGVIPPKKFITRLRKENELFDNYMQQDAHEFLNYLLNTIADILQEERKQEKQNGRLPNGNIDNENNNSTPDPTWVHEIFQGTLTNETRCLTCETISSKDEDFLDLSVDVEQNTSITHCLRGFSNTETLCSEYKYYCEECRSKQEAHKRMKVKKLPMILALHLKRFKYMDQLHRYTKLSYRVVFPLELRLFNTSGDATNPDRMYDLVAVVVHCGSGPNRGHYIAIVKSHDFWLLFDDDIVEKIDAQAIEEFYGLTSDISKNSESGYILFYQSRD","Homo sapiens","USP12, UBH1, USP12L1","Ubiquitin carboxyl-terminal hydrolase 12","1","5K16"
"5K19",,"X-RAY DIFFRACTION",2.1,41.36,"VAPOR DIFFUSION, HANGING DROP",5,"0.1 M sodium citrate, 7% PEG 3350, 0.15 M NaCl",277,"10.1016/j.molcel.2016.05.031",,"5K19",189.59,"2.602","2.602","Crystal structure of WD repeat-containing protein 20","MATEGGGKEMNEIKTQFTTREGLYKLLPHSEYSRPNRVPFNSQGSNPVRVSFVNLNDQSGNGDRLCFNVGRELYFYIYKGVRKAADLSKPIDKRIYKGTQPTCHDFNHLTATAESVSLLVGFSAGQVQLIDPIKKETSKLFNEERLIDKSRVTCVKWVPGSESLFLVAHSSGNMYLYNVEHTCGTTAPHYQLLKQGESFAVHTCKSKSTRNPLLKWTVGEGALNEFAFSPDGKFLACVSQDGFLRVFNFDSVELHGTMKSYFGGLLCVCWSPDGKYIVTGGEDDLVTVWSFVDCRVIARGHGHKSWVSVVAFDPYTTSVEEGDPMEFSGSDEDFQDLLHFGRDRANSTQSRLSKRNSTDSRPVSVTYRFGSVGQDTQLCLWDLTEDILFPHQPLSRARTHTNVMNATSPPAGSNGNSVTTPGNSVPPPLPRSNSLPHSAVSNAGSKSSVMDGAIASGVSKFATLSLHDRKERHHEKDHKRNHSMGHISSKSSDKLNLVTKTKTDPAKTLGTPLCPRMEDVPLLEPLICKKIAHERLTVLIFLEDCIVTACQEGFICTWGRPGKVVSFNP","Homo sapiens","WDR20","WD repeat-containing protein 20","1","5K19"
"5K1I",,"X-RAY DIFFRACTION",2.59,52.45,"VAPOR DIFFUSION",7.5,"19% PEG 3350, 36 % Ethylene Glycol and 10 % Isopropanol as a precipitant",293,"10.1021/acs.jmedchem.6b00829",,"5K1I",304.37,"2.61","2.61","PDE4 crystal structure in complex with small molecule inhibitor","TEQEDVLAKELEDVNKWGLHVFRIAELSGNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTHVLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHHLAVGFKLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGMEISPMCDKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIP","Homo sapiens","PDE4D, DPDE3","cAMP-specific 3',5'-cyclic phosphodiesterase 4D","1","5K1I"
"5K1J",,"X-RAY DIFFRACTION",2.29,46.24,"VAPOR DIFFUSION, SITTING DROP",6,"protein: 10 mg/ml Dialysed in 100 milli-M NaCl, 50 milli-M sodium acetate, pH 5.5
precipitant: 21% polyethylene glycol 4,000 (PEG4K), 0.14 M imidazole malate, pH 6.0
cryosoak: 40% SM2 (12.5 % ethylene glycol, 12.5 % glycerol, 12.5 %
1,2-propanediol, 25 % DMSO and 37.5% 1,4-dioxane) 50% PEG 8K and 0.2 milli-M of rhenium tris-carbonyl Pyta-C8 derivative.",293,"10.1016/j.jsb.2016.07.002",,"5K1J",26.37,"1.69","1.69","Human TTR altered by a rhenium tris-carbonyl Pyta-C8 derivative","CPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNP","Homo sapiens","TTR, PALB","Transthyretin","1","5K1J"
"5K1N",,"X-RAY DIFFRACTION",2.29,46.23,"VAPOR DIFFUSION, SITTING DROP",6,"protein: 10 mg/ml Dialysed in 100 milli-M NaCl, 50 milli-M sodium acetate, pH 5.5
precipitant: 21% polyethylene glycol 4,000 (PEG4K), 0.14 M imidazole malate, pH 6.0 + 3.6% polyethylene glycol monomethyl ether (MPEG5K), 30 mM sodium
acetate pH 5.5
cryosoak: 40% SM3 (25 % diethylene glycol + 25 % ethylene glycol + 25 % glycerol + 25 % 1,4-dioxane) 50% PEG 8K and 0.5 milli-M of rhenium tris-carbonyl Pyta-C12 derivative.",293,"10.1016/j.jsb.2016.07.002",,"5K1N",26.92,"1.81","1.81","Human TTR altered by a rhenium tris-carbonyl Pyta-C12 derivative","CPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5K1N"
"5K1V",,"X-RAY DIFFRACTION",2.87,57.18,"VAPOR DIFFUSION",6.2,"9 %(w/v) PEG 8000, 20 %(v/v) ethylene glycol, 69 mM 2-(N-morpholino)ethanesulfonic acid (MES), 31 mM imidazole",277,"10.1021/acsmedchemlett.6b00505","6PX","5K1V",228.03,"2.897","2.897","Crystal structure of Endoplasmic Reticulum aminopeptidase 2 (ERAP2) in complex with a diaminobenzoic acid derivative ligand.","MFHSSAMVNSHRKPMFNIHRGFYCLTAILPQICICSQFSVPSSYHFTEDPGAFPVATNGERFPWQELRLPSVVIPLHYDLFVHPNLTSLDFVASEKIEVLVSNATQFIILHSKDLEITNATLQSEEDSRYMKPGKELKVLSYPAHEQIALLVPEKLTPHLKYYVAMDFQAKLGDGFEGFYKSTYRTLGGETRILAVTDFEPTQARMAFPCFDEPLFKANFSIKIRRESRHIALSNMPKVKTIELEGGLLEDHFETTVKMSTYLVAYIVCDFHSLSGFTSSGVKVSIYASPDKRNQTHYALQASLKLLDFYEKYFDIYYPLSKLDLIAIPDFAPGAMENWGLITYRETSLLFDPKTSSASDKLWVTRVIAHELAHQWFGNLVTMEWWNDIWLKEGFAKYMELIAVNATYPELQFDDYFLNVCFEVITKDSLNSSRPISKPAETPTQIQEMFDEVSYNKGACILNMLKDFLGEEKFQKGIIQYLKKFSYRNAKNDDLWSSLSNSCLESDFTSGGVCHSDPKMTSNMLAFLGENAEVKEMMTTWTLQKGIPLLVVKQDGCSLRLQQERFLQGVFQEDPEWRALQERYLWHIPLTYSTSSSNVIHRHILKSKTDTLDLPEKTSWVKFNVDSNGYYIVHYEGHGWDQLITQLNQNHTLLRPKDRVGLIHDVFQLVGAGRLTLDKALDMTYYLQHETSSPALLEGLSYLESFYHMMDRRNISDISENLKRYLLQYFKPVIDRQSWSDKGSVWDRMLRSALLKLACDLNHAPCIQKAAELFSQWMESSGKLNIPTDVLKIVYSVGAQTTAGWNYLLEQYELSMSSAEQNKILYALSTSKHQEKLLKLIELGMEGKVIKTQNLAALLHAIARRPKGQQLAWDFVRENWTHLLKKFDLGSYDIRMIISGTTAHFSSKDKLQEVKLFFESLEAQGSHLDIFQTVLETITKNIKWLEKNLPTLRTWLMVNTRHHHHHH","Homo sapiens","ERAP2, LRAP","Endoplasmic reticulum aminopeptidase 2","1","5K1V"
"5K20",,"X-RAY DIFFRACTION",3.07,59.87,"VAPOR DIFFUSION, HANGING DROP",5.5,"2.1 M Sodium Formate
100 mM Sodium Citrate",293,,,"5K20",71.05,"2.2","2.2","Caspase-7 S239E Phosphomimetic","MADDQGCIEEQGVEDSANEDSVDAKPDRSSFVPSLFSKKKKNVTMRSIKTTRDRVPTYQYNMNFEKLGKCIIINNKNFDKVTGMGVRNGTDKDAEALFKCFRSLGFDVIVYNDCSCAKMQDLLKKASEEDHTNAACFACILLSHGEENVIYGKDGVTPIKDLTAHFRGDRCKTLLEKPKLFFIQACRGTELDDGIQAD","Homo sapiens","CASP7, MCH3","Caspase-7 large subunit","1","5K20"
,,,,,,,,,,,,,,,,"SGPINDTDANPRYKIPVEADFLFAYSTVPGYYSWRSPGRGEWFVQALCSILEEHGKDLEIMQILTRVNDRVARHFESQSDDPHFHEKKQIPCVVSMLTKELYFSQLEHHHHHH","Homo sapiens","CASP7, MCH3","Caspase-7 small subunit","2","5K20"
"5K28",,"X-RAY DIFFRACTION",2.67,53.91,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.4M NaMalonate pH 6.4",298,"10.1074/jbc.RA117.000262",,"5K28",13.8,"1.5","1.5","Structure of the unbound SH3 domain of MLK3","HMPVWTALFDYEPSGQDELALRKGDRVEVLSRDAAISGDEGWWAGQVGGQVGIFPSNYVSRGGG","Homo sapiens","MAP3K11, MLK3, PTK1, SPRK","Mitogen-activated protein kinase kinase kinase 11","1","5K28"
"5K31",,"X-RAY DIFFRACTION",3.37,63.55,"VAPOR DIFFUSION, HANGING DROP",,"18 % PEG 4000 and 0.1 M Tris pH 8.0",292,"10.1038/ncomms14671",,"5K31",172.93,"2.2","2.2","Crystal structure of Human fibrillar procollagen type I C-propeptide Homo-trimer","ETGHHHHHHDDANVVRDRDLEVDTTLKSLSQQIENIRSPEGSRKNPARTCRDLKMCHSDWKSGEYWIDPNQGCNLDAIKVFCNMETGETCVYPTQPSVAQKNWYISKNPKDKRHVWFGESMTDGFQFEYGGQGSDPADVAIQLTFLRLMSTEASQQITYHCKNSVAYMDQQTGNLKKALLLQGSNEIEIRAEGNSRFTYSVTVDGCTSHTGAWGKTVIEYKTTKSSRLPIIDVAPLDVGAPDQEFGFDVGPVCFL","Homo sapiens","COL1A1","Collagen alpha-1(I) chain","1","5K31"
"5K32",,"X-RAY DIFFRACTION",2.64,53.39,"VAPOR DIFFUSION",7.5,"19% PEG 3350, 36 % Ethylene Glycol and 10 % Isopropanol as a precipitant",293,"10.1021/acs.jmedchem.7b01751",,"5K32",77.7,"1.99","1.99","PDE4D crystal structure in complex with small molecule inhibitor","AQEDVLAKELEDVNKWGLHVFRIAELSGNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTHVLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHHLAVGFKLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGMEISPMCDKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIP","Homo sapiens","PDE4D, DPDE3","cAMP-specific 3',5'-cyclic phosphodiesterase 4D","1","5K32"
"5K38",,"X-RAY DIFFRACTION",3.48,64.64,"VAPOR DIFFUSION, SITTING DROP",8,"0.4M Potassium sodium tartrate tetrahydrate",289,,,"5K38",57.44,"2.05","2.05","Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding domain","GSHMASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFS","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5K38"
"5K3L",,"X-RAY DIFFRACTION",3.36,63.4,"VAPOR DIFFUSION, SITTING DROP",8,"0.4M Potassium sodium tartrate tetrahydrate",289,,"444","5K3L",116.81,"2.75","2.75","Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding domain complex with 444","GSHMASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFS","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5K3L"
"5K3M",,"X-RAY DIFFRACTION",3.11,64.35,"VAPOR DIFFUSION, SITTING DROP",8,"0.4M Potassium sodium tartrate tetrahydrate",289,,"6Q5","5K3M",58.36,"2.894","2.894","Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding domain complex with UUA","GSHMASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFS","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5K3M"
"5K3N",,"X-RAY DIFFRACTION",3.34,63.14,"VAPOR DIFFUSION, SITTING DROP",8,"0.4M Potassium sodium tartrate tetrahydrate",289,,"6Q6","5K3N",116.65,"2.666","2.666","Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding domain complex with ML209","GSHMASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFS","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5K3N"
"5K47","4.22","ELECTRON MICROSCOPY",,,,,,,"10.1038/nsmb.3343",,"5K47",259.41,"4.2, 4.22",,"CryoEM structure of the human Polycystin-2/PKD2 TRP channel","MPRVAWAERLVRGLRGLWGTRLMEESSTNREKYLKSVLRELVTYLLFLIVLCILTYGMMSSNVYYYTRMMSQLFLDTPVSKTEKTNFKTLSSMEDFWKFTEGSLLDGLYWKMQPSNQTEADNRSFIFYENLLLGVPRIRQLRVRNGSCSIPQDLRDEIKECYDVYSVSSEDRAPFGPRNGTAWIYTSEKDLNGSSHWGIIATYSGAGYYLDLSRTREETAAQVASLKKNVWLDRGTRATFIDFSVYNANINLFCVVRLLVEFPATGGVIPSWQFQPLKLIRYVTTFDFFLAACEIIFCFFIFYYVVEEILEIRIHKLHYFRSFWNCLDVVIVVLSVVAIGINIYRTSNVEVLLQFLEDQNTFPNFEHLAYWQIQFNNIAAVTVFFVWIKLFKFINFNRTMSQLSTTMSRCAKDLFGFAIMFFIIFLAYAQLAYLVFGTQVDDFSTFQECIFTQFRIILGDINFAEIEEANRVLGPIYFTTFVFFMFFILLNMFLAIINDTYSEVKSDLAQQKAEMELSDLIRKGYHKALVKLKLKKNTVDAENLYFQ","Homo sapiens","PKD2, TRPP2","Polycystin-2","1","5K47"
"5K4I",,"X-RAY DIFFRACTION",2.28,46.05,"EVAPORATION",7.5,"10% PEG3350, 0.2 M proline, 0.1 M HEPES pH 7.5",277,"10.1021/acs.jmedchem.6b00389","6QB","5K4I",41.39,"1.76","1.76","Crystal Structure of ERK2 in complex with compound 22","AGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5K4I"
"5K4J",,"X-RAY DIFFRACTION",2.04,39.66,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 4K, 50 mM Hepes pH7.5, 50 mM Ammonia Acetate",292,"10.1021/acs.jmedchem.6b00389",,"5K4J",34.49,"1.6","1.6","Crystal Structure of CDK2 in complex with compound 22","AMENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","Cyclin-dependent kinase 2","1","5K4J"
"5K4L",,"X-RAY DIFFRACTION",3.71,66.87,"VAPOR DIFFUSION",7.3,"20% PEG3350, 0.1 M HEPES, pH 7.3, and 12% glycerol",292,"10.1016/j.bmcl.2016.07.070",,"5K4L",183.99,"3.179","3.179","Crystal structure of KDM5A in complex with a naphthyridone inhibitor","SEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRLDFLDQLAKFWELQGSTLKIPVVERKILDLYALSKIVASKGGFEMVTKEKKWSKVGSRLGYLPGKGTGSLLKSHYERILYPYELFQSGVSLMGVQMPNLDLKEKVEPEVLSTDTQTSPEPGTRMNILPKRTRRVKTQSESGDVSRNTELKKLQIFGAGPKVVGLAMGTKDKEDEVTRRRKVTNRSDAFNMQMRQRKGTLSVNFVDLYVCMFCGRGNNEDKLLLCDGCDDSYHTFCLIPPLPDVPKGDWRCPKCVAEECSKPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCTADWLPIGRQCVNHYRRLRRHCVFSHEELIFKMAADPECLDVGLAAMVCKELTLMTEEETRLRESVVQMGVLMSEEEVFELVPDDERQCSACRTTCFLSALTCSCNPERLVCLYHPTDLCPCPMQKKCLRYRYPLEDLPSLLYGVKVRAQSYDTWVSRVTEALSANFNHKKDLIELRVMLEDAEDRKYPENDLFRKLRDAVKEAETCASVGNS","Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2","Lysine-specific demethylase 5A","1","5K4L"
,,,,,,,,,,,,,,,,"XXXXXXXXXX","Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2","Unknown Peptide","2","5K4L"
"5K54",,"X-RAY DIFFRACTION",2.08,41,"VAPOR DIFFUSION, HANGING DROP",7.4,"10mM magnesium chloride, 2M sodium chloride, 10% PEG6000, 10mM Tris",292,,,"5K54",36.67,"1.717","1.717","Human muscle fructose-1,6-bisphosphatase E69Q mutant in active R-state","TDRSPFETDMLTLTRYVMEKGRQAKGTGELTQLLNSMLTAIKAISSAVRKAGLAHLYGIAGSVNVTGDQVKKLDVLSNSLVINMLQSSYSTCVLVSEENKDAIITAKEKRGKYVVCFDPLDGSSNIDCLASIGTIFAIYRKTSEDEPSEKDALQCGRNIVAAGYALYGSATLVALSTGQGVDLFMLDPALGEFVLVEKDVKIKKKGKIYSLNEGYAKYFDAATTEYVQKKKFPEDGSAPYGARYVGSMVADVHRTLVYGGIFLYPANQKSPKGKLRLLYECNPVAYIIEQAGGLATTGTQPVLDVKPEAIHQRVPLILGSPEDVQEYLTCVQKNQAGS","Homo sapiens","FBP2","Fructose-1,6-bisphosphatase isozyme 2","1","5K54"
"5K55",,"X-RAY DIFFRACTION",2.06,40.29,"VAPOR DIFFUSION, HANGING DROP",7.4,"10mM magnesium chloride, 2M sodium chloride, 10% PEG6000, 10mM Tris",292,,,"5K55",36.93,"1.977","1.977","Human muscle fructose-1,6-bisphosphatase E69Q mutant in active R-state in complex with fructose-6-phosphate","TDRSPFETDMLTLTRYVMEKGRQAKGTGELTQLLNSMLTAIKAISSAVRKAGLAHLYGIAGSVNVTGDQVKKLDVLSNSLVINMLQSSYSTCVLVSEENKDAIITAKEKRGKYVVCFDPLDGSSNIDCLASIGTIFAIYRKTSEDEPSEKDALQCGRNIVAAGYALYGSATLVALSTGQGVDLFMLDPALGEFVLVEKDVKIKKKGKIYSLNEGYAKYFDAATTEYVQKKKFPEDGSAPYGARYVGSMVADVHRTLVYGGIFLYPANQKSPKGKLRLLYECNPVAYIIEQAGGLATTGTQPVLDVKPEAIHQRVPLILGSPEDVQEYLTCVQKNQAGS","Homo sapiens","FBP2","Fructose-1,6-bisphosphatase isozyme 2","1","5K55"
"5K56",,"X-RAY DIFFRACTION",2.4,48.86,"VAPOR DIFFUSION, HANGING DROP",7.4,"10mM magnesium chloride, 2M sodium chloride, 10% PEG6000, 10mM Tris",292,,,"5K56",37.01,"2.198","2.198","Human muscle fructose-1,6-bisphosphatase in active R-state in complex with fructose-1,6-bisphosphate","TDRSPFETDMLTLTRYVMEKGRQAKGTGELTQLLNSMLTAIKAISSAVRKAGLAHLYGIAGSVNVTGDEVKKLDVLSNSLVINMLQSSYSTCVLVSEENKDAIITAKEKRGKYVVCFDPLDGSSNIDCLASIGTIFAIYRKTSEDEPSEKDALQCGRNIVAAGYALYGSATLVALSTGQGVDLFMLDPALGEFVLVEKDVKIKKKGKIYSLNEGYAKYFDAATTEYVQKKKFPEDGSAPYGARYVGSMVADVHRTLVYGGIFLYPANQKSPKGKLRLLYECNPVAYIIEQAGGLATTGTQPVLDVKPEAIHQRVPLILGSPEDVQEYLTCVQKNQAGS","Homo sapiens","FBP2","Fructose-1,6-bisphosphatase isozyme 2","1","5K56"
"5K57",,"SOLUTION NMR",,,,,,,"10.1038/srep30443",,"5K57",11.13,,,"HDD domain from human Ddi2","SQQSHSSPGEITSSPQGLDNPALLRDMLLANPHELSLLKERNPPLAEALLSGDLEKFSRVLVEQQQDRARREQERIRLFSADPFDLEAQAKIEEDIRQ","Homo sapiens","DDI2","Protein DDI1 homolog 2","1","5K57"
"5K5E",,"X-RAY DIFFRACTION",2.94,58.19,"VAPOR DIFFUSION",7.4,"0.1M Ammonium acetate  pH 7.4, 13% Polyethylenglycol 3350",293,"10.1021/acs.jmedchem.6b00356",,"5K5E",124.14,"2.8","2.8","Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening","EDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKV","Homo sapiens","BCHE, CHE1","Cholinesterase","1","5K5E"
"5K5F",,"SOLUTION NMR",,,,,,,,,"5K5F",13.53,,,"NMR structure of the HLTF HIRAN domain","GSDEEVDSVLFGSLRGHVVGLRYYTGVVNNNEMVALQRDPNNPYDKNAIKVNNVNGNQVGHLKKELAGALAYIMDNKLAQIEGVVPFGANNAFTMPLHMTFWGKEENRKAVSDQLKKHGFKL","Homo sapiens","HLTF, HIP116A, RNF80, SMARCA3, SNF2L3, ZBU1","Helicase-like transcription factor","1","5K5F"
"5K5N",,"X-RAY DIFFRACTION",2.68,54.07,"VAPOR DIFFUSION, HANGING DROP",6.5,"Protein storage conditions: 20 mM Tris pH 7.8, 5% (v/v) glycerol, 200 mM NaCl, 1 mM TCEP, 0.5 mM EDTA, 0.5% DMSO, and 0.2 mM PF-4802367, Well solution: 18-23% (w/v) PEG MME 5000, 100-150 mM ammonium sulfate, and 100 mM MES pH 6.5, Crystallization set-up: 0.5 + 0.5 uL drops over a well-solution of 200 uL",295,"10.1002/anie.201603797","6QH","5K5N",85.17,"2.2","2.2","Crystal structure of GSK-3beta complexed with PF-04802367, a highly selective brain-penetrant kinase inhibitor","HHHHHHSSGLVPRGSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARI","Homo sapiens","GSK3B","Glycogen synthase kinase-3 beta","1","5K5N"
"5K5S",,"X-RAY DIFFRACTION",3.56,65.41,"VAPOR DIFFUSION, SITTING DROP",,"1.6 M NaH2PO4, 0.4 M K2HPO4, 100 mM Na2HPO4/citric acid pH 4.2, 10 mM CaCl2, 10 mM L-Trp",293,"10.7554/eLife.13662",,"5K5S",140.7,"2.6","2.6","Crystal structure of the active form of human calcium-sensing receptor extracellular domain","MAFYSCCWVLLALTWHTSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWLQAMIFAIEEINSSPALLPNLTLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQFKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDFSELISQYSDEEEIQHVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWASSSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPRKSVHNGFAKEFWEETFNCHLQEGAKGPLPVDTFLRGHEESGDRFSQSSTAFRPLCTGDENINSVETPYIDYTHLRISYNVYLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKHLRHLQFTNNMGEQVTFDECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEEKILWSGFSREVPFSNCSRDCLAGTRKGIIEGEPTCCFECVECPDGEYSDETDASACNKCPDDFWSNENHTSCIAKEIEFLSDYKDDDDK","Homo sapiens","CASR, GPRC2A, PCAR1","Extracellular calcium-sensing receptor","1","5K5S"
"5K5T",,"X-RAY DIFFRACTION",3.79,67.59,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M Li2SO4, 100 mM Tris pH 8.5, 2 mM CaCl2",293,"10.7554/eLife.13662",,"5K5T",71.1,"3.1","3.1","Crystal structure of the inactive form of human calcium-sensing receptor extracellular domain","MAFYSCCWVLLALTWHTSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWLQAMIFAIEEINSSPALLPNLTLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQFKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDFSELISQYSDEEEIQHVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWASSSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPRKSVHNGFAKEFWEETFNCHLQEGAKGPLPVDTFLRGHEESGDRFSQSSTAFRPLCTGDENINSVETPYIDYTHLRISYNVYLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTFDECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEEKILWSGFSREVPFSNCSRDCLAGTRKGIIEGEPTCCFECVECPDGEYSDETDASACNKCPDDFWSNENHTSCIAKEIEFLSDYKDDDDK","Homo sapiens","CASR, GPRC2A, PCAR1","Extracellular calcium-sensing receptor","1","5K5T"
"5K5X",,"X-RAY DIFFRACTION",4.06,69.72,"VAPOR DIFFUSION, SITTING DROP",,"0.1M HEPES pH7.5, 1.6M (NH4)2SO4, 0.1M NaCl",293,"10.1016/j.bbrc.2016.06.117",,"5K5X",40.88,"2.168","2.168","Crystal structure of human PDGFRA","GAMDKQKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRVLGSGAFGKVVEGTAYGLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNLLGACTKSGPIYIITEYCFYGDLVNYLHKNRDSFLSHKKKSMLDSEVKNLLSDDNSEGLTLLDLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLARDIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGILLWEIFSLGGTPYPGMMVDSTFYNKIKSGYRMAKPDHATSEVYEIMVKCWNSEPEKRPSFYHLSEIVENLLPGQYKKSYEKIHLDFLKSD","Homo sapiens","PDGFRA, PDGFR2, RHEPDGFRA","Platelet-derived growth factor receptor alpha","1","5K5X"
,,,,,,,,,,,,,,,,,"Homo sapiens","PDGFRA, PDGFR2, RHEPDGFRA"
"5K64",,"X-RAY DIFFRACTION",2.27,45.8,"VAPOR DIFFUSION, SITTING DROP",6,"0.05 M MES, 10% (w/v) PEG 3350",295,"10.1080/19420862.2017.1364825",,"5K64",53.94,"2.44","2.44","Crystal structure of VEGF binding IgG1-Fc (Fcab 448)","TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELRFYQVSLTCLVKGFYPSDIAVEWESNGQPDIFPNGLNYKTTPPVLDSDGSFFLYSKLTVPYPSWLMGTRFSCSVMHEALHNHYTQKSLSLSPGK","Homo sapiens","IGHG1","Ig gamma-1 chain C region","1","5K64"
"5K65",,"X-RAY DIFFRACTION",2.3,46.6,"VAPOR DIFFUSION, SITTING DROP",7.5,"Morpheus_C6
0.03M of each NPS: (sodium nitrate, disodium hydrogen phosphate, ammonium sulfate).
0.1M MOPS/HEPES-Na pH 7.5
10% w/v PEG 8000, 20% v/v ethylene glycol",295,"10.1080/19420862.2017.1364825",,"5K65",54.19,"2.5","2.5","Crystal structure of VEGF binding IgG1-Fc (Fcab CT6)","TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELRFYQVSLTCLVKGFYPSDIAVEWESNGQPDIFPNGLNYKTTPPVLDSDGSFFLYSKLTVPYPSWLMGTRFSCSVMHEALHNHYTQKHLEYQWPT","Homo sapiens","IGHG1","Ig gamma-1 chain C region","1","5K65"
"5K6E",,"X-RAY DIFFRACTION",4.54,72.89,"VAPOR DIFFUSION, SITTING DROP",8,"0.4M Potassium sodium tartrate tetrahydrate",289,,,"5K6E",58.43,"2.8","2.8","Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding domain complex with SBI0654919","GSHMASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFS","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5K6E"
"5K6J",,"X-RAY DIFFRACTION",2.23,44.9,"VAPOR DIFFUSION",,"RESERVOIR SOLUTION : NULL",293,,,"5K6J",38.86,"1.86","1.86","Human Phospodiesterase 4B in complex with pyridyloxy-benzoxaborole based inhibitor","NEDHLAKELEDLNKWGLNIFNVAGYSHNRPLTCIMYAIFQERDLLKTFRISSDTFITYMMTLEDHYHSDVAYHNSLHAADVAQSTHVLLSTPALDAVFTDLEILAAIFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEEHCDIFMNLTKKQRQTLRKMVIDMVLATDMSKHMSLLADLKTMVETKKVTSSGVLLLDNYTDRIQVLRNMVHCADLSNPTKSLELYRQWTDRIMEEFFQQGDKERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVQPDAQDILDTLEDNRNWYQSMI","Homo sapiens","PDE4B, DPDE4","cAMP-specific 3',5'-cyclic phosphodiesterase 4B","1","5K6J"
"5K6P",,"SOLUTION NMR",,,,,,,"10.1016/j.str.2016.08.018",,"5K6P",15.5,,,"The NMR structure of the m domain tri-helix bundle and C2 of human cardiac Myosin Binding Protein C","GPGSEDVWEILRQAPPSEYERIAFQYGVTDLRGMLKRLKGMRRDEKKSTAFQKKLEPAYQVSKGHKIRLTVELADHDAEVKWLKNGQEIQMSGSKYIFESIGAKRTLTISQCSLADDAAYQCVVGGEKCSTELFVKE","Homo sapiens","MYBPC3","Myosin-binding protein C, cardiac-type","1","5K6P"
"5K72",,"X-RAY DIFFRACTION",2.69,54.31,"VAPOR DIFFUSION, HANGING DROP",,"2.5 M ammonium sulfate, 0.1 M Hepes pH 7.2",293,"10.1021/acs.jmedchem.7b01290","6QY","5K72",137.36,"2.22","2.22","IRAK4 in complex with Compound 21","VSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS","Homo sapiens","IRAK4","Interleukin-1 receptor-associated kinase 4","1","5K72"
"5K74",,"X-RAY DIFFRACTION",3.42,64.05,"VAPOR DIFFUSION, SITTING DROP",8,"0.4M Potassium sodium tartrate tetrahydrate",289,,,"5K74",58.41,"2.75","2.75","Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding domain complex with SBI0655870","GSHMASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFS","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5K74"
"5K75",,"X-RAY DIFFRACTION",2.69,54.31,"VAPOR DIFFUSION, HANGING DROP",,"2.5 ammonium sulfate, 0.1 M Hepes pH 7.2",293,"10.1021/acs.jmedchem.7b01290","6QX","5K75",137.44,"2.03","2.03","IRAK4 in complex with Compound 1","VSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS","Homo sapiens","IRAK4","Interleukin-1 receptor-associated kinase 4","1","5K75"
"5K76",,"X-RAY DIFFRACTION",2.95,58.27,"VAPOR DIFFUSION, HANGING DROP",7.2,"2.5 M ammonium sulfate, 0.1 M Hepes",293,"10.1021/acs.jmedchem.7b01290","6R1","5K76",68.52,"2.74","2.74","IRAK4 in complex with Compound 28","VSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS","Homo sapiens","IRAK4","Interleukin-1 receptor-associated kinase 4","1","5K76"
"5K7B",,"X-RAY DIFFRACTION",2.28,45.96,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Bis-Tris pH 6.5, 0.1 M NaCl and 1.5 M (NH4)2SO4",293.15,"10.1002/pro.3140",,"5K7B",45.2,"2.3","2.3","Beclin 2 CCD homodimer","GAMDPEAAALRAELRDLELEEARLVQELEDVDRNNARAAADLQAAQAEAAELDQQERQHYRDYSALKRQQLELLDQLGNVENQLQYARVQRDRLKEIN","Homo sapiens","BECN2, BECN1L1, BECN1P1","Beclin-2","1","5K7B"
"5K7G",,"X-RAY DIFFRACTION",2.51,51.07,"VAPOR DIFFUSION, HANGING DROP",7.2,"2.5 M ammonium sulfate, 0.1 M Hepes",293,"10.1021/acs.jmedchem.7b01290","6R0","5K7G",137.8,"2.23","2.23","IRAK4 in complex with AZ3862","VSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS","Homo sapiens","IRAK4","Interleukin-1 receptor-associated kinase 4","1","5K7G"
"5K7I",,"X-RAY DIFFRACTION",2.55,51.85,"VAPOR DIFFUSION, HANGING DROP",7.2,"2.5 M ammonium sulfate, 0.1 M Hepes",293,"10.1021/acs.jmedchem.7b01290","6QZ","5K7I",68.75,"2.31","2.31","IRAK4 in complex with AZ3864","VSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS","Homo sapiens","IRAK4","Interleukin-1 receptor-associated kinase 4","1","5K7I"
"5K7K",,"X-RAY DIFFRACTION",2.53,51.38,"VAPOR DIFFUSION",8.5,"100mM Hepes at 8.5  with 2% Peg 4K. crystallizer Alec Tucker
 Cryoprotectand 40% peg 4K",293,"10.1021/acs.jmedchem.7b00598","6RJ","5K7K",55.4,"2.3","2.3","Design and Optimization of Biaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7: Discovery of Clinical Candidate PF-05089771","MAKKTSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKVYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKWKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFMKSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYIDLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFKKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVPPFYQLCFIPIHHHH","Homo sapiens","CYP2C9, CYP2C10","Cytochrome P450 2C9","1","5K7K"
"5K7N","1.1","ELECTRON CRYSTALLOGRAPHY",,,,,,,"10.1038/nmeth.4178",,"5K7N",0.75,"1.1, 1.1","1.1","MicroED structure of tau VQIVYK peptide at 1.1 A resolution","VQIVYK","Homo sapiens","MAPT, MAPTL, MTBT1, TAU","VQIVYK","1","5K7N"
"5K7Y",,"X-RAY DIFFRACTION",2.94,58.23,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM MES/imidazol containing 200 mM NaCl, 30 % glycerol and 10 % PEG 4000",298,"10.1186/s12915-016-0313-y",,"5K7Y",64.7,"1.79","1.79","Crystal structure of enzyme in purine metabolism","MGSSHHHHHHSSGLVPRGSMSTSWSDRLQNAADMPANMDKHALKKYRREAYHRVFVNRSLAMEKIKCFGFDMDYTLAVYKSPEYESLGFELTVERLVSIGYPQELLSFAYDSTFPTRGLVFDTLYGNLLKVDAYGNLLVCAHGFNFIRGPETREQYPNKFIQRDDTERFYILNTLFNLPETYLLACLVDFFTNCPRYTSCETGFKDGDLFMSYRSMFQDVRDAVDWVHYKGSLKEKTVENLEKYVVKDGKLPLLLSRMKEVGKVFLATNSDYKYTDKIMTYLFDFPHGPKPGSSHRPWQSYFDLILVDARKPLFFGEGTVLRQVDTKTGKLKIGTYTGPLQHGIVYSGGSSDTICDLLGAKGKDILYIGDHIFGDILKSKKRQGWQTFLVIPELAQELHVWTDKSSLFEELQSLDIFLAELYKHLDSSSNERPDISSIQRRIKKVTHDMDMCYGMMGSLFRSGSRQTLFASQVMRYADLYAASFINLLYYPFSYLFRAAHVLMPHESTVEHTHVDINEMESPLATRNRTSVDFKDTDYKRHQLTRSISEIKPPNL","Homo sapiens","NT5C2, NT5B, NT5CP, PNT5","Cytosolic purine 5'-nucleotidase","1","5K7Y"
"5K89",,"X-RAY DIFFRACTION",2.53,51.33,"VAPOR DIFFUSION, SITTING DROP",7,"PEG 8000, calcium chloride, cacodylate",298,"10.1107/S2053230X17003983",,"5K89",32.03,"2.249","2.249","Crystal Structure of Human Calcium-Bound S100A1","MGSELETAMETLINVFHAHSGKEGDKYKLSKKELKELLQTELSGFLDAQKDVDAVDKVMKELDENGDGEVDFQEYVVLVAALTVACNNFFWENS","Homo sapiens","S100A1, S100A","Protein S100-A1","1","5K89"
"5K8R",,"X-RAY DIFFRACTION",3.04,59.58,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M HEPES pH 7
4% ethylene glycol
5% PEG500MME",293,"10.7554/eLife.18449",,"5K8R",46.56,"2.5","2.5","Structure of human clustered protocadherin gamma B3 EC1-4","EPIRYAIPEELDRGSLVGNLAKDLGFGVGDLPTRNLRVIAEKKFFTVSPENGNLLVSDRIDREEICGKKSTCVLEFEMVAEKPLNFFHVTVLIQDINDNPPTFSQNITELEISELALTGATFALESAQDPDVGVNSLQQYYLSPDPHFSLIQKENLDGSRYPELVLKAPLDREEQPHHHLVLTAVDGGEPSRSCTTQIRVIVADANDNPPVFTQDMYRVNVAENLPAGSSVLKVMAIDMDEGINAEIIYAFINIGKEVRQLFKLDSKTGELTTIGELDFEERDSYTIGVEAKDGGHHTAYCKVQIDISDENDNAPEITLASESQHIQEDAELGTAVALIKTHDLDSGFNGEILCQLKGNFPFKIVQDTKNTYRLVTDGALDREQIPEYNVTITATDKGNPPLSSSKTITLHILD","Homo sapiens","PCDHGB3","Protocadherin gamma-B3","1","5K8R"
"5K9C",,"X-RAY DIFFRACTION",3.43,64.2,"VAPOR DIFFUSION, SITTING DROP",4.8,"0.1 M sodium acetate trihydrate pH 4.8
1.9 M ammonium sulfate
30% (v/v) glycerol",298,"10.1021/acsmedchemlett.6b00316","MLJ","5K9C",41.5,"1.66","1.66","Crystal structure of human dihydroorotate dehydrogenase with ML390","SMATGDERFYAEHLMPTLQGLLDPESAHRLAVRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQERDGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR","Homo sapiens","DHODH","Dihydroorotate dehydrogenase (quinone), mitochondrial","1","5K9C"
"5K9D",,"X-RAY DIFFRACTION",3.46,64.5,"VAPOR DIFFUSION, SITTING DROP",4.8,"0.1 M sodium acetate trihydrate pH 4.8
1.8 M ammonium sulfate
30% (v/v) glycerol",298,"10.1021/acsmedchemlett.6b00316",,"5K9D",41.71,"1.7","1.7","Crystal structure of human dihydroorotate dehydrogenase at 1.7 A resolution","SMATGDERFYAEHLMPTLQGLLDPESAHRLAVRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQERDGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR","Homo sapiens","DHODH","Dihydroorotate dehydrogenase (quinone), mitochondrial","1","5K9D"
"5K9J",,"X-RAY DIFFRACTION",2.57,52.19,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1M sodium acetate, pH 5.5, 25% (w/v) PEG-400 and 11% (w/v) PEG-8000",293,"10.1016/j.cell.2016.06.043",,"5K9J",50.71,"1.904","1.904","Crystal structure of multidonor HV6-1-class broadly neutralizing Influenza A antibody 56.a.09 isolated following H5 immunization.","QVQLQQSGPGLVKPSQTLSLTCVISGDTVSSNRAAWNWIRQSPSRGLEWLGRTYYRSKWYTDYAVSVKSRITITPDTSKNQFSLQMKSVTPEDTAVYYCARGSAMIFGIVIILESWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS","Homo sapiens",,"56.a.09 heavy chain","1","5K9J"
,,,,,,,,,,,,,,,,"EIVLTQSPGTLSLSPGERATLSCRASQSVASSYLAWYQQKPGQAPRLLIYGASSRATGVPDRFSGSGSGTDFILTISRLEPEDFAVYYCQQYDGSQYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR","Homo sapiens",,"56.a.09 light chain","2","5K9J"
"5K9L",,"X-RAY DIFFRACTION",2.28,46.08,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MgCl2 and 19% PEG3350",293.15,"10.1002/pro.3140",,"5K9L",45.2,"2.52","2.52","Beclin 2 CCD N187L mutant homodimer","GAMDPEAAALRAELRDLELEEARLVQELEDVDRNLARAAADLQAAQAEAAELDQQERQHYRDYSALKRQQLELLDQLGNVENQLQYARVQRDRLKEIN","Homo sapiens","BECN2, BECN1L1, BECN1P1","Beclin-2","1","5K9L"
"5K9P",,"X-RAY DIFFRACTION",2.19,43.92,"VAPOR DIFFUSION, HANGING DROP",7,"45% (w/v) PEG 400, 100 mM tris-HCl",293,"10.1016/j.celrep.2016.06.064",,"5K9P",8.66,"1.55","1.55","Ser20 phosphorylated ubiquitin","MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBB","Polyubiquitin-B","1","5K9P"
"5K9R",,"X-RAY DIFFRACTION",2.23,44.73,"VAPOR DIFFUSION",8.9,"Crystals of human C-His tagged 448-759 PDE10a were grown in 0.1 M Tris-HCl pH 8.9 with ~14% w/v PEG 3350 and 5 mM CaCl2",293,"10.1016/j.bmcl.2016.07.054",,"5K9R",73.4,"2.7","2.7","PDE10a with imidazopyrazine inhibitor","GLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVISLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGE","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5K9R"
"5K9V",,"X-RAY DIFFRACTION",2.54,51.58,"VAPOR DIFFUSION, SITTING DROP",7.8,"0.1 M Tris, pH 7.8, 0.2 M MgCl2, 18% PEG8000",277,"10.1016/j.molcel.2017.01.014",,"5K9V",36.1,"1.898","1.898","Protein Tyrosine Phosphatase 1B (1-301), open state","GHMASMEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWPDFGVPESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLEP","Homo sapiens","PTPN1, PTP1B","Tyrosine-protein phosphatase non-receptor type 1","1","5K9V"
"5K9W",,"X-RAY DIFFRACTION",3.38,63.58,"VAPOR DIFFUSION, SITTING DROP",8,"0.1 M Tris, pH 8.0, 0.2 M MgCl2, 20% PEG8000",277,"10.1016/j.molcel.2017.01.014","OTA","5K9W",36.21,"2.01","2.01","Protein Tyrosine Phosphatase 1B (1-301) in complex with TCS401, closed state","GHMASMEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWPDFGVPESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLEP","Homo sapiens","PTPN1, PTP1B","Tyrosine-protein phosphatase non-receptor type 1","1","5K9W"
"5KA0",,"X-RAY DIFFRACTION",2.5,50.71,"VAPOR DIFFUSION, SITTING DROP",7.8,"0.1 M HEPES, pH 7.8, 0.2 M MgCl2, 12% PEG8000",277,"10.1016/j.molcel.2017.01.014",,"5KA0",34.25,"1.991","1.991","Protein Tyrosine Phosphatase 1B Delta helix 7, open state","GHMASMEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWPDFGVPESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGD","Homo sapiens","PTPN1, PTP1B","Tyrosine-protein phosphatase non-receptor type 1","1","5KA0"
"5KA1",,"X-RAY DIFFRACTION",2.47,50.21,"VAPOR DIFFUSION, SITTING DROP",7.4,"0.1 M HEPES, pH 7.4, 0.2 M MgCl2, 18% PEG8000",277,"10.1016/j.molcel.2017.01.014","OTA","5KA1",34.78,"1.84","1.84","Protein Tyrosine Phosphatase 1B Delta helix 7 mutant in complex with TCS401, closed state","GHMASMEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWPDFGVPESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGD","Homo sapiens","PTPN1, PTP1B","Tyrosine-protein phosphatase non-receptor type 1","1","5KA1"
"5KA2",,"X-RAY DIFFRACTION",3.35,63.24,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris, pH 8.0, 0.2 M MgCl2, 24% PEG8000",277,"10.1016/j.molcel.2017.01.014",,"5KA2",35.88,"2.071","2.071","Protein Tyrosine Phosphatase 1B YAYA (Y152A, Y153A) mutant, open state","GHMASMEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSAATVRQLELENLTTQETREILHFHYTTWPDFGVPESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLEP","Homo sapiens","PTPN1, PTP1B","Tyrosine-protein phosphatase non-receptor type 1","1","5KA2"
"5KA3",,"X-RAY DIFFRACTION",3.45,64.37,"VAPOR DIFFUSION, SITTING DROP",,"0.1 HEPES, pH 7.8, 0.2 M MgCl2, 20.5% PEG8000",277,"10.1016/j.molcel.2017.01.014","OTA","5KA3",36.11,"2.141","2.141","Protein Tyrosine Phosphatase 1B YAYA (Y152A, Y153A) mutant in complex with TCS401, closed state","GHMASMEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSAATVRQLELENLTTQETREILHFHYTTWPDFGVPESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLEP","Homo sapiens","PTPN1, PTP1B","Tyrosine-protein phosphatase non-receptor type 1","1","5KA3"
"5KA4",,"X-RAY DIFFRACTION",2.51,50.9,"VAPOR DIFFUSION, SITTING DROP",8,"0.1 M Tris, pH 8.0, 0.2 M MgCl2, 17% PEG8000",277,"10.1016/j.molcel.2017.01.014",,"5KA4",35.51,"2.185","2.185","Protein Tyrosine Phosphatase 1B T178A mutant, open state","GHMASMEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTAWPDFGVPESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLEP","Homo sapiens","PTPN1, PTP1B","Tyrosine-protein phosphatase non-receptor type 1","1","5KA4"
"5KA7",,"X-RAY DIFFRACTION",3.39,63.71,"VAPOR DIFFUSION, SITTING DROP",7.6,"0.1 M Tris, pH 7.6, 0.2 M MgCl2, 24% PEG8000",277,"10.1016/j.molcel.2017.01.014","OTA","5KA7",36.18,"2.061","2.061","Protein Tyrosine Phosphatase 1B T178A mutant in complex with TCS401, closed state","GHMASMEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTAWPDFGVPESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLEP","Homo sapiens","PTPN1, PTP1B","Tyrosine-protein phosphatase non-receptor type 1","1","5KA7"
"5KA8",,"X-RAY DIFFRACTION",3.6,65.88,"VAPOR DIFFUSION, SITTING DROP",8,"0.1 M HEPES, pH 8.0, 0.2 M MgCl2, 19% PEG8000",277,"10.1016/j.molcel.2017.01.014",,"5KA8",35.87,"1.971","1.971","Protein Tyrosine Phosphatase 1B L192A mutant, open state","GHMASMEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWPDFGVPESPASFANFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLEP","Homo sapiens","PTPN1, PTP1B","Tyrosine-protein phosphatase non-receptor type 1","1","5KA8"
"5KA9",,"X-RAY DIFFRACTION",3.48,64.63,"VAPOR DIFFUSION, SITTING DROP",7.8,"0.1 M Tris, 0.2 M mgCl2, 18.5% PEG8000",277,"10.1016/j.molcel.2017.01.014","OTA","5KA9",36.13,"2.07","2.07","Protein Tyrosine Phosphatase 1B L192A mutant in complex with TCS401, open state","GHMASMEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWPDFGVPESPASFANFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLEP","Homo sapiens","PTPN1, PTP1B","Tyrosine-protein phosphatase non-receptor type 1","1","5KA9"
"5KAA",,"X-RAY DIFFRACTION",2.49,50.64,"VAPOR DIFFUSION, SITTING DROP",8,"0.1 M HEPES, pH 8.0, 0.2 M MgCl2, 19% PEG8000",277,"10.1016/j.molcel.2017.01.014",,"5KAA",34.08,"1.968","1.968","Protein Tyrosine Phosphatase 1B Delta helix 7, P185G mutant, open state","GHMASMEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWPDFGVGESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGD","Homo sapiens","PTPN1, PTP1B","Tyrosine-protein phosphatase non-receptor type 1","1","5KAA"
"5KAB",,"X-RAY DIFFRACTION",2.46,49.94,"VAPOR DIFFUSION, SITTING DROP",8,"0.1 M Tris, pH 8.0, 0.2 M MgCl2, 22% PEG8000",277,"10.1016/j.molcel.2017.01.014","OTA","5KAB",34.25,"1.968","1.968","Protein Tyrosine Phosphatase 1B Delta helix 7, P185G mutant in complex with TCS401, open state","GHMASMEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWPDFGVGESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGD","Homo sapiens","PTPN1, PTP1B","Tyrosine-protein phosphatase non-receptor type 1","1","5KAB"
"5KAC",,"X-RAY DIFFRACTION",2.51,51.04,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris, pH 7.4, 0.2 M MgCl2, 18% PEG8000",277,"10.1016/j.molcel.2017.01.014",,"5KAC",36.06,"1.9","1.9","Protein Tyrosine Phosphatase 1B P185G mutant, open state","GHMASMEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWPDFGVGESPASFLNFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLEP","Homo sapiens","PTPN1, PTP1B","Tyrosine-protein phosphatase non-receptor type 1","1","5KAC"
"5KAD",,"X-RAY DIFFRACTION",2.26,45.63,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris, pH 8.0, 0.2 M MgCl2, 17.5% PEG8000",277,"10.1016/j.molcel.2017.01.014","OTA","5KAD",71.99,"1.9","1.9","Protein Tyrosine Phosphatase 1B N193A mutant in complex with TCS401, closed state","GHMASMEMEKEFEQIDKSGSWAAIYQDIRHEASDFPCRVAKLPKNKNRNRYRDVSPFDHSRIKLHQEDNDYINASLIKMEEAQRSYILTQGPLPNTCGHFWEMVWEQKSRGVVMLNRVMEKGSLKCAQYWPQKEEKEMIFEDTNLKLTLISEDIKSYYTVRQLELENLTTQETREILHFHYTTWPDFGVPESPASFLAFLFKVRESGSLSPEHGPVVVHCSAGIGRSGTFCLADTCLLLMDKRKDPSSVDIKKVLLEMRKFRMGLIQTADQLRFSYLAVIEGAKFIMGDSSVQDQWKELSHEDLEP","Homo sapiens","PTPN1, PTP1B","Tyrosine-protein phosphatase non-receptor type 1","1","5KAD"
"5KAE",,"X-RAY DIFFRACTION",2.34,47.45,"VAPOR DIFFUSION",7.3,"20% PEG 3350, 250 mM ammonium sulfate, 100 mM Tris (pH 7.3), 2 mM dithiothreitol",298,,,"5KAE",110.55,"2.65","2.65","Crystal structure of human PI3K-gamma in complex with quinoline-containing inhibitor 5g","SEESQAFQRQLTALIGYDVTDVSNVHDDELEFTRRGLVTPRMAEVASRDPKLYAMHPWVTSKPLPEYLWKKIANNCIFIVIHRSTTSQTIKVSPDDTPGAILQSFFTKMAKKKSLMDIPESQSEQDFVLRVCGRDEYLVGETPIKNFQWVRHCLKNGEEIHVVLDTPPDPALDEVRKEEWPLVDDCTGVTGYHEQLTIHGKDHESVFTVSLWDCDRKFRVKIRGIDIPVLPRNTDLTVFVEANIQHGQQVLCQRRTSPKPFTEEVLWNVWLEFSIKIKDLPKGALLNLQIYCGKAPALSSKASAESPSSESKGKVQLLYYVNLLLIDHRFLLRRGEYVLHMWQISGKGEDQGSFNADKLTSATNPDKENSMSISILLDNYCHPIALPKHQPTPDPEGDRVRAEMPNQLRKQLEAIIATDPLNPLTAEDKELLWHFRYESLKHPKAYPKLFSSVKWGQQEIVAKTYQLLARREVWDQSALDVGLTMQLLDCNFSDENVRAIAVQKLESLEDDDVLHYLLQLVQAVKFEPYHDSALARFLLKRGLRNKRIGHFLFWFLRSEIAQSRHYQQRFAVILEAYLRGCGTAMLHDFTQQVQVIEMLQKVTLDIKSLSAEKYDVSSQVISQLKQKLENLQNSQLPESFRVPYDPGLKAGALAIEKCKVMASKKKPLWLEFKCADPTALSNETIGIIFKHGDDLRQDMLILQILRIMESIWETESLDLCLLPYGCISTGDKIGMIEIVKDATTIAKIQQSTVGNTGAFKDEVLNHWLKEKSPTEEKFQAAVERFVYSCAGYCVATFVLGIGDRHNDNIMITETGNLFHIDFGHILGNYKSFLGINKERVPFVLTPDFLFVMGTSGKKTSPHFQKFQDICVKAYLALRHHTNLLIILFSMMLMTGMPQLTSKEDIEYIRDALTVGKNEEDAKKYFLDQIEVCRDKGWTVQFNWFLHLVLGIKQGEKHSA","Homo sapiens","PIK3CG","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform","1","5KAE"
"5KAZ",,"X-RAY DIFFRACTION",2.44,49.54,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Na-Citrate pH 5.5, 24% PEG 4000, 50 mM (NH)2SO4",293,"10.2174/0929866523666160831162239",,"5KAZ",12.19,"1.7","1.7","Human SH2D1B structure","MDLPYYHGRLTKQDCETLLLKEGVDGNFLLRDSESIPGVLCLCVSFKNIVYTYRIFREKHGYYRIQTAEGSPKQVFPSLKELISKFEKPNQGMVVHLLKPIKRT","Homo sapiens","SH2D1B, EAT2","SH2 domain-containing protein 1B","1","5KAZ"
"5KBQ",,"X-RAY DIFFRACTION",2.5,50.74,"VAPOR DIFFUSION, HANGING DROP",7.6,"0.2M ammonium sulphate, 16% PEG 3350, 0.1M Hepes (pH 7.6)",293,"10.1021/acsmedchemlett.6b00322","IPV","5KBQ",65.15,"2.58","2.58","Pak1 in complex with bis-anilino pyrimidine inhibitor","LEKLRSIVSVGDPKKKYTRFEKIGQGASGTVYTAMDVATGQEVAIKQMNLQQQPKKELIINEILVMRENKNPNIVNYLDSYLVGDELWVVMEYLAGGSLTDVVTETCMDEGQIAAVCRECLQALEFLHSNQVIHRNIKSDNILLGMDGSVKLTDFGFCAQITPEQSKRSEMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMIEGEPPYLNENPLRALYLIATNGTPELQNPEKLSAIFRDFLNRCLDMDVEKRGSAKELLQHQFLKIAKPLSSLTPLIAAAKEATK","Homo sapiens","PAK1","Serine/threonine-protein kinase PAK 1","1","5KBQ"
"5KBR",,"X-RAY DIFFRACTION",2.46,50.1,"VAPOR DIFFUSION, HANGING DROP",7.6,"0.2M ammonium sulphate, 16% PEG 3350, 0.1M Hepes (pH 7.6)",293,"10.1021/acsmedchemlett.6b00322","IPW","5KBR",65.48,"2.36","2.36","Pak1 in complex with 7-azaindole inhibitor","LEKLRSIVSVGDPKKKYTRFEKIGQGASGTVYTAMDVATGQEVAIKQMNLQQQPKKELIINEILVMRENKNPNIVNYLDSYLVGDELWVVMEYLAGGSLTDVVTETCMDEGQIAAVCRECLQALEFLHSNQVIHRNIKSDNILLGMDGSVKLTDFGFCAQITPEQSKRSEMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMIEGEPPYLNENPLRALYLIATNGTPELQNPEKLSAIFRDFLNRCLDMDVEKRGSAKELLQHQFLKIAKPLSSLTPLIAAAKEATK","Homo sapiens","PAK1","Serine/threonine-protein kinase PAK 1","1","5KBR"
"5KBY",,"X-RAY DIFFRACTION",2.85,56.83,"VAPOR DIFFUSION, SITTING DROP",,"22.2% PEG MME 2000, 0.1M Bicine pH 8.5",277,"10.1371/journal.pone.0157509","6RL","5KBY",350.4,"2.24","2.24","Crystal structure of dipeptidyl peptidase IV in complex with SYR-472","ADPGGSHHHHHHSRKTYTLTDYLKNTYRLKLYSLRWISDHEYLYKQENNILVFNAEYGNSSVFLENSTFDEFGHSINDYSISPDGQFILLEYNYVKQWRHSYTASYDIYDLNKRQLITEERIPNNTQWVTWSPVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIIYNGITDWVYEEEVFSAYSALWWSPNGTFLAYAQFNDTEVPLIEYSFYSDESLQYPKTVRVPYPKAGAVNPTVKFFVVNTDSLSSVTNATSIQITAPASMLIGDHYLCDVTWATQERISLQWLRRIQNYSVMDICDYDESSGRWNCLVARQHIEMSTTGWVGRFRPSEPHFTLDGNSFYKIISNEEGYRHICYFQIDKKDCTFITKGTWEVIGIEALTSDYLYYISNEYKGMPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYSVSFSKEAKYYQLRCSGPGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKKLDFIILNETKFWYQMILPPHFDKSKKYPLLLDVYAGPCSQKADTVFRLNWATYLASTENIIVASFDGRGSGYQGDKIMHAINRRLGTFEVEDQIEAARQFSKMGFVDNKRIAIWGWSYGGYVTSMVLGSGSGVFKCGIAVAPVSRWEYYDSVYTERYMGLPTPEDNLDHYRNSTVMSRAENFKQVEYLLIHGTADDNVHFQQSAQISKALVDVGVDFQAMWYTDEDHGIASSTAHQHIYTHMSHFIKQCFSLP","Homo sapiens","DPP4, ADCP2, CD26","Dipeptidyl peptidase 4","1","5KBY"
"5KC5",,"X-RAY DIFFRACTION",3.05,59.71,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M sodium malonate pH 7.0, 20% (w/v) polyethylene glycol 3350",293,"10.1126/science.aae0104",,"5KC5",16.86,"2.351","2.351","Crystal structure of the Cbln1 C1q domain trimer","ETGSAKVAFSAIRSTNHEPSEMSNRTMIIYFDQVLVNIGNNFDSERSTFIAPRKGIYSFNFHVVKVYNRQTIQVSLMLNGWPVISAFAGDQDVTREAASNGVLIQMEKGDRAYLKLERGNLMGGWKYSTFSGFLVFPLGTKHHHHHH","Homo sapiens","CBLN1","Cerebellin-1","1","5KC5"
"5KC6",,"X-RAY DIFFRACTION",3.33,63.04,"VAPOR DIFFUSION, SITTING DROP",,"15% (v/v) glycerol, 8.5% (v/v) isopropanol, 17% (w/v) polyethylene glycol 4000, 0.085 M Na.HEPES pH 7.5 and 0.02 M sodium bromide",293,"10.1126/science.aae0104",,"5KC6",59.98,"2.801","2.801","Crystal structure of Cbln1 (Val55-Gly58 deletion mutant)","ETGETEPIVLEGKCLVVCDSNPTSDPTGTALGISSAKVAFSAIRSTNHEPSEMSNRTMIIYFDQVLVNIGNNFDSERSTFIAPRKGIYSFNFHVVKVYNRQTIQVSLMLNGWPVISAFAGDQDVTREAASNGVLIQMEKGDRAYLKLERGNLMGGWKYSTFSGFLVFPLGTKHHHHHH","Homo sapiens","CBLN1","Cerebellin-1","1","5KC6"
"5KC7",,"X-RAY DIFFRACTION",3.47,64.55,"VAPOR DIFFUSION, SITTING DROP",,"2.75 M 1,6-Hexanediol, 50 mM Tris pH 8.0 and 5 mM magnesium sulphate",293,"10.1126/science.aae0104",,"5KC7",79.09,"7.035","7.035","Crystal structure of Cbln1 (Val55-Gly58 deletion mutant)","ETGETEPIVLEGKCLVVCDSNPTSDPTGTALGISSAKVAFSAIRSTNHEPSEMSNRTMIIYFDQVLVNIGNNFDSERSTFIAPRKGIYSFNFHVVKVYNRQTIQVSLMLNGWPVISAFAGDQDVTREAASNGVLIQMEKGDRAYLKLERGNLMGGWKYSTFSGFLVFPLGTKHHHHHH","Homo sapiens","CBLN1","Cerebellin-1","1","5KC7"
"5KC8",,"X-RAY DIFFRACTION",2.27,45.84,"VAPOR DIFFUSION, SITTING DROP",,"20% (w/v) polyethylene glycol 1000, 0.2 M calcium Acetate, 0.1 M imidazole pH 8.0 and 0.4 M NDSB-221 (non-detergent sulfobetaine 221)",293,"10.1126/science.aae0104",,"5KC8",48.74,"1.751","1.751","Crystal structure of the amino-terminal domain (ATD) of iGluR Delta-2 (GluD2)","ETGDSIIHIGAIFDESAKKDDEVFRTAVGDLNQNEEILQTEKITFSVTFVDGNNPFQAVQEACELMNQGILALVSSIGCTSAGSLQSLADAMHIPHLFIQRSTAGTPRSGCGLTRSNRNDDYTLSVRPPVYLHDVILRVVTEYAWQKFIIFYDSEYDIRGIQEFLDKVSQQGMDVALQKVENNINKMITTLFDTMRIEELNRYRDTLRRAILVMNPATAKSFITEVVETNLVAFDCHWIIINEEINDVDVQELVRRSIGRLTIIRQTFPVPQNISQRCFRGNHRISSTLCDPKDPFAQNMEISNLYIYDTVLLLANAFHKKLEDRKWHSMASLSCIRKNSKPWQGGRSMLETIKKGGVSGLTGELEFGENGGNPNVHFEILGTNYGEELGRGVRKLGCWNPVTGLNGSLTDKKLENNMRGGTKHHHHHH","Homo sapiens","GRID2, GLURD2","Glutamate receptor ionotropic, delta-2","1","5KC8"
"5KCH",,"X-RAY DIFFRACTION",2.38,48.35,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG-3350, 0.2M lithium sulfate, 0.1M bis-tris. Trypsin had been added to the protein stock solution.",291,,,"5KCH",42.94,"1.7","1.7","SETDB1 in complex with an early stage, low affinity fragment candidate modelled at reduced occupancy into weak electron density","MHHHHHHSSGRENLYFQGDLIVSMRILGKKRTKTWHKGTLIAIQTVGPGKKYKVKFDNKGKSLLSGNHIAYDYHPPADKLYVGSRVVAKYKDGNQVWLYAGIVAETPNVKNKLRFLIFFDDGYASYVTQSELYPICRPLKKTWEDIEDISCRDFIEEYVTAYPNRPMVLLKSGQLIKTEWEGTWWKSRVEEVDGSLVRILFLDDKRCEWIYRGSTRLEPMFSMKT","Homo sapiens","SETDB1, KIAA0067, KMT1E, ESET","Histone-lysine N-methyltransferase SETDB1","1","5KCH"
"5KCO",,"X-RAY DIFFRACTION",2.38,48.33,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG-3350, 0.2M lithium sulfate, 0.1M bis-tris. Trypsin had been added to the protein stock solution.",291,,,"5KCO",31.48,"1.47","1.47","SETDB1 in complex with an early stage, low affinity fragment candidate modelled at reduced occupancy","MHHHHHHSSGRENLYFQGDLIVSMRILGKKRTKTWHKGTLIAIQTVGPGKKYKVKFDNKGKSLLSGNHIAYDYHPPADKLYVGSRVVAKYKDGNQVWLYAGIVAETPNVKNKLRFLIFFDDGYASYVTQSELYPICRPLKKTWEDIEDISCRDFIEEYVTAYPNRPMVLLKSGQLIKTEWEGTWWKSRVEEVDGSLVRILFLDDKRCEWIYRGSTRLEPMFSMKT","Homo sapiens","SETDB1, KIAA0067, KMT1E, ESET","Histone-lysine N-methyltransferase SETDB1","1","5KCO"
"5KCV",,"X-RAY DIFFRACTION",2.36,47.78,"VAPOR DIFFUSION, HANGING DROP",7.5,"16% butanol, 10mM ammonium sulfate, 0.1% 2-mercaptoethanol, 15% ethylene glycol, 50mM Tris, pH 7.5",277,"10.1021/acs.jmedchem.6b00619",,"5KCV",53.99,"2.7","2.7","Crystal structure of allosteric inhibitor, ARQ 092, in complex with autoinhibited form of AKT1","MGHHHHHHENLYFQGSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQAAAEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQM","Homo sapiens","AKT1, PKB, RAC","RAC-alpha serine/threonine-protein kinase","1","5KCV"
"5KCX",,"X-RAY DIFFRACTION",3.49,63.03,"VAPOR DIFFUSION, HANGING DROP",6.5,"protein stock: 6.26 mg/mL in Tris 20mM - DTT 5mM - NaCl 150mM - 0.5 mM inhibitor - pH8
crystallization solution: imidazole 0.1M - Na Acetate 0.6M - pH6.5
1:1 protein to solution ratio for hanging drop
freezing conditions: imidazole 0.1M - Na Acetate 1M - glycerol 20% - pH6.5",277,"10.1016/j.bmcl.2017.08.069","6S3","5KCX",34.13,"2.2","2.2","Pim-1 kinase in Complex with a Selective N-substituted 7-azaindole Inhibitor","KEKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLSPGPSKHHHHHH","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5KCX"
"5KDH",,"X-RAY DIFFRACTION",2.09,41.04,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 MG/ML BRD4, 5MM HEPES PH 7.5, 50MM SODIUM CHLORIDE, 0.5MM DTT, 50MM TRIS PH8.5, 0.1M AMMONIUM, SULFATE, 12.5% PEG 3,350, 10% DMSO, 1 MM INHIBITOR",291,"10.1021/acs.jmedchem.6b01336","6RX","5KDH",15.69,"1.5","1.5","CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH A DIHYDROPYRIDOPYRIMIDINE SCAFFOLD INHIBITOR","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5KDH"
"5KDI",,"X-RAY DIFFRACTION",2.46,50.03,"VAPOR DIFFUSION",,"13-15% PEG8000, 0.1M MES pH 6.5",299,"10.1074/jbc.RA117.000733",,"5KDI",48.43,"1.45","1.45","How FAPP2 Selects Simple Glycosphingolipids Using the GLTP-fold","PTFFSTMNTSFSDIELLEDSGIPTEAFLASCYAVVPVLDKLGPTVFAPVKMDLVGNIKKVNQKYITNKAKFTTLQKIVLHEVEADVAQVRNSATEALLWLKRGLKFLKGFLTEVKNGEKDIQTALNNAYGKTLRQHHGWVVRGVFALALRAAPSYEDFVAALTVKEGDHQKEAFSIGMQRDLSLYLPAMEKQLAILDTLYEVHGLESDEVV","Homo sapiens","PLEKHA8, FAPP2","Pleckstrin homology domain-containing family A member 8","1","5KDI"
"5KE2",,"X-RAY DIFFRACTION",2.46,49.91,"VAPOR DIFFUSION, SITTING DROP",7.2,"25% PEG 3350, 0.2M LiSO4, 0.1M Bis-Tris pH6.5",295,,,"5KE2",25.82,"1.56","1.56","Crystal structure of SETDB1 Tudor domain in complex with inhibitor XST06472A","ENLYFQGDLIVSMRILGKKRTKTWHKGTLIAIQTVGPGKKYKVKFDNKGKSLLSGNHIAYDYHPPADKLYVGSRVVAKYKDGNQVWLYAGIVAETPNVKNKLRFLIFFDDGYASYVTQSELYPICRPLKKTWEDIEDISCRDFIEEYVTAYPNRPMVLLKSGQLIKTEWEGTWWKSRVEEVDGSLVRILFLDDKRCEWIYRGSTRLEPMFSMK","Homo sapiens","SETDB1, KIAA0067, KMT1E, ESET","Histone-lysine N-methyltransferase SETDB1","1","5KE2"
"5KE3",,"X-RAY DIFFRACTION",2.39,48.54,"VAPOR DIFFUSION, SITTING DROP",7.2,"25% PEG 3350, 0.2M LiSO4, 0.1M Bis-Tris pH6.5",295,,,"5KE3",25.72,"1.7","1.7","Crystal structure of SETDB1 Tudor domain in complex with fragment MRT0181a","ENLYFQGDLIVSMRILGKKRTKTWHKGTLIAIQTVGPGKKYKVKFDNKGKSLLSGNHIAYDYHPPADKLYVGSRVVAKYKDGNQVWLYAGIVAETPNVKNKLRFLIFFDDGYASYVTQSELYPICRPLKKTWEDIEDISCRDFIEEYVTAYPNRPMVLLKSGQLIKTEWEGTWWKSRVEEVDGSLVRILFLDDKRCEWIYRGSTRLEPMFSMK","Homo sapiens","SETDB1, KIAA0067, KMT1E, ESET","Histone-lysine N-methyltransferase SETDB1","1","5KE3"
"5KF4",,"X-RAY DIFFRACTION",2.18,43.54,"VAPOR DIFFUSION, SITTING DROP",6.5,"80mM Magnesium Acetate, 50mM Sodium Cacodylate (pH6.5), 30%(w/v) PEG4000",293,"10.1107/S2053230X1701648X",,"5KF4",41.99,"2.5","2.5","Crystal structure of FN3 domain (Residues P368-P466) of Human collagen XX","GPAAAPALDTLPAPTSLVLSQVTSSSIRLSWTPAPRHPLKYLIVWRASRGGTPREVVVEGPAASTELHNLASRTEYLVSVFPIYEGGVGEGLRGLVTTAP","Homo sapiens","COL20A1, KIAA1510","Collagen alpha-1(XX) chain","1","5KF4"
"5KGD",,"X-RAY DIFFRACTION",3.49,64.74,"VAPOR DIFFUSION, HANGING DROP",7.3,"18% PEG 3350, 0.2 M Na2SO4, 6% ethylene glycol, 0.1 M Tris, pH 7.3",293,,,"5KGD",33.47,"1.98","1.98","Crystal structure of PIM1 with inhibitor: 2-pyridin-3-yl-1~{H}-benzimidazole","EKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLH","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5KGD"
"5KGE",,"X-RAY DIFFRACTION",3.43,64.13,"VAPOR DIFFUSION, HANGING DROP",7.3,"18% PEG 3350, 0.2 M Na2SO4, 6% ethylene glycol, 0.1 M Tris, pH 7.3",293,,,"5KGE",33.26,"2.23","2.23","Crystal structure of PIM1 with inhibitor: 5-(3,4-dichlorophenyl)-1~{H}-pyrazol-3-amine","EKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLH","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5KGE"
"5KGG",,"X-RAY DIFFRACTION",3.43,64.19,"VAPOR DIFFUSION, HANGING DROP",7.3,"18% PEG 3350, 0.2 M Na2SO4, 6% ethylene glycol, 0.1 M Tris, pH 7.3",293,,,"5KGG",33.63,"1.95","1.95","Crystal structure of PIM1 with inhibitor: 2-(5-chloranyl-1~{H}-indol-3-yl)ethanamine","EKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLH","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5KGG"
"5KGI",,"X-RAY DIFFRACTION",3.53,65.12,"VAPOR DIFFUSION, HANGING DROP",7.3,"18% PEG 3350, 0.2 M Na2SO4, 6% ethylene glycol, 0.1 M Tris, pH 7.3",293,,,"5KGI",33.11,"2.13","2.13","Crystal structure of PIM1 with inhibitor 2-[3,4-bis(chloranyl)phenoxy]ethanamine","EKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLH","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5KGI"
"5KGK",,"X-RAY DIFFRACTION",3.58,65.62,"VAPOR DIFFUSION, HANGING DROP",7.3,"18% PEG 3350, 0.2 M Na2SO4, 6% ethylene glycol, 0.1 M Tris, pH 7.3",293,,,"5KGK",32.66,"2.66","2.66","Crystal structure of PIM1 with inhibitor: 3-(4-methoxyphenyl)-1~{H}-pyrazol-5-amine","EKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLH","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5KGK"
"5KH3",,"X-RAY DIFFRACTION",2.1,41.38,"VAPOR DIFFUSION, SITTING DROP",4.6,"2M Na-formate, 0.2M Na-acetate pH4.6, 5% ethylene glycol",291,"10.1021/acs.jmedchem.7b00933","6U6","5KH3",13.22,"1.6","1.6","Crystal structure of fragment (3-(5-Chloro-1,3-benzothiazol-2-yl)propanoic acid) bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain","GSPLPWCPHLVAVCPIPAAGLDVTQPCGDCGTIQENWVCLSCYQVYCGRYINGHMLQHHGNSGHPLVLSYIDLSAWCYYCQAYVHHQALLDVKNIAHQNKFGEDMPH","Homo sapiens","HDAC6, KIAA0901, JM21","Histone deacetylase 6","1","5KH3"
"5KH6",,"X-RAY DIFFRACTION",2.54,51.57,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG-3350, 0.2M lithium sulfate, 0.1M bis-tris. Trypsin had been added to the protein stock solution.",291,,,"5KH6",26.27,"2.05","2.05","SETDB1 in complex with a fragment candidate","ENLYFQGDLIVSMRILGKKRTKTWHKGTLIAIQTVGPGKKYKVKFDNKGKSLLSGNHIAYDYHPPADKLYVGSRVVAKYKDGNQVWLYAGIVAETPNVKNKLRFLIFFDDGYASYVTQSELYPICRPLKKTWEDIEDISCRDFIEEYVTAYPNRPMVLLKSGQLIKTEWEGTWWKSRVEEVDGSLVRILFLDDKRCEWIYRGSTRLEPMFS","Homo sapiens","SETDB1, KIAA0067, KMT1E, ESET","Histone-lysine N-methyltransferase SETDB1","1","5KH6"
"5KH7",,"X-RAY DIFFRACTION",2.09,41.11,"VAPOR DIFFUSION, SITTING DROP",4.6,"2M Na-formate, 0.2M Na-acetate pH4.6, 5% ethylene glycol",291,"10.1021/acs.jmedchem.7b00933","6T7","5KH7",12.37,"1.7","1.7","Crystal structure of fragment (3-[6-Oxo-3-(3-pyridinyl)-1(6H)-pyridazinyl]propanoic acid) bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain","GSPLPWCPHLVAVCPIPAAGLDVTQPCGDCGTIQENWVCLSCYQVYCGRYINGHMLQHHGNSGHPLVLSYIDLSAWCYYCQAYVHHQALLDVKNIAHQNKFGEDMPH","Homo sapiens","HDAC6, KIAA0901, JM21","Histone deacetylase 6","1","5KH7"
"5KH9",,"X-RAY DIFFRACTION",2.17,43.26,"VAPOR DIFFUSION, SITTING DROP",4.6,"2M Na-formate, 0.2M Na-acetate pH4.6, 5% ethylene glycol",291,"10.1021/acs.jmedchem.7b00933",,"5KH9",12.44,"1.07","1.07","Crystal structure of a low occupancy fragment candidate (5-[(4-Isopropylphenyl)amino]-6-methyl-1,2,4-triazin-3(2H)-one) bound in the ubiquitin binding pocket of the HDAC6 zinc-finger domain","GSPLPWCPHLVAVCPIPAAGLDVTQPCGDCGTIQENWVCLSCYQVYCGRYINGHMLQHHGNSGHPLVLSYIDLSAWCYYCQAYVHHQALLDVKNIAHQNKFGEDMPH","Homo sapiens","HDAC6, KIAA0901, JM21","Histone deacetylase 6","1","5KH9"
"5KHM",,"X-RAY DIFFRACTION",2.21,44.44,"VAPOR DIFFUSION, SITTING DROP",,"0.2M tri-Potassium Citrate, 10% PEG 10K",277,"10.1021/acs.jmedchem.6b00070","XNH","5KHM",30.95,"1.48","1.48","The first BET bromodomain of BRD4 bound to compound 13 in a bivalent manner","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5KHM"
"5KHP",,"X-RAY DIFFRACTION",3.08,60.12,"VAPOR DIFFUSION, HANGING DROP",,"Acetate, Li2SO4, NaCl, ammonium Sulphate",296,"10.1021/acs.inorgchem.6b02041",,"5KHP",65.48,"2.65","2.65","Tightening the Recognition of Tetravalent Zr and Th Complexes by the Siderophore-Binding Mammalian Protein Siderocalin for Theranostic Applications","GSQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDG","Homo sapiens","LCN2, HNL, NGAL","Neutrophil gelatinase-associated lipocalin","1","5KHP"
"5KHQ",,"X-RAY DIFFRACTION",3.13,60.65,"VAPOR DIFFUSION, SITTING DROP",6,"1.5M Ammonium Sulfate and MES pH 6.0",293,"10.1016/j.str.2016.10.001",,"5KHQ",32.78,"2.8","2.8","Rasip1 RA domain","GAMGEPPLATRATAPPGVLKIFGAGLASGANYKSVLATARSTARELVAEALERYGLAGSPGGGPGESSCVDAFALCDALGRPAAAGVGSGEWRAEHLRVLGDSERPLLVQELWRARPGWARRFELRGREEARRLEQEAFGAADSEGTGAPSWRPQK","Homo sapiens","RASIP1","Ras-interacting protein 1","1","5KHQ"
"5KHW",,"X-RAY DIFFRACTION",2.05,39.95,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG1500, 8% MPD, 0.1M Tris pH 9.0",281,"10.1107/S2053230X16016356",,"5KHW",73.74,"2.47","2.47","Crystal structure of JAK1 in complex with ADP","GSIMRDINKLEEQNPDIVSEKKPATEVDPTHFEKRFLKRIRDLGEGHFGKVELCRYDPEGDNTGEQVAVKSLKPESGGNHIADLKKEIEILRNLYHENIVKYKGICTEDGGNGIKLIMEFLPSGSLKEYLPKNKNKINLKQQLKYAVQICKGMDYLGSRQYVHRDLAARNVLVESEHQVKIGDFGLTKAIETDKEYYTVKDDRDSPVFWYAPECLMQSKFYIASDVWSFGVTLHELLTYCDSDSSPMALFLKMIGPTHGQMTVTRLVNTLKEGKRLPCPPNCPDEVYQLMRKCWEFQPSNRTSFQNLIEGFEALLK","Homo sapiens","JAK1, JAK1A, JAK1B","Tyrosine-protein kinase JAK1","1","5KHW"
"5KHX",,"X-RAY DIFFRACTION",2.06,40.24,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 1500, 8% MPD, 0.1 M Tris pH 9.0",281,"10.1107/S2053230X16016356","6TE","5KHX",36.71,"2.4","2.4","Crystal structure of JAK1 in complex with PF-4950736","GSIMRDINKLEEQNPDIVSEKKPATEVDPTHFEKRFLKRIRDLGEGHFGKVELCRYDPEGDNTGEQVAVKSLKPESGGNHIADLKKEIEILRNLYHENIVKYKGICTEDGGNGIKLIMEFLPSGSLKEYLPKNKNKINLKQQLKYAVQICKGMDYLGSRQYVHRDLAARNVLVESEHQVKIGDFGLTKAIETDKEYYTVKDDRDSPVFWYAPECLMQSKFYIASDVWSFGVTLHELLTYCDSDSSPMALFLKMIGPTHGQMTVTRLVNTLKEGKRLPCPPNCPDEVYQLMRKCWEFQPSNRTSFQNLIEGFEALLK","Homo sapiens","JAK1, JAK1A, JAK1B","Tyrosine-protein kinase JAK1","1","5KHX"
"5KHY",,"X-RAY DIFFRACTION",2.81,56.25,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 3350, Zinc acetate",295,"10.1002/cbic.201600138",,"5KHY",17.54,"3.501","3.501","Crystal structure of oxime-linked K6 diubiquitin","MQIFVXTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRL","Homo sapiens","UBB","Polyubiquitin-B","1","5KHY"
,,,,,,,,,,,,,,,,"MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRG","Homo sapiens","UBB","Polyubiquitin-B","2","5KHY"
"5KI0",,"SOLUTION NMR",,,,,,,"10.3389/fmicb.2016.01799",,"5KI0",1.77,,,"NMR structure of human antimicrobial peptide KAMP-19","RAIGGGLSSVGGGSSTIKY","Homo sapiens","KRT6A, K6A, KRT6D","Antimicrobial peptide KAMP-19","1","5KI0"
"5KI9",,"X-RAY DIFFRACTION",2.19,43.82,"VAPOR DIFFUSION, HANGING DROP",4.5,"25.5% PEG 8,000, 0.085 M sodium acetate buffer pH 4.5, 0.17 M Lithium Sulfate, 15% Glycerol",293,,,"5KI9",5.66,"1.6","1.6","Crystal structure of human beta-defensin 4 (HBD4)","EFELDRICGYGTARCRKKCRSQEYRIGRCPNTYACCLRKWDES","Homo sapiens","DEFB104A, DEFB104, DEFB4, DEFB104B","Beta-defensin 104","1","5KI9"
"5KIC",,"X-RAY DIFFRACTION",3.13,60.73,"VAPOR DIFFUSION, HANGING DROP",,"NaCl, Li2SO4,Acetate, Ammonium Sulfate",298,"10.1038/nchem.2759",,"5KIC",65.5,"2.7","2.7","Long-sought stabilization of berkelium(IV) in solution: An anomaly within the heavy actinide series","GSQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDG","Homo sapiens","LCN2, HNL, NGAL","Neutrophil gelatinase-associated lipocalin","1","5KIC"
"5KID",,"X-RAY DIFFRACTION",3.2,61.55,"VAPOR DIFFUSION, HANGING DROP",,"NaCl,Li2SO4,Acetate, Ammonium Sulphate",298,"10.1021/acs.inorgchem.6b02041",,"5KID",65.58,"2.15","2.15","Tightening the Recognition of Tetravalent Zr and Th Complexes by the Siderophore-Binding Mammalian Protein Siderocalin for Theranostic Applications","GSQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDG","Homo sapiens","LCN2, HNL, NGAL","Neutrophil gelatinase-associated lipocalin","1","5KID"
"5KIJ",,"X-RAY DIFFRACTION",2.27,45.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"24% PEG 4000, 50mM ammonium sulfate, 0.1M MES, 10% 1,4-butanediol, pH 6.5, 200mM NDSB-200, vapor diffusion, temperature 298K",298,"10.1073/pnas.1611213113",,"5KIJ",54.44,"1.649","1.649","Crystal structure of the class I human endoplasmic reticulum 1,2-alpha-mannosidase and Man9GlcNAc2-PA complex","HLNYRQKGVIDVFLHAWKGYRKFAWGHDELKPVSRSFSEWFGLGLTLIDALDTMWILGLRKEFEEARKWVSKKLHFEKDVDVNLFESTIRILGGLLSAYHLSGDSLFLRKAEDFGNRLMPAFRTPSKIPYSDVNIGTGVAHPPRWTSDSTVAEVTSIQLEFRELSRLTGDKKFQEAVEKVTQHIHGLSGKKDGLVPMFINTHSGLFTHLGVFTLGARADSYYEYLLKQWIQGGKQETQLLEDYVEAIEGVRTHLLRHSEPSKLTFVGELAHGRFSAKMDHLVCFLPGTLALGVYHGLPASHMELAQELMETCYQMNRQMETGLSPEIVHFNLYPQPGRRDVEVKPADRHNLLRPETVESLFYLYRVTGDRKYQDWGWEILQSFSRFTRVPSGGYSSINNVQDPQKPEPRDKMESFFLGETLKYLFLLFSDDPNLLSLDAYVFNTEAHPLPIW","Homo sapiens","MAN1B1, UNQ747/PRO1477","Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase","1","5KIJ"
"5KIR",,"X-RAY DIFFRACTION",3.46,64.46,"VAPOR DIFFUSION, SITTING DROP",7,"PEG400, ammonium phosphate, HEPES",296,"10.1107/S2053230X16014230","RCX","5KIR",131,"2.697","2.697","The Structure of Vioxx Bound to Human COX-2","NPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFLTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADYGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGSNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKYQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCDVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVNHLSGYHFKLKFDPELLFNKQFQYQNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRVAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEALYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEVGFQIINTASIQSLICNNVKGCPFTSFSVP","Homo sapiens","PTGS2, COX2","Prostaglandin G/H synthase 2","1","5KIR"
"5KIT",,"X-RAY DIFFRACTION",2.41,48.96,"VAPOR DIFFUSION, HANGING DROP",8.6,"0.2uL + 0.2uL drops containing 6mg/mL Nampt, 0.1M Sodium phosphate, 25-29% polyethylene glycol 3350, 0.2M NaCl, 1mM compound, pH 8.6",292,"10.1021/acs.jmedchem.6b00697","6TA","5KIT",113.09,"1.6","1.6","Crystal Structure of Nicotinamide Phosphoribosyltransferase (Nampt) in Complex with Inhibitors 37","MNPAAEAEFNILLATDSYKVTHYKQYPPNTSKVYSYFECREKKTENSKLRKVKYEETVFYGLQYILNKYLKGKVVTKEKIQEAKDVYKEHFQDDVFNEKGWNYILEKYDGHLPIEIKAVPEGFVIPRGNVLFTVENTDPECYWLTNWIETILVQSWYPITVATNSREQKKILAKYLLETSGNLDGLEYKLHDFGYRGVSSQETAGIGASAHLVNFKGTDTVAGLALIKKYYGTKDPVPGYSVPAAEHSTITAWGKDHEKDAFEHIVTQFSSVPVSVVSDSYDIYNACEKIWGEDLRHLIVSRSTQAPLIIRPDSGNPLDTVLKVLEILGKKFPVTENSKGYKLLPPYLRVIQGDGVDINTLQEIVEGMKQKMWSIENIAFGSGGGLLQKLTRDLLNCSFKCSYVVTNGLGINVFKDPVADPNKRSKKGRLSLHRTPAGNFVTLEEGKGDLEEYGQDLLHTVFKNGKVTKSYSFDEIRKNAQLNIELEAAHH","Homo sapiens","NAMPT, PBEF, PBEF1","Nicotinamide phosphoribosyltransferase","1","5KIT"
"5KIU",,"X-RAY DIFFRACTION",1.9,35.33,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES, pH 6.0, 20 % 2-propanol, 20 % PEG MME 2000",288,"10.1038/celldisc.2017.45",,"5KIU",9.73,"2.2","2.2","VCP-interacting membrane protein (VIMP)","MHHHHHHQKLSARLRALRQRQLDRAAAAVEPDVVVKRQEALAAARLKMQEELNAQVEKHKEKLKQLEEEKRRQKIEMWDSM","Homo sapiens","VIMP, SELS, AD-015, SBBI8, SELENOS","Selenoprotein S","1","5KIU"
"5KIZ",,"SOLUTION NMR",,,,,,,"10.1016/j.str.2016.08.014",,"5KIZ",13.26,,,"Solution Structure of a repacked version of HIF-2 alpha PAS-B","GEFLDSKTFLSRFSMDMKFTYCDDRITELIGYHPEELLGRSASEFWHALDSENMTKSHQNLCTKGQVVSGQYRMLAKHGGYVWLETQMTVIYNPRNLQPQCIMAVNYVLSEIEK","Homo sapiens","EPAS1, BHLHE73, HIF2A, MOP2, PASD2","Endothelial PAS domain-containing protein 1","1","5KIZ"
"5KJ0",,"X-RAY DIFFRACTION",2.13,42.38,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 MG/ML BRD4, 5MM HEPES PH 7.5, 50MM SODIUM CHLORIDE, 0.5MM DTT, 50MM TRIS PH8.5, 0.1M AMMONIUM, SULFATE, 12.5% PEG 3,350, 10% DMSO, 1 MM DB-1-264-2",291,"10.1002/cmdc.201600502","6TB","5KJ0",16.07,"1.51","1.51","CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH DB-1-264-2","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5KJ0"
"5KJ2",,"X-RAY DIFFRACTION",2.61,52.92,"VAPOR DIFFUSION",,"25% (w/v) PEG3350, 0.2M Sodium Chloride, 0.1M BIS-TRIS buffer pH5.5",290,"10.1038/nature24028","6TF","5KJ2",40.82,"1.95","1.95","The novel p300/CBP inhibitor A-485 uncovers a unique mechanism of action to target AR in castrate resistant prostate cancer","KFSAKRLPSTRLGTFLENRVNDFLRRQNHPESGEVTVRVVHASDKTVEVKPGMKARFVDSGEMAESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYISYLDSVHFFRPKCLRTAVYHEILIGYLEYVKKLGYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAVSERIVHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQKTSKNKSSLSRGNKKKPGMPNVSNDLSQKLYATMEKHKEVFFVIRLIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLTLARDRHLEFSSLRRAQWSTGCMLVELHTQSQDRF","Homo sapiens","EP300, P300","Histone acetyltransferase p300","1","5KJ2"
"5KJ3",,"SOLUTION NMR",,,,,,,"10.1016/j.abb.2016.06.019",,"5KJ3",2.37,,,"Connexin 26 WT peptide NMR Structure","XMDWGTLQTILGGVNKHSTSIGK","Homo sapiens","GJB2","Gap junction beta-2 protein","1","5KJ3"
"5KJG",,"SOLUTION NMR",,,,,,,"10.1016/j.abb.2016.06.019",,"5KJG",2.47,,,"Connexin 26 G12R mutant NMR structure","XMDWGTLQTILGRVNKHSTSIGK","Homo sapiens","GJB2","Gap junction beta-2 protein","1","5KJG"
"5KJK",,"X-RAY DIFFRACTION",3.23,61.91,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 3350, 0.1 M Tris-HCl, 5% ethanol",293,"10.1021/acs.jmedchem.6b01303","6T1","5KJK",50.85,"1.93","1.93","SMYD2 in complex with AZ370","GLGGLERFCSPGKGRGLRALQPFQVGDLLFSCPAYAYVLTVNERGNHCEYCFTRKEGLSKCGRCKQAFYCNVECQKEDWPMHKLECSPMVVFGENWNPSETVRLTARILAKQKIHPERTPSEKLLAVKEFESHLDKLDNEKKDLIQSDIAALHHFYSKHLEFPDNDSLVVLFAQVNCNGFTIEDEELSHLGSAIFPDVALMNHSCCPNVIVTYKGTLAEVRAVQEIKPGEEVFTSYIDLLYPTEDRNDRLRDSYFFTCECQECTTKDKDKAKVEIRKLSDPPKAEAIRDMVRYARNVIEEFRRAKHYKSPSELLEICELSQEKMSSVFEDSNVYMLHMMYQAMGVCLYMQDWEGALQYGQKIIKPYSKHYPLYSLNVASMWLKLGRLYMGLEHKAAGEKALKKAIAIMEVAHGKDHPYISEIKQEIESH","Homo sapiens","SMYD2, KMT3C","N-lysine methyltransferase SMYD2","1","5KJK"
"5KJL",,"X-RAY DIFFRACTION",3.21,61.64,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 3350, 0.1 M Tris-HCl, 5% ethanol",293,"10.1021/acs.jmedchem.6b01303",,"5KJL",49.94,"2.7","2.7","SMYD2 in complex with AZ378","GLGGLERFCSPGKGRGLRALQPFQVGDLLFSCPAYAYVLTVNERGNHCEYCFTRKEGLSKCGRCKQAFYCNVECQKEDWPMHKLECSPMVVFGENWNPSETVRLTARILAKQKIHPERTPSEKLLAVKEFESHLDKLDNEKKDLIQSDIAALHHFYSKHLEFPDNDSLVVLFAQVNCNGFTIEDEELSHLGSAIFPDVALMNHSCCPNVIVTYKGTLAEVRAVQEIKPGEEVFTSYIDLLYPTEDRNDRLRDSYFFTCECQECTTKDKDKAKVEIRKLSDPPKAEAIRDMVRYARNVIEEFRRAKHYKSPSELLEICELSQEKMSSVFEDSNVYMLHMMYQAMGVCLYMQDWEGALQYGQKIIKPYSKHYPLYSLNVASMWLKLGRLYMGLEHKAAGEKALKKAIAIMEVAHGKDHPYISEIKQEIESH","Homo sapiens","SMYD2, KMT3C","N-lysine methyltransferase SMYD2","1","5KJL"
"5KJM",,"X-RAY DIFFRACTION",3.25,62.18,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 3350, 0.1 M Tris-HCl, 5% ethanol",293,"10.1021/acs.jmedchem.6b01303","6TM","5KJM",50.54,"2.19","2.19","SMYD2 in complex with AZ931","GLGGLERFCSPGKGRGLRALQPFQVGDLLFSCPAYAYVLTVNERGNHCEYCFTRKEGLSKCGRCKQAFYCNVECQKEDWPMHKLECSPMVVFGENWNPSETVRLTARILAKQKIHPERTPSEKLLAVKEFESHLDKLDNEKKDLIQSDIAALHHFYSKHLEFPDNDSLVVLFAQVNCNGFTIEDEELSHLGSAIFPDVALMNHSCCPNVIVTYKGTLAEVRAVQEIKPGEEVFTSYIDLLYPTEDRNDRLRDSYFFTCECQECTTKDKDKAKVEIRKLSDPPKAEAIRDMVRYARNVIEEFRRAKHYKSPSELLEICELSQEKMSSVFEDSNVYMLHMMYQAMGVCLYMQDWEGALQYGQKIIKPYSKHYPLYSLNVASMWLKLGRLYMGLEHKAAGEKALKKAIAIMEVAHGKDHPYISEIKQEIESH","Homo sapiens","SMYD2, KMT3C","N-lysine methyltransferase SMYD2","1","5KJM"
"5KJN",,"X-RAY DIFFRACTION",3.18,61.28,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 3350, 0.1 M Tris-HCl, 5% ethanol",293,"10.1021/acs.jmedchem.6b01303",,"5KJN",51.06,"2.72","2.72","SMYD2 in complex with AZ506","GLGGLERFCSPGKGRGLRALQPFQVGDLLFSCPAYAYVLTVNERGNHCEYCFTRKEGLSKCGRCKQAFYCNVECQKEDWPMHKLECSPMVVFGENWNPSETVRLTARILAKQKIHPERTPSEKLLAVKEFESHLDKLDNEKKDLIQSDIAALHHFYSKHLEFPDNDSLVVLFAQVNCNGFTIEDEELSHLGSAIFPDVALMNHSCCPNVIVTYKGTLAEVRAVQEIKPGEEVFTSYIDLLYPTEDRNDRLRDSYFFTCECQECTTKDKDKAKVEIRKLSDPPKAEAIRDMVRYARNVIEEFRRAKHYKSPSELLEICELSQEKMSSVFEDSNVYMLHMMYQAMGVCLYMQDWEGALQYGQKIIKPYSKHYPLYSLNVASMWLKLGRLYMGLEHKAAGEKALKKAIAIMEVAHGKDHPYISEIKQEIESH","Homo sapiens","SMYD2, KMT3C","N-lysine methyltransferase SMYD2","1","5KJN"
"5KJX",,"X-RAY DIFFRACTION",2.18,43.64,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% w/v PEG 8000, 100mM imidazole/hydrochloric acid pH 6.5, 3% v/v MPD",277.15,"10.1042/BCJ20160969",,"5KJX",17.29,"1.9","1.9","Co-crystal Structure of PKA RI alpha CNB-B domain with cAMP","GSILMGSTLRKRKMYEEFLSKVSILESLDKWERLTVADALEPVQFEDGQKIVVQGEPGDEFFIILEGSAAVLQRRSENEEFVEVGRLGPSDYFGEIALLMNRPRAATVVARGPLKCVKLDRPRFERVLGPCSDILKRNIQQYNSFVSLSV","Homo sapiens","PRKAR1A, PKR1, PRKAR1, TSE1","cAMP-dependent protein kinase type I-alpha regulatory subunit","1","5KJX"
"5KJY",,"X-RAY DIFFRACTION",2.98,58.68,"VAPOR DIFFUSION, HANGING DROP",4.7,"2.5M NaCl, 0.1M sodium acetate/acetic acid pH 4.7, 0.2M lithium sulfate",277.15,"10.1042/BCJ20160969",,"5KJY",17.42,"2","2","Co-crystal structure of PKA RI alpha CNB-B mutant (G316R/A336T) with cAMP","GSILMGSTLRKRKMYEEFLSKVSILESLDKWERLTVADALEPVQFEDGQKIVVQGEPGDEFFIILEGSAAVLQRRSENEEFVEVRRLGPSDYFGEIALLMNRPRTATVVARGPLKCVKLDRPRFERVLGPCSDILKRNIQQYNSFVSLSV","Homo sapiens","PRKAR1A, PKR1, PRKAR1, TSE1","cAMP-dependent protein kinase type I-alpha regulatory subunit","1","5KJY"
"5KJZ",,"X-RAY DIFFRACTION",2.28,46,"VAPOR DIFFUSION, HANGING DROP",6.4,"0.04 M critic acid, 0.06 M Bis-Tris propane, 24% w/v PEG 1500, 20% v/v glycerol",277.15,"10.1042/BCJ20160969",,"5KJZ",17.62,"1.347","1.347","Co-crystal structure of PKA RI alpha CNB-B mutant (G316R/A336T) with cGMP","GSILMGSTLRKRKMYEEFLSKVSILESLDKWERLTVADALEPVQFEDGQKIVVQGEPGDEFFIILEGSAAVLQRRSENEEFVEVRRLGPSDYFGEIALLMNRPRTATVVARGPLKCVKLDRPRFERVLGPCSDILKRNIQQYNSFVSLSV","Homo sapiens","PRKAR1A, PKR1, PRKAR1, TSE1","cAMP-dependent protein kinase type I-alpha regulatory subunit","1","5KJZ"
"5KK3",,"SOLID-STATE NMR",,,,,,,"10.1021/jacs.6b05129",,"5KK3",81.36,,,"Atomic Resolution Structure of Monomorphic AB42 Amyloid Fibrils","DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA","Homo sapiens","APP, A4, AD1","Beta-amyloid protein 42","1","5KK3"
"5KK7",,"X-RAY DIFFRACTION",2.23,44.87,"VAPOR DIFFUSION, HANGING DROP",6.5,"24% PEG 4000, 50mM ammonium sulfate, 0.1M MES, 10% 1,4-butanediol, pH 6.5, vapor diffusion, temperature 298K",298,"10.1073/pnas.1611213113",,"5KK7",106.71,"1.7324","1.7324","Crystal structure of the class I human endoplasmic reticulum 1,2-alpha-mannosidase T688A mutant and Thio-disaccharide substrate analog complex","HLNYRQKGVIDVFLHAWKGYRKFAWGHDELKPVSRSFSEWFGLGLTLIDALDTMWILGLRKEFEEARKWVSKKLHFEKDVDVNLFESTIRILGGLLSAYHLSGDSLFLRKAEDFGNRLMPAFRTPSKIPYSDVNIGTGVAHPPRWTSDSTVAEVTSIQLEFRELSRLTGDKKFQEAVEKVTQHIHGLSGKKDGLVPMFINTHSGLFTHLGVFTLGARADSYYEYLLKQWIQGGKQETQLLEDYVEAIEGVRTHLLRHSEPSKLTFVGELAHGRFSAKMDHLVCFLPGTLALGVYHGLPASHMELAQELMETCYQMNRQMETGLSPEIVHFNLYPQPGRRDVEVKPADRHNLLRPETVESLFYLYRVTGDRKYQDWGWEILQSFSRFTRVPSGGYSSINNVQDPQKPEPRDKMESFFLGETLKYLFLLFSDDPNLLSLDAYVFNAEAHPLPIWTPA","Homo sapiens","MAN1B1, UNQ747/PRO1477","Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase","1","5KK7"
"5KK9",,"SOLUTION NMR",,,,,,,"10.1016/j.abb.2016.06.019",,"5KK9",2.58,,,"Connexin 32 G12R N-Terminal Mutant,","XMNWTGLYTLLSRVNRHSTAIGR","Homo sapiens","GJB1, CX32","Gap junction beta-1 protein","1","5KK9"
"5KKN",,"X-RAY DIFFRACTION",3.41,63.89,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Tris pH 7, 2.8 M sodium formate",293,"10.1073/pnas.1520686113",,"5KKN",121.32,"2.6","2.6","Crystal structure of human ACC2 BC domain in complex with ND-646, the primary amide of ND-630","MGSSHHHHHHENLYFQGLHRDFTVASPAEFVTRFGGDRVIEKVLIANNGIAAVKCMRSIRRWAYEMFRNERAIRFVVMVTPEDLKANAEYIKMADHYVPVPGGPNNNNYANVELIVDIAKRIPVQAVWAGWGHASENPKLPELLCKNGVAFLGPPSEAMWALGDKIASTVVAQTLQVPTLPWSGSGLTVEWTEDDLQQGKRISVPEDVYDKGCVKDVDEGLEAAERIGFPLMIKASEGGGGKGIRKAESAEDFPILFRQVQSEIPGSPIFLMKLAQHARHLEVQILADQYGNAVSLFGRDCSIQRRHQKIVEEAPATIAPLAIFEFMEQCAIRLAKTVGYVSAGTVEYLYSQDGSFHFLELNPRLQVEHPCTEMIADVNLPAAQLQIAMGVPLHRLKDIRLLYGESPWGVTPISFETPSNPPLARGHVIAARITSENPDEGFKPSSGTVQELNFRSSKNVWGYFSVAATGGLHEFADSQFGHCFSWGENREEAISNMVVALKELSIRGDFRTTVEYLINLLETESFQNNDIDTGWLDYLI","Homo sapiens","ACACB, ACC2, ACCB","Acetyl-CoA carboxylase 2","1","5KKN"
"5KKP",,"X-RAY DIFFRACTION",2.22,44.52,"VAPOR DIFFUSION, SITTING DROP",7,"23% PEG 3350, 0.2 M Sodium formate, pH7.0",293,,,"5KKP",65.31,"2.26","2.26","Crystal Structure of Human Pseudouridylate Synthase 7","ESFADMMKHGLTEADVGITKFVSSHQGFSGILKERYSDFVVHEIGKDGRISHLNDLSIPVDEEDPSEDIFTVLTAEEKQRLEELQLFKNKETSVAIEVIEDTKEKRTIIHQAIKSLFPGLETKTEDREGKKYIVAYHAAGKKALANPRKHSWPKSRGSYCHFVLYKENKDTMDAINVLSKYLRVKPNIFSYMGTKDKRAITVQEIAVLKITAQRLAHLNKCLMNFKLGNFSYQKNPLKLGELQGNHFTVVLRNITGTDDQVQQAMNSLKEIGFINYYGMQRFGTTAVPTYQVGRAILQNSWTEVMDLILKPRSGAEKGYLVKCREEWAKTKDPTAALRKLPVKRCVEGQLLRGLSKYGMKNIVSAFGIIPRNNRLMYIHSYQSYVWNNMVSKRIEDYGLKPVPGDLVLKGATATYIEEDDVNNYSIHDVVMPLPGFDVIYPKHKIQEAYREMLTADNLDIDNMRHKIRDYSLSGAYRKIIIRPQNVSWEVVAYDDPKIPLFNTDVDNLEGKTPPVFASEGKYRALKMDFSLPPSTYATMAIREVLKMDTSIKNQTQLNTTWLR","Homo sapiens","PUS7, KIAA1897","Pseudouridylate synthase 7","1","5KKP"
"5KKS",,"X-RAY DIFFRACTION",4.53,72.84,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.45 mM protein, 5% PEG3350, 100 mM MES, 50 mM calcium chloride, 10 mM DTT",298,,"6U1","5KKS",96.88,"3.3","3.3","ROCK 1 bound to azaindole thiazole inhibitor","GSLHMSFETRFEKMDNLLRDPKSEVNSDCLLDGLDALVYDLDFPALRKNKNIDNFLSRYKDTINKIRDLRMKAEDYEVVKVIGRGAFGEVQLVRHKSTRKVYAMKLLSKFEMIKRSDSAFFWEERDIMAFANSPWVVQLFYAFQDDRYLYMVMEYMPGGDLVNLMSNYDVPEKWARFYTAEVVLALDAIHSMGFIHRDVKPDNMLLDKSGHLKLADFGTCMKMNKEGMVRCDTAVGTPDYISPEVLKSQGGDGYYGRECDWWSVGVFLYEMLVGDTPFYADSLVGTYSKIMNHKNSLTFPDDNDISKEAKNLICAFLTDREVRLGRNGVEEIKRHLFFKNDQWAWETLRDTVAPVVPDLSSDIDTSNFDDLEEDKGEEETFPIPKAFVGNQLPFVGFTYYSNRRYLSSANPNDNR","Homo sapiens","ROCK1","Rho-associated protein kinase 1","1","5KKS"
"5KKT",,"X-RAY DIFFRACTION",4.55,72.99,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.45 mM protein, 5% PEG3350, 100 mM MES, 50 mM calcium chloride, 10 mM DTT",298,,"6U2","5KKT",97.01,"2.8","2.8","ROCK 1 bound to azaindole thiazole piperazine inhibitor","GSLHMSFETRFEKMDNLLRDPKSEVNSDCLLDGLDALVYDLDFPALRKNKNIDNFLSRYKDTINKIRDLRMKAEDYEVVKVIGRGAFGEVQLVRHKSTRKVYAMKLLSKFEMIKRSDSAFFWEERDIMAFANSPWVVQLFYAFQDDRYLYMVMEYMPGGDLVNLMSNYDVPEKWARFYTAEVVLALDAIHSMGFIHRDVKPDNMLLDKSGHLKLADFGTCMKMNKEGMVRCDTAVGTPDYISPEVLKSQGGDGYYGRECDWWSVGVFLYEMLVGDTPFYADSLVGTYSKIMNHKNSLTFPDDNDISKEAKNLICAFLTDREVRLGRNGVEEIKRHLFFKNDQWAWETLRDTVAPVVPDLSSDIDTSNFDDLEEDKGEEETFPIPKAFVGNQLPFVGFTYYSNRRYLSSANPNDNR","Homo sapiens","ROCK1","Rho-associated protein kinase 1","1","5KKT"
"5KLY",,"X-RAY DIFFRACTION",2.05,39.99,"VAPOR DIFFUSION, HANGING DROP",6.4,"100 mM MES, 32% PEG 8000",293,"10.1021/acs.molpharmaceut.7b00664",,"5KLY",28.78,"1.3","1.3","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) H112N mutant adenosine nucleoside phosphoramidate substrate complex","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVNLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5KLY"
"5KLZ",,"X-RAY DIFFRACTION",2.49,50.66,"VAPOR DIFFUSION, HANGING DROP",6.7,"100 mM MES, 37% PEG 8000,",293,"10.1021/acs.molpharmaceut.7b00664",,"5KLZ",28.6,"1.5","1.5","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) AMP catalytic product complex","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5KLZ"
"5KM0",,"X-RAY DIFFRACTION",2.37,48.1,"VAPOR DIFFUSION, HANGING DROP",6.7,"100 mM MES, 34% PEG 8000",293,"10.1021/acs.molpharmaceut.7b00664",,"5KM0",57.08,"1.533","1.533","Human Histidine Triad Nucleotide Binding Protein 1 (hHint) IMP complex","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5KM0"
"5KM1",,"X-RAY DIFFRACTION",2.06,40.43,"VAPOR DIFFUSION, HANGING DROP",6.1,"100 mM MES, 31% PEG 8000,",293,"10.1021/acs.molpharmaceut.7b00664",,"5KM1",28.62,"1.65","1.65","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) GMP catalytic product complex","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5KM1"
"5KM2",,"X-RAY DIFFRACTION",2.05,40.14,"VAPOR DIFFUSION, HANGING DROP",6.1,"100 mM MES, 38% PEG 8000,",293,"10.1021/acs.molpharmaceut.7b00664",,"5KM2",28.64,"1.25","1.25","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) CMP catalytic product complex","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5KM2"
"5KM3",,"X-RAY DIFFRACTION",2.04,39.79,"VAPOR DIFFUSION, HANGING DROP",6.1,"100 mM MES, 38% PEG 8000,",293,"10.1021/acs.molpharmaceut.7b00664",,"5KM3",28.61,"1.2","1.2","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) UMP catalytic product complex","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5KM3"
"5KM4",,"X-RAY DIFFRACTION",2.06,40.33,"VAPOR DIFFUSION, HANGING DROP",6.7,"100 mM MES, 34-39% PEG 8000,",293,"10.1021/acs.molpharmaceut.7b00664",,"5KM4",28.64,"1.4","1.4","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1)-5-Iodo-UMP complex","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5KM4"
"5KM5",,"X-RAY DIFFRACTION",1.85,33.62,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM MES, 45% PEG 8000",293,"10.1021/acs.molpharmaceut.7b00664",,"5KM5",31.07,"2.1","2.1","Human Histidine Triad Nucleotide Binding Protein 2 (hHint2) triciribine 5'-monoposphate catalytic product complex","SNAMGQVRGAAGVTDGNEVAKAQQATPGGAAPTIFSRILDKSLPADILYEDQQCLVFRDVAPQAPVHFLVIPKKPIPRISQAEEEDQQLLGHLLLVAKQTAKAEGLGDGYRLVINDGKLGAQSVYHLHIHVLGGRQLQWPPG","Homo sapiens","HINT2","Histidine triad nucleotide-binding protein 2, mitochondrial","1","5KM5"
"5KM6",,"X-RAY DIFFRACTION",2.06,40.38,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM MES, 32% PEG 8000",293,"10.1021/acs.molpharmaceut.7b00664",,"5KM6",14.56,"1.6","1.6","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) H112N mutant Ara-A nucleoside phosphoramidate substrate complex","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVNLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5KM6"
"5KM8",,"X-RAY DIFFRACTION",1.78,31.08,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM MES, 45% PEG 8000",293,"10.1021/acs.molpharmaceut.7b00664",,"5KM8",31.05,"2","2","Human Histidine Triad Nucleotide Binding Protein 2 (hHint2) Cidofovir complex","SNAMGQVRGAAGVTDGNEVAKAQQATPGGAAPTIFSRILDKSLPADILYEDQQCLVFRDVAPQAPVHFLVIPKKPIPRISQAEEEDQQLLGHLLLVAKQTAKAEGLGDGYRLVINDGKLGAQSVYHLHIHVLGGRQLQWPPG","Homo sapiens","HINT2","Histidine triad nucleotide-binding protein 2, mitochondrial","1","5KM8"
"5KM9",,"X-RAY DIFFRACTION",1.8,31.86,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM MES, 38% PEG 8000",293,"10.1021/acs.molpharmaceut.7b00664",,"5KM9",31.03,"1.45","1.45","Human Histidine Triad Nucleotide Binding Protein 2 (hHint2) adenosine complex","SNAMGQVRGAAGVTDGNEVAKAQQATPGGAAPTIFSRILDKSLPADILYEDQQCLVFRDVAPQAPVHFLVIPKKPIPRISQAEEEDQQLLGHLLLVAKQTAKAEGLGDGYRLVINDGKLGAQSVYHLHIHVLGGRQLQWPPG","Homo sapiens","HINT2","Histidine triad nucleotide-binding protein 2, mitochondrial","1","5KM9"
"5KMA",,"X-RAY DIFFRACTION",2.05,40.1,"VAPOR DIFFUSION, HANGING DROP",6.4,"100 mM MES, 32% PEG 8000",293,"10.1021/acs.molpharmaceut.7b00664",,"5KMA",28.57,"1.55","1.55","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) H112N mutant nucleoside D-Trp phosphoramidate substrate complex","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVNLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5KMA"
"5KMB",,"X-RAY DIFFRACTION",2.04,39.77,"VAPOR DIFFUSION, HANGING DROP",6.7,"100 mM MES, 33% PEG 8000",293,"10.1021/acs.molpharmaceut.7b00664",,"5KMB",28.74,"1.6","1.6","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) H112N mutant nucleoside L-Trp phosphoramidate substrate complex","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVNLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5KMB"
"5KMC",,"X-RAY DIFFRACTION",2.15,42.81,"VAPOR DIFFUSION, HANGING DROP",6.1,"100 mM MES, 39% PEG 8000,",293,,,"5KMC",28.43,"1.35","1.35","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) non-nucleotidic covalent intermediate complex","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5KMC"
"5KMI",,"X-RAY DIFFRACTION",2.39,48.43,"VAPOR DIFFUSION, HANGING DROP",6.5,"50mM MES pH 6.5, 150 mM NaCl, 5mM TCEP, 0.1% beta-OctylGlucoside",298,"10.1073/pnas.1611577114",,"5KMI",37.66,"1.87","1.87","TrkA JM-kinase with 1-(9{H}-fluoren-9-yl)-3-(2-methyl-4-phenyl-pyrimidin-5-yl)urea","SSLSPTEGKGSGLQGHIIENPQYFSDACVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLGHHHHHH","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","5KMI"
"5KMJ",,"X-RAY DIFFRACTION",2.39,48.46,"VAPOR DIFFUSION, HANGING DROP",6.5,"50mM MES pH 6.5, 150 mM NaCl, 5mM TCEP, 0.1% beta-OctylGlucoside",298,"10.1073/pnas.1611577114","6UF","5KMJ",37.61,"2.04","2.04","TrkA JM-kinase with {N}-(2-pyridylmethyl)-2-[2-(2-thienyl)indol-1-yl]acetamide","SSLSPTEGKGSGLQGHIIENPQYFSDACVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLGHHHHHH","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","5KMJ"
"5KMK",,"X-RAY DIFFRACTION",2.38,48.39,"VAPOR DIFFUSION, HANGING DROP",6.5,"50mM MES pH 6.5, 150 mM NaCl, 5mM TCEP, 0.1% beta-OctylGlucoside",298,"10.1073/pnas.1611577114",,"5KMK",37.66,"2.24","2.24","TrkA JM-kinase with 2-fluoro-{N}-[2-(4-fluorophenyl)-6-methyl-3-pyridyl]-4-(trifluoromethyl)benzamide","SSLSPTEGKGSGLQGHIIENPQYFSDACVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLGHHHHHH","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","5KMK"
"5KML",,"X-RAY DIFFRACTION",2.41,49.02,"VAPOR DIFFUSION, HANGING DROP",6.5,"50mM MES pH 6.5, 150 mM NaCl, 5mM TCEP, 0.1% beta-OctylGlucoside",298,"10.1073/pnas.1611577114","6UH","5KML",37.67,"2.01","2.01","TrkA JM-kinase with 1-(5-methyl-3-phenyl-1,2-oxazol-4-yl)-3-[[2-(trifluoromethyl)phenyl]methyl]urea","XSSLSPTEGKGSGLQGHIIENPQYFSDACVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLGHHHHHH","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","5KML"
"5KMM",,"X-RAY DIFFRACTION",2.37,48.16,"VAPOR DIFFUSION, HANGING DROP",6.5,"50mM MES pH 6.5, 150 mM NaCl, 5mM TCEP, 0.1% beta-OctylGlucoside",298,"10.1073/pnas.1611577114","6UJ","5KMM",37.62,"2.12","2.12","TrkA JM-kinase with 1-(2-methyl-4-phenyl-pyrimidin-5-yl)-3-(1-naphthyl)urea","SSLSPTEGKGSGLQGHIIENPQYFSDACVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLGHHHHHH","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","5KMM"
"5KMN",,"X-RAY DIFFRACTION",2.41,48.93,"VAPOR DIFFUSION, HANGING DROP",6.5,"50mM MES pH 6.5, 150 mM NaCl, 5mM TCEP, 0.1% beta-OctylGlucoside",298,"10.1073/pnas.1611577114",,"5KMN",37.68,"2.14","2.14","TrkA JM-kinase with 1-(2-methyl-4-phenyl-pyrimidin-5-yl)-3-[[2-(trifluoromethyl)phenyl]methyl]urea","XSSLSPTEGKGSGLQGHIIENPQYFSDACVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLGHHHHHH","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","5KMN"
"5KMO",,"X-RAY DIFFRACTION",2.39,48.46,"VAPOR DIFFUSION, HANGING DROP",6.5,"50mM MES pH 6.5, 150 mM NaCl, 5mM TCEP, 0.1% beta-OctylGlucoside",298,"10.1073/pnas.1611577114","6UM","5KMO",37.57,"2.67","2.67","TrkA JM-kinase with 1-(2-methyl-4-phenyl-pyrimidin-5-yl)-3-(2-pyridyl)urea","SSLSPTEGKGSGLQGHIIENPQYFSDACVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLGHHHHHH","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","5KMO"
"5KNI",,"X-RAY DIFFRACTION",3.78,67.44,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M magnesium formate",298,"10.1016/j.str.2016.06.022",,"5KNI",52.97,"2.5","2.5","Crystal Structure of the wild-type SAM domain of human Tankyrase-1","SGLDMNISQFLKSLGLEHLRDIFETEQITLDVLADMGHEELKEIGINAYGHRHKLIKGVERLLGGQQ","Homo sapiens","TNKS, PARP5A, PARPL, TIN1, TINF1, TNKS1","Tankyrase-1","1","5KNI"
"5KNJ",,"X-RAY DIFFRACTION",2.22,44.51,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M Na Citrate and 15% PEG3350",291,"10.1371/journal.pone.0165983",,"5KNJ",65.61,"2.88","2.88","Pseudokinase Domain of MLKL bound to Compound 1.","GSEQIKEIKKEQLSGSPWILLRENEVSTLYKGEYHRAPVAIKVFKKLQAGSIAIVRQTFNKEIKTMKKFESPNILRIFGICIDETVTPPQFSIVMEYCELGTLRELLDREKDLTLGKRMVLVLGAARGLYRLHHSEAPELHGKIRSSNFLVTQGYQVKLAGFELRKTQTSMSLGTTRAATDRVKSTAYLSPQELEDVFYQYDVKSEIYSFGIVLWEIATGDIPFQGCNSEKIRKLVAVKRQQEPLGEDCPSELREIIDECRAHDPSVRPSVDEILKKLSTFSK","Homo sapiens","MLKL","Mixed lineage kinase domain-like protein","1","5KNJ"
"5KNN",,"X-RAY DIFFRACTION",2.55,51.74,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M Hepes pH 7.5, 20% Polyethylene glycol 3350, 0.2 M MgCl2",289,"10.1021/jacs.6b07121",,"5KNN",408.33,"2.68","2.68","Evolutionary gain of alanine mischarging to non-cognate tRNAs with a G4:U69 base pair","TLTASEIRQRFIDFFKRNEHTYVHSSATIPLDDPTLLFANAGMNQFKPIFLNTIDPSHPMAKLSRAANTQKCIRAGGKHNDLDDVGKDVYHHTFFEMLGSWSFGDYFKELACKMALELLTQEFGIPIERLYVTYFGGDEAAGLEADLECKQIWQNLGLDDTKILPGNMKDNFWEMGDTGPCGPCSEIHYDRIGGRDAAHLVNQDDPNVLEIWNLVFIQYNREADGILKPLPKKSIDTGMGLERLVSVLQNKMSNYDTDLFVPYFEAIQKGTGARPYTGKVGAEDADGIDMAYRVLADHARTITVALADGGRPDNTGRGYVLRRILRRAVRYAHEKLNASRGFFATLVDVVVQSLGDAFPELKKDPDMVKDIINEEEVQFLKTLSRGRRILDRKIQSLGDSKTIPGDTAWLLYDTYGFPVDLTGLIAEEKGLVVDMDGFEEERKLAQLKSQ","Homo sapiens","AARS, AARS1","Alanine--tRNA ligase, cytoplasmic","1","5KNN"
"5KNW",,"SOLUTION NMR",,,,,,,"10.1093/nar/gkw833",,"5KNW",14.4,,,"Solution NMR structure of human LARP7 xRRM2","MHHHHHHSNATGPQFVSGVIVKIISTEPLPGRKQVRDTLAAISEVLYVDLLEGDTECHARFKTPEDAQAVINAYTEINKKHCWKLEILSGDHEQRYWQKILVDRQAKLNQPREKKRGTEKLITKA","Homo sapiens","LARP7, HDCMA18P","La-related protein 7","1","5KNW"
"5KNZ","1.9","ELECTRON CRYSTALLOGRAPHY",,,"BATCH MODE",7.4,"1 mmol SGNNFGAILSS in 1 L phosphate-buffered saline with 1% DMSO incubated under quiescent conditions overnight",295,"10.7554/eLife.19273",,"5KNZ",1.07,"1.902, 1.9","1.902","Human Islet Amyloid Polypeptide Segment 19-SGNNFGAILSS-29 with Early Onset S20G Mutation Determined by MicroED","SGNNFGAILSS","Homo sapiens","IAPP","hIAPP(residues 19-29)S20G","1","5KNZ"
"5KO0","1.4","ELECTRON CRYSTALLOGRAPHY",,,"VAPOR DIFFUSION, HANGING DROP",,"2 uL 20 mg/mL FLVHSSNNFGA + 1 uL 35% MPD, 0.35 M sodium thiocyanate against a reservoir of 35% MPD, 0.35 M sodium thiocyanate. Crystals appeared within several hours.",277,"10.7554/eLife.19273",,"5KO0",2.44,"1.4, 1.4","1.4","Human Islet Amyloid Polypeptide Segment 15-FLVHSSNNFGA-25 Determined by MicroED","FLVHSSNNFGA","Homo sapiens","IAPP","hIAPP(15-25)WT","1","5KO0"
"5KO1",,"X-RAY DIFFRACTION",2.62,53.13,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M BisTRIS pH 6.5 20% PEG3350",291,"10.1371/journal.pone.0165983","6UY","5KO1",32.6,"2.16","2.16","Pseudokinase Domain of MLKL bound to Compound 4.","GSEQIKEIKKEQLSGSPWILLRENEVSTLYKGEYHRAPVAIKVFKKLQAGSIAIVRQTFNKEIKTMKKFESPNILRIFGICIDETVTPPQFSIVMEYCELGTLRELLDREKDLTLGKRMVLVLGAARGLYRLHHSEAPELHGKIRSSNFLVTQGYQVKLAGFELRKTQTSMSLGTTRAATDRVKSTAYLSPQELEDVFYQYDVKSEIYSFGIVLWEIATGDIPFQGCNSEKIRKLVAVKRQQEPLGEDCPSELREIIDECRAHDPSVRPSVDEILKKLSTFSK","Homo sapiens","MLKL","Mixed lineage kinase domain-like protein","1","5KO1"
"5KO9",,"X-RAY DIFFRACTION",2.44,44.89,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M BTP, 2% Tacsimate, 20% PEG3350",293,"10.1038/s41594-019-0246-6",,"5KO9",31.8,"1.5","1.5","Crystal Structure of the SRAP Domain of Human HMCES Protein","MCGRTSCHLPRDVLTRACAYQDRRGQQRLPEWRDPDKYCPSYNKSPQSNSPVLLSRLHFEKDADSSERIIAPMRWGLVPSWFKESDPSKLQFNTTNCRSDTVMEKRSFKVPLGKGRRCVVLADGFYEWQRCQGTNQRQPYFIYFPQIKTEKSGSIGAADSPENWEKVWDNWRLLTMAGIFDCWEPPEGGDVLYSYTIITVDSCKGLSDIHHRMPAILDGEEAVSKWLDFGEVSTQEALKLIHPTENITFHAVSSVVNNSRNNTPECLAPVAENLYFQ","Homo sapiens","HMCES, C3orf37, DC12, SRAPD1","Embryonic stem cell-specific 5-hydroxymethylcytosine-binding protein","1","5KO9"
"5KOQ",,"X-RAY DIFFRACTION",3,59.01,"VAPOR DIFFUSION, SITTING DROP",7.6,"23% PEG600, 100 mM citric acid",293,"10.1016/j.bmc.2016.09.030","6VR","5KOQ",75.25,"2.7","2.7","Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor","GNTTSSVILTNYMDTQYYGEIGIGTPPQTFKVVFDTGSSNVWVPSSKCSRLYTACVYHKLFDASDSSSYKHNGTELTLRYSTGTVSGFLSQDIITVGGITVTQMFGEVTEMPALPFMLAEFDGVVGMGFIEQAIGRVTPIFDNIISQGVLKEDVFSFYYNRDSENSQSLGGQIVLGGSDPQHYEGNFHYINLIKTGVWQIQMKGVSVGSSTLLCEDGCLALVDTGASYISGSTSSIEKLMEALGAKKRLFDYVVKCNEGPTLPDISFHLGGKEYTLTSADYVFQESYSSKKLCTLAIHAMDIPPPTGPTWALGATFIRKFYTEFDRRNNRIGFALAR","Homo sapiens","REN","Renin","1","5KOQ"
"5KOS",,"X-RAY DIFFRACTION",2.91,57.66,"VAPOR DIFFUSION, SITTING DROP",7.9,"23% PEG600, 100 mM citrate, Buffer: 25 mM Tris pH 7.9, 150 mM NaCl, ligand was soaked for 18h at 5mM",293,"10.1021/acsmedchemlett.6b00251","6VS","5KOS",76.46,"2.41","2.41","Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor","GNTTSSVILTNYMDTQYYGEIGIGTPPQTFKVVFDTGSSNVWVPSSKCSRLYTACVYHKLFDASDSSSYKHNGTELTLRYSTGTVSGFLSQDIITVGGITVTQMFGEVTEMPALPFMLAEFDGVVGMGFIEQAIGRVTPIFDNIISQGVLKEDVFSFYYNRDSENSQSLGGQIVLGGSDPQHYEGNFHYINLIKTGVWQIQMKGVSVGSSTLLCEDGCLALVDTGASYISGSTSSIEKLMEALGAKKRLFDYVVKCNEGPTLPDISFHLGGKEYTLTSADYVFQESYSSKKLCTLAIHAMDIPPPTGPTWALGATFIRKFYTEFDRRNNRIGFALAR","Homo sapiens","REN","Renin","1","5KOS"
"5KOT",,"X-RAY DIFFRACTION",3.06,59.75,"VAPOR DIFFUSION, SITTING DROP",7.9,"23% PEG600, 100 mM citrate, Buffer: 25 mM Tris pH 7.9, 150 mM NaCl, Ligand was soaked for 18h at 2mM",293,,"6VU","5KOT",77.14,"2.1","2.1","Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor","GNTTSSVILTNYMDTQYYGEIGIGTPPQTFKVVFDTGSSNVWVPSSKCSRLYTACVYHKLFDASDSSSYKHNGTELTLRYSTGTVSGFLSQDIITVGGITVTQMFGEVTEMPALPFMLAEFDGVVGMGFIEQAIGRVTPIFDNIISQGVLKEDVFSFYYNRDSENSQSLGGQIVLGGSDPQHYEGNFHYINLIKTGVWQIQMKGVSVGSSTLLCEDGCLALVDTGASYISGSTSSIEKLMEALGAKKRLFDYVVKCNEGPTLPDISFHLGGKEYTLTSADYVFQESYSSKKLCTLAIHAMDIPPPTGPTWALGATFIRKFYTEFDRRNNRIGFALAR","Homo sapiens","REN","Renin","1","5KOT"
"5KPK",,"X-RAY DIFFRACTION",2.98,58.78,"VAPOR DIFFUSION, SITTING DROP",7,"Reservoir: 0.15 M DL-malic acid, pH 7.0, 20% w/v PEG3350",298,"10.1126/scitranslmed.aam8460","6VK","5KPK",95.05,"2.4","2.4","Glycogen Synthase Kinase 3 beta Complexed with BRD0209","GSPGMSGRPRTTSFAESCKPVQQPSAFGSMKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQAAASTPTNATAASDANTGDRGQTNNAASASASNST","Homo sapiens","GSK3B","Glycogen synthase kinase-3 beta","1","5KPK"
"5KPL",,"X-RAY DIFFRACTION",2.64,53.47,"VAPOR DIFFUSION, SITTING DROP",6.5,"Reservoir: 0.1 M Bis-Tris, pH 6.5, 25% w/v PEG3350",298,"10.1126/scitranslmed.aam8460",,"5KPL",95,"2.6","2.6","Glycogen Synthase Kinase 3 beta Complexed with BRD0705","GSPGMSGRPRTTSFAESCKPVQQPSAFGSMKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQAAASTPTNATAASDANTGDRGQTNNAASASASNST","Homo sapiens","GSK3B","Glycogen synthase kinase-3 beta","1","5KPL"
"5KPM",,"X-RAY DIFFRACTION",2.96,58.4,"VAPOR DIFFUSION, SITTING DROP",7,"Reservoir: 0.2 M sodium acetate, pH 7.0, 20% w/v PEG3350",298,"10.1126/scitranslmed.aam8460",,"5KPM",95.11,"2.69","2.69","Glycogen Synthase Kinase 3 beta Complexed with BRD3731","GSPGMSGRPRTTSFAESCKPVQQPSAFGSMKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQAAASTPTNATAASDANTGDRGQTNNAASASASNST","Homo sapiens","GSK3B","Glycogen synthase kinase-3 beta","1","5KPM"
"5KPN",,"X-RAY DIFFRACTION",2.35,47.59,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.5M AMMONIUM SULFATE, 100mM TRIS",298,,,"5KPN",79.75,"2.3","2.3","Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor","HMKSKLPKPVQDLIKMIFDVESMKKAMVEYEIDLQKMPLGKLSKRQIQAAYSILSEVQQAVSQGSSDSQILDLSNRFYTLIPHDFGMKKPPLLNNADSVQAKAEMLDNLLDIEVAYSLLRGGSDDSSKDPIDVNYEKLKTDIKVVDRDSEEAEIIRKYVKNTHATTHNAYDLEVIDIFKIEREGECQRYKPFKQLHNRRLLWHGSRTTNFAGILSQGLRIAPPEAPVTGYMFGKGIYFADMVSKSANYCHTSQGDPIGLILLGEVALGNMYELKHASHISKLPKGKHSVKGLGKTTPDPSANISLDGVDVPLGTGISSGVNDTSLLYNEYIVYDIAQVNLKYLLKLKFNFKT","Homo sapiens","PARP1, ADPRT, PPOL","Poly [ADP-ribose] polymerase 1","1","5KPN"
"5KPO",,"X-RAY DIFFRACTION",2.33,47.3,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.5M AMMONIUM SULFATE, 100mM TRIS",298,,,"5KPO",79.73,"2.65","2.65","Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor","HMKSKLPKPVQDLIKMIFDVESMKKAMVEYEIDLQKMPLGKLSKRQIQAAYSILSEVQQAVSQGSSDSQILDLSNRFYTLIPHDFGMKKPPLLNNADSVQAKAEMLDNLLDIEVAYSLLRGGSDDSSKDPIDVNYEKLKTDIKVVDRDSEEAEIIRKYVKNTHATTHNAYDLEVIDIFKIEREGECQRYKPFKQLHNRRLLWHGSRTTNFAGILSQGLRIAPPEAPVTGYMFGKGIYFADMVSKSANYCHTSQGDPIGLILLGEVALGNMYELKHASHISKLPKGKHSVKGLGKTTPDPSANISLDGVDVPLGTGISSGVNDTSLLYNEYIVYDIAQVNLKYLLKLKFNFKT","Homo sapiens","PARP1, ADPRT, PPOL","Poly [ADP-ribose] polymerase 1","1","5KPO"
"5KPP",,"X-RAY DIFFRACTION",2.35,47.73,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.5M AMMONIUM SULFATE, 100mM TRIS",298,,,"5KPP",79.29,"2.33","2.33","Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor","KSKLPKPVQDLIKMIFDVESMKKAMVEYEIDLQKMPLGKLSKRQIQAAYSILSEVQQAVSQGSSDSQILDLSNRFYTLIPHDFGMKKPPLLNNADSVQAKAEMLDNLLDIEVAYSLLRGGSDDSSKDPIDVNYEKLKTDIKVVDRDSEEAEIIRKYVKNTHATTHNAYDLEVIDIFKIEREGECQRYKPFKQLHNRRLLWHGSRTTNFAGILSQGLRIAPPEAPVTGYMFGKGIYFADMVSKSANYCHTSQGDPIGLILLGEVALGNMYELKHASHISKLPKGKHSVKGLGKTTPDPSANISLDGVDVPLGTGISSGVNDTSLLYNEYIVYDIAQVNLKYLLKLKFNFKT","Homo sapiens","PARP1, ADPRT, PPOL","Poly [ADP-ribose] polymerase 1","1","5KPP"
"5KPQ",,"X-RAY DIFFRACTION",2.35,47.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.5M AMMONIUM SULFATE, 100mM TRIS",298,,,"5KPQ",79.21,"2.55","2.55","Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor","KSKLPKPVQDLIKMIFDVESMKKAMVEYEIDLQKMPLGKLSKRQIQAAYSILSEVQQAVSQGSSDSQILDLSNRFYTLIPHDFGMKKPPLLNNADSVQAKAEMLDNLLDIEVAYSLLRGGSDDSSKDPIDVNYEKLKTDIKVVDRDSEEAEIIRKYVKNTHATTHNAYDLEVIDIFKIEREGECQRYKPFKQLHNRRLLWHGSRTTNFAGILSQGLRIAPPEAPVTGYMFGKGIYFADMVSKSANYCHTSQGDPIGLILLGEVALGNMYELKHASHISKLPKGKHSVKGLGKTTPDPSANISLDGVDVPLGTGISSGVNDTSLLYNEYIVYDIAQVNLKYLLKLKFNFKT","Homo sapiens","PARP1, ADPRT, PPOL","Poly [ADP-ribose] polymerase 1","1","5KPQ"
"5KPR",,"X-RAY DIFFRACTION",2.31,46.8,"VAPOR DIFFUSION, SITTING DROP",5.6,"PEG 4000, ammonium acetate, citrate",291.15,"10.1074/jbc.M116.748061",,"5KPR",42.94,"1.827","1.827","PANK3-AMPPNP-Pantothenate complex","MGSSHHHHHHSSGLVPRGSPWFGMDIGGTLVKLSYFEPIDITAEEEQEEVESLKSIRKYLTSNVAYGSTGIRDVHLELKDLTLFGRRGNLHFIRFPTQDLPTFIQMGRDKNFSTLQTVLCATGGGAYKFEKDFRTIGNLHLHKLDELDCLVKGLLYIDSVSFNGQAECYYFANASEPERCQKMPFNLDDPYPLLVVNIGSGVSILAVHSKDNYKRVTGTSLGGGTFLGLCSLLTGCESFEEALEMASKGDSTQADKLVRDIYGGDYERFGLPGWAVASSFGNMIYKEKRESVSKEDLARATLVTITNNIGSVARMCAVNEKINRVVFVGNFLRVNTLSMKLLAYALDYWSKGQLKALFLEHEGYFGAVGALLGLPNFSDD","Homo sapiens","PANK3","Pantothenate kinase 3","1","5KPR"
"5KPT",,"X-RAY DIFFRACTION",2.31,46.8,"VAPOR DIFFUSION, SITTING DROP",5.6,"PEG 4000, ammonium acetate, citrate",291.15,"10.1074/jbc.M116.748061",,"5KPT",42.72,"2.301","2.301","PANK3-AMPPNP complex","MGSSHHHHHHSSGLVPRGSPWFGMDIGGTLVKLSYFEPIDITAEEEQEEVESLKSIRKYLTSNVAYGSTGIRDVHLELKDLTLFGRRGNLHFIRFPTQDLPTFIQMGRDKNFSTLQTVLCATGGGAYKFEKDFRTIGNLHLHKLDELDCLVKGLLYIDSVSFNGQAECYYFANASEPERCQKMPFNLDDPYPLLVVNIGSGVSILAVHSKDNYKRVTGTSLGGGTFLGLCSLLTGCESFEEALEMASKGDSTQADKLVRDIYGGDYERFGLPGWAVASSFGNMIYKEKRESVSKEDLARATLVTITNNIGSVARMCAVNEKINRVVFVGNFLRVNTLSMKLLAYALDYWSKGQLKALFLEHEGYFGAVGALLGLPNFSDD","Homo sapiens","PANK3","Pantothenate kinase 3","1","5KPT"
"5KPZ",,"X-RAY DIFFRACTION",2.31,46.8,"VAPOR DIFFUSION, SITTING DROP",5.6,"PEG 4000, ammonium acetate, citrate",291.15,"10.1074/jbc.M116.748061",,"5KPZ",42.88,"2.4","2.4","PANK3-ADP-PhosphoPantothenate complex","MGSSHHHHHHSSGLVPRGSPWFGMDIGGTLVKLSYFEPIDITAEEEQEEVESLKSIRKYLTSNVAYGSTGIRDVHLELKDLTLFGRRGNLHFIRFPTQDLPTFIQMGRDKNFSTLQTVLCATGGGAYKFEKDFRTIGNLHLHKLDELDCLVKGLLYIDSVSFNGQAECYYFANASEPERCQKMPFNLDDPYPLLVVNIGSGVSILAVHSKDNYKRVTGTSLGGGTFLGLCSLLTGCESFEEALEMASKGDSTQADKLVRDIYGGDYERFGLPGWAVASSFGNMIYKEKRESVSKEDLARATLVTITNNIGSVARMCAVNEKINRVVFVGNFLRVNTLSMKLLAYALDYWSKGQLKALFLEHEGYFGAVGALLGLPNFSDD","Homo sapiens","PANK3","Pantothenate kinase 3","1","5KPZ"
"5KQ8",,"X-RAY DIFFRACTION",2.31,46.8,"VAPOR DIFFUSION, SITTING DROP",5.6,"PEG 4000, ammonium acetate, citrate",291.15,"10.1074/jbc.M116.748061",,"5KQ8",42.64,"2.002","2.002","PANK3-AMPPN complex","MGSSHHHHHHSSGLVPRGSPWFGMDIGGTLVKLSYFEPIDITAEEEQEEVESLKSIRKYLTSNVAYGSTGIRDVHLELKDLTLFGRRGNLHFIRFPTQDLPTFIQMGRDKNFSTLQTVLCATGGGAYKFEKDFRTIGNLHLHKLDELDCLVKGLLYIDSVSFNGQAECYYFANASEPERCQKMPFNLDDPYPLLVVNIGSGVSILAVHSKDNYKRVTGTSLGGGTFLGLCSLLTGCESFEEALEMASKGDSTQADKLVRDIYGGDYERFGLPGWAVASSFGNMIYKEKRESVSKEDLARATLVTITNNIGSVARMCAVNEKINRVVFVGNFLRVNTLSMKLLAYALDYWSKGQLKALFLEHEGYFGAVGALLGLPNFSDD","Homo sapiens","PANK3","Pantothenate kinase 3","1","5KQ8"
"5KQD",,"X-RAY DIFFRACTION",3.57,65.55,"VAPOR DIFFUSION, SITTING DROP",7,"Ammonium sulfate, Tris, PEG 600, Glycerol",291.15,"10.1074/jbc.M116.748061",,"5KQD",43.23,"2.6","2.6","PANK3:Palmitoyl-CoA complex","MGSSHHHHHHSSGLVPRGSPWFGMDIGGTLVKLSYFEPIDITAEEEQEEVESLKSIRKYLTSNVAYGSTGIRDVHLELKDLTLFGRRGNLHFIRFPTQDLPTFIQMGRDKNFSTLQTVLCATGGGAYKFEKDFRTIGNLHLHKLDELDCLVKGLLYIDSVSFNGQAECYYFANASEPERCQKMPFNLDDPYPLLVVNIGSGVSILAVHSKDNYKRVTGTSLGGGTFLGLCSLLTGCESFEEALEMASKGDSTQADKLVRDIYGGDYERFGLPGWAVASSFGNMIYKEKRESVSKEDLARATLVTITNNIGSVARMCAVNEKINRVVFVGNFLRVNTLSMKLLAYALDYWSKGQLKALFLEHEGYFGAVGALLGLPNFSDD","Homo sapiens","PANK3","Pantothenate kinase 3","1","5KQD"
"5KQF",,"X-RAY DIFFRACTION",2.55,51.69,"VAPOR DIFFUSION",6.4,"10% PEG5000 MME, 9% PEG8000, 0.2 M ammonium iodide, 0.2 M sodium citrate, pH 6.4",295,"10.1021/acs.jmedchem.6b01012","6WD","5KQF",50.54,"1.98","1.98","(4~{S},6~{S})-4-[2,4-bis(fluoranyl)phenyl]-4-methyl-6-pyrimidin-5-yl-5,6-dihydro-1,3-thiazin-2-amine (compound 12) bound to BACE1","MASMTGGQQMGRGSAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5KQF"
"5KQG",,"X-RAY DIFFRACTION",2.26,45.53,"VAPOR DIFFUSION, HANGING DROP",,"25-30% PEGME 5000, 100 mM Bis-Tris, pH 6.0-6.5",293,"10.1021/acs.jmedchem.6b00993","6VX","5KQG",20.59,"1.5","1.5","Co-crystal structure of LMW-PTP in complex with 2-(benzothiazol-2-ylamino)-2-oxo-1-phenylethanesulfonic acid","MGSSHHHHHHSSGLVPRGSHMAEQATKSVLFVCLGNICRSPIAEAVFRKLVTDQNISENWRVDSAATSGYEIGNPPDYRGQSCMKRHGIPMSHVARQITKEDFATFDYILCMDESNLRDLNRKSNQVKTCKAKIELLGSYDPQKQLIIEDPYYGNDSDFETVYQQCVRCCRAFLEKAH","Homo sapiens","ACP1","Low molecular weight phosphotyrosine protein phosphatase","1","5KQG"
"5KQL",,"X-RAY DIFFRACTION",2.25,45.28,"VAPOR DIFFUSION, HANGING DROP",,"25-30% PEGME 5000, 100 mM Bis-Tris, pH 6.0-6.5",293,"10.1021/acs.jmedchem.6b00993",,"5KQL",20.53,"1.45","1.45","Co-crystal structure of LMW-PTP in complex with 2-oxo-1-phenyl-2-(phenylamino)ethanesulfonic acid","MGSSHHHHHHSSGLVPRGSHMAEQATKSVLFVCLGNICRSPIAEAVFRKLVTDQNISENWRVDSAATSGYEIGNPPDYRGQSCMKRHGIPMSHVARQITKEDFATFDYILCMDESNLRDLNRKSNQVKTCKAKIELLGSYDPQKQLIIEDPYYGNDSDFETVYQQCVRCCRAFLEKAH","Homo sapiens","ACP1","Low molecular weight phosphotyrosine protein phosphatase","1","5KQL"
"5KQM",,"X-RAY DIFFRACTION",2.17,43.37,"VAPOR DIFFUSION, HANGING DROP",6.5,"30% PEGME 5000, 0.2 M ammonium sulfate, 100 mM MES, pH=6.5",293,"10.1021/acs.jmedchem.6b00993",,"5KQM",20.43,"1.91","1.91","Co-crystal structure of LMW-PTP in complex with MES","MGSSHHHHHHSSGLVPRGSHMAEQATKSVLFVCLGNICRSPIAEAVFRKLVTDQNISENWRVDSAATSGYEIGNPPDYRGQSCMKRHGIPMSHVARQITKEDFATFDYILCMDESNLRDLNRKSNQVKTCKAKIELLGSYDPQKQLIIEDPYYGNDSDFETVYQQCVRCCRAFLEKAH","Homo sapiens","ACP1","Low molecular weight phosphotyrosine protein phosphatase","1","5KQM"
"5KQP",,"X-RAY DIFFRACTION",2.11,41.67,"VAPOR DIFFUSION, HANGING DROP",6.5,"Crystals grew under the following condition: 30% PEGME 5000, 0.2 M ammonium sulfate, 100 mM MES buffer, pH=6.5. Then crystal were transferred to buffer containing 30% PEGME 5000, 0.2 M ammonium sulfate, 100 mM Bis-Tris, pH=6.5 to deplete the bound MES.",293,"10.1021/acs.jmedchem.6b00993",,"5KQP",20.24,"2.052","2.052","Crystal structure of Apo-form LMW-PTP","MGSSHHHHHHSSGLVPRGSHMAEQATKSVLFVCLGNICRSPIAEAVFRKLVTDQNISENWRVDSAATSGYEIGNPPDYRGQSCMKRHGIPMSHVARQITKEDFATFDYILCMDESNLRDLNRKSNQVKTCKAKIELLGSYDPQKQLIIEDPYYGNDSDFETVYQQCVRCCRAFLEKAH","Homo sapiens","ACP1","Low molecular weight phosphotyrosine protein phosphatase","1","5KQP"
"5KR7",,"X-RAY DIFFRACTION",2.55,51.73,"VAPOR DIFFUSION, SITTING DROP",,"10-15% PEG 3350
0.2 magnesium chloride
0.1 HEPES pH 7.5",277,"10.1016/j.bmcl.2016.07.026","6X9","5KR7",85.42,"1.9","1.9","KDM4C bound to pyrazolo-pyrimidine scaffold","GSHMASMTGGQQMGRGSMEVAEVESPLNPSCKIMTFRPSMEEFREFNKYLAYMESKGAHRAGLAKVIPPKEWKPRQCYDDIDNLLIPAPIQQMVTGQSGLFTQYNIQKKAMTVKEFRQLANSGKYCTPRYLDYEDLERKYWKNLTFVAPIYGADINGSIYDEGVDEWNIARLNTVLDVVEEECGISIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHFGEPKSWYAIPPEHGKRLERLAQGFFPSSSQGCDAFLRHKMTLISPSVLKKYGIPFDKITQEAGEFMITFPYGYHAGFNHGFNCAESTNFATVRWIDYGKVAKLCTCRKDMVKISMDIFVRKFQPDRYQLWKQGKDIYTIDHTKPTP","Homo sapiens","KDM4C, GASC1, JHDM3C, JMJD2C, KIAA0780","Lysine-specific demethylase 4C","1","5KR7"
"5KR8",,"X-RAY DIFFRACTION",2.56,51.9,"VAPOR DIFFUSION",6.4,"10% PEG5000 MME, 9% PEG8000, 0.2 M ammonium iodide, 0.2 M sodium citrate, pH 6.4",295,"10.1021/acs.jmedchem.6b01012","6WE","5KR8",50.68,"2.118","2.118","(4~{S},6~{S})-4-[2,4-bis(fluoranyl)phenyl]-6-(3,5-dimethyl-1,2-oxazol-4-yl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine (compound 5) bound to BACE1","MASMTGGQQMGRGSAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5KR8"
"5KRE",,"X-RAY DIFFRACTION",2.09,41.04,"VAPOR DIFFUSION, HANGING DROP",8,"Reservoir: 22% PEG 3350 and 100mM ammonium nitrate, Protein Buffer: 20mM Tris pH 8.0, 30mM NaCl, 1mM TCEP",293,"10.1021/acschembio.6b00266",,"5KRE",26.77,"2","2","Covalent inhibitor of LYPLAL1","GPMAAASGSVLQRCIVSPAGRHSASLIFLHGSGDSGQGLRMWIKQVLNQDLTFQHIKIIYPTAPPRSYTPMKGGISNVWFDRFKITNDCPEHLESIDVMCQVLTDLIDEEVKSGIKKNRILIGGFSMGGCMAMHLAYRNHQDVAGVFALSSFLNKASAVYQALQKSNGVLPELFQCHGTADELVLHSWAEETNSMLKSLGVTTKFHSFPNVYHELSKTELDILKLWILTKLPGEMEKQK","Homo sapiens","LYPLAL1","Lysophospholipase-like protein 1","1","5KRE"
"5KS5",,"SOLUTION NMR",,,,,,,"10.1021/acs.biochem.6b00711",,"5KS5",11.86,,,"Structure of the C-terminal Helical Repeat Domain of Elongation Factor 2 Kinase","GSHMSPDRCQDWLEALHWYNTALEMTDCDEGGEYDGMQDEPRYMMLAREAEMLFTGGYGLEKDPQRSGDLYTQAAEAAMEAMKGRLANQYYQKAEEAWAQMEE","Homo sapiens","EEF2K","Eukaryotic elongation factor 2 kinase","1","5KS5"
"5KSO",,"X-RAY DIFFRACTION",2.32,47.1,"VAPOR DIFFUSION, SITTING DROP",5,"19 mg/mL protein, 5 mM magnesium chloride, 0.1 M SPG buffer, pH 5.0, 25% w/v PEG1500, GDP observed in the structure was carried through from the expression system during purification",294,"10.1038/srep33019",,"5KSO",22.54,"2.25","2.25","hMiro1 C-domain GDP-Pi Complex P3121 Crystal Form","KKQTQRNVFRCNVIGVKNCGKSGVLQALLGRNLMRQKKIREDHKSYYAINTVYVYGQEKYLLLHDISESEFLTEAEIICDVVCLVYDVSNPKSFEYCARIFKQHFMDSRIPCLIVAAKSDLHEVKQEYSISPTDFCRKHKMPPPQAFTCNTADAPSKDIFVKLTTMAMYPHVTQADLKSSTFLEHHHHHH","Homo sapiens","RHOT1, ARHT1","Mitochondrial Rho GTPase 1","1","5KSO"
"5KSP",,"X-RAY DIFFRACTION",2.07,40.6,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 mg/mL protein, 6 mM magnesium chloride, 0.1 M Tris, pH 8.5, 12% w/v PEG4000, GDP observed in the structure was carried through from the expression system during purification",294,"10.1038/srep33019",,"5KSP",44.96,"2.162","2.162","hMiro1 C-domain GDP Complex C2221 Crystal Form","KKQTQRNVFRCNVIGVKNCGKSGVLQALLGRNLMRQKKIREDHKSYYAINTVYVYGQEKYLLLHDISESEFLTEAEIICDVVCLVYDVSNPKSFEYCARIFKQHFMDSRIPCLIVAAKSDLHEVKQEYSISPTDFCRKHKMPPPQAFTCNTADAPSKDIFVKLTTMAMYPHVTQADLKSSTFLEHHHHHH","Homo sapiens","RHOT1, ARHT1","Mitochondrial Rho GTPase 1","1","5KSP"
"5KSX",,"X-RAY DIFFRACTION",2.66,53.75,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.6 M sodium phosphate, 0.6 M potassium phosphate, 25% glycerol, 0.075 M HEPES, pH 7.5",295.15,"10.1021/acs.jmedchem.6b01888","7AM","5KSX",44.18,"2.65","2.65","Crystal structure of human FPPS in complex with an allosteric inhibitor AM-02-072","MGSSHHHHHHSSGRENLYFQGHMNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK","Homo sapiens","FDPS, FPS, KIAA1293","Farnesyl pyrophosphate synthase","1","5KSX"
"5KSY",,"X-RAY DIFFRACTION",2.29,46.34,"VAPOR DIFFUSION, SITTING DROP",8.5,"12 mg/mL protein, 0.1 M Tris, pH 8.5, 16% w/v PEG10000, GDP observed in the structure was carried through from the expression system during purification",294,"10.1038/srep33019",,"5KSY",22.63,"2.482","2.482","hMiro1 C-domain GDP Complex P41212 Crystal Form","MGKKQTQRNVFRCNVIGVKNCGKSGVLQALLGRNLMRQKKIREDHKSYYAINTVYVYGQEKYLLLHDISESEFLTEAEIICDVVCLVYDVSNPKSFEYCARIFKQHFMDSRIPCLIVAAKSDLHEVKQEYSISPTDFCRKHKMPPPQAFTCNTADAPSKDIFVKLTTMAMYPHVTQADLKSSTFLEHHHHHH","Homo sapiens","RHOT1, ARHT1","Mitochondrial Rho GTPase 1","1","5KSY"
"5KSZ",,"X-RAY DIFFRACTION",3.07,59.91,"VAPOR DIFFUSION, SITTING DROP",,"12 mg/mL protein, 6 mM magnesium chloride, 10 mM GMPPCP, 0.2 M ammonium sulfate, 0.1 M trisodium citrate, pH 5.6, 17.5% w/v PEG4000",294,"10.1038/srep33019",,"5KSZ",49.67,"2.5","2.5","hMiro EF hand and cGTPase domains in the GMPPCP-bound state","EEKEMKPACIKALTRIFKISDQDNDGTLNDAELNFFQRICFNTPLAPQALEDVKNVVRKHISDGVADSGLTLKGFLFLHTLFIQRGRHETTWTVLRRFGYDDDLDLTPEYLFPLLKIPPDCTTELNHHAYLFLQSTFDKHDLDRDCALSPDELKDLFKVFPYIPWGPDVNNTVCTNERGWITYQGFLSQWTLTTYLDVQRCLEYLGYLGYSILTEQESQASAVTVTRDKKIDLQKKQTQRNVFRCNVIGVKNCGKSGVLQALLGRNLMRQKKIREDHKSYYAINTVYVYGQEKYLLLHDISESEFLTEAEIICDVVCLVYDVSNPKSFEYCARIFKQHFMDSRIPCLIVAAKSDLHEVKQEYSISPTDFCRKHKMPPPQAFTCNTADAPSKDIFVKLTTMAMYPHVTQADLKSSTFLEHHHHHH","Homo sapiens","RHOT1, ARHT1","Mitochondrial Rho GTPase 1","1","5KSZ"
"5KTU",,"X-RAY DIFFRACTION",2.22,44.55,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M magnesium chloride, 0.1 M Bis-Tris pH 6.5, and 25% polyethylene glycol (PEG) 3350",277,"10.1021/acs.jmedchem.6b01022","6XB","5KTU",28.32,"1.38","1.38","Crystal structure of the bromodomain of human CREBBP bound to pyrazolopiperidine scaffold","GSKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5KTU"
"5KTW",,"X-RAY DIFFRACTION",2.09,41.04,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M potassium thiocyanate, 
0.1 M Bis-Tris pH 5.5, 
5% v/v ethylene glycol, 
23% PEG 3350",277,"10.1021/acs.jmedchem.6b01022","6XG","5KTW",42.32,"1.087","1.087","CREBBP bromodomain in complex with Cpd 44 (3-((5-acetyl-1-(cyclopropylmethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)-N-isopropylbenzamide)","AAFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQAL","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5KTW"
"5KTX",,"X-RAY DIFFRACTION",2.58,52.24,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M potassium thiocyanate, 
0.1 M Bis-Tris pH 5.5, 
5% v/v ethylene glycol, 
23% PEG 3350",287,"10.1021/acs.jmedchem.6b01022","6XH","5KTX",14.17,"1.27","1.27","CREBBP bromodomain in complex with Cpd59 ((S)-1-(3-((2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)ethanone)","AAFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQAL","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5KTX"
"5KTY",,"X-RAY DIFFRACTION",3.11,60.39,"VAPOR DIFFUSION, SITTING DROP",,"10 mg/mL protein, 5 mM calcium chloride, 1 mM GDP, 0.04 M potassium phosphate, 16% w/v PEG8000, 20% v/v glycerol",294,"10.1038/srep33019",,"5KTY",50.06,"2.522","2.522","hMiro EF hand and cGTPase domains, GDP and Ca2+ bound state","EEKEMKPACIKALTRIFKISDQDNDGTLNDAELNFFQRICFNTPLAPQALEDVKNVVRKHISDGVADSGLTLKGFLFLHTLFIQRGRHETTWTVLRRFGYDDDLDLTPEYLFPLLKIPPDCTTELNHHAYLFLQSTFDKHDLDRDCALSPDELKDLFKVFPYIPWGPDVNNTVCTNERGWITYQGFLSQWTLTTYLDVQRCLEYLGYLGYSILTEQESQASAVTVTRDKKIDLQKKQTQRNVFRCNVIGVKNCGKSGVLQALLGRNLMRQKKIREDHKSYYAINTVYVYGQEKYLLLHDISESEFLTEAEIICDVVCLVYDVSNPKSFEYCARIFKQHFMDSRIPCLIVAAKSDLHEVKQEYSISPTDFCRKHKMPPPQAFTCNTADAPSKDIFVKLTTMAMYPHVTQADLKSSTFLEHHHHHH","Homo sapiens","RHOT1, ARHT1","Mitochondrial Rho GTPase 1","1","5KTY"
"5KU1",,"X-RAY DIFFRACTION",2.96,58.43,"VAPOR DIFFUSION, HANGING DROP",,"9 mg/mL protein, 5 mM magnesium chloride, 1 mM GDP, 0.2 M ammonium sulfate, 0.1 M trisodium citrate, pH 5.6, 25% w/v PEG4000",294,"10.1038/srep33019",,"5KU1",49.59,"2.501","2.501","hMiro1 EF hand and cGTPase domains in the GDP-bound state","EEKEMKPACIKALTRIFKISDQDNDGTLNDAELNFFQRICFNTPLAPQALEDVKNVVRKHISDGVADSGLTLKGFLFLHTLFIQRGRHETTWTVLRRFGYDDDLDLTPEYLFPLLKIPPDCTTELNHHAYLFLQSTFDKHDLDRDCALSPDELKDLFKVFPYIPWGPDVNNTVCTNERGWITYQGFLSQWTLTTYLDVQRCLEYLGYLGYSILTEQESQASAVTVTRDKKIDLQKKQTQRNVFRCNVIGVKNCGKSGVLQALLGRNLMRQKKIREDHKSYYAINTVYVYGQEKYLLLHDISESEFLTEAEIICDVVCLVYDVSNPKSFEYCARIFKQHFMDSRIPCLIVAAKSDLHEVKQEYSISPTDFCRKHKMPPPQAFTCNTADAPSKDIFVKLTTMAMYPHVTQADLKSSTFLEHHHHHH","Homo sapiens","RHOT1, ARHT1","Mitochondrial Rho GTPase 1","1","5KU1"
"5KU3",,"X-RAY DIFFRACTION",2.18,43.68,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M Bis-Tris pH 6.8, 18% PEG 3350, 20% ethylene glycol",287,"10.1021/acs.jmedchem.6b01022","6XH","5KU3",16.09,"1.14","1.14","BRD4 bromodomain in complex with Cpd59 ((S)-1-(3-((2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-1-(tetrahydrofuran-3-yl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)ethanone)","STNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5KU3"
"5KU6",,"X-RAY DIFFRACTION",2.5,50.87,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 mM Na acetate, 200 mM AmSO4 and 23% PEG 4000",277,"10.1007/s00249-017-1256-0","MZM, ACT, SO4","5KU6",124.07,"1.8","1.8","Crystal structure for the complex of human carbonic anhydrase IV and methazolamide","AESHWCYEVQAESSNYPCLVPVKWGGNCQKDRQSPINIVTTKAKVDKKLGRFFFSGYDKKQTWTVQNNGHSVMMLLENKASISGGGLPAPYQAKQLHLHWSDLPYKGSEHSLDGEHFAMEMHIVHEKEKGTSRNVKEAQDPEDEIAVLAFLVEAGTQVNEGFQPLVEALSNIPKPEMSTTMAESSLLDLLPKEEKLRHYFRYLGSLTTPTCDEKVVWTVFREPIQLHREQILAFSQKLYYDKEQTVSMKDNVRPLQQLGQRTVIKS","Homo sapiens","CA4","Carbonic anhydrase 4","1","5KU6"
"5KU8",,"X-RAY DIFFRACTION",3.12,60.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"22-26% PEG 6K, 200 mM ammonium sulfate, 100 mM MES",293,,,"5KU8",82.84,"2.22","2.22","Crystal structure of CK2","SGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQA","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5KU8"
"5KUE",,"X-RAY DIFFRACTION",2.2,44.19,"VAPOR DIFFUSION, HANGING DROP",8,"0.32 M magnesium chloride, 0.1 M Tris pH 8.5, 24 % PEG 400, 1.6 M ammonium sulfate",291,"10.1016/j.chembiol.2016.07.012",,"5KUE",14.31,"1.5","1.5","Human SeMet incorporated I141M/L146M mitochondrial calcium uniporter (residues 72-189) crystal structure with magnesium","GSHMASSDDVTVVYQNGLPVISVRLPSRRERCQFTLKPISDSVGVFLRQLQEEDRGIDRVAIYSPDGVRVAASTGMDLLLMDDFKLVINDLTYHVRPPKRDLLSHENAATLNDVKTLVQQLYTT","Homo sapiens","MCU, C10orf42, CCDC109A","Calcium uniporter protein, mitochondrial","1","5KUE"
"5KUG",,"X-RAY DIFFRACTION",2.25,45.21,"VAPOR DIFFUSION, HANGING DROP",8,"0.2 M lithium sulfate, 0.1 M imidazole pH 8.0, 10 % PEG 3000, 1.5 M ammonium sulfate.",291,"10.1016/j.chembiol.2016.07.012",,"5KUG",13.88,"1.9","1.9","Human mitochondrial calcium uniporter (residues 72-189) crystal structure with lithium","GSHMASSDDVTVVYQNGLPVISVRLPSRRERCQFTLKPISDSVGVFLRQLQEEDRGIDRVAIYSPDGVRVAASTGIDLLLLDDFKLVINDLTYHVRPPKRDLLSHENAATLNDVKTLVQQLYTT","Homo sapiens","MCU, C10orf42, CCDC109A","Calcium uniporter protein, mitochondrial","1","5KUG"
"5KUI",,"X-RAY DIFFRACTION",1.96,37.27,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M calcium acetate, 0.1 M imidazole pH 8.0, 10 % PEG 8000, 1.3 M ammonium sulfate.",291,"10.1016/j.chembiol.2016.07.012",,"5KUI",13.88,"2.701","2.701","Human mitochondrial calcium uniporter (residues 72-189) crystal structure with calcium.","GSHMASSDDVTVVYQNGLPVISVRLPSRRERCQFTLKPISDSVGVFLRQLQEEDRGIDRVAIYSPDGVRVAASTGIDLLLLDDFKLVINDLTYHVRPPKRDLLSHENAATLNDVKTLVQQLYTT","Homo sapiens","MCU, C10orf42, CCDC109A","Calcium uniporter protein, mitochondrial","1","5KUI"
"5KUJ",,"X-RAY DIFFRACTION",2.2,44.05,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.32 M magnesium chloride, 0.1 M Tris pH 8.5, 24 % PEG 400, 1.6 M ammonium sulfate.",291,"10.1016/j.chembiol.2016.07.012",,"5KUJ",13.91,"1.6","1.6","Human mitochondrial calcium uniporter (residues 72-189) crystal structure with magnesium.","GSHMASSDDVTVVYQNGLPVISVRLPSRRERCQFTLKPISDSVGVFLRQLQEEDRGIDRVAIYSPDGVRVAASTGIDLLLLDDFKLVINDLTYHVRPPKRDLLSHENAATLNDVKTLVQQLYTT","Homo sapiens","MCU, C10orf42, CCDC109A","Calcium uniporter protein, mitochondrial","1","5KUJ"
"5KUL",,"X-RAY DIFFRACTION",2.78,55.68,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KUL",17.91,"1.7","1.7","Human cyclophilin A at 100K, Data set 1","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KUL"
"5KUN",,"X-RAY DIFFRACTION",2.78,55.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KUN",17.91,"1.7","1.7","Human cyclophilin A at 100K, Data set 2","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KUN"
"5KUO",,"X-RAY DIFFRACTION",2.78,55.69,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KUO",17.91,"1.7","1.7","Human cyclophilin A at 100K, Data set 3","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KUO"
"5KUP",,"X-RAY DIFFRACTION",2.26,45.67,"VAPOR DIFFUSION, HANGING DROP",5.5,"PEG 10K, citrate, LiSO4",286,"10.1021/acschembio.6b00480","6XL","5KUP",32.81,"1.389","1.389","Bruton's tyrosine kinase (BTK) with pyridazinone compound 9","MGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDENLYFQ","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","5KUP"
"5KUQ",,"X-RAY DIFFRACTION",2.78,55.68,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KUQ",17.91,"1.7","1.7","Human cyclophilin A at 100K, Data set 4","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KUQ"
"5KUR",,"X-RAY DIFFRACTION",2.77,55.66,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KUR",17.91,"1.7","1.7","Human cyclophilin A at 100K, Data set 5","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KUR"
"5KUS",,"X-RAY DIFFRACTION",2.77,55.67,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KUS",17.91,"1.7","1.7","Human cyclophilin A at 100K, Data set 6","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KUS"
"5KUT",,"X-RAY DIFFRACTION",2.11,41.84,"VAPOR DIFFUSION, SITTING DROP",,"14 mg/mL protein, 0.2 M magnesium formate, 20% w/v PEG3350",294,"10.1038/srep33019",,"5KUT",62.17,"1.693","1.693","hMiro2 C-terminal GTPase domain, GDP-bound","MKGQTQRSVLLCKVVGACGVGKSAFLQAFLGRGLGHQDTREQPPGYAIDTVQVNGQEKYLILCEVGTDGLLATSLDATCDVACLMFDGSDPKSFAHCASVYKHHYMDGQTPCLFVSSKADLPEGVAVSGPSPAEFCRKHRLPAPVPFSCAGPAEPSTTIFTQLATMAAFPHLVHAELHPSSLEHHHHHH","Homo sapiens","RHOT2, ARHT2, C16orf39","Mitochondrial Rho GTPase 2","1","5KUT"
"5KUU",,"X-RAY DIFFRACTION",2.77,55.66,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KUU",17.91,"1.7","1.7","Human cyclophilin A at 100K, Data set 7","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KUU"
"5KUV",,"X-RAY DIFFRACTION",2.78,55.69,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KUV",17.91,"1.7","1.7","Human cyclophilin A at 100K, Data set 8","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KUV"
"5KUW",,"X-RAY DIFFRACTION",2.78,55.7,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KUW",17.91,"1.7","1.7","Human cyclophilin A at 100K, Data set 9","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KUW"
"5KUZ",,"X-RAY DIFFRACTION",2.82,56.31,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KUZ",17.91,"1.7","1.7","Human cyclophilin A at 278K, Data set 1","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KUZ"
"5KV0",,"X-RAY DIFFRACTION",2.81,56.28,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KV0",17.91,"1.7","1.7","Human cyclophilin A at 278K, Data set 2","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KV0"
"5KV1",,"X-RAY DIFFRACTION",2.81,56.22,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KV1",17.91,"1.7","1.7","Human cyclophilin A at 278K, Data set 3","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KV1"
"5KV2",,"X-RAY DIFFRACTION",2.81,56.24,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KV2",17.91,"1.7","1.7","Human cyclophilin A at 278K, Data set 4","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KV2"
"5KV3",,"X-RAY DIFFRACTION",2.82,56.32,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KV3",17.91,"1.7","1.7","Human cyclophilin A at 278K, Data set 5","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KV3"
"5KV4",,"X-RAY DIFFRACTION",2.82,56.31,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KV4",17.91,"1.7","1.7","Human cyclophilin A at 278K, Data set 6","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KV4"
"5KV5",,"X-RAY DIFFRACTION",2.82,56.33,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KV5",17.91,"1.7","1.7","Human cyclophilin A at 278K, Data set 7","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KV5"
"5KV6",,"X-RAY DIFFRACTION",2.81,56.3,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KV6",17.91,"1.7","1.7","Human cyclophilin A at 278K, Data set 8","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KV6"
"5KV7",,"X-RAY DIFFRACTION",2.82,56.44,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1107/S1600577516017343",,"5KV7",17.91,"1.7","1.7","Human cyclophilin A at 278K, Data set 9","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5KV7"
"5KVH",,"X-RAY DIFFRACTION",2.59,52.58,"VAPOR DIFFUSION, HANGING DROP",7.5,"300 mM Na2SO4, 16% PEG3350",291,"10.1016/j.str.2016.09.012",,"5KVH",120.37,"2.273","2.273","Crystal structure of human apoptosis-inducing factor with W196A mutation","MVGAGAYAYKTMKEDEKRYNERISGLGLTPEQKQKKAALSASEGEEVPQDKAPSHVPFLLIGGGTAAFAAARSIRARDPGARVLIVSEDPELPYMRPPLSKELWFSDDPNVTKTLRFKQANGKERSIYFQPPSFYVSAQDLPHIENGGVAVLTGKKVVQLDVRDNMVKLNDGSQITYEKCLIATGGTPRSLSAIDRAGAEVKSRTTLFRKIGDFRSLEKISREVKSITIIGGGFLGSELACALGRKARALGTEVIQLFPEKGNMGKILPEYLSNWTMEKVRREGVKVMPNAIVQSVGVSSGKLLIKLKDGRKVETDHIVAAVGLEPNVELAKTGGLEIDSDFGGFRVNAELQARSNIWVAGDAACFYDIKLGRRRVEHHDHAVVSGRLAGENMTGAAKPYWHQSMFWSDLGPDVGYEAIGLVDSSLPTVGVFAKATAQDNPKSATEQSGTGIRSESETESEASEITIPPSTPAVPQAPVQGEDYGKGVIFYLRDKVVVGIVLWNIFNRMPIARKIIKDGEQHEDLNEVAKLFNIHEDLEVLFQ","Homo sapiens","AIFM1, AIF, PDCD8","Apoptosis-inducing factor 1, mitochondrial","1","5KVH"
"5KVI",,"X-RAY DIFFRACTION",2.42,49.1,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM HEPES, pH 7.5, 50 mM NaCl, 24% PEG3350",291,"10.1016/j.str.2016.09.012",,"5KVI",60.36,"1.995","1.995","Crystal structure of monomeric human apoptosis-inducing factor with E413A/R422A/R430A mutations","MVGAGAYAYKTMKEDEKRYNERISGLGLTPEQKQKKAALSASEGEEVPQDKAPSHVPFLLIGGGTAAFAAARSIRARDPGARVLIVSEDPELPYMRPPLSKELWFSDDPNVTKTLRFKQWNGKERSIYFQPPSFYVSAQDLPHIENGGVAVLTGKKVVQLDVRDNMVKLNDGSQITYEKCLIATGGTPRSLSAIDRAGAEVKSRTTLFRKIGDFRSLEKISREVKSITIIGGGFLGSELACALGRKARALGTEVIQLFPEKGNMGKILPEYLSNWTMEKVRREGVKVMPNAIVQSVGVSSGKLLIKLKDGRKVETDHIVAAVGLEPNVELAKTGGLAIDSDFGGFAVNAELQAASNIWVAGDAACFYDIKLGRRRVEHHDHAVVSGRLAGENMTGAAKPYWHQSMFWSDLGPDVGYEAIGLVDSSLPTVGVFAKATAQDNPKSATEQSGTGIRSESETESEASEITIPPSTPAVPQAPVQGEDYGKGVIFYLRDKVVVGIVLWNIFNRMPIARKIIKDGEQHEDLNEVAKLFNIHEDLEVLFQ","Homo sapiens","AIFM1, AIF, PDCD8","Apoptosis-inducing factor 1, mitochondrial","1","5KVI"
"5KVT",,"X-RAY DIFFRACTION",2.8,55.9,"VAPOR DIFFUSION",6.5,"VAPOR DIFFUSION, HANGING DROP, 
WELL SOLUTION: 0.1M BIS-TRIS, PH6.5, 2.6-3.0M AMMONIUMACETATE
TEMPERATURE 277K",277,,"YMX","5KVT",34.16,"2.45","2.45","THE STRUCTURE OF TRKA KINASE DOMAIN BOUND TO THE INHIBITOR ENTRECTINIB","CVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAHHHHHH","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","5KVT"
"5KWH",,"X-RAY DIFFRACTION",3.11,60.46,"VAPOR DIFFUSION, HANGING DROP",6.5,"22-26% PEG 6K, 200 mM ammonium sulfate, 100 mM MES",293,,,"5KWH",83.17,"2.12","2.12","Crystal structure of CK2","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQAR","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5KWH"
"5KWQ",,"X-RAY DIFFRACTION",1.89,34.8,"VAPOR DIFFUSION, HANGING DROP",7.5,"1M Lithium sulfate, 0.1M HEPES (pH 7.5), 5% glycerol, mixed with an equal volume of 10 mg/ml protein",293,"10.1371/journal.pone.0242725",,"5KWQ",46.82,"2.8","2.8","Two Tandem RRM Domains of FBP-Interacting Repressor (FIR), also Known as PUF60","GSHMASMTGGQQMGRGSAAQRQGALAIMSRVYVGSIYYELGEDTIRQAFAPFGPIKSIDMSWDSVTMKHKGFAFVEYEVPEAAQLALEQMNSVMLGGRNIKVGRPSNIGQAQPIIDQLAEEARAFNRIYVASVHQDLSDDDIKSVFEAFGKIKSATLARDPTTGKHKGYGFIEYEKAQSSQDAVSSMNLFDLGGQYLRVGKAVTPPMPLLTPATPG","Homo sapiens","PUF60, FIR, ROBPI, SIAHBP1","Poly(U)-binding-splicing factor PUF60","1","5KWQ"
"5KX7",,"X-RAY DIFFRACTION",2.58,52.24,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.80 to 2.0 M Sodium Malonate, 0.2 M Sodium Acetate, 25 mM Hexamminecobalt(III)chloride, 0.05%w/v Pluronic-F-68",289,"10.1016/j.bmcl.2016.07.048","6YD","5KX7",68.24,"2.8","2.8","Irak4-inhibitor co-structure","VSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS","Homo sapiens","IRAK4","Interleukin-1 receptor-associated kinase 4","1","5KX7"
"5KX8",,"X-RAY DIFFRACTION",2.62,53.12,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.80 to 2.0 M Sodium Malonate, 0.2 M Sodium Acetate, 25 mM Hexamminecobalt(III)chloride, 0.05%w/v Pluronic-F-68",289,"10.1016/j.bmcl.2016.07.048","6YE","5KX8",137.3,"2.671","2.671","Irak4-inhibitor co-structure","VSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS","Homo sapiens","IRAK4","Interleukin-1 receptor-associated kinase 4","1","5KX8"
"5KXA",,"X-RAY DIFFRACTION",2.01,38.71,"VAPOR DIFFUSION, SITTING DROP",7,"20% PEG 3350, 0.1 M Sodium Acetate pH 7",293,"10.1124/jpet.116.237156",,"5KXA",100,"2.59","2.59","Selective Inhibition of Autotaxin is Effective in Mouse Models of Liver Fibrosis","MARRSSFQSCQIISLFTFAVGVNICLGFTAHRIKRAEGWEEGPPTVLSDSPWTAISGSCKGRCFELQEAGPPDCRCDNLCKSYTSCCHDFDELCLKTARGWECTKDRCGEVRNEENACHCSEDCLARGDCCTNYQVVCKGESHWVDDDCEEIKAAECPAGFVRPPLIIFSVDGFRASYMKKGSKVMPNIEKLRSCGTHSPYMRPVYPTKTFPNLYTLATGLYPESHGIVGNSMYDPVFDATFHLRGREKFNHRWWGGQPLWITATKQGVKAGTFFWSVVIPHERRILTILQWLTLPDHERPSVYAFYSEQPDFSGHKYGPFGPEMTNPLREIDKIVGQLMDGLKQLKLHRCVNVIFVGDHGMEDVTCDRTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAIIAALTCKKPDQHFKPYLKQHLPKRLHYANNRRIEDIHLLVERRWHVARKPLDVYKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGSTFKYKTKVPPFENIELYNVMCDLLGLKPAPNNGTHGSLNHLLRTNTFRPTMPEEVTRPNYPGIMYLQSDFDLGCTCDDKVEPKNKLDELNKRLHTKGSTEERHLLYGRPAVLYRTRYDILYHTDFESGYSEIFLMPLWTSYTVSKQAEVSSVPDHLTSCVRPDVRVSPSFSQNCLAYKNDKQMSYGFLFPPYLSSSPEAKYDAFLVTNMVPMYPAFKRVWNYFQRVLVKKYASERNGVNVISGPIFDYDYDGLHDTEDKIKQYVEGSSIPVPTHYYSIITSCLDFTQPADKCDGPLSVSSFILPHRPDNEESCNSSEDESKWVEELMKMHTARVRDIEHLTSLDFFRKTSRSYPEILTLKTYLHTYESEI","Homo sapiens","ENPP2, ATX, PDNP2","Ectonucleotide pyrophosphatase/phosphodiesterase family member 2","1","5KXA"
"5KY6",,"X-RAY DIFFRACTION",2.57,52.14,"VAPOR DIFFUSION, HANGING DROP",7,"1.6M ammonium citrate tribasic",292,,,"5KY6",157.36,"1.941","1.941","Human muscle fructose-1,6-bisphosphate aldolase","PYQYPALTPEQKKELSDIAHRIVAPGKGILAADESTGSIAKRLQSIGTENTEENRRFYRQLLLTADDRVNPCIGGVILFHETLYQKADDGRPFPQVIKSKGGVVGIKVDKGVVPLAGTNGETTTQGLDGLSERCAQYKKDGADFAKWRCVLKIGEHTPSALAIMENANVLARYASICQQNGIVPIVEPEILPDGDHDLKRCQYVTEKVLAAVYKALSDHHIYLEGTLLKPNMVTPGHACTQKFSHEEIAMATVTALRRTVPPAVTGITFLSGGQSEEEASINLNAINKCPLLKPWALTFSYGRALQASALKAWGGKKENLKAAQEEYVKRALANSLACQGKYTPSGQAGAAASESLFVSNHAY","Homo sapiens","ALDOA, ALDA","Fructose-bisphosphate aldolase A","1","5KY6"
"5KYB",,"X-RAY DIFFRACTION",2.44,49.5,"VAPOR DIFFUSION, HANGING DROP",7,"1% Tryptone, 0.05M HEPES Na pH 7.0, 20% PEG3350",292,"10.1016/j.str.2017.11.010",,"5KYB",81.42,"2.2","2.2","Crystal structure of the apo-form of USP7 catalytic domain [V302K] mutant","GSHMKKHTGYVGLKNQGATCYMNSLLQTLFFTNQLRKAVYMMPTEGDDSSKSVPLALQRVFYELQHSDKPVGTKKLTKSFGWETLDSFMQHDVQELCRKLLDNVENKMKGTCVEGTIPKLFRGKMVSYIQCKEVDYRSDRREDYYDIQLSIKGKKNIFESFVDYVAVEQLDGDNKYDAGEHGLQEAEKGVKFLTLPPVLHLQLMRFMYDPQTDQNIKINDRFEFPEQLPLDEFLQKTDPKDPANYILHAVLVHSGDNHGGHYVVYLNPKGDGKWCKFDDDVVSRCTKEEAIEHNYGGHDDDLSVRHCTNAYMLVYIRESKLSEVLQAVTDHDIPQQLVERLQEEKRIEAQK","Homo sapiens","USP7, HAUSP","Ubiquitin carboxyl-terminal hydrolase 7","1","5KYB"
"5KYK",,"X-RAY DIFFRACTION",3.01,59.19,"EVAPORATION",,"Protein was purified in buffer: 20 mM Hepes pH 8.0, 150 mM NaCl, 5 mM MgCl2 and 0.5 mM DTT. Crystals grew in five days at room temperature from hanging vapor diffusion drops with following condition: 0.1 M Citric acid pH 4.0, 20% PEG 3350. Crystals were cryoprotected in mother liquid with 40% PEG 3350 and flash frozen in liquid nitrogen.",293,"10.1021/acsmedchemlett.6b00373",,"5KYK",59.42,"2.702","2.702","Covalent GTP-competitive inhibitors of KRAS G12C: Guanosine bisphosphonate Analogs","GMTEYKLVVVGACGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQGVDDAFYTLVREIRKHKE","Homo sapiens","KRAS, KRAS2, RASK2","GTPase KRas","1","5KYK"
"5KZ0",,"X-RAY DIFFRACTION",2.09,41.19,"VAPOR DIFFUSION, HANGING DROP",,"HANGING DROP VAPOR DIFFUSION AT 13 DEGREES C. EQUAL VOLUMES OF PURIFIED PROTEIN SOLUTION(APPROXIMATELY 13-15 MG/ML)CONTAINING 0.0011M INHIBITOR COMPOUND WERE COMBINED WITH A SOLUTION CONTAINING:  0.15M AMMONIUM SULFATE, 9-10.5% MONOMETHYLETHER PEG5K AND 0.1M MES IN THE PH RANGE 5.3-6.5",286,"10.1021/jm500261q","6YL","5KZ0",37.31,"2.3","2.3","Structure of Human Anaplastic Lymphoma Kinase in Complex With 2-[(1R)-1-{[2-amino-5-(1,3-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl]oxy}ethyl]-4-fluoro-N,N-dimethylbenzamide","MAHHHHHHNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKV","Homo sapiens","ALK","ALK tyrosine kinase receptor","1","5KZ0"
"5KZ7",,"X-RAY DIFFRACTION",2.53,51.46,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BIS-TRIS PH 6.5, 14% PEG3350, 200MM AMM.SULFATE",298,"10.1016/j.bmcl.2016.08.068","6Z2","5KZ7",80.87,"3.2","3.2","Mark2 complex with 7-[(1S)-1-(4-fluorophenyl)ethyl]-5,5-dimethyl-2-(3-pyridylamino)pyrrolo[2,3-d]pyrimidin-6-one","MAHNHRHKHADYKDDDDKKLNSATSADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGKEVAVKIIDKTQLNSSSLQKLFREVRIMKVLNHPNIVKLFEVIETEKTLYLVMEYASGGEVFDYLVAHGRMKEKEARAKFRQIVSAVQYCHQKFIVHRDLKAENLLLDADMNIKIADFGFSNEFTFGNKLDTFCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTDCENLLKKFLILNPSKRGTLEQIMKDRWMNVGHEDDELKPYVEPLPDYKDPRRTELMVSMGYTREEIQDSLVGQRYNEVMATYLLLGYK","Homo sapiens","MARK2, EMK1","Serine/threonine-protein kinase MARK2","1","5KZ7"
"5KZ8",,"X-RAY DIFFRACTION",2.6,52.66,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BIS-TRIS PH 6.5, 14% PEG3350, 200MM AMM.SULFATE",298,"10.1016/j.bmcl.2016.08.068",,"5KZ8",80.88,"3.21","3.21","Mark2 complex with 7-[(1S)-1-(4-fluorophenyl)ethyl]-5,5-dimethyl-2-(3-pyridylamino)pyrrolo[2,3-d]pyrimidin-6-one","MAHNHRHKHADYKDDDDKKLNSATSADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGKEVAVKIIDKTQLNSSSLQKLFREVRIMKVLNHPNIVKLFEVIETEKTLYLVMEYASGGEVFDYLVAHGRMKEKEARAKFRQIVSAVQYCHQKFIVHRDLKAENLLLDADMNIKIADFGFSNEFTFGNKLDTFCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTDCENLLKKFLILNPSKRGTLEQIMKDRWMNVGHEDDELKPYVEPLPDYKDPRRTELMVSMGYTREEIQDSLVGQRYNEVMATYLLLGYK","Homo sapiens","MARK2, EMK1","Serine/threonine-protein kinase MARK2","1","5KZ8"
"5KZC",,"X-RAY DIFFRACTION",3.21,61.69,"VAPOR DIFFUSION, SITTING DROP",,"0.16 M ammonium sulfate, 20% (w/v) PEG4000, 20% (v/v) glycerol, 0.08 M sodium acetate, pH 4.6",293,"10.1371/journal.ppat.1005815",,"5KZC",206.91,"3.25","3.25","Crystal structure of an HIV-1 gp120 engineered outer domain with a Man9 glycan at position N276, in complex with broadly neutralizing antibody VRC01","QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLTVDDTAVYFCTRGKNCDYNWDFEHWGRGTPVIVSSPSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"VRC01 Fab heavy chain","1","5KZC"
,,,,,,,,,,,,,,,,"DTITLPCRPAPPPHCSSNITGLILTRDGGNSNAESEIFRPGGGDMRDIARCQIAGTVVSSQLFLNGSLAEEEVVIRSVNFTDNAKSICVQLATSVEIACTGAGHCAISRAKWANTLKQIASKLREQFGNAKTIIFKQSSGGDPEIVTHWFNCGGEFFYCASTQLFASTWFASTGTKHHHHHH","Homo sapiens",,"Engineered outer domain of gp120","2","5KZC"
,,,,,,,,,,,,,,,,"EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLRSPVTKSFNRGEC","Homo sapiens",,"VRC01 Fab light chain","3","5KZC"
"5KZI",,"X-RAY DIFFRACTION",3.27,62.37,"VAPOR DIFFUSION, HANGING DROP",8,"1.0M LiCl, 0.1M TRIS pH8.0, 20% PEG6K",277,"10.1016/j.bmcl.2016.09.067","6YN","5KZI",33.49,"2.1","2.1","Crystal structure of human Pim-1 kinase in complex with an imidazopyridazine inhibitor.","MAHHHHHHDEVDGPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLH","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5KZI"
"5KZN",,"X-RAY DIFFRACTION",4.84,74.58,"VAPOR DIFFUSION, SITTING DROP",,"100mM Tris HCl pH 8.5,.5% PEG MME 5K, 800mM Potassium Sodium Tartrate",294,"10.1021/acs.jmedchem.6b01119",,"5KZN",63.78,"2.8","2.8","Metabotropic Glutamate Receptor","MGSLLALLALLLLWGAVAEGPAKKVLTLEGDLVLGGLFPVHQKGGPAEDCGPVNEHRGIQRLEAMLFALDRINRDPHLLPGVRLGAHILDSCSKDTHALEQALDFVRASLSRGADGSRHICPDGSYATHGDAPTAITGVIGGSYSDVSIQVANLLRLFQIPQISYASTSAKLSDKSRYDYFARTVPPDFFQAKAMAEILRFFNWTYVSTVASEGDYGETGIEAFELEARARNICVATSEKVGRAMSRAAFEGVVRALLQKPSARVAVLFTRSEDARELLAASQRLNASFTWVASDGWGALESVVAGSEGAAEGAITIELASYPISDFASYFQSLDPWNNSRNPWFREFWEQRFRCSFRQRDCAAHSLRAVPFEQESKIMFVVNAVYAMAHALHNMHRALCPNTTRLCDAMRPVNGRRLYKDFVLNVKFDAPFRPADTHNEVRFDRFGDGIGRYNIFTYLRAGSGRYRYQKVGYWAEGLTLDTSLIPWASPSAGPLPASRCSEPCLQNEVKSVQPGEVCCWLCIPCQPYEYRLDEFTCADCGLGYWPNASLTGCFELPQEYIREGHHHHHH","Homo sapiens","GRM2, GPRC1B, MGLUR2","Metabotropic glutamate receptor 2","1","5KZN"
"5KZO",,"SOLUTION NMR",,,,,,,"10.1126/sciadv.1602794",,"5KZO",6.85,,,"Notch1 transmembrane and associated juxtamembrane segment","MGHHHHHHVQSETVEPPPPAQLHFMYVAAAAFVLLFFVGCGVLLSRKRRRQHGQLWFPE","Homo sapiens","NOTCH1, TAN1","Neurogenic locus notch homolog protein 1","1","5KZO"
"5KZQ",,"X-RAY DIFFRACTION",4.36,71.76,"VAPOR DIFFUSION, SITTING DROP",7.5,"18% PEG 20,000, 100 mM L-proline",294,"10.1021/acs.jmedchem.6b01119",,"5KZQ",63.89,"2.8","2.8","Metabotropic Glutamate Receptor in complex with antagonist (1~{S},2~{R},3~{S},4~{S},5~{R},6~{R})-2-azanyl-3-[[3,4-bis(fluoranyl)phenyl]sulfanylmethyl]-4-oxidanyl-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid","MGSLLALLALLLLWGAVAEGPAKKVLTLEGDLVLGGLFPVHQKGGPAEDCGPVNEHRGIQRLEAMLFALDRINRDPHLLPGVRLGAHILDSCSKDTHALEQALDFVRASLSRGADGSRHICPDGSYATHGDAPTAITGVIGGSYSDVSIQVANLLRLFQIPQISYASTSAKLSDKSRYDYFARTVPPDFFQAKAMAEILRFFNWTYVSTVASEGDYGETGIEAFELEARARNICVATSEKVGRAMSRAAFEGVVRALLQKPSARVAVLFTRSEDARELLAASQRLNASFTWVASDGWGALESVVAGSEGAAEGAITIELASYPISDFASYFQSLDPWNNSRNPWFREFWEQRFRCSFRQRDCAAHSLRAVPFEQESKIMFVVNAVYAMAHALHNMHRALCPNTTRLCDAMRPVNGRRLYKDFVLNVKFDAPFRPADTHNEVRFDRFGDGIGRYNIFTYLRAGSGRYRYQKVGYWAEGLTLDTSLIPWASPSAGPLPASRCSEPCLQNEVKSVQPGEVCCWLCIPCQPYEYRLDEFTCADCGLGYWPNASLTGCFELPQEYIREGHHHHHH","Homo sapiens","GRM2, GPRC1B, MGLUR2","Metabotropic glutamate receptor 2","1","5KZQ"
"5KZW",,"X-RAY DIFFRACTION",3.38,63.57,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 sodium HEPES, 2% (v/v) PEG 400, 2M ammonium sulfate",293,,,"5KZW",101.29,"2","2","Crystal structure of human GAA","PTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVHRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPIEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC","Homo sapiens","GAA","Lysosomal alpha-glucosidase","1","5KZW"
"5KZX",,"X-RAY DIFFRACTION",3.38,63.57,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 sodium HEPES, 2% (v/v) PEG 400, 2M ammonium sulfate",293,,,"5KZX",101.29,"2","2","Crystal structure of human GAA","PTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVHRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPIEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC","Homo sapiens","GAA","Lysosomal alpha-glucosidase","1","5KZX"
"5L01",,"X-RAY DIFFRACTION",1.51,18.76,"VAPOR DIFFUSION, SITTING DROP",7.6,"20% PEG 3350, 0.05M citrate/0.05 M Bis-tris Propane pH 7.6, 5% PEG 400",293,"10.1016/j.bmcl.2016.12.053","6Z4","5L01",51.68,"1.9","1.9","Tryptophan 5-hydroxylase in complex with inhibitor (3~{S})-8-[2-azanyl-6-[(1~{R})-1-(4-chloranyl-2-phenyl-phenyl)-2,2,2-tris(fluoranyl)ethoxy]pyrimidin-4-yl]-2,8-diazaspiro[4.5]decane-3-carboxylic acid","MIEDNKENKDHSLERGRASLIFSLKNEVGGLIKALKIFQEKHVNLLHIESRKSKRRNSEFEIFVDCDINREQLNDIFHLLKSHTNVLSVNLPDNFTLKEDGMETVPWFPKKISDLDHCANRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPTHACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPEPDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSGHAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNPYTRSIQILKDTKSITSAMNELQHDLDVVSDALAKVSRKPSI","Homo sapiens","TPH1, TPH, TPRH, TRPH","Tryptophan 5-hydroxylase 1","1","5L01"
"5L08","4.6","ELECTRON MICROSCOPY",,,,,,,"10.1016/j.molcel.2016.09.009",,"5L08",198,"4.6",,"Cryo-EM structure of Casp-8 tDED filament","MDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPIKDALMLFQRLQEKRMLEESNLSFLKELLFRINRLDLLITYLNTRKEEMERELQTPGRAQISAYRVMLYQISEEVSRSELRSFKFLLQEEISKCKLDDDMNLLDIFIEMEKRVILGEGKLDILKRVCAQINKSLLKIINDYEEFSKE","Homo sapiens","CASP8, MCH5","Caspase-8","1","5L08"
"5L0A",,"X-RAY DIFFRACTION",2.09,41.23,"VAPOR DIFFUSION, HANGING DROP",7.4,"10mM magnesium chloride, 2M sodium chloride, 10%PEG6000, 10mM Tris",292,,,"5L0A",37.01,"2.302","2.302","Human muscle fructose-1,6-bisphosphatase E69Q mutant in active R-state in complex with fructose-1,6-bisphosphate","TDRSPFETDMLTLTRYVMEKGRQAKGTGELTQLLNSMLTAIKAISSAVRKAGLAHLYGIAGSVNVTGDQVKKLDVLSNSLVINMLQSSYSTCVLVSEENKDAIITAKEKRGKYVVCFDPLDGSSNIDCLASIGTIFAIYRKTSEDEPSEKDALQCGRNIVAAGYALYGSATLVALSTGQGVDLFMLDPALGEFVLVEKDVKIKKKGKIYSLNEGYAKYFDAATTEYVQKKKFPEDGSAPYGARYVGSMVADVHRTLVYGGIFLYPANQKSPKGKLRLLYECNPVAYIIEQAGGLATTGTQPVLDVKPEAIHQRVPLILGSPEDVQEYLTCVQKNQAGS","Homo sapiens","FBP2","Fructose-1,6-bisphosphatase isozyme 2","1","5L0A"
"5L0C",,"X-RAY DIFFRACTION",3.28,62.4,"VAPOR DIFFUSION, HANGING DROP",,"20 mM citric acid, 80 mM Bis-Tris propane (pH 3.4), and 16% (w/v) PEG 3350",294,"10.1073/pnas.1600702113",,"5L0C",82.5,"3.1","3.1","Human metavinculin (residues 959-1134) in complex with PIP2","NQPVNQPILAAAQSLHREATKWSSKGNDIIAAAKRMALLMAEMSRLVRGGSGTKRALIQCAKDIAKASDEVTRLAKEVAKQCTDKRIRTNLLQVCERIPTISTQLKILSTVKATMLGRTNISDEESEQATEMLVHNAQNLMQSVKETVREAEAASIKIRTDAGFTLRWVRKTPWYQ","Homo sapiens","VCL","Vinculin","1","5L0C"
"5L0D",,"X-RAY DIFFRACTION",2.44,49.64,"VAPOR DIFFUSION, HANGING DROP",3.4,"20 mM citric acid, 80-100 mM Bis-Tris propane (pH 3.4), and 12-16% (w/v) PEG 3350",294,"10.1073/pnas.1600702113",,"5L0D",78.42,"2.75","2.75","Human Metavinculin(residues 959-1130) in complex with PIP2","NQPVNQPILAAAQSLHREATKWSSKGNDIIAAAKRMALLMAEMSRLVRGGSGTKRALIQCAKDIAKASDEVTRLAKEVAKQCTDKRIRTNLLQVCERIPTISTQLKILSTVKATMLGRTNISDEESEQATEMLVHNAQNLMQSVKETVREAEAASIKIRTDAGFTLRWVRKT","Homo sapiens","VCL","Vinculin","1","5L0D"
"5L0F",,"X-RAY DIFFRACTION",2.52,51.2,"VAPOR DIFFUSION, HANGING DROP",8.8,"20 mM citric acid, 80 mM Bis-Tris propane (pH 8.8), and 14 to 16% (w/v) PEG 3350",294,"10.1073/pnas.1600702113",,"5L0F",39.25,"2.76","2.76","Human metavinculin quadruple mutant (residues 959-1134)","NQPVNQPILAAAQSLHQEATQWSSKGNDIIAAAKRMALLMAEMSRLVRGGSGTKRALIQCAKDIAKASDEVTRLAKEVAKQCTDKRIRTNLLQVCERIPTISTQLKILSTVKATMLGRTNISDEESEQATEMLVHNAQNLMQSVKETVQEAEAASIKIRTDAGFTLRWVQKTPWYQ","Homo sapiens","VCL","Vinculin","1","5L0F"
"5L0G",,"X-RAY DIFFRACTION",2.3,46.5,"VAPOR DIFFUSION, HANGING DROP",7,"12% PEG 3350, 2% tryptone, and
0.05 M HEPES",293,"10.1073/pnas.1600702113",,"5L0G",80.14,"3.4","3.4","Human metavinculin MVt Q971R, R975D, T978R mutant (residues 959-1134) in complex with PIP2","NQPVNQPILAAARSLHDEARKWSSKGNDIIAAAKRMALLMAEMSRLVRGGSGTKRALIQCAKDIAKASDEVTRLAKEVAKQCTDKRIRTNLLQVCERIPTISTQLKILSTVKATMLGRTNISDEESEQATEMLVHNAQNLMQSVKETVREAEAASIKIRTDAGFTLRWVRKTPWYQ","Homo sapiens","VCL","Vinculin","1","5L0G"
"5L0H",,"X-RAY DIFFRACTION",3.18,61.3,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2 M LiSO4, 0.1 M HEPES (pH 7.5), and 22% PEG 3350",294,"10.1073/pnas.1600702113",,"5L0H",20.69,"2.9","2.9","Human metavinculin MVt cardiomyopathy-associated mutant R975W (residues 959-1134) in complex with PIP2","NQPVNQPILAAAQSLHWEATKWSSKGNDIIAAAKRMALLMAEMSRLVRGGSGTKRALIQCAKDIAKASDEVTRLAKEVAKQCTDKRIRTNLLQVCERIPTISTQLKILSTVKATMLGRTNISDEESEQATEMLVHNAQNLMQSVKETVREAEAASIKIRTDAGFTLRWVRKTPWYQ","Homo sapiens","VCL","Vinculin","1","5L0H"
"5L0I",,"X-RAY DIFFRACTION",2.1,41.4,"VAPOR DIFFUSION, HANGING DROP",5.6,"0.1 M Na-citrate tribasic
dihydrate, 2% Tacsimate (pH 5), and 16% PEG 3350",294,"10.1073/pnas.1600702113",,"5L0I",19.76,"2.45","2.45","Human metavinculin MVt R975W cardiomyopathy-associated mutant (residues 959-1134)","NQPVNQPILAAAQSLHWEATKWSSKGNDIIAAAKRMALLMAEMSRLVRGGSGTKRALIQCAKDIAKASDEVTRLAKEVAKQCTDKRIRTNLLQVCERIPTISTQLKILSTVKATMLGRTNISDEESEQATEMLVHNAQNLMQSVKETVREAEAASIKIRTDAGFTLRWVRKTPWYQ","Homo sapiens","VCL","Vinculin","1","5L0I"
"5L0J",,"X-RAY DIFFRACTION",4.79,74.33,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES sodium (pH 7.5), and 1.5 M Lithium sulfate monohydrate",294,"10.1073/pnas.1600702113",,"5L0J",39.43,"4","4","Human vinculin R903Q, D907R, R910T mutant(residues 891-1066)","GEVINQPMMMAAQQLHREATKWSSKGNDIIAAAKRMALLMAEMSRLVRGGSGTKRALIQCAKDIAKASDEVTRLAKEVAKQCTDKRIRTNLLQVCERIPTISTQLKILSTVKATMLGRTNISDEESEQATEMLVHNAQNLMQSVKETVREAEAASIKIRTDAGFTLRWVRKTPWYQ","Homo sapiens","VCL","Vinculin","1","5L0J"
"5L0N",,"X-RAY DIFFRACTION",2.04,39.7,"VAPOR DIFFUSION, HANGING DROP",4,"0.8 M Lithium sulfate monohydrate.  0.1 M Sodium acetate trihydrate pH 4.0,  4% v/v Polyethylene glycol 200",277,,,"5L0N",15.67,"1.285","1.285","PKG I's Carboxyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with RP-cGMP","GSTGLIKHTEYMEFLKSVPTFQSLPEEILSKLADVLEETHYENGEYIIRQGARGDTFFIISKGTVNVTREDSPSEDPVFLRTLGKGDWFGEKALQGEDVRTANVIAAEAVTCLVIDRDSFKHLIGGLDDVSNKAY","Homo sapiens","PRKG1, PRKG1B, PRKGR1A, PRKGR1B","cGMP-dependent protein kinase 1","1","5L0N"
"5L0O",,"X-RAY DIFFRACTION",2.96,58.44,"VAPOR DIFFUSION",8,"18% PEG 3350, 10% ethylene glycol, 10% glucose, 100mM -160mM potassium acetate",277,"10.1021/acs.biochem.6b00745",,"5L0O",89.45,"2.36","2.36","IQGAP1 calponin homology domain fragment (CHDF) mutant K161C under oxidizing conditions","GAMSAADEVDGLGVARPHYGSVLDNERLTAEEMDERRRQNVAYEYLCHLEEAKRWMEACLGEDLPPTTELEEGLRNGVYLAKLGNFFSPKVVSLKKIYDREQTRYKATGLHFRHTDNVIQWLNAMDEIGLPKIFYPETTDIYDRKNMPRCIYCIHALSLYLFCLGLAPQIQDLYGKVDFTEEEINNMKTELEK","Homo sapiens","IQGAP1, KIAA0051","Ras GTPase-activating-like protein IQGAP1","1","5L0O"
"5L13",,"X-RAY DIFFRACTION",2.15,42.82,"VAPOR DIFFUSION, SITTING DROP",6.4,"100 mM ACES, 100 mM guanidine-HCl, 10 mM MgCl2, 4 mM dithiothreitol, 18% PEG6000",300,"10.1021/acs.jmedchem.6b01825","6ZE","5L13",455.56,"2.4","2.4","Structure of ALDH2 in complex with 2P3","MLRAAARFGPRLGRRLLSAAATQAVPAPNQQPEVFCNQIFINNEWHDAVSRKTFPTVNPSTGEVICQVAEGDKEDVDKAVKAARAAFQLGSPWRRMDASHRGRLLNRLADLIERDRTYLAALETLDNGKPYVISYLVDLDMVLKCLRYYAGWADKYHGKTIPIDGDFFSYTRHEPVGVCGQIIPWNFPLLMQAWKLGPALATGNVVVMKVAEQTPLTALYVANLIKEAGFPPGVVNIVPGFGPTAGAAIASHEDVDKVAFTGSTEIGRVIQVAAGSSNLKRVTLELGGKSPNIIMSDADMDWAVEQAHFALFFNQGQCCCAGSRTFVQEDIYDEFVERSVARAKSRVVGNPFDSKTEQGPQVDETQFKKILGYINTGKQEGAKLLCGGGIAADRGYFIQPTVFGDVQDGMTIAKEEIFGPVMQILKFKTIEEVVGRANNSTYGLAAAVFTKDLDKANYLSQALQAGTVWVNCYDVFGAQSPFGGYKMSGSGRELGEYGLQAYTEVKTVTVKVPQKNS","Homo sapiens","ALDH2, ALDM","Aldehyde dehydrogenase, mitochondrial","1","5L13"
"5L19",,"X-RAY DIFFRACTION",2.01,38.71,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2M Ammonium Sulfate, 0.1M Bis-Tris:HCl, pH6.5, 20% (W/V) PEG3350, 0.01M Zinc Chloride",290,"10.1016/j.str.2016.09.009",,"5L19",17.61,"2","2","Crystal Structure of a human FasL mutant","MQIGHPSPPPEKKELRKVAHLTGKSNSRSMPLEWEHELGLALLSGVKYKKGGLVINETGLYFVYSKVYFRGQSCNNLPLSHKVYMRNSKYPQDLVMMEGKMMSYCTTGQMWARSSYLGAVFNLTSADHLYVNVSELSLVNFEESQTFFGLYKL","Homo sapiens","FASLG, APT1LG1, CD95L, FASL, TNFSF6","Tumor necrosis factor ligand superfamily member 6","1","5L19"
"5L1M",,"X-RAY DIFFRACTION",3.94,68.79,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris pH 7.5, 2.4 M sodium formate, 5 mM DTT",278,"10.1186/s12964-016-0140-3",,"5L1M",20.31,"2.751","2.751","CASKIN2 SAM domain tandem","GSSHHHHHHSSGLVPRGSHMASMTGGQQGSMGREQLLEGKDAQAIHNWLSEFQLEGYTAHFLQAGYDVPTISRMTPEDLTAIGVTKPGHRKKIASEIAQLSIAEWLPSYIPTDLLEWLCALGLPQYHKQLVSSGYDSMGLVADLTWEELQEIGVNKLGHQKKLMLGVKRLAELRRGLLQGEALS","Homo sapiens","CASKIN2, KIAA1139","Caskin-2","1","5L1M"
"5L2I",,"X-RAY DIFFRACTION",2.25,45.24,"VAPOR DIFFUSION, SITTING DROP",,"1:1 (protein to well buffer) with well buffer containing:  0.1 M MES pH 6.0, 70 - 80 mM NH4NO3, 10 - 15% polyethyleneglycol 3350.",286.15,"10.1158/1535-7163.MCT-16-0300","LQQ","5L2I",35.47,"2.75","2.75","The X-ray co-crystal structure of human CDK6 and Palbociclib.","MEKDGLCRADQQYECVAEIGEGAYGKVFKARDLKNGGRFVALKRVRVQTGEEGMPLSTIREVAVLRHLETFEHPNVVRLFDVCTVSRTDRETKLTLVFEHVDQDLTTYLDKVPEPGVPTETIKDMMFQLLRGLDFLHSHRVVHRDLKPQNILVTSSGQIKLADFGLARIYSFQMALTSVVVTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMFRRKPLFRGSSDVDQLGKILDVIGLPGEEDWPRDVALPRQAFHSKSAQPIEKFVTDIDELGKDLLLKCLTFNPAKRISAYSALSHPYFQHHHHHH","Homo sapiens","CDK6, CDKN6","Cyclin-dependent kinase 6","1","5L2I"
"5L2M",,"X-RAY DIFFRACTION",2.27,45.92,"VAPOR DIFFUSION, SITTING DROP",,"100 mM BisTris, 200 mM NaCl, 5 mM YbCl3, 9-11%  PEG3350",300,"10.1021/acs.jmedchem.6b01825","6ZY","5L2M",55.52,"1.7","1.7","Structure of ALDH1A1 in complex with BUC11","MSSSGTPDLPVLLTDLKIQYTKIFINNEWHDSVSGKKFPVFNPATEEELCQVEEGDKEDVDKAVKAARQAFQIGSPWRTMDASERGRLLYKLADLIERDRLLLATMESMNGGKLYSNAYLNDLAGCIKTLRYCAGWADKIQGRTIPIDGNFFTYTRHEPIGVCGQIIPWNFPLVMLIWKIGPALSCGNTVVVKPAEQTPLTALHVASLIKEAGFPPGVVNIVPGYGPTAGAAISSHMDIDKVAFTGSTEVGKLIKEAAGKSNLKRVTLELGGKSPCIVLADADLDNAVEFAHHGVFYHQGQCCIAASRIFVEESIYDEFVRRSVERAKKYILGNPLTPGVTQGPQIDKEQYDKILDLIESGKKEGAKLECGGGPWGNKGYFVQPTVFSNVTDEMRIAKEEIFGPVQQIMKFKSLDDVIKRANNTFYGLSAGVFTKDIDKAITISSALQAGTVWVNCYGVVSAQCPFGGFKMSGNGRELGEYGFHEYTEVKTVTVKISQKNS","Homo sapiens","ALDH1A1, ALDC, ALDH1, PUMB1","Retinal dehydrogenase 1","1","5L2M"
"5L2N",,"X-RAY DIFFRACTION",2.27,45.82,"VAPOR DIFFUSION, SITTING DROP",,"100mM BisTris, 200 mM NaCl, 5 mM YbCl3, 9-11% PEG3350",300,"10.1021/acs.jmedchem.6b01825","6ZU","5L2N",55.49,"1.7","1.7","Structure of ALDH1A1 in complex with BUC25","MSSSGTPDLPVLLTDLKIQYTKIFINNEWHDSVSGKKFPVFNPATEEELCQVEEGDKEDVDKAVKAARQAFQIGSPWRTMDASERGRLLYKLADLIERDRLLLATMESMNGGKLYSNAYLNDLAGCIKTLRYCAGWADKIQGRTIPIDGNFFTYTRHEPIGVCGQIIPWNFPLVMLIWKIGPALSCGNTVVVKPAEQTPLTALHVASLIKEAGFPPGVVNIVPGYGPTAGAAISSHMDIDKVAFTGSTEVGKLIKEAAGKSNLKRVTLELGGKSPCIVLADADLDNAVEFAHHGVFYHQGQCCIAASRIFVEESIYDEFVRRSVERAKKYILGNPLTPGVTQGPQIDKEQYDKILDLIESGKKEGAKLECGGGPWGNKGYFVQPTVFSNVTDEMRIAKEEIFGPVQQIMKFKSLDDVIKRANNTFYGLSAGVFTKDIDKAITISSALQAGTVWVNCYGVVSAQCPFGGFKMSGNGRELGEYGFHEYTEVKTVTVKISQKNS","Homo sapiens","ALDH1A1, ALDC, ALDH1, PUMB1","Retinal dehydrogenase 1","1","5L2N"
"5L2O",,"X-RAY DIFFRACTION",2.33,47.25,"VAPOR DIFFUSION, SITTING DROP",,"100 mM BisTris, 200 mM NaCl, 5 mM YbCl3, 9-11% PEG3350",300,"10.1021/acs.jmedchem.6b01825","6ZW","5L2O",442.92,"2.05","2.05","Crystal Structure of ALDH1A1 in complex with BUC22","MSSSGTPDLPVLLTDLKIQYTKIFINNEWHDSVSGKKFPVFNPATEEELCQVEEGDKEDVDKAVKAARQAFQIGSPWRTMDASERGRLLYKLADLIERDRLLLATMESMNGGKLYSNAYLNDLAGCIKTLRYCAGWADKIQGRTIPIDGNFFTYTRHEPIGVCGQIIPWNFPLVMLIWKIGPALSCGNTVVVKPAEQTPLTALHVASLIKEAGFPPGVVNIVPGYGPTAGAAISSHMDIDKVAFTGSTEVGKLIKEAAGKSNLKRVTLELGGKSPCIVLADADLDNAVEFAHHGVFYHQGQCCIAASRIFVEESIYDEFVRRSVERAKKYILGNPLTPGVTQGPQIDKEQYDKILDLIESGKKEGAKLECGGGPWGNKGYFVQPTVFSNVTDEMRIAKEEIFGPVQQIMKFKSLDDVIKRANNTFYGLSAGVFTKDIDKAITISSALQAGTVWVNCYGVVSAQCPFGGFKMSGNGRELGEYGFHEYTEVKTVTVKISQKNS","Homo sapiens","ALDH1A1, ALDC, ALDH1, PUMB1","Retinal dehydrogenase 1","1","5L2O"
"5L2Q",,"X-RAY DIFFRACTION",2.44,49.51,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM Tris-HCL 7.5
21% PEG 4000
6% Glycerol
5% Tert-butanol
200mM NaCl
1mM TCEP",293,"10.1016/j.str.2016.12.008",,"5L2Q",144.6,"2.53","2.53","Serine/threonine-protein kinase 40 (STK40) kinase homology domain","GSSGISGNNAKRAGPFILGPRLGNSPVPSIVQCLARKDGTDDFYQLKILTLEERGDQGIESQEERQGKMLLHTEYSLLSLLHTQDGVVHHHGLFQDRTCEIVEDTESSRMVKKMKKRICLVLDCLCAHDFSDKTADLINLQHYVIKEKRLSERETVVIFYDVVRVVEALHQKNIVHRDLKLGNMVLNKRTHRITITNFCLGKHLVSEGDLLKDQRGSPAYISPDVLSGRPYRGKPSDMWALGVVLFTMLYGQFPFYDSIPQELFRKIKAAEYTIPEDGRVSENTVCLIRKLLVLDPQQRLAAADVLEALSAIIASWQSLS","Homo sapiens","STK40, SGK495, SHIK","Serine/threonine-protein kinase 40","1","5L2Q"
,,,,,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM Tris-HCL 7.5
18% PEG 4000
9% Tert-butanol
75mM NaCl
1mM TCEP",293
"5L2S",,"X-RAY DIFFRACTION",2.28,46.13,"VAPOR DIFFUSION, SITTING DROP",,"1:1 (protein to well buffer) with well buffer containing:  0.1 M MES pH 6.0, 70 - 80 mM NH4NO3, 10 - 15% polyethyleneglycol 3350",286.15,"10.1158/1535-7163.MCT-16-0300","6ZV","5L2S",35.53,"2.27","2.27","The X-ray co-crystal structure of human CDK6 and Abemaciclib.","MEKDGLCRADQQYECVAEIGEGAYGKVFKARDLKNGGRFVALKRVRVQTGEEGMPLSTIREVAVLRHLETFEHPNVVRLFDVCTVSRTDRETKLTLVFEHVDQDLTTYLDKVPEPGVPTETIKDMMFQLLRGLDFLHSHRVVHRDLKPQNILVTSSGQIKLADFGLARIYSFQMALTSVVVTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMFRRKPLFRGSSDVDQLGKILDVIGLPGEEDWPRDVALPRQAFHSKSAQPIEKFVTDIDELGKDLLLKCLTFNPAKRISAYSALSHPYFQHHHHHH","Homo sapiens","CDK6, CDKN6","Cyclin-dependent kinase 6","1","5L2S"
"5L2T",,"X-RAY DIFFRACTION",2.26,45.56,"VAPOR DIFFUSION, SITTING DROP",,"1:1 (protein to well buffer) with well buffer containing:  0.1 M MES pH 6.0, 70 - 80 mM NH4NO3, 10 - 15% polyethyleneglycol 3350",286.15,"10.1158/1535-7163.MCT-16-0300","6ZZ","5L2T",35.45,"2.37","2.37","The X-ray co-crystal structure of human CDK6 and Ribociclib.","MEKDGLCRADQQYECVAEIGEGAYGKVFKARDLKNGGRFVALKRVRVQTGEEGMPLSTIREVAVLRHLETFEHPNVVRLFDVCTVSRTDRETKLTLVFEHVDQDLTTYLDKVPEPGVPTETIKDMMFQLLRGLDFLHSHRVVHRDLKPQNILVTSSGQIKLADFGLARIYSFQMALTSVVVTLWYRAPEVLLQSSYATPVDLWSVGCIFAEMFRRKPLFRGSSDVDQLGKILDVIGLPGEEDWPRDVALPRQAFHSKSAQPIEKFVTDIDELGKDLLLKCLTFNPAKRISAYSALSHPYFQHHHHHH","Homo sapiens","CDK6, CDKN6","Cyclin-dependent kinase 6","1","5L2T"
"5L2U",,"X-RAY DIFFRACTION",5.99,79.48,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 HEPES, 300 mM NaCl, 3.5% 2-propanol",303.15,,,"5L2U",68.6,"2.28","2.28","Oligomer crystal structure of CC chemokine 5 (CCL5)","SSDTTPCCFAYIARPLPRAHIKEYFYTSGKCSNPAVVFVTRKNRQVCANPEKKWVREYINSLEMS","Homo sapiens","CCL5, D17S136E, SCYA5","C-C motif chemokine 5","1","5L2U"
"5L2Y",,"X-RAY DIFFRACTION",3.91,68.51,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277,"10.1016/j.bmcl.2016.08.088","70D","5L2Y",35.37,"1.82","1.82","Factor VIIa in complex with the inhibitor 1-[(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,20-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl] cyclobutane-1-carboxylic acid","IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII (Heavy Chain)","1","5L2Y"
,,,,,,,,,,,,,,,,"ICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKR","Homo sapiens","F7","Coagulation factor VII (Light Chain)","2","5L2Y"
"5L2Z",,"X-RAY DIFFRACTION",3.44,64.27,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277,"10.1016/j.bmcl.2016.08.088","70C","5L2Z",35.66,"1.79","1.79","Factor VIIa in complex with the inhibitor 1-[(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-7-yl]cyclohexane-1-carboxylic acid","IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII (Heavy Chain)","1","5L2Z"
,,,,,,,,,,,,,,,,"DQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKR","Homo sapiens","F7","Coagulation factor VII (Light Chain)","2","5L2Z"
"5L30",,"X-RAY DIFFRACTION",3.77,67.38,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277,"10.1016/j.bmcl.2016.08.088","70A","5L30",35.72,"1.73","1.73","Factor VIIa in complex with the inhibitor (2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-7-[1-(1H-tetrazol-5-yl)cyclopropyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione","IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII (Heavy Chain)","1","5L30"
,,,,,,,,,,,,,,,,"DQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKR","Homo sapiens","F7","Coagulation factor VII (Light Chain)","2","5L30"
"5L3A",,"X-RAY DIFFRACTION",3.16,60,"VAPOR DIFFUSION, HANGING DROP",,"2.1M Na Malonate pH 6.0/6.5, 0.1M glycine pH 8.2",277,"10.1021/acsmedchemlett.6b00087","6DP","5L3A",34.74,"1.98","1.98","Fragment-based discovery of 6-arylindazole JAK inhibitors","GSDPTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEFFKVKEPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAG","Homo sapiens","JAK2","Tyrosine-protein kinase JAK2","1","5L3A"
"5L3L",,"SOLUTION NMR",,,,,,,"10.1074/jbc.M116.741041",,"5L3L",7.48,,,"D11 bound IGF-II","AYRPSETLCGGELVDTLQFVCGDRGFYFSRPASRVSRRSRGIVEECCFRSCDLALLETYCATPAKSE","Homo sapiens","IGF2, PP1446","Insulin-like growth factor II","1","5L3L"
"5L3M",,"SOLUTION NMR",,,,,,,"10.1074/jbc.M116.741041",,"5L3M",7.71,,,"D11 bound [S39_PQ]-IGF-II","AYRPSETLCGGELVDTLQFVCGDRGFYFSRPASRVSRRSPQRGIVEECCFRSCDLALLETYCATPAKSE","Homo sapiens","IGF2, PP1446","Insulin-like growth factor II","1","5L3M"
"5L3N",,"SOLUTION NMR",,,,,,,"10.1074/jbc.M116.741041",,"5L3N",7.74,,,"D11 bound [N29, S39_PQ]-IGF-II","AYRPSETLCGGELVDTLQFVCGDRGFYFNRPASRVSRRSPQRGIVEECCFRSCDLALLETYCATPAKSE","Homo sapiens","IGF2, PP1446","Insulin-like growth factor II","1","5L3N"
"5L3O",,"X-RAY DIFFRACTION",2.91,57.66,"VAPOR DIFFUSION, SITTING DROP",4.6,"NA acetate, PEG 4000, NaN3",293,"10.1021/jacs.7b00184",,"5L3O",64.93,"1.98","1.98","Crystal Structure of Human Carbonic Anhydrase II in Complex with a Quinoline Oligoamide Foldamer","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5L3O"
"5L46",,"X-RAY DIFFRACTION",2.32,47.01,"MICROBATCH",7.5,"10% w/v PEG 20000, 20% v/v PEG MME 550, 0.02 M of each amino acid and 0.1 M MOPS/HEPES-Na pH 7.5",293.15,"10.1111/febs.13828",,"5L46",190.19,"3.09","3.09","Crystal structure of human dimethylglycine-dehydrogenase","MVCGREGEEKPPLSAETQWKDRAETVIIGGGCVGVSLAYHLAKAGMKDVVLLEKSELTAGSTWHAAGLTTYFHPGINLKKIHYDSIKLYEKLEEETGQVVGFHQPGSIRLATTPVRVDEFKYQMTRTGWHATEQYLIEPEKIQEMFPLLNMNKVLAGLYNPGDGHIDPYSLTMALAAGARKCGALLKYPAPVTSLKARSDGTWDVETPQGSMRANRIVNAAGFWAREVGKMIGLEHPLIPVQHQYVVTSTIPEVKALKRELPVLRDLEGSYYLRQERDGLLFGPYESQEKMKVQDSWVTNGVPPGFGKELFESDLDRIMEHIKAAMEMVPVLKKADIINVVNGPITYSPDILPMVGPHQGVRNYWVAIGFGYGIIHAGGVGKYLSDWILHGEPPFDLIELDPNRYGKWTTTQYTEAKARESYGFNNIVGYPKEERFAGRPTQRVSGLYQRLESKCSMGFHAGWEQPHWFYKPGQDTQYRPSFRRTNWFEPVGSEYKQVMQRVAVTDLSPFGKFNIKGQDSIRLLDHLFANVIPKVGFTNISHMLTPKGRVYAELTVSHQSPGEFLLITGSGSELHDLRWIEEEAVKGGYDVEIKNITDELGVLGVAGPQARKVLQKLTSEDLSDDVFKFLQTKSLKVSNIPVTAIRISYTGELGWELYHRREDSVALYDAIMNAGQEEGIDNFGTYAMNALRLEKAFRAWGLEMNCDTNPLEAGLEYFVKLNKPADFIGKQALKQIKAKGLKRRLVCLTLATDDVDPEGNESIWYNGKVVGNTTSGSYSYSIQKSLAFAYVPVQLSEVGQQVEVELLGKNYPAVIIQEPLVLTEPTRNRLQKKGGKDKTRP","Homo sapiens","DMGDH","Dimethylglycine dehydrogenase, mitochondrial","1","5L46"
"5L4F",,"X-RAY DIFFRACTION",2.28,46,"VAPOR DIFFUSION, HANGING DROP",7.6,"Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. DNPC was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter",291,"10.1021/acs.est.6b02771","6J1","5L4F",27.97,"1.48","1.48","Crystal Structure of Human Transthyretin in Complex with 2,6-Dinitro-p-cresol (DNPC)","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5L4F"
"5L4I",,"X-RAY DIFFRACTION",2.17,43.27,"VAPOR DIFFUSION, HANGING DROP",7.6,"Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. Clonixin was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter",291,"10.1021/acs.est.6b02771","6J3","5L4I",28.1,"1.45","1.45","Crystal Structure of Human Transthyretin in Complex with Clonixin","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5L4I"
"5L4J",,"X-RAY DIFFRACTION",2.16,43.02,"VAPOR DIFFUSION, HANGING DROP",7.6,"Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. BPS was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter",291,"10.1021/acs.est.6b02771","6JD","5L4J",28.08,"1.62","1.62","Crystal Structure of Human Transthyretin in Complex with 4,4'-Dihydroxydiphenyl sulfone (Bisphenol S, BPS)","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5L4J"
"5L4M",,"X-RAY DIFFRACTION",2.11,41.79,"VAPOR DIFFUSION, HANGING DROP",7.6,"Purified TTRwt was dialyzed against 10 mM sodium phosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. Triclopyr was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter",291,"10.1021/acs.est.6b02771","SBK","5L4M",28.09,"1.581","1.581","Crystal Structure of Human Transthyretin in Complex with 3,5,6-Trichloro-2-pyridinyloxyacetic acid (Triclopyr)","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5L4M"
"5L4Q",,"X-RAY DIFFRACTION",1.83,32.81,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1M bis-tris pH 5.5, 26% PEG3350",293,"10.1021/acs.jmedchem.9b00136","LKB","5L4Q",78.71,"1.97","1.97","Crystal Structure of Adaptor Protein 2 Associated Kinase 1 (AAK1) in Complex with LKB1 (AAK1 Dual Inhibitor)","TSGLGSGYIGRVFGIGRQQVTVDEVLAEGGFAIVFLVRTSNGMKCALKRMFVNNEHDLQVCKREIQIMRDLSGHKNIVGYIDSSINNVSSGDVWEVLILMDFCRGGQVVNLMNQRLQTGFTENEVLQIFCDTCEAVARLHQCKTPIIHRDLKVENILLHDRGHYVLCDFGSATNKFQNPQTEGVNAVEDEIKKYTTLSYRAPEMVNLYSGKIITTKADIWALGCLLYKLCYFTLPFGESQVAICDGNFTIPDNSRYSQDMHCLIRYMLEPDPDKRPDIYQVSYFSFKLLKKECPIPNVQNSPIPAKLPEPVKASEAAAKKTQPKARLTDPIPTTETSIAAENLYFQ","Homo sapiens","AAK1, KIAA1048","AP2-associated protein kinase 1","1","5L4Q"
"5L4Z",,"X-RAY DIFFRACTION",2.94,58.16,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM MOPS/HEPES-Na containing 100 mM NaCl, 15 % glycerol and 10 % PEG 4000",298,"10.1186/s12915-016-0313-y",,"5L4Z",65.32,"1.84","1.84","Crystal structure of enzyme in purine metabolism","MGSSHHHHHHSSGLVPRGSMSTSWSDRLQNAADMPANMDKHALKKYRREAYHRVFVNRSLAMEKIKCFGFDMDYTLAVYKSPEYESLGFELTVERLVSIGYPQELLSFAYDSTFPTRGLVFDTLYGNLLKVDAYGNLLVCAHGFNFIRGPETREQYPNKFIQRDDTERFYILNTLFNLPETYLLACLVDFFTNCPRYTSCETGFKDGDLFMSYRSMFQDVRDAVDWVHYKGSLKEKTVENLEKYVVKDGKLPLLLSWMKEVGKVFLATNSDYKYTDKIMTYLFDFPHGPKPGSSHRPWQSYFDLILVDARKPLFFGEGTVLRQVDTKTGKLKIGTYTGPLQHGIVYSGGSSDTICDLLGAKGKDILYIGDHIFGDILKSKKRQGWRTFLVIPELAQELHVWTDKSSLFEELQSLDIFLAELYKHLDSSSNERPDISSIQRRIKKVTHDMDMCYGMMGSLFRSGSRQTLFASQVMRYADLYAASFINLLYYPFSYLFRAAHVLMPHESTVEHTHVDINEMESPLATRNRTSVDFKDTDYKRHQLTRSISEIKPPNL","Homo sapiens","NT5C2, NT5B, NT5CP, PNT5","Cytosolic purine 5'-nucleotidase","1","5L4Z"
"5L50",,"X-RAY DIFFRACTION",2.93,58.08,"VAPOR DIFFUSION, HANGING DROP",6.5,"200 mM MES/imidazol (pH 6.5) containing 100 mM NaCl, 30 % glycerol and 10 % PEG 4000",298,"10.1186/s12915-016-0313-y",,"5L50",65.23,"1.643","1.643","Crystal structure of enzyme in purine metabolism","MGSSHHHHHHSSGLVPRGSMSTSWSDRLQNAADMPANMDKHALKKYRREAYHRVFVNRSLAMEKIKCFGFDMDYTLAVYKSPEYESLGFELTVERLVSIGYPQELLSFAYDSTFPTRGLVFDTLYGNLLKVDAYGNLLVCAHGFNFIRGPETREQYPNKFIQRDDTERFYILNTLFNLPETYLLACLVDFFTNCPRYTSCETGFKDGDLFMSYRSMFQDVRDAVDWVHYKGSLKEKTVENLEKYVVKDGKLPLLLSRMKEVGKVFLATNSDYKYTDKIMTYLFDFPHGPKPGSSHRPWQSYFDLILVDARKPLFFGEGTVLRQVDTKTGKLKIGTYTGPLQHGIVYSGGSSDTICDLLGAKGKDILYIGDHIFGDILKSKKRQGWRTFLVIPEFAQELHVWTDKSSLFEELQSLDIFLAELYKHLDSSSNERPDISSIQRRIKKVTHDMDMCYGMMGSLFRSGSRQTLFASQVMRYADLYAASFINLLYYPFSYLFRAAHVLMPHESTVEHTHVDINEMESPLATRNRTSVDFKDTDYKRHQLTRSISEIKPPNL","Homo sapiens","NT5C2, NT5B, NT5CP, PNT5","Cytosolic purine 5'-nucleotidase","1","5L50"
"5L57",,"X-RAY DIFFRACTION",2.61,52.91,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.12M Ethylene Glycols, 0.1M Bicine pH 8.5, 50% (40% v/v PEG 500 MME, 20% w/v PEG 20K) [Morpheus A9] 200 plus 200nl drops (Mosquito)",277,"10.1021/acs.jmedchem.6b01320",,"5L57",47.64,"2.695","2.695","Crystal structure of Iso-citrate Dehydrogenase R132H in complex with a novel inhibitor (compound 13a)","MSKKISGGSVVEMQGDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDAAEAIKKHNVGVKCATITPDAARVEEFKLKQMWKSPNGTIRNILGGTVFREAIICKNIPRLVSGWVKPIIIGHHAYGDQYRATDFVVPGPGKVEITYTPSDGTQKVTYLVHNFEEGGGVAMGMYNQDKSIEDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFAAAAIWYEHRLIDDMVAQAMKSEGGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVLVCPDGKTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRAKLDNNKELAFFANALEEVSIETIEAGFMTKDLAACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAKL","Homo sapiens","IDH1, PICD","Isocitrate dehydrogenase [NADP] cytoplasmic","1","5L57"
"5L58",,"X-RAY DIFFRACTION",2.52,51.24,"VAPOR DIFFUSION, SITTING DROP",8.5,"200nl of protein with 200nl of a reservoir solution of 0.06M Divalents, 0.1M Tris / Bicine pH 8.5, 50% (40% v/v PEG 500 MME, 20% w/v PEG 20K) [Morpheus E9]",277,"10.1021/acs.jmedchem.6b01320",,"5L58",47.67,"3.04","3.04","Crystal structure of Iso-citrate Dehydrogenase 1 [IDH1 (R132H)] in complex with a novel inhibitor (Compound 2)","MSKKISGGSVVEMQGDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDAAEAIKKHNVGVKCATITPDAARVEEFKLKQMWKSPNGTIRNILGGTVFREAIICKNIPRLVSGWVKPIIIGHHAYGDQYRATDFVVPGPGKVEITYTPSDGTQKVTYLVHNFEEGGGVAMGMYNQDKSIEDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFAAAAIWYEHRLIDDMVAQAMKSEGGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVLVCPDGKTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRAKLDNNKELAFFANALEEVSIETIEAGFMTKDLAACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAKL","Homo sapiens","IDH1, PICD","Isocitrate dehydrogenase [NADP] cytoplasmic","1","5L58"
"5L6K",,"X-RAY DIFFRACTION",2.91,57.66,"VAPOR DIFFUSION, HANGING DROP",5.1,"NaAc, PEG 4000",293,"10.1021/jacs.7b00184",,"5L6K",64.33,"1.7","1.7","Crystal Structure of Human Carbonic Anhydrase II in Complex with a Quinoline Oligoamide Foldamer","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5L6K"
"5L6O",,"X-RAY DIFFRACTION",2.26,45.58,"VAPOR DIFFUSION, SITTING DROP",8.5,"1,4-dioxane, Tris buffer, magnesium chloride",293,"10.1021/jacs.6b05483",,"5L6O",34.12,"1.88","1.88","EphB3 kinase domain covalently bound to an irreversible inhibitor (compound 3)","GSSDPNEAVREFAKEIDVSCVKIEEVIGAGEFGEVCRGRLKQPGRREVFVAIKTLKVGYTERQRRDFLSEASIMGQFDHPNIIRLEGVVTKSRPVMILTEFMENCALDSFLRLNDGQFTVIQLVGMLRGIAAGMKYLSEMNYVHRDLAARNILVNSNLVCKVSDFGLSRFLEDDPSDPTYTSSLGGKIPIRWTAPEAIAYRKFTSASDVWSYGIVMWEVMSYGERPYWDMSNQDVINAVEQDYRLPPPMDCPTALHQLMLDCWVRDRNLRPKFSQIVNTLDKLIRNPASLKVIASAQS","Homo sapiens","EPHB3, ETK2, HEK2, TYRO6","Ephrin type-B receptor 3","1","5L6O"
"5L6P",,"X-RAY DIFFRACTION",2.52,51.28,"VAPOR DIFFUSION, SITTING DROP",8.5,"1,4-dioxane, Tris buffer, magnesium chloride",293,"10.1021/jacs.6b05483",,"5L6P",34.13,"2.26","2.26","EphB3 kinase domain covalently bound to an irreversible inhibitor (compound 6)","GSSDPNEAVREFAKEIDVSCVKIEEVIGAGEFGEVCRGRLKQPGRREVFVAIKTLKVGYTERQRRDFLSEASIMGQFDHPNIIRLEGVVTKSRPVMILTEFMENCALDSFLRLNDGQFTVIQLVGMLRGIAAGMKYLSEMNYVHRDLAARNILVNSNLVCKVSDFGLSRFLEDDPSDPTYTSSLGGKIPIRWTAPEAIAYRKFTSASDVWSYGIVMWEVMSYGERPYWDMSNQDVINAVEQDYRLPPPMDCPTALHQLMLDCWVRDRNLRPKFSQIVNTLDKLIRNPASLKVIASAQS","Homo sapiens","EPHB3, ETK2, HEK2, TYRO6","Ephrin type-B receptor 3","1","5L6P"
"5L6Q",,"X-RAY DIFFRACTION",2.2,43,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, 18% PEG 8000, 0.1 M Zinc acetate",293,"10.1002/anie.201701761",,"5L6Q",25.21,"1.4","1.4","Refolded AL protein from cardiac amyloidosis","SELTQDPAVSVALGQTVRITCQGDSLRSYSASWYQQKPGQAPVLVIFRKSNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSANHQVFGGGTKLTVLGQPKAAPS","Homo sapiens",,"H5AL","1","5L6Q"
"5L6R",,"SOLUTION NMR",,,,,,,"10.1016/j.bbrc.2017.01.078",,"5L6R",16.6,,,"PrP226* - Solution-state NMR structure of truncated human prion protein","GQGGGTHSQWNKPSKPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYYRENMHRYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERVVEQMCITQYERESQAYYGGHHHHHH","Homo sapiens","PRNP, ALTPRP, PRIP, PRP","Major prion protein","1","5L6R"
"5L6T",,"X-RAY DIFFRACTION",2.52,51.22,"VAPOR DIFFUSION, HANGING DROP",6.9,"ZnOAc 0.2M NaCac 0.1 M PEG 8000 pH 7.1 NaN3",293,,,"5L6T",62.74,"2.65","2.65","CRYSTAL STRUCTURE OF HUMAN CARBONIC ANHYDRASE II IN COMPLEX WITH A QUINOLINE OLIGOAMIDE FOLDAMER","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5L6T"
"5L6X",,"X-RAY DIFFRACTION",2.51,50.91,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM HEPES pH 6, 10 mM DTT, 100 mM CaCl2, 30% PEG 6000, Ligand was soaked o/n prior diffraction",298,,,"5L6X",48.27,"2","2","CRYSTAL STRUCTURE OF HGSTP1-1 COMPLEXED WITH FERROCENE-GLUTATHIONE CONJUGATE","MAPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ","Homo sapiens","GSTP1, FAEES3, GST3","Glutathione S-transferase P","1","5L6X"
"5L70",,"X-RAY DIFFRACTION",2.48,50.38,"VAPOR DIFFUSION, HANGING DROP",6.1,"ZnOAc, NaCac, PEG 8000, NaN3",293,,,"5L70",62.62,"2.2","2.2","CRYSTAL STRUCTURE OF HUMAN CARBONIC ANHYDRASE II IN COMPLEX WITH A QUINOLINE OLIGOAMIDE FOLDAMER","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5L70"
"5L73",,"X-RAY DIFFRACTION",2.14,42.53,"VAPOR DIFFUSION",,"0.06 M MgCl2
0.06 M CaCl2
0.1 M Tris (base), 0.1 M
BICINE pH 8.0
12.5 % MPD
12.5 % PEG 1000
12.5 % w/v PEG 3350.",289,"10.1016/j.str.2016.08.017",,"5L73",44.74,"2.24","2.24","MAM domain of human neuropilin-1","ADEKPDVIDDDIQDEFPDYGFNCEFGWGSHKTFCHWEHDNHVQLKWSVLTSKTGPIQDHTGDGNFIYSQADENQKGKVARLVSPVVYSQNSAHCMTFWYHMSGSHVGTLRVKLRYQKPEEYDQLVWMAIGHQGDHWKEGRVLLHKSLKLYQVIFEGEIGKGNLGGIAVDDISINNHISQEDCAKPAHHHHHH","Homo sapiens","NRP1, NRP, VEGF165R","Neuropilin-1","1","5L73"
"5L76",,"X-RAY DIFFRACTION",2.92,57.92,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350 -- 10% ethylene glycol -- 0.2M sodium malonate",293,,,"5L76",55.03,"2.57","2.57","Crystal structure of human aminoadipate semialdehyde synthase, saccharopine dehydrogenase domain (in apo form)","MGHHHHHHSSGVDLGTENLYFQSMALPDKYKYIQTLRESRERAQSLSMGTRRKVLVLGSGYISEPVLEYLSRDGNIEITVGSDMKNQIEQLGKKYNINPVSMDICKQEEKLGFLVAKQDLVISLLPYVLHPLVAKACITNKVNMVTASYITPALKELEKSVEDAGITIIGELGLDPGLDHMLAMESIDKAKEVGATIESYISYCGGLPAPEHSNNPLRYKFSWSPVGVLMNVMQSATYLLDGKVVNVAGGISFLDAVTSMDFFPGLNLEGYPNRDSTKYAEIYGISSAHTLLRGTLRYKGYMKALNGFVKLGLINREALPAFRPEANPLTWKQLLCDLVGISPSSEHDVLKEAVLKKLGGDNTQLEAAEWLGLLGDEQVPQAESILDALSKHLVMKLSYGPEEKDMIVMRDSFGIRHPSGHLEHKTIDLVAYGDINGFSAMAKTVGLPTAMAAKMLLDGEIGAKGLMGPFSKEIYGPILERIKAEGIIYTTQSTIKP","Homo sapiens","AASS","Alpha-aminoadipic semialdehyde synthase, mitochondrial","1","5L76"
"5L78",,"X-RAY DIFFRACTION",2.2,44.09,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2M sodium chloride -- 25% PEG3350 -- 0.1M tris pH 8.5",293,,,"5L78",110.76,"2.68","2.68","Crystal structure of human aminoadipate semialdehyde synthase, saccharopine dehydrogenase domain (in NAD+ bound form)","MGHHHHHHSSGVDLGTENLYFQSMALPDKYKYIQTLRESRERAQSLSMGTRRKVLVLGSGYISEPVLEYLSRDGNIEITVGSDMKNQIEQLGKKYNINPVSMDICKQEEKLGFLVAKQDLVISLLPYVLHPLVAKACITNKVNMVTASYITPALKELEKSVEDAGITIIGELGLDPGLDHMLAMETIDKAKEVGATIESYISYCGGLPAPEHSNNPLRYKFSWSPVGVLMNVMQSATYLLDGKVVNVAGGISFLDAVTSMDFFPGLNLEGYPNRDSTKYAEIYGISSAHTLLRGTLRYKGYMKALNGFVKLGLINREALPAFRPEANPLTWKQLLCDLVGISPSSEHDVLKEAVLKKLGGDNTQLEAAEWLGLLGDEQVPQAESILDALSKHLVMKLSYGPEEKDMIVMRDSFGIRHPSGHLEHKTIDLVAYGDINGFSAMAKTVGLPTAMAAKMLLDGEIGAKGLMGPFSKEIYGPILERIKAEGIIYTTQSTIKP","Homo sapiens","AASS","Alpha-aminoadipic semialdehyde synthase, mitochondrial","1","5L78"
"5L79",,"X-RAY DIFFRACTION",2.38,48.41,"VAPOR DIFFUSION, SITTING DROP",6.8,"protein: hMMP12 689 micro-M + 10 milli-M hydroxamic acid in .2 M NaCl, .02 M TRIS pH 7.5, 3 milli-M CaCl2, 0.1 milli-M ZnCl2 + 1 milli-M RXP470.1-PEG-Cy5.5 
precipitant: 20% PEG4K, 2% dioxane, 0.2 milli-M TRIS pH 9.5
cryoprotectant:  40% CM26 (12.5 % diethylene glycol + 12.5 % ethylene glycol + 12.5 % glycerol + 25 % 2,3-butanediol + 12.5 % DMSO), 25% MPEG 6K, 100 milii-M bistrisPhosphate/Na citrate pH 6.8",293,"10.1021/acs.bioconjchem.6b00377","R47","5L79",20.12,"2.07","2.07","Crystal structure of MMP12 in complex with RXP470.1 conjugated with fluorophore Cy5,5 in space group P21212.","MGPVWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDDHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTYKYVDINTFRLSADDIRGIQSLYG","Homo sapiens","MMP12, HME","Macrophage metalloelastase","1","5L79"
"5L7A",,"X-RAY DIFFRACTION",2.2,44.03,"VAPOR DIFFUSION",7.5,"1.4 M tri-sodium citrate and 100 mM HEPES pH 7.5",277,"10.1111/febs.14660",,"5L7A",32.54,"2.102","2.102","The crystal structure of the Human SNF5/INI1 domain","GGSEVLVPIRLDMEIDGQKLRDAFTWNMNEKLMTPEMFSEILCDDLDLNPLTFVPAIASAIRQQIESYPTDS","Homo sapiens","SMARCB1, BAF47, INI1, SNF5L1","SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1","1","5L7A"
"5L7B",,"SOLUTION NMR",,,,,,,"10.1111/febs.14660",,"5L7B",8.82,,,"Solution structure of the human SNF5/INI1 domain","GGSEVLVPIRLDMEIDGQKLRDAFTWNMNEKLMTPEMFSEILCDDLDLNPLTFVPAIASAIRQQIESYPTDSILEDQS","Homo sapiens","SMARCB1, BAF47, INI1, SNF5L1","SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1","1","5L7B"
"5L7F",,"X-RAY DIFFRACTION",2.48,50.34,"VAPOR DIFFUSION, SITTING DROP",9.5,"protein: MMP12-F171D-K241A  661 micro-M + 10 milli-M AHA, 10% DMSO, 0.5 milli-M fluorescent inhibitor (R47-CY5)
precipitant: 20% PEG4K, 2% gamma valerolactone, 0.2 milli-M TRIS pH 9.5
40% CM26 ((12.5 % diethylene glycol + 12.5 % ethylene glycol + 12.5 % glycerol + 25 % 2,3-butanediol + 12.5 % DMSO), 25% MPEG 6K",293,"10.1021/acs.bioconjchem.6b00377","R47","5L7F",39.87,"1.8","1.8","Crystal structure of MMP12 mutant K421A in complex with RXP470.1 conjugated with fluorophore Cy5,5 in space group P21.","MGPVWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDDHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTYAYVDINTFRLSADDIRGIQSLYG","Homo sapiens","MMP12, HME","Macrophage metalloelastase","1","5L7F"
"5L7T",,"X-RAY DIFFRACTION",2.39,48.48,"VAPOR DIFFUSION, SITTING DROP",,"CHES 0.1 M pH 9.50
tri-sodium-citrate 1.0 M",291,"10.1021/acs.jmedchem.6b01436","6QJ","5L7T",29.69,"1.983","1.983","17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal inhibitor.","GHMATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRATIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPSGS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5L7T"
"5L7W",,"X-RAY DIFFRACTION",2.39,48.54,"VAPOR DIFFUSION, SITTING DROP",7,"PEG 6000 20%
Hepes 0.1 M pH 7.00
DMSO 5%",291,"10.1021/acs.jmedchem.6b01436","6QU","5L7W",29.89,"1.76","1.76","17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal inhibitor.","GHMATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRATIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPSGS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5L7W"
"5L7Y",,"X-RAY DIFFRACTION",2.43,49.33,"VAPOR DIFFUSION, SITTING DROP",,"CHES 0.1 M pH 9.50
tri-sodium-citrate 1.00 M
DMSO 5%",291,"10.1021/acs.jmedchem.6b01436","6QO","5L7Y",30.02,"1.912","1.912","17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal inhibitor.","GHMATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRATIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPSGS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5L7Y"
"5L8I",,"X-RAY DIFFRACTION",2.04,39.78,"VAPOR DIFFUSION, HANGING DROP",5.5,"41% w/v PEG 3350 and 0.1 M Bis-tris pH 5.5",293.5,"10.1021/acs.jmedchem.6b00869",,"5L8I",43.94,"1.88","1.88","crystal structure of human FABP6 apo-protein","MAFTGKFEMESEKNYDEFMKLLGISSDVIEKARNFKIVTEVQQDGQDFTWSQHYSGGHTMTNKFTVGKESNIQTMGGKTFKATVQMEGGKLVVNFPNYHQTSEIVGDKLVEVSTIGGVTYERVSKRLA","Homo sapiens","FABP6, ILBP, ILLBP","Gastrotropin","1","5L8I"
"5L8N",,"X-RAY DIFFRACTION",2.08,40.73,"VAPOR DIFFUSION, HANGING DROP",5.5,"39% w/v PEG 3350 and 0.1 M Bis-tris pH 5.5",293.15,"10.1021/acs.jmedchem.6b00869","6RQ","5L8N",44.24,"2.12","2.12","crystal structure of human FABP6 protein with fragment 1","MAFTGKFEMESEKNYDEFMKLLGISSDVIEKARNFKIVTEVQQDGQDFTWSQHYSGGHTMTNKFTVGKESNIQTMGGKTFKATVQMEGGKLVVNFPNYHQTSEIVGDKLVEVSTIGGVTYERVSKRLA","Homo sapiens","FABP6, ILBP, ILLBP","Gastrotropin","1","5L8N"
"5L8O",,"X-RAY DIFFRACTION",2.08,40.84,"VAPOR DIFFUSION, HANGING DROP",5.5,"41% w/v PEG 3350 and 0.1 M Bis-tris pH 5.5",293.15,"10.1021/acs.jmedchem.6b00869",,"5L8O",43.79,"2.39","2.39","crystal structure of human FABP6 in complex with cholate","MAFTGKFEMESEKNYDEFMKLLGISSDVIEKARNFKIVTEVQQDGQDFTWSQHYSGGHTMTNKFTVGKESNIQTMGGKTFKATVQMEGGKLVVNFPNYHQTSEIVGDKLVEVSTIGGVTYERVSKRLA","Homo sapiens","FABP6, ILBP, ILLBP","Gastrotropin","1","5L8O"
"5L8T",,"X-RAY DIFFRACTION",4.15,70.36,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1021/acs.jmedchem.6b01258",,"5L8T",13.77,"1.85","1.85","Crystal Structure of BAZ2B bromodomain in complex with 3-amino-2-methylpyridine derivative 2","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5L8T"
"5L8U",,"X-RAY DIFFRACTION",4.2,70.69,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1021/acs.jmedchem.6b01258",,"5L8U",14.12,"1.85","1.85","Crystal Structure of BAZ2B bromodomain in complex with 3-amino-2-methylpyridine derivative 5","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5L8U"
"5L96",,"X-RAY DIFFRACTION",4.24,70.99,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1021/acs.jmedchem.6b01258",,"5L96",13.82,"2.15","2.15","Crystal Structure of BAZ2B bromodomain in complex with 3-amino-2-methylpyridine derivative 1","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5L96"
"5L97",,"X-RAY DIFFRACTION",4.21,70.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1021/acs.jmedchem.6b01258",,"5L97",13.79,"2.05","2.05","Crystal Structure of BAZ2B bromodomain in complex with 3-amino-2-methylpyridine derivative 3","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5L97"
"5L98",,"X-RAY DIFFRACTION",4.13,70.22,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1021/acs.jmedchem.6b01258",,"5L98",13.93,"2.263","2.263","Crystal Structure of BAZ2B bromodomain in complex with 3-amino-2-methylpyridine derivative 4","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5L98"
"5L99",,"X-RAY DIFFRACTION",4.24,70.99,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1021/acs.jmedchem.6b01258",,"5L99",13.8,"2","2","Crystal Structure of BAZ2B bromodomain in complex with 3-amino-2-methylpyridine derivative 6","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5L99"
"5L9E",,"X-RAY DIFFRACTION",2.82,56.36,"VAPOR DIFFUSION, HANGING DROP",7.1,"ZnOAc, NaCac, PEG 8000, NaN3",293,,,"5L9E",125.09,"2.9","2.9","CRYSTAL STRUCTURE OF HUMAN CARBONIC ANHYDRASE II IN COMPLEX WITH A QUINOLINE OLIGOAMIDE FOLDAMER","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5L9E"
"5L9R",,"X-RAY DIFFRACTION",2.49,50.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES-Na pH 7.5, 2% v/v Polyethylene glycol 400, 2.0 M ammonium sulfate",293,"10.1038/ncomms12673","OGA","5L9R",28.9,"1.81","1.81","HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with N-oxalylglycine (NOG)","GSHMASPNGQTKPLPALKLALEYIVPAMNKHGICVVDDFLGKETGQQIGDEVRALHDTGKFTDGQLVSQKSDSSKDIRGDKITWIEGKEPGCETIGLLMSSMDDLIRHCNGKLGSYKINGRTKAMVACYPGNGTGYVRHVDNPNGDGRCVTCIYYLNKDWDAKVSGGILRIFPEGKAQFADIEPKFDRLLFFWSDRRNPHEVQPAYATRYAITVWYFDADERAAAKVKYLTGEKGVRVELNKPSDSVGKDVF","Homo sapiens","EGLN1, C1orf12, PNAS-118, PNAS-137","Egl nine homolog 1","1","5L9R"
"5L9Y",,"X-RAY DIFFRACTION",2.49,50.56,"VAPOR DIFFUSION",,"0.1 M MES pH 5.5, 0.1 M MgCl2, 17% PEG3350, 200:500 nl protein:well ratio",293,"10.1038/nchembio.2395",,"5L9Y",53.63,"1.88","1.88","Crystal structure of human heparanase, in complex with glucuronic acid configured aziridine probe JJB355","DPGKKFKNSTYSRSSVDVLYTFANCSGLDLIFGLNALLRTADLQWNSSNAQLLLDYCSSKGYNISWELGNEPNSFLKKADIFINGSQLGEDFIQLHKLLRKSTFKNAKLYGPDVGQPRRKTAKMLKSFLKAGGEVIDSVTWHHYYLNGRTATREDFLNPDVLDIFISSVQKVFQVVESTRPGKKVWLGETSSAYGGGAPLLSDTFAAGFMWLDKLGLSARMGIEVVMRQVFFGAGNYHLVDENFDPLPDYWLSLLFKKLVGTKVLMASVQGSKRRKLRVYLHCTNTDNPRYKEGDLTLYAINLHNVTKYLRLPYPFSNKQVDKYLLRPLGPHGLLSKSVQLNGLTLKMVDDQTLPPLMEKPLRPGSSLGLPAFSYSFFVIRNAKVAACI","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","1","5L9Y"
,,,,,,,,,,,,,,,,"DPGQDVVDLDFFTQEPLHLVSPSFLSVTIDANLATDPRFLILLGSPKLRTLARGLSPAYLRFGGTKTDFLIFDPKKE","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","2","5L9Y"
"5L9Z",,"X-RAY DIFFRACTION",2.49,50.64,"VAPOR DIFFUSION, SITTING DROP",5.5,"17% PEG3350
0.1 M MES 5.5
0.1 M MgCl2
200 nL:500 nL protein:drop ratio",293,"10.1038/nchembio.2395",,"5L9Z",54.04,"1.57","1.57","Crystal structure of human heparanase nucleophile mutant (E343Q), in complex with unreacted glucuronic acid configured aziridine probe JJB355","DPGKKFKNSTYSRSSVDVLYTFANCSGLDLIFGLNALLRTADLQWNSSNAQLLLDYCSSKGYNISWELGNEPNSFLKKADIFINGSQLGEDFIQLHKLLRKSTFKNAKLYGPDVGQPRRKTAKMLKSFLKAGGEVIDSVTWHHYYLNGRTATREDFLNPDVLDIFISSVQKVFQVVESTRPGKKVWLGQTSSAYGGGAPLLSDTFAAGFMWLDKLGLSARMGIEVVMRQVFFGAGNYHLVDENFDPLPDYWLSLLFKKLVGTKVLMASVQGSKRRKLRVYLHCTNTDNPRYKEGDLTLYAINLHNVTKYLRLPYPFSNKQVDKYLLRPLGPHGLLSKSVQLNGLTLKMVDDQTLPPLMEKPLRPGSSLGLPAFSYSFFVIRNAKVAACI","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","1","5L9Z"
,,,,,,,,,,,,,,,,"DPGQDVVDLDFFTQEPLHLVSPSFLSVTIDANLATDPRFLILLGSPKLRTLARGLSPAYLRFGGTKTDFLIFDPKKE","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","2","5L9Z"
"5LA4",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION",7,"0.1 M Succinate pH 7.0
17% PEG3350
1:250 dilution seed stock

- Seed stock grown in 0.2M Ammonium Nitrate, 20% PEG3350",293,"10.1038/nchembio.2395",,"5LA4",59.43,"1.9","1.9","Crystal structure of apo human proheparanase","GQDVVDLDFFTQEPLHLVSPSFLSVTIDANLATDPRFLILLGSPKLRTLARGLSPAYLRFGGTKTDFLIFDPKKESTFEERSYWQSQVNQDICKYGSIPPDVEEKLRLEWPYQEQLLLREHYQKKFKNSTYSRSSVDVLYTFANCSGLDLIFGLNALLRTADLQWNSSNAQLLLDYCSSKGYNISWELGNEPNSFLKKADIFINGSQLGEDFIQLHKLLRKSTFKNAKLYGPDVGQPRRKTAKMLKSFLKAGGEVIDSVTWHHYYLNGRTATREDFLNPDVLDIFISSVQKVFQVVESTRPGKKVWLGETSSAYGGGAPLLSDTFAAGFMWLDKLGLSARMGIEVVMRQVFFGAGNYHLVDENFDPLPDYWLSLLFKKLVGTKVLMASVQGSKRRKLRVYLHCTNTDNPRYKEGDLTLYAINLHNVTKYLRLPYPFSNKQVDKYLLRPLGPHGLLSKSVQLNGLTLKMVDDQTLPPLMEKPLRPGSSLGLPAFSYSFFVIRNAKVAACI","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","1","5LA4"
"5LA7",,"X-RAY DIFFRACTION",2.27,45.85,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Succinate pH 7.0
17% PEG3350
1:250 dilution seed stock

Seed crystals grown in 0.2 M Ammonium Nitrate, 20% PEG3350",293,"10.1038/nchembio.2395",,"5LA7",59.69,"1.94","1.94","Crystal structure of human proheparanase, in complex with glucuronic acid configured aziridine probe JJB355","GQDVVDLDFFTQEPLHLVSPSFLSVTIDANLATDPRFLILLGSPKLRTLARGLSPAYLRFGGTKTDFLIFDPKKESTFEERSYWQSQVNQDICKYGSIPPDVEEKLRLEWPYQEQLLLREHYQKKFKNSTYSRSSVDVLYTFANCSGLDLIFGLNALLRTADLQWNSSNAQLLLDYCSSKGYNISWELGNEPNSFLKKADIFINGSQLGEDFIQLHKLLRKSTFKNAKLYGPDVGQPRRKTAKMLKSFLKAGGEVIDSVTWHHYYLNGRTATREDFLNPDVLDIFISSVQKVFQVVESTRPGKKVWLGETSSAYGGGAPLLSDTFAAGFMWLDKLGLSARMGIEVVMRQVFFGAGNYHLVDENFDPLPDYWLSLLFKKLVGTKVLMASVQGSKRRKLRVYLHCTNTDNPRYKEGDLTLYAINLHNVTKYLRLPYPFSNKQVDKYLLRPLGPHGLLSKSVQLNGLTLKMVDDQTLPPLMEKPLRPGSSLGLPAFSYSFFVIRNAKVAACI","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","1","5LA7"
"5LAB",,"X-RAY DIFFRACTION",2.26,45.26,"VAPOR DIFFUSION, SITTING DROP",8,"Tris, PEG6000, NNGH, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293,,"NGH","5LAB",18.18,"1.34","1.34","Crystal structure of the catalytic domain of human MMP12 complexed with the inhibitor NNGH","MGPVWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDDHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTYKYVDINTFRLSADDIRGIQSLYG","Homo sapiens","MMP12, HME","Macrophage metalloelastase","1","5LAB"
"5LAP",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"PROTEIN SOLUTION: 6 MG/ML PROTEIN IN 25 MM SODIUM PHOSPHATE, PH 7.2, 150 MM KCL, 5 MM DTT. RESERVOIR BUFFER: 100 MM HEPES, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 5 MM DTT. SOAKING BUFFER: 30 mM Phikan11000 IN 100 MM HEPES, PH 7.2, 10 MM SODIUM PHOSPHATE, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 20 % (V/V) GLYCEROL, 150 MM KCL.",293,"10.1073/pnas.1610421113",,"5LAP",49.51,"1.42","1.42","p53 cancer mutant Y220C with Cys182 alkylation","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","Cellular tumor antigen p53","1","5LAP"
"5LAQ",,"X-RAY DIFFRACTION",2.35,47.6,"VAPOR DIFFUSION, HANGING DROP",4.6,"50 mM calcium acetate, 20% PEG 400, 100 mM sodium acetate",293,"10.1021/acs.jmedchem.7b01670","6M5","5LAQ",49.29,"2.4","2.4","Crystal structure of human phosphodiesterase 4B catalytic domain with inhibitor NPD-001","MSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEYISNTFLDKQNDVEIPKVTAEEAPQPMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELEDLNKWGLNIFNVAGYSHNRPLTCIMYAIFQERDLLKTFRISSDTFITYMMTLEDHYHSDVAYHNSLHAADVAQSTHVLLSTPALDAVFTDLEILAAIFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEEHCDIFMNLTKKQRQTLRKMVIDMVLATDMSKHMSLLADLKTMVETKKVTSSGVLLLDNYTDRIQVLRNMVHCADLSNPTKSLELYRQWTDRIMEEFFQQGDKERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVQPDAQDILDTLEDNRNWYQSMIPQSHHHHHH","Homo sapiens","PDE4B, DPDE4","cAMP-specific 3',5'-cyclic phosphodiesterase 4B,cAMP-specific 3',5'-cyclic phosphodiesterase 4B","1","5LAQ"
,,,,,,,,,,,,,,,,,"Homo sapiens","PDE4B, DPDE4"
"5LAT",,"X-RAY DIFFRACTION",2.87,57.19,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.1 M tri-sodium citrate pH 5.6, 20% PEG 4000, 20% 2-propanol",293,"10.1038/ncomms12673","UN9","5LAT",28.65,"1.9","1.9","HIF prolyl hydroxylase 2 (PHD2/EGLN1) P317R variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/UN9)","GSHMASPNGQTKPLPALKLALEYIVPCMNKHGICVVDDFLGKETGQQIGDEVRALHDTGKFTDGQLVSQKSDSSKDIRGDKITWIEGKEPGCETIGLLMSSMDDLIRHCNGKLGSYKINGRTKAMVACYPGNGTGYVRHVDNRNGDGRCVTCIYYLNKDWDAKVSGGILRIFPEGKAQFADIEPKFDRLLFFWSDRRNPHEVQPAYATRYAITVWYFDADERARAKVKYLTGEKGVRVELNKPSDSVGKDVF","Homo sapiens","EGLN1, C1orf12, PNAS-118, PNAS-137","Egl nine homolog 1","1","5LAT"
"5LAV",,"X-RAY DIFFRACTION",2.3,46.65,"VAPOR DIFFUSION, HANGING DROP",4.5,"RESERVOIR SOLUTION : NULL",277,"10.1021/acs.jmedchem.6b00900",,"5LAV",11.4,"1.73","1.73","Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) in complex with compound 6b","IPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVN","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","5LAV"
"5LAW",,"X-RAY DIFFRACTION",2.27,45.79,"VAPOR DIFFUSION, HANGING DROP",4.5,"RESERVOIR SOLUTION : NULL",277,"10.1021/acs.jmedchem.6b00900",,"5LAW",11.79,"1.64","1.64","Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) IN COMPLEX WITH COMPOUND 14","QIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVN","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","5LAW"
"5LAY",,"X-RAY DIFFRACTION",2.99,58.93,"VAPOR DIFFUSION, HANGING DROP",4.5,"NULL",277,"10.1021/acs.jmedchem.6b00900",,"5LAY",70.53,"2.71","2.71","Discovery of New Natural-product-inspired Spiro-oxindole Compounds as Orally Active Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) IN COMPLEX WITH COMPOUND 6g","SQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVN","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","5LAY"
"5LAZ",,"X-RAY DIFFRACTION",2.25,45.37,"VAPOR DIFFUSION, HANGING DROP",4.6,"RESERVOIR SOLUTION : NULL",293,"10.1021/acs.jmedchem.6b00900",,"5LAZ",11.74,"1.66","1.66","Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2) IN COMPLEX WITH COMPOUND BI-0252","QIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVN","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","5LAZ"
"5LB3",,"X-RAY DIFFRACTION",2.41,48.94,"VAPOR DIFFUSION",,"23% PEG6K, 0.15M lithium chloride, 2.5% ethylene glycol",293,"10.1093/nar/gkw1362",,"5LB3",100.11,"1.8","1.8","Crystal structure of human RECQL5 helicase in complex with ADP/Mg.","MSDPERRVRSTLKKVFGFDSFKTPLQESATMAVVKGNKDVFVCMPTGAGKSLCYQLPALLAKGITIVVSPLIALIQDQVDHLLTLKVRVSSLNSKLSAQERKELLADLEREKPQTKILYITPEMAASSSFQPTLNSLVSRHLLSYLVVDEAHCVSQWGHDFRPDYLRLGALRSRLGHAPCVALTATATPQVQEDVFAALHLKKPVAIFKTPCFRANLFYDVQFKELISDPYGNLKDFCLKALGQEADKGLSGCGIVYCRTREACEQLAIELSCRGVNAKAYHAGLKASERTLVQNDWMEEKVPVIVATISFGMGVDKANVRFVAHWNIAKSMAGYYQESGRAGRDGKPSWCRLYYSRNDRDQVSFLIRKEVAKLQEKRGNKASDKATIMAFDALVTFCEELGCRHAAIAKYFGDALPACAKGCDHCQNPTAVRRRLEALERSSSW","Homo sapiens","RECQL5, RECQ5","ATP-dependent DNA helicase Q5","1","5LB3"
"5LB5",,"X-RAY DIFFRACTION",2.72,54.86,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M tris pH 7.5, 23% PEG3350, 0.1M sodium chloride",293,"10.1093/nar/gkw1362",,"5LB5",200.45,"2","2","Crystal structure of human RECQL5 helicase in complex with ADP/Mg (tricilinc form).","SMDPERRVRSTLKKVFGFDSFKTPLQESATMAVVKGNKDVFVCMPTGAGKSLCYQLPALLAKGITIVVSPLIALIQDQVDHLLTLKVRVSSLNSKLSAQERKELLADLEREKPQTKILYITPEMAASSSFQPTLNSLVSRHLLSYLVVDEAHCVSQWGHDFRPDYLRLGALRSRLGHAPCVALTATATPQVQEDVFAALHLKKPVAIFKTPCFRANLFYDVQFKELISDPYGNLKDFCLKALGQEADKGLSGCGIVYCRTREACEQLAIELSCRGVNAKAYHAGLKASERTLVQNDWMEEKVPVIVATISFGMGVDKANVRFVAHWNIAKSMAGYYQESGRAGRDGKPSWCRLYYSRNDRDQVSFLIRKEVAKLQEKRGNKASDKATIMAFDALVTFCEELGCRHAAIAKYFGDALPACAKGCDHCQNPTAVRRRLEALERSSSW","Homo sapiens","RECQL5, RECQ5","ATP-dependent DNA helicase Q5","1","5LB5"
"5LB6",,"X-RAY DIFFRACTION",2.9,57.68,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES-Na pH 6.5, 30% polyethylene glycol monomethyl ether 5000, 0.2 M ammonium sulphate",293,"10.1038/ncomms12673","UN9","5LB6",28.6,"1.7","1.7","HIF prolyl hydroxylase 2 (PHD2/EGLN1) R371H variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/UN9)","GSHMASPNGQTKPLPALKLALEYIVPCMNKHGICVVDDFLGKETGQQIGDEVRALHDTGKFTDGQLVSQKSDSSKDIRGDKITWIEGKEPGCETIGLLMSSMDDLIRHCNGKLGSYKINGRTKAMVACYPGNGTGYVRHVDNPNGDGRCVTCIYYLNKDWDAKVSGGILRIFPEGKAQFADIEPKFDRLLFFWSDRHNPHEVQPAYATRYAITVWYFDADERARAKVKYLTGEKGVRVELNKPSDSVGKDVF","Homo sapiens","EGLN1, C1orf12, PNAS-118, PNAS-137","Egl nine homolog 1","1","5LB6"
"5LB8",,"X-RAY DIFFRACTION",2.02,39.26,"VAPOR DIFFUSION",7,"17.5% Peg 3350, 0.2M Potassium Thiocyanate, 0.1M Hepes pH 7.0, 10% ethelene glycol",293,"10.1093/nar/gkw1362",,"5LB8",115.73,"3.4","3.4","Crystal structure of human RECQL5 helicase APO form.","SMDPERRVRSTLKKVFGFDSFKTPLQESATMAVVKGNKDVFVCMPTGAGKSLCYQLPALLAKGITIVVSPLIALIQDQVDHLLTLKVRVSSLNSKLSAQERKELLADLEREKPQTKILYITPEMAASSSFQPTLNSLVSRHLLSYLVVDEAHCVSQWGHDFRPDYLRLGALRSRLGHAPCVALTATATPQVQEDVFAALHLKKPVAIFKTPCFRANLFYDVQFKELISDPYGNLKDFCLKALGQEADKGLSGCGIVYCRTREACEQLAIELSCRGVNAKAYHAGLKASERTLVQNDWMEEKVPVIVATISFGMGVDKANVRFVAHWNIAKSMAGYYQESGRAGRDGKPSWCRLYYSRNDRDQVSFLIRKEVAKLQEKRGNKASDKATIMAFDALVTFCEELGCRHAAIAKYFGDALPACAKGCDHCQNPTAVRRRLEALERSSSWSKTCIGPSQGNGFDPELYEGGRKGYGDFSRYDEGSGGSGDEGRDEAHKREWNLFYQKQMQLRKGKDPKIEEFV","Homo sapiens","RECQL5, RECQ5","ATP-dependent DNA helicase Q5","1","5LB8"
"5LBA",,"X-RAY DIFFRACTION",2.72,54.72,"VAPOR DIFFUSION, SITTING DROP",,"0.1M tris pH 9.0 -- 29% PEG3350 -- 0.1M sodium chloride",293,,,"5LBA",200.68,"2.5","2.5","Crystal structure of human RECQL5 helicase in complex with DSPL fragment(1-cyclohexyl-3-(oxolan-2-ylmethyl)urea, SGC - Diamond XChem I04-1 fragment screening.","SMDPERRVRSTLKKVFGFDSFKTPLQESATMAVVKGNKDVFVCMPTGAGKSLCYQLPALLAKGITIVVSPLIALIQDQVDHLLTLKVRVSSLNSKLSAQERKELLADLEREKPQTKILYITPEMAASSSFQPTLNSLVSRHLLSYLVVDEAHCVSQWGHDFRPDYLRLGALRSRLGHAPCVALTATATPQVQEDVFAALHLKKPVAIFKTPCFRANLFYDVQFKELISDPYGNLKDFCLKALGQEADKGLSGCGIVYCRTREACEQLAIELSCRGVNAKAYHAGLKASERTLVQNDWMEEKVPVIVATISFGMGVDKANVRFVAHWNIAKSMAGYYQESGRAGRDGKPSWCRLYYSRNDRDQVSFLIRKEVAKLQEKRGNKASDKATIMAFDALVTFCEELGCRHAAIAKYFGDALPACAKGCDHCQNPTAVRRRLEALERSSSW","Homo sapiens","RECQL5, RECQ5","ATP-dependent DNA helicase Q5","1","5LBA"
"5LBB",,"X-RAY DIFFRACTION",2.74,55.09,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5, 2.1 M ammonium sulphate, 2% v/v dioxane, 0.002 M MnCl2",293,"10.1038/ncomms12673","UN9","5LBB",28.44,"1.7","1.7","HIF prolyl hydroxylase 2 (PHD2/EGLN1) R396T variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/UN9)","GSHMASPNGQTKPLPALKLALEYIVPCMNKHGICVVDDFLGKETGQQIGDEVRALHDTGKFTDGQLVSQKSDSSKDIRGDKITWIEGKEPGCETIGLLMSSMDDLIRHCNGKLGSYKINGRTKAMVACYPGNGTGYVRHVDNPNGDGRCVTCIYYLNKDWDAKVSGGILRIFPEGKAQFADIEPKFDRLLFFWSDRRNPHEVQPAYATRYAITVWYFDADETARAKVKYLTGEKGVRVELNKPSDSVGKDVF","Homo sapiens","EGLN1, C1orf12, PNAS-118, PNAS-137","Egl nine homolog 1","1","5LBB"
"5LBC",,"X-RAY DIFFRACTION",2.88,57.29,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5, 1.8 M ammonium sulphate, 5% v/v dioxane, 0.002 M MnCl2",293,"10.1038/ncomms12673","UN9","5LBC",28.83,"1.816","1.816","HIF prolyl hydroxylase 2 (PHD2/EGLN1) I280V/R281L/I292V variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/FG2216)","GSHMASPNGQTKPLPALKLALEYIVPCMNKHGICVVDDFLGKETGQQIGDEVRALHDTGKFTDGQLVSQKSDSSKDIRGDKITWIEGKEPGCETIGLLMSSMDDLVLHCNGKLGSYKVNGRTKAMVACYPGNGTGYVRHVDNPNGDGRCVTCIYYLNKDWDAKVSGGILRIFPEGKAQFADIEPKFDRLLFFWSDRRNPHEVQPAYATRYAITVWYFDADERARAKVKYLTGEKGVRVELNKPSDSVGKDVF","Homo sapiens","EGLN1, C1orf12, PNAS-118, PNAS-137","Egl nine homolog 1","1","5LBC"
"5LBE",,"X-RAY DIFFRACTION",2.83,56.56,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5, 2.0 M ammonium sulphate, 7% v/v dioxane, 0.002 M MnCl2",293,"10.1038/ncomms12673","UN9","5LBE",28.57,"1.749","1.749","HIF prolyl hydroxylase 2 (PHD2/EGLN1) G294E variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/FG2216)","GSHMASPNGQTKPLPALKLALEYIVPCMNKHGICVVDDFLGKETGQQIGDEVRALHDTGKFTDGQLVSQKSDSSKDIRGDKITWIEGKEPGCETIGLLMSSMDDLIRHCNGKLGSYKINERTKAMVACYPGNGTGYVRHVDNPNGDGRCVTCIYYLNKDWDAKVSGGILRIFPEGKAQFADIEPKFDRLLFFWSDRRNPHEVQPAYATRYAITVWYFDADERARAKVKYLTGEKGVRVELNKPSDSVGKDVF","Homo sapiens","EGLN1, C1orf12, PNAS-118, PNAS-137","Egl nine homolog 1","1","5LBE"
"5LBF",,"X-RAY DIFFRACTION",2.72,54.86,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5, 1.8 M ammonium sulphate, 2% v/v dioxane, 0.002 M MnCl2",293,"10.1038/ncomms12673","UN9","5LBF",28.77,"1.8995","1.8995","HIF prolyl hydroxylase 2 (PHD2/EGLN1) K293K/G294E variant in complex with Mn(II) and N-[(1-chloro-4-hydroxyisoquinolin-3-yl)carbonyl]glycine (IOX3/FG2216)","GSHMASPNGQTKPLPALKLALEYIVPCMNKHGICVVDDFLGKETGQQIGDEVRALHDTGKFTDGQLVSQKSDSSKDIRGDKITWIEGKEPGCETIGLLMSSMDDLIRHCNGKLGSYKIKERTKAMVACYPGNGTGYVRHVDNPNGDGRCVTCIYYLNKDWDAKVSGGILRIFPEGKAQFADIEPKFDRLLFFWSDRRNPHEVQPAYATRYAITVWYFDADERARAKVKYLTGEKGVRVELNKPSDSVGKDVF","Homo sapiens","EGLN1, C1orf12, PNAS-118, PNAS-137","Egl nine homolog 1","1","5LBF"
"5LBN",,"X-RAY DIFFRACTION",2.1,39.8,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Sodium citrate pH 6 and 8% (w/v) PEG 8000",277,,,"5LBN",17.8,"1.42","1.42","High-resolution crystal structure of the UBC core domain of UBE2E1/UbcH6","GSMSKNSKLLSTSAKRIQKELADITLDPPPNCSAGPKGDNIYEWRSTILGPPGSVYEGGVFFLDITFTPEYPFKPPKVTFRTRIYHCNINSQGVICLDILKDNWSPALTISKVLLSICSLLTDCNPADPLVGSIATQYMTNRAEHDRMARQWTKRYAT","Homo sapiens","UBE2E1, UBCH6","Ubiquitin-conjugating enzyme E2 E1","1","5LBN"
"5LBO",,"X-RAY DIFFRACTION",2.63,53.19,"VAPOR DIFFUSION, HANGING DROP",7.5,"24% PEG 3350, 30% Ethylene Glycol, 0.1 M HEPES",293,"10.1021/acs.jmedchem.7b01670","6M5","5LBO",172.82,"2.25","2.25","Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-001","GSHMIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELSGNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTHVLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHHLAVGFKLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGMEISPMCDKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQSPSPAPDDPEEGRQGQTEKFQFELTL","Homo sapiens","PDE4D, DPDE3","cAMP-specific 3',5'-cyclic phosphodiesterase 4D","1","5LBO"
"5LBT",,"X-RAY DIFFRACTION",2.31,46.86,"VAPOR DIFFUSION",,"0.1 M Tris HCl pH 8.5
2 M ammonium sulphate",293,,,"5LBT",56.5,"1.75","1.75","Structure of the human quinone reductase 2 (NQO2) in complex with imiquimod","MAGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNLEPRATDKDITGTLSNPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGLLQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCGFKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQHHHHHH","Homo sapiens","NQO2, NMOR2","Ribosyldihydronicotinamide dehydrogenase [quinone]","1","5LBT"
"5LBU",,"X-RAY DIFFRACTION",2.31,46.72,"VAPOR DIFFUSION",,"0.1 M Tris HCl pH 8.5
2 M ammonium sulphate",293,,,"5LBU",56.7,"1.65","1.65","Structure of the human quinone reductase 2 (NQO2) in complex with to CL097","MAGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNLEPRATDKDITGTLSNPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGLLQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCGFKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQHHHHHH","Homo sapiens","NQO2, NMOR2","Ribosyldihydronicotinamide dehydrogenase [quinone]","1","5LBU"
"5LBW",,"X-RAY DIFFRACTION",2.32,46.98,"VAPOR DIFFUSION",,"200 mM sodium sulphate, 2.2 M ammonium sulphate",293,"10.1126/science.aan4368",,"5LBW",55.94,"1.9","1.9","Structure of the human quinone reductase 2 (NQO2) in complex with volitinib","MAGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNLEPRATDKDITGTLSNPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGLLQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCGFKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQHHHHHH","Homo sapiens","NQO2, NMOR2","Ribosyldihydronicotinamide dehydrogenase [quinone]","1","5LBW"
"5LBY",,"X-RAY DIFFRACTION",2.43,49.44,"VAPOR DIFFUSION",,"180 mM tri-ammonium citrate, 2.2 M ammonium sulphate",293,"10.1126/science.aan4368",,"5LBY",56.14,"1.4","1.4","Structure of the human quinone reductase 2 (NQO2) in complex with crenolanib","MAGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNLEPRATDKDITGTLSNPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGLLQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCGFKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQHHHHHH","Homo sapiens","NQO2, NMOR2","Ribosyldihydronicotinamide dehydrogenase [quinone]","1","5LBY"
"5LBZ",,"X-RAY DIFFRACTION",2.41,49.06,"VAPOR DIFFUSION",,"200 mM sodium sulphate, 2.2 M ammonium sulphate",293,"10.1126/science.aan4368",,"5LBZ",56.58,"1.4","1.4","Structure of the human quinone reductase 2 (NQO2) in complex with pacritinib","MAGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNLEPRATDKDITGTLSNPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGLLQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCGFKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQHHHHHH","Homo sapiens","NQO2, NMOR2","Ribosyldihydronicotinamide dehydrogenase [quinone]","1","5LBZ"
"5LC2",,"X-RAY DIFFRACTION",2.06,40.2,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG monomer ether 550, 100 mM MES pH 6.5, 10mM ZnSO4",277,"10.1074/jbc.M117.782904",,"5LC2",45.33,"1.8","1.8","Xray structure of human FAM3C ILEI monomer","MPLLLLLPLLWAGALAELHHHHHHENLYFQSGRYKCGISKACPEKHFAFKMASGAANVVGPKICLEDNVLMSGVKNNVGRGINVALANGKTGEVLDTKYFDMWGGDVAPFIEFLKAIQDGTIVLMGTYDDGATKLNDEARRLIADLGSTSITNLGFRDNWVFCGGKGIKTKSPFEQHIKNNKDTNKYEGWPEVVEMEGCIPQKQD","Homo sapiens","FAM3C, ILEI, GS3786","Protein FAM3C","1","5LC2"
"5LCI",,"SOLUTION NMR",,,,,,,"10.7554/eLife.16673",,"5LCI",12.88,,,"Solution structure of BOLA1 from Homo sapiens","GIDPFTQGSAGSGAIGPVEAAIRTKLEEALSPEVLELRNESGGHAVPPGSETHFRVAVVSSRFEGLSPLQRHRLVHAALAEELGGPVHALAIQARTPAQWRENSQLDTSPPCLGGNKKTLGTP","Homo sapiens","BOLA1, CGI-143","BolA-like protein 1","1","5LCI"
"5LCJ",,"X-RAY DIFFRACTION",2.31,46.65,"BATCH MODE",7.2,".2M (NH4)2SO4
32% MPEG 2000
.02M Mercaptoethanol
.1M pH=7.2 HEPES/NaOH",297,"10.1039/c6mb00367b",,"5LCJ",43.33,"1.78","1.78","In-Gel Activity-Based Protein Profiling of a Clickable Covalent Erk 1/2 Inhibitor","MAHHHHHHMAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5LCJ"
"5LCK",,"X-RAY DIFFRACTION",2.44,49.6,"BATCH MODE",7.2,"2M (NH4)2SO4
32% MPEG 2000
.02M Mercaptoethanol
.1M pH=7.2 HEPES/NaOH",293,"10.1039/c6mb00367b",,"5LCK",42.41,"1.89","1.89","A Clickable Covalent ERK 1/2 Inhibitor","MAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5LCK"
"5LDZ",,"X-RAY DIFFRACTION",2.83,56.6,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris-HCl pH 8.5, 2 M (NH4)2SO4",295,"10.1107/S2059798316016715",,"5LDZ",224.81,"2.2","2.2","Quadruple space group ambiguity due to rotational and translational non-crystallographic symmetry in human liver fructose-1,6-bisphosphatase","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYARDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, FBP","Fructose-1,6-bisphosphatase 1","1","5LDZ"
"5LE0",,"X-RAY DIFFRACTION",3.74,67.09,"VAPOR DIFFUSION, HANGING DROP",,"EG",290,"10.1038/ncomms14528",,"5LE0",17.67,"3.3","3.3","MICAL1 Cterminal domain","KEEEMKRFCKAQTIQRRLNEIEAALRELEAEGVKLELALRRQSSSPEQQKKLWVGQLLQLVDKKNSLVAEEAELMITVQELNLEEKQWQLDQELRGYMNREENLKTAADRQAEDQVLRKLVDLVNQRDALIRFQEERRLSELALGTGAQG","Homo sapiens","MICAL1, MICAL, NICAL","Protein-methionine sulfoxide oxidase MICAL1","1","5LE0"
"5LEV",,"X-RAY DIFFRACTION",3.99,69.18,"VAPOR DIFFUSION, SITTING DROP",9,"0.1M bicine pH 9.0, 0.05M sodium chloride, 38% PEG300, 5mM Na2WO4",293,"10.1016/j.cell.2018.10.037",,"5LEV",46.96,"3.2","3.2","Crystal structure of human UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1) (V264G mutant)","SMWAFSELPMPLLINLIVSLLGFVATVTLIPAFRGHFIAARLCGQDLNKTSRQQIPESQGVISGAVFLIILFCFIPFPFLNCFVKEQCKAFPHHEFVALIGALLAICCMIFLGFADDVLNLRWRHKLLLPTAASLPLLMVYFTNFGNTTIVVPKPFRPILGLHLDLGILYYVYMGLLAVFCTNAINILAGINGLEAGQSLVISASIIVFNLVELEGDCRDDHVFSLYFMIPFFFTTLGLLYHNWYPSRVFVGDTFCYFAGMTFAGVGILGHFSKTMLLFFMPQVFNFLYSLPQLLHIIPCPRHRIPRLNIKTGKLEMSYSKFKTKSLSFLGTFILKVAESLQLVTVHQSETEDGEFTECNNMTLINLLLKVLGPIHERNLTLLLLLLQILGSAITFSIRYQLVRLFYDV","Homo sapiens","DPAGT1, DPAGT2","UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase","1","5LEV"
"5LF8",,"X-RAY DIFFRACTION",2.52,51.12,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M SPG pH 7.0
30% PEG1K",277,,,"5LF8",36.52,"2.56","2.56","Human Nucleoside diphosphate-linked moiety X motif 17 (NUDT17)","MAEVRVQLLLSRRPESVSFARSVCGLLGAGPGLGTWPIHCSLKRGRLVLSSRPFPGASARLPLQRPPFCPFAALEERPRVPGAELPTDRGVDLGVAVILQSSDKTVLLTRRARTLSVSPNLWVPPGGHVELEEELLDGGLRELWEESGLHLPQGQFSWVPLGLWESAYPPRLSWGLPKYHHIVLYLLVISQESQQQLQARIQPNPNEVSALMWLTPDVAAAVAAAEDGTETPGLLPQDLPPSVLAVELEEDGRARPLVLHMSTLLRMIPTMAEDKERVSTGTKFALKLWLQHLGRTPPPCKSAAYLDPGPAKEEWNMDPLPPNQGSGK","Homo sapiens","NUDT17","Nucleoside diphosphate-linked moiety X motif 17","1","5LF8"
"5LF9",,"X-RAY DIFFRACTION",2.02,39.18,"VAPOR DIFFUSION, SITTING DROP",7.5,"15% HighPEG, 0.1 M hepes pH 7.5, 0.1 M NaKPO, 10% EDO",277,,,"5LF9",32.71,"1.45","1.45","Crystal structure of human NUDT22","SMDPEVTLLLQCPGGGLPQEQIQAELSPAHDRRPLPGGDEAITAIWETRLKAQPWLFDAPKFRLHSATLAPIGSRGPQLLLRLGLTSYRDFLGTNWSSSAAWLRQQGATDWGDTQAYLADPLGVGAALATADDFLVFLRRSRQVAEAPGLVDVPGGHPEPQALCPGGSPQHQDLAGQLVVHELFSSVLQEICDEVNLPLLTLSQPLLLGIARNETSAGRASAEFYVQCSLTSEQVRKHYLSGGPEAHESTGIFFVETQNVRRLPETEMWAELCPSAKGAIILYNRVQGSPTGAALGSPALLPPL","Homo sapiens","NUDT22, PP11246","Nucleoside diphosphate-linked moiety X motif 22","1","5LF9"
"5LFF",,"SOLUTION NMR",,,,,,,"10.1021/acs.jmedchem.6b00695",,"5LFF",0.9,,,"NMR structure of peptide 2 targeting CXCR4","RACRFFC","Homo sapiens",,"ARG-ALA-CYS-ARG-PHE-PHE-CYS","1","5LFF"
"5LFH",,"SOLUTION NMR",,,,,,,"10.1021/acs.jmedchem.6b00695",,"5LFH",0.93,,,"NMR structure of peptide 10 targeting CXCR4","XRACRFFC","Homo sapiens",,"ACE-ARG-ALA-DCY-ARG-PHE-PHE-CYS","1","5LFH"
"5LFN",,"X-RAY DIFFRACTION",2.63,53.8,"VAPOR DIFFUSION",9.5,"21% PEG 3350, 6% xylitol, 0.1 M glycine-NaOH pH 9.5-10.5, 0.2 M ammonium sulfate. Protein at 1.2 mg/ml in 20 mM Tris pH 7.0, 200 mM NaCl. Mixed in 1:1 ratio with reservoir.",293,"10.1107/S205979831601980X",,"5LFN",153.34,"2.1","2.1","Crystal structure of human chondroadherin","CPQNCHCHSDLQHVICDKVGLQKIPKVSEKTKLLNLQRNNFPVLAANSFRAMPNLVSLHLQHCQIREVAAGAFRGLKQLIYLYLSHNDIRVLRAGAFDDLTELTYLYLDHNKVTELPRGLLSPLVNLFILQLNNNKIRELRAGAFQGAKDLRWLYLSENALSSLQPGALDDVENLAKFHVDRNQLSSYPSAALSKLRVVEELKLSHNPLKSIPDNAFQSFGRYLETLWLDNTNLEKFSDGAFLGVTTLKHVHLENNRLNQLPSNFPFDSLETLALTNNPWKCTCQLRGLRRWLEAKASRPDATCASPAKFKGQHIRDTDAFRSCKFPTKRSKKAGRH","Homo sapiens","CHAD, SLRR4A","Chondroadherin","1","5LFN"
"5LFY",,"SOLUTION NMR",,,,,,,"10.1002/anie.201704615",,"5LFY",2.57,,,"Zinc bound dimer of the fragment of human amyloid-beta peptide with Alzheimer's disease pathogenic Taiwanese mutation D7H","DAEFRHHSGYX","Homo sapiens","APP, A4, AD1","Amyloid beta A4 protein","1","5LFY"
"5LG0",,"SOLUTION NMR",,,,,,,"10.1016/j.jmb.2017.06.012",,"5LG0",7.98,,,"Solution NMR structure of Tryptophan to Alanine mutant of Arkadia RING domain.","MKQDGEEGTEEDTEEKCTICLSILEEGEDVRRLPCMHLFHQVCVDQALITNKKCPICRVDIEAQLPSES","Homo sapiens","RNF111","E3 ubiquitin-protein ligase Arkadia","1","5LG0"
"5LG1",,"X-RAY DIFFRACTION",3.22,61.75,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M MES, 18-20% PEG 20 000",291,"10.1016/j.molimm.2016.11.021",,"5LG1",51.42,"2.7","2.7","Room temperature structure of human IgG4-Fc from crystals analysed in situ","FLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK","Homo sapiens","IGHG4","Ig gamma-4 chain C region","1","5LG1"
"5LG7",,"SOLUTION NMR",,,,,,,"10.1016/j.jmb.2017.06.012",,"5LG7",8.06,,,"Solution NMR structure of Tryptophan to Arginine mutant of Arkadia RING domain","MKQDGEEGTEEDTEEKCTICLSILEEGEDVRRLPCMHLFHQVCVDQRLITNKKCPICRVDIEAQLPSES","Homo sapiens","RNF111","E3 ubiquitin-protein ligase Arkadia","1","5LG7"
"5LG8",,"X-RAY DIFFRACTION",3.65,66.28,"VAPOR DIFFUSION, HANGING DROP",5,"100 mM Cd(NO3)2, 100 mM ammonium sulfate, and 200 mM sodium acetate pH 5",281,"10.1073/pnas.1614302114",,"5LG8",21.4,"1.98","1.98","Human L-type ferritin iron loaded for 60 minutes","MSSQIRQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVALEGVSHFFRELAEEKREGYERLLKMQNQRGGRALFQDIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSARTDPHLCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEAGLGEYLFERLTLKHD","Homo sapiens","FTL","Ferritin light chain","1","5LG8"
"5LGE",,"X-RAY DIFFRACTION",2.76,55.36,"VAPOR DIFFUSION",7,"PROTEIN BUFFER: 15 MG/ML. PROTEIN IN 25 MM HEPES, 300 MM NACL, 5 MM BETA-ME, COMPLETE PROTEASE INHIBITOR MIXTURE, PH 7.7 RESERVOIR: 100 
MM BIS-TRIS, PH 7.0,  200 MM CA-ACETATE,  20.0 %(W/V) PEG 3350",293,"10.1007/s00401-017-1677-y","6VN","5LGE",196.6,"2.7","2.7","Crystal Structure of human IDH1 mutant (R132H) in complex with NADP+ and an Inhibitor related to BAY 1436032","MSKKISGGSVVEMQGDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDAAEAIKKHNVGVKCATITPDEKRVEEFKLKQMWKSPNGTIRNILGGTVFREAIICKNIPRLVSGWVKPIIIGHHAYGDQYRATDFVVPGPGKVEITYTPSDGTQKVTYLVHNFEEGGGVAMGMYNQDKSIEDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFEAQKIWYEHRLIDDMVAQAMKSEGGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVLVCPDGKTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRAKLDNNKELAFFANALEEVSIETIEAGFMTKDLAACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAKLSLEHHHHHHHH","Homo sapiens","IDH1, PICD","Isocitrate dehydrogenase [NADP] cytoplasmic","1","5LGE"
"5LGG",,"X-RAY DIFFRACTION",2.45,49.85,"VAPOR DIFFUSION, SITTING DROP",5,"0.1 M citric acid, pH5.0, 2M NaCl",277,"10.1073/pnas.1607147113",,"5LGG",47.91,"2.15","2.15","The N-terminal WD40 domain of Apc1 (Anaphase promoting complex subunit 1)","MSNFYEERTTMIAARDLQEFVPFGRDHCKHHPNGSAGSAQKESWQLRKGVSEIGEDVDYDEELYVAGNMVIWSKGSKSQALAVYKAFTVDSPVQQALWCDFIISQDKSEKAYSSNEVEKCICILQSSCINMHSIEGKDYIASLPFQVANVWPTKYGLLFERSASSHEVPPGSPREPLPTMFSMLHPLDEITPLVCKSGSLFGSSRVQYVVDHAMKIVFLNTDPSIVMTYDAVQNVHSVWTLRRVKSEEENVVLKFSEQGGTPQNVATSSSLTAHLRGSIVPELCIDHLWTETITNIREKNSQASKVFITSDLCGQKFLCFLVESQLQLRCVKFQESNDKTQLIFGSVTNIPAKDAAPVEKIDTMLVLEGSGNLVLYTGVVRVGKVFIPGLPAPSLTMSGTYIHSIRDPVHNRVTLELSNGSMVRITIPEIA","Homo sapiens","ANAPC1, TSG24","Anaphase-promoting complex subunit 1,Anaphase-promoting complex subunit 1,Anaphase-promoting complex subunit 1,Anaphase-promoting complex subunit 1","1","5LGG"
,,,,,,,,,,,,,,,,,"Homo sapiens","ANAPC1, TSG24"
,,,,,,,,,,,,,,,,,"Homo sapiens","ANAPC1, TSG24"
,,,,,,,,,,,,,,,,,"Homo sapiens","ANAPC1, TSG24"
"5LGJ",,"X-RAY DIFFRACTION",2.7,54.41,"VAPOR DIFFUSION, SITTING DROP",8.5,"16% w/v PEG 8,000, 0.1M Tris-HCl pH 8.5, 0.2 M lithium sulfate",294,,,"5LGJ",74.13,"2.6","2.6","THE CRYSTAL STRUCTURE OF IGE FC MUTANT - P333C","DFTPPTVKILQSSCDGGGHFPPTIQLLCLVSGYTPGTIQITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQGHTFEDSTKKCADSNCRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVQLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNP","Homo sapiens","IGHE","Ig epsilon chain C region","1","5LGJ"
,,,,,,,,,,,,,,,,"DFTPPTVKILQSSCDGGGHFPPTIQLLCLVSGYTPGTIQITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQGHTFEDSTKKCADSNCRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVQLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPG","Homo sapiens","IGHE","Ig epsilon chain C region","2","5LGJ"
"5LHB",,"X-RAY DIFFRACTION",2.44,49.62,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% PEG 3350, 36.4MM PCTP PH 4, 63.6MM  PCTP PH 10, 0.2M AMMONIUM SULPHATE",293,"10.1021/acschembio.6b00609",,"5LHB",62.08,"2.23","2.23","POLYADPRIBOSYL GLYCOSIDASE IN COMPLEX WITH PDD00017262","GSSPDKKWLGTPIEEMRRMPRCGIRLPLLRPSANHTVTIRVDLLRAGEVPKPFPTHYKDLWDNKHVKMPCSEQNLYPVEDENGERTAGSRWELIQTALLNKFTRPQNLKDAILKYNVAYSKKWDFTALIDFWDKVLEEAEAQHLYQSILPDMVKIALCLPNICTQPIPLLAAAMNHSITMSQEQIASLLANAFFCTFPRRNAKMKSEYSSYPDINFNRLFEGRSSRKPEKLKTLFCYFRRVTAAAPTGLVTFTRQSLEDFPEWERCEKPLTRLHVTYEGTIEENGQGMLQVDFANRFVGGGVTSAGLVQEEIRFLINPELIISRLFTEVLDHNECLIITGTEQYSEYTGYAETYRWSRSHEDGSERDDWQRRCTEIVAIDALHFRRYLDQFVPEKMRRELNKAYCGFLRPGVSSENLSAVATGNWGCGAFGGDARLKALIQILAAAAAERDVVYFTFGDSELMRDIYSMHIFLTERKLTVGDVYKLLLRYYNEECRNCSTPGPDIKLYPFIYHAVESCAETADHSGQRTGT","Homo sapiens","PARG","Poly(ADP-ribose) glycohydrolase","1","5LHB"
"5LHD",,"X-RAY DIFFRACTION",2.91,57.66,"VAPOR DIFFUSION, SITTING DROP",,"50 mM Imidazol-HCl pH 8.0, 20% PEG6000",294,"10.1038/srep46045",,"5LHD",454.61,"2.6","2.6","Structure of glycosylated human aminopeptidase N","YPYDVPDYAGAQPARSPGEKNKNANSSPVASTTPSASATTNPASATTLDQSKAWNRYRLPNTLKPDSYRVTLRPYLTPNDRGLYVFKGSSTVRFTCKEATDVIIIHSKKLNYTLSQGHRVVLRGVGGSQPPDIDKTELVEPTEYLVVHLKGSLVKDSQYEMDSEFEGELADDLAGFYRSEYMEGNVRKVVATTQMQAADARKSFPCFDEPAMKAEFNITLIHPKDLTALSNMLPKGPSTPLPEDPNWNVTEFHTTPKMSTYLLAFIVSEFDYVEKQASNGVLIRIWARPSAIAAGHGDYALNVTGPILNFFAGHYDTPYPLPKSDQIGLPDFNAGAMENWGLVTYRENSLLFDPLSSSSSNKERVVTVIAHELAHQWFGNLVTIEWWNDLWLNEGFASYVEYLGADYAEPTWNLKDLMVLNDVYRVMAVDALASSHPLSTPASEINTPAQISELFDAISYSKGASVLRMLSSFLSEDVFKQGLASYLHTFAYQNTIYLNLWDHLQEAVNNRSIQLPTTVRDIMNRWTLQMGFPVITVDTSTGTLSQEHFLLDPDSNVTRPSEFNYVWIVPITSIRDGRQQQDYWLIDVRAQNDLFSTSGNEWVLLNLNVTGYYRVNYDEENWRKIQTQLQRDHSAIPVINRAQIINDAFNLASAHKVPVTLALNNTLFLIEERQYMPWEAALSSLSYFKLMFDRSEVYGPMKNYLKKQVTPLFIHFRNNTNNWREIPENLMDQYSEVNAISTACSNGVPECEEMVSGLFKQWMENPNNNPIHPNLRSTVYCNAIAQGGEEEWDFAWEQFRNATLVNEADKLRAALACSKELWILNRYLSYTLNPDLIRKQDATSTIISITNNVIGQGLVWDFVQSNWKKLFNDYGGGSFSFSNLIQAVTRRFSTEYELQQLEQFKKDNEETGFGSGTRALEQALEKTKANIKWVKENKEVVLQWFTENSK","Homo sapiens","ANPEP, APN, CD13, PEPN","Aminopeptidase N","1","5LHD"
"5LHW",,"X-RAY DIFFRACTION",1.86,33.71,"VAPOR DIFFUSION, SITTING DROP",9,"150 nl protein solution (58.6 mg/ml protein in 20 mM Tris pH 7.5, 150 mM NaCl, 2 mM TCEP) and 150 nl of mother liquor (7 mM HEPES pH 8.2, 93 mM Tris pH 9.0, 55.36% v/v PEG 550 MME, 10% v/v glycerol)",292,"10.1242/bio.024661",,"5LHW",3.48,"0.91","0.91","Central Coiled-Coil Domain of Human STIL","GGSLTEQDRQLRLLQAQIQRLLEAQSLM","Homo sapiens","STIL, SIL","SCL-interrupting locus protein","1","5LHW"
"5LHY",,"X-RAY DIFFRACTION",3.32,62.99,"VAPOR DIFFUSION, SITTING DROP",,"100 nl protein solution (52.3 mg/ml protein in 20 mM Tris pH 7.5, 150 mM NaCl, 2 mM DTT) and 100 nl mother liquor (32.27% v/v PPG400, 100 mM NaCl, 50 mM MgCl2, unbuffered)",292,"10.1242/bio.024661",,"5LHY",594.91,"3.31","3.31","PB3 Domain of Human PLK4 (apo)","GPMGSAQLLKSVFVKNVGWATQLTSGAVWVQFNDGSQLVVQAGVSSISYTSPNGQTTRYGENEKLPDYIKQKLQCLSSILLMFSNPTPNFH","Homo sapiens","PLK4, SAK, STK18","Serine/threonine-protein kinase PLK4","1","5LHY"
"5LI9",,"X-RAY DIFFRACTION",2.29,46.19,"VAPOR DIFFUSION, SITTING DROP",6.3,"25% Morpheus precipitant mix 4, 10% Morpheus Carboxylic acids, Morpheus Buffer system 1",293,"10.1016/j.devcel.2016.07.018",,"5LI9",41.89,"1.79","1.79","Structure of a nucleotide-bound form of PKCiota core kinase domain","FSLGLQDFDLLRVIGRGSYAKVLLVRLKKTDRIYAMKVVKKELVNDDEDIDWVQTEKHVFEQASNHPFLVGLHSCFQTESRLFFVIEYVNGGDLMFHMQRQRKLPEEHARFYSAEISLALNYLHERGIIYRDLKLDNVLLDSEGHIKLTDYGMCKEGLRPGDTTSTFCGTPNYIAPEILRGEDYGFSVDWWALGVLMFEMMAGRSPFDIVGSSDNPDQNTEDYLFQVILEKQIRIPRSLSVKAASVLKSFLNKDPKERLGCHPQTGFADIQGHPFFRNVDWDMMEQKQVVPPFKPNISGEFGLDNFDSQFTNEPVQLTPDDDDIVRKIDQSEFEGFEYINPLLMSAEECV","Homo sapiens","PRKCI, DXS1179E","Protein kinase C iota type","1","5LI9"
"5LIG",,"SOLUTION NMR",,,,,,,"10.1002/anie.201606877",,"5LIG",7.09,,,"G-Quadruplex formed at the 5'-end of NHEIII_1 Element in human c-MYC promoter bound to triangulenium based fluorescence probe DAOTA-M2","TAGGGAGGGTAGGGAGGGT","Homo sapiens",,"DNA (5'-D(*TP*AP*GP*GP*GP*AP*GP*GP*GP*TP*AP*GP*GP*GP*AP*GP*GP*GP*T)-3')","1","5LIG"
"5LIK",,"X-RAY DIFFRACTION",2.37,48.03,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,"10.1021/acschembio.6b00382","W8X","5LIK",37.6,"2.05","2.05","Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK181","MATFVELSTKAKMPIVGLGTWKSPLGKVKEAVKVAIDAGYRHIDCAYVYQNEHEVGEAIQEKIQEKAVKREDLFIVSKLWPTFFERPLVRKAFEKTLKDLKLSYLDVYLIHWPQGFKSGDDLFPRDDKGNAIGGKATFLDAWEAMEELVDEGLVKALGVSNFSHFQIEKLLNKPGLKYKPVTNQVECHPYLTQEKLIQYCHSKGITVTAYSPLGSPDRPWAKPEDPSLLEDPKIKEIAAKHKKTAAQVLIRFHIQRNVIVIPKSVTPARIVENIQVFDFKLSDEEMATILSFNRNWRACNLLQSSHLEDYPFNAEY","Homo sapiens","AKR1B10, AKR1B11","Aldo-keto reductase family 1 member B10","1","5LIK"
"5LIU",,"X-RAY DIFFRACTION",2.5,50.89,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,"10.1021/acschembio.6b00382","388","5LIU",37.62,"1.75","1.75","Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor IDD388","MATFVELSTKAKMPIVGLGTWKSPLGKVKEAVKVAIDAGYRHIDCAYVYQNEHEVGEAIQEKIQEKAVKREDLFIVSKLWPTFFERPLVRKAFEKTLKDLKLSYLDVYLIHWPQGFKSGDDLFPRDDKGNAIGGKATFLDAWEAMEELVDEGLVKALGVSNFSHFQIEKLLNKPGLKYKPVTNQVECHPYLTQEKLIQYCHSKGITVTAYSPLGSPDRPWAKPEDPSLLEDPKIKEIAAKHKKTAAQVLIRFHIQRNVIVIPKSVTPARIVENIQVFDFKLSDEEMATILSFNRNWRACNLLQSSHLEDYPFNAEY","Homo sapiens","AKR1B10, AKR1B11","Aldo-keto reductase family 1 member B10","1","5LIU"
"5LIW",,"X-RAY DIFFRACTION",2.51,51.02,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,"10.1021/acschembio.6b00382","1WX","5LIW",38.05,"1.75","1.75","Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK319","MATFVELSTKAKMPIVGLGTWKSPLGKVKEAVKVAIDAGYRHIDCAYVYQNEHEVGEAIQEKIQEKAVKREDLFIVSKLWPTFFERPLVRKAFEKTLKDLKLSYLDVYLIHWPQGFKSGDDLFPRDDKGNAIGGKATFLDAWEAMEELVDEGLVKALGVSNFSHFQIEKLLNKPGLKYKPVTNQVECHPYLTQEKLIQYCHSKGITVTAYSPLGSPDRPWAKPEDPSLLEDPKIKEIAAKHKKTAAQVLIRFHIQRNVIVIPKSVTPARIVENIQVFDFKLSDEEMATILSFNRNWRACNLLQSSHLEDYPFNAEY","Homo sapiens","AKR1B10, AKR1B11","Aldo-keto reductase family 1 member B10","1","5LIW"
"5LIX",,"X-RAY DIFFRACTION",2.51,51.05,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,"10.1021/acschembio.6b00382","MK4","5LIX",37.77,"1.95","1.95","Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK184","MATFVELSTKAKMPIVGLGTWKSPLGKVKEAVKVAIDAGYRHIDCAYVYQNEHEVGEAIQEKIQEKAVKREDLFIVSKLWPTFFERPLVRKAFEKTLKDLKLSYLDVYLIHWPQGFKSGDDLFPRDDKGNAIGGKATFLDAWEAMEELVDEGLVKALGVSNFSHFQIEKLLNKPGLKYKPVTNQVECHPYLTQEKLIQYCHSKGITVTAYSPLGSPDRPWAKPEDPSLLEDPKIKEIAAKHKKTAAQVLIRFHIQRNVIVIPKSVTPARIVENIQVFDFKLSDEEMATILSFNRNWRACNLLQSSHLEDYPFNAEY","Homo sapiens","AKR1B10, AKR1B11","Aldo-keto reductase family 1 member B10","1","5LIX"
"5LIY",,"X-RAY DIFFRACTION",2.48,50.43,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,"10.1021/acschembio.6b00382","DQP","5LIY",37.82,"2.05","2.05","Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK204","MATFVELSTKAKMPIVGLGTWKSPLGKVKEAVKVAIDAGYRHIDCAYVYQNEHEVGEAIQEKIQEKAVKREDLFIVSKLWPTFFERPLVRKAFEKTLKDLKLSYLDVYLIHWPQGFKSGDDLFPRDDKGNAIGGKATFLDAWEAMEELVDEGLVKALGVSNFSHFQIEKLLNKPGLKYKPVTNQVECHPYLTQEKLIQYCHSKGITVTAYSPLGSPDRPWAKPEDPSLLEDPKIKEIAAKHKKTAAQVLIRFHIQRNVIVIPKSVTPARIVENIQVFDFKLSDEEMATILSFNRNWRACNLLQSSHLEDYPFNAEY","Homo sapiens","AKR1B10, AKR1B11","Aldo-keto reductase family 1 member B10","1","5LIY"
"5LJ0",,"X-RAY DIFFRACTION",3.98,69.06,"VAPOR DIFFUSION, SITTING DROP",,"0.1M trisHCl, pH 7.0-8.0, 1.2-1.5M ammonium sulphate, 20-25% PEG3350,277K",277,"10.1002/anie.201603928","6XX","5LJ0",16.33,"1.82","1.82","Crystal structure of human ATAD2 bromodomain in complex with 8-(((3R,4R,5S)-3-((4,4-difluorocyclohexyl)methoxy)-5-methoxypiperidin-4-yl)amino)-3-methyl-5-(5-methylpyridin-3-yl)-1,7-naphthyridin-2(1H)-one","SMQEEDTFRELRIFLRNVTHRLAIDKRFRVFTKPVDPDEVPDYVTVIKQPMDLSSVISKIDLHKYLTVKDYLRDIDLICSNALEYNPDRDPGDRLIRHRACALRDTAYAIIKEELDEDFEQLCEEIQESR","Homo sapiens","ATAD2, L16, PRO2000","ATPase family AAA domain-containing protein 2","1","5LJ0"
"5LJ1",,"X-RAY DIFFRACTION",2.28,46.04,"VAPOR DIFFUSION, SITTING DROP",,"0.2NaNO3, 20% PEG3350 at 20C",293,"10.1002/anie.201603928","6XX","5LJ1",15.69,"1.9","1.9","N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 8-(((3R,4R,5S)-3-((4,4-difluorocyclohexyl)methoxy)-5-methoxypiperidin-4-yl)amino)-3-methyl-5-(5-methylpyridin-3-yl)-1,7-naphthyridin-2(1H)-one","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5LJ1"
"5LJ2",,"X-RAY DIFFRACTION",2.15,42.75,"VAPOR DIFFUSION, SITTING DROP",,"0.1 Tris pH 8.5, 0.2M Li2SO4, 20% v/v PEG400 at 20C",293,"10.1002/anie.201603928","6XW","5LJ2",15.8,"1.19","1.19","N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 5-(5-aminopyridin-3-yl)-8-(((3R,4R)-3-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methoxy)piperidin-4-yl)amino)-3-methyl-1,7-naphthyridin-2(1H)-one","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5LJ2"
"5LJ4",,"X-RAY DIFFRACTION",2.44,49.68,"VAPOR DIFFUSION, HANGING DROP",7,"20 mM Sodium Cacodylate, pH 7.0
600 mM Calcium chloride
50% hexylene glycol",298,,,"5LJ4",7.58,"2.17","2.17","Crystal structure of DNA duplex containing ZP base pair","CGCXAATTXGCG","Homo sapiens",,"ODN2","1","5LJ4"
"5LJB",,"X-RAY DIFFRACTION",2.03,40,"VAPOR DIFFUSION",5,".2 M ammonium chloride, 0.1 M sodium acetate, 0.2 mM zinc chloride, pH 5,0, 20% PEG 6000",279,"10.1016/j.jsb.2016.12.012","RTL","5LJB",16.16,"1.263","1.263","Crystal structure of holo human CRBP1","MPVDFTGYWKMLVNENFEEYLRALDVNVALRKIANLLKPDKEIVQDGDHMIIRTLSTFRNYIMDFQVGKEFEEDLTGIDDRKCMTTVSWDGDKLQCVQKGEKEGRGWTQWIEGDELHLEMRVEGVVCKQVFKKVQ","Homo sapiens","RBP1, CRBP1","Retinol-binding protein 1","1","5LJB"
"5LJC",,"X-RAY DIFFRACTION",2.02,40,"VAPOR DIFFUSION",5,"0.2 M ammonium chloride, 0.1 M sodium acetate, 0.2 mM zinc chloride, pH 5,0, 20% PEG 6000",279,"10.1016/j.jsb.2016.12.012","RTL","5LJC",16.17,"1.433","1.433","Crystal structure of holo human CRBP1","MPVDFTGYWKMLVNENFEEYLRALDVNVALRKIANLLKPDKEIVQDGDHMIIRTLSTFRNYIMDFQVGKEFEEDLTGIDDRKCMTTVSWDGDKLQCVQKGEKEGRGWTLWIEGDELHLEMRVEGVVCKQVFKKVQ","Homo sapiens","RBP1, CRBP1","Retinol-binding protein 1","1","5LJC"
"5LJD",,"X-RAY DIFFRACTION",2,40,"VAPOR DIFFUSION",5,"0.2 M ammonium chloride, 0.1 M sodium acetate, 0.2 mM zinc chloride, pH 5,0, 20% PEG 6000",279,"10.1016/j.jsb.2016.12.012","RTL","5LJD",16.16,"1.61","1.61","Crystal structure of holo human CRBP1/K40L mutant","MPVDFTGYWKMLVNENFEEYLRALDVNVALRKIANLLKPDLEIVQDGDHMIIRTLSTFRNYIMDFQVGKEFEEDLTGIDDRKCMTTVSWDGDKLQCVQKGEKEGRGWTQWIEGDELHLEMRVEGVVCKQVFKKVQ","Homo sapiens","RBP1, CRBP1","Retinol-binding protein 1","1","5LJD"
"5LJE",,"X-RAY DIFFRACTION",2,40,"VAPOR DIFFUSION",5,"0.2 M ammonium chloride, 0.1 M sodium acetate, 0.2 mM zinc chloride, pH 5,0, 20% PEG 6000",279,"10.1016/j.jsb.2016.12.012","RTL","5LJE",16.15,"1.4","1.4","Crystal structure of holo human CRBP1/K40L,Q108L mutant","MPVDFTGYWKMLVNENFEEYLRALDVNVALRKIANLLKPDLEIVQDGDHMIIRTLSTFRNYIMDFQVGKEFEEDLTGIDDRKCMTTVSWDGDKLQCVQKGEKEGRGWTLWIEGDELHLEMRVEGVVCKQVFKKVQ","Homo sapiens","RBP1, CRBP1","Retinol-binding protein 1","1","5LJE"
"5LJG",,"X-RAY DIFFRACTION",2,40,"VAPOR DIFFUSION",5,"0.2 M ammonium chloride, 0.1 M sodium acetate, 0.2 mM zinc chloride, pH 5,0, 20% PEG 6000",279,"10.1016/j.jsb.2016.12.012",,"5LJG",16.13,"1.146","1.146","Crystal structure of holo human CRBP1","MPVDFTGYWKMLVNENFEEYLRALDVNVALRKIANLLKPDKEIVQDGDHMIIRTLSTFRNYIMDFQVGKEFEEDLTGIDDRKCMTTVSWDGDKLQCVQKGEKEGRGWTQWIEGDELHLEMRVEGVVCKQVFKKVQ","Homo sapiens","RBP1, CRBP1","Retinol-binding protein 1","1","5LJG"
"5LJH",,"X-RAY DIFFRACTION",2,40,"VAPOR DIFFUSION",5,"0.2 M ammonium chloride, 0.1 M sodium acetate, 0.2 mM zinc chloride, pH 5,0, 20% PEG 6000",279,"10.1016/j.jsb.2016.12.012",,"5LJH",15.88,"1.52","1.52","Crystal structure of human apo CRBP1/K40L mutant","MPVDFTGYWKMLVNENFEEYLRALDVNVALRKIANLLKPDLEIVQDGDHMIIRTLSTFRNYIMDFQVGKEFEEDLTGIDDRKCMTTVSWDGDKLQCVQKGEKEGRGWTQWIEGDELHLEMRVEGVVCKQVFKKVQ","Homo sapiens","RBP1, CRBP1","Retinol-binding protein 1","1","5LJH"
"5LJJ",,"X-RAY DIFFRACTION",3.04,59.5,"VAPOR DIFFUSION, SITTING DROP",7.5,"Protein sollution: 200 uM (7.2 mg/mL) mps1, 250 uM reversine. Reservoir solution: 7.6% (w/v) PEG 350 MME, 0.5 mM MgCl2, and 100 mM Tris/HCl",291,"10.1002/prot.25174",,"5LJJ",36.63,"3","3","Crystal structure of human Mps1 (TTK) in complex with Reversine","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMEYGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5LJJ"
"5LJK",,"X-RAY DIFFRACTION",2,40,"VAPOR DIFFUSION",5,"0.2 M ammonium chloride, 0.1 M sodium acetate, 0.2 mM zinc chloride, pH 5,0, 20% PEG 6000",279,"10.1016/j.jsb.2016.12.012",,"5LJK",15.89,"1.7","1.7","Crystal structure of human apo CRBP1","MPVDFTGYWKMLVNENFEEYLRALDVNVALRKIANLLKPDKEIVQDGDHMIIRTLSTFRNYIMDFQVGKEFEEDLTGIDDRKCMTTVSWDGDKLQCVQKGEKEGRGWTQWIEGDELHLEMRVEGVVCKQVFKKVQ","Homo sapiens","RBP1, CRBP1","Retinol-binding protein 1","1","5LJK"
"5LJM",,"X-RAY DIFFRACTION",2.56,51.92,"BATCH MODE",6,"Crystals grew at 277K over two weeks in:
20 mM MES pH 6.0, 200 mM NaCl, 4 mM DTT",277,"10.1016/j.molcel.2016.08.001",,"5LJM",25.04,"1.454","1.454","Structure of SPATA2 PUB domain","GPMDTKFKDDLFRKYVQFHESKVDTTTSRQRPGSDECLRVAASTLLSLHKVDPFYRFRLIQFYEVVESSLRSLSSSSLRALHGAFSMLETVGINLFLYPWKKEFRSIKTYTGPFVYYVKSTLLEEDIRAILSCMGYTPELGTAYKLRELVETLQVKMVSFELFLAKVECEQMLEIHSQVKDKGYSELDIVSERKSSAEDVRGCSDALRRRAEGRE","Homo sapiens","SPATA2, KIAA0757, PD1","Spermatogenesis-associated protein 2","1","5LJM"
"5LJQ",,"X-RAY DIFFRACTION",2.11,41.77,"VAPOR DIFFUSION",8,"1.5 M sodium citrate, Tris 50 mM",296,"10.1021/acs.jmedchem.6b01389","ANV","5LJQ",29.56,"1.05","1.05","Crystal structure of human carbonic anhydrase II in complex with the 4-(4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl)benzenesulfonamide inhibitor","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5LJQ"
"5LJT",,"X-RAY DIFFRACTION",2.11,41.67,"VAPOR DIFFUSION",8,"1.5 M sodium citrate, Tris 50 mM",296,"10.1021/acs.jmedchem.6b01389","A6N","5LJT",29.56,"1","1","Crystal structure of human carbonic anhydrase II in complex with the 4-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)benzenesulfonamide inhibitor","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5LJT"
"5LK5",,"X-RAY DIFFRACTION",2.18,43.6,"VAPOR DIFFUSION, HANGING DROP",8.5,"30% PEG4000
0.2 M MgCl2
0.1 M Tris-HCl",277,"10.1107/S2052252516012847",,"5LK5",302.04,"2.3","2.3","Crystal structure of the globular domain of human calreticulin mutant D71K","NKGSIEGREPAVYFKEQFLDGDGWTSRWIESKHKSDFGKFVLSSGKFYGDEEKDKGLQTSQKARFYALSASFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPNSLDQTDMHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDNTYEVKIDNSQVESGSLEDDWDFLPGSGDPSIYAYDNFGVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDKQDEEQRLK","Homo sapiens","CALR, CRTC","Calreticulin,Calreticulin","1","5LK5"
,,,,,,,,,,,,,,,,,"Homo sapiens","CALR, CRTC"
"5LKN",,"SOLUTION NMR",,,,,,,"10.1074/jbc.M116.743435",,"5LKN",11.86,,,"NMR solution structure of human FNIII domain 2 of NCAM","MQPVREPSAPKLEGQMGEDGNSIKVNLIKQDDGGSPIRHYLVRYRALSSEWKPEIRLPSGSDHVMLKSLDWNAEYEVYVVAENQQGKSKAAHFVFRTHHHHHH","Homo sapiens","NCAM1, NCAM","Neural cell adhesion molecule 1","1","5LKN"
"5LKR",,"X-RAY DIFFRACTION",2.57,52.16,"VAPOR DIFFUSION, HANGING DROP",7.4,"0.2M ammonium acetate, 18% PEG 4000, 20 mM Tris pH 7.4",293,"10.1016/j.bmc.2016.11.032","6YC","5LKR",136.63,"2.52","2.52","Human Butyrylcholinesterase complexed with N-Propargyliperidines","EDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCVGL","Homo sapiens","BCHE, CHE1","Cholinesterase","1","5LKR"
"5LKT",,"X-RAY DIFFRACTION",2.91,57.74,"VAPOR DIFFUSION, SITTING DROP",,"Tris, PEG MME 2000",277,"10.1038/nchembio.2217",,"5LKT",68.59,"2.04","2.04","Crystal structure of the p300 acetyltransferase catalytic core with butyryl-coenzyme A.","GAMAGKAVPMQSKKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKSPMDLSTIKRKLDTGQYQEPWQYVDDIWLMFNNAWLYNRKTSRVYKYCSKLSEVFEQEIDPVMQSLGYCCGRKLEFSPQTLCCYGKQLCTIPRDATYYSYQNRYHFCEKCFNEIQGESVSLGDDPSQPQTTINKEQFSKRKNDTLDPELFVECTECGRKMHQICVLHHEIIWPAGFVCDGCLKKSARTRKENKFSAKRLPSTRLGTFLENRVNDFLRRQNHPESGEVTVRVVHASDKTVEVKPGMKARFVDSGEMAESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYISYLDSVHFFRPKCLRTAVYHEILIGYLEYVKKLGYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWFKKMLDKAVSERIVHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKESGGSGSQKLYATMEKHKEVFFVIRLIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLTLARDKHLEFSSLRRAQWSTMCMLVELHTQSQDRF","Homo sapiens","EP300, P300","Histone acetyltransferase p300,Histone acetyltransferase p300","1","5LKT"
,,,,,,,,,,,,,,,,,"Homo sapiens","EP300, P300"
"5LKU",,"X-RAY DIFFRACTION",3.03,59.4,"VAPOR DIFFUSION, SITTING DROP",,"Tris, PEG MME 2000",277,"10.1038/nchembio.2217","COA","5LKU",68.13,"3.5","3.5","Crystal structure of the p300 acetyltransferase catalytic core with coenzyme A.","GAMAGKAVPMQSKKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKSPMDLSTIKRKLDTGQYQEPWQYVDDIWLMFNNAWLYNRKTSRVYKYCSKLSEVFEQEIDPVMQSLGYCCGRKLEFSPQTLCCYGKQLCTIPRDATYYSYQNRYHFCEKCFNEIQGESVSLGDDPSQPQTTINKEQFSKRKNDTLDPELFVECTECGRKMHQICVLHHEIIWPAGFVCDGCLKKSARTRKENKFSAKRLPSTRLGTFLENRVNDFLRRQNHPESGEVTVRVVHASDKTVEVKPGMKARFVDSGEMAESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYISYLDSVHFFRPKCLRTAVYHEILIGYLEYVKKLGYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWFKKMLDKAVSERIVHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKESGGSGSQKLYATMEKHKEVFFVIRLIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLTLARDKHLEFSSLRRAQWSTMCMLVELHTQSQDRF","Homo sapiens","EP300, P300","Histone acetyltransferase p300,Histone acetyltransferase p300","1","5LKU"
,,,,,,,,,,,,,,,,,"Homo sapiens","EP300, P300"
"5LKX",,"X-RAY DIFFRACTION",3.1,60.27,"VAPOR DIFFUSION, SITTING DROP",,"Tris, PEG MME 2000, DMSO",277,"10.1038/nchembio.2217",,"5LKX",68.45,"2.52","2.52","Crystal structure of the p300 acetyltransferase catalytic core with propionyl-coenzyme A.","GAMAGKAVPMQSKKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKSPMDLSTIKRKLDTGQYQEPWQYVDDIWLMFNNAWLYNRKTSRVYKYCSKLSEVFEQEIDPVMQSLGYCCGRKLEFSPQTLCCYGKQLCTIPRDATYYSYQNRYHFCEKCFNEIQGESVSLGDDPSQPQTTINKEQFSKRKNDTLDPELFVECTECGRKMHQICVLHHEIIWPAGFVCDGCLKKSARTRKENKFSAKRLPSTRLGTFLENRVNDFLRRQNHPESGEVTVRVVHASDKTVEVKPGMKARFVDSGEMAESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYISYLDSVHFFRPKCLRTAVYHEILIGYLEYVKKLGYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWFKKMLDKAVSERIVHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKESGGSGSQKLYATMEKHKEVFFVIRLIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLTLARDKHLEFSSLRRAQWSTMCMLVELHTQSQDRF","Homo sapiens","EP300, P300","Histone acetyltransferase p300,Histone acetyltransferase p300","1","5LKX"
,,,,,,,,,,,,,,,,,"Homo sapiens","EP300, P300"
"5LKZ",,"X-RAY DIFFRACTION",2.99,58.9,"VAPOR DIFFUSION, SITTING DROP",,"Tris, PEG MME 2000",277,"10.1038/nchembio.2217",,"5LKZ",68.48,"2.5","2.5","Crystal structure of the p300 acetyltransferase catalytic core with crotonyl-coenzyme A.","GAMAGKAVPMQSKKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKSPMDLSTIKRKLDTGQYQEPWQYVDDIWLMFNNAWLYNRKTSRVYKYCSKLSEVFEQEIDPVMQSLGYCCGRKLEFSPQTLCCYGKQLCTIPRDATYYSYQNRYHFCEKCFNEIQGESVSLGDDPSQPQTTINKEQFSKRKNDTLDPELFVECTECGRKMHQICVLHHEIIWPAGFVCDGCLKKSARTRKENKFSAKRLPSTRLGTFLENRVNDFLRRQNHPESGEVTVRVVHASDKTVEVKPGMKARFVDSGEMAESFPYRTKALFAFEEIDGVDLCFFGMHVQEYGSDCPPPNQRRVYISYLDSVHFFRPKCLRTAVYHEILIGYLEYVKKLGYTTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWFKKMLDKAVSERIVHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKESGGSGSQKLYATMEKHKEVFFVIRLIAGPAANSLPPIVDPDPLIPCDLMDGRDAFLTLARDKHLEFSSLRRAQWSTMCMLVELHTQSQDRF","Homo sapiens","EP300, P300","Histone acetyltransferase p300,Histone acetyltransferase p300","1","5LKZ"
,,,,,,,,,,,,,,,,,"Homo sapiens","EP300, P300"
"5LL4",,"X-RAY DIFFRACTION",2.02,38.6,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M sodium bicine (pH 9), 0.2M ammonium sulfate and 2M sodium malonate (pH 7)",291,,"6YH","5LL4",60.14,"1.12","1.12","Crystal structure of human carbonic anhydrase isozyme II with 4-(1H-benzimidazol-1-ylacetyl)benzenesulfonamide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5LL4"
"5LL5",,"X-RAY DIFFRACTION",2.06,39.9,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M ammonium citrate (pH 7), 0.2M ammonium sulfate and 30% PEG4000",291,,"6YH","5LL5",121.88,"1.42","1.42","Crystal structure of human carbonic anhydrase isozyme XII with 4-(1H-benzimidazol-1-ylacetyl)benzenesulfonamide","MSKWTYFGPDGENSWSKKYPSCGGLLQSPIDLHSDILQYDASLTPLEFQGYNLSANKQFLLTNNGHSVKLNLPSDMHIQGLQSRYSATQLHLHWGNPNDPHGSEHTVSGQHFAAELHIVHYNSDLYPDASTASNKSEGLAVLAVLIEMGSFNPSYDKIFSHLQHVKYKGQEAFVPGFNIEELLPERTAEYYRYRGSLTTPPCNPTVLWTVFRNPVQISQEQLLALETALYCTHMDDPSPREMINNFRQVQKFDERLVYTSFSQ","Homo sapiens","CA12","Carbonic anhydrase 12","1","5LL5"
"5LL8",,"X-RAY DIFFRACTION",2.1,41.3,"VAPOR DIFFUSION, HANGING DROP",7.8,"2.0 uL of protein solution (10.5 mg/mL in 50 mM Tris pH=7.8) were mixed with 2.0 uL of the well solution (2.7 M (NH4)2SO4, 100 mM Tris, pH=7.8, saturated with PCMB) and placed as hanging drop. Crystals appeared after several days. The crystals were soaked in 3.0 M (NH4)2SO4, 100 mM Tris, pH=7.8, saturated with inhibitor) for 1 day.",291,,"6YP","5LL8",31.01,"1.03","1.03","Human Carbonic Anhydrase II in complex with aliphatic Benzenesulfonamide inhibitor.","GSPEFMSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5LL8"
"5LL9",,"X-RAY DIFFRACTION",2.06,39.8,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M ammonium citrate (pH 7), 0.2M ammonium sulfate and 30% PEG4000",291,,"6YQ","5LL9",122.3,"1.45","1.45","Crystal structure of human carbonic anhydrase isozyme XII with 4-(1H-benzimidazol-1-ylacetyl)-2-chlorobenzenesulfonamide","MSKWTYFGPDGENSWSKKYPSCGGLLQSPIDLHSDILQYDASLTPLEFQGYNLSANKQFLLTNNGHSVKLNLPSDMHIQGLQSRYSATQLHLHWGNPNDPHGSEHTVSGQHFAAELHIVHYNSDLYPDASTASNKSEGLAVLAVLIEMGSFNPSYDKIFSHLQHVKYKGQEAFVPGFNIEELLPERTAEYYRYRGSLTTPPCNPTVLWTVFRNPVQISQEQLLALETALYCTHMDDPSPREMINNFRQVQKFDERLVYTSFSQ","Homo sapiens","CA12","Carbonic anhydrase 12","1","5LL9"
"5LLA",,"X-RAY DIFFRACTION",2.16,42.99,"EVAPORATION",,"Crystallization buffer: 0.1M ammonium citrate (pH 7), 0.1M sodium acetate (pH 4.5) and 26% PEG3350",291,,"6YQ","5LLA",60.57,"1.5","1.5","Crystal structure of human carbonic anhydrase isozyme XIII with 4-(1H-benzimidazol-1-ylacetyl)-2-chlorobenzenesulfonamide","MMSRLSWGYREHNGPIHWKEFFPIADGDQQSPIEIKTKEVKYDSSLRPLSIKYDPSSAKIISNSGHSFNVDFDDTENKSVLRGGPLTGSYRLRQVHLHWGSADDHGSEHIVDGVSYAAELHVVHWNSDKYPSFVEAAHEPDGLAVLGVFLQIGEPNSQLQKITDTLDSIKEKGKQTRFTNFDLLSLLPPSWDYWTYPGSLTVPPLLESVTWIVLKQPINISSQQLAKFRSLLCTAEGEAAAFLVSNHRPPQPLKGRKVRASFH","Homo sapiens","CA13","Carbonic anhydrase 13","1","5LLA"
"5LLC",,"X-RAY DIFFRACTION",2.02,38.6,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M sodium bicine (pH 9), 0.2 M ammonium sulfate and 2M sodium malonate (pH 7)",291,"10.7717/peerj.4412","V26","5LLC",30.17,"1.1","1.1","Crystal structure of human carbonic anhydrase isozyme II with 3-(Methylamino)-2,5,6-trifluoro-4-[(2-phenylethyl)sulfonyl]benzenesulfonamide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5LLC"
"5LLE",,"X-RAY DIFFRACTION",2,37.9,"VAPOR DIFFUSION, SITTING DROP",7.5,"Crystallization buffer: 2.5M sodium malonate (Ph 7.5) and 0.075M sodium bicine (pH 9)",291,"10.7717/peerj.4412","V51","5LLE",30.17,"1.9","1.9","Crystal structure of human carbonic anhydrase isozyme II with 4-(1-Adamantylamino)-2,3,5,6-tetrafluorobenzenesulfonamide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5LLE"
"5LLG",,"X-RAY DIFFRACTION",2.01,38.4,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M sodium bicine (pH 9), 0.2M ammonium sulfate and 2M sodium malonate (pH 7)",291,"10.7717/peerj.4412","VD9","5LLG",30.14,"1.12","1.12","Crystal structure of human carbonic anhydrase isozyme II with 4-Propylthiobenzenesulfonamide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5LLG"
"5LLH",,"X-RAY DIFFRACTION",2.01,38.5,"VAPOR DIFFUSION, SITTING DROP",7.5,"Crystallization buffer: 2.03M sodium malonate (pH 7.5)",291,"10.7717/peerj.4412","V49","5LLH",30.26,"1.9","1.9","Crystal structure of human carbonic anhydrase isozyme II with 4-(1,3-Benzothiazol-2-ylthio)-2,3,5,6-tetrafluorobenzenesulfonamide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5LLH"
"5LLK",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.8 M Sodium Citrate",277,"10.1002/2211-5463.12259",,"5LLK",28.68,"1.8","1.8","Crystal structure of human alpha-dystroglycan","GSSVLSDLHEAVPTVVGIPDGTAVVGRSFRVTIPTDLIASSGDIIKVSAAGKEALPSWLHWDSQSHTLEGLPLDTDKGVHYISVSATRLGANGSHIPQTSSVFSIEVYPEDHSELQSVHTASPDPGEVVSSACAADEPVTVLTVILDADLTKMTPKQRIDLLHRMRSFSEVELHNMKLVPVVNNRLFDMSAFMAGPGNAKKVVENGALLSWKLGCSLNQNSVPDIHGVEAPAREGAMSAQLGYPVVGWHIANKKPPLPKRVRRQIH","Homo sapiens","DAG1","Dystroglycan","1","5LLK"
"5LLL",,"X-RAY DIFFRACTION",1.89,34.91,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M CaCl2
0.1 M HEPES sodium pH 7.5
28% v/v PEG 400",293,"10.1007/s00018-017-2533-x",,"5LLL",27.82,"1.42","1.42","Crystal structure of DACM wild type Transthyretin","MGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5LLL"
"5LLN",,"X-RAY DIFFRACTION",2.18,43.7,"VAPOR DIFFUSION, SITTING DROP",5,"Crystallization buffer: 0.1M ammonium citrate (pH 5) and 20% PEG4000",291,,"3TV","5LLN",60.54,"1.6","1.6","Crystal structure of human carbonic anhydrase isozyme XIII with 2,3,5,6-Tetrafluoro-4-(propylthio)benzenesulfonamide","MMSRLSWGYREHNGPIHWKEFFPIADGDQQSPIEIKTKEVKYDSSLRPLSIKYDPSSAKIISNSGHSFNVDFDDTENKSVLRGGPLTGSYRLRQVHLHWGSADDHGSEHIVDGVSYAAELHVVHWNSDKYPSFVEAAHEPDGLAVLGVFLQIGEPNSQLQKITDTLDSIKEKGKQTRFTNFDLLSLLPPSWDYWTYPGSLTVPPLLESVTWIVLKQPINISSQQLAKFRSLLCTAEGEAAAFLVSNHRPPQPLKGRKVRASFH","Homo sapiens","CA13","Carbonic anhydrase 13","1","5LLN"
"5LLO",,"X-RAY DIFFRACTION",2.07,40.1,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M ammonium citrate (pH 7), 0.2 M ammonium sulfate and 26% PEG4000",291,"10.7717/peerj.4412",,"5LLO",121.92,"1.6","1.6","Crystal structure of human carbonic anhydrase isozyme XII with 3-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-2,5,6-trifluoro-4-[(2-hy-droxyethyl)sulfonyl]benzenesulfonamide","MSKWTYFGPDGENSWSKKYPSCGGLLQSPIDLHSDILQYDASLTPLEFQGYNLSANKQFLLTNNGHSVKLNLPSDMHIQGLQSRYSATQLHLHWGNPNDPHGSEHTVSGQHFAAELHIVHYNSDLYPDASTASNKSEGLAVLAVLIEMGSFNPSYDKIFSHLQHVKYKGQEAFVPGFNIEELLPERTAEYYRYRGSLTTPPCNPTVLWTVFRNPVQISQEQLLALETALYCTHMDDPSPREMINNFRQVQKFDERLVYTSFSQ","Homo sapiens","CA12","Carbonic anhydrase 12","1","5LLO"
"5LLP",,"X-RAY DIFFRACTION",2.08,40.4,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M ammonium citrate (pH 7), 0.2M ammonium sulfate and 26% PEG4000",291,"10.7717/peerj.4412",,"5LLP",121.79,"1.48","1.48","Crystal structure of human carbonic anhydrase isozyme XII with 3-[(1S)-1,2,3,4-Tetrahydronapthalen-1-ylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide","MSKWTYFGPDGENSWSKKYPSCGGLLQSPIDLHSDILQYDASLTPLEFQGYNLSANKQFLLTNNGHSVKLNLPSDMHIQGLQSRYSATQLHLHWGNPNDPHGSEHTVSGQHFAAELHIVHYNSDLYPDASTASNKSEGLAVLAVLIEMGSFNPSYDKIFSHLQHVKYKGQEAFVPGFNIEELLPERTAEYYRYRGSLTTPPCNPTVLWTVFRNPVQISQEQLLALETALYCTHMDDPSPREMINNFRQVQKFDERLVYTSFSQ","Homo sapiens","CA12","Carbonic anhydrase 12","1","5LLP"
"5LLV",,"X-RAY DIFFRACTION",1.84,33.1,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.2 M CaCl2
0.1 M Sodium Acetate pH 4.6
20% v/v 2-propanol",293,"10.1007/s00018-017-2533-x",,"5LLV",55.98,"1.7","1.7","Crystal structure of DACM F87M/L110M Transthyretin mutant","MGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPMHEHAEVVFTANDSGPRRYTIAAMLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5LLV"
"5LM2",,"X-RAY DIFFRACTION",2.73,54.86,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bis-Tris pH 6.0, 0.1-0.2 M Na-Formate and 13-15% PEG3350",294,"10.1016/j.str.2016.10.006",,"5LM2",81.45,"2.54","2.54","Crystal Structure of HD-PTP phosphatase","PMAAHEASSLYSEEKAKLLREMMAKIEDKNEVLDQFMDSMQLDPETVDNLDAYSHIPPQLMEKCAALSVRPDTVRNLVQSMQVLSGVFTDVEASLKDIRDLLEEDELLEQKFQEAVGQAGAISITSKAELAEVRREWAKYMEVHEKASFTNSELHRAMNLHVGNLRLLSGPLDQVRAALPTPALSPEDKAVLQNLKRILAKVQEMRDQRVSLEQQLRELIQKDDITASLVTTDHSEMKKLFEEQLKKYDQLKVYLEQNLAAQDRVLCALTEANVQYAAVRRVLSDLDQKWNSTLQTLVASYEAYEDLMKKSQEGRDFYADLESKVAALLERTQSTCQAREAARQQLLDRELK","Homo sapiens","PTPN23, KIAA1471","Tyrosine-protein phosphatase non-receptor type 23","1","5LM2"
"5LMA",,"X-RAY DIFFRACTION",2.11,41.76,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, Sodium formate.",293,"10.1016/j.bmcl.2016.08.070","6ZG","5LMA",32.73,"1.43","1.43","HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR","GPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN","Homo sapiens","SYK","Tyrosine-protein kinase SYK","1","5LMA"
"5LMB",,"X-RAY DIFFRACTION",2.18,43.66,"VAPOR DIFFUSION, SITTING DROP",6.8,"PEG1500, HEPES, TACSIMATE, GLYCEROL",293,"10.1016/j.bmcl.2016.08.070","6ZF","5LMB",65.7,"1.95","1.95","HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR","GPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN","Homo sapiens","SYK","Tyrosine-protein kinase SYK","1","5LMB"
"5LMD",,"X-RAY DIFFRACTION",2.13,42.15,"VAPOR DIFFUSION, HANGING DROP",8.7,"1.4 M Sodium Citrate
0.1 M Tris-HCl",293,"10.1039/c6cc06399c",,"5LMD",29.87,"1.7","1.7","The crystal structure of hCA II in complex with a benzoxaborole inhibitor","MGMSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5LMD"
"5LN2",,"X-RAY DIFFRACTION",2.15,42.78,"VAPOR DIFFUSION, HANGING DROP",5,"2.5M (NH4)2SO4, 0.1M NaCitrate",298,"10.1016/j.bmcl.2016.08.010","6ZT","5LN2",11.88,"1.58","1.58","Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument","GSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVN","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","5LN2"
"5LNF",,"SOLUTION NMR",,,,,,,"10.1038/ncomms14635",,"5LNF",15.87,,,"Solution NMR structure of farnesylated PEX19, C-terminal domain","GMDEGDGEGNILPIMQSIMQNLLSKDVLYPSLKEITEKYPEWLQSHRESLPPEQFEKYQEQHSVMCKICEQFEAETPTDSETTQKARFEMVLDLMQQLQDLGHPPKELAGEMPPGLNFDLDALNLSGPPGASGEQCLIM","Homo sapiens","PEX19, HK33, PXF, OK/SW-cl.22","Peroxisomal biogenesis factor 19","1","5LNF"
"5LNP",,"X-RAY DIFFRACTION",2.5,50.88,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES, pH=6.5
0.1 M NaCl
0.1 M Li2SO4
23 % PEG400",293,"10.1016/j.molcel.2016.08.026",,"5LNP",43.53,"1.99","1.99","Domain-swapped dimer of human Dishevelled2 DEP domain: monoclinic crystal form crystallised from monomeric fraction","SSGLSVHTDMASVTKAMAAPESGLEVRDRMWLKITIPNAFLGSDVVDWLYHHVEGFPERREARKYASGLLKAGLIRHTVNKITFSEQCYYVFGDLSG","Homo sapiens","DVL2","Segment polarity protein dishevelled homolog DVL-2","1","5LNP"
,,,,,,,,,,,,,,,,"SSGLSVHTDMASVTKAMAAPESGLEVRDRMWLKITIPNAFLGSDVVDWLYHHVEGFPERREARKYASGLLKAGLIRHTVNKITFSEQCYYVFGDLSG","Homo sapiens","DVL2","Segment polarity protein dishevelled homolog DVL-2","2","5LNP"
"5LNY",,"X-RAY DIFFRACTION",3.43,64.15,"VAPOR DIFFUSION, SITTING DROP",8.5,"30% PEG 4000, 0.1 M Tris HCl pH  8.5, 0.2 M Magnesium Chloride",277,"10.1021/acs.jmedchem.8b00080","70K","5LNY",26.18,"1.88","1.88","HSP90 WITH indazole derivative","GDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5LNY"
"5LNZ",,"X-RAY DIFFRACTION",2.99,58.86,"VAPOR DIFFUSION, SITTING DROP",7.5,"28% PEG 400, 0.1 M Na Hepes pH 7.5, 0.2 M Calcium Chloride",277,"10.1021/acs.jmedchem.8b00080",,"5LNZ",26.18,"1.54","1.54","HSP90 WITH indazole derivative","GDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5LNZ"
"5LO0",,"X-RAY DIFFRACTION",2.91,57.74,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM BisTris pH 6.5, 250 mM NaF, 21-26% PEG3350",277,"10.1021/acs.jmedchem.8b00080",,"5LO0",26.28,"2.3","2.3","HSP90 WITH indazole derivative","GDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5LO0"
"5LO1",,"X-RAY DIFFRACTION",2.87,57.17,"VAPOR DIFFUSION, HANGING DROP",6.5,"Bis-Tris Propan, pH 6.5
22% PEG 3350
0,2M NaF",277,"10.1021/acs.jmedchem.8b00080",,"5LO1",26.13,"2.7","2.7","HSP90 WITH indazole derivative","GDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5LO1"
"5LO5",,"X-RAY DIFFRACTION",3.44,64.22,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M Bis Tris pH 5.5, 0.2 M Ammonium actetate, 25 % PEG 3350",277,"10.1021/acs.jctc.8b00230",,"5LO5",26.11,"1.44","1.44","HSP90 WITH indole derivative","GDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5LO5"
"5LO6",,"X-RAY DIFFRACTION",3.32,62.9,"VAPOR DIFFUSION, HANGING DROP",6.5,"Bis-Tris Propan, pH 6.5, 22% PEG 3350, 0.2M NaF",277,"10.1021/acs.jctc.8b00230",,"5LO6",26.16,"2.4","2.4","HSP90 WITH indazole derivative","GDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5LO6"
"5LOH",,"X-RAY DIFFRACTION",2.03,39.32,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonium citrate, 20% w/v polyethylene glycol 3350",277.15,"10.18632/oncotarget.11511",,"5LOH",77.58,"3.1","3.1","Kinase domain of human Greatwall","GPHMDPTAGSKKEPGGGAATEEGVNRIAVPKPPSIEEFSIVKPISRGAFGKVYLGQKGGKLYAVKVVKKADMINKNMTHQVQAERDALALSKSPFIVHLYYSLQSANNVYLVMEYLIGGDVKSLLHIYGYFDEEMAVKYISEVALALDYLHRHGIIHRDLKPDNMLISNEGHIKLTDFGLSKVTLNRDINMMDILTTRTFCGTPDYLAPELLLGRAHGPAVDWWALGVCLFEFLTGIPPFNDETPQQVFQNILKRDIPWPEGEEKLSDNAQSAVEILLTIDDTKRAGMKELKRHPLFSDVDWENLQHQTMPFIPQPDDETDTSYFEARNTAQHLTVSGFSL","Homo sapiens","MASTL, GW, GWL, THC2","Serine/threonine-protein kinase greatwall,Serine/threonine-protein kinase greatwall","1","5LOH"
,,,,,,,,,,,,,,,,,"Homo sapiens","MASTL, GW, GWL, THC2"
"5LOR",,"X-RAY DIFFRACTION",2.06,40.4,"VAPOR DIFFUSION, SITTING DROP",,"27.5% PEG3350, 0.1 M Bis Tris pH 5.25, 0.1 M ammonium sulfate, and 0.1 M MgCl2",291.15,,,"5LOR",71.62,"2.192","2.192","human NUDT22","MGSSHHHHHHSSGLVPRGSHMSCPVQTMDPEVTLLLQCPGGGLPQEQIQAELSPAHDRRPLPGGDEAITAIWETRLKAQPWLFDAPKFRLHSATLAPIGSRGPQLLLRLGLTSYRDFLGTNWSSSAAWLRQQGATDWGDTQAYLADPLGVGAALATADDFLVFLRRSRQVAEAPGLVDVPGGHPEPQALCPGGSPQHQDLAGQLVVHELFSSVLQEICDEVNLPLLTLSQPLLLGIARNETSAGRASAEFYVQCSLTSEQVRKHYLSGGPEAHESTGIFFVETQNVQRLLETEMWAELCPSAKGAIILYNRVQGSPTGAALGSPALLPPL","Homo sapiens","NUDT22, PP11246","Nucleoside diphosphate-linked moiety X motif 22","1","5LOR"
"5LOU",,"X-RAY DIFFRACTION",2.14,42.55,"VAPOR DIFFUSION, SITTING DROP",,"0.4M sodium phosphate monobasic, 0.8M potassium phosphate dibasic, pH 6.1",291.15,"10.1016/j.str.2018.01.004",,"5LOU",71.24,"1.8","1.8","human NUDT22","MGSSHHHHHHSSGLVPRGSHMSCPVQTMDPEVTLLLQCPGGGLPQEQIQAELSPAHDRRPLPGGDEAITAIWETRLKAQPWLFDAPKFRLHSATLAPIGSRGPQLLLRLGLTSYRDFLGTNWSSSAAWLRQQGATDWGDTQAYLADPLGVGAALATADDFLVFLRRSRQVAEAPGLVDVPGGHPEPQALCPGGSPQHQDLAGQLVVHELFSSVLQEICDEVNLPLLTLSQPLLLGIARNETSAGRASAEFYVQCSLTSEQVRKHYLSGGPEAHESTGIFFVETQNVQRLLETEMWAELCPSAKGAIILYNRVQGSPTGAALGSPALLPPL","Homo sapiens","NUDT22, PP11246","Nucleoside diphosphate-linked moiety X motif 22","1","5LOU"
"5LP1",,"X-RAY DIFFRACTION",2.49,50.58,"VAPOR DIFFUSION, HANGING DROP",7.3,"Sodium chloride, PEG 3350, HEPES.",293,"10.1021/acsmedchemlett.6b00281","71H","5LP1",44.93,"1.91","1.91","CRYSTAL STRUCTURE OF HUMAN LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN COMPLEX WITH A [1.1.1]BICYCLOPENTANE-CONTAINING INHIBITOR AT 1.91A RESOLUTION.","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5LP1"
"5LP8",,"X-RAY DIFFRACTION",4.56,73.03,"VAPOR DIFFUSION, SITTING DROP",,"Hepes pH 7, PEG20000",293,"10.7554/eLife.21036",,"5LP8",105.9,"2.7","2.7","Crystal structure of an asymmetric dimer of the ubiquitin ligase HUWE1","MKHHHHHHPMSDYDIPTTENLYFQGADTQKFLRFAETHRTVLNQILRQSTTHLADGPFAVLVDYIRVLDFDVKRKYFRQELERLDEGLRKEDMAVHVRRDHVFEDSYRELHRKSPEEMKNRLYIVFEGEEGQDAGGLLREWYMIISREMFNPMYALFRTSPGDRVTYTINPSSHCNPNHLSYFKFVGRIVAKAVYDNRLLECYFTRSFYKHILGKSVRYTDMESEDYHFYQGLVYLLENDVSTLGYDLTFSTEVQEFGVCEVRDLKPNGANILVTEENKKEYVHLVCQMRMTGAIRKQLAAFLEGFYEIIPKRLISIFTEQELELLISGLPTIDIDDLKSNTEYHKYQSNSIQIQWFWRALRSFDQADRAKFLQFVTGTSKVPLQGFAALEGMNGIQKFQIHRDDRSTDRLPSAHTCFNQLDLPAYESFEKLRHMLLLAIQECSEGFGLA","Homo sapiens","HUWE1, KIAA0312, KIAA1578, UREB1, HSPC272","E3 ubiquitin-protein ligase HUWE1","1","5LP8"
"5LPE",,"X-RAY DIFFRACTION",1.93,36.23,"VAPOR DIFFUSION, SITTING DROP",5.6,"100 mM  ammonium sulphate, 100 mM MES",291,"10.1515/hsz-2016-0205",,"5LPE",52.16,"2.65","2.65","Kallikrein-related peptidase 10 complex with Zn2+","LDPEAYGSPCARGSQPWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNKPLWARVGDDHLLLLQGEQLRRTTRSVVHPKYHQGSGPILPRRTDEHDLMLLKLARPVVLGPRVRALQLPYRCAQPGDQCQVAGWGTTAARRVKYNKGLTCSSITILSPKECEVFYPGVVTNNMICAGLDRGQDPCQSDSGGPLVCDETLQGILSWGVYPCGSAQHPAVYTQICKYMSWINKVIRSN","Homo sapiens","KLK10, NES1, PRSSL1","Kallikrein-10","1","5LPE"
"5LPF",,"X-RAY DIFFRACTION",1.95,37.03,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.1 M ammonium sulphate, 0.1 M MES",291,"10.1515/hsz-2016-0205",,"5LPF",52.13,"2.7","2.7","Kallikrein-related peptidase 10","LDPEAYGSPCARGSQPWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNKPLWARVGDDHLLLLQGEQLRRTTRSVVHPKYHQGSGPILPRRTDEHDLMLLKLARPVVLGPRVRALQLPYRCAQPGDQCQVAGWGTTAARRVKYNKGLTCSSITILSPKECEVFYPGVVTNNMICAGLDRGQDPCQSDSGGPLVCDETLQGILSWGVYPCGSAQHPAVYTQICKYMSWINKVIRSN","Homo sapiens","KLK10, NES1, PRSSL1","Kallikrein-10","1","5LPF"
"5LPG",,"X-RAY DIFFRACTION",2.1,42,"VAPOR DIFFUSION, HANGING DROP",8.5,"30% PEG3350, 0.1M Tris pH 8.5, and 0.24M MgCl2",294,"10.1158/0008-5472.CAN-16-0584",,"5LPG",37.77,"1.7","1.7","Structure of NUDT15 in complex with 6-thio-GMP","MTASAQPRGRRPGVGVGVVVTSCKHPRCVLLGKRKGSVGAGSFQLPGGHLEFGETWEECAQRETWEEAALHLKNVHFASVVNSFIEKENYHYVTILMKGEVDVTHDSEPKNVEPEKNESWEWVPWEELPPLDQLFWGLRCLKEQGYDPFKEDLNHLVGYKGNHL","Homo sapiens","NUDT15, MTH2","Probable 8-oxo-dGTP diphosphatase NUDT15","1","5LPG"
"5LPH",,"X-RAY DIFFRACTION",3.38,63.58,"VAPOR DIFFUSION, SITTING DROP",6,"0.1 M MES pH 6.0
11 % PEG 20K",292,"10.1016/j.str.2016.11.014",,"5LPH",65.18,"2.25","2.25","Structure of the TOG domain of human Cep104","GPHGEAVVEPEMSNADISDARRGGMLGEPEPLTEKALREASSAIDVLGETLVAEAYCKTWSYREDALLALSKKLMEMPVGTPKEDLKNTLRASVFLVRRAIKDIVTSVFQASLKLLKMIITQYIPKHKLSKLETAHCVERTIPVLLTRTGDSSARLRVTAANFIQEMALFKEVKSLQIIPSYLVQPLKANSSVHLAMSQMGLLARLLKDLGTGSSGFTIDNVMKFSVSALEHRVYEVRETAVRIILDMYRQHQASILEYLPPDDSNTRRNILYKTIFEGFAKIDGRAT","Homo sapiens","CEP104, KIAA0562","Centrosomal protein of 104 kDa","1","5LPH"
"5LPI",,"X-RAY DIFFRACTION",2.83,56.51,"VAPOR DIFFUSION, SITTING DROP",6.5,"10 % PEG 4K
20% Glycerol
30 mM CaCl2
30 mM MgCl2
0.1M MES/imidazole pH 6.5",277,"10.1016/j.str.2016.11.014",,"5LPI",63.24,"1.8","1.8","Structure of the zinc finger array of Cep104","GPHMDEHYLDNLCIFCGERSEEFTEEGLDLHYWKHCLMLTRCDHCKQVVEISSLTEHLLTECDKKDGFGKCYRCSEAVFKEELPRHIKHKDCNPAKPEKLANRCPLCHENFSPGEEAWKAHLMGPAGCTMNLRK","Homo sapiens","CEP104, KIAA0562","Centrosomal protein of 104 kDa","1","5LPI"
"5LPJ",,"X-RAY DIFFRACTION",2.46,49.91,"EVAPORATION",6.5,"LiSO4, PEG 3350",277,"10.1002/anie.201705516","XDM","5LPJ",14.54,"1.65","1.65","Crystal structure of the bromodomain of human CREBBP bound to the inhibitor XDM1","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5LPJ"
"5LPK",,"X-RAY DIFFRACTION",2.71,54.59,"EVAPORATION",6.5,"PEG 3350, NaCl",277,"10.1002/anie.201705516","XDM","5LPK",105.14,"2.1","2.1","Crystal structure of the bromodomain of human EP300 bound to the inhibitor XDM1","APGQSKKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKSPMDLSTIKRKLDTGQYQEPWQYVDDIWLMFNNAWLYNRKTSRVYKYCSKLSEVFEQEIDPVMQSLG","Homo sapiens","EP300, P300","Histone acetyltransferase p300","1","5LPK"
"5LPL",,"X-RAY DIFFRACTION",2.24,45.01,"EVAPORATION",7.5,"NaCl, PEG 3350",277,"10.1002/anie.201705516","71X","5LPL",14.6,"1.65","1.65","Crystal structure of the bromodomain of human CREBBP bound to the inhibitor XDM3c","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5LPL"
"5LPM",,"X-RAY DIFFRACTION",2.33,47.14,"EVAPORATION",5.5,"NaCl, PEG 3350",277,"10.1002/anie.201705516","71Y","5LPM",29.33,"1.5","1.5","Crystal structure of the bromodomain of human Ep300 bound to the inhibitor XDM3d","SMIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKSPMDLSTIKRKLDTGQYQEPWQYVDDIWLMFNNAWLYNRKTSRVYKYCSKLSEVFEQEIDPVMQSLG","Homo sapiens","EP300, P300","Histone acetyltransferase p300","1","5LPM"
"5LPX",,"X-RAY DIFFRACTION",3.81,67.69,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris pH 6, 0.2 M ammonium acetate, 5% PEG 3350",296,"10.1016/j.str.2017.06.001",,"5LPX",39.04,"1.9","1.9","Crystal structure of PKC phosphorylation-mimicking mutant (S26E) Annexin A2","XSTVHEILCKLSLEGDHSTPPSAYGEVKAYTNFDAERDALNIETAIKTKGVDEVTIVNILTNRSNEQRQDIAFAYQRRTKKELASALKSALSGHLETVILGLLKTPAQYDASELKASMKGLGTDEDSLIEIICSRTNQELQEINRVYKEMYKTDLEKDIISDTSGDFRKLMVALAKGRRAEDGSVIDYELIDQDARDLYDAGVKRKGTDVPKWISIMTERSVPHLQKVFDRYKSYSPYDMLESIRKEVKGDLENAFLNLVQCIQNKPLYFADRLYDSMKGKGTRDKVLIRIMVSRSEVDMLKIRSEFKRKYGKSLYYYIQQDTKGDYQKALLYLCGGDD","Homo sapiens","ANXA2, ANX2, ANX2L4, CAL1H, LPC2D","Annexin A2","1","5LPX"
"5LQ0",,"X-RAY DIFFRACTION",3.11,60.48,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES pH 6, 0.1 M magnesium chloride, 4% PEG6000",296,"10.1016/j.str.2017.06.001",,"5LQ0",77.63,"2.9","2.9","Crystal structure of Tyr24 phosphorylated Annexin A2 at 2.9 A resolution","XSTVHEILCKLSLEGDHSTPPSAYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNILTNRSNEQRQDIAFAYQRRTKKELASALKSALSGHLETVILGLLKTPAQYDASELKASMKGLGTDEDSLIEIICSRTNQELQEINRVYKEMYKTDLEKDIISDTSGDFRKLMVALAKGRRAEDGSVIDYELIDQDARDLYDAGVKRKGTDVPKWISIMTERSVPHLQKVFDRYKSYSPYDMLESIRKEVKGDLENAFLNLVQCIQNKPLYFADRLYDSMKGKGTRDKVLIRIMVSRSEVDMLKIRSEFKRKYGKSLYYYIQQDTKGDYQKALLYLCGGDD","Homo sapiens","ANXA2, ANX2, ANX2L4, CAL1H, LPC2D","Annexin A2","1","5LQ0"
"5LQ2",,"X-RAY DIFFRACTION",3.4,63.85,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Tris pH 8.5, 10% ethanol",296,"10.1016/j.str.2017.06.001",,"5LQ2",77.79,"3.4","3.4","Crystal structure of Tyr24 phosphorylated Annexin A2 at 3.4 A resolution","XSTVHEILCKLSLEGDHSTPPSAYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNILTNRSNEQRQDIAFAYQRRTKKELASALKSALSGHLETVILGLLKTPAQYDASELKASMKGLGTDEDSLIEIICSRTNQELQEINRVYKEMYKTDLEKDIISDTSGDFRKLMVALAKGRRAEDGSVIDYELIDQDARDLYDAGVKRKGTDVPKWISIMTERSVPHLQKVFDRYKSYSPYDMLESIRKEVKGDLENAFLNLVQCIQNKPLYFADRLYDSMKGKGTRDKVLIRIMVSRSEVDMLKIRSEFKRKYGKSLYYYIQQDTKGDYQKALLYLCGGDD","Homo sapiens","ANXA2, ANX2, ANX2L4, CAL1H, LPC2D","Annexin A2","1","5LQ2"
"5LQ9",,"X-RAY DIFFRACTION",3.2,61.55,"VAPOR DIFFUSION, HANGING DROP",,"1.0 to 1.4M Sodium Citrate",277,,,"5LQ9",23.66,"1.9","1.9","CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR200323.","METFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5LQ9"
"5LQG",,"SOLUTION NMR",,,,,,,"10.1002/anie.201507569",,"5LQG",6.96,,,"A two-quartet G-quadruplex formed by human telomere in KCl solution at neutral pH","TAGGGTTAGGGTTAGGGTTAGG","Homo sapiens",,"DNA (5'-D(*TP*AP*GP*GP*GP*TP*TP*AP*GP*GP*GP*TP*TP*AP*GP*GP*GP*TP*TP*AP*GP*G)-3')","1","5LQG"
"5LQH",,"SOLUTION NMR",,,,,,,"10.1002/anie.201507569",,"5LQH",6.96,,,"A two-quartet G-quadruplex formed by human telomere in KCl solution at pH 5.0","TAGGGTTAGGGTTAGGGTTAGG","Homo sapiens",,"DNA (5'-D(*TP*AP*GP*GP*GP*TP*TP*AP*GP*GP*GP*TP*TP*AP*GP*GP*GP*TP*TP*AP*GP*G)-3')","1","5LQH"
"5LQO",,"X-RAY DIFFRACTION",2.41,48.89,"VAPOR DIFFUSION, HANGING DROP",7,"0.025 M Magnesium Sulfate, 0.05 M Tris Hydrochloride pH 8.5, 1.8 M Ammonium Sulfate",293,"10.15252/embr.201743967",,"5LQO",6.62,"1.87","1.87","RNA duplex has central consecutive GA pairs flanked by G-C basepairs","GCCGGACGGC","Homo sapiens",,"RNA (5'-R(*GP*(CBV)P*CP*GP*GP*AP*CP*GP*GP*C)-3')","1","5LQO"
"5LQT",,"X-RAY DIFFRACTION",2.29,46.23,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.02 M Calcium Chloride dihydrate,
0.1 M Sodium Acetate trihydrate pH 4.6,
30% v/v 2-Methyl-2,4-pentanediol",293,"10.15252/embr.201743967",,"5LQT",6.76,"1.5","1.5","RNA duplex has central consecutive GA pairs flanked by G-C basepairs","GCCGGACGGC","Homo sapiens",,"RNA (5'-R(*GP*(CBV)P*CP*GP*GP*(6MZ)P*CP*GP*GP*C)-3')","1","5LQT"
"5LR1",,"X-RAY DIFFRACTION",3.2,61.62,"VAPOR DIFFUSION, HANGING DROP",,"1.0 to 1.4 M Sodium Citrate",277,,,"5LR1",23.63,"1.44","1.44","CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH A003498614A.","HMETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5LR1"
"5LR3",,"X-RAY DIFFRACTION",2.53,51.4,"VAPOR DIFFUSION, HANGING DROP",6,"0.015 M Magnesium Acetate,
0.05 M Sodium Cacodylate pH 6.0,
1.7 M Ammonium Sulfate",293,"10.15252/embr.201743967",,"5LR3",6.72,"1.65","1.65","RNA duplex has central consecutive GA pairs flanked by G-U basepairs","GCCGGAUGGC","Homo sapiens",,"RNA (5'-R(*GP*(CBV)P*CP*GP*GP*AP*UP*GP*GP*C)-3')","1","5LR3"
"5LR4",,"X-RAY DIFFRACTION",2.89,57.47,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Sodium Chloride, 0.1M Bis-Tris pH 6.5, 1.5 M Ammonium Sulfate",293,"10.15252/embr.201743967",,"5LR4",13.39,"1.8","1.8","RNA duplex has central consecutive GA pairs flanked by G-U basepairs with a methyl group on the adenine N6","GCCGGAUGGC","Homo sapiens",,"RNA (5'-R(*GP*(CBV)P*CP*GP*GP*(6MZ)P*UP*GP*GP*C)-3')","1","5LR4"
"5LR5",,"X-RAY DIFFRACTION",3.05,59.72,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium Sulfate 0.1 M Sodium Acetate trihydrate pH 4.6 25% w/v Polyethylene Glycol 4000",293,"10.15252/embr.201743967",,"5LR5",13.18,"2.4","2.4","N6-methyladenine is accommodated in a conventional A-U basepair","GGACUAGUCC","Homo sapiens",,"RNA (5'-R(*GP*GP*(6MZ)P*CP*UP*AP*GP*UP*(CBV)P*C)-3')","1","5LR5"
"5LR7",,"X-RAY DIFFRACTION",3.2,61.62,"VAPOR DIFFUSION, HANGING DROP",,"1.0 - 1.4M Sodium Citrate",277,,,"5LR7",23.76,"1.86","1.86","CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR567530","HMETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5LR7"
"5LRL",,"X-RAY DIFFRACTION",3.2,61.62,"VAPOR DIFFUSION, HANGING DROP",,"1.0 - 1.4M Sodium Citrate",277,"10.1021/acs.jcim.9b00592",,"5LRL",23.76,"1.33","1.33","CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH A003492875","HMETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5LRL"
"5LRQ",,"X-RAY DIFFRACTION",2.22,44.5,"VAPOR DIFFUSION, SITTING DROP",7,"BRD4 10mg/ml
30w/v Jeffamine ED-2001
0.1M HEPES pH7.0",278,"10.1016/j.ejmech.2019.05.057",,"5LRQ",17.39,"1.7","1.7","BRD4 in complex with ERK5 inhibitor XMD8-92","MHHHHHHSSGVDLGTENLYFQSMNPPPPETSNPNKPKAQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5LRQ"
"5LRU",,"X-RAY DIFFRACTION",3.31,62.86,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bis-Tris (pH 6.1), 0.2 M magnesium formate",291,"10.1038/nature19836",,"5LRU",36.36,"2.2","2.2","Structure of Cezanne/OTUD7B OTU domain","MEMPICAFQLPDLTVYNEDFRSFIERDLIEQSMLVALEQAGRLNWWVSVDPTSQRLLPLATTGDGNCLLHAASLGMWGFHDRDLMLRKALYALMEKGVEKEALKRRWRWQQTQQNKESGLVYTEDEWQKEWNELIKLASSEPRMHLGTNGANCGGVESSEEPVYESLEEFHVFVLAHVLRRPIVVVADTMLRDSGGEAFAPIPFGGIYLPLEVPASQCHRSPLVLAYDQAHFSALVSMEQKENTKEQAVIPLTDSEYKLLPLHFAVDPGKGWEWGKDDSDNVRLASVILSLEVKLHLLHSYMNVKWIPLSSKHHHHHH","Homo sapiens","OTUD7B, ZA20D1","OTU domain-containing protein 7B","1","5LRU"
"5LRZ",,"X-RAY DIFFRACTION",3.15,60.99,"VAPOR DIFFUSION, HANGING DROP",,"1.0 to 1.4 M Sodium Citrate",277,,,"5LRZ",23.84,"2","2","CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH A003643501","HMETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5LRZ"
"5LS1",,"X-RAY DIFFRACTION",3.17,61.17,"VAPOR DIFFUSION, HANGING DROP",,"1.0-1.4M Sodium Citrate",277,,,"5LS1",23.57,"1.85","1.85","CRYSTAL STRUCTURE OF HSP90 IN COMPLEX WITH SAR166475","METFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5LS1"
"5LSA",,"X-RAY DIFFRACTION",2.12,42.09,"VAPOR DIFFUSION, SITTING DROP",9,"AMMONIUM SULPHATE, CHES, PH 9",295,,,"5LSA",25.14,"1.5","1.5","human catechol O-methyltransferase in complex with SAM and DNC at 1.50A","MGDTKEQRILNHVLQHAEPGNAQSVLEAIDTYCEQKEWAMNVGDKKGKIVDAVIQEHQPSVLLELGAYCGYSAVRMARLLSPGARLITIEINPDCAAITQRMVDFAGVKDKVTLVVGASQDIIPQLKKKYDVDTLDMVFLDHWKDRYLPDTLLLEECGLLRKGTVLLADNVICPGAPDFLAHVRGSSCFECTHYQSFLEYREVVDGLEKAIYKGPGSEAGP","Homo sapiens","COMT","Catechol O-methyltransferase","1","5LSA"
"5LSG",,"X-RAY DIFFRACTION",2.35,47.74,"VAPOR DIFFUSION, SITTING DROP",8,"reservoir: 0.8M NACITRATE, 0.15M TRIS, PH8.0.
The crystals were soaked for one week in a storage solution (1.2 M Na Citrate, 0.15M Tris, pH 8.0) containing the ligand BA (0.5 mM).",290,"10.1038/s41598-017-05666-6","QZQ","5LSG",69.62,"2","2","PPARgamma complex with the betulinic acid","MGSSHHHHHHSSGLVPRGSHMAEISSDIDQLNPESADLRALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLASLMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVIILSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQLLQVIKKTETDMSLHPLLQEIYKDLY","Homo sapiens","PPARG, NR1C3","Peroxisome proliferator-activated receptor gamma","1","5LSG"
"5LSH",,"X-RAY DIFFRACTION",1.91,35.51,"VAPOR DIFFUSION, HANGING DROP",,"0.8 M NaCl, 25 mM NaOAc, pH 5.4",291,"10.1017/S0033583517000075",,"5LSH",15.56,"1.061","1.061","human lysozyme in complex with a tetrasaccharide fragment of the O-chain of LPS from Klebsiella pneumoniae","KVFERCELARTLKRLGMDGYRGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV","Homo sapiens","LYZ, LZM","Lysozyme C","1","5LSH"
"5LSS",,"X-RAY DIFFRACTION",1.87,34.33,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M KSCN, 31.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7",293,"10.1021/acschembio.6b00308",,"5LSS",34.78,"1.79","1.79","Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives","MHHHHHHSSGRENLYFQGETSVPPGSALVGPSCVMDDFRDPQRWKECAKQGKMPCYFDLIEENVYLTERKKNKSHRDIKRMQCECTPLSKDERAQGEIACGEDCLNRLLMIECSSRCPNGDYCSNRRFQRKQHADVEVILTEKKGWGLRAAKDLPSNTFVLEYCGEVLDHKEFKARVKEYARNKNIHYYFMALKNDEIIDATQKGNCSRFMNHSCEPNCETQKWTVNGQLRVGFFTTKLVPSGSELTFDYQFQRYGKEAQKCFCGSANCRGYLGGENRVSIRAAGGKMKKERSRK","Homo sapiens","SETD2, HIF1, HYPB, KIAA1732, KMT3A, SET2, HSPC069","Histone-lysine N-methyltransferase SETD2","1","5LSS"
"5LST",,"X-RAY DIFFRACTION",3.12,60.62,"VAPOR DIFFUSION, HANGING DROP",9,"Imidazole, Sodium formate",293.15,"10.1038/ncomms15907",,"5LST",76.48,"2.75","2.75","Crystal structure of the human RecQL4 helicase.","GPMAVGPEPLVPSPQPVPEVPSLDPTVLPLYSLGPSGQLAETPAEVFQALEQLGHQAFRPGQERAVMRILSGISTLLVLPTGAGKSLCYQLPALLYSRRSPCLTLVVSPLLSLMDDQVSGLPPCLKAACIHSGMTRKQRESVLQKIRAAQVHVLMLTPEALVGAGGLPPAAQLPPVAFACIDEAHCLSQWSHNFRPCYLRVCKVLRERMGVHCFLGLTATATRRTASDVAQHLAVAEEPDLHGPAPVPTNLHLSVSMDRDTDQALLTLLQGKRFQNLDSIIIYCNRREDTERIAALLRTCLHAAWVPGSGGRAPKTTAEAYHAGMCSRERRRVQRAFMQGQLRVVVATVAFGMGLDRPDVRAVLHLGLPPSFESYVQAVGRAGRDGQPAHCHLFLQPQGEDLRELRRHVHADSTDFLAVKRLVQRVFPACTCTCTRPPSEQEGAVGGERPVPKYPPQEAEQLSHQAAPGPRRVCMGHERALPIQLTVQALDMPEEAIETLLCYLELHPHHWLELLATTYTHCRLNCPGGPAQLQALAHRCPPLAVCLAQQLPEDPGQGSSSVEFDMVKLVDSMGWELASVRRALCQLQWDHEPRTGVRRGTGVLVEFSELAFHLRSPGDLTAEEKDQICDFLYGRVQARERQALARLRRTFQAFHSVAFPSCGPCLEQQDEERSTRLKDLLGRYFEEEEGQEP","Homo sapiens","RECQL4, RECQ4","ATP-dependent DNA helicase Q4","1","5LST"
"5LSU",,"X-RAY DIFFRACTION",2.1,41.49,"VAPOR DIFFUSION, SITTING DROP",,"16.0%w/v PEG 3350, 0.1M NH4Cl",293,"10.1021/acschembio.6b00308",,"5LSU",58.76,"2.14","2.14","Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives","MGSSHHHHHHSSGLVPRGSHMKLLRELRETQESERKPPPYKHIKVNKPYGKVQIYTADISEIPKCNCKPTDENPCGFDSECLNRMLMFECHPQVCPAGEFCQNQCFTKRQYPETKIIKTLQRGWGLVAKRDIRKGEFVNEYVGELIDEEECMARIKHAHENDITHFYMLTIDKDRIIDAGPKGNYSRFMNHSCQPNCETLKWTVNGDTRVGLFAVCDIPAGTELTFNYNLDCLGNEKTVCRCGASNCSGFLG","Homo sapiens","WHSC1, KIAA1090, MMSET, NSD2, TRX5","Histone-lysine N-methyltransferase NSD2","1","5LSU"
"5LSX",,"X-RAY DIFFRACTION",2.2,44.1,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes, pH 7.3, 0.1MKSCN, 25-30%MPEG2000",293,"10.1021/acschembio.6b00308",,"5LSX",34.77,"2.9","2.9","Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives","MHHHHHHSSGRENLYFQGETSVPPGSALVGPSCVMDDFRDPQRWKECAKQGKMPCYFDLIEENVYLTERKKNKSHRDIKRMQCECTPLSKDERAQGEIACGEDCLNRLLMIECSSRCPNGDYCSNRRFQRKQHADVEVILTEKKGWGLRAAKDLPSNTFVLEYCGEVLDHKEFKARVKEYARNKNIHYYFMALKNDEIIDATQKGNCSRFMNHSCEPNCETQKWTVNGQLRVGFFTTKLVPSGSELTFDYQFQRYGKEAQKCFCGSANCRGYLGGENRVSIRAAGGKMKKERSRK","Homo sapiens","SETD2, HIF1, HYPB, KIAA1732, KMT3A, SET2, HSPC069","Histone-lysine N-methyltransferase SETD2","1","5LSX"
"5LSY",,"X-RAY DIFFRACTION",2.06,40.18,"VAPOR DIFFUSION",,"0.1M Hepes, PH7.3, 0.1MKSCN, 25-30%MPEG2000",293,"10.1021/acschembio.6b00308",,"5LSY",34.79,"1.62","1.62","Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives","MHHHHHHSSGRENLYFQGETSVPPGSALVGPSCVMDDFRDPQRWKECAKQGKMPCYFDLIEENVYLTERKKNKSHRDIKRMQCECTPLSKDERAQGEIACGEDCLNRLLMIECSSRCPNGDYCSNRRFQRKQHADVEVILTEKKGWGLRAAKDLPSNTFVLEYCGEVLDHKEFKARVKEYARNKNIHYYFMALKNDEIIDATQKGNCSRFMNHSCEPNCETQKWTVNGQLRVGFFTTKLVPSGSELTFDYQFQRYGKEAQKCFCGSANCRGYLGGENRVSIRAAGGKMKKERSRK","Homo sapiens","SETD2, HIF1, HYPB, KIAA1732, KMT3A, SET2, HSPC069","Histone-lysine N-methyltransferase SETD2","1","5LSY"
"5LSZ",,"X-RAY DIFFRACTION",2.1,41.41,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH7.3, 0.1MKSCN, 25-30%MPEG2000",293,"10.1021/acschembio.6b00308",,"5LSZ",34.85,"1.62","1.62","Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives","MHHHHHHSSGRENLYFQGETSVPPGSALVGPSCVMDDFRDPQRWKECAKQGKMPCYFDLIEENVYLTERKKNKSHRDIKRMQCECTPLSKDERAQGEIACGEDCLNRLLMIECSSRCPNGDYCSNRRFQRKQHADVEVILTEKKGWGLRAAKDLPSNTFVLEYCGEVLDHKEFKARVKEYARNKNIHYYFMALKNDEIIDATQKGNCSRFMNHSCEPNCETQKWTVNGQLRVGFFTTKLVPSGSELTFDYQFQRYGKEAQKCFCGSANCRGYLGGENRVSIRAAGGKMKKERSRK","Homo sapiens","SETD2, HIF1, HYPB, KIAA1732, KMT3A, SET2, HSPC069","Histone-lysine N-methyltransferase SETD2","1","5LSZ"
"5LT0",,"X-RAY DIFFRACTION",2.58,52.4,"VAPOR DIFFUSION",,"0.1 M Na-acetate pH 4.5-5.5
20-25% PEG 4000
0.2 M ammonium sulfate
0.1 mM SrCl2",293,"10.1038/srep42558",,"5LT0",36.64,"2","2","nucleotide-free kinesin-1 motor domain, P212121 crystal form","MADLAESNIKVMCRFRPLNESEVNRGDKYIAKFQGEDTVVIASKPYAFDRVFQSSTSQEQVYNDAAKKIVKDVLEGYNGTIFAYGQTSSGKTHTMEGKLHDPEGMGIIPRIVQDIFNYIYSMDENLEFHIKVSYFEIYLDKIRDLLDVSKTNLSVHEDKNRVPYVKGATERFVSSPDEVMDTIDEGKSNRHVAVTNMNEHSSRSHSIFLINVKQENTQTEQKLSGKLYLVDLAGSEKVSKTGAEGAVLDEAKNINKSLSALGNVISALAEGSTYVPYRDSKMTRILQDSLGGNARTTIVICCSPSSYNESETKSTLLFGQRAKTI","Homo sapiens","KIF5B, KNS, KNS1","Kinesin-like protein","1","5LT0"
"5LT1",,"X-RAY DIFFRACTION",2.55,51.86,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Na-Acetate pH 4.5-5.5
23% PEG 4000
0.2 M Ammonium Sulfate
0.1 M SrCl2",293,"10.1038/srep42558",,"5LT1",73.16,"1.949","1.949","nucleotide-free kinesin-1 motor domain T92V mutant, P21 crystal form","MADLAESNIKVMCRFRPLNESEVNRGDKYIAKFQGEDTVVIASKPYAFDRVFQSSTSQEQVYNDAAKKIVKDVLEGYNGTIFAYGQTSSGKVHTMEGKLHDPEGMGIIPRIVQDIFNYIYSMDENLEFHIKVSYFEIYLDKIRDLLDVSKTNLSVHEDKNRVPYVKGATERFVSSPDEVMDTIDEGKSNRHVAVTNMNEHSSRSHSIFLINVKQENTQTEQKLSGKLYLVDLAGSEKVSKTGAEGAVLDEAKNINKSLSALGNVISALAEGSTYVPYRDSKMTRILQDSLGGNARTTIVICCSPSSYNESETKSTLLFGQRAKTI","Homo sapiens","KIF5B, KNS, KNS1","Kinesin-like protein","1","5LT1"
"5LT2",,"X-RAY DIFFRACTION",2.45,49.71,"VAPOR DIFFUSION, HANGING DROP",6.5,"50 mM Mes pH 6.5
0.16 M ammonium sulfate
30% mPEG 5000",293,"10.1038/srep42558",,"5LT2",218.72,"2.6","2.6","nucleotide-free kinesin-1 motor domain, P1 crystal form","MADLAESNIKVMCRFRPLNESEVNRGDKYIAKFQGEDTVVIASKPYAFDRVFQSSTSQEQVYNDAAKKIVKDVLEGYNGTIFAYGQTSSGKTHTMEGKLHDPEGMGIIPRIVQDIFNYIYSMDENLEFHIKVSYFEIYLDKIRDLLDVSKTNLSVHEDKNRVPYVKGATERFVSSPDEVMDTIDEGKSNRHVAVTNMNEHSSRSHSIFLINVKQENTQTEQKLSGKLYLVDLAGSEKVSKTGAEGAVLDEAKNINKSLSALGNVISALAEGSTYVPYRDSKMTRILQDSLGGNARTTIVICCSPSSYNESETKSTLLFGQRAKTI","Homo sapiens","KIF5B, KNS, KNS1","Kinesin-like protein","1","5LT2"
"5LT3",,"X-RAY DIFFRACTION",2.33,47.13,"VAPOR DIFFUSION, HANGING DROP",6.5,"50 mM Mes pH 6.5
0.2M ammonium sulfate
30% mPEG 5000",293,"10.1038/srep42558",,"5LT3",218.25,"2.59","2.59","nucleotide-free kinesin-1 motor domain T87A mutant, P1 crystal form","MADLAESNIKVMCRFRPLNESEVNRGDKYIAKFQGEDTVVIASKPYAFDRVFQSSTSQEQVYNDAAKKIVKDVLEGYNGTIFAYGQASSGKTHTMEGKLHDPEGMGIIPRIVQDIFNYIYSMDENLEFHIKVSYFEIYLDKIRDLLDVSKTNLSVHEDKNRVPYVKGATERFVSSPDEVMDTIDEGKSNRHVAVTNMNEHSSRSHSIFLINVKQENTQTEQKLSGKLYLVDLAGSEKVSKTGAEGAVLDEAKNINKSLSALGNVISALAEGSTYVPYRDSKMTRILQDSLGGNARTTIVICCSPSSYNESETKSTLLFGQRAKTI","Homo sapiens","KIF5B, KNS, KNS1","Kinesin-1 heavy chain","1","5LT3"
"5LT4",,"X-RAY DIFFRACTION",2.38,48.28,"VAPOR DIFFUSION, HANGING DROP",6.5,"50 mM Mes pH 6.5
0.16 M ammonium sulfate
30% mPEG 5000",293,"10.1038/srep42558",,"5LT4",218.8,"2.881","2.881","nucleotide-free kinesin-1 motor domain T92V mutant, P1 crystal form","MADLAESNIKVMCRFRPLNESEVNRGDKYIAKFQGEDTVVIASKPYAFDRVFQSSTSQEQVYNDAAKKIVKDVLEGYNGTIFAYGQTSSGKVHTMEGKLHDPEGMGIIPRIVQDIFNYIYSMDENLEFHIKVSYFEIYLDKIRDLLDVSKTNLSVHEDKNRVPYVKGATERFVSSPDEVMDTIDEGKSNRHVAVTNMNEHSSRSHSIFLINVKQENTQTEQKLSGKLYLVDLAGSEKVSKTGAEGAVLDEAKNINKSLSALGNVISALAEGSTYVPYRDSKMTRILQDSLGGNARTTIVICCSPSSYNESETKSTLLFGQRAKTI","Homo sapiens","KIF5B, KNS, KNS1","Kinesin-1 heavy chain","1","5LT4"
"5LT6",,"X-RAY DIFFRACTION",1.89,34.96,"VAPOR DIFFUSION, HANGING DROP",,"0.1MHepes,pH7.3, 0.1MKSCN, 25-30%MPEG2000.",293,"10.1021/acschembio.6b00308",,"5LT6",69.61,"2.05","2.05","Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives","MHHHHHHSSGRENLYFQGETSVPPGSALVGPSCVMDDFRDPQRWKECAKQGKMPCYFDLIEENVYLTERKKNKSHRDIKRMQCECTPLSKDERAQGEIACGEDCLNRLLMIECSSRCPNGDYCSNRRFQRKQHADVEVILTEKKGWGLRAAKDLPSNTFVLEYCGEVLDHKEFKARVKEYARNKNIHYYFMALKNDEIIDATQKGNCSRFMNHSCEPNCETQKWTVNGQLRVGFFTTKLVPSGSELTFDYQFQRYGKEAQKCFCGSANCRGYLGGENRVSIRAAGGKMKKERSRK","Homo sapiens","SETD2, HIF1, HYPB, KIAA1732, KMT3A, SET2, HSPC069","Histone-lysine N-methyltransferase SETD2","1","5LT6"
"5LT7",,"X-RAY DIFFRACTION",2.08,40.91,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes, PH7.3, 0.1MKSCN, 25-30%MPEG2000",293,"10.1021/acschembio.6b00308",,"5LT7",34.85,"1.51","1.51","Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives","MHHHHHHSSGRENLYFQGETSVPPGSALVGPSCVMDDFRDPQRWKECAKQGKMPCYFDLIEENVYLTERKKNKSHRDIKRMQCECTPLSKDERAQGEIACGEDCLNRLLMIECSSRCPNGDYCSNRRFQRKQHADVEVILTEKKGWGLRAAKDLPSNTFVLEYCGEVLDHKEFKARVKEYARNKNIHYYFMALKNDEIIDATQKGNCSRFMNHSCEPNCETQKWTVNGQLRVGFFTTKLVPSGSELTFDYQFQRYGKEAQKCFCGSANCRGYLGGENRVSIRAAGGKMKKERSRK","Homo sapiens","SETD2, HIF1, HYPB, KIAA1732, KMT3A, SET2, HSPC069","Histone-lysine N-methyltransferase SETD2","1","5LT7"
"5LT8",,"X-RAY DIFFRACTION",1.87,34.28,"VAPOR DIFFUSION, HANGING DROP",,"0.1M HEPES, PH7.3, 0.1MKSCN, 25-30%MPEG2000",293,"10.1021/acschembio.6b00308",,"5LT8",34.68,"1.57","1.57","Structure of the Epigenetic Oncogene MMSET and inhibition by N-Alkyl Sinefungin Derivatives","MHHHHHHSSGRENLYFQGETSVPPGSALVGPSCVMDDFRDPQRWKECAKQGKMPCYFDLIEENVYLTERKKNKSHRDIKRMQCECTPLSKDERAQGEIACGEDCLNRLLMIECSSRCPNGDYCSNRRFQRKQHADVEVILTEKKGWGLRAAKDLPSNTFVLEYCGEVLDHKEFKARVKEYARNKNIHYYFMALKNDEIIDATQKGNCSRFMNHSCEPNCETQKWTVNGQLRVGFFTTKLVPSGSELTFDYQFQRYGKEAQKCFCGSANCRGYLGGENRVSIRAAGGKMKKERSRK","Homo sapiens","SETD2, HIF1, HYPB, KIAA1732, KMT3A, SET2, HSPC069","Histone-lysine N-methyltransferase SETD2","1","5LT8"
"5LTL",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.05 M sodium phosphate,
0.5 M sodium chloride,
10 % (v/v) glycerol,
1.6 M sodium citrate",293,,,"5LTL",23.03,"1.45","1.45","Structure of human chemokine CCL16","GPSQPKVPEWVNTPSTCCLKYYEKVLPRRLVVGYRKALNCHLPAIIFVTKRNREVCTNPNDDWVQEYIKDPNLPLLPTRNLSTVKIITAKNGQPQLLNSQ","Homo sapiens","CCL16, ILINCK, NCC4, SCYA16","C-C motif chemokine 16","1","5LTL"
"5LTU",,"X-RAY DIFFRACTION",2.14,42.64,"VAPOR DIFFUSION, SITTING DROP",8.5,"2M Ammonium Sulphate, 0.1M Tris pH 8.5",277,,,"5LTU",41.16,"2.23","2.23","Crystal Structure of NUDT4A- Diphosphoinositol polyphosphate phosphohydrolase 2","MMKFKPNQTRTYDREGFKKRAACLCFRSEQEDEVLLVSSSRYPDQWIVPGGGMEPEEEPGGAAVREVYEEAGVKGKLGRLLGIFENQDRKHRTYVYVLTVTEILEDWEDSVNIGRKREWFKVEDAIKVLQCHKPVHAEYLEKLKLGCSPANGNSTVPSLPDNNALFVTAAQTSGLPSSVR","Homo sapiens","NUDT4, DIPP2, KIAA0487, HDCMB47P","Diphosphoinositol polyphosphate phosphohydrolase 2","1","5LTU"
"5LUA",,"X-RAY DIFFRACTION",2.34,47.41,"VAPOR DIFFUSION, SITTING DROP",,"22 % PEG 3350, 0.1 M sodium acetate pH 4.5",293,"10.1038/ncomms14740",,"5LUA",61.87,"2","2","Crystal structure of human legumain (AEP) in complex with compound 11b","GGKHWVVIVAGSNGWYNYRHQADACHAYQIIHRNGIPDEQIVVMMYDDIAYSEDNPTPGIVINRPNGTDVYQGVPKDYTGEDVTPQNFLAVLRGDAEAVKGIGSGKVLKSGPQDHVFIYFTNHGSTGILVFPNEDLHVKDLNETIHYMYKHKMYRKMVFYIEACESGSMMNHLPDNINVYATTAANPRESSYACYYDEKRSTYLGDWYSVNWMEDSDVEDLTKETLHKQYHLVKSHTQTSHVMQYGNKTISTMKVMQFQGMK","Homo sapiens","LGMN, PRSC1","Legumain","1","5LUA"
"5LUB",,"X-RAY DIFFRACTION",2.36,47.84,"VAPOR DIFFUSION, SITTING DROP",,"22 % PEG 3350, 0.1 M sodium acetate pH 4.5",293,"10.1038/ncomms14740","3Y7","5LUB",61.83,"2.1","2.1","Crystal structure of human legumain (AEP) in complex with compound 11","GGKHWVVIVAGSNGWYNYRHQADACHAYQIIHRNGIPDEQIVVMMYDDIAYSEDNPTPGIVINRPNGTDVYQGVPKDYTGEDVTPQNFLAVLRGDAEAVKGIGSGKVLKSGPQDHVFIYFTNHGSTGILVFPNEDLHVKDLNETIHYMYKHKMYRKMVFYIEACESGSMMNHLPDNINVYATTAANPRESSYACYYDEKRSTYLGDWYSVNWMEDSDVEDLTKETLHKQYHLVKSHTQTSHVMQYGNKTISTMKVMQFQGMK","Homo sapiens","LGMN, PRSC1","Legumain","1","5LUB"
"5LUC",,"X-RAY DIFFRACTION",3.37,63.5,"VAPOR DIFFUSION, HANGING DROP",5.5,"mixing equal volumes of
protein solution: 15 mg/ml in
40 mM PhO pH 7.4 - 60 mM Hepes pH 7.0
reservoir: ammonium acetate o.1 M - BIS TRIS pH 5.5 0.1M - 17% PEG 10K",294,"10.1038/s41598-017-11948-w",,"5LUC",357.89,"1.8","1.8","Crystal structure of the D183N variant of human Alanine:Glyoxylate Aminotransferase major allele (AGT-Ma) at 1.8 Angstrom; internal aldimine with PLP in the active site","MGGSHHHHHHGMASHKLLVTPPKALLKPLSIPNQLLLGPGPSNLPPRIMAAGGLQMIGSMSKDMYQIMDEIKEGIQYVFQTRNPLTLVISGSGHCALEAALVNVLEPGDSFLVGANGIWGQRAVDIGERIGARVHPMTKDPGGHYTLQEVEEGLAQHKPVLLFLTHGESSTGVLQPLDGFGELCHRYKCLLLVNSVASLGGTPLYMDRQGIDILYSGSQKALNAPPGTSLISFSDKAKKKMYSRKTKPFSFYLDIKWLANFWGCDDQPRMYHHTIPVISLYSLRESLALIAEQGLENSWRQHREAAAYLHGRLQALGLQLFVKDPALRLPTVTTVAVPAGYDWRDIVSYVIDHFDIEIMGGLGPSTGKVLRIGLLGCNATRENVDRVTEALRAALQHCPKKKL","Homo sapiens","AGXT, AGT1, SPAT","Serine--pyruvate aminotransferase","1","5LUC"
"5LUD",,"X-RAY DIFFRACTION",2.79,55.88,"VAPOR DIFFUSION, HANGING DROP",8,"Tris, PEG8000",277,"10.1002/2211-5463.12201",,"5LUD",18.15,"1.25","1.25","Structure of Cyclophilin A in complex with 2,3-Diaminopyridine","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","HEL-S-69p, PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase","1","5LUD"
"5LUP",,"X-RAY DIFFRACTION",2.6,52.76,"VAPOR DIFFUSION, HANGING DROP",8.5,"Tris-HCl 0.1M PH8.5
PEG1500 2%
Glycerol 16%",298,"10.1074/jbc.M116.761510",,"5LUP",76.97,"2.032","2.032","Structures of DHBN domain of human BLM helicase","MDARQISLQQQLIHVMEHICKLIDTIPDDKLKLLDCGNELLQQRNIRRKLLTEV","Homo sapiens","BLM, RECQ2, RECQL3","BLM protein","1","5LUP"
,,,,,,,,,,,,,,,,"MDARQLSLQQQLIHVMEHICKLIDTIPDDKLKLLDCGNELLQQRNIRRKLLTEV","Homo sapiens","BLM, RECQ2, RECQL3","BLM protein","2","5LUP"
"5LUU",,"X-RAY DIFFRACTION",2.16,43.13,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2M Na2SO4
0.1M BTProp pH 8.5
20% PEG3350
10% EtGly",277,"10.1021/acsmedchemlett.6b00154","77X","5LUU",15.48,"1.61","1.61","Structure of the first bromodomain of BRD4 with a pyrazolo[4,3-c]pyridin fragment","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5LUU"
"5LV6",,"SOLUTION NMR",,,,,,,"10.1021/acs.biochem.6b01085",,"5LV6",9.47,,,"N-terminal motif dimerization of EGFR transmembrane domain in bicellar environment","EGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKR","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5LV6"
"5LVE",,"X-RAY DIFFRACTION",3,59,,7.5,"2.0 M AMMONIUM SULFATE, 0.1M HEPES PH 7.5, 1MM ZINC ACETATE",,"10.1110/ps.9.9.1852",,"5LVE",12.66,"2","2","STRUCTURE OF THE VARIABLE DOMAIN OF HUMAN IMMUNOGLOBULIN K-4 LIGHT CHAIN LEN","DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNSKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCAQYYSTPYSFGQGTKLEIKR","Homo sapiens","IGKV4-1","BENCE-JONES PROTEIN LEN","1","5LVE"
"5LVK",,"X-RAY DIFFRACTION",2.55,51.71,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M ammonium sulfate, 0.1 M sodium acetate, 21% PEG4000",298,,,"5LVK",30.24,"2.491","2.491","Human Lysozyme soaked with [H2Ind][trans-RuCl4(DMSO)(HInd)]","KVFERCELARTLKRLGMDGYRGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV","Homo sapiens","LYZ, LZM","Lysozyme C","1","5LVK"
"5LVL",,"X-RAY DIFFRACTION",2.16,43.12,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.2 M NA CITRATE, 0.1 M HEPES PH 7.5, 0.01 M DTT",293,"10.1016/j.chembiol.2016.06.017","537","5LVL",36,"1.4","1.4","Human PDK1 Kinase Domain in Complex with Compound PS653 Bound to the ATP-Binding Site","GAMDGTAAEPRPGAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEGLIFAKIIKLEYDFPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLT","Homo sapiens","PDPK1, PDK1","3-phosphoinositide-dependent protein kinase 1","1","5LVL"
"5LVM",,"X-RAY DIFFRACTION",2.13,42.35,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.2 M NA CITRATE, 0.1 M HEPES PH 7.5, 10 MM DTT",293,"10.1016/j.chembiol.2016.06.017",,"5LVM",35.68,"1.26","1.26","Human PDK1 Kinase Domain in Complex with Adenine Bound to the ATP-Binding Site","GAMDGTAAEPRPGAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEGLIFAKIIKLEYDFPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLT","Homo sapiens","PDPK1, PDK1","3-phosphoinositide-dependent protein kinase 1","1","5LVM"
"5LVN",,"X-RAY DIFFRACTION",2.16,42.95,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.2 M NA CITRATE, 0.1 M HEPES PH 7.5, 0.01 M DTT",293,"10.1016/j.chembiol.2016.06.017","ADN","5LVN",35.85,"1.379","1.379","Human PDK1 Kinase Domain in Complex with Adenosine Bound to the ATP-Binding Site","GAMDGTAAEPRPGAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEGLIFAKIIKLEYDFPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLT","Homo sapiens","PDPK1, PDK1","3-phosphoinositide-dependent protein kinase 1","1","5LVN"
"5LVO",,"X-RAY DIFFRACTION",2.18,43.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.2 M NA CITRATE, 0.1 M HEPES PH 7.5, 0.01 M DTT",293,"10.1016/j.chembiol.2016.06.017",,"5LVO",36.56,"1.09","1.09","Human PDK1 Kinase Domain in Complex with Allosteric Compound PSE10 Bound to the PIF-Pocket","GAMDGTAAEPRPGAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEGLIFAKIIKLEYDFPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLT","Homo sapiens","PDPK1, PDK1","3-phosphoinositide-dependent protein kinase 1","1","5LVO"
"5LVQ",,"X-RAY DIFFRACTION",3.41,63.94,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,"10.1021/acsmedchemlett.6b00154","2LX","5LVQ",28.97,"2.05","2.05","Crystal structure of human PCAF bromodomain in complex with compound-D (CPD-D), N-methyl-2-(tetrahydro-2H-pyran-4-yloxy)benzamide","SMGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLID","Homo sapiens","KAT2B, PCAF","Histone acetyltransferase KAT2B","1","5LVQ"
"5LVR",,"X-RAY DIFFRACTION",3.38,63.65,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,"10.1021/acsmedchemlett.6b00154","78Y","5LVR",29,"2.05","2.05","Crystal structure of human PCAF bromodomain in complex with compound-E (CPD-E)","SMGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLID","Homo sapiens","KAT2B, PCAF","Histone acetyltransferase KAT2B","1","5LVR"
"5LVS",,"X-RAY DIFFRACTION",2.91,57.77,"VAPOR DIFFUSION, HANGING DROP",5.3,"Ammonium sulfate 200 mM
Sodium acetate 100 mM
PEG 4000 24%
NaN3 3 mM",293,"10.1021/jacs.7b00184",,"5LVS",63.41,"1.42","1.42","Self-assembled protein-aromatic foldamer complexes with 2:3 and 2:2:1 stoichiometries","SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5LVS"
"5LVV",,"X-RAY DIFFRACTION",3.22,61.78,"VAPOR DIFFUSION, SITTING DROP",8.5,"3.5M sodium formate, 0.1M Tris pH 8.5",291,"10.1098/rsob.170078","UDP","5LVV",84.87,"2.54","2.54","Human OGT in complex with UDP and fused substrate peptide (Tab1)","HHHHHHVPYSSAQSTSKTSVTLSLGGGTHADSLNNLANIKREQGNIEEAVRLYRKALEVFPEFAAAHSNLASVLQQQGKLQEALMHYKEAIRISPTFADAYSNMGNTLKEMQDVQGALQCYTRAIQINPAFADAHSNLASIHKDSGNIPEAIASYRTALKLKPDFPDAYCNLAHCLQIVCDWTDYDERMKKLVSIVADQLEKNRLPSVHPHHSMLYPLSHGFRKAIAERHGNLCLDKINVLHKPPYEHPKDLKLSDGRLRVGYVSSDFGNHPTSHLMQSIPGMHNPDKFEVFCYALSPDDGTNFRVKVMAEANHFIDLSQIPCNGKAADRIHQDGIHILVNMNGYTKGARNELFALRPAPIQAMWLGYPGTSGALFMDYIITDQETSPAEVAEQYSEKLAYMPHTFFIGDHANMFPHLKKKAVIDFKSNGHIYDNRIVLNGIDLKAFLDSLPDVKIVKMKCPDGGDNADSSNTALNMPVIPMNTIAEAVIEMINRGQIQITINGFSISNGLATTQINNKAATGEEVPRTIIVTTRSQYGLPEDAIVYCNFNQLYKIDPSTLQMWANILKRVPNSVLWLLRFPAVGEPNIQQYAQNMGLPQNRIIFSPVAPKEEHVRRGQLADVCLDTPLCNGHTTGMDVLWAGTPMVTMPGETLASRVAASQLTCLGCLELIAKNRQEYEDIAVKLGTDLEYLKKVRGKVWKQRISSPLFNTKQYTMELERLYLQMWEHYAAGNKPDHMIKPVEVTESA","Homo sapiens","OGT","UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit,UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit","1","5LVV"
,,,,,,,,,,,,,,,,,"Homo sapiens","OGT"
"5LVX",,"X-RAY DIFFRACTION",2.88,57.34,"VAPOR DIFFUSION",4.5,"20 %w/v PEG 3350
0.2 M (NH4)2SO4
0.1 M Na Acet pH=4.50
0.50 %w/v LDAO",293,"10.1021/jacs.7b13003",,"5LVX",230.63,"2.2","2.2","Crystal structure of glucocerebrosidase with an inhibitory quinazoline modulator","ARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ","Homo sapiens","GBA, GC, GLUC","Glucosylceramidase","1","5LVX"
"5LW9",,"X-RAY DIFFRACTION",4.26,71.12,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES PH 8.0, 0.8M                   POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE                 MONOBASIC",277,,"5UJ","5LW9",56.46,"2.3","2.3","Crystal structure of human JARID1B in complex with S40563a","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKINK","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","Lysine-specific demethylase 5B,Lysine-specific demethylase 5B","1","5LW9"
,,,,,,,,,,,,,,,,,"Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1"
"5LWB",,"X-RAY DIFFRACTION",4.4,72.03,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 0.8M Pottassium Phosphate- dibasic, 0.8M Sodium Phosphate monobasic",277,,,"5LWB",56.67,"2.39","2.39","Crystal structure of human JARID1B in complex with S40650a","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKINK","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","Lysine-specific demethylase 5B,Lysine-specific demethylase 5B,Lysine-specific demethylase 5B","1","5LWB"
,,,,,,,,,,,,,,,,,"Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1"
,,,,,,,,,,,,,,,,,"Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1"
"5LWE",,"X-RAY DIFFRACTION",2.98,58.81,"LIPIDIC CUBIC PHASE",8,"0.1 M BICINE
0.2 M SODIUM MALONATE
28-43% PEG400",293,"10.1038/nature20606","79K","5LWE",85.15,"2.8","2.8","Crystal structure of the human CC chemokine receptor type 9 (CCR9) in complex with vercirnon","ASMEDYVNFNFEDFYCEKNNVRQFASHFLPPLYWLVFIVGALGNSLVILVYWYCARAKTATDMFLLNLAIADLLFLVTLPFWAIAAADQWKFQTFMCKVVNSMYKMNFYSCVLLIMCICVDRYIAIAQAMRAHTWREKRLLYSKMVCFTIWVLAAALCIPEILYSQIKEESGIAICTMVYPSDESTKLKSAVLALKVILGFFLPFVVMACCYTIIIHTLIQAKKSSKHKALKATITVLTVFVLSQFPYNCILLVQTIDAYAMFISNCAVSTAIDICFQVTQAIAFFHSCLNPVLYVFVGERFRRDLVKTLKNLGAISQAAAHHHHHHHHHH","Homo sapiens","CCR9, GPR28","C-C chemokine receptor type 9","1","5LWE"
"5LWM",,"X-RAY DIFFRACTION",2.01,38.83,"VAPOR DIFFUSION, SITTING DROP",,"18-25% PEG 3350, 0.1-0.2 M MgCl2 and 0.1 M MES, pH 5.5-6.1",277.15,"10.1016/j.chembiol.2016.10.008","79T","5LWM",34.35,"1.55","1.55","Crystal structure of JAK3 in complex with Compound 4 (FM381)","SMQDPTIFEERHLKYISQLGKGNFGSVELCRYDPLGDNTGALVAVKQLQHSGPDQQRDFQREIQILKALHSDFIVKYRGVSYGPGRQSLRLVMEYLPSGCLRDFLQRHRARLDASRLLLYSSQICKGMEYLGSRRCVHRALAARNILVESEAHVKIADFGLAKLLPLDKDYYVVREPGQSPIFWYAPESLSDNIFSRQSDVWSFGVVLYELFTYCDKSCSPSAEFLRMMGSERDVPALSRLLELLEEGQRLPAPPACPAEVHELMKLCWAPSPQDRPSFSALGPQLDMLWSGSR","Homo sapiens","JAK3","Tyrosine-protein kinase JAK3","1","5LWM"
"5LWN",,"X-RAY DIFFRACTION",2.01,38.77,"VAPOR DIFFUSION, SITTING DROP",,"18-25% PEG 3350, 0.1-0.2 M MgCl2 and 0.1 M MES, pH 5.5-6.1",277.15,"10.1016/j.chembiol.2016.10.008","79R","5LWN",34.81,"1.6","1.6","Crystal structure of JAK3 in complex with Compound 5 (FM409)","SMQDPTIFEERHLKYISQLGKGNFGSVELCRYDPLGDNTGALVAVKQLQHSGPDQQRDFQREIQILKALHSDFIVKYRGVSYGPGRQSLRLVMEYLPSGCLRDFLQRHRARLDASRLLLYSSQICKGMEYLGSRRCVHRALAARNILVESEAHVKIADFGLAKLLPLDKDYYVVREPGQSPIFWYAPESLSDNIFSRQSDVWSFGVVLYELFTYCDKSCSPSAEFLRMMGSERDVPALSRLLELLEEGQRLPAPPACPAEVHELMKLCWAPSPQDRPSFSALGPQLDMLWSGSR","Homo sapiens","JAK3","Tyrosine-protein kinase JAK3","1","5LWN"
"5LWP",,"X-RAY DIFFRACTION",3.49,64.75,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Hepes pH8.5, 0.1M MgCl2, 7% PEG6000",278,"10.1016/j.bmcl.2016.10.023","79U","5LWP",28.99,"2.4","2.4","Discovery of phenoxyindazoles and phenylthioindazoles as RORg inverse agonists","HMASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELF","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5LWP"
"5LX3",,"X-RAY DIFFRACTION",2.45,49.88,"VAPOR DIFFUSION, HANGING DROP",8.5,"Tris 100mM - PEG8000 16% - pH8,5",292,,,"5LX3",112.52,"2.1","2.1","CRYSTAL STRUCTURE OF VISFATIN IN COMPLEX WITH SAR154782.","GAMNPAAEAEFNILLATDSYKVTHYKQYPPNTSKVYSYFECREKKTENSKLRKVKYEETVFYGLQYILNKYLKGKVVTKEKIQEAKDVYKEHFQDDVFNEKGWNYILEKYDGHLPIEIKAVPEGFVIPRGNVLFTVENTDPECYWLTNWIETILVQSWYPITVATNSREQKKILAKYLLETSGNLDGLEYKLHDFGYRGVSSQETAGIGASAHLVNFKGTDTVAGLALIKKYYGTKDPVPGYSVPAAEHSTITAWGKDHEKDAFEHIVTQFSSVPVSVVSDSYDIYNACEKIWGEDLRHLIVSRSTQAPLIIRPDSGNPLDTVLKVLEILGKKFPVTENSKGYKLLPPYLRVIQGDGVDINTLQEIVEGMKQKMWSIENIAFGSGGGLLQKLTRDLLNCSFKCSYVVTNGLGINVFKDPVADPNKRSKKGRLSLHRTPAGNFVTLEEGKGDLEEYGQDLLHTVFKNGKVTKSYSFDEIRKNAQLNIELEAAHH","Homo sapiens","NAMPT, PBEF, PBEF1","Nicotinamide phosphoribosyltransferase","1","5LX3"
"5LX5",,"X-RAY DIFFRACTION",2.41,48.92,"VAPOR DIFFUSION, HANGING DROP",8.8,"CHES 100mM - PEG8000 14% - Malonate Na 200mM - pH8.8",292,,,"5LX5",113.29,"1.88","1.88","CRYSTAL STRUCTURE OF VISFATIN IN COMPLEX WITH SAR154782-RP.","GAMNPAAEAEFNILLATDSYKVTHYKQYPPNTSKVYSYFECREKKTENSKLRKVKYEETVFYGLQYILNKYLKGKVVTKEKIQEAKDVYKEHFQDDVFNEKGWNYILEKYDGHLPIEIKAVPEGFVIPRGNVLFTVENTDPECYWLTNWIETILVQSWYPITVATNSREQKKILAKYLLETSGNLDGLEYKLHDFGYRGVSSQETAGIGASAHLVNFKGTDTVAGLALIKKYYGTKDPVPGYSVPAAEHSTITAWGKDHEKDAFEHIVTQFSSVPVSVVSDSYDIYNACEKIWGEDLRHLIVSRSTQAPLIIRPDSGNPLDTVLKVLEILGKKFPVTENSKGYKLLPPYLRVIQGDGVDINTLQEIVEGMKQKMWSIENIAFGSGGGLLQKLTRDLLNCSFKCSYVVTNGLGINVFKDPVADPNKRSKKGRLSLHRTPAGNFVTLEEGKGDLEEYGQDLLHTVFKNGKVTKSYSFDEIRKNAQLNIELEAAHH","Homo sapiens","NAMPT, PBEF, PBEF1","Nicotinamide phosphoribosyltransferase","1","5LX5"
"5LX6",,"X-RAY DIFFRACTION",3.04,59.53,"VAPOR DIFFUSION, SITTING DROP",7,"12% PEG3350, 0.1 M Ammonium tartrate",277,"10.1021/acs.jmedchem.6b00990","78P","5LX6",43.75,"1.25","1.25","Human PARP10 (ARTD10), catalytic fragment in complex with PARP inhibitor Veliparib","SMNLERLAENTGEFQEVVRAFYDTLDAARSSIRVVRVERVSHPLLQQQYELYRERLLQRCERRPVEQVLYHGTTAPAVPDICAHGFNRSFCGRNATVYGKGVYFARRASLSVQDRYSPPNADGHKAVFVARVLTGDYGQGRRGLRAPPLRGPGHVLLRYDSAVDCICQPSIFVIFHDTQALPTHLITCEHV","Homo sapiens","PARP10","Poly [ADP-ribose] polymerase 10","1","5LX6"
"5LXC",,"X-RAY DIFFRACTION",3.04,59.5,"VAPOR DIFFUSION, SITTING DROP",5.5,"25% PEG 3350, 0.2 M NaCl and 0.1 M bis-tris, pH 5.5",277.15,"10.1021/acs.jmedchem.6b01083","7AA","5LXC",95.43,"2.15","2.15","Crystal structure of DYRK2 in complex with EHT 5372 (Compound 1)","SMGKVKATPMTPEQAMKQYMQKLTAFEHHEIFSYPEIYFLGLNAKKRQGMTGGPNNGGYDDDQGSYVQVPHDHVAYRYEVLKVIGKGSFGQVVKAYDHKVHQHVALKMVRNEKRFHRQAAEEIRILEHLRKQDKDNTMNVIHMLENFTFRNHICMTFELLSMNLYELIKKNKFQGFSLPLVRKFAHSILQCLDALHKNRIIHCDLKPENILLKQQGRSGIKVIDFGSSCYEHQRVYTYIQSRFYRAPEVILGARYGMPIDMWSLGCILAELLTGYPLLPGEDEGDQLACMIELLGMPSQKLLDASKRAKNFVSSKGYPRYCTVTTLSDGSVVLNGGRSRRGKLRGPPESREWGNALKGCDDPLFLDFLKQCLEWDPAVRMTPGQALRHPWLRRRLPKPPTGEKTSVKR","Homo sapiens","DYRK2","Dual specificity tyrosine-phosphorylation-regulated kinase 2","1","5LXC"
"5LXD",,"X-RAY DIFFRACTION",3.12,60.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.5 M Li2SO4 and 0.1 M HEPES, pH 7.5",277.15,"10.1021/acs.jmedchem.6b01083",,"5LXD",95.33,"2.58","2.58","Crystal structure of DYRK2 in complex with EHT 1610 (compound 2)","SMGKVKATPMTPEQAMKQYMQKLTAFEHHEIFSYPEIYFLGLNAKKRQGMTGGPNNGGYDDDQGSYVQVPHDHVAYRYEVLKVIGKGSFGQVVKAYDHKVHQHVALKMVRNEKRFHRQAAEEIRILEHLRKQDKDNTMNVIHMLENFTFRNHICMTFELLSMNLYELIKKNKFQGFSLPLVRKFAHSILQCLDALHKNRIIHCDLKPENILLKQQGRSGIKVIDFGSSCYEHQRVYTYIQSRFYRAPEVILGARYGMPIDMWSLGCILAELLTGYPLLPGEDEGDQLACMIELLGMPSQKLLDASKRAKNFVSSKGYPRYCTVTTLSDGSVVLNGGRSRRGKLRGPPESREWGNALKGCDDPLFLDFLKQCLEWDPAVRMTPGQALRHPWLRRRLPKPPTGEKTSVKR","Homo sapiens","DYRK2","Dual specificity tyrosine-phosphorylation-regulated kinase 2","1","5LXD"
"5LXF",,"X-RAY DIFFRACTION",1.88,34.54,"VAPOR DIFFUSION, SITTING DROP",5.8,"0.03M Bis-Tris pH 6.5; 0.17M Mg Formate; 16.67% PEG 3350; 0.07M Bis-Tris pH 5.5",293,"10.1042/BCJ20170276",,"5LXF",42.71,"2","2","Crystal structure of the human Macrophage Colony Stimulating Factor M- CSF_C31S variant","YVDYKDDDDKEFEEVSEYCSHMIGSGHLQSLQRLIDSQMETSSQITFEFVDQEQLKDPVCYLKKAFLLVQDIMEDTMRFRDNTPNAIAIVQLQELSLRLKSCFTKDYEEHDKACVRTFYETPLQLLEKVKNVFNETKNLLDKDWNIFSKNCNNSFAECSSQGHERQSEGSPRHHHHHHAAAN","Homo sapiens","CSF1","Macrophage colony-stimulating factor 1","1","5LXF"
"5LXN",,"X-RAY DIFFRACTION",2.989,58.9,"VAPOR DIFFUSION, SITTING DROP",8.5,"35 % PEG 400, 0.05 M Sodium sulphate, 0.05 M Lithium sulphate, 0.05 M Tris pH 8.5",289.15,,,"5LXN",76.83,"2.08","2.08","Coiled-coil protein","TQEGQRYQALKAHAEEKLQLANEEIAQVRSKAQAEALALQASLRKEQMRIQSLEKTVEQKTKENEELTRICDDLISKMEKI","Homo sapiens","TACC3, ERIC1","Transforming acidic coiled-coil-containing protein 3","1","5LXN"
"5LXO",,"X-RAY DIFFRACTION",2.54,51.6,"VAPOR DIFFUSION, SITTING DROP",8.5,"35 % PEG 400, 0.05 M Sodium sulphate, 0.05 M Lithium sulphate, 0.05 M Tris pH 8.5",289.15,,,"5LXO",76.08,"2.179","2.179","Coiled-coil protein","TQEGQRYQALKAHAEEKLQLANEEIAQVRSKAQAEALALQASLRKEQMRIQSLEKTVEQKTKENEELTRICDDLISKMEKI","Homo sapiens","TACC3, ERIC1","Transforming acidic coiled-coil-containing protein 3","1","5LXO"
"5LXP",,"X-RAY DIFFRACTION",2.46,50.04,"VAPOR DIFFUSION, SITTING DROP",5.8,"17.5% PEG3350, 0.175 Sodium nitrate, 0.1M Bis-Tris",293,"10.1002/anie.201609655","7AG","5LXP",45.13,"2.07","2.07","Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor H5","SMDMKQQNFCVVELLPSDPEYNTVASKFNQTCSHFRIEKIERIQNPDLWNSYQAKKKTMDAKNGQTMNEKQLFHGTDAGSVPHVNRNGFNRSYAGKNAVAYGKGTYFAVNANYSANDTYSRPDANGRKHVYYVRVLTGIYTHGNHSLIVPPSKNPQNPTDLYDTVTDNVHHPSLFVAFYDYQAYPEYLITFRK","Homo sapiens","PARP14, BAL2, KIAA1268","Poly [ADP-ribose] polymerase 14","1","5LXP"
"5LXX",,"X-RAY DIFFRACTION",2.43,49.39,"VAPOR DIFFUSION, SITTING DROP",5.5,"bis-tris, PEG3350, ammonium sulphate, glycerol",293,"10.1007/s00726-016-2376-z",,"5LXX",111.09,"1.25","1.25","High-resolution structure of human collapsin response mediator protein 2","MHHHHHHSSGVDLGTENLYFQSMTSDRLLIKGGKIVNDDQSFYADIYMEDGLIKQIGENLIVPGGVKTIEAHSRMVIPGGIDVHTRFQMPDQGMTSADDFFQGTKAALAGGTTMIIDHVVPEPGTSLLAAFDQWREWADSKSCCDYSLHVDISEWHKGIQEEMEALVKDHGVNSFLVYMAFKDRFQLTDCQIYEVLSVIRDIGAIAQVHAENGDIIAEEQQRILDLGITGPEGHVLSRPEEVEAEAVNRAITIANQTNCPLYITKVMSKSSAEVIAQARKKGTVVYGEPITASLGTDGSHYWSKNWAKAAAFVTSPPLSPDPTTPDFLNSLLSCGDLQVTGSAHCTFNTAQKAVGKDNFTLIPEGTNGTEERMSVIWDKAVVTGKMDENQFVAVTSTNAAKVFNLYPRKGRIAVGSDADLVIWDPDSVKTISAKTHNSSLEYNIFEGMECRGSPLVVISQGKIVLEDGTLHVTEGSGRYIPRKPFPDFVYKRIKARSRLAE","Homo sapiens","DPYSL2, CRMP2, ULIP2","Dihydropyrimidinase-related protein 2","1","5LXX"
"5LYG",,"X-RAY DIFFRACTION",2.67,53.85,"VAPOR DIFFUSION, HANGING DROP",7,"20% PEG 3350 and 0.2M Sodium malonate dibasic monohydrate",298,"10.1021/acschembio.7b00694",,"5LYG",21.78,"1.6","1.6","CRYSTAL STRUCTURE OF INTRACELLULAR B30.2 DOMAIN OF BTN3A1 BOUND TO MALONATE","SAYNEWKKALFKPADVILDPKTANPILLVSEDQRSVQRAKEPQDLPDNPERFNWHYCVLGCESFISGRHYWEVEVGDRKEWHIGVCSKNVQRKGWVKMTPENGFWTMGLTDGNKYRTLTEPRTNLKLPKPPKKVGVFLDYETGDISFYNAVDGSHIHTFLDVSFSEALYPVFRILTLEPTALTICPA","Homo sapiens","BTN3A1, BTF5","Butyrophilin subfamily 3 member A1","1","5LYG"
"5LYH",,"X-RAY DIFFRACTION",2.75,55.21,"VAPOR DIFFUSION, SITTING DROP",6.8,"22.5% PEG3350, 0.225M Sodium malonate",293,"10.1002/anie.201609655","7B8","5LYH",45.35,"2.17","2.17","Human PARP14 (ARTD8), catalytic fragment in complex with inhibitor H10","SMDMKQQNFCVVELLPSDPEYNTVASKFNQTCSHFRIEKIERIQNPDLWNSYQAKKKTMDAKNGQTMNEKQLFHGTDAGSVPHVNRNGFNRSYAGKNAVAYGKGTYFAVNANYSANDTYSRPDANGRKHVYYVRVLTGIYTHGNHSLIVPPSKNPQNPTDLYDTVTDNVHHPSLFVAFYDYQAYPEYLITFRK","Homo sapiens","PARP14, BAL2, KIAA1268","Poly [ADP-ribose] polymerase 14","1","5LYH"
"5LYK",,"X-RAY DIFFRACTION",2.6,52.65,"VAPOR DIFFUSION, HANGING DROP",7,"20% PEG 3350 and  0.2M Ammonium Citrate tribasic",298,"10.1021/acschembio.7b00694",,"5LYK",21.74,"1.7","1.7","CRYSTAL STRUCTURE OF INTRACELLULAR B30.2 DOMAIN OF BTN3A1 BOUND TO CITRATE","SAYNEWKKALFKPADVILDPKTANPILLVSEDQRSVQRAKEPQDLPDNPERFNWHYCVLGCESFISGRHYWEVEVGDRKEWHIGVCSKNVQRKGWVKMTPENGFWTMGLTDGNKYRTLTEPRTNLKLPKPPKKVGVFLDYETGDISFYNAVDGSHIHTFLDVSFSEALYPVFRILTLEPTALTICPA","Homo sapiens","BTN3A1, BTF5","Butyrophilin subfamily 3 member A1","1","5LYK"
"5LYO",,"X-RAY DIFFRACTION",2.45,49.79,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES 6.5, 2.0 M ammonium sulfate",293,"10.1074/jbc.RA118.004126",,"5LYO",89.42,"2.498","2.498","Crystal structure of the zymogen matriptase catalytic domain","SMNSHHHHHHGTACGLRSFTRQAAVVGGTDADEGEWPWQVSLHALGQGHICGASLISPNWLVSAAHCYIDDRGFRYSDPTQWTAFLGLHDQSQRSAPGVQERRLKRIISHPFFNDFTFDYDIALLELEKPAEYSSMVRPICLPDASHVFPAGKAIWVTGWGHTQYGGTGALILQKGEIRVIQQTTCENLLPQQITPRMMCVGFLSGGVDSCQGDAGGPLSSVEADGRIFQAGVVSWGDGCAQRNKPGVYTRLPLFRDWIKENTGV","Homo sapiens","ST14, PRSS14, SNC19, TADG15","Suppressor of tumorigenicity 14 protein","1","5LYO"
"5LYS",,"X-RAY DIFFRACTION",2.06,40.26,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 1000, 50 mM Tris pH 7.5, 50 to 75 mM NaCl, 50 mM MgCl2, 3% DMSO",277,"10.1093/nar/gkw1351",,"5LYS",37.1,"2.32","2.32","The crystal structure of 7SK 5'-hairpin - Gold derivative","GGGAUCUGUCACCCCAUUGAUCGCCUUCGGGCUGAUCUGGCUGGCUAGGCGGGUCCC","Homo sapiens",,"7SK RNA","1","5LYS"
"5LYU",,"X-RAY DIFFRACTION",2.02,39.14,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 1000, 50 mM Tris pH 7.5, 50 to 75 mM NaCl, 50 mM MgCl2",277,"10.1093/nar/gkw1351",,"5LYU",37.47,"2.2","2.2","The native crystal structure of 7SK 5'-hairpin","GGGGAUCUGUCACCCCAUUGAUCGCCUUCGGGCUGAUCUGGCUGGCUAGGCGGGUCCC","Homo sapiens",,"7SK RNA","1","5LYU"
"5LYV",,"X-RAY DIFFRACTION",2.04,39.74,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 1000, 50 mM Tris pH 7.5, 50 to 75 mM NaCl, 50 mM MgCl2, 3% DMSO",277,"10.1093/nar/gkw1351",,"5LYV",37.01,"2.35","2.35","The crystal structure of 7SK 5'-hairpin - Osmium derivative","GGGAUCUGUCACCCCAUUGAUCGCCUUCGGGCUGAUCUGGCUGGCUAGGCGGGUCCC","Homo sapiens",,"7SK RNA","1","5LYV"
"5LYW",,"X-RAY DIFFRACTION",2.66,53.73,"VAPOR DIFFUSION, HANGING DROP",6,"24% methanol, 100 mM citrate",277,"10.1016/j.bmcl.2016.12.019","7BH","5LYW",42.89,"1.69","1.69","CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX; WITH AN INHIBITOR 6-((R)-2-o-Tolyloxymethyl-pyrrolidin-1-yl)-9H-purine","MGPKVQTDPPSVPICDLYPNGVFPKGQECEYPPTQDGRTAAWRTTSEEKKALDQASEEIWNDFREAAEAHRQVRKYVMSWIKPGMTMIEICEKLEDCSRKLIKENGLNAGLAFPTGCSLNNCAAHYTPNAGDTTVLQYDDICKIDFGTHISGRIIDCAFTVTFNPKYDTLLKAVKDATNTGIKCAGIDVRLCDVGEAIQEVMESYEVEIDGKTYQVKPIRNLNGHSIGQYRIHAGKTVPIVKGGEATRMEEGEVYAIETFGSTGKGVVHDDMECSHYMKNFDVGHVPIRLPRTKHLLNVINENFGTLAFCRRWLDRLGESKYLMALKNLCDLGIVDPYPPLCDIKGSYTAQFEHTILLRPTCKEVVSRGDDYHHHHHH","Homo sapiens","METAP2, MNPEP, P67EIF2","Methionine aminopeptidase 2","1","5LYW"
"5LYX",,"X-RAY DIFFRACTION",2.65,53.56,"VAPOR DIFFUSION, HANGING DROP",6,"20% methanol, 0.1 M citrate",277,"10.1016/j.bmcl.2016.12.019","7BF","5LYX",42.93,"1.9","1.9","CRYSTAL STRUCTURE OF HUMAN METHIONINE AMINOPEPTIDASE-2 IN COMPLEX; WITH AN INHIBITOR 5-((R)-1-[1,2,4]Triazolo[1,5-a]pyrimidin-7-yl-pyrrolidin-2-ylmethoxy)-isoquinoline","MGPKVQTDPPSVPICDLYPNGVFPKGQECEYPPTQDGRTAAWRTTSEEKKALDQASEEIWNDFREAAEAHRQVRKYVMSWIKPGMTMIEICEKLEDCSRKLIKENGLNAGLAFPTGCSLNNCAAHYTPNAGDTTVLQYDDICKIDFGTHISGRIIDCAFTVTFNPKYDTLLKAVKDATNTGIKCAGIDVRLCDVGEAIQEVMESYEVEIDGKTYQVKPIRNLNGHSIGQYRIHAGKTVPIVKGGEATRMEEGEVYAIETFGSTGKGVVHDDMECSHYMKNFDVGHVPIRLPRTKHLLNVINENFGTLAFCRRWLDRLGESKYLMALKNLCDLGIVDPYPPLCDIKGSYTAQFEHTILLRPTCKEVVSRGDDYHHHHHH","Homo sapiens","METAP2, MNPEP, P67EIF2","Methionine aminopeptidase 2","1","5LYX"
"5LYY",,"X-RAY DIFFRACTION",2.45,49.88,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293,"10.1021/acs.jmedchem.6b01427","7BJ","5LYY",44.51,"2.17","2.17","Fragment-based inhibitors of Lipoprotein associated Phospholipase A2","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5LYY"
"5LZ1",,"X-RAY DIFFRACTION",3.34,63.16,"VAPOR DIFFUSION, SITTING DROP",,"100mM Tris pH 8.8, 25% w/v PEG 3.350, 20% glycerol, 20mM 2-propanol/1,2 -propanediol/1,3-propanediol/1-butanol/1,4-butanediol/1,6-hexanediol",291,"10.1016/j.str.2016.11.021",,"5LZ1",19.39,"2","2","Crystal structure of human ACBD3 GOLD domain","GAMESLPVIAAPSMWTRPQIKDFKEKIQQDADSVITVGRGEVVTVRVPTHEEGSYLFWEFATDNYDIGFGVYFEWTDSPNTAVSVHVSESSDDDEEEEENIGCEEKAKKNANKPLLDEIVPVYRRDCHEEVYAGSHQYPGRGVYLLKFDNSYSLWRSKSVYYRVYYTR","Homo sapiens","ACBD3, GCP60, GOCAP1, GOLPH1","Golgi resident protein GCP60","1","5LZ1"
"5LZ2",,"X-RAY DIFFRACTION",2.44,49.63,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl,",293,"10.1021/acs.jmedchem.6b01427","7BX","5LZ2",44.48,"2.1","2.1","Fragment-based inhibitors of Lipoprotein associated Phospholipase A2","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5LZ2"
"5LZ4",,"X-RAY DIFFRACTION",2.45,49.78,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293,"10.1021/acs.jmedchem.6b01427","7BW","5LZ4",44.55,"2.07","2.07","Fragment-based inhibitors of Lipoprotein associated Phospholipase A2","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5LZ4"
"5LZ5",,"X-RAY DIFFRACTION",2.36,47.9,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293,"10.1021/acs.jmedchem.6b01427","7K4","5LZ5",44.61,"2.05","2.05","Fragment-based inhibitors of Lipoprotein associated Phospholipase A2","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5LZ5"
"5LZ7",,"X-RAY DIFFRACTION",2.45,49.89,"VAPOR DIFFUSION, SITTING DROP",,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293,"10.1021/acs.jmedchem.6b01427","7BK","5LZ7",44.58,"2.1","2.1","Fragment-based inhibitors of Lipoprotein associated Phospholipase A2","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5LZ7"
"5LZ8",,"X-RAY DIFFRACTION",2.28,46.14,"VAPOR DIFFUSION, SITTING DROP",7.4,"28.0%w/v PEG 3350, 0.1M HEPES/NaOHpH=7.4, 1.3M NaCl",293,"10.1021/acs.jmedchem.6b01427","7BP","5LZ8",44.58,"2.11","2.11","Fragment-based inhibitors of Lipoprotein associated Phospholipase A2","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5LZ8"
"5LZ9",,"X-RAY DIFFRACTION",2.46,50.03,"VAPOR DIFFUSION, SITTING DROP",7.4,"0.1M HEPES/NaOHpH=7.4, 1.3M NaCl, 32.0%w/v PEG 3350,",293,"10.1021/acs.jmedchem.6b01427","7BR","5LZ9",44.66,"2.06","2.06","Fragment-based inhibitors of Lipoprotein associated Phospholipase A2","MAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHHHHHH","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5LZ9"
"5LZK",,"X-RAY DIFFRACTION",2.09,41.21,"VAPOR DIFFUSION, SITTING DROP",,"29% PEG3350
0.1M bis-tris-propane pH 8.0
0.2M sodium iodide
10% ethylene glycol",277,,,"5LZK",42.51,"1.575","1.575","Structure of the domain of unknown function DUF1669 from human FAM83B","SMGGTHIDLLFHPPRAHLLTIKETIRKMIKEARKVIALVMDIFTDVDIFKEIVEASTRGVSVYILLDESNFNHFLNMTEKQGCSVQRLRNIRVRTVKGQDYLSKTGAKFHGKMEQKFLLVDCQKVMYGSYSYMWSFEKAHLSMVQIITGQLVESFDEEFRTLYARSCVPSSFAQEESARV","Homo sapiens","FAM83B, C6orf143","Protein FAM83B","1","5LZK"
"5M0A",,"SOLUTION NMR",,,,,,,,,"5M0A",9.34,,,"Solution structure of isolated 15th Fibronectin III domain from human fibronectin","NASTGQEALSQTTISWAPFQDTSEYIISCHPVGTDEEPLQFRVPGTSTSATLTGLTRGATYNIIVEALKDQQRHKVREEVVTVGNS","Homo sapiens","FN1, FN","Fibronectin","1","5M0A"
"5M1L",,"SOLUTION NMR",,,,,,,"10.1038/ncomms15355",,"5M1L",9.53,,,"Structure of DNA AGCGA-quadruplex adopted by 15-mer d(GCGAGGGAGCGAGGG), VK34, oligonucleotide found in regulatory region of the PLEKHG3 human gene","GCGAGGGAGCGAGGG","Homo sapiens",,"DNA (5'-D(*GP*CP*GP*AP*GP*GP*GP*AP*GP*CP*GP*AP*GP*GP*G)-3')","1","5M1L"
"5M1R",,"X-RAY DIFFRACTION",1.93,35.83,"VAPOR DIFFUSION, HANGING DROP",6.5,"Sodium Citrate, 1.6 M",294,"10.1371/journal.pone.0199191",,"5M1R",45.08,"1.64","1.64","X-ray structure of human G166D PGK-1 mutant","SLSNKLTLDKLDVKGKRVVMRVDFNVPMKNNQITNNQRIKAAVPSIKFCLDNGAKSVVLMSHLGRPDGVPMPDKYSLEPVAVELKSLLGKDVLFLKDCVGPEVEKACANPAAGSVILLENLRFHVEEEGKGKDASGNKVKAEPAKIEAFRASLSKLGDVYVNDAFDTAHRAHSSMVGVNLPQKAGGFLMKKELNYFAKALESPERPFLAILGGAKVADKIQLINNMLDKVNEMIIGGGMAFTFLKVLNNMEIGTSLFDEEGAKIVKDLMSKAEKNGVKITLPVDFVTADKFDENAKTGQATVASGIPAGWMGLDCGPESSKKYAEAVTRAKQIVWNGPVGVFEWEAFARGTKALMDEVVKATSRGCITIIGGGDTATCCAKWNTEDKVSHVSTGGGASLELLEGKVLPGVDALSNI","Homo sapiens","PGK1, PGKA, MIG10, OK/SW-cl.110","Phosphoglycerate kinase 1","1","5M1R"
"5M23",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",,"12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.02 M carboxylic acid 0.1 M bicine/Trizma base pH 8.5",291,"10.1039/c7sc00137a",,"5M23",48.84,"1.97","1.97","Modulation of MLL1 Methyltransferase Activity","MGSSHHHHHHSSGLVPRGSHMASMSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKKTTPLRRLMEAFAKRQGKEMDSLRFLYDGIRIQADQTPEDLDMEDNDIIEAHREQIGGSATQSKPTPVKPNYALKFTLAGHTKAVSSVKFSPNGEWLASSSADKLIKIWGAYDGKFEKTISGHKLGISDVAWSSDSNLLVSASDDKTLKIWDVSSGKCLKTLKGHSNYVFCCNFNPQSNLIVSGSFDESVRIWDVKTGKCLKTLPAHSDPVSAVHFNRDGSLIVSSSYDGLCRIWDTASGQCLKTLIDDDNPPVSFVKFSPNGKYILAATLDNTLKLWDYSKGKCLKTYTGHKNEKYCIFANFSVTGGKWIVSGSEDNLVYIWNLQTKEIVQKLQGHTDVVISTACHPTENIIASAALENDKTIKLWKSDC","Homo sapiens","WDR5, BIG3","WD repeat-containing protein 5","1","5M23"
"5M24",,"X-RAY DIFFRACTION",2.49,50.55,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Calcium Chloride, 0.1 M, Tris HCl pH 7.5, 14% Peg 6K",290,"10.1371/journal.pone.0171043","9CR","5M24",29.19,"1.69","1.69","RARg mutant-S371E","GSHMDSYELSPQLEELITKVSKAHQETFPSLCQLGKYTTNSSADHRVQLDLGLWDKFSELATKCIIKIVEFAKRLPGFTGLSIADQITLLKAACLDILMLRICTRYTPEQDTMTFSDGLTLNRTQMHNAGFGPLTDLVFAFAGQLLPLEMDDTETGLLSAICLICGDRMDLEEPEKVDKLQEPLLEALRLYARRRRPEQPYMFPRMLMKITDLRGISTKGAERAITLKMEIPGPMPPLIREMLENPEMFE","Homo sapiens","RARG, NR1B3","Retinoic acid receptor gamma","1","5M24"
"5M25",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",,"12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD 0.02 M carboxylic acid 0.1 M bicine/Trizma base pH 8.5",291,"10.1039/c7sc00137a",,"5M25",48.74,"2.43","2.43","Modulation of MLL1 Methyltransferase Activity","MGSSHHHHHHSSGLVPRGSHMASMSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIKKTTPLRRLMEAFAKRQGKEMDSLRFLYDGIRIQADQTPEDLDMEDNDIIEAHREQIGGSATQSKPTPVKPNYALKFTLAGHTKAVSSVKFSPNGEWLASSSADKLIKIWGAYDGKFEKTISGHKLGISDVAWSSDSNLLVSASDDKTLKIWDVSSGKCLKTLKGHSNYVFCCNFNPQSNLIVSGSFDESVRIWDVKTGKCLKTLPAHSDPVSAVHFNRDGSLIVSSSYDGLCRIWDTASGQCLKTLIDDDNPPVSFVKFSPNGKYILAATLDNTLKLWDYSKGKCLKTYTGHKNEKYCIFANFSVTGGKWIVSGSEDNLVYIWNLQTKEIVQKLQGHTDVVISTACHPTENIIASAALENDKTIKLWKSDC","Homo sapiens","WDR5, BIG3","WD repeat-containing protein 5","1","5M25"
"5M2C",,"X-RAY DIFFRACTION",2.13,42.16,"VAPOR DIFFUSION, SITTING DROP",5,"29% EtOH,          
0.092 M Citrate       pH 2.2,
0.113 M Na2HPO4   pH 9.3,  (pH ~5)
39% PEG 300",294.15,"10.1016/j.str.2016.11.003",,"5M2C",22.55,"1.961","1.961","Structural tuning of CD81LEL (space group P32 1 2)","ETGFVNKDQIAKDVKQFYDQALQQAVVDDDANNAKAVVKTFHETLDCCGSSTLTALTTSVLKNNLCPSGSNIISNLFKEDCHQKIDDLFSGKGTKHHHHHH","Homo sapiens","CD81, TAPA1, TSPAN28","CD81 antigen","1","5M2C"
"5M2F",,"X-RAY DIFFRACTION",2.49,50.65,"VAPOR DIFFUSION, HANGING DROP",9,"30% PEG 6000, 100 mM sodium cacodylate",293,"10.1016/j.cbi.2017.01.026","UV8","5M2F",37.68,"1.503","1.503","Crystal structure of human AKR1B10 complexed with NADP+ and the synthetic retinoid UVI2008","MATFVELSTKAKMPIVGLGTWKSPLGKVKEAVKVAIDAGYRHIDCAYVYQNEHEVGEAIQEKIQEKAVKREDLFIVSKLWPTFFERPLVRKAFEKTLKDLKLSYLDVYLIHWPQGFKSGDDLFPRDDKGNAIGGKATFLDAWEAMEELVDEGLVKALGVSNFSHFQIEKLLNKPGLKYKPVTNQVECHPYLTQEKLIQYCHSKGITVTAYSPLGSPDRPWAKPEDPSLLEDPKIKEIAAKHKKTAAQVLIRFHIQRNVIVIPKSVTPARIVENIQVFDFKLSDEEMATILSFNRNWRACNLLQSSHLEDYPFNAEY","Homo sapiens","AKR1B10, AKR1B11","Aldo-keto reductase family 1 member B10","1","5M2F"
"5M2L",,"SOLUTION NMR",,,,,,,"10.1038/ncomms15355",,"5M2L",19.06,,,"Structure of DNA tetrameric AGCGA-quadruplex adopted by 15-mer d(GCGAGGGAGCGAGGG), VK34, oligonucleotide found in regulatory region of the PLEKHG3 human gene","GCGAGGGAGCGAGGG","Homo sapiens",,"DNA (5'-D(*GP*CP*GP*AP*GP*GP*GP*AP*GP*CP*GP*AP*GP*GP*G)-3')","1","5M2L"
"5M33",,"X-RAY DIFFRACTION",1.87,34.4,"VAPOR DIFFUSION, SITTING DROP",5,"Protein: 10 mg/ml
Buffer: 0.1 M MIB          pH 5.0,
25% w/v PEG 1500

grown in presence of synthetic claudin-I long-extracellular-loop (CLDN1-EL1) - but not visible in electron density. 

cryo-protectant: 25% glycerol + peptide",294.15,"10.1016/j.str.2016.11.003",,"5M33",22.8,"1.28","1.28","Structural tuning of CD81LEL (space group P21)","ETGFVNKDQIAKDVKQFYDQALQQAVVDDDANNAKAVVKTFHETLDCCGSSTLTALTTSVLKNNLCPSGSNIISNLFKEDCHQKIDDLFSGKGTKHHHHHH","Homo sapiens","CD81, TAPA1, TSPAN28","CD81 antigen","1","5M33"
"5M39",,"X-RAY DIFFRACTION",2.19,43.86,"VAPOR DIFFUSION, HANGING DROP",7,"27% PEG3350
0.2M Disodium malonate
0.01 M HEPES",294,"10.1021/acs.jmedchem.7b00845","7EA","5M39",30.74,"1.38","1.38","Crystal structure of BRD4 BROMODOMAIN 1 IN COMPLEX WITH LIGAND 1","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5M39"
"5M3A",,"X-RAY DIFFRACTION",2.14,42.5,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.1M HEPES
PEG3350 22%
Di-Sodium malonate",294,"10.1021/acs.jmedchem.7b00845","7E7","5M3A",15.53,"1.65","1.65","Crystal structure of BRD4 BROMODOMAIN 1 IN COMPLEX WITH LIGAND 2","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5M3A"
"5M3D",,"X-RAY DIFFRACTION",2.44,49.52,"VAPOR DIFFUSION, SITTING DROP",,"Protein: 10 mg/ml
Buffer: 40% EtOH,         0.097 M Citrate     
pH 2.2,               0.113 M Na2HPO4   pH 9.3,  (pH ~6) 2.5% PEG 1000",294.15,"10.1016/j.str.2016.11.003",,"5M3D",45.67,"2.38","2.38","Structural tuning of CD81LEL (space group P31)","ETGFVNKDQIAKDVKQFYDQALQQAVVDDDANNAKAVVKTFHETLDCCGSSTLTALTTSVLKNNLCPSGSNIISNLFKEDCHQKIDDLFSGKGTKHHHHHH","Homo sapiens","CD81, TAPA1, TSPAN28","CD81 antigen","1","5M3D"
"5M3N",,"X-RAY DIFFRACTION",2.32,47.03,"VAPOR DIFFUSION",6,"Crystals were grown using the sitting drop vapor-diffusion method by mixing equal volumes of protein (10-15 mg/mL) and reservoir solution containing 0.1 M MES pH 6.0, 1 M LiCl, and 15-20% (w/v) PEG-6000",293,"10.1038/cddis.2017.487",,"5M3N",36.17,"1.649","1.649","HTRA2 wild-type structure","MAVPSPPPASPRSQYNFIADVVEKTAPAVVYIEILDRHPFLGREVPISNGSGFVVAADGLIVTNAHVVADRRRVRVRLLSGDTYEAVVTAVDPVADIATLRIQTKEPLPTLPLGRSADVRQGEFVVAMGSPFALQNTITSGIVSSAQRPARDLGLPQTNVEYIQTDAAIDFGNSGGPLVNLDGEVIGVNTMKVTAGISFAIPSDRLREFLHRGEKKNSSSGISGSQRRYIGVMMLTLSPSILAELQLREPSFPDVQHGVLIHKVILGSPAHRAGLRPGDVILAIGEQMVQNAEDVYEAVRTQSQLAVQIRRGRETLTLYVTPEVTEHHHHHH","Homo sapiens","HTRA2, OMI, PRSS25","Serine protease HTRA2, mitochondrial","1","5M3N"
"5M3O",,"X-RAY DIFFRACTION",2.41,49.02,"VAPOR DIFFUSION, SITTING DROP",6,"0.1 M MES pH 6.0, 1 M LiCl, and 15-20% (w/v) PEG-6000",293,"10.1038/cddis.2017.487",,"5M3O",36.46,"1.7","1.7","HTRA2 A141S mutant structure","MAVPSPPPSSPRSQYNFIADVVEKTAPAVVYIEILDRHPFLGREVPISNGSGFVVAADGLIVTNAHVVADRRRVRVRLLSGDTYEAVVTAVDPVADIATLRIQTKEPLPTLPLGRSADVRQGEFVVAMGSPFALQNTITSGIVSSAQRPARDLGLPQTNVEYIQTDAAIDFGNSGGPLVNLDGEVIGVNTMKVTAGISFAIPSDRLREFLHRGEKKNSSSGISGSQRRYIGVMMLTLSPSILAELQLREPSFPDVQHGVLIHKVILGSPAHRAGLRPGDVILAIGEQMVQNAEDVYEAVRTQSQLAVQIRRGRETLTLYVTPEVTEHEHHHHHH","Homo sapiens","HTRA2, OMI, PRSS25","Serine protease HTRA2, mitochondrial","1","5M3O"
"5M3T",,"X-RAY DIFFRACTION",2.68,54.14,"VAPOR DIFFUSION, SITTING DROP",5,"Protein: 10 mg/ml
Buffer: 0.1 MMT pH 5,
25% w/v PEG 1500
grown in presence of fexofenadine although not visible in the electron density map",294.15,"10.1016/j.str.2016.11.003",,"5M3T",22.84,"2.021","2.021","Structural tuning of CD81LEL (space group P64)","ETGFVNKDQIAKDVKQFYDQALQQAVVDDDANNAKAVVKTFHETLDCCGSSTLTALTTSVLKNNLCPSGSNIISNLFKEDCHQKIDDLFSGKGTKHHHHHH","Homo sapiens","CD81, TAPA1, TSPAN28","CD81 antigen","1","5M3T"
"5M3U",,"X-RAY DIFFRACTION",2.02,38.68,"VAPOR DIFFUSION, HANGING DROP",,"2.2-2.5 M NAKPO4, PH 8.2-8.4,",298,"10.1371/journal.pone.0199191","3PG","5M3U",45.28,"1.81","1.81","The X-ray structure of human V216F phosphoglycerate kinase 1 mutant","SLSNKLTLDKLDVKGKRVVMRVDFNVPMKNNQITNNQRIKAAVPSIKFCLDNGAKSVVLMSHLGRPDGVPMPDKYSLEPVAVELKSLLGKDVLFLKDCVGPEVEKACANPAAGSVILLENLRFHVEEEGKGKDASGNKVKAEPAKIEAFRASLSKLGDVYVNDAFGTAHRAHSSMVGVNLPQKAGGFLMKKELNYFAKALESPERPFLAILGGAKFADKIQLINNMLDKVNEMIIGGGMAFTFLKVLNNMEIGTSLFDEEGAKIVKDLMSKAEKNGVKITLPVDFVTADKFDENAKTGQATVASGIPAGWMGLDCGPESSKKYAEAVTRAKQIVWNGPVGVFEWEAFARGTKALMDEVVKATSRGCITIIGGGDTATCCAKWNTEDKVSHVSTGGGASLELLEGKVLPGVDALSNI","Homo sapiens","PGK1, PGKA, MIG10, OK/SW-cl.110","Phosphoglycerate kinase 1","1","5M3U"
"5M3X",,"X-RAY DIFFRACTION",2.22,44.57,"VAPOR DIFFUSION, SITTING DROP",,"1.7M Ammonium Sulfate,
0.1M Citric Acid, pH3.6",293.15,"10.1074/jbc.RA118.006608",,"5M3X",98.73,"2.63","2.63","Crystal structure of human angiotensin I-deleted angiotensinogen","VIHNESTCEQLAKANAGKPKDPTFIPAPIQAKTSPVDEKALQDQLVLVAAKLDTEDKLRAAMVGMLANFLGFRIYGMHSELWGVVHGATVLSPTAVFGTLASLYLGALDHTADRLQAILGVPWKDKQCTSRLDAHKVLSALQAVQGLLVAQGRADSQAQLLLSTVVGVFTAPGLHLKQPFVQGLALYTPVVLPRSLDFTELDVAAEKIDRFMQAVTGWKTGSSLMGASVDSTLAFNTYVHFQGKMKGFSLLAEPQEFWVDQSTSVSVPMLSGMGTFQHWSDIQDQFSVTQVPFTESASLLLIQPHYASDLDKVEGLTFQQNSLNWMKKLSPRTIHLTMPQLVLQGSYDLQDLLAQAELPAILHTELNLQKLSNDRIRVGEVLNSIFFELEADEREPTESTQQLNKPEVLEVTLNRPFLFAVYDQSATALHFLGRVANPLSTAHHHHHH","Homo sapiens","AGT, SERPINA8","Angiotensinogen","1","5M3X"
"5M3Y",,"X-RAY DIFFRACTION",3.15,60.94,"VAPOR DIFFUSION, SITTING DROP",,"2.0M Ammonium Sulfate,
0.1M Bicine, pH9.0",293.15,"10.1074/jbc.RA118.006608",,"5M3Y",51.23,"2.3","2.3","Crystal structure of human glycosylated angiotensinogen","DRVYIHPFHLVIHNESTCEQLAKANAGKPKDPTFIPAPIQAKTSPVDEKALQDQLVLVAAKLDTEDKLRAAMVGMLANFLGFRIYGMHSELWGVVHGATVLSPTAVFGTLASLYLGALDHTADRLQAILGVPWKDKQCTSRLDAHKVLSALQAVQGLLVAQGRADSQAQLLLSTVVGVFTAPGLHLKQPFVQGLALYTPVVLPRSLDFTELDVAAEKIDRFMQAVTGWKTGSSLMGASVDSTLAFNTYVHFQGKMKGFSLLAEPQEFWVDQSTSVSVPMLSGMGTFQHWSDIQDQFSVTQVPFTESASLLLIQPHYASDLDKVEGLTFQQNSLNWMKKLSPRTIHLTMPQLVLQGSYDLQDLLAQAELPAILHTELNLQKLSNDRIRVGEVLNSIFFELEADEREPTESTQQLNKPEVLEVTLNRPFLFAVYDQSATALHFLGRVANPLSTAHHHHHH","Homo sapiens","AGT, SERPINA8","Angiotensinogen","1","5M3Y"
"5M44",,"X-RAY DIFFRACTION",2.13,42.3,"VAPOR DIFFUSION, SITTING DROP",5,"Protein stock solution: 6 mg/ml CK2alpha1-335 in 0.5 M NaCl, 25 mM Tris/HCl, pH 8.5;
Inhibitor stock solution: 10 mM inhibitor in DMSO;
Protein/inhibitor complex solution: 90 microliter protein stock solution + 10 microliter inhibitor stock solution;
Reservoir solution: 4.2 M NaCl, 0.1 M sodium citrate, pH 5.0;
Drop solution before equlibration: 0.5 microliter  protein/inhibitor complex solution + 0.5 microliter reservoir solution",293,"10.3390/ph10010009",,"5M44",40.57,"2.71","2.71","Complex structure of human protein kinase CK2 catalytic subunit with a thieno[2,3-d]pyrimidin inhibitor crystallized under high-salt conditions","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMG","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5M44"
"5M4C",,"X-RAY DIFFRACTION",1.96,37.33,"VAPOR DIFFUSION, SITTING DROP",,"PROTEIN STOCK SOLUTION: 6 MG/M CK2ALPHA1-335 IN 0.5 M NACL, 25 MM TRIS/HCL, PH 8.5; 

INHIBITOR STOCK SOLUTION: 10 MM INHIBITOR IN DMSO;

PROTEIN/INHIBITOR COMPLEX SOLUTION: 90 MICROLITER PROTEIN STOCK SOLUTION + 10 MICROLITER INHIBITOR STOCK SOLUTION;

RESERVOIR SOLUTION: 24 % (w/v) PEG8000, 0.2 M KCl;

DROP SOLUTION BEFORE EQULIBRATION: 0.3 MICROLITER PROTEIN/INHIBITOR COMPLEX SOLUTION + 0.3 MICROLITER RESERVOIR SOLUTION",293,"10.3390/ph10010009",,"5M4C",40.62,"1.935","1.935","Complex structure of human protein kinase CK2 catalytic subunit with a thieno[2,3-d]pyrimidin inhibitor crystallized under low-salt conditions","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMG","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5M4C"
"5M4E",,"X-RAY DIFFRACTION",2.54,51.56,"VAPOR DIFFUSION",6.5,"0.1 M Na Cacodylate pH 6.5
25% PEG 2K MME
0.2 M MgCl2",277,"10.1021/acs.jmedchem.6b01478",,"5M4E",28.96,"1.9","1.9","Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase","MGHHHHHHHHHHSSGHIDDADKHMDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5M4E"
"5M4F",,"X-RAY DIFFRACTION",1.96,37.21,"VAPOR DIFFUSION, SITTING DROP",,"PROTEIN STOCK SOLUTION: 6 MG/ML CK2ALPHA1-335 IN 0.5 M NACL, 25 MM TRIS/HCL, PH 8.5; 

INHIBITOR STOCK SOLUTION: 10 MM INHIBITOR IN DMSO;

PROTEIN/INHIBITOR COMPLEX SOLUTION: 90 MICROLITER PROTEIN STOCK SOLUTION + 10 MICROLITER INHIBITOR STOCK SOLUTION; 

RESERVOIR SOLUTION: 24 % PEG3350, 0.2 M KCl; 

DROP SOLUTION BEFORE EQULIBRATION: 0.5 MICROLITER PROTEIN/INHIBITOR COMPLEX SOLUTION + 0.5 MICROLITER RESERVOIR SOLUTION",293,"10.3390/ph10010009",,"5M4F",40.77,"1.519","1.519","Complex structure of human protein kinase CK2 catalytic subunit with the inhibitor 4'-carboxy-6,8-chloro-flavonol (FLC21) crystallized under low-salt conditions","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMG","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5M4F"
"5M4G",,"X-RAY DIFFRACTION",2.76,55.51,"VAPOR DIFFUSION",,"10mM NaBorate, 690-760mM NaCitrate",293,"10.1111/febs.14158",,"5M4G",108.2,"1.48","1.48","Crystal Structure of Wild-Type Human Prolidase with Mn ions","GPSFWLGNETLKVPLALFALNRQRLCERLRKNPAVQAGSIVVLQGGEETQRYCTDTGVLFRQESFFHWAFGVTEPGCYGVIDVDTGKSTLFVPRLPASHATWMGKIHSKEHFKEKYAVDDVQYVDEIASVLTSQKPSVLLTLRGVNTDSGSVCREASFDGISKFEVNNTILHPEIVECRVFKTDMELEVLRYTNKISSEAHREVMKAVKVGMKEYELESLFEHYCYSRGGMRHSSYTCICGSGENSAVLHYGHAGAPNDRTIQNGDMCLFDMGGEYYCFASDITCSFPANGKFTADQKAVYEAVLRSSRAVMGAMKPGVWWPDMHRLADRIHLEELAHMGILSGSVDAMVQAHLGAVFMPHGLGHFLGIDVHDVGGYPEGVERIDEPGLRSLRTARHLQPGMVLTVEPGIYFIDHLLDEALADPARASFLNREVLQRFRGFGGVRIEEDVVVTDSGIELLTCVPRTVEEIEACMAGCDKAFTP","Homo sapiens","PEPD, PRD","Xaa-Pro dipeptidase","1","5M4G"
"5M4H",,"X-RAY DIFFRACTION",2.35,47.75,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Na Cacodylate pH 6.5
25% PEG 2K MME
0.2M MgCl2",277,"10.1021/acs.jmedchem.6b01478",,"5M4H",28.95,"2","2","Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase","MGHHHHHHHHHHSSGHIDDADKHMDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5M4H"
"5M4I",,"X-RAY DIFFRACTION",2.19,43.85,"VAPOR DIFFUSION, SITTING DROP",,"PROTEIN STOCK SOLUTION: 6 MG/ML          
CK2ALPHA1-335 IN 0.5 M NACL, 25 MM TRIS/HCL, PH 8.5;

INHIBITOR STOCK SOLUTION: 10 MM INHIBITOR IN DMSO; 

PROTEIN/INHIBITOR COMPLEX SOLUTION: 90 MICROLITER PROTEIN STOCK SOLUTION + 10 MICROLITER INHIBITOR STOCK SOLUTION;

RESERVOIR SOLUTION: 4.3 M       
NACL, 0.1 M SODIUM CITRATE, PH 5.2;

DROP SOLUTION BEFORE EQULIBRATION: 0.5 MICROLITER PROTEIN/INHIBITOR COMPLEX SOLUTION + 0.5 MICROLITER RESERVOIR SOLUTION",293,"10.3390/ph10010009",,"5M4I",40.6,"2.218","2.218","Complex structure of human protein kinase CK2 catalytic subunit with the inhibitor 4'-carboxy-6,8-chloro-flavonol (FLC21) crystallized under high-salt conditions","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMG","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5M4I"
"5M4J",,"X-RAY DIFFRACTION",2.78,55.7,"VAPOR DIFFUSION",,"10mM NaBorate, 690-760mM NaCitrate",293,"10.1111/febs.14158",,"5M4J",108.53,"1.55","1.55","Crystal Structure of Wild-Type Human Prolidase with GlyPro ligand","GPSFWLGNETLKVPLALFALNRQRLCERLRKNPAVQAGSIVVLQGGEETQRYCTDTGVLFRQESFFHWAFGVTEPGCYGVIDVDTGKSTLFVPRLPASHATWMGKIHSKEHFKEKYAVDDVQYVDEIASVLTSQKPSVLLTLRGVNTDSGSVCREASFDGISKFEVNNTILHPEIVECRVFKTDMELEVLRYTNKISSEAHREVMKAVKVGMKEYELESLFEHYCYSRGGMRHSSYTCICGSGENSAVLHYGHAGAPNDRTIQNGDMCLFDMGGEYYCFASDITCSFPANGKFTADQKAVYEAVLRSSRAVMGAMKPGVWWPDMHRLADRIHLEELAHMGILSGSVDAMVQAHLGAVFMPHGLGHFLGIDVHDVGGYPEGVERIDEPGLRSLRTARHLQPGMVLTVEPGIYFIDHLLDEALADPARASFLNREVLQRFRGFGGVRIEEDVVVTDSGIELLTCVPRTVEEIEACMAGCDKAFTPF","Homo sapiens","PEPD, PRD","Xaa-Pro dipeptidase","1","5M4J"
"5M4K",,"X-RAY DIFFRACTION",3.08,60.02,"VAPOR DIFFUSION",5.8,"0.1 M SODIUM ACETATE PH 5.8
0.125 M MAGNESIUM CHLORIDE
6% ISOPROPANOL",277,"10.1021/acs.jmedchem.6b01478","7F9","5M4K",47.02,"2.6","2.6","Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase","MRWVWALLKNASLAGSAPKYIEHFSKFSPSPLSMKQFLDFGSSNACEKTSFTFLRQELPVRLANIMKEINLLPDRVLSTPSVQLVQSWYVQSLLDIMEFLDKDPEDHRTLSQFTDALVTIRNRHNDVVPTMAQGVLEYKDTYGDDPVSNQNIQYFLDRFYLSRISIRMLINQHTLIFDGSTNPAHPKHIGSIDPNCNVSEVVKDAYDMAKLLCDKYYMASPDLEIQEINAANSKQPIHMVYVPSHLYHMLFELFKNAMRATVESHESSLILPPIKVMVALGEEDLSIKMSDRGGGVPLRKIERLFSYMYSTAPTPQPGTGGTPLAGFGYGLPISRLYAKYFQGDLQLFSMEGFGTDAVIYLKALSTDSVERLPVYNKSAWRHYQTIQEAGDWCVPSTEPKNTSTYRVS","Homo sapiens","PDK2, PDHK2","[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial","1","5M4K"
"5M4L",,"X-RAY DIFFRACTION",2.78,55.73,"VAPOR DIFFUSION",,"10mM NaBorate, 690-760mM NaCitrate",293,"10.1111/febs.14158",,"5M4L",108.89,"1.49","1.49","Crystal Structure of Wild-Type Human Prolidase with Mg ions and LeuPro ligand","GPSFWLGNETLKVPLALFALNRQRLCERLRKNPAVQAGSIVVLQGGEETQRYCTDTGVLFRQESFFHWAFGVTEPGCYGVIDVDTGKSTLFVPRLPASHATWMGKIHSKEHFKEKYAVDDVQYVDEIASVLTSQKPSVLLTLRGVNTDSGSVCREASFDGISKFEVNNTILHPEIVECRVFKTDMELEVLRYTNKISSEAHREVMKAVKVGMKEYELESLFEHYCYSRGGMRHSSYTCICGSGENSAVLHYGHAGAPNDRTIQNGDMCLFDMGGEYYCFASDITCSFPANGKFTADQKAVYEAVLRSSRAVMGAMKPGVWWPDMHRLADRIHLEELAHMGILSGSVDAMVQAHLGAVFMPHGLGHFLGIDVHDVGGYPEGVERIDEPGLRSLRTARHLQPGMVLTVEPGIYFIDHLLDEALADPARASFLNREVLQRFRGFGGVRIEEDVVVTDSGIELLTCVPRTVEEIEACMAGCDKAFTPF","Homo sapiens","PEPD, PRD","Xaa-Pro dipeptidase","1","5M4L"
"5M4M",,"X-RAY DIFFRACTION",3.08,60.06,"VAPOR DIFFUSION",5.8,"0.1 M SODIUM ACETATE PH 5.8
0.125 M MAGNESIUM CHLORIDE
6% ISOPROPANOL",277,"10.1021/acs.jmedchem.6b01478","7FW","5M4M",47.28,"2.4","2.4","Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase","MRWVWALLKNASLAGSAPKYIEHFSKFSPSPLSMKQFLDFGSSNACEKTSFTFLRQELPVRLANIMKEINLLPDRVLSTPSVQLVQSWYVQSLLDIMEFLDKDPEDHRTLSQFTDALVTIRNRHNDVVPTMAQGVLEYKDTYGDDPVSNQNIQYFLDRFYLSRISIRMLINQHTLIFDGSTNPAHPKHIGSIDPNCNVSEVVKDAYDMAKLLCDKYYMASPDLEIQEINAANSKQPIHMVYVPSHLYHMLFELFKNAMRATVESHESSLILPPIKVMVALGEEDLSIKMSDRGGGVPLRKIERLFSYMYSTAPTPQPGTGGTPLAGFGYGLPISRLYAKYFQGDLQLFSMEGFGTDAVIYLKALSTDSVERLPVYNKSAWRHYQTIQEAGDWCVPSTEPKNTSTYRVS","Homo sapiens","PDK2, PDHK2","[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial","1","5M4M"
"5M4N",,"X-RAY DIFFRACTION",3.11,60.5,"VAPOR DIFFUSION",5.8,"0.1 M SODIUM ACETATE PH 5.8
0.125 M MAGNESIUM CHLORIDE
6% ISOPROPANOL",277,"10.1021/acs.jmedchem.6b01478",,"5M4N",47.22,"2.6","2.6","Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase","MRWVWALLKNASLAGSAPKYIEHFSKFSPSPLSMKQFLDFGSSNACEKTSFTFLRQELPVRLANIMKEINLLPDRVLSTPSVQLVQSWYVQSLLDIMEFLDKDPEDHRTLSQFTDALVTIRNRHNDVVPTMAQGVLEYKDTYGDDPVSNQNIQYFLDRFYLSRISIRMLINQHTLIFDGSTNPAHPKHIGSIDPNCNVSEVVKDAYDMAKLLCDKYYMASPDLEIQEINAANSKQPIHMVYVPSHLYHMLFELFKNAMRATVESHESSLILPPIKVMVALGEEDLSIKMSDRGGGVPLRKIERLFSYMYSTAPTPQPGTGGTPLAGFGYGLPISRLYAKYFQGDLQLFSMEGFGTDAVIYLKALSTDSVERLPVYNKSAWRHYQTIQEAGDWCVPSTEPKNTSTYRVS","Homo sapiens","PDK2, PDHK2","[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial","1","5M4N"
"5M4P",,"X-RAY DIFFRACTION",3.16,61.03,"VAPOR DIFFUSION",5.8,"0.1 M SODIUM ACETATE PH 5.8
0.125 M MAGNESIUM CHLORIDE
6% ISOPROPANOL",277,"10.1021/acs.jmedchem.6b01478",,"5M4P",47.25,"2.3","2.3","Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase","MRWVWALLKNASLAGSAPKYIEHFSKFSPSPLSMKQFLDFGSSNACEKTSFTFLRQELPVRLANIMKEINLLPDRVLSTPSVQLVQSWYVQSLLDIMEFLDKDPEDHRTLSQFTDALVTIRNRHNDVVPTMAQGVLEYKDTYGDDPVSNQNIQYFLDRFYLSRISIRMLINQHTLIFDGSTNPAHPKHIGSIDPNCNVSEVVKDAYDMAKLLCDKYYMASPDLEIQEINAANSKQPIHMVYVPSHLYHMLFELFKNAMRATVESHESSLILPPIKVMVALGEEDLSIKMSDRGGGVPLRKIERLFSYMYSTAPTPQPGTGGTPLAGFGYGLPISRLYAKYFQGDLQLFSMEGFGTDAVIYLKALSTDSVERLPVYNKSAWRHYQTIQEAGDWCVPSTEPKNTSTYRVS","Homo sapiens","PDK2, PDHK2","[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial","1","5M4P"
"5M4Q",,"X-RAY DIFFRACTION",2.78,55.74,"VAPOR DIFFUSION",,"10mM NaBorate, 690-760mM NaCitrate",293,"10.1111/febs.14158","PRO","5M4Q",108.73,"1.73","1.73","Crystal Structure of Wild-Type Human Prolidase with Mn ions and Pro ligand","GPSFWLGNETLKVPLALFALNRQRLCERLRKNPAVQAGSIVVLQGGEETQRYCTDTGVLFRQESFFHWAFGVTEPGCYGVIDVDTGKSTLFVPRLPASHATWMGKIHSKEHFKEKYAVDDVQYVDEIASVLTSQKPSVLLTLRGVNTDSGSVCREASFDGISKFEVNNTILHPEIVECRVFKTDMELEVLRYTNKISSEAHREVMKAVKVGMKEYELESLFEHYCYSRGGMRHSSYTCICGSGENSAVLHYGHAGAPNDRTIQNGDMCLFDMGGEYYCFASDITCSFPANGKFTADQKAVYEAVLRSSRAVMGAMKPGVWWPDMHRLADRIHLEELAHMGILSGSVDAMVQAHLGAVFMPHGLGHFLGIDVHDVGGYPEGVERIDEPGLRSLRTARHLQPGMVLTVEPGIYFIDHLLDEALADPARASFLNREVLQRFRGFGGVRIEEDVVVTDSGIELLTCVPRTVEEIEACMAGCDKAFTPF","Homo sapiens","PEPD, PRD","Xaa-Pro dipeptidase","1","5M4Q"
"5M4R",,"X-RAY DIFFRACTION",3.85,68.1,"VAPOR DIFFUSION, SITTING DROP",4,"Protein: ~10mg/ml
Buffer: 0.1 M NaCitrate          pH 4.0,
0.8 M (NH4)2 SO4",294.15,"10.1016/j.str.2016.11.003",,"5M4R",56.39,"3.1","3.1","Structural tuning of CD81LEL (space group C2)","ETGFVNKDQIAKDVKQFYDQALQQAVVDDDANNAKAVVKTFHETLDCCGSSTLTALTTSVLKNNLCPSGSNIISNLFKEDCHQKIDDLFSGKGTKHHHHHH","Homo sapiens","CD81, TAPA1, TSPAN28","CD81 antigen","1","5M4R"
"5M4U",,"X-RAY DIFFRACTION",3.32,62.99,"VAPOR DIFFUSION, SITTING DROP",6.5,"PROTEIN STOCK SOLUTION: 5.5 MG/ML CK2ALPHA'D39G-C336S IN 0.5 M NACL, 25 MM TRIS/HCL, PH 8.5; 

INHIBITOR STOCK SOLUTION: 10 MM INHIBITOR IN DMSO;

PROTEIN/INHIBITOR COMPLEX SOLUTION: 90 MICROLITER PROTEIN STOCK SOLUTION + 10 MICROLITER INHIBITOR STOCK SOLUTION;

RESERVOIR SOLUTION: 25 % PEG5000 MME, 0.2 M ammonium sulphate, 0.1 M MES buffer, pH 6.5; 

DROP SOLUTION BEFORE EQULIBRATION: 0.3 MICROLITER PROTEIN/INHIBITOR COMPLEX SOLUTION + 0.3 MICROLITER RESERVOIR SOLUTION",277,"10.3390/ph10010009",,"5M4U",43.94,"2.195","2.195","ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA') WITH THE INHIBITOR 4'-CARBOXY-6,8-CHLORO- FLAVONOL (FLC21)","MGSSHHHHHHSQDPMPGPAAGSRARVYAEVNSLRSREYWDYEAHVPSWGNQDGYQLVRKLGRGKYSEVFEAINITNNERVVVKILKPVKKKKIKREVKILENLRGGTNIIKLIDTVKDPVSKTPALVFEYINNTDFKQLYQILTDFDIRFYMYELLKALDYCHSKGIMHRDVKPHNVMIDHQQKKLRLIDWGLAEFYHPAQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRREPFFHGQDNYDQLVRIAKVLGTEELYGYLKKYHIDLDPHFNDILGQHSRKRWENFIHSENRHLVSPEALDLLDKLLRYDHQQRLTAKEAMEHPYFYPVVKEQSQPSADNAVLSSGLTAAR","Homo sapiens","CSNK2A2, CK2A2","Casein kinase II subunit alpha'","1","5M4U"
"5M4W",,"SOLUTION NMR",,,,,,,"10.1038/ncomms15355",,"5M4W",9.5,,,"Structure of DNA AGCGA-quadruplex adopted by 15-mer oligonucleotide found in regulatory region of the PLEKHG3 human gene with G11 to I11 mutation, d(GCGAGGGAGCIAGGG),VK34_I11","GCGAGGGAGCIAGGG","Homo sapiens",,"DNA (5'-D(*GP*CP*GP*AP*GP*GP*GP*AP*GP*CP*IP*AP*GP*GP*G)-3')","1","5M4W"
"5M51",,"X-RAY DIFFRACTION",2.4,48.82,"VAPOR DIFFUSION, HANGING DROP",,"3 % PEG 8000, 50 mM Tris pH 8.5",293,"10.18632/oncotarget.13249","NU6","5M51",33.03,"1.899","1.899","Nek2 bound to arylaminopurine compound 8","MPSRAEDYEVLYTIGTGSYGRCQKIRRKSDGKILVWKELDYGSMTEAEKQMLVSEVNLLRELKHPNIVRYYDRIIDRTNTTLYIVMEYCEGGDLASVITKGTKERQYLDEEFVLRVMTQLTLALKECHRRSDGGHTVLHRDLKPANVFLDGKQNVKLGDFGLARILNHDTSFAKTFVGTPYYMSPEQMNRMSYNEKSDIWSLGCLLYELCALMPPFTAFSQKELAGKIREGKFRRIPYRYSDELNEIITRMLNLKDYHRPSVEEILENPLILEHHHHHH","Homo sapiens","NEK2, NEK2A, NLK1","Serine/threonine-protein kinase Nek2","1","5M51"
"5M53",,"X-RAY DIFFRACTION",2.36,47.98,"VAPOR DIFFUSION, HANGING DROP",,"3 % PEG 8000, 50 mM Tris pH 8.5",293,"10.18632/oncotarget.13249","7GJ","5M53",33.99,"1.9","1.9","Nek2 bound to arylaminopurine inhibitor 11","MPSRAEDYEVLYTIGTGSYGRCQKIRRKSDGKILVWKELDYGSMTEAEKQMLVSEVNLLRELKHPNIVRYYDRIIDRTNTTLYIVMEYCEGGDLASVITKGTKERQYLDEEFVLRVMTQLTLALKECHRRSDGGHTVLHRDLKPANVFLDGKQNVKLGDFGLARILNHDTSFAKAFVGTPYYMSPEQMNRMSYNEKSDIWSLGCLLYELCALMPPFTAFSQKELAGKIREGKFRRIPYRYSDELNEIITRMLNLKDYHRPSVEEILENPLILEHHHHHH","Homo sapiens","NEK2, NEK2A, NLK1","Serine/threonine-protein kinase Nek2","1","5M53"
"5M55",,"X-RAY DIFFRACTION",2.59,52.43,"VAPOR DIFFUSION, HANGING DROP",,"3 % PEG 8000, 50 mM Tris pH 8.5",293,"10.18632/oncotarget.13249","7GG","5M55",33.29,"2.4","2.4","Nek2 bound to arylaminopurine 71","MPSRAEDYEVLYTIGTGSYGRCQKIRRKSDGKILVWKELDYGSMTEAEKQMLVSEVNLLRELKHPNIVRYYDRIIDRTNTTLYIVMEYCEGGDLASVITKGTKERQYLDEEFVLRVMTQLTLALKECHRRSDGGHTVLHRDLKPANVFLDGKQNVKLGDFGLARILNHDTSFAKTFVGTPYYMSPEQMNRMSYNEKSDIWSLGCLLYELCALMPPFTAFSQKELAGKIREGKFRRIPYRYSDELNEIITRMLNLKDYHRPSVEEILENPLILEHHHHHH","Homo sapiens","NEK2, NEK2A, NLK1","Serine/threonine-protein kinase Nek2","1","5M55"
"5M56",,"X-RAY DIFFRACTION",2.48,50.46,"VAPOR DIFFUSION, SITTING DROP",,"PROTEIN STOCK SOLUTION: 5.5 MG/ML CK2ALPHA'-D39G-C336S IN 0.5 M NACL, 25 MM TRIS/HCL, PH 8.5;
INHIBITOR STOCK SOLUTION: 10 MM INHIBITOR IN DMSO;
PROTEIN/INHIBITOR COMPLEX SOLUTION: 90 MICROLITER PROTEIN STOCK SOLUTION + 10 MICROLITER INHIBITOR STOCK SOLUTION; 
RESERVOIR SOLUTION: 25 % PEG4000, 15 % glycerol, 0.17 M sodium acetate, 0.08 M Tris/HCl, pH 8.5;
DROP SOLUTION BEFORE EQULIBRATION: 0.3 MICROLITER PROTEIN/INHIBITOR COMPLEX SOLUTION + 0.3 MICROLITER RESERVOIR SOLUTION",277,"10.3390/ph10010009",,"5M56",86.79,"2.237","2.237","Monoclinic complex structure of human protein kinase CK2 catalytic subunit (isoform CK2alpha') with the inhibitor 4'-carboxy-6,8-chloro-flavonol (FLC21)","MGSSHHHHHHSQDPMPGPAAGSRARVYAEVNSLRSREYWDYEAHVPSWGNQDGYQLVRKLGRGKYSEVFEAINITNNERVVVKILKPVKKKKIKREVKILENLRGGTNIIKLIDTVKDPVSKTPALVFEYINNTDFKQLYQILTDFDIRFYMYELLKALDYCHSKGIMHRDVKPHNVMIDHQQKKLRLIDWGLAEFYHPAQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRREPFFHGQDNYDQLVRIAKVLGTEELYGYLKKYHIDLDPHFNDILGQHSRKRWENFIHSENRHLVSPEALDLLDKLLRYDHQQRLTAKEAMEHPYFYPVVKEQSQPSADNAVLSSGLTAAR","Homo sapiens","CSNK2A2, CK2A2","Casein kinase II subunit alpha'","1","5M56"
"5M57",,"X-RAY DIFFRACTION",2.41,49,"VAPOR DIFFUSION, HANGING DROP",,"3 % PEG 8000, 50 mM Tris pH 8.5",293,"10.18632/oncotarget.13249","4SP","5M57",33.03,"2.3","2.3","Nek2 bound to arylaminopurine 6","MPSRAEDYEVLYTIGTGSYGRCQKIRRKSDGKILVWKELDYGSMTEAEKQMLVSEVNLLRELKHPNIVRYYDRIIDRTNTTLYIVMEYCEGGDLASVITKGTKERQYLDEEFVLRVMTQLTLALKECHRRSDGGHTVLHRDLKPANVFLDGKQNVKLGDFGLARILNHDTSFAKAFVGTPYYMSPEQMNRMSYNEKSDIWSLGCLLYELCALMPPFTAFSQKELAGKIREGKFRRIPYRYSDELNEIITRMLNLKDYHRPSVEEILENPLILEHHHHHH","Homo sapiens","NEK2, NEK2A, NLK1","Serine/threonine-protein kinase Nek2","1","5M57"
"5M5A",,"X-RAY DIFFRACTION",2.35,47.64,"VAPOR DIFFUSION, HANGING DROP",6.5,"10-20% PEG 3350 or PEG 4000, 0.1M BIS TRIS pH 6.5, 0.6 M NaCl",293,"10.1126/science.aan4368",,"5M5A",40.77,"1.9","1.9","Crystal structure of MELK in complex with an inhibitor","GPKDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKIMDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQMLQVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCVTELSVHHRNNRQTMEDLISLWQYDHLTATYLLLLAKKARGKPVRLRLSSFSCGHHHHHH","Homo sapiens","MELK, KIAA0175","Maternal embryonic leucine zipper kinase","1","5M5A"
"5M5Q",,"X-RAY DIFFRACTION",3.12,60.63,"VAPOR DIFFUSION, SITTING DROP",6,"35% MPD, 0.2M LiSO4, 0,1 M Mes pH 6.0",277,"10.1002/anie.201608672","7K1","5M5Q",29.68,"2.2","2.2","COPS5(2-257) IN COMPLEX WITH A AZAINDOLE (COMPOUND 4)","GAASGSGMAQKTWELANNMQEAQSIDEIYKYDKKQQQEILAAKPWTKDHHYFKYCKISALALLKMVMHARSGGNLEVMGLMLGKVDGETMIIMDSFALPVEGTETRVNAQAAAYEYMAAYIENAKQVGRLENAIGWYHSHPGYGCWLSGIDVSTQMLNQQFQEPFVAVVIDPTRTISAGKVNLGAFRTYPKGYKPPDEGPSEYQTIPLNKIEDFGVHCKQYYALEVSYFKSSLDRKLLELLWNKYWVNTLSSSSLLT","Homo sapiens","COPS5, CSN5, JAB1","COP9 signalosome complex subunit 5","1","5M5Q"
"5M6A",,"X-RAY DIFFRACTION",2.85,56.8,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M Sodium citrate, 16 % w/v PEG 4000, 10 % v/v 2-Propanol",293,"10.1038/s41598-017-16953-7",,"5M6A",90.85,"1.64","1.64","Crystal structure of cardiotoxic Bence-Jones light chain dimer H9","QSALTQPPSASGSPGQSVTISCTGTSSDVGGSDSVSWYQQHPGKAPKLIIYEVSQRPSGVPNRFSGSKSGNTASLTVSGLQAEDDADYYCSSYGGDNNLFFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"Bence-Jones light chain","1","5M6A"
"5M6C",,"X-RAY DIFFRACTION",2.38,48,"VAPOR DIFFUSION",5.5,"0.1 M SODIUM CITRATE TRIBASIC            
DIHYDRATE PH 5.5, 18% V/V 2-PROPANOL, 16% W/V PEG 4000",293,"10.1093/hmg/ddx133",,"5M6C",45.2,"3","3","CRYSTAL STRUCTURE OF T71N MUTANT OF HUMAN HIPPOCALCIN","MGKQNSKLRPEMLQDLRENTEFSELELQEWYKGFLKDCPTGILNVDEFKKIYANFFPYGDASKFAEHVFRNFDTNSDGTIDFREFIIALSVTSRGRLEQKLMWAFSMYDLDGNGYISREEMLEIVQAIYKMVSSVMKMPEDESTPEKRTEKIFRQMDTNNDGKLSLEEFIRGAKSDPSIVRLLQCDPSSASQF","Homo sapiens","HPCA, BDR2","Neuron-specific calcium-binding protein hippocalcin","1","5M6C"
,,,,,,,,,,,,,,,,"MGKQNSKLRPEMLQDLRENTEFSELELQEWYKGFLKDCPTGILNVDEFKKIYANFFPYGDASKFAEHVFRNFDTNSDGTIDFREFIIALSVTSRGRLEQKLMWAFSMYDLDGNGYISREEMLEIVQAIYKMVSSVMKMPEDESTPEKRTEKIFRQMDTNNDGKLSLEEFIRGAKSDPSIVRLLQCDPSSTSQF","Homo sapiens","HPCA, BDR2","Neuron-specific calcium-binding protein hippocalcin","2","5M6C"
"5M6E",,"X-RAY DIFFRACTION",4.64,73.48,"VAPOR DIFFUSION, SITTING DROP",8,"3.2M NaCl, 0.1M HEPES/NaOHpH=8",277,"10.1021/acs.jmedchem.6b01877",,"5M6E",15.22,"2.32","2.32","Small Molecule inhibitors of IAP","MGSSHHHHHHSSGLVPRGSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5M6E"
"5M6F",,"X-RAY DIFFRACTION",4.67,73.68,"VAPOR DIFFUSION, SITTING DROP",8,"0.1M HEPES/NaOHpH=8, 3.3M NaCl,",277,"10.1021/acs.jmedchem.6b01877","7HU","5M6F",15.09,"2.39","2.39","Small Molecule inhibitors of IAP","MGSSHHHHHHSSGLVPRGSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5M6F"
"5M6H",,"X-RAY DIFFRACTION",4.57,73.06,"VAPOR DIFFUSION, SITTING DROP",8,"0.1M HEPES/NaOH pH8, 3.3M NaCl",277,"10.1021/acs.jmedchem.6b01877","7J6","5M6H",15.16,"2.5","2.5","Small Molecule inhibitors of IAP","MGSSHHHHHHSSGLVPRGSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5M6H"
"5M6I",,"X-RAY DIFFRACTION",4.38,71.93,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.2 M Sodium acetate, 2.0 M NaCl",293,"10.1038/s41598-017-16953-7",,"5M6I",45.76,"2.2","2.2","Crystal structure of non-cardiotoxic Bence-Jones light chain dimer M8","QSALTQPASVSGSPGQSITISCTGTSSDVGAYNLVSWYQQHPGKTPKLLIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQPEDEADYYCCSNAGSYTHVFGTGTKVTVLVQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"light chain dimer","1","5M6I"
,,,,,,,,,,,,,,,,"QSALTQPASVSGSPGQSITISCTGTSSDVGAYNLVSWYQQHPGKTPKLLIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQPEDEADYYCCSNAGSYTHVFGTGTKVTVLVQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"light chain dimer","2","5M6I"
"5M6L",,"X-RAY DIFFRACTION",4.62,73.4,"VAPOR DIFFUSION, SITTING DROP",8,"3.3M NaCl
.1M pH=8 HEPES/NaOH",277,"10.1021/acs.jmedchem.6b01877",,"5M6L",15.17,"2.61","2.61","Small Molecule inhibitors of IAP","MGSSHHHHHHSSGLVPRGSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5M6L"
"5M6M",,"X-RAY DIFFRACTION",4.58,73.16,"VAPOR DIFFUSION, SITTING DROP",8,"3.3M NaCl
.1M pH=8 HEPES/NaOH",277,"10.1021/acs.jmedchem.6b01877","7H8","5M6M",15.14,"2.37","2.37","Small Molecule inhibitors of IAP","MGSSHHHHHHSSGLVPRGSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5M6M"
"5M6N",,"X-RAY DIFFRACTION",2.35,47.6,"VAPOR DIFFUSION, SITTING DROP",5.6,".65M (NH4)2SO4
10% Glycerol
.4M Li2SO4
.005M TCEP
.1M pH=5.6 Na3 citrate/HCl",291,"10.1021/acs.jmedchem.6b01877",,"5M6N",28.97,"1.8","1.8","Small Molecule inhibitors of IAP","MGSSHHHHHHSSGLVPRGSHMQTHAARMRTFMYWPSSVPVQPEQLASAGFYYVGRNDDVKCFCCDGGLRCWESGDDPWVEHAKWFPRCEFLIRMKGQEFVDEIQGRYPHLLEQLLSTS","Homo sapiens","BIRC2, API1, MIHB, RNF48","Baculoviral IAP repeat-containing protein 2","1","5M6N"
"5M6R",,"X-RAY DIFFRACTION",2.83,56.6,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.1 M Na HEPES pH 7.2, 0.9 M Na dihydrogen phosphate/0.9 M K dihydrogen phosphate",294,"10.1016/j.bbagen.2018.06.013",,"5M6R",87.64,"2.73","2.73","Human porphobilinogen deaminase in complex with reaction intermediate","MKHHHHHHPMSDYDIPTTENLYFQGAMAMSGNGNAAATAEENSPKMRVIRVGTRKSQLARIQTDSVVATLKASYPGLQFEIIAMSTTGDKILDTALSKIGEKSLFTKELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICKRENPHDAVVFHPKFVGKTLETLPEKSVVGTSSLRRAAQLQRKFPHLEFRSIRGNLNTRLRKLDEQQEFSAIILATAGLQRMGWHNRVGQILHPEECMYAVGQGALGVEVRAKDQDILDLVGVLHDPETLLRCIAERAFLRHLEGGCSVPVAVHTAMKDGQLYLTGGVWSLDGSDSIQETMQATIHVPAQHEDGPEDDPQLVGITARNIPRGPQLAAQNLGISLANLLLSKGAKNILDVARQLNDAH","Homo sapiens","HMBS, PBGD, UPS","Porphobilinogen deaminase","1","5M6R"
"5M6Z",,"X-RAY DIFFRACTION",2.02,38.51,"VAPOR DIFFUSION, HANGING DROP",8.6,"2.5 M Na//KPO4, pH=8.6",294,"10.1371/journal.pone.0199191","3PG","5M6Z",45.28,"1.67","1.67","The X-ray structure of human M189I PGK-1 mutant in partially closed conformation","SLSNKLTLDKLDVKGKRVVMRVDFNVPMKNNQITNNQRIKAAVPSIKFCLDNGAKSVVLMSHLGRPDGVPMPDKYSLEPVAVELKSLLGKDVLFLKDCVGPEVEKACANPAAGSVILLENLRFHVEEEGKGKDASGNKVKAEPAKIEAFRASLSKLGDVYVNDAFGTAHRAHSSMVGVNLPQKAGGFLIKKELNYFAKALESPERPFLAILGGAKVADKIQLINNMLDKVNEMIIGGGMAFTFLKVLNNMEIGTSLFDEEGAKIVKDLMSKAEKNGVKITLPVDFVTADKFDENAKTGQATVASGIPAGWMGLDCGPESSKKYAEAVTRAKQIVWNGPVGVFEWEAFARGTKALMDEVVKATSRGCITIIGGGDTATCCAKWNTEDKVSHVSTGGGASLELLEGKVLPGVDALSNI","Homo sapiens","PGK1, PGKA, MIG10, OK/SW-cl.110","Phosphoglycerate kinase 1","1","5M6Z"
"5M76",,"X-RAY DIFFRACTION",2.13,42.25,"VAPOR DIFFUSION, SITTING DROP",,"0.05M KBr, 30% PEG 2000",293,"10.1038/s41598-017-16953-7",,"5M76",45.25,"2.5","2.5","Crystal structure of cardiotoxic Bence-Jones light chain dimer H10","QSALTQEASVSGTVGQKVTLSCTGNTNNIGSYPVGWYQQISHGPPKTVMFGNSLPSGIPDRFSGSKSGTTASLTISGLQPEDEADYYCSTWDSSLSVQVIGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"light chain dimer","1","5M76"
"5M78",,"X-RAY DIFFRACTION",2.06,40.38,"VAPOR DIFFUSION, HANGING DROP",7.8,"Crystallization: 2 uL protein solution in 50 mM Tris, pH=7.8 mixed with 2 uL (NH4)2SO4, 100 mM Tris, pH=7.8, satured with PCMB and placed as hanging drop. Crystals appeared after a few days. The crystal for data collection was soaked in 5 uL containing 35 % PEG 3350 (50 % w/v), 20 % NaCl (1 M), 25 % PEG 400, 10 % H2O, 10 % Ligandstock in DMSO (1 M)",291,"10.3390/biom10040518","SAL","5M78",30.41,"1.077","1.077","Human Carbonic Anhydrase II in complex with fragment-like inhibitor.","GSPEFMSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5M78"
"5M79",,"X-RAY DIFFRACTION",2.24,45.19,"VAPOR DIFFUSION, HANGING DROP",7,"MOPS buffer, Manganese chloride,ammonium sulfate, PEG 3350",293,,,"5M79",35.5,"1.3","1.3","Blood group synthase AAGlyB in complex with UMP and cryoprotected with glycerol","MAIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYGGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNP","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5M79"
"5M7A",,"X-RAY DIFFRACTION",2.28,46.01,"VAPOR DIFFUSION, HANGING DROP",7,"MOPS buffer, manganese chloride, ammonium sulfate, PEG 3350",293,,,"5M7A",35.13,"1.304","1.304","Blood group synthase AAGlyB in complex with UMP and cryoprotected with PEG 3350","MAIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYGGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNP","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5M7A"
"5M7B",,"X-RAY DIFFRACTION",2.26,45.47,"VAPOR DIFFUSION, HANGING DROP",7,"MOPS buffer, manganese chloride, ammonium sulfate, PEG 3350",293,,,"5M7B",35.49,"1.5","1.5","Blood group synthase AAGlyB in complex with UDP and cryoprotected with glycerol","MAIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYGGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNP","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5M7B"
"5M7C",,"X-RAY DIFFRACTION",2.24,44.97,"VAPOR DIFFUSION, HANGING DROP",7,"MOPS buffer, manganese chloride, ammonium sulfate, PEG 3350",293,,,"5M7C",70.63,"1.6","1.6","Blood group synthase AAGlyB in complex with UDP and cryoprotected with PEG 3350","MAIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYGGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNP","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5M7C"
"5M7D",,"X-RAY DIFFRACTION",2.25,45.44,"VAPOR DIFFUSION, HANGING DROP",7,"MOPS buffer, manganese chloride, ammonium sulfate, PEG 3350",293,,,"5M7D",35.84,"1.2","1.2","Blood group synthase AAGlyB in complex with UDP-Gal and cryoprotected with glycerol","MAIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYGGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNP","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5M7D"
"5M7F",,"X-RAY DIFFRACTION",2.79,56,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M sodium cacodylate pH 6.5, 0.2 M sodium chloride, 2 M ammonium sulphate",294,"10.1016/j.bbagen.2018.06.013",,"5M7F",81.99,"2.78","2.78","Human porphobilinogen deaminase in complex with DPM cofactor","MGHHHHHHHHHHSSGHIEGRHMRVIRVGTRKSQLARIQTDSVVATLKASYPGLQFEIIAMSTTGDKILDTALSKIGEKSLFTKELEHALEKNEVDLVVHSLKDLPTVLPPGFTIGAICKRENPHDAVVFHPKFVGKTLETLPEKSVVGTSSLRRAAQLQRKFPHLEFRSIRGNLNTRLRKLDEQQEFSAIILATAGLQRMGWHNRVGQILHPEECMYAVGQGALGVEVRAKDQDILDLVGVLHDPETLLRCIAERAFLRHLEGGCSVPVAVHTAMKDGQLYLTGGVWSLDGSDSIQETMQATIHVPAQHEDGPEDDPQLVGITARNIPRGPQLAAQNLGISLANLLLSKGAKNILDVARQLNDAH","Homo sapiens","HMBS, PBGD, UPS","Porphobilinogen deaminase","1","5M7F"
"5M7M",,"X-RAY DIFFRACTION",2.4,48.67,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350 25%, 0.2M thiocyanate, 0.1M ammonium iodide",293,"10.1021/acs.jmedchem.7b00647","7HR","5M7M",102.84,"2.7","2.7","Novel Imidazo[1,2-a]pyridine Derivatives with Potent Autotaxin/ENPP2 Inhibitor Activity","MARRSSFQSCQIISLFTFAVGVNICLGFTAHRIKRAEGWEEGPPTVLSDSPWTNISGSCKGRCFELQEAGPPDCRCDNLCKSYTSCCHDFDELCLKTARGWECTKDRCGEVRNEENACHCSEDCLARGDCCTNYQVVCKGESHWVDDDCEEIKAAECPAGFVRPPLIIFSVDGFRASYMKKGSKVMPNIEKLRSCGTHSPYMRPVYPTKTFPNLYTLATGLYPESHGIVGNSMYDPVFDATFHLRGREKFNHRWWGGQPLWITATKQGVKAGTFFWSVVIPHERRILTILQWLTLPDHERPSVYAFYSEQPDFSGHKYGPFGPEMTNPLREIDKIVGQLMDGLKQLKLHRCVNVIFVGDHGMEDVTCDRTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAIIANLTCKKPDQHFKPYLKQHLPKRLHYANNRRIEDIHLLVERRWHVARKPLDVYKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGPTFKYKTKVPPFENIELYNVMCDLLGLKPAPNNGTHGSLNHLLRTNTFRPTMPEEVTRPNYPGIMYLQSDFDLGCTCDDKNKLDELNKRLHTKGSTEERHLLYGRPAVLYRTRYDILYHTDFESGYSEIFLMPLWTSYTVSKQAEVSSVPDHLTSCVRPDVRVSPSFSQNCLAYKNDKQMSYGFLFPPYLSSSPEAKYDAFLVTNMVPMYPAFKRVWNYFQRVLVKKYASERNGVNVISGPIFDYDYDGLHDTEDKIKQYVEGSSIPVPTHYYSIITSCLDFTQPADKCDGPLSVSSFILPHRPDNEESCNSSEDESKWVEELMKMHTARVRDIEHLTSLDFFRKTSRSYPEILTLKTYLHTYESEILVPRGSHHHHHH","Homo sapiens","ENPP2, ATX, PDNP2","Ectonucleotide pyrophosphatase/phosphodiesterase family member 2","1","5M7M"
"5M7R",,"X-RAY DIFFRACTION",2.5,50.7,"VAPOR DIFFUSION",,"0.14 - 0.2 M triammonium citrate pH 7.5, 16-20 % PEG 3350",292,"10.1038/nchembio.2358",,"5M7R",206.04,"2.35","2.35","Structure of human O-GlcNAc hydrolase","MVQKESQATLEERESELSSNPAASAGASLEPPAAPAPGEDNPAGAGGAAVAGAAGGARRFLCGVVEGFYGRPWVMEQRKELFRRLQKWELNTYLYAPKDDYKHRMFWREMYSVEEAEQLMTLISAAREYEIEFIYAISPGLDITFSNPKEVSTLKRKLDQVSQFGCRSFALLFDDIDHNMCAADKEVFSSFAHAQVSITNEIYQYLGEPETFLFCPTEYCGTFCYPNVSQSPYLRTVGEKLLPGIEVLWTGPKVVSKEIPVESIEEVSKIIKRAPVIWDNIHANDYDQKRLFLGPYKGRSTELIPRLKGVLTNPNCEFEANYVAIHTLATWYKSNMNGVRKDVVMTDSEDSTVSIQIKLENEGSDEDIETDVLYSPQMALKLALTEWLQEFGVPHQYSSRQVAHSGAKASVVDGTPLVAAPSLNATTVVTTVYQEPIMSQGAALSGEPTTLTKEEEKKQPDEEPMDMVVEKQEETDHKNDNQILSEIVEAKMAEELKPMDTDKESIAESKSPEMSMQEDCISDIAPMQTDEQTNKEQFVPGPNEKPLYTAEPVTLEDLQLLADLFYLPYEHGPKGAQMLREFQWLRANSSVVSVNCKGKDSEKIEEWRSRAAKFEEMCGLVMGMFTRLSNCANRTILYDMYSYVWDIKSIMSMVKSFVQWLGCRSHSSAQFLIGDQEPWAFRGGLAGEFQRLLPIDGANDLFFQPPPLTPTSKVYTIRPYFPKDEASVYKICREMYDDGVGLPFQSQPDLIGDKLVGGLLSLSLDYCFVLEDEDGICGYALGTVDVTPFIKKCKISWIPFMQEKYTKPNGDKELSEAEKIMLSFHEEQEVLPETFLANFPSLIKMDIHKKVTDPSVAKSMMACLLSSLKANGSRGAFCEVRPDDKRILEFYSKLGCFEIAKMEGFPKDVVILGRSL","Homo sapiens","MGEA5, HEXC, KIAA0679, MEA5, OGA","Protein O-GlcNAcase","1","5M7R"
"5M7S",,"X-RAY DIFFRACTION",2.45,49.9,"VAPOR DIFFUSION",,"0.1-0.2 M tri ammonium citrate pH 7.5
16-20 % PEG 3350",292,"10.1038/nchembio.2358","NHT","5M7S",206.54,"2.4","2.4","Structure of human O-GlcNAc hydrolase with bound transition state analog ThiametG","MVQKESQATLEERESELSSNPAASAGASLEPPAAPAPGEDNPAGAGGAAVAGAAGGARRFLCGVVEGFYGRPWVMEQRKELFRRLQKWELNTYLYAPKDDYKHRMFWREMYSVEEAEQLMTLISAAREYEIEFIYAISPGLDITFSNPKEVSTLKRKLDQVSQFGCRSFALLFDDIDHNMCAADKEVFSSFAHAQVSITNEIYQYLGEPETFLFCPTEYCGTFCYPNVSQSPYLRTVGEKLLPGIEVLWTGPKVVSKEIPVESIEEVSKIIKRAPVIWDNIHANDYDQKRLFLGPYKGRSTELIPRLKGVLTNPNCEFEANYVAIHTLATWYKSNMNGVRKDVVMTDSEDSTVSIQIKLENEGSDEDIETDVLYSPQMALKLALTEWLQEFGVPHQYSSRQVAHSGAKASVVDGTPLVAAPSLNATTVVTTVYQEPIMSQGAALSGEPTTLTKEEEKKQPDEEPMDMVVEKQEETDHKNDNQILSEIVEAKMAEELKPMDTDKESIAESKSPEMSMQEDCISDIAPMQTDEQTNKEQFVPGPNEKPLYTAEPVTLEDLQLLADLFYLPYEHGPKGAQMLREFQWLRANSSVVSVNCKGKDSEKIEEWRSRAAKFEEMCGLVMGMFTRLSNCANRTILYDMYSYVWDIKSIMSMVKSFVQWLGCRSHSSAQFLIGDQEPWAFRGGLAGEFQRLLPIDGANDLFFQPPPLTPTSKVYTIRPYFPKDEASVYKICREMYDDGVGLPFQSQPDLIGDKLVGGLLSLSLDYCFVLEDEDGICGYALGTVDVTPFIKKCKISWIPFMQEKYTKPNGDKELSEAEKIMLSFHEEQEVLPETFLANFPSLIKMDIHKKVTDPSVAKSMMACLLSSLKANGSRGAFCEVRPDDKRILEFYSKLGCFEIAKMEGFPKDVVILGRSL","Homo sapiens","MGEA5, HEXC, KIAA0679, MEA5, OGA","Protein O-GlcNAcase","1","5M7S"
"5M7T",,"X-RAY DIFFRACTION",2.5,49.9,"VAPOR DIFFUSION",,"0.1-0.2 M tri Ammonium citrate 16-20 % PEG 3350",292,"10.1038/nchembio.2358",,"5M7T",206.76,"2.6","2.6","Structure of human O-GlcNAc hydrolase with PugNAc type inhibitor","MVQKESQATLEERESELSSNPAASAGASLEPPAAPAPGEDNPAGAGGAAVAGAAGGARRFLCGVVEGFYGRPWVMEQRKELFRRLQKWELNTYLYAPKDDYKHRMFWREMYSVEEAEQLMTLISAAREYEIEFIYAISPGLDITFSNPKEVSTLKRKLDQVSQFGCRSFALLFDDIDHNMCAADKEVFSSFAHAQVSITNEIYQYLGEPETFLFCPTEYCGTFCYPNVSQSPYLRTVGEKLLPGIEVLWTGPKVVSKEIPVESIEEVSKIIKRAPVIWDNIHANDYDQKRLFLGPYKGRSTELIPRLKGVLTNPNCEFEANYVAIHTLATWYKSNMNGVRKDVVMTDSEDSTVSIQIKLENEGSDEDIETDVLYSPQMALKLALTEWLQEFGVPHQYSSRQVAHSGAKASVVDGTPLVAAPSLNATTVVTTVYQEPIMSQGAALSGEPTTLTKEEEKKQPDEEPMDMVVEKQEETDHKNDNQILSEIVEAKMAEELKPMDTDKESIAESKSPEMSMQEDCISDIAPMQTDEQTNKEQFVPGPNEKPLYTAEPVTLEDLQLLADLFYLPYEHGPKGAQMLREFQWLRANSSVVSVNCKGKDSEKIEEWRSRAAKFEEMCGLVMGMFTRLSNCANRTILYDMYSYVWDIKSIMSMVKSFVQWLGCRSHSSAQFLIGDQEPWAFRGGLAGEFQRLLPIDGANDLFFQPPPLTPTSKVYTIRPYFPKDEASVYKICREMYDDGVGLPFQSQPDLIGDKLVGGLLSLSLDYCFVLEDEDGICGYALGTVDVTPFIKKCKISWIPFMQEKYTKPNGDKELSEAEKIMLSFHEEQEVLPETFLANFPSLIKMDIHKKVTDPSVAKSMMACLLSSLKANGSRGAFCEVRPDDKRILEFYSKLGCFEIAKMEGFPKDVVILGRSL","Homo sapiens","MGEA5, HEXC, KIAA0679, MEA5, OGA","Protein O-GlcNAcase","1","5M7T"
"5M7U",,"X-RAY DIFFRACTION",2.47,50.32,"VAPOR DIFFUSION",,"0.1-0.2 M tri Ammonium citrate pH 7.5 16-20 % PEG 3350",292,"10.1038/nchembio.2358","XHA","5M7U",206.82,"2.3","2.3","Structure of human O-GlcNAc hydrolase with new iminocyclitol type inhibitor","MVQKESQATLEERESELSSNPAASAGASLEPPAAPAPGEDNPAGAGGAAVAGAAGGARRFLCGVVEGFYGRPWVMEQRKELFRRLQKWELNTYLYAPKDDYKHRMFWREMYSVEEAEQLMTLISAAREYEIEFIYAISPGLDITFSNPKEVSTLKRKLDQVSQFGCRSFALLFDDIDHNMCAADKEVFSSFAHAQVSITNEIYQYLGEPETFLFCPTEYCGTFCYPNVSQSPYLRTVGEKLLPGIEVLWTGPKVVSKEIPVESIEEVSKIIKRAPVIWDNIHANDYDQKRLFLGPYKGRSTELIPRLKGVLTNPNCEFEANYVAIHTLATWYKSNMNGVRKDVVMTDSEDSTVSIQIKLENEGSDEDIETDVLYSPQMALKLALTEWLQEFGVPHQYSSRQVAHSGAKASVVDGTPLVAAPSLNATTVVTTVYQEPIMSQGAALSGEPTTLTKEEEKKQPDEEPMDMVVEKQEETDHKNDNQILSEIVEAKMAEELKPMDTDKESIAESKSPEMSMQEDCISDIAPMQTDEQTNKEQFVPGPNEKPLYTAEPVTLEDLQLLADLFYLPYEHGPKGAQMLREFQWLRANSSVVSVNCKGKDSEKIEEWRSRAAKFEEMCGLVMGMFTRLSNCANRTILYDMYSYVWDIKSIMSMVKSFVQWLGCRSHSSAQFLIGDQEPWAFRGGLAGEFQRLLPIDGANDLFFQPPPLTPTSKVYTIRPYFPKDEASVYKICREMYDDGVGLPFQSQPDLIGDKLVGGLLSLSLDYCFVLEDEDGICGYALGTVDVTPFIKKCKISWIPFMQEKYTKPNGDKELSEAEKIMLSFHEEQEVLPETFLANFPSLIKMDIHKKVTDPSVAKSMMACLLSSLKANGSRGAFCEVRPDDKRILEFYSKLGCFEIAKMEGFPKDVVILGRSL","Homo sapiens","MGEA5, HEXC, KIAA0679, MEA5, OGA","Protein O-GlcNAcase","1","5M7U"
"5M8L",,"X-RAY DIFFRACTION",3.03,59.47,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",295.15,"10.1002/anie.201704616",,"5M8L",213.57,"2.35","2.35","Crystal structure of human tyrosinase related protein 1","QFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSSGRGRCEAVTADSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGAACDQRVLIVRRNLLDLSKEEKNHFVRALDMAKRTTHPLFVIATRRSEEILGPDGNTPQFENISIYNYFVWTHYYSVKKTFLGVGQESFGEVDFSHEGPAFLTWHRYHLLRLEKDMQEMLQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWRVVCDSLEDYDTLGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRNTVEGYSDPTGKYDPAVRSLHNLAHLFLNGTGGQTHLSPNDPIFVLLHTFTDAVFDEWLRRYNADISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYEIQWPS","Homo sapiens","TYRP1, CAS2, TYRP, TYRRP","5,6-dihydroxyindole-2-carboxylic acid oxidase","1","5M8L"
"5M8M",,"X-RAY DIFFRACTION",3.03,59.41,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290,"10.1002/anie.201704616",,"5M8M",214.04,"2.65","2.65","Crystal structure of human tyrosinase related protein 1 in complex with kojic acid","QFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSSGRGRCEAVTADSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGAACDQRVLIVRRNLLDLSKEEKNHFVRALDMAKRTTHPLFVIATRRSEEILGPDGNTPQFENISIYNYFVWTHYYSVKKTFLGVGQESFGEVDFSHEGPAFLTWHRYHLLRLEKDMQEMLQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWRVVCDSLEDYDTLGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRNTVEGYSDPTGKYDPAVRSLHNLAHLFLNGTGGQTHLSPNDPIFVLLHTFTDAVFDEWLRRYNADISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYEIQWPS","Homo sapiens","TYRP1, CAS2, TYRP, TYRRP","5,6-dihydroxyindole-2-carboxylic acid oxidase","1","5M8M"
"5M8N",,"X-RAY DIFFRACTION",3.01,59.09,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290,"10.1002/anie.201704616",,"5M8N",213.21,"2.6","2.6","Crystal structure of human tyrosinase related protein 1 in complex with mimosine","QFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSSGRGRCEAVTADSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGAACDQRVLIVRRNLLDLSKEEKNHFVRALDMAKRTTHPLFVIATRRSEEILGPDGNTPQFENISIYNYFVWTHYYSVKKTFLGVGQESFGEVDFSHEGPAFLTWHRYHLLRLEKDMQEMLQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWRVVCDSLEDYDTLGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRNTVEGYSDPTGKYDPAVRSLHNLAHLFLNGTGGQTHLSPNDPIFVLLHTFTDAVFDEWLRRYNADISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYEIQWPS","Homo sapiens","TYRP1, CAS2, TYRP, TYRRP","5,6-dihydroxyindole-2-carboxylic acid oxidase","1","5M8N"
"5M8O",,"X-RAY DIFFRACTION",2.97,58.53,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290,"10.1002/anie.201704616",,"5M8O",214.73,"2.5","2.5","Crystal structure of human tyrosinase related protein 1 in complex with tropolone","QFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSSGRGRCEAVTADSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGAACDQRVLIVRRNLLDLSKEEKNHFVRALDMAKRTTHPLFVIATRRSEEILGPDGNTPQFENISIYNYFVWTHYYSVKKTFLGVGQESFGEVDFSHEGPAFLTWHRYHLLRLEKDMQEMLQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWRVVCDSLEDYDTLGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRNTVEGYSDPTGKYDPAVRSLHNLAHLFLNGTGGQTHLSPNDPIFVLLHTFTDAVFDEWLRRYNADISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYEIQWPS","Homo sapiens","TYRP1, CAS2, TYRP, TYRRP","5,6-dihydroxyindole-2-carboxylic acid oxidase","1","5M8O"
"5M8P",,"X-RAY DIFFRACTION",2.97,58.62,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290,"10.1002/anie.201704616",,"5M8P",215.12,"2.8","2.8","Crystal structure of human tyrosinase related protein 1 in complex with tyrosine","QFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSSGRGRCEAVTADSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGAACDQRVLIVRRNLLDLSKEEKNHFVRALDMAKRTTHPLFVIATRRSEEILGPDGNTPQFENISIYNYFVWTHYYSVKKTFLGVGQESFGEVDFSHEGPAFLTWHRYHLLRLEKDMQEMLQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWRVVCDSLEDYDTLGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRNTVEGYSDPTGKYDPAVRSLHNLAHLFLNGTGGQTHLSPNDPIFVLLHTFTDAVFDEWLRRYNADISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYEIQWPS","Homo sapiens","TYRP1, CAS2, TYRP, TYRRP","5,6-dihydroxyindole-2-carboxylic acid oxidase","1","5M8P"
"5M8Q",,"X-RAY DIFFRACTION",2.98,58.76,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290,"10.1002/anie.201704616",,"5M8Q",210.39,"2.85","2.85","Crystal structure of human tyrosinase related protein 1 mutant (T391V-R374S-Y362F) in complex with kojic acid","QFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSSGRGRCEAVTADSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGAACDQRVLIVRRNLLDLSKEEKNHFVRALDMAKRTTHPLFVIATRRSEEILGPDGNTPQFENISIYNYFVWTHYYSVKKTFLGVGQESFGEVDFSHEGPAFLTWHRYHLLRLEKDMQEMLQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWRVVCDSLEDYDTLGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRNTVEGFSDPTGKYDPAVSSLHNLAHLFLNGTGGQVHLSPNDPIFVLLHTFTDAVFDEWLRRYNADISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYEIQWPS","Homo sapiens","TYRP1, CAS2, TYRP, TYRRP","5,6-dihydroxyindole-2-carboxylic acid oxidase","1","5M8Q"
"5M8R",,"X-RAY DIFFRACTION",2.95,58.29,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290,"10.1002/anie.201704616",,"5M8R",210.93,"2.4","2.4","Crystal structure of human tyrosinase related protein 1 (T391V-R374S-Y362F) in complex with mimosine","QFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSSGRGRCEAVTADSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGAACDQRVLIVRRNLLDLSKEEKNHFVRALDMAKRTTHPLFVIATRRSEEILGPDGNTPQFENISIYNYFVWTHYYSVKKTFLGVGQESFGEVDFSHEGPAFLTWHRYHLLRLEKDMQEMLQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWRVVCDSLEDYDTLGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRNTVEGFSDPTGKYDPAVSSLHNLAHLFLNGTGGQVHLSPNDPIFVLLHTFTDAVFDEWLRRYNADISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYEIQWPS","Homo sapiens","TYRP1, CAS2, TYRP, TYRRP","5,6-dihydroxyindole-2-carboxylic acid oxidase","1","5M8R"
"5M8S",,"X-RAY DIFFRACTION",3.03,59.39,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290,,,"5M8S",212.93,"2.2","2.2","Crystal structure of human tyrosinase related protein 1 mutant (T391V-R374S-Y362F) in complex with phenylthiourea (PTU)","QFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSSGRGRCEAVTADSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGAACDQRVLIVRRNLLDLSKEEKNHFVRALDMAKRTTHPLFVIATRRSEEILGPDGNTPQFENISIYNYFVWTHYYSVKKTFLGVGQESFGEVDFSHEGPAFLTWHRYHLLRLEKDMQEMLQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWRVVCDSLEDYDTLGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRNTVEGFSDPTGKYDPAVSSLHNLAHLFLNGTGGQVHLSPNDPIFVLLHTFTDAVFDEWLRRYNADISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYEIQWPS","Homo sapiens","TYRP1, CAS2, TYRP, TYRRP","5,6-dihydroxyindole-2-carboxylic acid oxidase","1","5M8S"
"5M8T",,"X-RAY DIFFRACTION",2.98,58.79,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris (pH 7.0),
0.2 M NaCl and 30% (w/v) PEG 3000",290,"10.1002/anie.201704616",,"5M8T",213.38,"2.35","2.35","Crystal structure of human tyrosinase related protein 1 (T391V-R374S-Y362F) in complex with tropolone","QFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSSGRGRCEAVTADSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGAACDQRVLIVRRNLLDLSKEEKNHFVRALDMAKRTTHPLFVIATRRSEEILGPDGNTPQFENISIYNYFVWTHYYSVKKTFLGVGQESFGEVDFSHEGPAFLTWHRYHLLRLEKDMQEMLQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWRVVCDSLEDYDTLGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRNTVEGFSDPTGKYDPAVSSLHNLAHLFLNGTGGQVHLSPNDPIFVLLHTFTDAVFDEWLRRYNADISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYEIQWPS","Homo sapiens","TYRP1, CAS2, TYRP, TYRRP","5,6-dihydroxyindole-2-carboxylic acid oxidase","1","5M8T"
"5M93",,"X-RAY DIFFRACTION",2.47,50.2,"VAPOR DIFFUSION, SITTING DROP",,"0.1M sodium acetate pH 4 - 5.5, 0.2M lithium sulfate and 30% PEG 8000",291,"10.1016/j.cell.2016.11.019",,"5M93",27.06,"1.793","1.793","Crystal structure of SdeA-modified ubiquitin.","GPLGSQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBB","Polyubiquitin-B","1","5M93"
"5M96",,"X-RAY DIFFRACTION",3.12,60.52,"VAPOR DIFFUSION, HANGING DROP",7,"1.75M NaFormate, 0.1M PIPES",298,"10.1002/cmdc.201600500",,"5M96",55.51,"1.77","1.77","Synthesis and biological evaluation of new triazolo and imidazolopyridine RORgt inverse agonists","GPYASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLSKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHP","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5M96"
"5M9A",,"X-RAY DIFFRACTION",1.83,32.85,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Na/K tartrate
20% PEG 3350",289,"10.1038/srep41996",,"5M9A",14.47,"1.95","1.95","Human angiogenin PD variant H13R","MQDNSRYTHFLTQRYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRRP","Homo sapiens","ANG, RNASE5","Angiogenin","1","5M9A"
"5M9C",,"X-RAY DIFFRACTION",3.13,60.75,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.4 M Na/K tartrate
0.1 M Na citrate
20 % PEG 4000",289,"10.1038/srep41996",,"5M9C",14.58,"2.05","2.05","Human angiogenin ALS variant K40R","MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCRDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRRP","Homo sapiens","ANG, RNASE5","Angiogenin","1","5M9C"
"5M9G",,"X-RAY DIFFRACTION",3.18,61.35,"VAPOR DIFFUSION, HANGING DROP",7,"0.2 M Na/K tartrate
0.1 M HEPES
3% propanol
20% PEG 8000",289,"10.1038/srep41996",,"5M9G",14.58,"2.28","2.28","Human angiogenin PD variant K54R","MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIRAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRRP","Homo sapiens","ANG, RNASE5","Angiogenin","1","5M9G"
"5M9J",,"X-RAY DIFFRACTION",3.17,61.17,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M Na/K tartrate
0.1 M Na cacodylate
25% PEG 4000",289,"10.1038/srep41996",,"5M9J",14.45,"1.9","1.9","Human angiogenin PD variant K60E","MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENENGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRRP","Homo sapiens","ANG, RNASE5","Angiogenin","1","5M9J"
"5M9M",,"X-RAY DIFFRACTION",2.35,47.73,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2 M ammonium sulphate
0.1 M bis-tris methane
25% PEG 3350",289,"10.1038/srep41996",,"5M9M",58.99,"1.65","1.65","Human angiogenin PD variant Q77P","MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFPVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRRP","Homo sapiens","ANG, RNASE5","Angiogenin","1","5M9M"
"5M9P",,"X-RAY DIFFRACTION",2.3,46.58,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M ammonium sulphate
0.1 M bis-tris propane
25% PEG 3350",289,"10.1038/srep41996",,"5M9P",14.67,"1.8","1.8","Human angiogenin ALS variant T80S","MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTSCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRRP","Homo sapiens","ANG, RNASE5","Angiogenin","1","5M9P"
"5M9Q",,"X-RAY DIFFRACTION",2.33,47.22,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M ammonium sulphate
0.1 M Na cacodylate
30% PEG 8000",289,"10.1038/srep41996",,"5M9Q",15.12,"1.35","1.35","Human angiogenin PD variant R95Q","MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYQATAGFRNVVVACENGLPVHLDQSIFRRP","Homo sapiens","ANG, RNASE5","Angiogenin","1","5M9Q"
"5M9R",,"X-RAY DIFFRACTION",1.97,37.62,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M Na/K tartrate
0.1 M Na cacodylate
20% PEG 4000",289,"10.1038/srep41996",,"5M9R",29.24,"1.44","1.44","Human angiogenin ALS variant F100I","MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGIRNVVVACENGLPVHLDQSIFRRP","Homo sapiens","ANG, RNASE5","Angiogenin","1","5M9R"
"5M9S",,"X-RAY DIFFRACTION",3.12,60.62,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M Na/K tartrate
0.1 M MES
20% PEG 4000",289,"10.1038/srep41996",,"5M9S",14.46,"1.85","1.85","Human angiogenin ALS variant V103I","MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNIVVACENGLPVHLDQSIFRRP","Homo sapiens","ANG, RNASE5","Angiogenin","1","5M9S"
"5M9T",,"X-RAY DIFFRACTION",2.87,57.19,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.01 M Na borate
1.1 M Na citrate",289,"10.1038/srep41996",,"5M9T",28.81,"2.2","2.2","Human angiogenin ALS variant H114R","MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVRLDQSIFRRP","Homo sapiens","ANG, RNASE5","Angiogenin","1","5M9T"
"5M9V",,"X-RAY DIFFRACTION",3.2,61.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M Na/K tartrate
0.1 M bis-tris propane
16% PEG 4000",289,"10.1038/srep41996",,"5M9V",14.7,"1.7","1.7","Human angiogenin PD/ALS variant R121C","MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFCRP","Homo sapiens","ANG, RNASE5","Angiogenin","1","5M9V"
"5MAE",,"X-RAY DIFFRACTION",1.97,37.56,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG3350, 0.1M Bis-Tris",295,"10.1002/cmdc.201600563",,"5MAE",24.81,"1","1","CATHEPSIN L IN COMPLEX WITH (2S,4R)-4-(2-Chloro-4-methoxy-benzenesulfonyl)-1-[3-(5-chloro-pyridin-2-yl)-azetidine-3-carbonyl]-pyrrolidine-2-car boxylic acid (1-cyano-cyclopropyl)-amide","APRSVDWREKGYVTPVKNQGQCGSCWAFSATGALEGQMFRKTGRLISLSEQNLVDCSGPQGNEGCNGGLMDYAFQYVQDNGGLDSEESYPYEATEESCKYNPKYSVANDTGFVDIPKQEKALMKAVATVGPISVAIDAGHESFLFYKEGIYFEPDCSSEDMDHGVLVVGYGFESTESDNNKYWLVKNSWGEEWGMGGYVKMAKDRRNHCGIASAASYPTV","Homo sapiens","CTSL, CTSL1","Cathepsin L1","1","5MAE"
"5MAF",,"X-RAY DIFFRACTION",2.17,43.22,"VAPOR DIFFUSION, HANGING DROP",6.5,"10-20% PEG 3350 or PEG 4000, 0.1 M BIS TRIS pH 6.5, 0.6M NaCl",293,"10.1126/science.aan4368","XIN","5MAF",40.87,"2.8","2.8","Crystal structure of MELK in complex with an inhibitor","GPKDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKIMDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQMLQVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCVTELSVHHRNNRQTMEDLISLWQYDHLTATYLLLLAKKARGKPVRLRLSSFSCGHHHHHH","Homo sapiens","MELK, KIAA0175","Maternal embryonic leucine zipper kinase","1","5MAF"
"5MAG",,"X-RAY DIFFRACTION",2.26,45.28,"VAPOR DIFFUSION, HANGING DROP",6.5,"10-20% PEG 3350 or PEG 4000, 0.1 M BIS TRIS pH 6.5, 0.6M NaCl",293,"10.1126/science.aan4368",,"5MAG",40.88,"2.35","2.35","Crystal structure of MELK in complex with an inhibitor","GPKDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKIMDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQMLQVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCVTELSVHHRNNRQTMEDLISLWQYDHLTATYLLLLAKKARGKPVRLRLSSFSCGHHHHHH","Homo sapiens","MELK, KIAA0175","Maternal embryonic leucine zipper kinase","1","5MAG"
"5MAH",,"X-RAY DIFFRACTION",2.15,42.76,"VAPOR DIFFUSION, HANGING DROP",6.5,"10-20% PEG 3350 or PEG 4000, 0.1 M BIS TRIS pH 6.5, 0.6M NaCl",293,"10.1126/science.aan4368",,"5MAH",40.9,"2","2","Crystal structure of MELK in complex with an inhibitor","GPKDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKIMDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQMLQVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCVTELSVHHRNNRQTMEDLISLWQYDHLTATYLLLLAKKARGKPVRLRLSSFSCGHHHHHH","Homo sapiens","MELK, KIAA0175","Maternal embryonic leucine zipper kinase","1","5MAH"
"5MAI",,"X-RAY DIFFRACTION",2.51,50.92,"VAPOR DIFFUSION, HANGING DROP",6.5,"10-20% PEG 3350 or PEG 4000, 0.1 M BIS TRIS pH 6.5, 0.6M NaCl",293,"10.1126/science.aan4368",,"5MAI",40.76,"2.15","2.15","Crystal structure of MELK in complex with an inhibitor","GPKDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKIMDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQMLQVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCVTELSVHHRNNRQTMEDLISLWQYDHLTATYLLLLAKKARGKPVRLRLSSFSCGHHHHHH","Homo sapiens","MELK, KIAA0175","Maternal embryonic leucine zipper kinase","1","5MAI"
"5MAJ",,"X-RAY DIFFRACTION",2.03,39.36,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% PEG3350, 0.2M ammonium acetate, 0.1M HEPES",295,"10.1002/cmdc.201600563",,"5MAJ",24.66,"1","1","CATHEPSIN L IN COMPLEX WITH 4-[cyclopentyl(imidazo[1,2-a]pyridin-2-ylmethyl)amino]-6-morpholino-1,3,5-triazine-2-carbonitrile","APRSVDWREKGYVTPVKNQGQCGSCWAFSATGALEGQMFRKTGRLISLSEQNLVDCSGPQGNEGCNGGLMDYAFQYVQDNGGLDSEESYPYEATEESCKYNPKYSVANDTGFVDIPKQEKALMKAVATVGPISVAIDAGHESFLFYKEGIYFEPDCSSEDMDHGVLVVGYGFESTESDNNKYWLVKNSWGEEWGMGGYVKMAKDRRNHCGIASAASYPTV","Homo sapiens","CTSL, CTSL1","Cathepsin L1","1","5MAJ"
"5MAM",,"X-RAY DIFFRACTION",2.2,43.9,"VAPOR DIFFUSION, HANGING DROP",7.5,"Zn-free human insulin was dissolved in 20 mM HCl at 5 mg/mL. The well solution contained 5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5,  40 mM serotonin. Hanging drops were set up in 1:1 protein:well volume ratios.",293,"10.1074/jbc.M117.775924","SRO","5MAM",96.36,"2.2","2.2","Human insulin in complex with serotonin","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin A chain","1","5MAM"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKT","Homo sapiens","INS","Insulin B chain","2","5MAM"
"5MAR",,"X-RAY DIFFRACTION",2.45,49.74,"VAPOR DIFFUSION, HANGING DROP",5.8,"15-18 % PEG 10,000, 0.1M ammonium acetate, and 0.1M Bis-Tris pH 5.8",293,"10.1021/acs.jmedchem.6b01609","7KE","5MAR",71.7,"1.89","1.89","Structure of human SIRT2 in complex with 1,2,4-Oxadiazole inhibitor and ADP ribose.","HMERLLDELTLEGVARYMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAELLGWKKELEDLVRREHASIDAQS","Homo sapiens","SIRT2, SIR2L, SIR2L2","NAD-dependent protein deacetylase sirtuin-2","1","5MAR"
"5MAT",,"X-RAY DIFFRACTION",2.32,47.09,"VAPOR DIFFUSION, HANGING DROP",5.83,"2.6M ammonium sulfate, 5% PEG 300, 0.1 M MES",293,"10.1021/acs.jmedchem.6b01690","7KJ","5MAT",71.17,"2.069","2.069","Structure of human Sirtuin 2 in complex with a selective thienopyrimidinone based inhibitor","HMERLLDELTLEGVARYMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAELLGWKKELEDLVRREHASIDAQS","Homo sapiens","SIRT2, SIR2L, SIR2L2","NAD-dependent protein deacetylase sirtuin-2","1","5MAT"
"5MBR",,"SOLUTION NMR",,,,,,,"10.1021/acschembio.6b01096",,"5MBR",7.65,,,"Quadruplex with flipped tetrad formed by a human telomeric sequence","TTXGGTTAXGGTTAGGGTTAXGGA","Homo sapiens",,"G-quadruplex formed by a human telomeric sequence modified with 2'-fluoro-2'-deoxyriboguanosine","1","5MBR"
"5MBY",,"X-RAY DIFFRACTION",2.8,56.04,"VAPOR DIFFUSION",6.9,"100mM NaCacodylate, 690-760mM NaCitrate",293,"10.1111/febs.14620",,"5MBY",108.9,"1.55","1.55","Crystal Structure of Arg184Gln mutant of Human Prolidase with Mn ions and GlyPro ligand","GPSFWLGNETLKVPLALFALNRQRLCERLRKNPAVQAGSIVVLQGGEETQRYCTDTGVLFRQESFFHWAFGVTEPGCYGVIDVDTGKSTLFVPRLPASHATWMGKIHSKEHFKEKYAVDDVQYVDEIASVLTSQKPSVLLTLRGVNTDSGSVCREASFDGISKFEVNNTILHPEIVECQVFKTDMELEVLRYTNKISSEAHREVMKAVKVGMKEYELESLFEHYCYSRGGMRHSSYTCICGSGENSAVLHYGHAGAPNDRTIQNGDMCLFDMGGEYYCFASDITCSFPANGKFTADQKAVYEAVLRSSRAVMGAMKPGVWWPDMHRLADRIHLEELAHMGILSGSVDAMVQAHLGAVFMPHGLGHFLGIDVHDVGGYPEGVERIDEPGLRSLRTARHLQPGMVLTVEPGIYFIDHLLDEALADPARASFLNREVLQRFRGFGGVRIEEDVVVTDSGIELLTCVPRTVEEIEACMAGCDKAFTPFS","Homo sapiens","PEPD, PRD","Xaa-Pro dipeptidase","1","5MBY"
"5MBZ",,"X-RAY DIFFRACTION",2.78,55.71,"VAPOR DIFFUSION",,"10mM NaBorate, 690-760mM NaCitrate",293,"10.1111/febs.14620",,"5MBZ",108.8,"1.5","1.5","Crystal Structure of Ser202Phe mutant of Human Prolidase with Mn ions and GlyPro ligand","GPSFWLGNETLKVPLALFALNRQRLCERLRKNPAVQAGSIVVLQGGEETQRYCTDTGVLFRQESFFHWAFGVTEPGCYGVIDVDTGKSTLFVPRLPASHATWMGKIHSKEHFKEKYAVDDVQYVDEIASVLTSQKPSVLLTLRGVNTDSGSVCREASFDGISKFEVNNTILHPEIVECRVFKTDMELEVLRYTNKIFSEAHREVMKAVKVGMKEYELESLFEHYCYSRGGMRHSSYTCICGSGENSAVLHYGHAGAPNDRTIQNGDMCLFDMGGEYYCFASDITCSFPANGKFTADQKAVYEAVLRSSRAVMGAMKPGVWWPDMHRLADRIHLEELAHMGILSGSVDAMVQAHLGAVFMPHGLGHFLGIDVHDVGGYPEGVERIDEPGLRSLRTARHLQPGMVLTVEPGIYFIDHLLDEALADPARASFLNREVLQRFRGFGGVRIEEDVVVTDSGIELLTCVPRTVEEIEACMAGCDKAFTPF","Homo sapiens","PEPD, PRD","Xaa-Pro dipeptidase","1","5MBZ"
"5MC0",,"X-RAY DIFFRACTION",2.78,55.82,"VAPOR DIFFUSION",7.4,"10mM NaBorate, 640mM NaCitrate",278,"10.1111/febs.14620",,"5MC0",108.49,"1.56","1.56","Crystal Structure of delTyr231 mutant of Human Prolidase with Mn ions and GlyPro ligand","GPSFWLGNETLKVPLALFALNRQRLCERLRKNPAVQAGSIVVLQGGEETQRYCTDTGVLFRQESFFHWAFGVTEPGCYGVIDVDTGKSTLFVPRLPASHATWMGKIHSKEHFKEKYAVDDVQYVDEIASVLTSQKPSVLLTLRGVNTDSGSVCREASFDGISKFEVNNTILHPEIVECRVFKTDMELEVLRYTNKISSEAHREVMKAVKVGMKEYELESLFEHYCSRGGMRHSSYTCICGSGENSAVLHYGHAGAPNDRTIQNGDMCLFDMGGEYYCFASDITCSFPANGKFTADQKAVYEAVLRSSRAVMGAMKPGVWWPDMHRLADRIHLEELAHMGILSGSVDAMVQAHLGAVFMPHGLGHFLGIDVHDVGGYPEGVERIDEPGLRSLRTARHLQPGMVLTVEPGIYFIDHLLDEALADPARASFLNREVLQRFRGFGGVRIEEDVVVTDSGIELLTCVPRTVEEIEACMAGCDKAF","Homo sapiens","PEPD, PRD","Xaa-Pro dipeptidase","1","5MC0"
"5MC1",,"X-RAY DIFFRACTION",2.76,55.49,"VAPOR DIFFUSION",7.4,"10mM NaBorate, 760mM NaCitrate",278,"10.1111/febs.14620",,"5MC1",109.25,"1.43","1.43","Crystal Structure of Asp276Asn mutant of Human Prolidase with Mn ions and GlyPro ligand","GPSFWLGNETLKVPLALFALNRQRLCERLRKNPAVQAGSIVVLQGGEETQRYCTDTGVLFRQESFFHWAFGVTEPGCYGVIDVDTGKSTLFVPRLPASHATWMGKIHSKEHFKEKYAVDDVQYVDEIASVLTSQKPSVLLTLRGVNTDSGSVCREASFDGISKFEVNNTILHPEIVECRVFKTDMELEVLRYTNKISSEAHREVMKAVKVGMKEYELESLFEHYCYSRGGMRHSSYTCICGSGENSAVLHYGHAGAPNDRTIQNGDMCLFNMGGEYYCFASDITCSFPANGKFTADQKAVYEAVLRSSRAVMGAMKPGVWWPDMHRLADRIHLEELAHMGILSGSVDAMVQAHLGAVFMPHGLGHFLGIDVHDVGGYPEGVERIDEPGLRSLRTARHLQPGMVLTVEPGIYFIDHLLDEALADPARASFLNREVLQRFRGFGGVRIEEDVVVTDSGIELLTCVPRTVEEIEACMAGCDKAFTPFS","Homo sapiens","PEPD, PRD","Xaa-Pro dipeptidase","1","5MC1"
"5MC2",,"X-RAY DIFFRACTION",2.76,55.49,"VAPOR DIFFUSION",7.4,"10mM NaBorate, 760mM NaCitrate",278,"10.1111/febs.14620",,"5MC2",108.74,"1.7","1.7","Crystal Structure of Gly278Asp mutant of Human Prolidase with Mn ions and GlyPro ligand","AGPSFWLGNETLKVPLALFALNRQRLCERLRKNPAVQAGSIVVLQGGEETQRYCTDTGVLFRQESFFHWAFGVTEPGCYGVIDVDTGKSTLFVPRLPASHATWMGKIHSKEHFKEKYAVDDVQYVDEIASVLTSQKPSVLLTLRGVNTDSGSVCREASFDGISKFEVNNTILHPEIVECRVFKTDMELEVLRYTNKISSEAHREVMKAVKVGMKEYELESLFEHYCYSRGGMRHSSYTCICGSGENSAVLHYGHAGAPNDRTIQNGDMCLFDMDGEYYCFASDITCSFPANGKFTADQKAVYEAVLRSSRAVMGAMKPGVWWPDMHRLADRIHLEELAHMGILSGSVDAMVQAHLGAVFMPHGLGHFLGIDVHDVGGYPEGVERIDEPGLRSLRTARHLQPGMVLTVEPGIYFIDHLLDEALADPARASFLNREVLQRFRGFGGVRIEEDVVVTDSGIELLTCVPRTVEEIEACMAGCDKAFTP","Homo sapiens","PEPD, PRD","Xaa-Pro dipeptidase","1","5MC2"
"5MC3",,"X-RAY DIFFRACTION",2.78,55.71,"VAPOR DIFFUSION",,"10mM NaBorate, 690-760mM NaCitrate",293,"10.1111/febs.14620",,"5MC3",109.09,"1.52","1.52","Crystal Structure of Glu412Lys mutant of Human Prolidase with Mn ions and GlyPro ligand","GPSFWLGNETLKVPLALFALNRQRLCERLRKNPAVQAGSIVVLQGGEETQRYCTDTGVLFRQESFFHWAFGVTEPGCYGVIDVDTGKSTLFVPRLPASHATWMGKIHSKEHFKEKYAVDDVQYVDEIASVLTSQKPSVLLTLRGVNTDSGSVCREASFDGISKFEVNNTILHPEIVECRVFKTDMELEVLRYTNKISSEAHREVMKAVKVGMKEYELESLFEHYCYSRGGMRHSSYTCICGSGENSAVLHYGHAGAPNDRTIQNGDMCLFDMGGEYYCFASDITCSFPANGKFTADQKAVYEAVLRSSRAVMGAMKPGVWWPDMHRLADRIHLEELAHMGILSGSVDAMVQAHLGAVFMPHGLGHFLGIDVHDVGGYPEGVERIDEPGLRSLRTARHLQPGMVLTVKPGIYFIDHLLDEALADPARASFLNREVLQRFRGFGGVRIEEDVVVTDSGIELLTCVPRTVEEIEACMAGCDKAFTPF","Homo sapiens","PEPD, PRD","Xaa-Pro dipeptidase","1","5MC3"
"5MC4",,"X-RAY DIFFRACTION",2.74,55.06,"VAPOR DIFFUSION",,"10mM NaBorate, 690-760mM NaCitrate",293,"10.1111/febs.14620",,"5MC4",108.13,"1.8","1.8","Crystal Structure of Gly448Arg mutant of Human Prolidase with Mn ions and GlyPro ligand","GPSFWLGNETLKVPLALFALNRQRLCERLRKNPAVQAGSIVVLQGGEETQRYCTDTGVLFRQESFFHWAFGVTEPGCYGVIDVDTGKSTLFVPRLPASHATWMGKIHSKEHFKEKYAVDDVQYVDEIASVLTSQKPSVLLTLRGVNTDSGSVCREASFDGISKFEVNNTILHPEIVECRVFKTDMELEVLRYTNKISSEAHREVMKAVKVGMKEYELESLFEHYCYSRGGMRHSSYTCICGSGENSAVLHYGHAGAPNDRTIQNGDMCLFDMGGEYYCFASDITCSFPANGKFTADQKAVYEAVLRSSRAVMGAMKPGVWWPDMHRLADRIHLEELAHMGILSGSVDAMVQAHLGAVFMPHGLGHFLGIDVHDVGGYPEGVERIDEPGLRSLRTARHLQPGMVLTVEPGIYFIDHLLDEALADPARASFLNREVLQRFRGFGRVRIEEDVVVTDSGIELLTCVPRTVEEIEACMAGCDKAFT","Homo sapiens","PEPD, PRD","Xaa-Pro dipeptidase","1","5MC4"
"5MC5",,"X-RAY DIFFRACTION",2.78,55.75,"VAPOR DIFFUSION",,"10mM NaBorate, 690-760mM NaCitrate",293,"10.1111/febs.14620",,"5MC5",107.03,"1.9","1.9","Crystal Structure of delGlu452 mutant of Human Prolidase with Mn ions and GlyPro ligand","GPSFWLGNETLKVPLALFALNRQRLCERLRKNPAVQAGSIVVLQGGEETQRYCTDTGVLFRQESFFHWAFGVTEPGCYGVIDVDTGKSTLFVPRLPASHATWMGKIHSKEHFKEKYAVDDVQYVDEIASVLTSQKPSVLLTLRGVNTDSGSVCREASFDGISKFEVNNTILHPEIVECRVFKTDMELEVLRYTNKISSEAHREVMKAVKVGMKEYELESLFEHYCYSRGGMRHSSYTCICGSGENSAVLHYGHAGAPNDRTIQNGDMCLFDMGGEYYCFASDITCSFPANGKFTADQKAVYEAVLRSSRAVMGAMKPGVWWPDMHRLADRIHLEELAHMGILSGSVDAMVQAHLGAVFMPHGLGHFLGIDVHDVGGYPEGVERIDEPGLRSLRTARHLQPGMVLTVEPGIYFIDHLLDEALADPARASFLNREVLQRFRGFGGVRIEDVVVTDSGIELLTCVPRTVEEIEACMAGCDK","Homo sapiens","PEPD, PRD","Xaa-Pro dipeptidase","1","5MC5"
"5MC7",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, HANGING DROP",6.2,"2.2 M DL-Malic acid
0.2 M Na Malonate",295,"10.1107/S2053230X16018896",,"5MC7",33.39,"1.6","1.6","Crystal structure of Truncated Human Coatomer Protein Complex, subunit Z1 (CopZ1)","GAMEPSLYTVKAILILDNDGDRLFAKYYDDTYPSVKEQKAFEKNIFNKTHRTDSEIALLEGLTVVYKSSIDLYFYVIGSSYENELMLMAVLNCLFDSLSQMLRKNVEKRALLENMEGLFLAVDEIVDGGVILESDPQQVVHRVALRG","Homo sapiens","COPZ1, COPZ, CGI-120, HSPC181","Coatomer subunit zeta-1","1","5MC7"
"5MDI",,"X-RAY DIFFRACTION",2.62,53.13,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M sodium cacodylate pH 6.5, 1.4 M sodium acetate",277.15,"10.1038/s41467-017-00062-0",,"5MDI",22.95,"2.1","2.1","Crystal structure of TDP-43 N-terminal domain at 2.1 A resolution","MGSSHHHHHHSSGLVPRGSHMASSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYVVNYPKD","Homo sapiens","TARDBP, TDP43","TAR DNA-binding protein 43","1","5MDI"
"5ME8",,"X-RAY DIFFRACTION",5.11,75.92,"VAPOR DIFFUSION, SITTING DROP",6.5,"22 % MPD, 0.1 M MES pH 6.5, 5% PEG 3350",273,"10.1016/j.jmb.2019.04.018",,"5ME8",25.8,"3.2","3.2","N-terminal domain of the human tumor suppressor ING5","GAMATAMYLEHYLDSIENLPCELQRNFQLMRELDQRTEDKKAEIDILAAEYISTVKTLSPDQRVERLQKIQNAYSKCKEYSDDKVQLAMQTYEMVDKHIRRLDADLA","Homo sapiens","ING5","Inhibitor of growth protein 5","1","5ME8"
"5MF6",,"X-RAY DIFFRACTION",2.59,52.45,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, Bis-Tris buffer pH 5.7",293,"10.1002/anie.201610082","7M2","5MF6",70.11,"1.87","1.87","Human Sirt6 in complex with activator UBCS039","GIDPFTADKGKCGLPEIFDPPEELERKVWELARLVWQSSSVVFHTGAGISTASGIPDFRGPHGVWTMEERGLAPKFDTTFESARPTQTHMALVQLERVGLLRFLVSQNVDGLHVRSGFPRDKLAELHGNMFVEECAKCKTQYVRDTVVGTMGLKATGRLCTVAKARGLRACRGELRDTILDWEDSLPDRDLALADEASRNADLSITLGTSLQIRPSGNLPLATKRRGGRLVIVNLQPTKHDRHADLRIHGYVDEVMTRLMKHLGLEIPAWDGPRVLERALPPLPRPPTPKLEPKEESPTRIN","Homo sapiens","SIRT6, SIR2L6","NAD-dependent protein deacetylase sirtuin-6","1","5MF6"
"5MFA",,"X-RAY DIFFRACTION",2.59,52.51,"VAPOR DIFFUSION, HANGING DROP",,"10% w/v PEG20000, 20% PEG MME 550, 0.1 mM Tris-Bicine, pH 8.5, 0.05 mM CaCl2",295.15,"10.1074/jbc.M117.775031",,"5MFA",82.74,"1.2","1.2","Crystal structure of human promyeloperoxidase (proMPO)","AAPAVLGEVDTSLVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLHVALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMCNNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTDQLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPNDPRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQLGLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLLREHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYRSYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLEGGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYNAWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPLLACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMSNSYPRDFVNCSTLPALNLASWREAS","Homo sapiens","MPO","Myeloperoxidase","1","5MFA"
"5MFP",,"X-RAY DIFFRACTION",2.59,52.45,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293,"10.1002/anie.201610082",,"5MFP",70.46,"1.98","1.98","Human Sirt6 in complex with activator UBCS58","GIDPFTADKGKCGLPEIFDPPEELERKVWELARLVWQSSSVVFHTGAGISTASGIPDFRGPHGVWTMEERGLAPKFDTTFESARPTQTHMALVQLERVGLLRFLVSQNVDGLHVRSGFPRDKLAELHGNMFVEECAKCKTQYVRDTVVGTMGLKATGRLCTVAKARGLRACRGELRDTILDWEDSLPDRDLALADEASRNADLSITLGTSLQIRPSGNLPLATKRRGGRLVIVNLQPTKHDRHADLRIHGYVDEVMTRLMKHLGLEIPAWDGPRVLERALPPLPRPPTPKLEPKEESPTRIN","Homo sapiens","SIRT6, SIR2L6","NAD-dependent protein deacetylase sirtuin-6","1","5MFP"
"5MFY",,"SOLUTION NMR",,,,,,,"10.7554/eLife.14707",,"5MFY",7.44,,,"RBM5 OCRE domain","GAMGTKYAVPDTSTYQYDESSGYYYDPTTGLYYDPNSQYYYNSLTQQYLYWDGEKETYVPAAES","Homo sapiens","RBM5, H37, LUCA15","RNA-binding protein 5","1","5MFY"
"5MFZ",,"X-RAY DIFFRACTION",2.59,52.49,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293,"10.1002/anie.201610082",,"5MFZ",69.65,"2.1","2.1","Human Sirt6 in complex with small molecule UBCS40","GIDPFTADKGKCGLPEIFDPPEELERKVWELARLVWQSSSVVFHTGAGISTASGIPDFRGPHGVWTMEERGLAPKFDTTFESARPTQTHMALVQLERVGLLRFLVSQNVDGLHVRSGFPRDKLAELHGNMFVEECAKCKTQYVRDTVVGTMGLKATGRLCTVAKARGLRACRGELRDTILDWEDSLPDRDLALADEASRNADLSITLGTSLQIRPSGNLPLATKRRGGRLVIVNLQPTKHDRHADLRIHGYVDEVMTRLMKHLGLEIPAWDGPRVLERALPPLPRPPTPKLEPKEESPTRIN","Homo sapiens","SIRT6, SIR2L6","NAD-dependent protein deacetylase sirtuin-6","1","5MFZ"
"5MG2",,"X-RAY DIFFRACTION",1.93,36.21,"VAPOR DIFFUSION, SITTING DROP",7.5,"20%PEG 10K, 0.20 M NaCl, 0.1M citrate/phosphate pH 4.2",277.15,"10.1021/acs.jmedchem.7b00306","7M8","5MG2",16.5,"1.75","1.75","Crystal structure of the second bromodomain of human TAF1 in complex with BAY-299 chemical probe","SMDDDQVAFSFILDNIVTQKMMAVPDSWPFHHPVNKKFVPDYYKVIVNPMDLETIRKNISKHKYQSRESFLDDVNLILANSVKYNGPESQYTKTAQEIVNVCYQTLTEYDEHLTQLEKDICTAKEAALEEAELESLD","Homo sapiens","TAF1, BA2R, CCG1, CCGS, TAF2A","Transcription initiation factor TFIID subunit 1","1","5MG2"
"5MGE",,"X-RAY DIFFRACTION",4.14,70.31,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1016/j.ejmech.2017.08.028","7MX","5MGE",13.75,"1.95","1.95","Crystal structure of BAZ2B bromodomain in complex with 1-methylpyridine derivative 1","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5MGE"
"5MGF",,"X-RAY DIFFRACTION",4.14,70.29,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1016/j.ejmech.2017.08.028","7MW","5MGF",13.71,"1.9","1.9","Crystal Structure of BAZ2B bromodomain in complex with 4-propionyl-pyrrole derivative 2","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5MGF"
"5MGG",,"X-RAY DIFFRACTION",4.15,70.35,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1016/j.ejmech.2017.08.028","7MU","5MGG",13.7,"2.1","2.1","Crystal Structure of BAZ2B bromodomain in complex with 4-chloropyridine derivative 3","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5MGG"
"5MGH",,"X-RAY DIFFRACTION",2.52,51.19,"VAPOR DIFFUSION, HANGING DROP",,"2 mM DTT, 100 mM bis-Tris propane pH 7 and 1.8 M sodium acetate pH 7",292,"10.1002/pro.3176",,"5MGH",47.61,"1.87","1.87","Crystal structure of pathogenic mutants of human mitochodnrial PheRS","PGSVVELLGKSYPQDDHSNLTRKVLTRVGRNLHNQQHHALWLIKERVKEHFYKQYVGRFGTPLFSVYDNLSPVVTTWQNFDSLLIPADHPSRKKGDNYYLNRTHMLRAHTSAHQWDLLHAGLDAFLVVGDVYRRDQIDSQHYPIFHQLEAVRLFSKHELFAGIKDGESLQLFEQSSRSAHKQETHTMEAVKLVEFDLKQTLTRLMAHLFGDELEIRWVDCYFPFTHPSFEMEINFHGEWLEVLGCGVMEQQLVNSAGAQDRIGWAFGLGLERLAMILYDIPDIRLFWCEDERFLKQFCVSNINQKVKFQPLSKYPAVINDISFWLPSENYAENDFYDLVRTIGGDLVEKVDLIDKFVHPKTHKTSHCYRITYRHMERTLSQREVRHIHQALQEAAVQLLGVEGRF","Homo sapiens","FARS2, FARS1, HSPC320","Phenylalanine--tRNA ligase, mitochondrial","1","5MGH"
"5MGJ",,"X-RAY DIFFRACTION",3.52,65.08,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 0.2 M MgCl2",277,"10.1016/j.ejmech.2017.08.028","7MX","5MGJ",12.6,"2.1","2.1","Crystal Structure of BAZ2A bromodomain in complex with 1-methylpyridine derivative 1","SMHSDLTFCEIILMEMESHDAAWPFLEPVNPRLVSGYRRIIKNPMDFSTMRERLLRGGYTSSEEFAADALLVFDNCQTFNEDDSEVGKAGHIMRRFFESRWEEFY","Homo sapiens","BAZ2A, KIAA0314, TIP5","Bromodomain adjacent to zinc finger domain protein 2A","1","5MGJ"
"5MGK",,"X-RAY DIFFRACTION",3.49,64.71,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 0.2 M MgCl2",277,"10.1016/j.ejmech.2017.08.028","7MW","5MGK",12.56,"2.301","2.301","Crystal Structure of BAZ2A bromodomain in complex with 4-propionyl-pyrrole derivative 2","SMHSDLTFCEIILMEMESHDAAWPFLEPVNPRLVSGYRRIIKNPMDFSTMRERLLRGGYTSSEEFAADALLVFDNCQTFNEDDSEVGKAGHIMRRFFESRWEEFY","Homo sapiens","BAZ2A, KIAA0314, TIP5","Bromodomain adjacent to zinc finger domain protein 2A","1","5MGK"
"5MGL",,"X-RAY DIFFRACTION",3.5,64.81,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 0.2 M MgCl2",277,"10.1016/j.ejmech.2017.08.028","7MU","5MGL",12.55,"2.651","2.651","Crystal Structure of BAZ2A bromodomain in complex with 4-chloropyridine derivative 3","SMHSDLTFCEIILMEMESHDAAWPFLEPVNPRLVSGYRRIIKNPMDFSTMRERLLRGGYTSSEEFAADALLVFDNCQTFNEDDSEVGKAGHIMRRFFESRWEEFY","Homo sapiens","BAZ2A, KIAA0314, TIP5","Bromodomain adjacent to zinc finger domain protein 2A","1","5MGL"
"5MGM",,"X-RAY DIFFRACTION",3.44,64.2,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 0.2 M MgCl2",277,"10.1016/j.ejmech.2017.08.028","7MZ","5MGM",12.6,"2.8","2.8","Crystal Structure of BAZ2A bromodomain in complex with acetophenone derivative 4","SMHSDLTFCEIILMEMESHDAAWPFLEPVNPRLVSGYRRIIKNPMDFSTMRERLLRGGYTSSEEFAADALLVFDNCQTFNEDDSEVGKAGHIMRRFFESRWEEFY","Homo sapiens","BAZ2A, KIAA0314, TIP5","Bromodomain adjacent to zinc finger domain protein 2A","1","5MGM"
"5MGN",,"X-RAY DIFFRACTION",2.64,53.38,"VAPOR DIFFUSION, HANGING DROP",5.7,"1.6 M (NH4)2SO4, 10% PEG 400, and Bis-Tris buffer pH 5.7",293,"10.1002/anie.201610082",,"5MGN",69.96,"2.07","2.07","Human Sirt6 in complex with activator UBCS38","GIDPFTADKGKCGLPEIFDPPEELERKVWELARLVWQSSSVVFHTGAGISTASGIPDFRGPHGVWTMEERGLAPKFDTTFESARPTQTHMALVQLERVGLLRFLVSQNVDGLHVRSGFPRDKLAELHGNMFVEECAKCKTQYVRDTVVGTMGLKATGRLCTVAKARGLRACRGELRDTILDWEDSLPDRDLALADEASRNADLSITLGTSLQIRPSGNLPLATKRRGGRLVIVNLQPTKHDRHADLRIHGYVDEVMTRLMKHLGLEIPAWDGPRVLERALPPLPRPPTPKLEPKEESPTRIN","Homo sapiens","SIRT6, SIR2L6","NAD-dependent protein deacetylase sirtuin-6","1","5MGN"
"5MGQ",,"SOLUTION NMR",,,,,,,"10.1038/srep44041",,"5MGQ",3.91,,,"Solution structure of oxidized and amidated human IAPP (1-37), the diabetes II peptide.","KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTX","Homo sapiens","IAPP","Islet amyloid polypeptide","1","5MGQ"
"5MGR",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, SITTING DROP",7.2,"20% (w/v) PEG 3350, 200 mM di-sodium tartrate pH 7.2
PROTEIN CONCENTRATION 20 MG/ML",294,,,"5MGR",36.8,"1.8","1.8","Human receptor NKR-P1 in glycosylated form, extracellular domain","ETGGLLNCPIYWQQLREKCLLFSHTVNPWNNSLADCSTKESSLLLIRDKDELIHTQNLIRDKAILFWIGLNFSLSEKNWKWINGSFLNSNDLEIRGDAKENSCISISQTSVYSEYCSTEIRWICQKELTPVRNKVYPDSKHHHHHH","Homo sapiens","KLRB1, CLEC5B, NKRP1A","Killer cell lectin-like receptor subfamily B member 1","1","5MGR"
"5MGS",,"X-RAY DIFFRACTION",2.13,42,"VAPOR DIFFUSION, SITTING DROP",6.2,"20% (w/v) PEG 3350, 200 mM ammonium fluoride, 200 mM lithium chloride pH 6.2, protein concentration 12 mg/ml.",294,,,"5MGS",140.41,"1.9","1.9","Human receptor NKR-P1 in deglycosylated form, extracellular domain","ETGGLLNCPIYWQQLREKCLLFSHTVNPWNNSLADCSTKESSLLLIRDKDELIHTQNLIRDKAILFWIGLNFSLSEKNWKWINGSFLNSNDLEIRGDAKENSCISISQTSVYSEYCSTEIRWICQKELTPVRNKVYPDSKHHHHHH","Homo sapiens","KLRB1, CLEC5B, NKRP1A","Killer cell lectin-like receptor subfamily B member 1","1","5MGS"
"5MGU",,"X-RAY DIFFRACTION",2.51,51.08,"VAPOR DIFFUSION, HANGING DROP",,"2 mM DTT, 100 mM bis-Tris propane pH 7 and 1.8 M sodium acetate pH 7",292,"10.1002/pro.3176",,"5MGU",47.81,"1.89","1.89","Kinetic and Structural Changes in HsmtPheRS, Induced by Pathogenic Mutations in Human FARS2","AAPGSVVELLGKSYPQDDHSNLTRKVLTRVGRNLHNQQHHPLWLIKERVKEHFYKQYVGRFGTPLFSVYDNLSPVVTTWQNFDSLLIPADHPSRKKGDNYYLNRTHMLRAHTSAHQWDLLHAGLDAFLVVGDVYRRDQIDSQHYPIFHQLEAVRLFSKHELFAGIKDGESLQLFEQSSRSAHKQETHTMEAVKLVEFDLKQMLTRLMAHLFGDELEIRWVDCYFPFTHPSFEMEINFHGEWLEVLGCGVMEQQLVNSAGAQDRIGWAFGLGLERLAMILYDIPDIRLFWCEDERFLKQFCVSNINQKVKFQPLSKYPAVINDISFWLPSENYAENDFYDLVRTIGGDLVEKVDLIDKFVHPKTHKTSHCYRITYRHMERTLSQREVRHIHQALQEAAVQLLGVEGRF","Homo sapiens","FARS2, FARS1, HSPC320","Phenylalanine--tRNA ligase, mitochondrial","1","5MGU"
"5MGV",,"X-RAY DIFFRACTION",2.48,50.37,"VAPOR DIFFUSION, HANGING DROP",,"2 mM DTT, 100 mM bis-Tris propane pH 7 and 1.8 M sodium acetate pH 7",292,"10.1002/pro.3176",,"5MGV",47.52,"2.05","2.05","Kinetic and Structural Changes in HsmtPheRS, Induced by Pathogenic Mutations in Human FARS2","PGSVVELLGKSYPQDDHSNLTRKVLTRVGRNLHNQQHHPLWLIKERVKEHFYKQYVGRFGTPLFSVYDNLSPVVTTWQNFDSLLIPADHPSRKKGDNYYLNRTHMLRAHTSAHQWDLLHAGLDAFLVVGDVYRRDQIDSQHYPIFHQLEAVRLFSKHELFAGIKDGESLQLFEQSSRSAHKQETHTMEAVKLVEFDLKQTLTRLMAHLFGDELEIRWVDCYFPFTHPSFEMEINFHGEWLEVLGCGVMEQQLVNSAGAQDRIGWAFGLGLERLAMILYYIPDIRLFWCEDERFLKQFCVSNINQKVKFQPLSKYPAVINDISFWLPSENYAENDFYDLVRTIGGDLVEKVDLIDKFVHPKTHKTSHCYRITYRHMERTLSQREVRHIHQALQEAAVQLLGVEGRF","Homo sapiens","FARS2, FARS1, HSPC320","Phenylalanine--tRNA ligase, mitochondrial","1","5MGV"
"5MGW",,"X-RAY DIFFRACTION",2.51,50.96,"VAPOR DIFFUSION, HANGING DROP",,"2 mM DTT, 100 mM bis-Tris propane pH 7 and 1.8 M sodium acetate pH 7",292,"10.1002/pro.3176",,"5MGW",47.65,"1.46","1.46","Kinetic and Structural Changes in HsmtPheRS, Induced by Pathogenic Mutations in Human FARS2","APGSVVELLGKSYPQDDHSNLTRKVLTRVGRNLHNQQHHPLWLIKERVKEHFYKQYVGRFGTPLFSVYDNLSPVVTTWQNFDSLLIPADHPSRKKGDNYYLNRTHMLRAHTSAHQWDLLHAGLDAFLVVGDVYRRDQIDSQHYPIFHQLEAVRLFSKHELFAGIKDGESLQLFEQSSRSAHKQETHTMEAVKLVEFDLKQTLTRLMAHLFGDELEIRWVDCYFPFTHPSFEMEINFHGEWLEVLGCGVMEQQLVNSAGAQDRIGWAFGLGLERLAMILYDIPDIRLFWCEDERFLKQFCVSNINQKVKFQPLSKYPAVINDISFWLPSENYAENDFYDLVRTIGGDLVEKVDLIDKFVHPKTHKTSHCYRITYCHMERTLSQREVRHIHQALQEAAVQLLGVEGRF","Homo sapiens","FARS2, FARS1, HSPC320","Phenylalanine--tRNA ligase, mitochondrial","1","5MGW"
"5MHD",,"SOLUTION NMR",,,,,,,"10.1016/j.jpba.2016.12.005",,"5MHD",6.08,,,"Biosynthetic engineered A22S-B3K-B31R human insulin monomer structure in water/acetonitrile solutions.","GIVEQCCTSICSLYQLENYCNS","Homo sapiens","INS","Insulin","1","5MHD"
,,,,,,,,,,,,,,,,"FVKQHLCGSHLVEALYLVCGERGFFYTPKTR","Homo sapiens","INS","Insulin","2","5MHD"
"5MHH",,"X-RAY DIFFRACTION",2.14,42.52,"VAPOR DIFFUSION, HANGING DROP",7.4,"2.4 M ammonium sulfate",293,"10.1021/acssynbio.7b00199",,"5MHH",22.16,"2","2","Crystal structure of engineered human lipocalin 2 carrying p-boronophenylalanine at position 36","QDSTSDLIPAPPLSKVPLQQNFQDNQFHGKWYVVGFAGNAILREDKDPQKMFATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKWVSQNREYFNITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDGSAWSHPQFEK","Homo sapiens","LCN2, HNL, NGAL","Neutrophil gelatinase-associated lipocalin","1","5MHH"
"5MHP",,"X-RAY DIFFRACTION",2.4,48.81,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350 15%, thiocyanate 0.4 M and ammonium iodide 0.1 M",293,"10.1021/acs.jmedchem.7b00032","7NB","5MHP",102.85,"2.43","2.43","Novel Imidazo[1,2-a]pyridine Derivatives with Potent Autotaxin/ENPP2 Inhibitor Activity","MARRSSFQSCQIISLFTFAVGVNICLGFTAHRIKRAEGWEEGPPTVLSDSPWTNISGSCKGRCFELQEAGPPDCRCDNLCKSYTSCCHDFDELCLKTARGWECTKDRCGEVRNEENACHCSEDCLARGDCCTNYQVVCKGESHWVDDDCEEIKAAECPAGFVRPPLIIFSVDGFRASYMKKGSKVMPNIEKLRSCGTHSPYMRPVYPTKTFPNLYTLATGLYPESHGIVGNSMYDPVFDATFHLRGREKFNHRWWGGQPLWITATKQGVKAGTFFWSVVIPHERRILTILQWLTLPDHERPSVYAFYSEQPDFSGHKYGPFGPEMTNPLREIDKIVGQLMDGLKQLKLHRCVNVIFVGDHGMEDVTCDRTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAIIANLTCKKPDQHFKPYLKQHLPKRLHYANNRRIEDIHLLVERRWHVARKPLDVYKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGPTFKYKTKVPPFENIELYNVMCDLLGLKPAPNNGTHGSLNHLLRTNTFRPTMPEEVTRPNYPGIMYLQSDFDLGCTCDDKNKLDELNKRLHTKGSTEERHLLYGRPAVLYRTRYDILYHTDFESGYSEIFLMPLWTSYTVSKQAEVSSVPDHLTSCVRPDVRVSPSFSQNCLAYKNDKQMSYGFLFPPYLSSSPEAKYDAFLVTNMVPMYPAFKRVWNYFQRVLVKKYASERNGVNVISGPIFDYDYDGLHDTEDKIKQYVEGSSIPVPTHYYSIITSCLDFTQPADKCDGPLSVSSFILPHRPDNEESCNSSEDESKWVEELMKMHTARVRDIEHLTSLDFFRKTSRSYPEILTLKTYLHTYESEILVPRGSHHHHHH","Homo sapiens","ENPP2, ATX, PDNP2","Ectonucleotide pyrophosphatase/phosphodiesterase family member 2","1","5MHP"
"5MHQ",,"X-RAY DIFFRACTION",1.91,35.77,"VAPOR DIFFUSION, SITTING DROP",7.4,"10mg/ml CDK2
10% V/V PEG3350, 50 mM HEPES/NAOH, 50 mM NA/K PHOSPHATE, pH 7.5.",293,"10.1002/1878-0261.12148","8QT","5MHQ",35.17,"1.3","1.3","CCT068127 in complex with CDK2","GPLGSPEFMENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","Cyclin-dependent kinase 2","1","5MHQ"
"5MIM",,"X-RAY DIFFRACTION",3.75,67.2,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION SOLUTION: 100 MM MES, 200 MM K/NAH2PO4, PH 5.5-6.0, 3-4 M NACL, 3% DMSO; RESERVOIR SOLUTION: 3-4 M NACL",293.15,"10.1021/acschembio.6b01110","1N","5MIM",53.81,"1.9","1.9","Xray structure of human furin bound with the 2,5-dideoxystreptamine derived small molecule inhibitor 1n","DVYQEPTDPKFPQQWYLSGVTQRDLNVKAAWAQGYTGHGIVVSILDDGIEKNHPDLAGNYDPGASFDVNDQDPDPQPRYTQMNDNRHGTRCAGEVAAVANNGVCGVGVAYNARIGGVRMLDGEVTDAVEARSLGLNPNHIHIYSASWGPEDDGKTVDGPARLAEEAFFRGVSQGRGGLGSIFVWASGNGGREHDSCNCDGYTNSIYTLSISSATQFGNVPWYSEACSSTLATTYSSGNQNEKQIVTTDLRQKCTESHTGTSASAPLAAGIIALTLEANKNLTWRDMQHLVVQTSKPAHLNANDWATNGVGRKVSHSYGYGLLDAGAMVALAQNWTTVAPQRKCIIDILTEPKDIGKRLEVRKTVTACLGEPNHITRLEHAQARLTLSYNRRGDLAIHLVSPMGTRSTLLAARPHDYSADGFNDWAFMTTHSWDEDPSGEWVLEIENTSEANNYGTLTKFTLVLYGTASGSLVPRGSHHHHHH","Homo sapiens","FURIN, FUR, PACE, PCSK3","Furin","1","5MIM"
"5MIX",,"X-RAY DIFFRACTION",1.79,31.45,"VAPOR DIFFUSION, SITTING DROP",,"0.4 microliter protein (39 mg/ml in 50 mM Tris-HCl (pH 8.0) buffer) were mixed with 0.2 microliter reservoir solution (1 M ammonium sulfate, 0.1 M HEPES (pH 7.0), 0.5% w/v polyethylene glycol (PEG) 8000) and equilibrated against 70 microliter of reservoir solution",293,"10.1016/j.jmb.2017.03.009",,"5MIX",12.77,"1.701","1.701","Extracellular domain of human CD83 - trigonal crystal form","GSPGTPEVKVASSEDVDLPCTAPWDPQVPYTVSWVKLLEGGEERMETPQEDHLRGQHYHQKGQNGSFDAPNERPYSLKIRNTTSSNSGTYRCTLQDPDGQRNLSGKVILRVTGSPA","Homo sapiens","CD83","CD83 antigen","1","5MIX"
"5MJ0",,"X-RAY DIFFRACTION",2.73,54.94,"VAPOR DIFFUSION, SITTING DROP",,"0.2 microliter protein (21 mg/ml in 25 mM Tris-HCl (pH 7.2) buffer) were mixed with 0.2 microliter reservoir solution (0.2 M L-proline, 0.1 M HEPES (pH 7.5), 24% w/v PEG 1500) and equilibrated against 70 microliter of reservoir solution
Crystals appeared after ~ 10 months",293,"10.1016/j.jmb.2017.03.009",,"5MJ0",25.53,"3.2","3.2","Extracellular domain of human CD83 - cubic crystal form","GSPGTPEVKVASSEDVDLPCTAPWDPQVPYTVSWVKLLEGGEERMETPQEDHLRGQHYHQKGQNGSFDAPNERPYSLKIRNTTSSNSGTYRCTLQDPDGQRNLSGKVILRVTGSPA","Homo sapiens","CD83","CD83 antigen","1","5MJ0"
"5MJ1",,"X-RAY DIFFRACTION",2,38.64,"VAPOR DIFFUSION, SITTING DROP",,"0.2 microliter protein (39 mg/ml in ultrapure water) mixed with 0.4 microliter reservoir solution (0.2 M DL-malic acid (pH 7.0), 20% w/v PEG 3350) was equilibrated against 70 microliter of reservoir solution. Crystals appeared after ~ 13 months",293,"10.1016/j.jmb.2017.03.009",,"5MJ1",12.87,"1.8","1.8","Extracellular domain of human CD83 - rhombohedral crystal form","GSPGTPEVKVASSEDVDLPCTAPWDPQVPYTVSWVKLLEGGEERMETPQEDHLRGQHYHQKGQNGSFDAPNERPYSLKIRNTTSSNSGTYRCTLQDPDGQRNLSGKVILRVTGSPA","Homo sapiens","CD83","CD83 antigen","1","5MJ1"
"5MJ2",,"X-RAY DIFFRACTION",2.03,39.33,"VAPOR DIFFUSION, SITTING DROP",,"0.2 microliter protein (39 mg/ml in ultrapure water) and 0.4 microliter reservoir solution (0.2 M DL-malic acid (pH 7.0), 20% w/v PEG 3350) were mixed and equilibrated against 70 microliter of reservoir solution
Crystals appeared after ~13 months",293,"10.1016/j.jmb.2017.03.009",,"5MJ2",12.87,"1.98","1.98","Extracellular domain of human CD83 - rhombohedral crystal form after UV-RIP (S-SAD data)","GSPGTPEVKVASSEDVDLPCTAPWDPQVPYTVSWVKLLEGGEERMETPQEDHLRGQHYHQKGQNGSFDAPNERPYSLKIRNTTSSNSGTYRCTLQDPDGQRNLSGKVILRVTGSPA","Homo sapiens","CD83","CD83 antigen","1","5MJ2"
"5MJ6",,"X-RAY DIFFRACTION",2.39,58.98,"VAPOR DIFFUSION, SITTING DROP",8.5,"18.8% (w/v) PEG of mean MW 20000, 37.6% (v/v) PEG monomethyl ether of mean MW 500, 50.2 mM Bicine, 43.8 mM Trizma base (pH of buffer mixture: 8.5) and 0.282 M each of the following halogens: Sodium fluoride, Sodium bromide and Sodium iodide",291,"10.1021/acs.jmedchem.6b01890","7O2","5MJ6",217.25,"2.53","2.53","Ligand-induced conformational change of Insulin-regulated aminopeptidase: insights on catalytic mechanism and active site plasticity.","ATNGKLFPWAQIRLPTAVVPLRYELSLHPNLTSMTFRGSVTISVQALQVTWNIILHSTGHNISRVTFMSAVSSQEKQAEILEYAYHGQIAIVAPEALLAGHNYTLKIEYSANISSSYYGFYGFSYTDESNEKKYFAATQFEPLAARSAFPCFDEPAFKATFIIKIIRDEQYTALSNMPKKSSVVLDDGLVQDEFSESVKMSTYLVAFIVGEMKNLSQDVNGTLVSIYAVPEKIGQVHYALETTVKLLEFFQNYFEIQYPLKKLDLVAIPDFEAGAMENWGLLTFREETLLYDSNTSSMADRKLVTKIIAHELAHQWFGNLVTMKWWNDLWLNEGFATFMEYFSLEKIFKELSSYEDFLDARFKTMKKDSLNSSHPISSSVQSSEQIEEMFDSLSYFKGSSLLLMLKTYLSEDVFQHAVVLYLHNHSYASIQSDDLWDSFNEVTNQTLDVKRMMKTWTLQKGFPLVTVQKKGKELFIQQERFFLNMKPEIQPSDTSYLWHIPLSYVTEGRNYSKYQSVSLLDKKSGVINLTEEVLWVKVNINMNGYYIVHYADDDWEALIHQLKINPYVLSDKDRANLINNIFELAGLGKVPLKRAFDLINYLGNENHTAPITEALFQTDLIYNLLEKLGYMDLASRLVTRVFKLLQNQIQQQTWTDEGTPSMRELRSALLEFACTHNLGNCSTTAMKLFDDWMASNGTQSLPTDVMTTVFKVGAKTDKGWSFLLGKYISIGSEAEKNKILEALASSEDVRKLYWLMKSSLNGDNFRTQKLSFIIRTVGRHFPGHLLAWDFVKENWNKLVQKFPLGSYTIQNIVAGSTYLFSTKTHLSEVQAFFENQSEATFRLRCVQEALEVIQLNIQWMEKNLKSLTWWLRTETSQVAPA","Homo sapiens","LNPEP, OTASE","Leucyl-cystinyl aminopeptidase","1","5MJ6"
"5MJA",,"X-RAY DIFFRACTION",3.39,63.71,"VAPOR DIFFUSION, SITTING DROP",,"18 % PEG3350, 0.1-0.2 M ammonium sulfate, 0.1 M PCTP (Sodium propionate, Sodium cacodylate trihydrate, Bis-Tris propane) buffer pH 6-9",293,"10.1021/acschembio.6b01083","7O3","5MJA",70.63,"2.14","2.14","Kinase domain of human EphB1 bound to a quinazoline-based inhibitor","MGHHHHHHGSDPNEAVREFAKEIDVSFVKIEEVIGAGEFGEVYKGRLKLPGKREIYVAIKTLKAGYSEKQRRDFLSEASIMGQFDHRNIIRLEGVVTKSRPVMIITEFMENGALDSFLRQNDGQFTVIQLVGMLRGIAAGMKYLSEMNYVHRDLAARNILVNSNLVCKVSDFGLSRYLQDDTSDPTYTSSLGGKIPVRWTAPEAIAYRKFTSASDVWSYGIVMWEVMSFGERPYWDMSNQDVINAIEQDYRLPPPMDCPAALHQLMLDCWQKDRNSRPRFAEIVNTLDKMIRNPASLKTVATITA","Homo sapiens","EPHB1, ELK, EPHT2, HEK6, NET","Ephrin type-B receptor 1","1","5MJA"
"5MJB",,"X-RAY DIFFRACTION",3.42,64.08,"VAPOR DIFFUSION, SITTING DROP",,"18 % PEG3350, 0.1-0.2 M ammonium sulfate and 0.1 M PCTP (Sodium propionate, Sodium cacodylate trihydrate, Bis-Tris propane) buffer pH 6-9",293,"10.1021/acschembio.6b01083",,"5MJB",71.01,"2.23","2.23","Kinase domain of human EphB1, G703C mutant, covalently bound to a quinazoline-based inhibitor","MGHHHHHHGSDPNEAVREFAKEIDVSFVKIEEVIGAGEFGEVYKGRLKLPGKREIYVAIKTLKAGYSEKQRRDFLSEASIMGQFDHRNIIRLEGVVTKSRPVMIITEFMENCALDSFLRQNDGQFTVIQLVGMLRGIAAGMKYLSEMNYVHRDLAARNILVNSNLVCKVSDFGLSRYLQDDTSDPTYTSSLGGKIPVRWTAPEAIAYRKFTSASDVWSYGIVMWEVMSFGERPYWDMSNQDVINAIEQDYRLPPPMDCPAALHQLMLDCWQKDRNSRPRFAEIVNTLDKMIRNPASLKTVATITA","Homo sapiens","EPHB1, ELK, EPHT2, HEK6, NET","Ephrin type-B receptor 1","1","5MJB"
"5MJN",,"X-RAY DIFFRACTION",2.1,42,"VAPOR DIFFUSION, SITTING DROP",9,"1,54 M  SODIUM CITRATE 60 MM TRIS- HCL, PH 9.0, PROTEIN 10 MG/ML 5-10 MM INHIBITOR (STOCK SOLUTION WAS 100 MM INHIBITOR DISSOLVED IN 100%             DIMETHYL SULFOXIDE) VAPOR DIFFUSION, SITTING DROP,                  
TEMPERATURE 294K,  TIME 2-5 DAYS",294,"10.1016/j.bmc.2016.11.045","7O8","5MJN",29.54,"1.17","1.17","Three dimensional structure of human carbonic anhydrase II in complex with 5-[(4Chlorobenzyl)sulfanyl]thiophene-2-sulfonamide","SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5MJN"
"5MJZ",,"X-RAY DIFFRACTION",2.26,45.57,"VAPOR DIFFUSION, SITTING DROP",7.4,"Apo- HD-PTPBro1 crystals were obtained in 0.2M L-Na-Glutamate, 0.2M Alanine, 0.2M Glycine, 0.2M Lysine HCl, 0.2M Serine, 0.1 M Imidazole; MES monohydrate at pH 6.5 and 30% Ethylene glycol, PEG8K.",277,"10.1016/j.str.2017.05.005",,"5MJZ",81.44,"1.867","1.867","Crystal structure of the His Domain Protein Tyrosine Phosphatase (HD-PTP/PTPN23) Bro1 domain (Apo structure)","MEAVPRMPMIWLDLKEAGDFHFQPAVKKFVLKNYGENPEAYNEELKKLELLRQNAVRVPRDFEGCSVLRKYLGQLHYLQSRVPMGSGQEAAVPVTWTEIFSGKSVAHEDIKYEQACILYNLGALHSMLGAMDKRVSEEGMKVSCTHFQCAAGAFAYLREHFPQAYSVDMSRQILTLNVNLMLGQAQECLLEKSMLDNRKSFLVARISAQVVDYYKEACRALENPDTASLLGRIQKDWKKLVQMKIYYFAAVAHLHMGKQAEEQQKFGERVAYFQSALDKLNEAIKLAKGQPDTVQDALRFTMDVIGGKYNSAKKDNDFIYHEAVPALDTLQPVKGAPLVKPLPVNPTDPAVTGPDIFAKLV","Homo sapiens","PTPN23, KIAA1471","Tyrosine-protein phosphatase non-receptor type 23","1","5MJZ"
"5MK5",,"X-RAY DIFFRACTION",2.35,47.62,"VAPOR DIFFUSION, SITTING DROP",8.5,"Tris-HCl 0.1M pH8.5
PEG 1500 26%
Glycerol 16%",298,"10.1074/jbc.M116.761510",,"5MK5",28.22,"2.16","2.16","Structures of DHBN domain of human BLM helicase","MDARQISLQQQLIHVMEHICKLIDTIPDDKLKLLDCGNELLQQRNIRRKLLTEV","Homo sapiens","BLM, RECQ2, RECQL3","Bloom syndrome protein","1","5MK5"
"5MKE","4.3","ELECTRON MICROSCOPY",,,,,,,"10.1038/nsmb.3357",,"5MKE",450.24,"4.3, 4.3",,"cryoEM Structure of Polycystin-2 in complex with cations and lipids","MVNSSRVQPQQPGDAKRPPAPRAPDPGRLMAGCAAVGASLAAPGGLCEQRGLEIEMQRIRQAAARDPPAGAAASPSPPLSSCSRQAWSRDNPGFEAEEEEEEVEGEEGGMVVEMDVEWRPGSRRSAASSAVSSVGARSRGLGGYHGAGHPSGRRRRREDQGPPCPSPVGGGDPLHRHLPLEGQPPRVAWAERLVRGLRGLWGTRLMEESSTNREKYLKSVLRELVTYLLFLIVLCILTYGMMSSNVYYYTRMMSQLFLDTPVSKTEKTNFKTLSSMEDFWKFTEGSLLDGLYWKMQPSNQTEADNRSFIFYENLLLGVPRIRQLRVRNGSCSIPQDLRDEIKECYDVYSVSSEDRAPFGPRNGTAWIYTSEKDLNGSSHWGIIATYSGAGYYLDLSRTREETAAQVASLKKNVWLDRGTRATFIDFSVYNANINLFCVVRLLVEFPATGGVIPSWQFQPLKLIRYVTTFDFFLAACEIIFCFFIFYYVVEEILEIRIHKLHYFRSFWNCLDVVIVVLSVVAIGINIYRTSNVEVLLQFLEDQNTFPNFEHLAYWQIQFNNIAAVTVFFVWIKLFKFINFNRTMSQLSTTMSRCAKDLFGFAIMFFIIFLAYAQLAYLVFGTQVDDFSTFQECIFTQFRIILGDINFAEIEEANRVLGPIYFTTFVFFMFFILLNMFLAIINDTYSEVKSDLAQQKAEMELSDLIRKGYHKALVKLKLKKNTVDDISESLRQGGGKLNFDELRQDLKGKGHTDAEIEAIFTKYDQDGDQELTEHEHQQMRDDLEKEREDLDLDHSSLPRPMSSRSFPRSLDDSEEDDDEDSGHSSRRRGSISSGVSYEEFQVLVRRVDRMEHSIGSIVSKIDAVIVKLEIMERAKLKRREVLGRLLDGVAEDERLGRDSEIHREQMERLVREELERWESDDAASQISHGLGTPVGLNGQPRPRSSRPSSSQSTEGMEGAGGNGSSNVHV","Homo sapiens","PKD2, TRPP2","Polycystin-2","1","5MKE"
"5MKF","4.2","ELECTRON MICROSCOPY",,,,,,,"10.1038/nsmb.3357",,"5MKF",451.22,"4.2",,"cryoEM Structure of Polycystin-2 in complex with calcium and lipids","MVNSSRVQPQQPGDAKRPPAPRAPDPGRLMAGCAAVGASLAAPGGLCEQRGLEIEMQRIRQAAARDPPAGAAASPSPPLSSCSRQAWSRDNPGFEAEEEEEEVEGEEGGMVVEMDVEWRPGSRRSAASSAVSSVGARSRGLGGYHGAGHPSGRRRRREDQGPPCPSPVGGGDPLHRHLPLEGQPPRVAWAERLVRGLRGLWGTRLMEESSTNREKYLKSVLRELVTYLLFLIVLCILTYGMMSSNVYYYTRMMSQLFLDTPVSKTEKTNFKTLSSMEDFWKFTEGSLLDGLYWKMQPSNQTEADNRSFIFYENLLLGVPRIRQLRVRNGSCSIPQDLRDEIKECYDVYSVSSEDRAPFGPRNGTAWIYTSEKDLNGSSHWGIIATYSGAGYYLDLSRTREETAAQVASLKKNVWLDRGTRATFIDFSVYNANINLFCVVRLLVEFPATGGVIPSWQFQPLKLIRYVTTFDFFLAACEIIFCFFIFYYVVEEILEIRIHKLHYFRSFWNCLDVVIVVLSVVAIGINIYRTSNVEVLLQFLEDQNTFPNFEHLAYWQIQFNNIAAVTVFFVWIKLFKFINFNRTMSQLSTTMSRCAKDLFGFAIMFFIIFLAYAQLAYLVFGTQVDDFSTFQECIFTQFRIILGDINFAEIEEANRVLGPIYFTTFVFFMFFILLNMFLAIINDTYSEVKSDLAQQKAEMELSDLIRKGYHKALVKLKLKKNTVDDISESLRQGGGKLNFDELRQDLKGKGHTDAEIEAIFTKYDQDGDQELTEHEHQQMRDDLEKEREDLDLDHSSLPRPMSSRSFPRSLDDSEEDDDEDSGHSSRRRGSISSGVSYEEFQVLVRRVDRMEHSIGSIVSKIDAVIVKLEIMERAKLKRREVLGRLLDGVAEDERLGRDSEIHREQMERLVREELERWESDDAASQISHGLGTPVGLNGQPRPRSSRPSSSQSTEGMEGAGGNGSSNVHV","Homo sapiens","PKD2, TRPP2","Polycystin-2","1","5MKF"
"5MKR",,"X-RAY DIFFRACTION",2.54,51.57,"VAPOR DIFFUSION, SITTING DROP",4.1,"16% w/v PEG-3350, 0.06 M citric acid, 0.04 M BIS-TRIS propane. Inhibitor was pre-incubated with protein prior to co-crystallisation.",291,"10.1002/anie.201611907","TI8","5MKR",43.87,"1.87","1.87","HSP72-NBD bound to compound TCI 8 - Tyr15 in up-conformation","GPLGSMAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILIKSTRAAAS","Homo sapiens","HSPA1A, HSPA1, HSX70, HSP72","Heat shock 70 kDa protein 1A","1","5MKR"
"5MKS",,"X-RAY DIFFRACTION",2.24,45.1,"VAPOR DIFFUSION, SITTING DROP",8.8,"16% w/v PEG-3350, 0.02 M citric acid, 0.08 M BIS-TRIS propane. Inhibitor was pre-incubated with protein prior to co-crystallisation.",291,"10.1002/anie.201611907","TI8","5MKS",43.68,"1.99","1.99","HSP72-NBD bound to compound TCI 8 - Tyr15 in down-conformation","GPLGSMAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILIKSTRAAAS","Homo sapiens","HSPA1A, HSPA1, HSX70, HSP72","Heat shock 70 kDa protein 1A","1","5MKS"
"5MKV",,"X-RAY DIFFRACTION",2.49,50.62,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2M ammonium acetate, 30% PEG 4000 and 0.1M citrate buffer pH 5.5",293,"10.1038/s41467-017-02811-7",,"5MKV",221.78,"1.8","1.8","Crystal Structure of Human Dihydropyrimidinease-like 2 (DPYSL2A)/Collapsin Response Mediator Protein (CRMP2) residues 13-516","TSDRLLIKGGKIVNDDQSFYADIYMEDGLIKQIGENLIVPGGVKTIEAHSRMVIPGGIDVHTRFQMPDQGMTSADDFFQGTKAALAGGTTMIIDHVVPEPGTSLLAAFDQWREWADSKSCCDYSLHVDISEWHKGIQEEMEALVKDHGVNSFLVYMAFKDRFQLTDCQIYEVLSVIRDIGAIAQVHAENGDIIAEEQQRILDLGITGPEGHVLSRPEEVEAEAVNRAITIANQTNCPLYITKVMSKSSAEVIAQARKKGTVVYGEPITASLGTDGSHYWSKNWAKAAAFVTSPPLSPDPTTPDFLNSLLSCGDLQVTGSAHCTFNTAQKAVGKDNFTLIPEGTNGTEERMSVIWDKAVVTGKMDENQFVAVTSTNAAKVFNLYPRKGRIAVGSDADLVIWDPDSVKTISAKTHNSSLEYNIFEGMECRGSPLVVISQGKIVLEDGTLHVTEGSGRYIPRKPFPDFVYKRIKARSRLAELRGVPRGLYDGPVCEVSVTPKTVTPA","Homo sapiens","DPYSL2, CRMP2, ULIP2","Dihydropyrimidinase-related protein 2","1","5MKV"
"5MKW",,"X-RAY DIFFRACTION",3.17,61.21,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% (w/v) PEG10,000 + 100 mM HEPES pH 7.5",277,"10.1038/ncomms15847",,"5MKW",28.52,"2","2","Crystal structure of the human ZRANB3 HNH domain","SMSNNSYLRAKVFETEHGVCQLCNVNAQELFLRLRDAPKSQRKNLLYATWTSKLPLEQLNEMIRNPGEGHFWQVDHIKPVYGGGGQCSLDNLQTLCTVCHKERTARQAKERSQVRRQSLASK","Homo sapiens","ZRANB3","DNA annealing helicase and endonuclease ZRANB3","1","5MKW"
"5MKX",,"X-RAY DIFFRACTION",3.73,67.05,"VAPOR DIFFUSION, SITTING DROP",,"Morpheus condition 37",278,"10.1021/acs.jmedchem.6b01566","82I","5MKX",29.12,"1.68","1.68","1.68A STRUCTURE PCAF BROMODOMAIN WITH 4-chloro-2-methyl-5-(methylamino)pyridazin-3(2H)-one","SMGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLID","Homo sapiens","KAT2B, PCAF","Histone acetyltransferase KAT2B","1","5MKX"
"5MKY",,"X-RAY DIFFRACTION",2.49,50.67,"VAPOR DIFFUSION, SITTING DROP",,"Morpheus condition 54 - 0.1M morpheus buffer 2 pH 7.5, 30% morpheus_EDO_P8K, 0.1M Morpheus ethylene glycols",293,"10.1021/acs.jmedchem.6b01566","I0D","5MKY",12.84,"1.67","1.67","BROMODOMAIN OF HUMAN BRD9 WITH 4-chloro-2-methyl-5-((2-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)amino)pyridazin-3(2H)-one","GAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMS","Homo sapiens","BRD9, UNQ3040/PRO9856","Bromodomain-containing protein 9","1","5MKY"
"5MKZ",,"X-RAY DIFFRACTION",2.14,42.53,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Sodium nitrate 0.1 M Bis Tris propane pH 6.5 20% (w/v) PEG 3350",293,"10.1021/acs.jmedchem.6b01566","RNK","5MKZ",15.65,"1.62","1.62","N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 4-chloro-2-methyl-5-(((3-methylthiophen-2-yl)methyl)amino)pyridazin-3(2H)-one","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5MKZ"
"5ML2",,"X-RAY DIFFRACTION",3.08,60.07,"VAPOR DIFFUSION",,"30 % PEG 4000, 0.2 M NaOAc, 0.1 M TRIS-HCL, pH 8.5",293,"10.1002/anie.201610957","NH6","5ML2",17.83,"1.6","1.6","The crystal structure of PDE6D in complex with inhibitor-3","SAKDERAREILRGFKLNWMNLRDAETGKILWQGTEDLSVPGVEHEARVPKKILKCKAVSRELNFSSTEQMEKFRLEQKVYFKGQCLEEWFFEFGFVIPNSTNTWQSLIEAAPESQMMPASVLTGNVIIETKFFDDDLLVSTSRVRLFYV","Homo sapiens","PDE6D, PDED","Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta","1","5ML2"
"5ML3",,"X-RAY DIFFRACTION",3.02,59.28,"VAPOR DIFFUSION",,"0.2 M NaOAc, 0.1 M Na3Cit, pH 5.5, 10 % PEG 4000",293,"10.1002/anie.201610957","DL3","5ML3",17.96,"1.4","1.4","The crystal structure of PDE6D in complex to Deltasonamide1","SAKDERAREILRGFKLNWMNLRDAETGKILWQGTEDLSVPGVEHEARVPKKILKCKAVSRELNFSSTEQMEKFRLEQKVYFKGQCLEEWFFEFGFVIPNSTNTWQSLIEAAPESQMMPASVLTGNVIIETKFFDDDLLVSTSRVRLFYV","Homo sapiens","PDE6D, PDED","Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta","1","5ML3"
"5ML4",,"X-RAY DIFFRACTION",3.02,59.27,"VAPOR DIFFUSION",,"1.4 M NaOAc, 0.1 M NaCAC, pH 6.8",293,"10.1002/anie.201610957","RRQ","5ML4",18,"2.4","2.4","The crystal structure of PDE6D in complex to inhibitor-7","SAKDERAREILRGFKLNWMNLRDAETGKILWQGTEDLSVPGVEHEARVPKKILKCKAVSRELNFSSTEQMEKFRLEQKVYFKGQCLEEWFFEFGFVIPNSTNTWQSLIEAAPESQMMPASVLTGNVIIETKFFDDDLLVSTSRVRLFYV","Homo sapiens","PDE6D, PDED","Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta","1","5ML4"
"5ML5",,"X-RAY DIFFRACTION",2.07,40.54,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2, 
20-30 % PEG4000,
50 mM BOG",293.15,"10.3390/molecules22040522","1VI","5ML5",42.71,"1.9","1.9","Human p38alpha MAPK in complex with imidazolyl pyridine inhibitor 11b","MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5ML5"
"5ML6",,"X-RAY DIFFRACTION",3.05,59.73,"VAPOR DIFFUSION",,"0.1 M NaOAc, pH 4.6, 30 % PEG 4000, 0.2 M (NH4)2SO4",293,"10.1002/anie.201610957","9GD","5ML6",17.99,"1.87","1.87","The crystal structure of PDE6D in complex to inhibitor-8","SAKDERAREILRGFKLNWMNLRDAETGKILWQGTEDLSVPGVEHEARVPKKILKCKAVSRELNFSSTEQMEKFRLEQKVYFKGQCLEEWFFEFGFVIPNSTNTWQSLIEAAPESQMMPASVLTGNVIIETKFFDDDLLVSTSRVRLFYV","Homo sapiens","PDE6D, PDED","Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta","1","5ML6"
"5ML8",,"X-RAY DIFFRACTION",3.14,60.88,"VAPOR DIFFUSION",,"20 % PEG 3350, 0.2 M Na2SO4",293,"10.1002/anie.201610957",,"5ML8",17.93,"2.6","2.6","The crystal structure of PDE6D in complex to inhibitor-4","SAKDERAREILRGFKLNWMNLRDAETGKILWQGTEDLSVPGVEHEARVPKKILKCKAVSRELNFSSTEQMEKFRLEQKVYFKGQCLEEWFFEFGFVIPNSTNTWQSLIEAAPESQMMPASVLTGNVIIETKFFDDDLLVSTSRVRLFYV","Homo sapiens","PDE6D, PDED","Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta","1","5ML8"
"5MLE",,"X-RAY DIFFRACTION",2.94,58.12,"VAPOR DIFFUSION, SITTING DROP",6.5,"(0.2M magnesium chloride, 25% PEG 3350 and 0.1M bis-tris buffer pH 6.5",293,"10.1038/s41467-017-02811-7",,"5MLE",111.13,"2.48","2.48","Crystal Structure of Human Dihydropyrimidinease-like 2 (DPYSL2A)/Collapsin Response Mediator Protein (CRMP2 13-516) Mutant Y479E/Y499E","TSDRLLIKGGKIVNDDQSFYADIYMEDGLIKQIGENLIVPGGVKTIEAHSRMVIPGGIDVHTRFQMPDQGMTSADDFFQGTKAALAGGTTMIIDHVVPEPGTSLLAAFDQWREWADSKSCCDYSLHVDISEWHKGIQEEMEALVKDHGVNSFLVYMAFKDRFQLTDCQIYEVLSVIRDIGAIAQVHAENGDIIAEEQQRILDLGITGPEGHVLSRPEEVEAEAVNRAITIANQTNCPLYITKVMSKSSAEVIAQARKKGTVVYGEPITASLGTDGSHYWSKNWAKAAAFVTSPPLSPDPTTPDFLNSLLSCGDLQVTGSAHCTFNTAQKAVGKDNFTLIPEGTNGTEERMSVIWDKAVVTGKMDENQFVAVTSTNAAKVFNLYPRKGRIAVGSDADLVIWDPDSVKTISAKTHNSSLEYNIFEGMECRGSPLVVISQGKIVLEDGTLHVTEGSGRYIPRKPFPDFVEKRIKARSRLAELRGVPRGLEDGPVCEVSVTPKTVTPA","Homo sapiens","DPYSL2, CRMP2, ULIP2","Dihydropyrimidinase-related protein 2","1","5MLE"
"5MLI",,"X-RAY DIFFRACTION",2.09,41.19,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M SPG buffer pH 6 25% (w/v) PEG 1500",293,"10.1021/acs.jmedchem.6b01566","82I","5MLI",15.27,"1.63","1.63","N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 4-chloro-2-methyl-5-(methylamino)pyridazin-3(2H)-one","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5MLI"
"5MLJ",,"X-RAY DIFFRACTION",2.55,51.7,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium acetate, 0.1 M Tris pH 8.5, 25% w/v Polyethylene glycol 3,350",277,"10.1021/acs.jmedchem.6b01566","9ST","5MLJ",27.45,"1.8","1.8","Bromodomain of Human GCN5 with 4-bromo-2-methyl-5-(((3R,5R)-1-methyl-5-phenylpiperidin-3-yl)amino)pyridazin-3(2H)-one","SMEDPDQLYTTLKNLLAQIKSHPSAWPFMEPVKKSEAPDYYEVIRFPIDLKTMTERLRSRYYVTRKLFVADLQRVIANCREYNPPDSEYCRCASALEKFFYFKLKEGGLIDK","Homo sapiens","KAT2A, GCN5, GCN5L2, HGCN5","Histone acetyltransferase KAT2A","1","5MLJ"
"5MME",,"X-RAY DIFFRACTION",2.06,40.37,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Cacodylate, pH6.5, 0.2 M Calcium acetate, 18% PEG8000",277,"10.1021/acsmedchemlett.8b00286","8Q6","5MME",29.19,"1.35","1.35","Crystal structure of CREBBP bromodomain complexd with US46C","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5MME"
"5MMF",,"X-RAY DIFFRACTION",2.23,44.82,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1016/j.bmc.2017.04.037",,"5MMF",83.49,"1.99","1.99","Crystal Structure of CK2alpha with Compound 7 bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5MMF"
"5MMG",,"X-RAY DIFFRACTION",2.38,48.42,"VAPOR DIFFUSION, HANGING DROP",,"0.15 M KSCN, 10% Ethylene Glycol, 20% PEG3350",277,"10.1021/acsmedchemlett.8b00286","UT0","5MMG",14.6,"1.23","1.23","Crystal structure of CREBBP bromodomain complexed with UT07C","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5MMG"
"5MMR",,"X-RAY DIFFRACTION",2.2,44.07,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1016/j.bmc.2017.04.037",,"5MMR",84.13,"2","2","Crystal Structure of CK2alpha with N-((2-chloro-[1,1'-biphenyl]-4-yl)methyl)butane-1,4-diamine bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5MMR"
"5MMS",,"X-RAY DIFFRACTION",2.31,47.31,"VAPOR DIFFUSION, SITTING DROP",,"35% w/v PEG 2000 MME
0.15 M KBr",293,"10.1155/2017/8940321",,"5MMS",273.65,"2.8","2.8","Human cystathionine beta-synthase (CBS) p.P49L delta409-551 variant","MPSETPQAEVGPTGCPHRSGPHSAKGSLEKGSPEDKEAKEPLWIRPDALSRCTWQLGRPASESPHHHTAPAKSPKILPDILKKIGDTPMVRINKIGKKFGLKCELLAKCEFFNAGGSVKDRISLRMIEDAERDGTLKPGDTIIEPTSGNTGIGLALAAAVRGYRCIIVMPEKMSSEKVDVLRALGAEIVRTPTNARFDSPESHVGVAWRLKNEIPNSHILDQYRNASNPLAHYDTTADEILQQCDGKLDMLVASVGTGGTITGIARKLKEKCPGCRIIGVDPEGSILAEPEELNQTEQTTYEVEGIGYDFIPTVLDRTVVDKWFKSNDEEAFTFARMLIAQEGLLCGGSAGSTVAVAVKAAQELQEGQRCVVILPDSVRNYMTKFLSDRWMLQKGFLKEEDLTEKKPW","Homo sapiens","CBS","Cystathionine beta-synthase","1","5MMS"
"5MMV",,"X-RAY DIFFRACTION",2.26,45.56,"VAPOR DIFFUSION",,"0.1 M HEPES (pH 7.4), 2 M (NH4)2SO4, and 25 mM DTT",277,,,"5MMV",30.92,"2.15","2.15","Crystal structure of human Caspase-1 with 2-((2-naphthoyl)-L-valyl)-4-hydroxy-N-((3S)-2-hydroxy-5-oxotetrahydrofuran-3-yl)-2-azabicyclo[2.2.2]octane-3-carboxamide (Compound 1)","MNPAMPTSSGSEGNVKLCSLEEAQRIWKQKSAEIYPIMDKSSRTRLALIICNEEFDSIPRRTGAEVDITGMTMLLQNLGYSVDVKKNLTASDMTTELEAFAHRPEHKTSDSTFLVFMSHGIREGICGKKHSEQVPDILQLNAIFNMLNTKNCPSLKDKPKVIIIQACRGDSPGVVWFKD","Homo sapiens","CASP1, IL1BC, IL1BCE","Caspase-1","1","5MMV"
,,,,,,,,,,,,,,,,"MAIKKAHIEKDFIAFCSSTPDNVSWRHPTMGSVFIGRLIEHMQEYACSCDVEEIFRKVRFSFEQPDGRAQMPTTERVTLTRCFYLFPGH","Homo sapiens","CASP1, IL1BC, IL1BCE","Caspase-1","2","5MMV"
"5MNW",,"SOLUTION NMR",,,,,,,,,"5MNW",23.03,,,"Solution structure of the cinaciguat bound human beta1 H-NOX.","MYGFVNHALELLVIRNYGPEVWEDIKKEAQLDEEGQFLVRIIYDDSKTYDLVAAASKVLNLNAGEILQMFGKMFFVFCQESGYDTILRVLGSNVREFLQNLDALHDHLATIYPGMRAPSFRCTDAEKGKGLILHYYSEREGLQDIVIGIIKTVAQQIHGTEIDMKVIQQRNEECDHTQFLIEEKESKEHHHHHH","Homo sapiens","GUCY1B3, GUC1B3, GUCSB3, GUCY1B1","Guanylate cyclase soluble subunit beta-1","1","5MNW"
"5MO4",,"X-RAY DIFFRACTION",2.44,49.57,"VAPOR DIFFUSION, HANGING DROP",7.5,"Reservoir: 18 % (W/V) PEG 3350, 0.2 M POTASSIUM FORMATE, 0.1 M TRIS PH 7.5
Protein: 35.7 MG/ML   20 MM TRIS PH 8, 200 MM NACL, 2 MM TCEP
Protocol: 0.6 UL protein solution plus 0.6 UL reservoir solution",298,"10.1038/nature21702","NIL","5MO4",57.16,"2.17","2.17","ABL1 kinase (T334I_D382N) in complex with asciminib and nilotinib","GAMDPSEALQRPVASDFEPQGLSEAARWNSKENLLAGPSENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNSLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTASDGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIIIEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRNLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELGKQGV","Homo sapiens","ABL1, ABL, JTK7","Tyrosine-protein kinase ABL1","1","5MO4"
"5MO5",,"X-RAY DIFFRACTION",2.23,44.74,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1016/j.bmc.2017.04.037",,"5MO5",83.69,"2.04","2.04","Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5MO5"
"5MO6",,"X-RAY DIFFRACTION",2.23,44.88,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1016/j.bmc.2017.04.037","KXZ","5MO6",83.6,"1.825","1.825","Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5MO6"
"5MO7",,"X-RAY DIFFRACTION",2.22,44.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1016/j.bmc.2017.04.037",,"5MO7",83.51,"2.15","2.15","Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5MO7"
"5MO8",,"X-RAY DIFFRACTION",2.2,44.11,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1016/j.bmc.2017.04.037","C98","5MO8",84.26,"1.82","1.82","Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5MO8"
"5MOD",,"X-RAY DIFFRACTION",2.23,44.81,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1016/j.bmc.2017.04.037","86L","5MOD",83.37,"2.08","2.08","Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5MOD"
"5MOE",,"X-RAY DIFFRACTION",2.22,44.49,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1016/j.bmc.2017.04.037","OQC","5MOE",86.75,"1.89","1.89","Crystal Structure of CK2alpha with N-(3-(((2-chloro-[1,1'-biphenyl]-4-yl)methyl)amino)propyl)methanesulfonamide bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5MOE"
"5MOH",,"X-RAY DIFFRACTION",2.04,39.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298,"10.1016/j.bmc.2017.04.037",,"5MOH",39.33,"1.38","1.38","Crystal structure of CK2alpha with ZT0583 bound.","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5MOH"
"5MOI",,"X-RAY DIFFRACTION",2.42,49.12,"VAPOR DIFFUSION, SITTING DROP",,"25% (v/v) PEG1500, 0.1M SPG (succinic acid, sodium dihydrogen phosphate and glycine in the ratio 2:7:7)",291,"10.1016/j.bbapap.2017.08.005",,"5MOI",155.97,"2.2","2.2","Crystal structure of human IgE-Fc epsilon 3-4","ADPCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVQLTWSRASGKPVQHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGK","Homo sapiens","IGHE","Ig epsilon chain C region","1","5MOI"
"5MOJ",,"X-RAY DIFFRACTION",2.65,53.57,"VAPOR DIFFUSION, SITTING DROP",5.5,"25% PEG 4000
0.15M Ammonium Sulphate
0.1M MES",291,"10.1016/j.bbapap.2017.08.005",,"5MOJ",52.56,"2.26","2.26","Crystal structure of IgE-Fc epsilon 3-4","ADPCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVQLTWSRASGKPVQHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGK","Homo sapiens","IGHE","Ig epsilon chain C region","1","5MOJ"
"5MOK",,"X-RAY DIFFRACTION",2.58,52.4,"VAPOR DIFFUSION, SITTING DROP",,"25% (v/v) PEG1500
0.1M SPG (succinic acid, sodium dihydrogen phosphate and glycine in the ratio 2:7:7) at pH 6.0",291,"10.1016/j.bbapap.2017.08.005",,"5MOK",104.13,"2","2","Crystal structure of human IgE-Fc epsilon 3-4","ADPCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVQLTWSRASGKPVQHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGK","Homo sapiens","IGHE","Ig epsilon chain C region","1","5MOK"
"5MOL",,"X-RAY DIFFRACTION",2.72,54.74,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Tris HCL pH 8.5
25% PEG 550 MME",291,"10.1016/j.bbapap.2017.08.005",,"5MOL",75.75,"1.75","1.75","Human IgE-Fc crystal structure","DIVASRDFTPPTVKILQSSCDGGGHFPPTIQLLCLVSGYTPGTIQITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVQLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGK","Homo sapiens","IGHE","Ig epsilon chain C region","1","5MOL"
"5MOM",,"X-RAY DIFFRACTION",5.44,77.39,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1M NaAcO, 2M (NH4)2SO4",293,"10.1016/j.dnarep.2016.12.003",,"5MOM",85.65,"2.27","2.27","Crystal Structure of PCNA encoding the hypomorphic mutation S228I","MFEARLVQGSILKKVLEALKDLINEACWDISSSGVNLQSMDSSHVSLVQLTLRSEGFDTYRCDRNLAMGVNLTSMSKILKCAGNEDIITLRAEDNADTLALVFEAPNQEKVSDYEMKLMDLDVEQLGIPEQEYSCVVKMPSGEFARICRDLSHIGDAVVISCAKDGVKFSASGELGNGNIKLSQTSNVDKEEEAVTIEMNEPVQLTFALRYLNFFTKATPLSSTVTLIMSADVPLVVEYKIADMGHLKYYLAPKIEDE","Homo sapiens","PCNA","Proliferating cell nuclear antigen","1","5MOM"
"5MOT",,"X-RAY DIFFRACTION",1.99,38.15,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298,"10.1016/j.bmc.2017.04.037",,"5MOT",39.48,"2.09","2.09","Crystal structure of CK2alpha with ZT0627 bound","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5MOT"
"5MOV",,"X-RAY DIFFRACTION",1.98,37.97,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298,"10.1016/j.bmc.2017.04.037",,"5MOV",38.88,"2.2","2.2","Crystal structure of Ck2alpha with ZT0633 bound","GPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTV","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5MOV"
"5MOW",,"X-RAY DIFFRACTION",2.24,44.97,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1016/j.bmc.2017.04.037",,"5MOW",83.24,"1.86","1.86","Crystal Structure of CK2alpha with ZT0432 bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5MOW"
"5MP0",,"X-RAY DIFFRACTION",2.51,50.96,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M acetate pH 4.5
25% PEG3350",277,,,"5MP0",19.11,"1.63","1.63","Human m7GpppN-mRNA Hydrolase (DCP2, NUDT20) Catalytic Domain","MGVPTYGAIILDETLENVLLVQGYLAKSGWGFPKGKVNKEEAPHDCAAREVFEETGFDIKDYICKDDYIELRINDQLARLYIIPGIPKDTKFNPKTRREIRNIEWFSIEKLPCHRNDMTPKSKLGLAPNKFFMAIPFIRPLRDWLSRRFGDSSDSDNGFSSTGSTP","Homo sapiens","DCP2, NUDT20","m7GpppN-mRNA hydrolase","1","5MP0"
"5MP6",,"X-RAY DIFFRACTION",2.01,38.76,"VAPOR DIFFUSION, HANGING DROP",,"10.25% PEG4000
87.5 mM ammonium sulphate
Cryoprotectant: 25% PEG400",298.15,"10.1371/journal.ppat.1006074",,"5MP6",99.91,"1.959","1.959","Structure of the Unliganded Fab from HIV-1 Neutralizing Antibody CAP248-2B that Binds to the gp120 C-terminus - gp41 Interface, at two Angstrom resolution.","QVQLQQSGPGLVKPSQTLSLTCNVYGVAISNEDYYWTWIRQHPGKGLEWIGDIYYNSGTTHYNPSLKSRASVSVDLSRNQFTLKVTSVTTADAAVYYCAREASTKITDDGGAFDFWGRGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKGLEVLFQ","Homo sapiens",,"CAP248-2B Heavy Chain","1","5MP6"
,,,,,,,,,,,,,,,,"QSALTQPASVSGSPGQSISISCTGTSSDIGGYKYVSWYQQHPGRAPKLIIYDVIKRPSGISDRFSGSKSANTASLTISGLQAGDEASYYCSSYTTKKTSFFGPATRAYVFGSGTQVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"CAP248-2B Light Chain","2","5MP6"
"5MP8",,"X-RAY DIFFRACTION",2.22,44.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1016/j.bmc.2017.04.037",,"5MP8",84.84,"1.92","1.92","Crystal Structure of CK2alpha with ZT0432 bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5MP8"
"5MPH",,"X-RAY DIFFRACTION",3.45,64.4,"VAPOR DIFFUSION, SITTING DROP",5.5,"2.1 M (NH4)2SO4 and 0.1 M NaOAc, pH 5.5",277,"10.1093/nar/gkx1299",,"5MPH",27.88,"2.337","2.337","Structural Basis of Gene Regulation by the Grainyhead Transcription Factor Superfamily","SGNNFEYTLEASKSLRQKPGDSTMTYLNKGQFYPITLKEVSSSEGIHHPISKVRSVIMVVFAEDKSREDQLRHWKYWHSRQHTAKQRCIDIADYKESFNTISNVEEIAYNAISFTWDINDEAKVFISVNCLSTDFSSQKGVKGLPLNIQIDTYSYNNRSNKPVHRAYCQIKVFCDKGAERKIRDEERKQSKRKVSDVKVPLLPSHKRMDITVFKPFIDLDTQPVLFIPDVHFANLQRG","Homo sapiens","GRHL1, LBP32, MGR, TFCP2L2","Grainyhead-like protein 1 homolog","1","5MPH"
"5MPI",,"X-RAY DIFFRACTION",3.45,64.4,"VAPOR DIFFUSION, SITTING DROP",5.5,"2.1 M (NH4)2SO4 and 0.1 M NaOAc, pH 5.5",277,"10.1093/nar/gkx1299",,"5MPI",27.6,"2.345","2.345","Structural Basis of Gene Regulation by the Grainyhead Transcription Factor Superfamily","SGNNFEYTLEASKSLRQKPGDSTMTYLNKGQFYPITLKEVSSSEGIHHPISKVRSVIMVVFAEDKSREDQLRHWKYWHSRQHTAKQRCIDIADYKESFNTISNVEEIAYNAISFTWDINDEAKVFISVNCLSTDFSSQKGVKGLPLNIQIDTYSYNNRSNKPVHRAYCQIKVFCDKGAEQKIRDEERKQSKRKVSDVKVPLLPSHKRMDITVFKPFIDLDTQPVLFIPDVHFANLQRG","Homo sapiens","GRHL1, LBP32, MGR, TFCP2L2","Grainyhead-like protein 1 homolog","1","5MPI"
"5MPJ",,"X-RAY DIFFRACTION",2.24,45.01,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1016/j.bmc.2017.04.037",,"5MPJ",84.27,"2.14","2.14","1-(2-chloro-[1,1'-biphenyl]-4-yl)-N-methylethanamine","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5MPJ"
"5MPK",,"X-RAY DIFFRACTION",2.09,41.15,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES-Na, pH7.5, 0.2 M MgCl2, 25% P3350",277,"10.1021/acsmedchemlett.8b00286","0BC","5MPK",29.32,"1.9","1.9","Crystal structure of CREBBP bromodomain complexed with DK19","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5MPK"
"5MPN",,"X-RAY DIFFRACTION",2.13,42.24,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2 M MgCl2, 0.1 M Bis-Tris, pH6.5, 5% EG, 23% PEG3350",277,"10.1021/acsmedchemlett.8b00286","YE5","5MPN",14.96,"1.23","1.23","Crystal structure of CREBBP bromodomain complexed with FA26","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5MPN"
"5MPR",,"X-RAY DIFFRACTION",2.59,52.59,"EVAPORATION",6.5,"0.2 M Sodiumfluoride, 0.1 M Bis Tris propane pH 6.5, 20% w/v Polyethylene glycol 3350",293,"10.1007/s13361-017-1705-0",,"5MPR",41.98,"1.6","1.6","Single Amino Acid Variant of Human Mitochondrial Branched Chain Amino Acid Aminotransferase 2","GASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPRRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5MPR"
"5MPZ",,"X-RAY DIFFRACTION",2.08,40.93,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M MgCl2, 0.1 M Bis-Tris, pH 6.5, 5% v/v ethylene glycol, 23% PEG3350",277,"10.1016/j.bmcl.2017.04.001","4I8","5MPZ",14.61,"1.4","1.4","Crystal structure of CREBBP bromodomain complexed with CBP007","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5MPZ"
"5MQ1",,"X-RAY DIFFRACTION",2.61,52.85,"VAPOR DIFFUSION, SITTING DROP",7,"20% PEG6000, 10%EDO, 0.1 M HEPES pH 7.0, 0.01 M ZnCl2",277,,"5U6","5MQ1",14.47,"1.5","1.5","Crystal structure of the BRD7 bromodomain in complex with BI-9564","MEEVEQTPLQEALNQLMRQLQRKDPSAFFSFPVTDFIAPGYSMIIKHPMDFSTMKEKIKNNDYQSIEELKDNFKLMCTNAMIYNKPETIYYKAAKKLLHSGMKILSQERIQS","Homo sapiens","BRD7, BP75, CELTIX1","Bromodomain-containing protein 7","1","5MQ1"
"5MQ4",,"X-RAY DIFFRACTION",4.59,73.22,"VAPOR DIFFUSION, SITTING DROP",6.3,"1M ammonium sulfate -- 0.1M MES pH 6.3",274,,,"5MQ4",91.61,"2.7","2.7","Crystal Structure of the leucine zipper of human PRKCBP1","SMSKNTTGSTIAEIRRLRIEIEKLQWLHQQELSEMKHNLELTMAEMRQSLEQERDRLIAEVKKQLELEKQQAVDETKKKQWCANCKKEAIFYCCWNTSYCDYPCQQAHWPEHMKSCTQSATAPQQEA","Homo sapiens","ZMYND8, KIAA1125, PRKCBP1, RACK7","Protein kinase C-binding protein 1","1","5MQ4"
"5MQE",,"X-RAY DIFFRACTION",2.02,39.22,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350",277,"10.1016/j.bmcl.2017.04.001","PKU","5MQE",28.85,"1.65","1.65","Crystal structure of CREBBP bromodomain complexed with CBP006","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5MQE"
"5MQG",,"X-RAY DIFFRACTION",2.01,38.77,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350",277,"10.1016/j.bmcl.2017.04.001",,"5MQG",28.78,"1.35","1.35","Crystal structure of CREBBP bromodomain complexed with CBP015","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5MQG"
"5MQI",,"X-RAY DIFFRACTION",2.56,51.93,"VAPOR DIFFUSION, SITTING DROP",,"reservoir solution: 20% (w/v) PEG 3350, 200 mM Na2SO4
protein solution: 8.5 mg/mL, 150 mM KCl, 25 mM Heps pH 7.2, 1 mM TCEP

200 nL protein solution and 200 nL of reservoir solution were mixed.",292,"10.1093/nar/gkx139",,"5MQI",44.24,"1.847","1.847","Crystal structure of the N-terminal domain of human Timeless","DPMDLHMMNCELLATCSALGYLEGDTYHKEPDCLESVKDLIRYLRHEDETRDVRQQLGAAQILQSDLLPILTQHHQDKPLFDAVIRLMVNLTQPALLCFGNLPKEPSFRHHFLQVLTYLQAYKEAFASEKAFGVLSETLYELLQLGWEERQEEDNLLIERILLLVRNILHVPADLDQEKKIDDDASAHDQLLWAIHLSGLDDLLLFLASSSAEEQWSLHVLEIVSLMFRDQNPEQLAGVGGSTGSTQRRSALNVRLFLRDFCSEFLENCYNRLMGSVKDHLLREKAQQHDETYYMWALAFFMAFNRAASFRPGLVSETLSVRTFHFIEQNLTNYYEMMLTDRKEAASWARRMHLALKAYQELLATVNEMDISPDEAVRE","Homo sapiens","TIMELESS, TIM, TIM1, TIMELESS1","Protein timeless homolog,Protein timeless homolog","1","5MQI"
,,,,,,,,,,,,,,,,,"Homo sapiens","TIMELESS, TIM, TIM1, TIMELESS1"
"5MQJ",,"X-RAY DIFFRACTION",2.75,55.21,"VAPOR DIFFUSION, HANGING DROP",5.5,"100 mM Sodium acetate pH 5.5, 20% PEG 3350, 50 mM NaCl",291.15,"10.1038/s41467-017-01582-5",,"5MQJ",135.11,"3.7","3.7","Crystal structure of dCK mutant C3S","MSYYHHHHHHLESTSLYKKAGLATPPKRSSPSFSASSEGTRIKKISIEGNIAAGKSTFVNILKQLSEDWEVVPEPVARWSNVQSTQDEFEELTMSQKNGGNVLQMMYEKPERWSFTFQTYACLSRIRAQLASLNGKLKDAEKPVLFFERSVYSDRYIFASNLYESECMNETEWTIYQDWHDWMNNQFGQSLELDGIIYLQATPETCLHRIYLRGRNEEQGIPLEYLEKLHYKHESWLLHRTLKTNFDYLQEVPILTLDVNEDFKDKYESLVEKVKEFLSTL","Homo sapiens","DCK","Deoxycytidine kinase","1","5MQJ"
"5MQK",,"X-RAY DIFFRACTION",2.04,39.83,"VAPOR DIFFUSION, SITTING DROP",,"0.15 M KSCN, 20% PEG3350, 10% EG",277,"10.1016/j.bmcl.2017.04.001",,"5MQK",28.79,"1.53","1.53","Crystal structure of CREBBP bromodomain complexed with CBP019","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5MQK"
"5MQL",,"X-RAY DIFFRACTION",2.45,49.87,"VAPOR DIFFUSION, HANGING DROP",5.5,"100 mM sodium acetate, 20% PEG 3350, 50 mM NaCl, 24h soaking with 10 mM Masitinib",291.15,"10.1038/s41467-017-01582-5",,"5MQL",138.85,"3.25","3.25","Crystal structure of dCK mutant C3S in complex with masitinib and UDP","MSYYHHHHHHLESTSLYKKAGLENLYFQGMATPPKRSSPSFSASSEGTRIKKISIEGNIAAGKSTFVNILKQLSEDWEVVPEPVARWSNVQSTQDEFEELTMSQKNGGNVLQMMYEKPERWSFTFQTYACLSRIRAQLASLNGKLKDAEKPVLFFERSVYSDRYIFASNLYESECMNETEWTIYQDWHDWMNNQFGQSLELDGIIYLQATPETCLHRIYLRGRNEEQGIPLEYLEKLHYKHESWLLHRTLKTNFDYLQEVPILTLDVNEDFKDKYESLVEKVKEFLSTL","Homo sapiens","DCK","Deoxycytidine kinase","1","5MQL"
"5MQT",,"X-RAY DIFFRACTION",3.23,61.97,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM sodium acetate pH 6, 13% PEG 4000 (w/v), and 6% isopropanol. 18h soaking with 10 mM imatinib",291,"10.1038/s41467-017-01582-5",,"5MQT",139.34,"3.2","3.2","Crystal structure of dCK mutant C3S in complex with imatinib and UDP","MSYYHHHHHHLESTSLYKKAGLENLYFQGMATPPKRSSPSFSASSEGTRIKKISIEGNIAAGKSTFVNILKQLSEDWEVVPEPVARWSNVQSTQDEFEELTMSQKNGGNVLQMMYEKPERWSFTFQTYACLSRIRAQLASLNGKLKDAEKPVLFFERSVYSDRYIFASNLYESECMNETEWTIYQDWHDWMNNQFGQSLELDGIIYLQATPETCLHRIYLRGRNEEQGIPLEYLEKLHYKHESWLLHRTLKTNFDYLQEVPILTLDVNEDFKDKYESLVEKVKEFLSTL","Homo sapiens","DCK","Deoxycytidine kinase","1","5MQT"
"5MQV",,"X-RAY DIFFRACTION",4.09,69.94,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Hepes pH 7.0, 0.7 M NaH2PO4, 0.7 M KH2PO4",277,"10.3390/molecules22040522","D5Q","5MQV",223.52,"2.154","2.154","Crystal structure of human Casein Kinase I delta in complex with 4-(2,5-Dimethoxyphenyl)-N-(4-(5-(4-fluorphenyl)-2-(methylthio)-1H-imidazol-4-yl)-pyridin-2-yl)-1-methyl-1H-pyrrole-2-carboxamide","MGSSHHHHHHSSGLVPRGSHMELRVGNRYRLGRKIGSGSFGDIYLGTDIAAGEEVAIKLECVKTKHPQLHIESKIYKMMQGGVGIPTIRWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIHSKNFIHRDVKPDNFLMGLGKKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLESLGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFATYLNFCRSLRFDDKPDYSYLRQLFRNLFHRQGFSYDYVFDWNMLK","Homo sapiens","CSNK1D, HCKID","Casein kinase I isoform delta","1","5MQV"
"5MQY",,"X-RAY DIFFRACTION",2.06,40.15,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG3350, 0.1M Bis-Tris",294,"10.1021/acs.jmedchem.6b01881",,"5MQY",25.08,"1.13","1.13","CATHEPSIN L IN COMPLEX WITH 4-[1,3-benzodioxol-5-ylmethyl(2-phenoxyethyl)amino]-5-fluoropyrimidine-2-carbonitrile","APRSVDWREKGYVTPVKNQGQCGSCWAFSATGALEGQMFRKTGRLISLSEQNLVDCSGPQGNEGCNGGLMDYAFQYVQDNGGLDSEESYPYEATEESCKYNPKYSVANDTGFVDIPKQEKALMKAVATVGPISVAIDAGHESFLFYKEGIYFEPDCSSEDMDHGVLVVGYGFESTESDNNKYWLVKNSWGEEWGMGGYVKMAKDRRNHCGIASAASYPTV","Homo sapiens","CTSL, CTSL1","Cathepsin L1","1","5MQY"
"5MR1",,"X-RAY DIFFRACTION",2.4,48.71,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Lithium Sulfate, 25% PEG 3350, 0.1 M Bis Tris pH 5.5",294,,,"5MR1",12.06,"1.2","1.2","Crystal structure of the Pleckstrin homology domain of Interactor protein for cytohesin exchange factors 1 (IPCEF1)","SMADCQGWLYKKKEKGSFLSNKWKKFWVILKGSSLYWYSNQMAEKADGFVNLPDFTVERASECKKKHAFKISHPQIKTFYFAAENVQEMNVWLNKLGSAVIHQ","Homo sapiens","IPCEF1, KIAA0403","Interactor protein for cytohesin exchange factors 1","1","5MR1"
"5MR7",,"X-RAY DIFFRACTION",2.02,39.17,"VAPOR DIFFUSION, SITTING DROP",,"reservoir with 21% PEG 3350, 0.2 M sodium formate",277,"10.1093/nar/gkx1299",,"5MR7",63.87,"2.5","2.5","Crystal structure of the DBD domain of human Grhl2","GSSESFKDAATEKFRSASVGAEEYMYDQTSSGTFQYTLEATKSLRQKQGEGPMTYLNKGQFYAITLSETGDNKCFRHPISKVRSVVMVVFSEDKNRDEQLKYWKYWHSRQHTAKQRVLDIADYKESFNTIGNIEEIAYNAVSFTWDVNEEAKIFITVNCLSTDFSSQKGVKGLPLMIQIDTYSYNNRSNKPIHRAYCQIKVFCDKGAERKIRDEERKQNRKKGKGQASQTQCNSSSDGKLAAIPLQKKSDITYFKTMPDLHSQPVLFIPDVHFANLQR","Homo sapiens","GRHL2, BOM, TFCP2L3","Grainyhead-like protein 2 homolog","1","5MR7"
"5MR9",,"X-RAY DIFFRACTION",2.45,49.74,"VAPOR DIFFUSION",10.5,"40% MPD and 100 mM CAPS pH 10.5.",293,,,"5MR9",23.41,"2.4","2.4","Ligand-receptor complex.","ARLGARPCGLRELEVRVSELGLGYASDETVLFRYCAGACEAAARVYDLGLRRLRQRRRLRRERVRAQPCCRPTAYEDEVSFLDAHSRYHTVHELSARECACV","Homo sapiens","NRTN","Neurturin","1","5MR9"
"5MRA",,"X-RAY DIFFRACTION",3.63,66.13,"VAPOR DIFFUSION, SITTING DROP",7,"0.2 M MgCl2, 0.1 M Tris pH=7, NaCl 2.5 M",298,"10.1038/cddis.2017.342",,"5MRA",76.26,"3.74","3.74","human SCBD (sorcin calcium binding domain) in complex with doxorubicin","MDPLYGYFAAVAGQDGQIDADELQRCLTQSGIAGGYKPFNLETCRLMVSMLDRDMSGTMGFNEFKELWAVLNGWRQHFISFDTDRSGTVDPQELQKALTTMGFRLSPQAVNSIAKRYSTNGKITFDDYIACCVKLRALTDSFRRRDTAQQGVVNFPYDDFIQCVMSV","Homo sapiens","SRI","Sorcin","1","5MRA"
"5MRB",,"X-RAY DIFFRACTION",3.13,60.65,"VAPOR DIFFUSION, SITTING DROP",8.8,"Protein solution: 200 uM (7.2 mg/mL) Mps1, 250 uM Cpd-5. 
Reservoir solution: 15.5% (w/v) PEG 350 MME, 10 mM MgCl2, and 100 mM Tris/HCl",291,"10.1074/jbc.M117.783555","C5N","5MRB",37.54,"2.2","2.2","Crystal structure of human Mps1 (TTK) in complex with Cpd-5","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMEYGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5MRB"
"5MRD",,"X-RAY DIFFRACTION",2.17,43.27,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.2 M NA CITRATE, 0.1 M HEPES PH 7.5, 10 MM DTT",293,"10.1021/acschembio.6b00827","S26","5MRD",36.52,"1.41","1.41","Human PDK1-PKCiota Kinase Chimera in Complex with Allosteric Compound PS267 Bound to the PIF-Pocket","AMDGTAAEPRPGAGSLQHAQPPPQPRSKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKIVEKRHVNKENKIPYVQREKDVMSRLDHPFFVKLYFCFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEGLIFAKIIKLEYDFPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLT","Homo sapiens","PDPK1, PDK1","3-phosphoinositide-dependent protein kinase 1","1","5MRD"
"5MRG",,"SOLUTION NMR",,,,,,,"10.1074/jbc.M117.775965",,"5MRG",12.67,,,"Solution structure of TDP-43 (residues 1-102)","MAGSHHHHHHGSMSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQK","Homo sapiens","TARDBP, TDP43","TAR DNA-binding protein 43","1","5MRG"
"5MRH",,"X-RAY DIFFRACTION",3.6,65.4,"VAPOR DIFFUSION, SITTING DROP",7.3,"0.1M HEPES-Tris pH=7.3
0.4 M Sodium malonate
22 % (w/V) PEG 3350
8 (V/V) glycerol",292,"10.1016/j.bmcl.2017.02.028","Q9Z","5MRH",78.95,"2.5","2.5","Crystal structure of the Vps10p domain of human sortilin/NTS3 in complex with Triazolone 1","SAPGEDEECGRVRDFVAKLANNTHQHVFDDLRGSVSLSWVGDSTGVILVLTTFHVPLVIMTFGQSKLYRSEDYGKNFKDITDLINNTFIRTEFGMAIGPENSGKVVLTAEVSGGSRGGRIFRSSDFAKNFVQTDLPFHPLTQMMYSPQNSDYLLALSTENGLWVSKNFGGKWEEIHKAVCLAKWGSDNTIFFTTYANGSCKADLGALELWRTSDLGKSFKTIGVKIYSFGLGGRFLFASVMADKDTTRRIHVSTDQGDTWSMAQLPSVGQEQFYSILAANDDMVFMHVDEPGDTGFGTIFTSDDRGIVYSKSLDRHLYTTTGGETDFTNVTSLRGVYITSVLSEDNSIQTMITFDQGGRWTHLRKPENSECDATAKNKNECSLHIHASYSISQKLNVPMAPLSEPNAVGIVIAHGSVGDAISVMVPDVYISDDGGYSWTKMLEGPHYYTILDSGGIIVAIEHSSRPINVIKFSTDEGQCWQTYTFTRDPIYFTGLASEPGARSMNISIWGFTESFLTSQWVSYTIDFKDILERNCEEKDYTIWLAHSTDPEDYEDGCILGYKEQFLRLRKSSMCQNGRDYVVTKQPSICLCSLEDFLCDFGYYRPENDSKCVEQPELKGHDLEFCLYGREEHLTTNGYRKIPGDKCQGGVNPVREVKDLKKKCTSNFLSPEKQNSKSNSGSAMIEGRGVGHHHHHH","Homo sapiens","SORT1","Sortilin","1","5MRH"
"5MRI",,"X-RAY DIFFRACTION",3.28,62.55,"VAPOR DIFFUSION, SITTING DROP",7.3,"0.1 M HEPES-Tris pH 7.3
0.4 M Sodium malonate
6 % (V/V) glycerol
26 % (w/V) PEG 3350",292,"10.1016/j.bmcl.2017.02.028",,"5MRI",79.24,"2","2","Crystal structure of the Vps10p domain of human sortilin/NTS3 in complex with Triazolone 18","SAPGEDEECGRVRDFVAKLANNTHQHVFDDLRGSVSLSWVGDSTGVILVLTTFHVPLVIMTFGQSKLYRSEDYGKNFKDITDLINNTFIRTEFGMAIGPENSGKVVLTAEVSGGSRGGRIFRSSDFAKNFVQTDLPFHPLTQMMYSPQNSDYLLALSTENGLWVSKNFGGKWEEIHKAVCLAKWGSDNTIFFTTYANGSCKADLGALELWRTSDLGKSFKTIGVKIYSFGLGGRFLFASVMADKDTTRRIHVSTDQGDTWSMAQLPSVGQEQFYSILAANDDMVFMHVDEPGDTGFGTIFTSDDRGIVYSKSLDRHLYTTTGGETDFTNVTSLRGVYITSVLSEDNSIQTMITFDQGGRWTHLRKPENSECDATAKNKNECSLHIHASYSISQKLNVPMAPLSEPNAVGIVIAHGSVGDAISVMVPDVYISDDGGYSWTKMLEGPHYYTILDSGGIIVAIEHSSRPINVIKFSTDEGQCWQTYTFTRDPIYFTGLASEPGARSMNISIWGFTESFLTSQWVSYTIDFKDILERNCEEKDYTIWLAHSTDPEDYEDGCILGYKEQFLRLRKSSMCQNGRDYVVTKQPSICLCSLEDFLCDFGYYRPENDSKCVEQPELKGHDLEFCLYGREEHLTTNGYRKIPGDKCQGGVNPVREVKDLKKKCTSNFLSPEKQNSKSNSGSAMIEGRGVGHHHHHH","Homo sapiens","SORT1","Sortilin","1","5MRI"
"5MRL",,"X-RAY DIFFRACTION",2.7,54.51,"VAPOR DIFFUSION, SITTING DROP",6.5,"PEG4000, ADA, lithium sulfate",277,"10.1021/acschemneuro.6b00377",,"5MRL",119.55,"2.42","2.42","Crystal structure of human monoamine oxidase B (MAO B) in complex with N(Furan2ylmethyl)Nmethylprop2yn1amine (F2MPA)","MSNKCDVVVVGGGISGMAAAKLLHDSGLNVVVLEARDRVGGRTYTLRNQKVKYVDLGGSYVGPTQNRILRLAKELGLETYKVNEVERLIHHVKGKSYPFRGPFPPVWNPITYLDHNNFWRTMDDMGREIPSDAPWKAPLAEEWDNMTMKELLDKLCWTESAKQLATLFVNLCVTAETHEVSALWFLWYVKQCGGTTRIISTTNGGQERKFVGGSGQVSERIMDLLGDRVKLERPVIYIDQTRENVLVETLNHEMYEAKYVISAIPPTLGMKIHFNPPLPMMRNQMITRVPLGSVIKCIVYYKEPFWRKKDYCGTMIIDGEEAPVAYTLDDTKPEGNYAAIMGFILAHKARKLARLTKEERLKKLCELYAKVLGSLEALEPVHYEEKNWCEEQYSGGCYTTYFPPGILTQYGRVLRQPVDRIYFAGTETATHWSGYMEGAVEAGERAAREILHAMGKIPEDEIWQSEPESVDVPAQPITTTFLERHLPSVPGLLRLIGLTTIFSATALGFLAHKRGLLVRV","Homo sapiens","MAOB","Amine oxidase [flavin-containing] B","1","5MRL"
"5MS3",,"X-RAY DIFFRACTION",2.01,38.92,"VAPOR DIFFUSION, HANGING DROP",5.6,"35% (v/v) tert-Butanol, 0.1 M tri-Na citrate/citric acid",291,,,"5MS3",24.52,"2.3","2.3","Kallikrein-related peptidase 8 calcium complex","VLGGHECQPHSQPWQAALFQGQQLLCGGVLVGGNWVLTAAHCKKPKYTVRLGDHSLQNKDGPEQEIPVVQSIPHPCYNSSDVEDHNHDLMLLQLRDQASLGSKVKPISLADHCTQPGQKCTVSGWGTVTSPRENFPDTLNCAEVKIFPQKKCEDAYPGQITDGMVCAGSSKGADTCQGDSGGPLVCDGALQGITSWGSDPCGRSDKPGVYTNICRYLDWIKKIIGSKG","Homo sapiens","KLK8, NRPN, PRSS19, TADG14, UNQ283/PRO322","Kallikrein-8","1","5MS3"
"5MS6",,"X-RAY DIFFRACTION",2.21,44.44,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium acetate and 3 M NaCl",277.15,"10.7554/eLife.23905",,"5MS6",31.94,"1.9","1.9","High-salt structure of RavZ LIR2-fused human LC3B","GHMGSDIDEFDLLEGDEGSPSEKTFKQRRTFEQRVEDVRLIREQHPTKIPVIIERYKGEKQLPVLDKTKFLVPDHVNMSELIKIIRRRLQLNANQAFFLLVNGHSMVSVSTPISEVYESEKDEDGFLYMVYASQETF","Homo sapiens","MAP1LC3B, MAP1ALC3","Microtubule-associated proteins 1A/1B light chain 3B","1","5MS6"
"5MS9",,"SOLUTION NMR",,,,,,,"10.1016/j.str.2017.06.003",,"5MS9",18.91,,,"Solution structure of Human Fibrillin-1 EGF2-EGF3-Hybrid1-cbEGF1 four domain fragment","SASRSIQHCNIRCMNGGSCSDDHCLCQKGYIGTHCGQPVCESGCLNGGRCVAPNRCACTYGFTGPQCERDYRTGPCFTVISNQMCQGQLSGIVSTKTLCCATVGRAWGHPCEMCPAQPHPCRRGFIPNIRTGACQDVDECQAIPGLCQGGNCINTVGSFECKCPAGHKLNEVSQKCE","Homo sapiens","FBN1, FBN","Fibrillin-1","1","5MS9"
"5MSA",,"X-RAY DIFFRACTION",2.07,40.3,"VAPOR DIFFUSION, SITTING DROP",7.2,"Crystallization buffer: 0.1M ammonium citrate (pH 7.2), 0.2 M ammonium sulfate and 26% PEG4000",291,,"3TV","5MSA",122.89,"1.2","1.2","Crystal structure of human carbonic anhydrase isozyme XII with 2,3,5,6-Tetrafluoro-4-(propylthio)benzenesulfonamide","MSKWTYFGPDGENSWSKKYPSCGGLLQSPIDLHSDILQYDASLTPLEFQGYNLSANKQFLLTNNGHSVKLNLPSDMHIQGLQSRYSATQLHLHWGNPNDPHGSEHTVSGQHFAAELHIVHYNSDLYPDASTASNKSEGLAVLAVLIEMGSFNPSYDKIFSHLQHVKYKGQEAFVPGFNIEELLPERTAEYYRYRGSLTTPPCNPTVLWTVFRNPVQISQEQLLALETALYCTHMDDPSPREMINNFRQVQKFDERLVYTSFSQ","Homo sapiens","CA12","Carbonic anhydrase 12","1","5MSA"
"5MSB",,"X-RAY DIFFRACTION",2.06,40,"VAPOR DIFFUSION, SITTING DROP",7.2,"Crystallization buffer: 0.1M ammonium citrate (pH 7.2), 0.2 M ammonium sulfate and 26% PEG4000",291,"10.7717/peerj.4412","V13","5MSB",121.76,"1.3","1.3","Crystal structure of human carbonic anhydrase isozyme XII with 2,3,5,6-tetrafluoro-4[(2-hydroxyethyl)sulfonyl]benzenesulfonamide","MSKWTYFGPDGENSWSKKYPSCGGLLQSPIDLHSDILQYDASLTPLEFQGYNLSANKQFLLTNNGHSVKLNLPSDMHIQGLQSRYSATQLHLHWGNPNDPHGSEHTVSGQHFAAELHIVHYNSDLYPDASTASNKSEGLAVLAVLIEMGSFNPSYDKIFSHLQHVKYKGQEAFVPGFNIEELLPERTAEYYRYRGSLTTPPCNPTVLWTVFRNPVQISQEQLLALETALYCTHMDDPSPREMINNFRQVQKFDERLVYTSFSQ","Homo sapiens","CA12","Carbonic anhydrase 12","1","5MSB"
"5MT0",,"X-RAY DIFFRACTION",2.09,41.21,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 100 mM BIS-TRIS pH 6.5",293,"10.1021/acs.jmedchem.6b01684","QJS","5MT0",25.17,"1.29","1.29","COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE INDOLE CARBOXYLIC ACID BASED INHIBITOR","ILGGREAEAHARPYMASVQLNGAHLCGGVLVAEQWVLSAAHCLEDAADGKVQVLLGAHSLSQPEPSKRLYDVLRAVPHPDSQPDTIDHDLLLLQLSEKATLGPAVRPLPWQRVDRDVAPGTLCDVAGWGIVNHAGRRPDSLQHVLLPVLDRATCNRRTHHDGAITERLMCAESNRRDSCKGDSGGPLVCGGVLEGVVTSGSRVCGNRKKPGIYTRVASYAAWIDSVLASAAA","Homo sapiens","CFD, DF, PFD","Complement factor D","1","5MT0"
"5MT3",,"X-RAY DIFFRACTION",2.3,46.1,"VAPOR DIFFUSION, HANGING DROP",7.5,"5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine.",293,"10.1074/jbc.M117.775924","SRO","5MT3",96.63,"2.02","2.02","Human insulin in complex with serotonin and arginine","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin","1","5MT3"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKT","Homo sapiens","INS","Insulin","2","5MT3"
"5MT4",,"X-RAY DIFFRACTION",2.17,43.27,"VAPOR DIFFUSION, SITTING DROP",,"26% PEGME2000, 100mM Bis-Tris pH 6.5",293,"10.1021/acs.jmedchem.6b01684","M7O","5MT4",25.01,"1.65","1.65","COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE BENZOIC ACID BASED INHIBITOR","ILGGREAEAHARPYMASVQLNGAHLCGGVLVAEQWVLSAAHCLEDAADGKVQVLLGAHSLSQPEPSKRLYDVLRAVPHPDSQPDTIDHDLLLLQLSEKATLGPAVRPLPWQRVDRDVAPGTLCDVAGWGIVNHAGRRPDSLQHVLLPVLDRATCNRRTHHDGAITERLMCAESNRRDSCKGDSGGPLVCGGVLEGVVTSGSRVCGNRKKPGIYTRVASYAAWIDSVLASAAA","Homo sapiens","CFD, DF, PFD","Complement factor D","1","5MT4"
"5MT9",,"X-RAY DIFFRACTION",2.3,45.5,"VAPOR DIFFUSION, HANGING DROP",7.5,"5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine",293,"10.1074/jbc.M117.775924","SRO","5MT9",97.41,"1.88","1.88","Human insulin in complex with serotonin and arginine","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin","1","5MT9"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKT","Homo sapiens","INS","Insulin","2","5MT9"
"5MTK",,"X-RAY DIFFRACTION",2.76,55.5,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES (pH 7.4), 2 M (NH4)2SO4 and 25 mM DTT",277,,,"5MTK",30.87,"2.53","2.53","Crystal structure of human Caspase-1 with (3S,6S,10aS)-N-((2S,3S)-2-hydroxy-5-oxotetrahydrofuran-3-yl)-6-(isoquinoline-1-carboxamido)-5-oxodecahydropyrrolo[1,2-a]azocine-3-carboxamide (PGE-3935199)","MNPAMPTSSGSEGNVKLCSLEEAQRIWKQKSAEIYPIMDKSSRTRLALIICNEEFDSIPRRTGAEVDITGMTMLLQNLGYSVDVKKNLTASDMTTELEAFAHRPEHKTSDSTFLVFMSHGIREGICGKKHSEQVPDILQLNAIFNMLNTKNCPSLKDKPKVIIIQACRGDSPGVVWFKD","Homo sapiens","CASP1, IL1BC, IL1BCE","Caspase-1","1","5MTK"
,,,,,,,,,,,,,,,,"MAIKKAHIEKDFIAFCSSTPDNVSWRHPTMGSVFIGRLIEHMQEYACSCDVEEIFRKVRFSFEQPDGRAQMPTTERVTLTRCFYLFPGH","Homo sapiens","CASP1, IL1BC, IL1BCE","Caspase-1","2","5MTK"
"5MTL",,"X-RAY DIFFRACTION",2.88,57.27,"VAPOR DIFFUSION, SITTING DROP",6.5,"Sodium cacodylate, 27% w/v PEG 2000 MME",293,"10.1038/s41598-017-16953-7",,"5MTL",91.02,"2.45","2.45","Crystal structure of an amyloidogenic light chain","QSVLTQPPSTSGTPGQRVTISCSGSSSNIETNTVNWYQQLPGTAPKLVMHTNNQRPSGVPDRFSGSRSGTSASLAIGGLQSEDEADYFCAAWDDNLNGVIFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens","IGL@","light chain dimer,IGL@ protein,IGL@ protein","1","5MTL"
,,,,,,,,,,,,,,,,,"Homo sapiens","IGL@"
"5MTO",,"X-RAY DIFFRACTION",5.27,76.68,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.78 M NPS
0.08 HEPES/MOPS Buffer pH 7.5
32.8% MPD_PEG1K_PEG3350",291,"10.1016/j.jmb.2019.04.018",,"5MTO",25.21,"3.1","3.1","N-terminal domain of the human tumor suppressor ING5 C19S mutant","GAMATAMYLEHYLDSIENLPSELQRNFQLMRELDQRTEDKKAEIDILAAEYISTVKTLSPDQRVERLQKIQNAYSKCKEYSDDKVQLAMQTYEMVDKHIRRLDADLA","Homo sapiens","ING5","Inhibitor of growth protein 5","1","5MTO"
"5MTX",,"X-RAY DIFFRACTION",2.14,42.57,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.3
20-30 % PEG4000
25 mM BOG",293.15,"10.1021/acs.jmedchem.7b00745","FJI","5MTX",42.52,"1.8","1.8","Dibenzooxepinone inhibitor 12b in complex with p38 MAPK","MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5MTX"
"5MTY",,"X-RAY DIFFRACTION",2.13,42.31,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.3
20-30 % PEG4000
25 mM BOG",293.15,"10.1021/acs.jmedchem.7b00745","HB9","5MTY",42.48,"2.31","2.31","Dibenzosuberone inhibitor 8e in complex with p38 MAPK","MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5MTY"
"5MU6",,"X-RAY DIFFRACTION",2.27,45.96,"VAPOR DIFFUSION, SITTING DROP",,"23% (v/w) MME2K, 0.2M KBr, 100 mM sodium citrate pH 4.5, and 5% (v/v) glycerol",293,"10.1038/s41557-018-0039-2","KFK","5MU6",94.19,"1.88","1.88","Human N-myristoyltransferase (NMT1) with Myristoyl-CoA and IMP-1088 inhibitor bound","GPHMEEASKRSYQFWDTQPVPKLGEVVNTHGPVEPDKDNIRQEPYTLPQGFTWDALDLGDRGVLKELYTLLNENYVEDDDNMFRFDYSPEFLLWALRPPGWLPQWHCGVRVVSSRKLVGFISAIPANIHIYDTEKKMVEINFLCVHKKLRSKRVAPVLIREITRRVHLEGIFQAVYTAGVVLPKPVGTCRYWHRSLNPRKLIEVKFSHLSRNMTMQRTMKLYRLPETPKTAGLRPMETKDIPVVHQLLTRYLKQFHLTPVMSQEEVEHWFYPQENIIDTFVVENANGEVTDFLSFYTLPSTIMNHPTHKSLKAAYSFYNVHTQTPLLDLMSDALVLAKMKGFDVFNALDLMENKTFLEKLKFGIGDGNLQYYLYNWKCPSMGAEKVGLVLQ","Homo sapiens","NMT1, NMT","Glycylpeptide N-tetradecanoyltransferase 1","1","5MU6"
"5MU8",,"X-RAY DIFFRACTION",2.81,56.25,"VAPOR DIFFUSION, SITTING DROP",,"PEG",293,"10.1021/acs.jmedchem.6b01836","JNI","5MU8",867.17,"3","3","HUMAN TNF-ALPHA IN COMPLEX WITH JNJ525","AMVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL","Homo sapiens","TNF, TNFA, TNFSF2","Tumor necrosis factor","1","5MU8"
"5MUD",,"X-RAY DIFFRACTION",2.62,53.13,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bicine pH 9.0, 2% w/v 1,4-Dioxane, 10% w/v PEG 20K",293,"10.1038/s41598-017-16953-7",,"5MUD",45.53,"2.34","2.34","Crystal structure of an amyloidogenic light chain dimer H6","QSVLTQPPSVSAAPGQKVTISCSGNNSNIGKNYVSWYQQLPGRTPKVIMYENNKRSSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGVWDSSLSGGVFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"light chain dimer,IGL@ protein","1","5MUD"
"5MUE",,"X-RAY DIFFRACTION",3.73,67.03,"EVAPORATION",7.5,"0.1 M Ammonium sulfate,10% w/v Polyethylene glycol 4,000",291.15,"10.1038/s41598-017-05148-9","VIV","5MUE",27.19,"2.397","2.397","Self-assembled alpha-Tocopherol Transfer Protein Nanoparticles Promote Vitamin E Delivery Across an Endothelial Barrier","TDSFLLRFLRARDFDLDLAWRLLKNYYKWRAECPEISADLHPRSIIGLLKAGYHGVLRSRDPTGSKVLIYRIAHWDPKVFTAYDVFRVSLITSELIVQEVETQRNGIKAIFDLEGWQFSHAFQITPSVAKKIAAVLTDSFPLKVRGIHLINEPVIFHAVFSMIKPFLTEKIKERIHMHGNNYKQSLLQHFPDILPLEYGGEEFSMEDICQEWTNFIMKSEDYLSSISE","Homo sapiens","TTPA, TPP1","Alpha-tocopherol transfer protein","1","5MUE"
"5MUF",,"X-RAY DIFFRACTION",3.27,62.37,"VAPOR DIFFUSION, SITTING DROP",5.7,"18% PEG 3350 and 0.1 M MES, pH 5.7",293,"10.1016/j.str.2017.05.020",,"5MUF",81.7,"3.1","3.1","Crystal structure of human phosphoglycerate mutase family member 5 (PGAM5) in its enzymatically active dodecameric form induced by the presence of the N-terminal WDPNWD motif","SMGPGVWDPNWDRREPLSLINVRKRNVESGEEELASKLDHYKAKATRHIFLIRHSQYHVDGSLEKDRTLTPLGREQAELTGLRLASLGLKFNKIVHSSMTRAIETTDIISRHLPGVCKVSTDLLREGAPIEPDPPVSHWKPEAVQYYEDGARIEAAFRNYIHRADARQEEDSYEIFICHANVIRYIVCRALQFPPEGWLRLSLNNGSITHLVIRPNGRVALRTLGDTGFMPPDKITRS","Homo sapiens","PGAM5","Serine/threonine-protein phosphatase PGAM5, mitochondrial","1","5MUF"
"5MUG",,"X-RAY DIFFRACTION",3.69,66.66,"EVAPORATION",7.5,"0.1 M Ammonium sulfate,10% w/v Polyethylene glycol 4,000",291.15,"10.1038/s41598-017-05148-9","VIV","5MUG",27.56,"2.42","2.42","Self-assembled alpha-Tocopherol Transfer Protein Nanoparticles Promote Vitamin E Delivery Across an Endothelial Barrier","TDSFLLRFLRARDFDLDLAWRLLKNYYKWRAECPEISADLHPRSIIGLLKAGYHGVLRSRDPTGSKVLIYRIAHWDPKVFTAYDVFRVSLITSELIVQEVETQRNGIKAIFDLEGWQFSHAFQITPSVAKKIAAVLTDSFPLKVRGIHLINEPVIFHAVFSMIKPFLTEKIKERIHMHGNNYKQSLLQHFPDILPLEYGGEEFSMEDICQEWTNFIMKSEDYLSSISESIQ","Homo sapiens","TTPA, TPP1","Alpha-tocopherol transfer protein","1","5MUG"
"5MUH",,"X-RAY DIFFRACTION",2.57,52.12,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH7.5, 10% 2-propanol, 20% w/v PEG 4K",293,"10.1038/s41598-017-16953-7",,"5MUH",44.7,"2.65","2.65","Crystal structure of an amyloidogenic light chain dimer H7","QSVLTQPPSVSAAPGQKVTISCSNVGKNFVSWYQQFPGTAPKVVIYDTDKRPSDIPDRFSGSKSGTSATLDITGLQTGDEADYYCGTWDSGLNGGVFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"light chain dimer","1","5MUH"
"5MUT",,"X-RAY DIFFRACTION",3.7,66.75,"VAPOR DIFFUSION, SITTING DROP",5,"0.2M KBr, 0.2M KSCN, 0.1M NaAc pH 5.2, 25% PEG 400, 2% PGA-LM",293,"10.1016/j.ejmech.2017.02.017","HYT","5MUT",40.86,"1.75","1.75","Crystal structure of potent human Dihydroorotate Dehydrogenase inhibitors based on hydroxylated azole scaffolds","TGDERFYAEHLMPTLQGLLDPESAHRLAVRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQERDGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR","Homo sapiens","DHODH","Dihydroorotate dehydrogenase (quinone), mitochondrial","1","5MUT"
"5MV7",,"X-RAY DIFFRACTION",2.58,52.36,"VAPOR DIFFUSION, HANGING DROP",8.5,"31-34% (v/v) PEG 400, 100 mM Tris-HCl pH 8.5 and 200 mM Li2SO4",290,"10.1038/ncomms15864",,"5MV7",60.74,"2.44","2.44","Structure of human Myosin 7b C-terminal MyTH4-FERM MF2 domain","HHHHHHSSGHKEKLHTLEEFSYEFFRAPEKDAVSMAVLPLARARGHLWAYSCEPLRQPLLKRVHANVDLWDIACQIFVAILRYMGDYPSRQAWPTLELTDQIFTLALQHPALQDEVYCQILKQLTHNSNRHSEERGWQLLWLCTGLFPPSKGLLPHAQKFIDTRRGKLLAPDCSRRIQKVLRTGPRKQPPHQVEVEAAEQNVSRICHKIYFPNDTSEMLEVVANTRVRDVCDSIATRLQLASWEGCSLFIKISDKVISQKEGDFFFDSLREVSDWVKKNKPQKEGAPVTLPYQVYFMRKLWLNISPGKDVNADTILHYHQELPKYLRGFHKCSREDAIHLAGLIYKAQFNNDRSQLASVPKILRELVPENLTRLMSSEEWKKSILLAYDKHKDKTVEEAKVAFLKWICRWPTFGSAFFEVKQTSEPSYPDVILIAINRHGVLLIHPKTKDLLTTYPFTKISSWSSGSTYFHMALGSLGRGSRLLCETSLGYKMDDLLTSYVQQLLSAMNKQRGSKAPALAST","Homo sapiens","MYO7B","Unconventional myosin-VIIb","1","5MV7"
"5MVB",,"SOLUTION NMR",,,,,,,"10.1002/anie.201702135",,"5MVB",9.07,,,"Solution structure of a human G-Quadruplex hybrid-2 form in complex with a Gold-ligand.","TTAGGGTTAGGGTTAGGGTTAGGGTT","Homo sapiens",,"DNA (26-MER)","1","5MVB"
"5MVC",,"X-RAY DIFFRACTION",3.85,68.02,"VAPOR DIFFUSION, SITTING DROP",5,"0.2M KBr, 0.2M KSCN, 0.1M NaAc pH 5.2, 35% PEG 400, 5% PGA-LM",293,"10.1016/j.ejmech.2017.02.017","Y9B","5MVC",43.91,"1.85","1.85","Crystal structure of potent human Dihydroorotate Dehydrogenase inhibitors based on hydroxylated azole scaffolds","MGHHHHHHHHHHSSGHIDDDDKHMATGDERFYAEHLMPTLQGLLDPESAHRLAVRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQERDGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR","Homo sapiens","DHODH","Dihydroorotate dehydrogenase (quinone), mitochondrial","1","5MVC"
"5MVD",,"X-RAY DIFFRACTION",3.87,68.22,"VAPOR DIFFUSION, SITTING DROP",5,"0.2M KBr, 0.2M KSCN, 0.1M NaAc pH 5.2, 35% PEG 400, 5% PGA-LM",293,"10.1016/j.ejmech.2017.02.017","U91","5MVD",40.71,"1.95","1.95","Crystal structure of potent human Dihydroorotate Dehydrogenase inhibitors based on hydroxylated azole scaffolds","DERFYAEHLMPTLQGLLDPESAHRLAVRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQERDGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR","Homo sapiens","DHODH","Dihydroorotate dehydrogenase (quinone), mitochondrial","1","5MVD"
"5MVG",,"X-RAY DIFFRACTION",2.72,54.8,"VAPOR DIFFUSION, SITTING DROP",4,"0.1 M MMT (Malic acid, MES and Tris-base buffer) pH 4.0, 25% w/v PEG 1.5K",293,"10.1038/s41598-017-16953-7",,"5MVG",45.71,"2.2","2.2","Crystal structure of non-amyloidogenic light chain dimer M7","SSELTQDPAVSVALGQTVKITCQGDSLRMYYASWYQQKPAQAPVLVIYAEKNRPSGIPDRFSASSSGSTASLTITGAQAEDEADYYCNSRDNSGDHLVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"light chain dimer","1","5MVG"
"5MVS",,"X-RAY DIFFRACTION",3.47,64.53,"VAPOR DIFFUSION",,"1.4M K/Na tartrate, 0.1M Hepes pH6.8",293,"10.1021/acsmedchemlett.6b00519","ADN, 5JJ","5MVS",78.34,"2.18","2.18","Crystal structure of Dot1L in complex with adenosine and inhibitor CPD1 [N6-(2,6-dichlorophenyl)-N6-(pent-2-yn-1-yl)quinoline-4,6-diamine]","GPGEKLELRLKSPVGAEPAVYPWPLPVYDKHHDAAHEIIETIRWVCEEIPDLKLAMENYVLIDYDTKSFESMQRLCDKYNRAIDSIHQLWKGTTQPMKLNTRPSTGLLRHILQQVYNHSVTDPEKLNNYEPFSPEVYGETSFDLVAQMIDEIKMTDDDLFVDLGSGVGQVVLQVAAATNCKHHYGVEKADIPAKYAETMDREFRKWMKWYGKKHAEYTLERGDFLSEEWRERIANTSVIFVNNFAFGPEVDHQLKERFANMKEGGRIVSSKPFAPLNFRINSRNLSDIGTIMRVVELSPLKGSVSWTGKPVSYYLHTIDRTILENYFSSLKNPG","Homo sapiens","DOT1L, KIAA1814, KMT4","Histone-lysine N-methyltransferase, H3 lysine-79 specific","1","5MVS"
"5MVX",,"X-RAY DIFFRACTION",2.95,58.33,"VAPOR DIFFUSION, SITTING DROP",6.5,"PEG 20K, MES",293,"10.15252/embj.201796632",,"5MVX",34.4,"2.17","2.17","Human DLL4 C2-EGF3","SGVFQLQLQEFINERGVLASGRPCEPGCRTFFRVCLKHFQAVVSPGPCTFGTVSTPVLGTNSFAVRDDSSGGGRNPLQLPFNFTWPGTFSLIIEAWHAPGDDLRPEALPPDALISKIAIQGSLAVGQNWLLDEQTSTLTRLRYSYRVICSDNYYGDNCSRLCKKRNDHFGHYVCQPDGNLSCLPGWTGEYCQQPICLSGCHEQNGYCSKPAECLCRPGWQGRLCNECIPHNGCRHGTCSTPWQCTCDEGWGGLFCDQDLNYCTHHSPCKNGATCSNSGQRSYTCTCRPGYTGVDCELELGSHHHHHHHH","Homo sapiens","DLL4, UNQ1895/PRO4341","Delta-like protein 4","1","5MVX"
"5MW2",,"X-RAY DIFFRACTION",2.07,40.69,"VAPOR DIFFUSION, SITTING DROP",8,"22.5 % PEG 3350
2 % isopropanol
0.1 M Calcium cloride
0.1 M HEPES",296,"10.1016/j.celrep.2017.08.081","U52","5MW2",14.99,"2.35","2.35","CRYSTAL STRUCTURE OF BCL-6 BTB-domain with BI-3802","SADSQIQFTRHASDVLLNLNRLRSRDILTDVVIVVSREQFRAHKTVLMACSGLFYSIFTDQLKRNLSVINLDPEINPEGFNILLDFMYTSRLNLREGNIMAVMATAMYLQMEHVVDTCRKFIKASE","Homo sapiens","BCL6, BCL5, LAZ3, ZBTB27, ZNF51","B-cell lymphoma 6 protein","1","5MW2"
"5MW3",,"X-RAY DIFFRACTION",3.49,64.77,"VAPOR DIFFUSION",,"1.4M K/Na tartrate, 0.1M Hepes pH6.6",293,"10.1021/acsmedchemlett.6b00519","5JJ, 5JT","5MW3",78.24,"2.09","2.09","Crystal structure of Dot1L in complex with inhibitor CPD1 [N6-(2,6-dichlorophenyl)-N6-(pent-2-yn-1-yl)quinoline-4,6-diamine] and inhibitor CPD2 [(R)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-amine]","GPGEKLELRLKSPVGAEPAVYPWPLPVYDKHHDAAHEIIETIRWVCEEIPDLKLAMENYVLIDYDTKSFESMQRLCDKYNRAIDSIHQLWKGTTQPMKLNTRPSTGLLRHILQQVYNHSVTDPEKLNNYEPFSPEVYGETSFDLVAQMIDEIKMTDDDLFVDLGSGVGQVVLQVAAATNCKHHYGVEKADIPAKYAETMDREFRKWMKWYGKKHAEYTLERGDFLSEEWRERIANTSVIFVNNFAFGPEVDHQLKERFANMKEGGRIVSSKPFAPLNFRINSRNLSDIGTIMRVVELSPLKGSVSWTGKPVSYYLHTIDRTILENYFSSLKNPG","Homo sapiens","DOT1L, KIAA1814, KMT4","Histone-lysine N-methyltransferase, H3 lysine-79 specific","1","5MW3"
"5MW4",,"X-RAY DIFFRACTION",3.51,64.96,"VAPOR DIFFUSION",,"0.92M  Lithium sulfate monohydrate, 0.1M Ammonium sulfate, 0.1M Sodium citrate tribasic dihydrate",293,"10.1021/acsmedchemlett.6b00519","5JU","5MW4",78.59,"2.19","2.19","Crystal structure of Dot1L in complex with inhibitor CPD7 [N-(3-(((R)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)(methyl)amino)propyl)-2-(3-(2-chloro-3-(2-methylpyridin-3-yl)benzo[b]thiophen-5-yl)ureido)acetamide]","GPGEKLELRLKSPVGAEPAVYPWPLPVYDKHHDAAHEIIETIRWVCEEIPDLKLAMENYVLIDYDTKSFESMQRLCDKYNRAIDSIHQLWKGTTQPMKLNTRPSTGLLRHILQQVYNHSVTDPEKLNNYEPFSPEVYGETSFDLVAQMIDEIKMTDDDLFVDLGSGVGQVVLQVAAATNCKHHYGVEKADIPAKYAETMDREFRKWMKWYGKKHAEYTLERGDFLSEEWRERIANTSVIFVNNFAFGPEVDHQLKERFANMKEGGRIVSSKPFAPLNFRINSRNLSDIGTIMRVVELSPLKGSVSWTGKPVSYYLHTIDRTILENYFSSLKNPG","Homo sapiens","DOT1L, KIAA1814, KMT4","Histone-lysine N-methyltransferase, H3 lysine-79 specific","1","5MW4"
"5MW5",,"X-RAY DIFFRACTION",3.09,60.18,"VAPOR DIFFUSION",,"PEG 8000, potassium dihydrogen phosphate",293,"10.15252/embj.201796632",,"5MW5",32.89,"2.7","2.7","Human Jagged2 C2-EGF2","MGYFELQLSALRNVNGELLSGACCDGDGRTTRAGGCGHDECDTYVRVCLKEYQAKVTPTGPCSYGHGATPVLGGNSFYLPPAGAAGDRARARARAGGDQDPGLVVIPFQFAWPRSFTLIVEAWDWDNDTTPNEELLIERVSHAGMINPEDRWKSLHFSGHVAHLELQIRVRCDENYYSATCNKFCRPRNDFFGHYTCDQYGNKACMDGWMGKECKEAVCKQGCNLLHGGCTVPGECRCSYGWQGRFCDECVPYPGCVHGSCVEPWQCNCETNWGGLLCDKDLNGSHHHHHHHH","Homo sapiens","JAG2","Protein jagged-2","1","5MW5"
"5MW6",,"X-RAY DIFFRACTION",2.03,39.37,"VAPOR DIFFUSION, SITTING DROP",6,"0.1 M Na/K phosphate
20 % PEG 400
15 % PEG 1500",296,"10.1016/j.celrep.2017.08.081","RC0","5MW6",29.67,"1.65","1.65","Crystal structure of the BCL6 BTB-domain with compound 1","SADSQIQFTRHASDVLLNLNRLRSRDILTDVVIVVSREQFRAHKTVLMACSGLFYSIFTDQLKRNLSVINLDPEINPEGFNILLDFMYTSRLNLREGNIMAVMATAMYLQMEHVVDTCRKFIKASE","Homo sapiens","BCL6, BCL5, LAZ3, ZBTB27, ZNF51","B-cell lymphoma 6 protein","1","5MW6"
"5MW7",,"X-RAY DIFFRACTION",2.37,48.04,"VAPOR DIFFUSION",5.3,"PEG-5000 MME, Sodium citrate",293,"10.15252/embj.201796632",,"5MW7",36.94,"2.8","2.8","Human Jagged2 C2-EGF3","MGYFELQLSALRNVNGELLSGACCDGDGRTTRAGGCGHDECDTYVRVCLKEYQAKVTPTGPCSYGHGATPVLGGNSFYLPPAGAAGDRARARARAGGDQDPGLVVIPFQFAWPRSFTLIVEAWDWDNDTTPNEELLIERVSHAGMINPEDRWKSLHFSGHVAHLELQIRVRCDENYYSATCNKFCRPRNDFFGHYTCDQYGNKACMDGWMGKECKEAVCKQGCNLLHGGCTVPGECRCSYGWQGRFCDECVPYPGCVHGSCVEPWQCNCETNWGGLLCDKDLNYCGSHHPCTNGGTCINAEPDQYRCTCPDGYSGRNCEKAEGSHHHHHHHH","Homo sapiens","JAG2","Protein jagged-2","1","5MW7"
"5MWA",,"X-RAY DIFFRACTION",2.28,46.19,"VAPOR DIFFUSION, SITTING DROP",5.5,"Protein solution: 20 mM Tris, 100 mM NaCl, 0,5 mM TCEP, pH7.5 (HCl) with 30mg/mL protein and 2,08% of a 50 mM inhibitor DMSO stock
 
Precipitant solution:
25% PEG3350 - 0,1M bis-tris pH 5.5",293,"10.1021/acs.jmedchem.9b00445",,"5MWA",27.84,"1.55","1.55","human sEH Phosphatase in complex with 3-4-3,4-dichlorophenyl-5-phenyl-1,3-oxazol-2-yl-benzoic-acid","MGHHHHHHDYDIPTTENLYFQGTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNT","Homo sapiens","EPHX2","Bifunctional epoxide hydrolase 2","1","5MWA"
"5MWB",,"X-RAY DIFFRACTION",1.84,33.04,"VAPOR DIFFUSION",6.5,"PEG 8000, Sodium acetate, Sodium cacodylate",293,"10.15252/embj.201796632",,"5MWB",17.92,"1.86","1.86","Human Notch-2 EGF11-13","EDVDECAMANSNPCEHAGKCVNTDGAFHCECLKGYAGPRCEMDINECHSDPCQNDATCLDKIGGFTCLCMPGFKGVHCELEINECQSNPCVNNGQCVDKVNRFQCLCPPGFTGPVCQIDGSGLEVLFQGPGSLHHILDAQKMVWNHRGHHHHHHHH","Homo sapiens","NOTCH2","Neurogenic locus notch homolog protein 2","1","5MWB"
"5MWD",,"X-RAY DIFFRACTION",1.98,37.82,"VAPOR DIFFUSION, SITTING DROP",4.5,"25 % PEG 3350
15 % Isopropanol
0.2 M Citrate",296,"10.1016/j.celrep.2017.08.081","TJ3","5MWD",14.86,"1.85","1.85","Crystal structure of the BCL6 BTB-domain with compound 2","SADSQIQFTRHASDVLLNLNRLRSRDILTDVVIVVSREQFRAHKTVLMACSGLFYSIFTDQLKRNLSVINLDPEINPEGFNILLDFMYTSRLNLREGNIMAVMATAMYLQMEHVVDTCRKFIKASE","Homo sapiens","BCL6, BCL5, LAZ3, ZBTB27, ZNF51","B-cell lymphoma 6 protein","1","5MWD"
"5MWF",,"X-RAY DIFFRACTION",2.71,54.65,"VAPOR DIFFUSION",6.5,"PEG 8000, Ammonium sulphate, Sodium cacodylate",293,"10.15252/embj.201796632",,"5MWF",199.98,"2.8","2.8","Human Jagged2 C2-EGF2","MGYFELQLSALRNVNGELLSGACCDGDGRTTRAGGCGHDECDTYVRVCLKEYQAKVTPTGPCSYGHGATPVLGGNSFYLPPAGAAGDRARARARAGGDQDPGLVVIPFQFAWPRSFTLIVEAWDWDNDTTPNEELLIERVSHAGMINPEDRWKSLHFSGHVAHLELQIRVRCDENYYSATCNKFCRPRNDFFGHYTCDQYGNKACMDGWMGKECKEAVCKQGCNLLHGGCTVPGECRCSYGWQGRFCDECVPYPGCVHGSCVEPWQCNCETNWGGLLCDKDLNGSHHHHHHHH","Homo sapiens","JAG2","Protein jagged-2","1","5MWF"
"5MWG",,"X-RAY DIFFRACTION",2.58,52.27,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-tris propane, pH6.5, 0.2 M Sodium Nitrate, 20% PEG3350",277,"10.1016/j.ejmech.2018.05.037","WGX","5MWG",28.43,"1.5","1.5","Crystal structure of the human BRPF1 bromodomain in complex with BZ091","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5MWG"
"5MWH",,"X-RAY DIFFRACTION",2.69,54.32,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-tris propane, pH6.5, 0.2 M Sodium nitrate, 20% PEG3350",277,"10.1016/j.ejmech.2018.05.037","UWX","5MWH",28.5,"1.65","1.65","Crystal structure of the human BRPF1 bromodomain in complex with BZ089","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5MWH"
"5MWI",,"X-RAY DIFFRACTION",2.19,43.72,"VAPOR DIFFUSION, SITTING DROP",6.5,"magnesium acetate, cacodylate and lithium sulfate",292,"10.1093/nar/gkx122",,"5MWI",8.45,"1.51","1.51","Crystal structure of G(CUG)8G duplex","GCUGCUGCUGCUGCUGCUGCUGCUGC","Homo sapiens",,"RNA G(CUG)8C duplex","1","5MWI"
"5MWJ",,"X-RAY DIFFRACTION",2.31,46.81,"MICROBATCH",8,"PEG 8000 (22%), 100mM sodium cacodylate, 100 mM Ca(OAc)2",293.15,"10.1002/chem.201700747","EBU","5MWJ",75.48,"2.04","2.04","Structure Enabled Discovery of a Stapled Peptide Inhibitor to Target the Oncogenic Transcriptional Repressor TLE1","DYFQGAMGSKPAYSFHVTADGQMQPVPFPPDALIGPGIPRHARQINTLNHGEVVCAVTISNPTRHVYTGGKGCVKVWDISHPGNKSPVSQLDCLNRDNYIRSCKLLPDGCTLIVGGEASTLSIWDLAAPTPRIKAELTSSAPACYALAISPDSKVCFSCCSDGNIAVWDLHNQTLVRQFQGHTDGASCIDISNDGTKLWTGGLDNTVRSWDLREGRQLQQHDFTSQIFSLGYCPTGEWLAVGMESSNVEVLHVNKPDKYQLHLHESCVLSLKFAYCGKWFVSTGKDNLLNAWRTPYGASIFQSKESSSVLSCDISVDDKYIVTGSGDKKATVYEVIY","Homo sapiens","TLE1","Transducin-like enhancer protein 1","1","5MWJ"
"5MWQ",,"SOLUTION NMR",,,,,,,,,"5MWQ",6.12,,,"Biosynthetic engineered A21K-B31K-B32R human insulin monomer structure in water/acetonitrile solution","GIVEQCCTSICSLYQLENYCK","Homo sapiens","INS","Insulin","1","5MWQ"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKTKR","Homo sapiens","INS","Insulin","2","5MWQ"
"5MWT",,"X-RAY DIFFRACTION",2.38,48.23,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M AMMONIUM SULFATE, PH 7.5,",298,,,"5MWT",31.07,"1.711","1.711","Galectin-1 in Complex with Ligand JB97","CGLVASNLNLKPGECLRVRGEVAPDAKSFVLNLGKDSNNLCLHFNPRFNAHGDANTIVCNSKDGGAWGTEQREAVFPFQPGSVAEVCITFDQANLTVKLPDGYEFKFPNRLNLEAINYMAADGDFKIKCVAFD","Homo sapiens","LGALS1","Galectin-1","1","5MWT"
"5MWX",,"X-RAY DIFFRACTION",2.37,48.2,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M AMMONIUM SULFATE, PH 7.5",298,,,"5MWX",30.99,"1.29","1.29","Galectin-1 in Complex with Ligand JB60","CGLVASNLNLKPGECLRVRGEVAPDAKSFVLNLGKDSNNLCLHFNPRFNAHGDANTIVCNSKDGGAWGTEQREAVFPFQPGSVAEVCITFDQANLTVKLPDGYEFKFPNRLNLEAINYMAADGDFKIKCVAFD","Homo sapiens","LGALS1","Galectin-1","1","5MWX"
"5MWZ",,"X-RAY DIFFRACTION",2.46,50.04,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Bis-Tris Propane pH7.4, 25% PEG3350, 5% EG, 0.15 M NaNO3",277,"10.1016/j.ejmech.2018.05.037","KGU","5MWZ",14.16,"1.25","1.25","Crystal structure of the human BRPF1 bromodomain in complex with BZ073","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5MWZ"
"5MX0",,"X-RAY DIFFRACTION",3.75,67.23,"VAPOR DIFFUSION, SITTING DROP",,"10 mg/ml protein + 26% (w/v) PEG 3350, 200 mM lithium sulphate monohydrate, 100 mM Tris-HCl (pH 8.5)",295,"10.1016/j.matbio.2017.02.002",,"5MX0",87.67,"2.21","2.21","Crystal structure of human fibromodulin","GALAQYEDDPHWWFHYLRSQQSTSSDPSDPSPSETSEPSPSGVDEGPASTSGSPSPPDPRDCPQECDCPPNFPTAMYCDNRNLKYLPFVPSRMKYVYFQNNQITSIQEGVFDNATGLLWIALHGNQITSDKVGRKVFSKLRHLERLYLDHNNLTRMPGPLPRSLRELHLDHNQISRVPNNALEGLENLTALYLQHNEIQEVGSSMRGLRSLILLDLSYNHLRKVPDGLPSALEQLYMEHNNVYTVPDSYFRGAPKLLYVRLSHNSLTNNGLASNTFNSSSLLELDLSYNQLQKIPPVNTNLENLYLQGNRINEFSISSFCTVVDVVNFSKLQVLRLDGNEIKRSAMPADAPLCLRLASLIEI","Homo sapiens","FMOD, FM, SLRR2E","Fibromodulin","1","5MX0"
"5MX1",,"X-RAY DIFFRACTION",2.39,48.57,"VAPOR DIFFUSION, SITTING DROP",,"10 mg/ml protein + 200 mM monobasic potassium phosphate (pH 4.8), 20% (w/v) polyethylene glycol 3350",295,"10.1016/j.matbio.2017.02.002",,"5MX1",77.92,"2.17","2.17","Crystal structure of human chondroadherin","APLAACPQNCHCHSDLQHVICDKVGLQKIPKVSEKTKLLNLQRNNFPVLAANSFRAMPNLVSLHLQHCQIREVAAGAFRGLKQLIYLYLSHNDIRVLRAGAFDDLTELTYLYLDHNKVTELPRGLLSPLVNLFILQLNNNKIRELRAGAFQGAKDLRWLYLSENALSSLQPGALDDVENLAKFHVDRNQLSSYPSAALSKLRVVEELKLSHNPLKSIPDNAFQSFGRYLETLWLDNTNLEKFSDGAFLGVTTLKHVHLENNRLNQLPSNFPFDSLETLALTNNPWKCTCQLRGLRRWLEAKASRPDATCASPAKFKGQHIRDTDAFRSCKFPTKRSKKAGRH","Homo sapiens","CHAD, SLRR4A","Chondroadherin","1","5MX1"
"5MXD",,"X-RAY DIFFRACTION",2.57,52.24,"VAPOR DIFFUSION, HANGING DROP",,"PEG4000",293,,,"5MXD",145.17,"2.52","2.52","BACE-1 IN COMPLEX WITH LIGAND 32397778","MHHHHHHTQHGIRLPLRSGLGGAPLGLRLPRETDEEPEEPGTTGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYN","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5MXD"
"5MXM",,"X-RAY DIFFRACTION",2.14,42.5,"VAPOR DIFFUSION, HANGING DROP",,"PEG MME 30% w/v, Bis Tris 0.1 M pH=7",298,"10.1371/journal.pone.0199191","3PG","5MXM",45.37,"2.05","2.05","The X-ray structure of human M190I phosphoglycerate kinase 1 mutant","SLSNKLTLDKLDVKGKRVVMRVDFNVPMKNNQITNNQRIKAAVPSIKFCLDNGAKSVVLMSHLGRPDGVPMPDKYSLEPVAVELKSLLGKDVLFLKDCVGPEVEKACANPAAGSVILLENLRFHVEEEGKGKDASGNKVKAEPAKIEAFRASLSKLGDVYVNDAFGTAHRAHSSMVGVNLPQKAGGFLIKKELNYFAKALESPERPFLAILGGAKVADKIQLINNMLDKVNEMIIGGGMAFTFLKVLNNMEIGTSLFDEEGAKIVKDLMSKAEKNGVKITLPVDFVTADKFDENAKTGQATVASGIPAGWMGLDCGPESSKKYAEAVTRAKQIVWNGPVGVFEWEAFARGTKALMDEVVKATSRGCITIIGGGDTATCCAKWNTEDKVSHVSTGGGASLELLEGKVLPGVDALSNI","Homo sapiens","PGK1, PGKA, MIG10, OK/SW-cl.110","Phosphoglycerate kinase 1","1","5MXM"
"5MXX",,"X-RAY DIFFRACTION",2.51,51.11,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M tris pH 7.5,  0.1 M CaCl2, 20% PEG6K, 11% ethylene glycol",277.15,"10.1021/acschembio.6b01048","W4A","5MXX",46.83,"1.75","1.75","Crystal structure of human SR protein kinase 1 (SRPK1) in complex with compound 1","SMPEQEEEILGSDDDEQEDPNDYCKGGYHLVKIGDLFNGRYHVIRKLGWGHFSTVWLSWDIQGKKFVAMKVVKSAEHYTETALDEIRLLKSVRNSDPNDPNREMVVQLLDDFKISGVNGTHICMVFEVLGHHLLKWIIKSNYQGLPLPCVKKIIQQVLQGLDYLHTKCRITHTDIKPENILLSVNEQYIRRLAAEATEWQRSGAPPPSGSAVSTAPATAGNFLVNPLEPKNAEKLKVKIADLGNACWVHKHFTEDIQTRQYRSLEVLIGSGYNTPADIWSTACMAFELATGDYLFEPHSGEEYTRDEDHIALIIELLGKVPRKLIVAGKYSKEFFTKKGDLKHITKLKPWGLFEVLVEKYEWSQEEAAGFTDFLLPMLELIPEKRATAAECLRHPWLNS","Homo sapiens","SRPK1","SRPK1","1","5MXX"
"5MY8",,"X-RAY DIFFRACTION",2.88,57.27,"VAPOR DIFFUSION, SITTING DROP",5.5,"22% broad-molecular-weight PEG smears (BMW PEG smears) and 0.1 M citrate, pH 5.5",277.15,"10.1021/acschembio.6b01048","RXZ","5MY8",45.71,"1.7","1.7","Crystal structure of SRPK1 in complex with SPHINX31","SMDPNDYCKGGYHLVKIGDLFNGRYHVIRKLGWGHFSTVWLSWDIQGKKFVAMKVVKSAEHYTETALDEIRLLKSVRNSDPNDPNREMVVQLLDDFKISGVNGTHICMVFEVLGHHLLKWIIKSNYQGLPLPCVKKIIQQVLQGLDYLHTKCRIIHTDIKPENILLSVNEQYIRRLAAEATEWQRSGAPPPSGSAVSTAPATAGNFLVNPLEPKNAEKLKVKIADLGNACWVHKHFTEDIQTRQYRSLEVLIGSGYNTPADIWSTACMAFELATGDYLFEPHSGEEYTRDEDHIALIIELLGKVPRKLIVAGKYSKEFFTKKGDLKHITKLKPWGLFEVLVEKYEWSQEEAAGFTDFLLPMLELIPEKRATAAECLRHPWLNS","Homo sapiens","SRPK1","SRSF protein kinase 1,SRSF protein kinase 1","1","5MY8"
,,,,,,,,,,,,,,,,,"Homo sapiens","SRPK1"
"5MYA",,"X-RAY DIFFRACTION",2.7,54,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris buffer at pH 7.0 - 8.5 and 14-20% PEG 3350 (w/v)",294,"10.1073/pnas.1616166114",,"5MYA",77.81,"2.9","2.9","Homodimerization of Tie2 Fibronectin-like domains 1-3 in space group C2","MKFLVNVALVFMVVYISYIYADPVLPKPLNAPNVIDTGHNFAVINISSEPYFGDGPIKSKKLLYKPVNHYEAWQHIQVTNEIVTLNYLEPRTEYELCVQLVRRGEGGEGHPGPVRRFTTASIGLPPPRGLNLLPKSQTTLNLTWQPIFPSSEDDFYVEVERRSVQKSDQQNIKVPGNLTSVLLNNLHPREQYVVRARVNTKAQGEWSEDLTAWTLSDILPPQPENIKISNITHSSAVISWTILDGYSISSITIRYKVQGKNEDQHVDVKIKNATITQYQLKGLEPETAYQVDIFAENNIGSSNPAFSHELVTLPESQAPADLGIEGRHHHHHH","Homo sapiens","TEK, TIE2, VMCM, VMCM1","Angiopoietin-1 receptor","1","5MYA"
"5MYB",,"X-RAY DIFFRACTION",2.05,39.9,"VAPOR DIFFUSION, SITTING DROP",8,"0.1 M Tris buffer at pH 7.0 - 8.5 and 14-20% PEG 3350 (w/v)",294,"10.1073/pnas.1616166114",,"5MYB",77.06,"2.6","2.6","Homodimerization of Tie2 Fibronectin-like domains 2 and 3 in space group P21","MKFLVNVALVFMVVYISYIYADPVLPKPLNAPNVIDTGHNFAVINISSEPYFGDGPIKSKKLLYKPVNHYEAWQHIQVTNEIVTLNYLEPRTEYELCVQLVRRGEGGEGHPGPVRRFTTASIGLPPPRGLNLLPKSQTTLNLTWQPIFPSSEDDFYVEVERRSVQKSDQQNIKVPGNLTSVLLNNLHPREQYVVRARVNTKAQGEWSEDLTAWTLSDILPPQPENIKISNITHSSAVISWTILDGYSISSITIRYKVQGKNEDQHVDVKIKNATITQYQLKGLEPETAYQVDIFAENNIGSSNPAFSHELVTLPESQAPADLGIEGRHHHHHH","Homo sapiens","TEK, TIE2, VMCM, VMCM1","Angiopoietin-1 receptor","1","5MYB"
"5MYG",,"X-RAY DIFFRACTION",2.88,57.26,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M ammonium acetate, 17% PEG 10K, 0.1 M bis-tris pH 5.5",277,"10.1021/acs.jmedchem.7b00611","LS8","5MYG",56.35,"2.3","2.3","Crystal structure of the bromodomain of human BRPF1 in complex with NI-57 chemical probe","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5MYG"
"5MYV",,"X-RAY DIFFRACTION",4.87,74.72,"VAPOR DIFFUSION, SITTING DROP",5.25,"1.0 M ammonium sulfate and 0.1 M acetate pH 5.25",277.15,"10.1021/acschembio.6b01048",,"5MYV",183.52,"2.9","2.9","Crystal structure of SRPK2 in complex with compound 1","SMGSDDEEQEDPADYCKGGYHPVKIGDLFNGRYHVIRKLGWGHFSTVWLCWDMQGKRFVAMKVVKSAQHYTETALDEIKLLKCVRESDPSDPNKDMVVQLIDDFKISGMNGIHVCMVFEVLGHHLLKWIIKSNYQGLPVRCVKSIIRQVLQGLDYLHSKCKIIHTDIKPENILMCVDDAYVRRMAAEATEWQKAGAPPPSGSAVSTAPAADLLVNPLDPRNADKIRVKIADLGNACWVHKHFTEDIQTRQYRSIEVLIGAGYSTPADIWSTACMAFELATGDYLFEPHSGEDYSRDEDHIAHIIELLGSIPRHFALSGKYSREFFNRRGELRHITKLKPWSLFDVLVEKYGWPHEDAAQFTDFLIPMLEMVPEKRASAGECLRHPWLNS","Homo sapiens","SRPK2","SRSF protein kinase 2,SRSF protein kinase 2","1","5MYV"
,,,,,,,,,,,,,,,,,"Homo sapiens","SRPK2"
"5MZ3",,"X-RAY DIFFRACTION",2.95,58.32,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG8000, 20mM Mg acetate and 0.1M Hepes pH7",293,"10.1016/j.bmcl.2017.10.047","8EN","5MZ3",42.9,"2.15","2.15","P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide]","MASHHHHHHMSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDSELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5MZ3"
"5N06",,"X-RAY DIFFRACTION",2,37,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris buffer at pH 8.0 - 9.0 and 18-24% PEG 8000 (w/v)",294,"10.1073/pnas.1616166114",,"5N06",28.13,"2.501","2.501","Crystal structure of Tie1 Fibronectin-like domain 3","MKFLVNVALVFMVVYISYIYADPSGPPAPRHLHAQALSDSEIQLTWKHPEALPGPISKYVVEVQVAGGAGDPLWIDVDRPEETSTIIRGLNASTRYLFRMRASIQGLGDWSNTVEESTLGHHHHHH","Homo sapiens","TIE1, TIE","Tyrosine-protein kinase receptor Tie-1","1","5N06"
"5N0D",,"X-RAY DIFFRACTION",2.06,40.4,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate, 0.1 M Tris-HCl, pH 8.5.",293,"10.1021/acs.jmedchem.7b00264","8F2","5N0D",30.06,"1.7","1.7","Crystal structure of human carbonic anhydrase II in complex with (R)-4-(6,7-dihydroxy-1-phenyl-3,4-tetrahydroisoquinoline-1H-2-carbonyl)benzenesulfonamide.","MGMSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5N0D"
"5N0E",,"X-RAY DIFFRACTION",2.07,40.61,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate, 0.1 M Tris-HCl, pH 8.5.",293,"10.1021/acs.jmedchem.7b00264","8F3","5N0E",29.97,"1.75","1.75","Crystal structure of human carbonic anhydrase II in complex with (S)-4-(6,7-dihydroxy-1-phenyl-3,4-tetrahydroisoquinoline-1H-2-carbonyl)benzenesulfonamide.","MGMSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5N0E"
"5N0M",,"X-RAY DIFFRACTION",2.88,57.27,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M imidazole pH7.5, 0.2M LiSO4, 8-11% PEG3350",283,"10.1021/acs.jmedchem.7b00274",,"5N0M",75.65,"2.18","2.18","hPAD4 crystal complex with BB-F-amidine","GPLGSPQMAQGTLIRVTPEQPTHAVCVLGTLTQLDICSSAPEDCTSFSINASPGVVVDIAHSPPAKKKSTGSSTWPLDPGVEVTLTMKAASGSTGDQKVQISYYGPKTPPVKALLYLTAVEISLCADITRTGKVKPTRAVKDQRTWTWGPCGQGAILLVNCDRDNLESSAMDCEDDEVLDSEDLQDMSLMTLSTKTPKDFFTNHTLVLHVARSEMDKVRVFQATRGKLSSKCSVVLGPKWPSHYLMVPGGKHNMDFYVEALAFPDTDFPGLITLTISLLDTSNLELPEAVVFQDSVVFRVAPWIMTPNTQPPQEVYACSIFENEDFLKSVTTLAMKAKCKLTICPEEENMDDQWMQDEMEIGYIQAPHKTLPVVFDSPRNRGLKEFPIKRVMGPDFGYVTRGPQTGGISGLDSFGNLEVSPPVTVRGKEYPLGRILFGDSCYPSNDSRQMHQALQDFLSAQQVQAPVKLYSDWLSVGHVDEFLSFVPAPDRKGFRLLLASPRSCYKLFQEQQNEGHGEALLFEGIKKKKQQKIKNILSNKTLREHNSFVERCIDWNRELLKRELGLAESDIIDIPQLFKLKEFSKAEAFFPNMVNMLVLGKHLGIPKPFGPVINGRCCLEEKVCSLLEPLGLQCTFINDFFTYHIRHGEVHCGTNVRRKPFSFKWWNMVP","Homo sapiens","PADI4, PAD4, PADI5, PDI5","Protein-arginine deiminase type-4","1","5N0M"
"5N0Y",,"X-RAY DIFFRACTION",2.86,56.95,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 imidazole pH7.5, 0.2mM LiSO4, 8-11% PEG3350",283,"10.1021/acs.jmedchem.7b00274",,"5N0Y",75.68,"2.23","2.23","hPAD4 crystal complex with AFM-30a","GPLGSPQMAQGTLIRVTPEQPTHAVCVLGTLTQLDICSSAPEDCTSFSINASPGVVVDIAHSPPAKKKSTGSSTWPLDPGVEVTLTMKAASGSTGDQKVQISYYGPKTPPVKALLYLTAVEISLCADITRTGKVKPTRAVKDQRTWTWGPCGQGAILLVNCDRDNLESSAMDCEDDEVLDSEDLQDMSLMTLSTKTPKDFFTNHTLVLHVARSEMDKVRVFQATRGKLSSKCSVVLGPKWPSHYLMVPGGKHNMDFYVEALAFPDTDFPGLITLTISLLDTSNLELPEAVVFQDSVVFRVAPWIMTPNTQPPQEVYACSIFENEDFLKSVTTLAMKAKCKLTICPEEENMDDQWMQDEMEIGYIQAPHKTLPVVFDSPRNRGLKEFPIKRVMGPDFGYVTRGPQTGGISGLDSFGNLEVSPPVTVRGKEYPLGRILFGDSCYPSNDSRQMHQALQDFLSAQQVQAPVKLYSDWLSVGHVDEFLSFVPAPDRKGFRLLLASPRSCYKLFQEQQNEGHGEALLFEGIKKKKQQKIKNILSNKTLREHNSFVERCIDWNRELLKRELGLAESDIIDIPQLFKLKEFSKAEAFFPNMVNMLVLGKHLGIPKPFGPVINGRCCLEEKVCSLLEPLGLQCTFINDFFTYHIRHGEVHCGTNVRRKPFSFKWWNMVP","Homo sapiens","PADI4, PAD4, PADI5, PDI5","Protein-arginine deiminase type-4","1","5N0Y"
"5N0Z",,"X-RAY DIFFRACTION",2.84,56.71,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M imidazole pH7.5, 0.2mM LiSO4, 8-11% PEG3350",283,"10.1021/acs.jmedchem.7b00274",,"5N0Z",75.7,"2.52","2.52","hPAD4 crystal complex with AFM-41a","GPLGSPQMAQGTLIRVTPEQPTHAVCVLGTLTQLDICSSAPEDCTSFSINASPGVVVDIAHSPPAKKKSTGSSTWPLDPGVEVTLTMKAASGSTGDQKVQISYYGPKTPPVKALLYLTAVEISLCADITRTGKVKPTRAVKDQRTWTWGPCGQGAILLVNCDRDNLESSAMDCEDDEVLDSEDLQDMSLMTLSTKTPKDFFTNHTLVLHVARSEMDKVRVFQATRGKLSSKCSVVLGPKWPSHYLMVPGGKHNMDFYVEALAFPDTDFPGLITLTISLLDTSNLELPEAVVFQDSVVFRVAPWIMTPNTQPPQEVYACSIFENEDFLKSVTTLAMKAKCKLTICPEEENMDDQWMQDEMEIGYIQAPHKTLPVVFDSPRNRGLKEFPIKRVMGPDFGYVTRGPQTGGISGLDSFGNLEVSPPVTVRGKEYPLGRILFGDSCYPSNDSRQMHQALQDFLSAQQVQAPVKLYSDWLSVGHVDEFLSFVPAPDRKGFRLLLASPRSCYKLFQEQQNEGHGEALLFEGIKKKKQQKIKNILSNKTLREHNSFVERCIDWNRELLKRELGLAESDIIDIPQLFKLKEFSKAEAFFPNMVNMLVLGKHLGIPKPFGPVINGRCCLEEKVCSLLEPLGLQCTFINDFFTYHIRHGEVHCGTNVRRKPFSFKWWNMVP","Homo sapiens","PADI4, PAD4, PADI5, PDI5","Protein-arginine deiminase type-4","1","5N0Z"
"5N14",,"SOLUTION NMR",,,,,,,,,"5N14",3.32,,,"NMR structure calculation of a composite Cys2His2 type zinc finger protein containing a non-peptide (or oligourea) helical domain","PFACDICGRKFARSXXXXXXXXRKD","Homo sapiens","EGR1, KROX24, ZNF225","Protein (chimeric oligourea-peptide zinc finger)","1","5N14"
"5N1B",,"X-RAY DIFFRACTION",2.85,56.88,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M imidazole pH7.5, 0.2mM LiSO4, 8-11% PEG3350",283,"10.1021/acs.jmedchem.7b00274",,"5N1B",75.61,"2.9","2.9","hPAD4 crystal complex with AFM-14a","GPLGSPQMAQGTLIRVTPEQPTHAVCVLGTLTQLDICSSAPEDCTSFSINASPGVVVDIAHSPPAKKKSTGSSTWPLDPGVEVTLTMKAASGSTGDQKVQISYYGPKTPPVKALLYLTAVEISLCADITRTGKVKPTRAVKDQRTWTWGPCGQGAILLVNCDRDNLESSAMDCEDDEVLDSEDLQDMSLMTLSTKTPKDFFTNHTLVLHVARSEMDKVRVFQATRGKLSSKCSVVLGPKWPSHYLMVPGGKHNMDFYVEALAFPDTDFPGLITLTISLLDTSNLELPEAVVFQDSVVFRVAPWIMTPNTQPPQEVYACSIFENEDFLKSVTTLAMKAKCKLTICPEEENMDDQWMQDEMEIGYIQAPHKTLPVVFDSPRNRGLKEFPIKRVMGPDFGYVTRGPQTGGISGLDSFGNLEVSPPVTVRGKEYPLGRILFGDSCYPSNDSRQMHQALQDFLSAQQVQAPVKLYSDWLSVGHVDEFLSFVPAPDRKGFRLLLASPRSCYKLFQEQQNEGHGEALLFEGIKKKKQQKIKNILSNKTLREHNSFVERCIDWNRELLKRELGLAESDIIDIPQLFKLKEFSKAEAFFPNMVNMLVLGKHLGIPKPFGPVINGRCCLEEKVCSLLEPLGLQCTFINDFFTYHIRHGEVHCGTNVRRKPFSFKWWNMVP","Homo sapiens","PADI4, PAD4, PADI5, PDI5","Protein-arginine deiminase type-4","1","5N1B"
"5N1R",,"X-RAY DIFFRACTION",2.08,40.92,"VAPOR DIFFUSION",8,"1.5 M sodium citrate, Tris 50 mM pH 8.0",296,,"8GH","5N1R",29.76,"1.3","1.3","Crystal structure of human carbonic anhydrase II in complex with the inhibitor 4'-Pyrazol-1-ylmethyl-biphenyl-4-sulfonamide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5N1R"
"5N1S",,"X-RAY DIFFRACTION",2.08,40.97,"VAPOR DIFFUSION",8,"1.5 M sodium citrate, Tris 50 mM",296,,"8GE","5N1S",29.72,"1.3","1.3","Crystal structure of human carbonic anhydrase II in complex with the inhibitor 4-(1H-Indol-2-yl)-benzenesulfonamide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5N1S"
"5N1V",,"X-RAY DIFFRACTION",3.19,61.39,"VAPOR DIFFUSION, SITTING DROP",,"unknown",293,"10.1021/acs.jmedchem.7b00359",,"5N1V",84.61,"2.52","2.52","Crystal structure of the protein kinase CK2 catalytic subunit in complex with pyrazolo-pyrimidine macrocyclic ligand","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMGSHHHHHH","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5N1V"
"5N1X",,"X-RAY DIFFRACTION",2.05,40.12,"VAPOR DIFFUSION, SITTING DROP",,"unknown",293,"10.1021/acs.jmedchem.7b00359","8HH","5N1X",56.59,"1.72","1.72","Crystal structure of the BCL6 BTB domain in complex with pyrazolo-pyrimidine ligand","QIQFTRHASDVLLNLNRLRSRDILTDVVIVVSREQFRAHKTVLMACSGLFYSIFTDQLKRNLSVINLDPEINPEGFNILLDFMYTSRLNLREGNIMAVMATAMYLQMEHVVDTARKFIKAS","Homo sapiens","BCL6, BCL5, LAZ3, ZBTB27, ZNF51","B-cell lymphoma 6 protein","1","5N1X"
,,,,,,,,,,,,,,,,"SQIQFTRHASDVLLNLNRLRSRDILTDVVIVVSREQFRAHKTVLMACSGLFYSIFTDQLKRNLSVINLDPEINPEGFNILLDFMYTSRLNLREGNIMAVMATAMYLQMEHVVDTARKFIKA","Homo sapiens","BCL6, BCL5, LAZ3, ZBTB27, ZNF51","B-cell lymphoma 6 protein","2","5N1X"
,,,,,,,,,,,,,,,,"QIQFTRHASDVLLNLNRLRSRDILTDVVIVVSREQFRAHKTVLMACSGLFYSIFTDQLKRNLSVINLDPEINPEGFNILLDFMYTSRLNLREGNIMAVMATAMYLQMEHVVDTARKFI","Homo sapiens","BCL6, BCL5, LAZ3, ZBTB27, ZNF51","B-cell lymphoma 6 protein","3","5N1X"
"5N1Z",,"X-RAY DIFFRACTION",2.06,40.4,"VAPOR DIFFUSION, SITTING DROP",,"unknown",293,"10.1021/acs.jmedchem.7b00359","8GQ","5N1Z",14.74,"1.81","1.81","Crystal structure of the BCL6 BTB domain in complex with pyrazolo-pyrimidine macrocyclic ligand","DSQIQFTRHASDVLLNLNRLRSRDILTDVVIVVSREQFRAHKTVLMACSGLFYSIFTDQLKRNLSVINLDPEINPEGFNILLDFMYTSRLNLREGNIMAVMATAMYLQMEHVVDTCRKFIKAS","Homo sapiens","BCL6, BCL5, LAZ3, ZBTB27, ZNF51","B-cell lymphoma 6 protein","1","5N1Z"
"5N20",,"X-RAY DIFFRACTION",2.03,39.39,"VAPOR DIFFUSION, SITTING DROP",,"unknown",293,"10.1021/acs.jmedchem.7b00359","8GN","5N20",14.68,"1.38","1.38","Crystal structure of the BCL6 BTB domain in complex with pyrazolo-pyrimidine ligand","DSQIQFTRHASDVLLNLNRLRSRDILTDVVIVVSREQFRAHKTVLMACSGLFYSIFTDQLKRNLSVINLDPEINPEGFNILLDFMYTSRLNLREGNIMAVMATAMYLQMEHVVDTCRKFIKAS","Homo sapiens","BCL6, BCL5, LAZ3, ZBTB27, ZNF51","B-cell lymphoma 6 protein","1","5N20"
"5N21",,"X-RAY DIFFRACTION",2.06,40.24,"VAPOR DIFFUSION, SITTING DROP",,"unknown",293,"10.1021/acs.jmedchem.7b00359","8HN","5N21",29.13,"1.58","1.58","Crystal structure of the BCL6 BTB domain in complex with pyrazolo-pyrimidine ligand","SQIQFTRHASDVLLNLNRLRSRDILTDVVIVVSREQFRAHKTVLMACSGLFYSIFTDQLKRNLSVINLDPEINPEGFNILLDFMYTSRLNLREGNIMAVMATAMYLQMEHVVDTCRKFIKAS","Homo sapiens","BCL6, BCL5, LAZ3, ZBTB27, ZNF51","B-cell lymphoma 6 protein","1","5N21"
"5N24",,"X-RAY DIFFRACTION",2.04,39.67,"VAPOR DIFFUSION",8,"1.5 M sodium citrate, Tris 50 mM",296,,"8HE","5N24",29.96,"1.5","1.5","Crystal structure of human carbonic anhydrase II in complex with the inhibitor b4'-Cyano-biphenyl-4-sulfonic acid amide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5N24"
"5N25",,"X-RAY DIFFRACTION",2.07,40.65,"VAPOR DIFFUSION",8,"1.5 M sodium citrate, Tris 50 mM",296,,"8HK","5N25",29.92,"1.4","1.4","Crystal structure of human carbonic anhydrase II in complex with the inhibitor 4-Pyridin-3-yl-benzenesulfonamide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5N25"
"5N26",,"X-RAY DIFFRACTION",3.03,59.34,"VAPOR DIFFUSION, HANGING DROP",9,"2.0 M Magnesium chloride, 0.1 M bicine pH 9.0",293,"10.1021/acs.inorgchem.7b01072",,"5N26",22.64,"2.05","2.05","X-ray structure of human heavy chain ferritin in complex with cisplatin","TTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIKKPDCDDWESGLNAMECALHLEKNVNQSLLELHKLATDKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSDNES","Homo sapiens","FTH1, FTH, FTHL6, OK/SW-cl.84, PIG15","Ferritin heavy chain","1","5N26"
"5N27",,"X-RAY DIFFRACTION",3.02,59.27,"VAPOR DIFFUSION, HANGING DROP",,"2.0 M MgCl2, 0.1 M bicine pH 9.0",293,"10.1021/acs.inorgchem.7b01072",,"5N27",21.53,"1.74","1.74","X-ray structure of human heavy chain ferritin (apo form)","TTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIKKPDCDDWESGLNAMECALHLEKNVNQSLLELHKLATDKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSDNES","Homo sapiens","FTH1, FTH, FTHL6, OK/SW-cl.84, PIG15","Ferritin heavy chain","1","5N27"
"5N2D",,"X-RAY DIFFRACTION",2.13,42.13,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris pH 8.5, 0.2 M magnesium chloride, 30% (w/v) PEG 4000",293,"10.1021/acs.jmedchem.7b00293","8J8","5N2D",67.83,"2.35","2.35","Structure of PD-L1/small-molecule inhibitor complex","RIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYAAALEHHHHHH","Homo sapiens","CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1","Programmed cell death 1 ligand 1","1","5N2D"
"5N2F",,"X-RAY DIFFRACTION",2.65,53.63,"VAPOR DIFFUSION, HANGING DROP",,"0.01 M Tris pH 8.4 , 0.28 M sodium chloride, 27% (w/v) PEG 4000",293,"10.1021/acs.jmedchem.7b00293","8HW","5N2F",29.03,"1.7","1.7","Structure of PD-L1/small-molecule inhibitor complex","AFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYAAALEHHHH","Homo sapiens","CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1","Programmed cell death 1 ligand 1","1","5N2F"
,,,,,,,,,,,,,,,,"AFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYAAALEHH","Homo sapiens","CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1","Programmed cell death 1 ligand 1","2","5N2F"
"5N2K",,"X-RAY DIFFRACTION",2.15,42.89,"VAPOR DIFFUSION, SITTING DROP",,"Microseed matrix screen. Seed stock 22% (w/v) PEG 3350, 40 mM Glycine. Mother liquor 200 mM NH4I, 20% (w/v) PEG 3350.",287,"10.1016/j.immuni.2017.12.008",,"5N2K",453.19,"2.219","2.219","Structure of unbound Briakinumab FAb","MGILPSPGMPALLSLVSLLSVLLMGCVAQSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"Briakinumab FAb light chain","1","5N2K"
,,,,,,,,,,,,,,,,"MGILPSPGMPALLSLVSLLSVLLMGCVAQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKGTSGLVPRGSGGSGGSGLNDIFEAQKIEWHEGRTKHHHHHH","Homo sapiens",,"Briakinumab FAb heavy chain","2","5N2K"
,,,,,,,,,,,,,,,,"MGILPSPGMPALLSLVSLLSVLLMGCVAQSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"Briakinumab FAb light chain","3","5N2K"
,,,,,,,,,,,,,,,,"MGILPSPGMPALLSLVSLLSVLLMGCVAQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKGTSGLVPRGSGGSGGSGLNDIFEAQKIEWHEGRTKHHHHHH","Homo sapiens",,"Briakinumab FAb heavy chain","4","5N2K"
"5N2L",,"X-RAY DIFFRACTION",2.5,50.82,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% PEG3350, 0.2 M ammonium sulfate, 0.1 M Bis-tris pH 5.5",277.15,,,"5N2L",56.02,"1.89","1.89","Crystal structure of the second bromodomain of human BRD2 in complex with a tetrahydroquinoline analogue","SMGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGLHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5N2L"
"5N2M",,"X-RAY DIFFRACTION",2.5,50.86,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M NH4SO4, 25% PEG3350, 0.1M Tris pH 8.5",277,,,"5N2M",15.65,"1.54","1.54","Crystal structure of the first bromodomain of human BRD4 in complex with a tetrahydroquinoline analogue","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5N2M"
"5N3W",,"X-RAY DIFFRACTION",2.42,49.13,"VAPOR DIFFUSION, HANGING DROP",,"20 % PEG 8000, 0.1 M Sodium Acetate, 0.15 mM Imidazole pH7.8, 5 mM YbCl3",291,"10.1038/srep44449","8KW","5N3W",71.02,"2.3","2.3","Crystal structure of LTA4H bound to a selective inhibitor against LTB4 generation","MPEIVDTCSLASPASVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGSPMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIRDGETPDPEDPSRKIYKFIQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFSETESMLKIAEDLGGPYVWGQYDLLVLPPSFPYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVYLERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPDVAYSSVPYEKGFALLFYLEQLLGGPEIFLGFLKAYVEKFSYKSITTDDWKDFLYSYFKDKVDVLNQVDWNAWLYSPGLPPIKPNYDMTLTNACIALSQRWITAKEDDLNSFNATDLKDLSSHQLNEFLAQTLQRAPLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKMATEQGRMKFTRPLFKDLAAFDKSHDQAVRTYQEHKASMHPVTAMLVGKDLKVDVDHHHHHH","Homo sapiens","LTA4H, LTA4","Leukotriene A-4 hydrolase","1","5N3W"
"5N49",,"X-RAY DIFFRACTION",2.62,53,"VAPOR DIFFUSION, SITTING DROP",6.5,"100 mM bis-tris pH 6.5, 30% (w/v) PEG 3350",295,"10.1021/acs.jmedchem.7b00306","8LW","5N49",31.88,"1.94","1.94","BRPF2 in complex with Compound 7","SMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5N49"
"5N4G",,"X-RAY DIFFRACTION",2.59,52.45,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.2 M potassium sodium tartrate
0.1 M sodium citrate
2 M ammonium sulphate",293.15,"10.1107/S2053230X17006021",,"5N4G",52.45,"2.75","2.75","human Fab fragment 12E1 against NHBA from Neisseria meningitidis","QVQLVQSGAEVKKPGASVKVSCKASGYIFTSHPIHWVRQAPGQRPEWMGWINAGNGNTKYSQKFQDRVNLTRDTSASTVFMELINLRFEDTAIYYCIRETKFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKGSENLYFQGSWSHPQFEKGGSGGGSGGGSWSHPQFEK","Homo sapiens",,"HEAVY CHAIN","1","5N4G"
,,,,,,,,,,,,,,,,"EIVLTQSPLSLPVTLGQPASISCRSSQDLVYRDGITYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLRISRVEAEDIGVYYCMQGTHWPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"LIGHT CHAIN","2","5N4G"
"5N4J",,"X-RAY DIFFRACTION",2.33,47.3,"VAPOR DIFFUSION, SITTING DROP",,"0.17 M ammonium sulfate, 
15% v/v glycerol,
25.5% w/v PEG 4000",293.15,"10.1107/S2053230X17006021",,"5N4J",50.09,"1.503","1.503","human Fab fragment 10C3 against NHBA from Neisseria meningitidis","QSALTQPPSVSGSPGQSVTISCTGTSSDVGSYNRVSWFQQPPGTAPKLIIYEVSNRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCSLYISSSTWVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"LIGHT CHAIN","1","5N4J"
,,,,,,,,,,,,,,,,"MQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLHWVRQAPGQGLEWMGWVSTNNGHTNYAQKVQGRVTMTTDTSTSTAYMELRSLRSDDTAIYYCARGVDLDYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKGSENLYFQGSWSHPQFEKGGGSGGGSGGGSWSHPQFEK","Homo sapiens",,"HEAVY CHAIN","2","5N4J"
"5N4M",,"X-RAY DIFFRACTION",3.56,65.45,"VAPOR DIFFUSION, SITTING DROP",7.5,"2.1 M DL-malic acid",293,"10.1038/s41598-017-06781-0",,"5N4M",15.67,"1.59","1.59","Human myelin protein P2, mutant I43N","GMSNKFLGTWKLVSSENFDDYMKALGVGLATRKLGNLAKPTVINSKKGDIITIRTESTFKNTEISFKLGQEFEETTADNRKTKSIVTLQRGSLNQVQRWDGKETTIKRKLVNGKMVAECKMKGVVCTRIYEKV","Homo sapiens","PMP2","Myelin P2 protein","1","5N4M"
"5N4P",,"X-RAY DIFFRACTION",3.55,65.34,"VAPOR DIFFUSION, SITTING DROP",7.5,"2.1 M DL-malic acid",293,"10.1038/s41598-017-06781-0",,"5N4P",15.65,"1.533","1.533","Human myelin P2, mutant I52T","GMSNKFLGTWKLVSSENFDDYMKALGVGLATRKLGNLAKPTVIISKKGDIITTRTESTFKNTEISFKLGQEFEETTADNRKTKSIVTLQRGSLNQVQRWDGKETTIKRKLVNGKMVAECKMKGVVCTRIYEKV","Homo sapiens","PMP2","Myelin P2 protein","1","5N4P"
"5N4Q",,"X-RAY DIFFRACTION",3.67,66.46,"VAPOR DIFFUSION, SITTING DROP",7.5,"2.1 M DL-malic acid",293,"10.1038/s41598-017-06781-0",,"5N4Q",15.66,"1.72","1.72","Human myelin protein P2, mutant T51P","GMSNKFLGTWKLVSSENFDDYMKALGVGLATRKLGNLAKPTVIISKKGDIIPIRTESTFKNTEISFKLGQEFEETTADNRKTKSIVTLQRGSLNQVQRWDGKETTIKRKLVNGKMVAECKMKGVVCTRIYEKV","Homo sapiens","PMP2","Myelin P2 protein","1","5N4Q"
"5N53",,"X-RAY DIFFRACTION",2.26,45.46,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M PCTP, pH 7, 23-25 % PEG 1500",298,"10.18632/oncotarget.11487","8NB","5N53",42.3,"1.48","1.48","Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with N-(3-chloro-4-methoxyphenyl) acetamide","NGNSLSAAELTCGMIMCLARQIPQATASMKDGKWERKKFMGTELNGKTLGILGLGRIGREVATRMQSFGMKTIGYDPIISPEVSASFGVQQLPLEEIWPLCDFITVHTPLLPSTTGLLNDNTFAQCKKGVRVVNCARGGIVDEGALLRALQSGQCAGAALDVFTEEPPRDRALVDHENVISCPHLGASTKEAQSR","Homo sapiens","PHGDH, PGDH3","D-3-phosphoglycerate dehydrogenase","1","5N53"
"5N5A",,"SOLUTION NMR",,,,,,,"10.1038/s41467-017-02230-8",,"5N5A",4.03,,,"Structure of Tau(254-290) bound to F-actin","KNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSK","Homo sapiens","MAPT, MAPTL, MTBT1, TAU","Microtubule-associated protein tau","1","5N5A"
"5N5B",,"SOLUTION NMR",,,,,,,"10.1038/s41467-017-02230-8",,"5N5B",2.93,,,"Structure of Tau(292-319) bound to F-actin","GSKDNIKHVPGGGSVQIVYKPVDLSKVT","Homo sapiens","MAPT, MAPTL, MTBT1, TAU","Microtubule-associated protein tau","1","5N5B"
"5N5C",,"SOLUTION NMR",,,,,,,"10.1038/s41467-018-04110-1",,"5N5C",6.05,,,"NMR solution structure of the TSL2 RNA hairpin","AUUCCUUAAAUUAAGGAGU","Homo sapiens",,"RNA (19-MER)","1","5N5C"
"5N5J",,"X-RAY DIFFRACTION",2.16,42.96,"VAPOR DIFFUSION, SITTING DROP",8,"0.1 M Tris-HCl, 20% PEG 6000",293,"10.1021/acs.jmedchem.7b01237",,"5N5J",18.14,"1.8","1.8","Human MMP12 in complex with 3-(5-(1,2-dithiolan-3-yl)pentanamido)propane-1-sulfonate","GPVWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDDHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTYKYVDINTFRLSADDIRGIQSLYG","Homo sapiens","MMP12, HME","Macrophage metalloelastase","1","5N5J"
"5N5K",,"X-RAY DIFFRACTION",2.15,42.88,"VAPOR DIFFUSION, SITTING DROP",8,"0.1 M Tris-HCl, 20% PEG 6000",293,"10.1021/acs.jmedchem.7b01237",,"5N5K",17.92,"1.8","1.8","Human catalytic MMP-12 in complex with 5-(1,2-dithiolan-3-yl)-N-(3-hydroxypropyl)pentanamide","VWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDDHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTYKYVDINTFRLSADDIRGIQSLYG","Homo sapiens","MMP12, HME","Macrophage metalloelastase","1","5N5K"
"5N5Q",,"X-RAY DIFFRACTION",2.39,48.52,"VAPOR DIFFUSION, SITTING DROP",6,"protein: 10 mg/ml Dialysed in 100 milli-M NaCl, 50 milli-M sodium acetate, pH 5.5 precipitant: 27 % polyethylene glycol 4,000, 0.2 M imidazole malate, pH 6.0. cryosoak: 40% 
SM3 (, 25 % MPEG 5K, 25 %
diethylene glycol + 25 % ethylene glycol + 25 % glycerol + 25 % 1,4-dioxane)  25 % MPEG 5K, 
0.1 M CHC (citric acid, HEPES, CHES: 90 % acid /10 % basic), 30 mM FeCl2, 2 h soak.",293,"10.1038/s41598-018-31808-5",,"5N5Q",26.25,"2.53","2.53","Human TTR altered conformation from soaking in iron chloride.","CPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNP","Homo sapiens","TTR, PALB","Transthyretin","1","5N5Q"
"5N62",,"X-RAY DIFFRACTION",2.31,46.79,"VAPOR DIFFUSION, SITTING DROP",6,"protein: 10 mg/ml Dialysed in 100 milli-M NaCl, 50 milli-M sodium acetate, pH 5.5 precipitant: 26% polyethylene glycol 4,000 (PEG4K), 0.16 M imidazole malate, pH 6.0 cryosoak: 40 % CM7 (12.5 % di-ethylene glycol + 12.5 % ethylene glycol + 12.5 % glycerol + 25 % 1,2-propanediol + 12.5 % DMSO), 25 % MPEG 5K, 5 mM MnCl2, 10 min soak.",293,"10.1038/s41598-018-31808-5",,"5N62",25.77,"1.8","1.8","Human TTR crystals soaked in manganese chloride.","CPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPK","Homo sapiens","TTR, PALB","Transthyretin","1","5N62"
"5N63",,"X-RAY DIFFRACTION",2.31,46.78,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2,
20-30 % PEG4000",293.15,"10.1371/journal.pone.0184627",,"5N63",41.69,"2.4","2.4","Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9c","MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5N63"
"5N64",,"X-RAY DIFFRACTION",2.34,47.33,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2
20-30 % PEG4000
50 mM BOG",293.15,"10.1371/journal.pone.0184627",,"5N64",41.68,"2.4","2.4","Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9g","MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5N64"
"5N65",,"X-RAY DIFFRACTION",2.17,43.42,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2
20-30 % PEG4000
50 mM BOG",293.15,"10.1371/journal.pone.0184627",,"5N65",42.04,"2","2","Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9h","MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5N65"
"5N66",,"X-RAY DIFFRACTION",2.39,48.48,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2
20-30 % PEG4000
50 mM BOG",293.15,"10.1371/journal.pone.0184627","B96","5N66",42.24,"2.4","2.4","Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9j","MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5N66"
"5N67",,"X-RAY DIFFRACTION",2.35,47.61,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2
20-30 % PEG4000
50 mM BOG",293.15,"10.1371/journal.pone.0184627",,"5N67",41.81,"1.9","1.9","Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9l","MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5N67"
"5N68",,"X-RAY DIFFRACTION",2.37,48.16,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2
20-30 % PEG4000
50 mM BOG",293.15,"10.1371/journal.pone.0184627",,"5N68",41.77,"1.85","1.85","Crystal Structure of p38alpha in Complex with Lipid Pocket Ligand 9m","MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5N68"
"5N6C",,"X-RAY DIFFRACTION",2.48,50.35,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5
0.2 M MgCl2 hexahydrate
20 % (w/v) PEG 3350",277,"10.18632/oncotarget.22327","NAD","5N6C",65.79,"2.3","2.3","Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with NAD and L-Tartrate","AKVLISDSLDPCCRKILQDGGLQVVEKQNLSKEELIAELQDCEGLIVRSATKVTADVINAAEKLQVVGRAGTGVDNVDLEAATRKGILVMNTPNGNSLSAAELTCGMIMCLARQIPQATASMKDGKWERKKFMGTELNGKTLGILGLGRIGREVATRMQSFGMKTIGYDPIISPEVSASFGVQQLPLEEIWPLCDFITVHTPLLPSTTGLLNDNTFAQCKKGVRVVNCARGGIVDEGALLRALQSGQCAGAALDVFTEEPPRDRALVDHENVISCPHLGASTKEAQSRCGEEIAVQFVDM","Homo sapiens","PHGDH, PGDH3","D-3-phosphoglycerate dehydrogenase","1","5N6C"
"5N6O",,"X-RAY DIFFRACTION",2.33,47.14,"VAPOR DIFFUSION, SITTING DROP",,"0,1 mM MES ph 6.5
PEG 3350 20%",291.15,"10.1038/s41598-017-13619-2",,"5N6O",40.09,"2.59","2.59","Wild type human Rac1-GDP","QAIKCVVVGDGAVGKTCLLISYTTNAFPGEYIPTVFDNYSANVMVDGKPVNLGLWDTAGQEDYDRLRPLSYPQTDVFLICFSLVSPASFENVRAKWYPEVRHHCPNTPIILVGTKLDLRDDKDTIEKLKEKKLTPITYPQGLAMAKEIGAVKYLECSALTQRGLKTVFDEAIRAVL","Homo sapiens","RAC1, TC25, MIG5","Ras-related C3 botulinum toxin substrate 1","1","5N6O"
"5N6R",,"SOLUTION NMR",,,,,,,"10.1038/s41467-017-02313-6",,"5N6R",24.84,,,"Solution structure of the Dbl-homology domain of Bcr-Abl","AMASELDLEKGLEMRKWVLSGILASEETYLSHLEALLLPMKPLKAAATTSQPVLTSQQIETIFFKVPELYEIHKEFYDGLFPRVQQWSHQQRVGDLFQKLASQLGVYRAFVDNYGVAMEMAEKCCQANAQFAEISENLRARSNKDAKDPTTKNSLETLLYKPVDRVTRSTLVLHDLLKHTPASHPDHPLLQDALRISQNFLSSINEEITPRRQSMTVK","Homo sapiens","BCR, BCR1, D22S11","Breakpoint cluster region protein","1","5N6R"
"5N6W","4.2","ELECTRON MICROSCOPY",,,,,,,"10.1093/hmg/ddw345",,"5N6W",368.67,"4.2",,"Retinoschisin R141H Mutant","STEDEGEDPWYQKACKCDCQGGPNALWSAGATSLDCIPECPYHKPLGFESGEVTPDQITCSNPEQYVGWYSSWTANKARLNSQGFGCAWLSKFQDSSQWLQIDLKEIKVISGILTQGHCDIDEWMTKYSVQYRTDERLNWIYYKDQTGNNRVFYGNSDRTSTVQNLLRPPIISRFIRLIPLGWHVRIAIRMELLECVSKCA","Homo sapiens","RS1, XLRS1","Retinoschisin","1","5N6W"
"5N7C",,"X-RAY DIFFRACTION",2.37,48.02,"VAPOR DIFFUSION, SITTING DROP",6,"protein: 10 mg/ml Dialysed in 100 milli-M NaCl, 50 milli-M sodium acetate, pH 5.5 Precipitant: 21 % PEG4K, .14 M imidazole malate, pH 6.0, 3.6% MPEG 5K, 0.03 M sodium acetate, pH 5.5 cryosoak: 40% CM1 (12.5 % di-ethylene glycol + 12.5 % MPD + 37.5 % 1,2-propanediol + 12.5 % DMSO ), 25 % MPEG 5K,0.1 M CHC (citric acid, HEPES, CHES) 90 % acid at pH 4.0 / 10 % basic at pH 10.0), 30 min soak.",293,"10.1038/s41598-018-31808-5",,"5N7C",26.34,"2.45","2.45","Human TTR altered conformation from soaking in CuCl2.","CPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5N7C"
"5N7H",,"X-RAY DIFFRACTION",2.03,39.44,"VAPOR DIFFUSION, SITTING DROP",,"10% (v/v) isopropanol, 0.1 M citrate pH 5.0",277,"10.1111/nyas.13408",,"5N7H",13.98,"2.2","2.2","Crystal structure of the coiled-coil domain of human tricellulin","GSMPDYVAKYPVIQTDDERERYKAVFQDQFSEYKELSAEVQAVLRKFDELDAVMSRLPHHSESRQEHERISRIHEEFKKKKNDPTFLEKKERCDYLKNKLSHIKQRIQEYDKVMN","Homo sapiens","MARVELD2, TRIC","MARVEL domain-containing protein 2","1","5N7H"
"5N7I",,"X-RAY DIFFRACTION",2.87,57.16,"VAPOR DIFFUSION, SITTING DROP",,"8.5% (w/v) PEG4000, 20% 2-propanol, 0.1 M HEPES-NaOH pH 7.0",293,"10.1111/nyas.13408",,"5N7I",27.61,"2.88","2.88","Crystal structure of the coiled-coil domain of human tricellulin","GSMPDYVAKYPVIQTDDEREAYKAVFQDQFSEYKELSAEVQAVLRKFDELDAVMSRLPHHSESRQEHEAISRIHEEFKKKKNDPTFLEKKERCDYLKNKLSHIKQRIQEYDKVMN","Homo sapiens","MARVELD2, TRIC","MARVEL domain-containing protein 2","1","5N7I"
"5N7K",,"X-RAY DIFFRACTION",3.33,63.04,"VAPOR DIFFUSION, SITTING DROP",,"55% (v/v) MPD, 0.1 M Mes pH 5.0",277,"10.1111/nyas.13408",,"5N7K",55.91,"2.81","2.81","Crystal structure of the coiled-coil domain of human tricellulin","GSMPDYVAKYPVIQTDDERERYKAVFQDQFSEYKELSAEVQAVLRKFDELDAVMSRLPHHSESRQEHERISRIHEEFKKKKNDPTFLEKKERCDYLKNKLSHIKQRIQEYDKVMN","Homo sapiens","MARVELD2, TRIC","MARVEL domain-containing protein 2","1","5N7K"
"5N7V",,"X-RAY DIFFRACTION",3.14,60.82,"VAPOR DIFFUSION, HANGING DROP",6.3,"32 - 37% PEG400 (Acros, Geel, Belgium), 0.1 M Na/K phosphate pH 6.3 and 250 mM NaCl",273,"10.1016/j.jmb.2017.05.014","8PT","5N7V",37.24,"2.52","2.52","TTK kinase domain in complex with MPI-0479605","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHLVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5N7V"
"5N84",,"X-RAY DIFFRACTION",3.2,61.62,"VAPOR DIFFUSION, HANGING DROP",6.3,"32 - 37% PEG400 (Acros, Geel, Belgium), 0.1 M Na/K phosphate pH 6.3 and 250 mM NaCl",293,"10.1016/j.jmb.2017.05.014","8Q5","5N84",36.72,"2.3","2.3","TTK kinase domain in complex with Mps-BAY2b","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHLVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5N84"
"5N86",,"X-RAY DIFFRACTION",1.89,35.03,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris pH 8.5, 0.8 M sodium/potassium tartrate, 0.5% PEG 5000 MME",298,"10.1107/S2059798318007271",,"5N86",31.45,"1.484","1.484","Crystal structure of FAS1 domain of hyaluronic acid receptor stabilin-2","GPLGSSGNLLQVLMSFPSLTNFLTEVLAYSNSSARGRAFLEHLTDLSIRGTLFVPQNSGLGENETLSGRDIEHHLANVSMFFYNDLVNGTTLQTRVGSKLLITASQDPLQPTETRFVDGRAILQWDIFASNGIIHVISRPLKAP","Homo sapiens","STAB2, FEEL2, FELL, FEX2, HARE","Stabilin-2","1","5N86"
"5N87",,"X-RAY DIFFRACTION",3.14,60.82,"VAPOR DIFFUSION, HANGING DROP",6.3,"32 - 37% PEG400 (Acros, Geel, Belgium), 0.1 M Na/K phosphate pH 6.3 and 250 mM NaCl.",293,"10.1016/j.jmb.2017.05.014","N66","5N87",36.98,"2.29","2.29","TTK kinase domain in complex with NTRC 0066-0","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5N87"
"5N93",,"X-RAY DIFFRACTION",2.98,58.74,"VAPOR DIFFUSION, HANGING DROP",6.3,"32 - 37% PEG400 (Acros, Geel, Belgium), 0.1 M Na/K phosphate pH 6.3 and 250 mM NaCl.pH 6.3",293,"10.1016/j.jmb.2017.05.014","8QE","5N93",36.54,"2.1","2.1","TTK kinase domain in complex with TC-Mps1-12","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHLVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5N93"
"5N9B",,"X-RAY DIFFRACTION",2.31,46.74,"VAPOR DIFFUSION",7,"Tris-HCl, PEG 2000 MME, lithium sulfate",293,"10.1016/j.celrep.2022.111489",,"5N9B",34.08,"1.9","1.9","Crystal Structure of unliganded human IL-17RA","LRLLDHRALVCSQPGLNCTVKNSTCLDDSWIHPRNLTPSSPKDLQIQLHFAHTQQGDLFPVAHIEWTLQTDASILYLEGAELSVLQLNTNERLCVRFEFLSKLRHHHRRWRFTFSHFVVDPDQEYEVTVHHLPKPIPDGDPNHQSKNFLVPDCEHARMKVTTPCMSSGSLWDPNITVETLEAHQLRVSFTLWNESTHYQILLTSFPHMENHSCFEHMHHIPAPRPEEFHQRSNVTLTLRNLKGCCRHQVQIQPFFSSCLNDCLRHSATVSCPEMPDTPEPIPDYMP","Homo sapiens","IL17RA, IL17R","Interleukin-17 receptor A","1","5N9B"
"5N9K",,"X-RAY DIFFRACTION",1.96,37.29,"VAPOR DIFFUSION, SITTING DROP",5.6,"Prior to the crystallization the inhibitor was solubilized in 100 % DMSO in a concentration of 10 mM. Then, this inhibitor stock solution was mixed in a Ratio of 1:10 with human CK2alpha (construct 1-335; solved with a Protein concentration of 8-10 mg/ml in 500 mM sodium chloride, 25 mM Tris/HCl pH 8.5). 
After a short time of incubation this mixture were mixed with reservoir solution [32 % (w/v) PEG4000, 0.2 M ammonium acetate, 0.1 M citrate pH 5.6] in a ratio of 2.5:1. 3.5 microliter of this final mixture was then equilibrated against the reservoir solution. The crystal growth was induced by seeding with 150 nanoliter seed suspension after an equilibration time of two days.",293,"10.3390/ph11010023","8QK","5N9K",40.92,"1.643","1.643","Crystal structure of human Protein kinase CK2 catalytic subunit in complex with the ATP-competitive, tight-binding dibenzofuran inhibitor TF107 (5)","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMG","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5N9K"
"5N9L",,"X-RAY DIFFRACTION",1.93,36.38,"VAPOR DIFFUSION, SITTING DROP",5.6,"Prior to the crystallization TF was solubilized in 100 % DMSO in a concentration of 10 mM. TF was mixed with human CK2alpha (construct 1-335; 8-10 mg/ml in 500 mM sodium chloride, 25 mM Tris/HCl pH 8.5) in a ratio of 1:5. After a short time of incubation this mixture was mixed with reservoir solution [32 % (w/v) PEG4000, 0.2 M ammonium acetate, 0.1 M citrate pH 5.6] in a ratio of 5:2. 3.5 microliter of the resulting mixture was then equilibrated against the reservoir solution. The crystal growth was induced by seeding with 150 nanoliter seed suspension after an equilibration time of two days.",293,"10.3390/ph11010023","8QH","5N9L",40.94,"1.79","1.79","Crystal structure of human Protein kinase CK2 catalytic subunit in complex with the ATP-competitive dibenzofuran inhibitor TF (4b)","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMG","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5N9L"
"5N9N",,"X-RAY DIFFRACTION",1.93,36.43,"VAPOR DIFFUSION, SITTING DROP",5.6,"Prior to the crystallization the Inhibitor TF85 was solubilized in 100 % DMSO in a concentration of 10 mM. This TF85 stock solution was mixed with human CK2alpha (construct 1-335; Protein concentration 8-10 mg/ml in 500 mM sodium chloride, 25 mM Tris/HCl pH 8.5) in a ratio of 1:10. After a short time of incubation, this mixture was mixed with reservoir solution [32 % (w/v) PEG4000, 0.2 M ammonium acetate, 0.1 M citrate pH 5.6] in a ratio of 5:2. 3.5 microliter of these mixtures were then equilibrated against the reservoir solution. The crystal growth was induced by seeding with 150 nanoliter seeding suspension after an equilibration time of two days.",293,"10.3390/ph11010023","KC5","5N9N",41.23,"1.841","1.841","Crystal structure of human Protein kinase CK2 catalytic subunit in complex with the ATP-competitive, tight-binding dibenzofuran inhibitor TF85 (4a)","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMG","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5N9N"
"5N9R",,"X-RAY DIFFRACTION",2.37,48.18,"VAPOR DIFFUSION, HANGING DROP",,"PEG 4000, Tris, Li2-Sulfate.",277,"10.1038/nchembio.2528","8RN","5N9R",84.62,"2.23","2.23","Crystal structure of USP7 in complex with a potent, selective and reversible small-molecule inhibitor","MSKKHTGYVGLKNQGATCYMNSLLQTLFFTNQLRKAVYMMPTEGDDSSKSVPLALQRVFYELQHSDKPVGTKKLTKSFGWETLDSFMQHDVQELCRVLLDNVENKMKGTCVEGTIPKLFRGKMVSYIQCKEVDYRSDRREDYYDIQLSIKGKKNIFESFVDYVAVEQLDGDNKYDAGEHGLQEAEKGVKFLTLPPVLHLQLMRFMYDPQTDQNIKINDRFEFPEQLPLDEFLQKTDPKDPANYILHAVLVHSGDNHGGHYVVYLNPKGDGKWCKFDDDVVSRCTKEEAIEHNYGGHDDDLSVRHCTNAYMLVYIRESKLSEVLQAVTDHDIPQQLVERLQEEKRIEAQKRKERQEHH","Homo sapiens","USP7, HAUSP","Ubiquitin carboxyl-terminal hydrolase 7","1","5N9R"
"5N9S",,"X-RAY DIFFRACTION",3.16,61.02,"VAPOR DIFFUSION, HANGING DROP",6.3,"32 - 37% PEG400 (Acros, Geel, Belgium), 0.1 M Na/K phosphate pH 6.3 and 250 mM NaCl.pH 6.3",293,"10.1016/j.jmb.2017.05.014","8QW","5N9S",36.77,"2.3","2.3","TTK kinase domain in complex with BAY 1161909","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHLVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5N9S"
"5N9T",,"X-RAY DIFFRACTION",2.4,48.69,"VAPOR DIFFUSION, HANGING DROP",8.5,"PEG 4000, Li2 Sulfate, Tris",277,"10.1038/nchembio.2528","8QQ","5N9T",84.71,"1.73","1.73","Crystal structure of USP7 in complex with a potent, selective and reversible small-molecule inhibitor","SKKHTGYVGLKNQGATCYMNSLLQTLFFTNQLRKAVYMMPTEGDDSSKSVPLALQRVFYELQHSDKPVGTKKLTKSFGWETLDSFMQHDVQELCRVLLDNVENKMKGTCVEGTIPKLFRGKMVSYIQCKEVDYRSDRREDYYDIQLSIKGKKNIFESFVDYVAVEQLDGDNKYDAGEHGLQEAEKGVKFLTLPPVLHLQLMRFMYDPQTDQNIKINDRFEFPEQLPLDEFLQKTDPKDPANYILHAVLVHSGDNHGGHYVVYLNPKGDGKWCKFDDDVVSRCTKEEAIEHNYGGHDDDLSVRHCTNAYMLVYIRESKLSEVLQAVTDHDIPQQLVERLQEEKRIEAQKRKERQEHHH","Homo sapiens","USP7, HAUSP","Ubiquitin carboxyl-terminal hydrolase 7","1","5N9T"
"5NA0",,"X-RAY DIFFRACTION",3.22,61.8,"VAPOR DIFFUSION, HANGING DROP",6.3,"32 - 37% PEG400 (Acros, Geel, Belgium), 0.1 M Na/K phosphate pH 6.3 and 250 mM NaCl.pH 6.3",293,"10.1016/j.jmb.2017.05.014",,"5NA0",36.97,"2.9","2.9","TTK kinase domain in complex with a PEG-linked pyrimido-indolizine","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHLVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5NA0"
"5NAD",,"X-RAY DIFFRACTION",3.05,59.7,"VAPOR DIFFUSION, HANGING DROP",6.3,"32 - 37% PEG400 (Acros, Geel, Belgium), 0.1 M Na/K phosphate pH 6.3 and 250 mM NaCl.pH 6.3",293,"10.1016/j.jmb.2017.05.014",,"5NAD",36.77,"2.8","2.8","TTK kinase domain in complex with BAY 1217389","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHLVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5NAD"
"5NAJ",,"X-RAY DIFFRACTION",2.28,46.1,"VAPOR DIFFUSION, SITTING DROP",7,"2.2M ammonium sulfate, 200mM ammonium chloride",293.15,"10.1073/pnas.2007213117",,"5NAJ",54.8,"1.46","1.46","ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-1]-[ProM-1]-OH","GSMSEQSICQARAAVMVYDDANKKWVPAGGSTGFSRVHIYHHTGNNTFRVVGRKIQDHQVVINCAIPKGLKYNQATQTFHQWRDARQVYGLNFGSKEDANVFASAMMHALEVL","Homo sapiens","ENAH, MENA","Protein enabled homolog","1","5NAJ"
"5NAL",,"X-RAY DIFFRACTION",3,59.06,"VAPOR DIFFUSION, SITTING DROP",4.6,"2 M Na-formate, 0.1 M NaAcanh, pH 4.6",293,"10.1016/j.chembiol.2017.03.015",,"5NAL",18.11,"2.2","2.2","The crystal structure of inhibitor-15 covalently bound to PDE6D","MSAKDERAREILRGFKLNWMNLRDAETGKILWQGTEDLSVPGVEHEARVPKKILKCKAVSRELNFSSTEQMEKFRLEQKVYFKGQCLEEWFFEFGFVIPNSTNTWQSLIEAAPESQMMPASVLTGNVIIETKFFDDDLLVSTSRVRLFYV","Homo sapiens","PDE6D, PDED","Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta","1","5NAL"
"5NAM",,"SOLUTION NMR",,,,,,,"10.1038/s41598-017-07250-4",,"5NAM",5.28,,,"NMR structure of TLR4 transmembrane domain (624-670) in DMPG/DHPC bicelles","MNITSQMNKTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRG","Homo sapiens","TLR4","Toll-like receptor 4","1","5NAM"
"5NAO",,"SOLUTION NMR",,,,,,,"10.1038/s41598-017-07250-4",,"5NAO",3.9,,,"NMR structure of TLR4 transmembrane domain (624-657) in DPC micelles","MNITSQMNKTIIGVSVLSVLVVSVVAVLVYKFYFH","Homo sapiens","TLR4","Toll-like receptor 4","1","5NAO"
"5NAR",,"X-RAY DIFFRACTION",1.98,37.74,"VAPOR DIFFUSION, SITTING DROP",,"MM NACL, 0.5MM NVP-BVT244-NX-1
                      + 1 UL RESERVOIR SOLUTION",298,"10.1021/acs.jmedchem.7b00425","8RW","5NAR",25.31,"1.55","1.55","Complement factor D in complex with the inhibitor (S)-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]","ILGGREAEAHARPYMASVQLNGAHLCGGVLVAEQWVLSAAHCLEDAADGKVQVLLGAHSLSQPEPSKRLYDVLRAVPHPDSQPDTIDHDLLLLQLSEKATLGPAVRPLPWQRVDRDVAPGTLCDVAGWGIVNHAGRRPDSLQHVLLPVLDRATCNRRTHHDGAITERLMCAESNRRDSCKGDSGGPLVCGGVLEGVVTSGSRVCGNRKKPGIYTRVASYAAWIDSVLASAAA","Homo sapiens","CFD, DF, PFD","Complement factor D","1","5NAR"
"5NAT",,"X-RAY DIFFRACTION",2.11,41.83,"VAPOR DIFFUSION, SITTING DROP",,"MM NACL
                      + 1 UL RESERVOIR SOLUTION",298,"10.1021/acs.jmedchem.7b00425","8RT","5NAT",25.37,"1.17","1.17","Complement factor D in complex with the inhibitor (S)-Pyrrolidine-1,2-dicarboxylic acid 1-[(1-methyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]","ILGGREAEAHARPYMASVQLNGAHLCGGVLVAEQWVLSAAHCLEDAADGKVQVLLGAHSLSQPEPSKRLYDVLRAVPHPDSQPDTIDHDLLLLQLSEKATLGPAVRPLPWQRVDRDVAPGTLCDVAGWGIVNHAGRRPDSLQHVLLPVLDRATCNRRTHHDGAITERLMCAESNRRDSCKGDSGGPLVCGGVLEGVVTSGSRVCGNRKKPGIYTRVASYAAWIDSVLASAAA","Homo sapiens","CFD, DF, PFD","Complement factor D","1","5NAT"
"5NAW",,"X-RAY DIFFRACTION",2.1,41.43,"VAPOR DIFFUSION, SITTING DROP",,"27% PEG 3350
100 mM HEPES pH 7.5",298,"10.1021/acs.jmedchem.7b00425","8RZ","5NAW",25.23,"1.25","1.25","Complement factor D in complex with the inhibitor (1R,3S,5R)-2-Aza-bicyclo[3.1.0]hexane-2,3-dicarboxylic acid 2-[(1-carbamoyl-1H-indol-3-yl)-amide] 3-[(3-trifluoromethoxy-phenyl)-amide]","ILGGREAEAHARPYMASVQLNGAHLCGGVLVAEQWVLSAAHCLEDAADGKVQVLLGAHSLSQPEPSKRLYDVLRAVPHPDSQPDTIDHDLLLLQLSEKATLGPAVRPLPWQRVDRDVAPGTLCDVAGWGIVNHAGRRPDSLQHVLLPVLDRATCNRRTHHDGAITERLMCAESNRRDSCKGDSGGPLVCGGVLEGVVTSGSRVCGNRKKPGIYTRVASYAAWIDSVLASAAA","Homo sapiens","CFD, DF, PFD","Complement factor D","1","5NAW"
"5NAY",,"X-RAY DIFFRACTION",2.59,52.45,"VAPOR DIFFUSION, SITTING DROP",,"1.4 M lithium sulfate and 0.1 M Mes pH 6.5",294,"10.1107/S2052252518012459",,"5NAY",153.34,"1.8","1.8","Crystal structures of homooligomers of collagen type IV. alpha1NC1","SVDHGFLVTRHSQTIDDPQCPSGTKILYHGYSLLYVQGNERAHGQDLGTAGSCLRKFSTMPFLFCNINNVCNFASRNDYSYWLSTPEPMPMSMAPITGENIRPFISRCAVCEAPAMVMAVHSQTIQIPPCPSGWSSLWIGYSFVMHTSAGAEGSGQALASPGSCLEEFRSAPFIECHGRGTCNYYANAYSFWLATIERSEMFKKPTPSTLKAGELRTHVSRCQVCMRRT","Homo sapiens","COL4A1","Collagen alpha-1(IV) chain","1","5NAY"
"5NAZ",,"X-RAY DIFFRACTION",2.96,58.46,"VAPOR DIFFUSION, SITTING DROP",,"20%PEG8000, 0.2 M NaCl, CAPS pH 10.5",294,"10.1107/S2052252518012459",,"5NAZ",25.82,"1.85","1.85","Crystal structures of homooligomers of collagen type IV. alpha5NC1","SVAHGFLITRHSQTTDAPQCPQGTLQVYEGFSLLYVQGNKRAHGQDLGTAGSCLRRFSTMPFMFCNINNVCNFASRNDYSYWLSTPEPMPMSMQPLKGQSIQPFISRCAVCEAPAVVIAVHSQTIQIPHCPQGWDSLWIGYSFMMHTSAGAEGSGQALASPGSCLEEFRSAPFIECHGRGTCNYYANSYSFWLATVDVSDMFSKPQSETLKAGDLRTRISRCQVCMKRT","Homo sapiens","COL4A5","Collagen alpha-5(IV) chain","1","5NAZ"
"5NB0",,"X-RAY DIFFRACTION",2.07,40.61,"VAPOR DIFFUSION, SITTING DROP",,"6% PEG3350, BisTrisPropane pH 7.5 and MgCl2 0.2 M",294,"10.1107/S2052252518012459",,"5NB0",205.11,"2.7","2.7","Crystal structures of homooligomers of collagen type IV. alpha3NC1","WTTRGFVFTRHSQTTAIPSCPEGTVPLYSGFSFLFVQGNQRAHGQDLGTLGSCLQRFTTMPFLFCNVNDVCNFASRNDYSYWLSTPALMPMNMAPITGRALEPYISRCTVCEGPAIAIAVHSQTTDIPPCPHGWISLWKGFSFIMFTSAGSEGTGQALASPGSCLEEFRASPFLECHGRGTCNYYSNSYSFWLASLNPERMFRKPIPSTVKAGELEKIISRCQVCMKKRH","Homo sapiens","COL4A3","Collagen alpha-3(IV) chain","1","5NB0"
"5NB1",,"X-RAY DIFFRACTION",3.45,64.37,"VAPOR DIFFUSION, SITTING DROP",,"6% PEG3350, 0.2 M sodium acetate and 0.1 M Mes pH 6.5",294,"10.1107/S2052252518012459",,"5NB1",152.66,"2.82","2.82","Crystal structures of homooligomers of collagen type IV. alpha4NC1","GYLGGFLLVLHSQTDQEPTCPLGMPRLWTGYSLLYLEGQEKAHNQDLGLAGSCLPVFSTLPFAYCNIHQVCHYAQRNDRSYWLASAAPLPMMPLSEEAIRPYVSRCAVCEAPAQAVAVHSQDQSIPPCPQTWRSLWIGYSFLMHTGAGDQGGGQALMSPGSCLEDFRAAPFLECQGRQGTCHFFANKYSFWLTTVKADLQFSSAPAPDTLKESQAQRQKISRCQVCVKYS","Homo sapiens","COL4A4","Collagen alpha-4(IV) chain","1","5NB1"
"5NB2",,"X-RAY DIFFRACTION",3.21,61.62,"VAPOR DIFFUSION, SITTING DROP",,"22% polyvinylpyrrolidone K15, 0.1M Na2SO4 and Mes pH 6.5",294,"10.1107/S2052252518012459",,"5NB2",50.23,"2.5","2.5","Crystal structures of homooligomers of collagen type IV. alpha2NC1","SVSIGYLLVKHSQTDQEPMCPVGMNKLWSGYSLLYFEGQEKAHNQDLGLAGSCLARFSTMPFLYCNPGDVCYYASRNDKSYWLSTTAPLPMMPVAEDEIKPYISRCSVCEAPAIAIAVHSQDVSIPHCPAGWRSLWIGYSFLMHTAAGDEGGGQSLVSPGSCLEDFRATPFIECNGGRGTCHYYANKYSFWLTTIPEQSFQGSPSADTLKAGLIRTHISRCQVCMKNL","Homo sapiens","COL4A2","Collagen alpha-2(IV) chain","1","5NB2"
"5NB6",,"X-RAY DIFFRACTION",2.03,39.45,"VAPOR DIFFUSION, SITTING DROP",,"22% PEG3350, 0.1 M HEPES pH 7.5, 50 mM NaCl",298,"10.1021/acs.jmedchem.7b00425","8S2","5NB6",25.23,"1.75","1.75","Complement factor D in complex with the inhibitor (2S,4S)-4-Amino-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]","ILGGREAEAHARPYMASVQLNGAHLCGGVLVAEQWVLSAAHCLEDAADGKVQVLLGAHSLSQPEPSKRLYDVLRAVPHPDSQPDTIDHDLLLLQLSEKATLGPAVRPLPWQRVDRDVAPGTLCDVAGWGIVNHAGRRPDSLQHVLLPVLDRATCNRRTHHDGAITERLMCAESNRRDSCKGDSGGPLVCGGVLEGVVTSGSRVCGNRKKPGIYTRVASYAAWIDSVLASAAA","Homo sapiens","CFD, DF, PFD","Complement factor D","1","5NB6"
"5NB7",,"X-RAY DIFFRACTION",2.13,42.12,"VAPOR DIFFUSION, SITTING DROP",,"22% PEG 3350, 0.1 m HEPES pH 7.5, 50 mM NaCl",298,"10.1021/acs.jmedchem.7b00425","8NQ","5NB7",25.24,"1.33","1.33","Complement factor D","ILGGREAEAHARPYMASVQLNGAHLCGGVLVAEQWVLSAAHCLEDAADGKVQVLLGAHSLSQPEPSKRLYDVLRAVPHPDSQPDTIDHDLLLLQLSEKATLGPAVRPLPWQRVDRDVAPGTLCDVAGWGIVNHAGRRPDSLQHVLLPVLDRATCNRRTHHDGAITERLMCAESNRRDSCKGDSGGPLVCGGVLEGVVTSGSRVCGNRKKPGIYTRVASYAAWIDSVLASA","Homo sapiens","CFD, DF, PFD","Complement factor D","1","5NB7"
"5NBA",,"X-RAY DIFFRACTION",2.09,41.24,"VAPOR DIFFUSION, SITTING DROP",,"23% PEG 3350, 0.1 M HEPES pH 7.5, 50 mM NaCl",293,"10.1021/acs.jmedchem.7b00425","8S5","5NBA",25.09,"1.87","1.87","Complement factor D in complex with the inhibitor (2S,4R)-4-Fluoro-pyrrolidine-1,2-dicarboxylic acid 1-[(1-carbamoyl-1H-indol-3-yl)-amide] 2-[(3-trifluoromethoxy-phenyl)-amide]","ILGGREAEAHARPYMASVQLNGAHLCGGVLVAEQWVLSAAHCLEDAADGKVQVLLGAHSLSQPEPSKRLYDVLRAVPHPDSQPDTIDHDLLLLQLSEKATLGPAVRPLPWQRVDRDVAPGTLCDVAGWGIVNHAGRRPDSLQHVLLPVLDRATCNRRTHHDGAITERLMCAESNRRDSCKGDSGGPLVCGGVLEGVVTSGSRVCGNRKKPGIYTRVASYAAWIDSVLASA","Homo sapiens","CFD, DF, PFD","Complement factor D","1","5NBA"
"5NBF",,"X-RAY DIFFRACTION",2.33,47.17,"VAPOR DIFFUSION, SITTING DROP",7,"2.1M ammonium sulfate, 180mM ammonium nitrate",293.15,"10.1073/pnas.2007213117",,"5NBF",13.45,"1.15","1.15","ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-3]-OH","GSMSEQSICQARAAVMVYDDANKKWVPAGGSTGFSRVHIYHHTGNNTFRVVGRKIQDHQVVINCAIPKGLKYNQATQTFHQWRDARQVYGLNFGSKEDANVFASAMMHALEVL","Homo sapiens","ENAH, MENA","Protein enabled homolog","1","5NBF"
"5NBU",,"X-RAY DIFFRACTION",2.3,46.57,"VAPOR DIFFUSION, SITTING DROP",,"PEG 4000, carboxylic acid mixture",293,,,"5NBU",42.7,"1.67","1.67","Crystal structure of native alpha-1-antitrypsin with seven stabilising mutations","GDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNILFSPVSIAAAFAMLSLGAKGDTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHSKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVFLIIEQNTKAPLFMGRVVNPTQK","Homo sapiens","SERPINA1, AAT, PI, PRO0684, PRO2209","Alpha-1-antitrypsin","1","5NBU"
"5NBV",,"X-RAY DIFFRACTION",2.32,46.87,"VAPOR DIFFUSION, SITTING DROP",,"PEG 4000, carboxylic acid mixture",293,,,"5NBV",42.62,"1.73","1.73","Crystal structure of native alpha-1-antitrypsin with seven stabilising mutations","GDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNILFSPVSIAAAFAMLSLGAKGDTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHSKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDKKGTEAAGAMFLEAIPMSIPPEVKFNKPFVFLIIEQNTKAPLFMGRVVNPTQK","Homo sapiens","SERPINA1, AAT, PI, PRO0684, PRO2209","Alpha-1-antitrypsin","1","5NBV"
"5NCF",,"X-RAY DIFFRACTION",2.29,46.3,"VAPOR DIFFUSION, SITTING DROP",7,"1.9M ammonium sulfate, 200mM ammonium nitrate",293.15,"10.1073/pnas.2007213117","8T5","5NCF",27.23,"1.4","1.4","ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-4]-OH","GSMSEQSICQARAAVMVYDDANKKWVPAGGSTGFSRVHIYHHTGNNTFRVVGRKIQDHQVVINCAIPKGLKYNQATQTFHQWRDARQVYGLNFGSKEDANVFASAMMHALEVL","Homo sapiens","ENAH, MENA","Protein enabled homolog","1","5NCF"
"5NCG",,"X-RAY DIFFRACTION",1.88,34.7,"VAPOR DIFFUSION, SITTING DROP",7,"2.2M ammonium sulfate, 200mM ammonium nitrate",293.15,"10.1073/pnas.2007213117",,"5NCG",28.97,"1.02","1.02","ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-9]-OH","GSMSEQSICQARAAVMVYDDANKKWVPAGGSTGFSRVHIYHHTGNNTFRVVGRKIQDHQVVINCAIPKGLKYNQATQTFHQWRDARQVYGLNFGSKEDANVFASAMMHALEVL","Homo sapiens","ENAH, MENA","Protein enabled homolog","1","5NCG"
"5NCP",,"X-RAY DIFFRACTION",2.13,42.3,"VAPOR DIFFUSION, SITTING DROP",7,"1.7M ammonium sulfate, 180mM ammonium nitrate",293.15,"10.1073/pnas.2007213117",,"5NCP",13.53,"1.65","1.65","ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-12]-OH","GSMSEQSICQARAAVMVYDDANKKWVPAGGSTGFSRVHIYHHTGNNTFRVVGRKIQDHQVVINCAIPKGLKYNQATQTFHQWRDARQVYGLNFGSKEDANVFASAMMHALEVL","Homo sapiens","ENAH, MENA","Protein enabled homolog","1","5NCP"
"5NDF",,"X-RAY DIFFRACTION",2.3,46.45,"VAPOR DIFFUSION, HANGING DROP",,"10% PEG 8000, 6% ethylene glycol, 100 mM Hepes pH 7",296,"10.1074/jbc.M117.814202","LU2","5NDF",393.18,"2.3","2.3","Small-molecule inhibition of ppGalNAc-Ts selectively reduces mucin-type O-glycosylation","MRRRSRMLLCFAFLWVLGIAYYMYSGGGSALAGGAGGGAGRKEDWNEIDPIKKKDLHHSNGEEKAQSMETLPPGKVRWPDFNQEAYVGGTMVRSGQDPYARNKFNQVESDKLRMDRAIPDTRHDQCQRKQWRVDLPATSVVITFHNEARSALLRTVVSVLKKSPPHLIKEIILVDDYSNDPEDGALLGKIEKVRVLRNDRREGLMRSRVRGADAAQAKVLTFLDSHCECNEHWLEPLLERVAEDRTRVVSPIIDVINMDNFQYVGASADLKGGFDWNLVFKWDYMTPEQRRSRQGNPVAPIKTPMIAGGLFVMDKFYFEELGKYDMMMDVWGGENLEISFRVWQCGGSLEIIPCSRVGHVFRKQHPYTFPGGSGTVFARNTRRAAEVWMDEYKNFYYAAVPSARNVPYGNIQSRLELRKKLSCKPFKWYLENVYPELRVPDHQDIAFGALQQGTNCLDTLGHFADGVVGVYECHNAGGNQEWALTKEKSVKHMDLCLTVVDRAPGSLIKLQGCREDDSRQKWEQIEGNSKLRHVGSNLCLDSRTAKSGGLSVEVCGPALSQQWKFTLNLQQ","Homo sapiens","GALNT2","Polypeptide N-acetylgalactosaminyltransferase 2","1","5NDF"
"5NDU",,"X-RAY DIFFRACTION",2.03,39.5,"VAPOR DIFFUSION, SITTING DROP",7,"2.0M ammonium sulfate, 220mM ammonium nitrate",293.15,"10.1073/pnas.2007213117",,"5NDU",27.83,"1.42","1.42","ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-12]-OMe","GSMSEQSICQARAAVMVYDDANKKWVPAGGSTGFSRVHIYHHTGNNTFRVVGRKIQDHQVVINCAIPKGLKYNQATQTFHQWRDARQVYGLNFGSKEDANVFASAMMHALEVL","Homo sapiens","ENAH, MENA","Protein enabled homolog","1","5NDU"
"5NEA",,"X-RAY DIFFRACTION",2.08,40.95,"VAPOR DIFFUSION",8,"1.6 M sodium citrate, Tris 50 mM",296,"10.1016/j.bmc.2017.06.054","8V8","5NEA",29.99,"1.3","1.3","Crystal structure of human carbonic anhydrase II in complex with the inhibitor 4-(2-methyl-1,3-oxazol-5-yl)benzene-1-sulfonammide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5NEA"
"5NEE",,"X-RAY DIFFRACTION",2.07,40.7,"VAPOR DIFFUSION",8,"1.5 M sodium citrate, Tris 50 mM",296,"10.1016/j.bmc.2017.06.054","8V5","5NEE",29.79,"1.7","1.7","Crystal structure of human carbonic anhydrase II in complex with the inhibitor 5-[2-(morpholine-4-carbonyl)1,3-oxazol-5-yl)]thiophene-2-sulfonammide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5NEE"
"5NEG",,"X-RAY DIFFRACTION",2.19,43.8,"VAPOR DIFFUSION, SITTING DROP",7,"1.8M ammonium sulfate, 260mM ammonium nitrate",293.15,"10.1073/pnas.2007213117",,"5NEG",27.26,"1.29","1.29","ENAH EVH1 in complex with Ac-[2-Cl-F]-[ProM-2]-[ProM-13]-OEt","GSMSEQSICQARAAVMVYDDANKKWVPAGGSTGFSRVHIYHHTGNNTFRVVGRKIQDHQVVINCAIPKGLKYNQATQTFHQWRDARQVYGLNFGSKEDANVFASAMMHALEVL","Homo sapiens","ENAH, MENA","Protein enabled homolog","1","5NEG"
"5NEI",,"X-RAY DIFFRACTION",1.98,37.81,"VAPOR DIFFUSION",,"10% PEG 3350, 100 mM Na/K tartrate",292,,,"5NEI",27.83,"2.68","2.68","The structure of the polo-box domain (PBD) of polo-like kinase 1 (Plk1) in complex with JES107","GAHMDCHLSDMLQQLHSVNASKPSERGLVRQEEAEDPACIPIFWVSKWVDYSDKYGLGYQLCDNSVGVLFNDSTRLILYNDGDSLQYIERDGTESYLTVSSHPNSLMKKITLLKYFRNYMSEHLLKAGANITPREGDELARLPYLRTWFRTRSAIILHLSNGSVQINFFQDHTKLILCPLMAAVTYIDEKRDFRTYRLSLLEEYGCCKELASRLRYARTMVDKLLSSRSASNRLKAS","Homo sapiens","PLK1, PLK","Serine/threonine-protein kinase PLK1","1","5NEI"
"5NF7",,"X-RAY DIFFRACTION",,27.43,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM Tris HCl pH7.5; 30-34% PEG4000; 100mM MgCl2; 400mM NaSCN; 8mM beta-mercaptoethanol",277,"10.1016/j.bbrc.2017.05.150",,"5NF7",20.36,"1.59","1.59","Structure of Galectin-3 CRD in complex with compound 1","MGSSHNHNHNHNHNHNDYDIPTTENLYFQGSPYGAPAGPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI","Homo sapiens","LGALS3, MAC2","Galectin-3","1","5NF7"
"5NF9",,"X-RAY DIFFRACTION",2.04,39.82,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM Tris HCl pH7.5; 30-34% PEG4000; 100mM MgCl2; 400mM NaSCN; 8mM beta-mercaptoethanol",277,"10.1016/j.bbrc.2017.05.150","8VW","5NF9",16.98,"1.87","1.87","Structure of Galectin-3 CRD in complex with compound 2","GSPYGAPAGPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI","Homo sapiens","LGALS3, MAC2","Galectin-3","1","5NF9"
"5NFA",,"X-RAY DIFFRACTION",2.05,27.33,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM Tris HCl pH7.5; 30-34% PEG4000; 100mM MgCl2; 400mM NaSCN; 8mM beta-mercaptoethanol",277,"10.1016/j.bbrc.2017.05.150",,"5NFA",17,"1.59","1.59","Structure of Galectin-3 CRD in complex with compound 3","GSPYGAPAGPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI","Homo sapiens","LGALS3, MAC2","Galectin-3","1","5NFA"
"5NFB",,"X-RAY DIFFRACTION",,25.37,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM Tris HCl pH7.5; 30-34% PEG4000; 100mM MgCl2; 400mM NaSCN; 8mM beta-mercaptoethanol",277,"10.1016/j.bbrc.2017.05.150","8VT","5NFB",20.57,"1.59","1.59","Structure of Galectin-3 CRD in complex with compound 4","MGSSHNHNHNHNHNHNDYDIPTTENLYFQGSPYGAPAGPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI","Homo sapiens","LGALS3, MAC2","Galectin-3","1","5NFB"
"5NFC",,"X-RAY DIFFRACTION",2.05,27.17,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM Tris HCl pH7.5; 30-34% PEG4000; 100mM MgCl2; 400mM NaSCN; 8mM beta-mercaptoethanol",277,"10.1016/j.bbrc.2017.05.150",,"5NFC",16.55,"1.59","1.59","Structure of Galectin-3 CRD in complex with glycerol","GSPYGAPAGPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI","Homo sapiens","LGALS3, MAC2","Galectin-3","1","5NFC"
"5NFD",,"X-RAY DIFFRACTION",2.32,46.92,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES, pH 7.0, 20% isopropanol",293.15,"10.1042/BSR20181073",,"5NFD",18.93,"2.18","2.18","Antiparallel monomeric coiled coil of Kif21A","GSMTISNMEADCNRLLKQREELTKRREKLSKRREKIVKENGEGDKNVANINEEMESLTANIDYINDSISDCQANIMQMEEAK","Homo sapiens","KIF21A, KIAA1708, KIF2","Kinesin-like protein KIF21A","1","5NFD"
"5NFE",,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.19,43.85,"VAPOR DIFFUSION, SITTING DROP",,"1.9M sodium malonate pD5.9, 40mg/ml protein",291,"10.1038/s41467-019-08609-z",,"5NFE",28.13,"1.853, 1.85","1.853, 1.85","Neutron structure of human transthyretin (TTR) T119M mutant at room temperature to 1.85A resolution","GAMGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTMAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5NFE"
"5NFJ",,"X-RAY DIFFRACTION",3.43,64.2,"VAPOR DIFFUSION, SITTING DROP",7.5,"Well solution: 12% PEG 1000, 28% glycerol, 1.5%(w/v) PEG 3350
Cryo: 25% propylene glycol
Protein concentration: 11 mg/mL",277.15,,,"5NFJ",73.49,"1.96","1.96","Crystal structure of the methyltransferase subunit of human mitochondrial Ribonuclease P (MRPP1) bound to S-adenosyl-methionine (SAM)","MQPLVFDMAYENYMKRKELQNTVSQLLESEGWNRRNVDPFHIYFCNLKIDGALHRELVKRYQEKWDKLLLTSTEKSHVDLFPKDSIIYLTADSPNVMTTFRHDKVYVIGSFVDKSMQPGTSLAKAKRLNLATECLPLDKYLQWEIGNKNLTLDQMIRILLCLKNNGNWQEALQFVPKRKHTGFLEISQHSQEFINRLKKAKT","Homo sapiens","TRMT10C, MRPP1, RG9MTD1","Mitochondrial ribonuclease P protein 1","1","5NFJ"
"5NFN",,"X-RAY DIFFRACTION",3.04,59.5,"VAPOR DIFFUSION, SITTING DROP",4.6,"25 mg/mL His6-JMJD7, 2 mM MnCl2, 4 mM 2OG, 1.5 M Sodium Nitrate, 0.1 M Sodium Acetate pH 4.6",298,,,"5NFN",153.49,"2.982","2.982","JMJD7 IN COMPLEX WITH MN AND 2OG IN THE H32 FORM","GSSHHHHHHSSGLVPRGSHMAEAALEAVRSELREFPAAARELCVPLAVPYLDKPPTPLHFYRDWVCPNRPCIIRNALQHWPALQKWSLPYFRATVGSTEVSVAVTPDGYADAVRGDRFMMPAERRLPLSFVLDVLEGRAQHPGVLYVQKQCSNLPSELPQLLPDLESHVPWASEALGKMPDAVNFWLGEAAAVTSLHKDHYENLYCVVSGEKHFLFHPPSDRPFIPYELYTPATYQLTEEGTFKVVDEEAMEKVPWIPLDPLAPDLARYPSYSQAQALRCTVRAGEMLYLPALWFHHVQQSQGCIAVNFWYDMEYDLKYSYFQLLDSLTKASGLD","Homo sapiens","JMJD7","JmjC domain-containing protein 7","1","5NFN"
"5NFO",,"X-RAY DIFFRACTION",2.49,50.61,"VAPOR DIFFUSION, SITTING DROP",4.6,"26 mg/mL His6-JMJD7-R260C, 2 mM MnCl2, 4 mM 2OG, 1.5 M Sodium Nitrate, 0.1 M Sodium Acetate pH 4.6 and additives (0.25% beta-NADP, 0.25% ATP, 0.25% N-Acetyl-D-galactosamine, 0.25% Gentamicin sulfate, 0.02 M HEPES-Na pH 6.8)",298,,,"5NFO",76.99,"2.173","2.173","Human JMJD7 in complex with Mn and 2OG in the P21212 form","GSSHHHHHHSSGLVPRGSHMAEAALEAVRSELREFPAAARELCVPLAVPYLDKPPTPLHFYRDWVCPNRPCIIRNALQHWPALQKWSLPYFRATVGSTEVSVAVTPDGYADAVRGDRFMMPAERRLPLSFVLDVLEGRAQHPGVLYVQKQCSNLPSELPQLLPDLESHVPWASEALGKMPDAVNFWLGEAAAVTSLHKDHYENLYCVVSGEKHFLFHPPSDRPFIPYELYTPATYQLTEEGTFKVVDEEAMEKVPWIPLDPLAPDLARYPSYSQAQALCCTVRAGEMLYLPALWFHHVQQSQGCIAVNFWYDMEYDLKYSYFQLLDSLTKASGLD","Homo sapiens","JMJD7","JmjC domain-containing protein 7","1","5NFO"
"5NFW",,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.2,44.17,"VAPOR DIFFUSION, SITTING DROP",,"1.9M sodium malonate pD 6.4, 25mg/ml protein",293,"10.1038/s41467-019-08609-z",,"5NFW",28.09,"1.8, 1.8","1.8","Neutron structure of human transthyretin (TTR) S52P mutant at room temperature to 1.8A resolution (quasi-Laue)","GAMGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSEPGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5NFW"
"5NG0",,"X-RAY DIFFRACTION",3.2,61.58,"VAPOR DIFFUSION, SITTING DROP",,"Hepes 100 mM pH 7.5, 1 mM MgCl2, 2.0 M LiCl and 5% PEG 6000",293,"10.1371/journal.pone.0177161",,"5NG0",70.81,"2","2","Structure of RIP2K(L294F) with bound AMPPCP","GAMAMNGEAICSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSERKDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLLHHDLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVFRTFEEI","Homo sapiens","RIPK2, CARDIAK, RICK, RIP2, UNQ277/PRO314/PRO34092","Receptor-interacting serine/threonine-protein kinase 2","1","5NG0"
"5NG2",,"X-RAY DIFFRACTION",3.35,63.31,"VAPOR DIFFUSION, SITTING DROP",,".1 M MES pH6.5, 2M NaCl, 0.1 mM Na(H2PO4), 0.1 mM of K(H2PO4)",293,"10.1371/journal.pone.0177161",,"5NG2",71.12,"2.8","2.8","Structure of RIP2K(D146N) with bound Staurosporine","GAMAMNGEAICSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSERKDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLLHHNLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEI","Homo sapiens","RIPK2, CARDIAK, RICK, RIP2, UNQ277/PRO314/PRO34092","Receptor-interacting serine/threonine-protein kinase 2","1","5NG2"
"5NG3",,"X-RAY DIFFRACTION",2.91,57.77,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris pH 8.5, 0.5 mM (NH4)2SO4",293,"10.1371/journal.pone.0177161",,"5NG3",141.63,"2.6","2.6","Structure of inactive kinase RIP2K(K47R)","GAMAMNGEAICSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVRHLHIHTPLLDSERKDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLLHHDLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEI","Homo sapiens","RIPK2, CARDIAK, RICK, RIP2, UNQ277/PRO314/PRO34092","Receptor-interacting serine/threonine-protein kinase 2","1","5NG3"
,,,,,,,,,,,,,,,,"GAMAMNGEAICSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVRHLHIHTPLLDSERKDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLLHHDLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEI","Homo sapiens","RIPK2, CARDIAK, RICK, RIP2, UNQ277/PRO314/PRO34092","Receptor-interacting serine/threonine-protein kinase 2","2","5NG3"
"5NG4",,"X-RAY DIFFRACTION",2.41,48.92,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG 1500, SPG buffer, pH 6.0",293.15,"10.1042/BSR20181073",,"5NG4",15.46,"2.14","2.14","Human CEP135 parallel dimeric coiled coil 82-144","GSNNELYLELMKLREHSDQHVKELKTSLKKCARETADLKFLNNQYAHKLKLLEKESKAKNERIQQ","Homo sapiens","CEP135, CEP4, KIAA0635","Centrosomal protein of 135 kDa","1","5NG4"
"5NGE",,"X-RAY DIFFRACTION",2.37,48.17,"VAPOR DIFFUSION, SITTING DROP",8,"25% (w/v) polyethylene glycol (PEG) 1500, 100 mM MMT pH 8.0",293,"10.1038/nature24451","8WK","5NGE",83.36,"2.35","2.35","Crystal structure of USP7 in complex with the non-covalent inhibitor, FT671","GSKKHTGYVGLKNQGATCYMNSLLQTLFFTNQLRKAVYMMPTEGDDSSKSVPLALQRVFYELQHSDKPVGTKKLTKSFGWETLDSFMQHDVQELCRVLLDNVENKMKGTCVEGTIPKLFRGKMVSYIQCKEVDYRSDRREDYYDIQLSIKGKKNIFESFVDYVAVEQLDGDNKYDAGEHGLQEAEKGVKFLTLPPVLHLQLMRFMYDPQTDQNIKINDRFEFPEQLPLDEFLQKTDPKDPANYILHAVLVHSGDNHGGHYVVYLNPKGDGKWCKFDDDVVSRCTKEEAIEHNYGGHDDDLSVRHCTNAYMLVYIRESKLSEVLQAVTDHDIPQQLVERLQEEKRIEAQKRKERQE","Homo sapiens","USP7, HAUSP","Ubiquitin carboxyl-terminal hydrolase 7","1","5NGE"
"5NGF",,"X-RAY DIFFRACTION",2.5,50.88,"VAPOR DIFFUSION, SITTING DROP",7.5,"20 % (w/v) PEG3350, 100 mM Bis-Tris propane pH 7.5, 0.2 M sodium formate",293,"10.1038/nature24451",,"5NGF",83.46,"2.33","2.33","Crystal structure of USP7 in complex with the covalent inhibitor, FT827","GSKKHTGYVGLKNQGATCYMNSLLQTLFFTNQLRKAVYMMPTEGDDSSKSVPLALQRVFYELQHSDKPVGTKKLTKSFGWETLDSFMQHDVQELCRVLLDNVENKMKGTCVEGTIPKLFRGKMVSYIQCKEVDYRSDRREDYYDIQLSIKGKKNIFESFVDYVAVEQLDGDNKYDAGEHGLQEAEKGVKFLTLPPVLHLQLMRFMYDPQTDQNIKINDRFEFPEQLPLDEFLQKTDPKDPANYILHAVLVHSGDNHGGHYVVYLNPKGDGKWCKFDDDVVSRCTKEEAIEHNYGGHDDDLSVRHCTNAYMLVYIRESKLSEVLQAVTDHDIPQQLVERLQEEKRIEAQKRKERQE","Homo sapiens","USP7, HAUSP","Ubiquitin carboxyl-terminal hydrolase 7","1","5NGF"
"5NGR",,"X-RAY DIFFRACTION",2.29,46.19,"VAPOR DIFFUSION, SITTING DROP",,"5 mmol/L compound and 6 mmol/L MgCl2 were added to MTH1. Sitting drop vapor diffusion experiments at 293K were performed, and MTH1 (9.34 mg/mL) was mixed with reservoir solution (30% (w/v) PEG6000, 0.1 mol/L Sodium Acetate pH 3.7 and 0.2 mol/L LiSO4 in a 1:1 ratio.",293,"10.1021/acs.jmedchem.7b01006","8WT","5NGR",37.45,"2.2","2.2","Crystal structure of human MTH1 in complex with fragment inhibitor 8-(methylsulfanyl)-7H-purin-6-amine","GSHMGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-dihydro-8-oxoguanine triphosphatase","1","5NGR"
"5NGS",,"X-RAY DIFFRACTION",2.29,46.19,"VAPOR DIFFUSION, SITTING DROP",,"5 mmol/L compound and 6 mmol/L MgCl2 were added to MTH1. Sitting drop vapor diffusion experiments at 293K were performed, and MTH1 (9.34 mg/mL) was mixed with reservoir solution (28% (w/v) PEG8000, 0.1 mol/L Sodium Acetate pH 4.0 and 0.2 mol/L LiSO4) in a 3:5 ratio.",293,"10.1021/acs.jmedchem.7b01006","8WW","5NGS",37.97,"1.85","1.85","Crystal structure of human MTH1 in complex with inhibitor 6-[(2-phenylethyl)sulfanyl]-7H-purin-2-amine","GSHMGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-dihydro-8-oxoguanine triphosphatase","1","5NGS"
"5NGT",,"X-RAY DIFFRACTION",2.01,38.83,"VAPOR DIFFUSION, SITTING DROP",,"5 mmol/L compound and 6 mmol/L MgCl2 were added to MTH1. Sitting drop vapor diffusion experiments at 293K were performed, and MTH1 (9.34 mg/mL) was mixed with reservoir solution (32% (w/v) PEG3350, 0.1 mol/L Sodium Acetate pH 4.0 and 0.2 mol/L LiSO4) in a 1:1 ratio.",293,"10.1021/acs.jmedchem.7b01006",,"5NGT",18.66,"1.54","1.54","Crystal structure of human MTH1 in complex with inhibitor 7-(furan-2-yl)-5-methyl-1,3-benzoxazol-2-amine","GSHMGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-dihydro-8-oxoguanine triphosphatase","1","5NGT"
"5NGU",,"X-RAY DIFFRACTION",2.25,45.4,"VAPOR DIFFUSION",,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",293,"10.1021/acs.jmedchem.7b00267","8X2","5NGU",44.58,"2.74","2.74","Human Erk2 with an Erk1/2 inhibitor","MHHHHHHGGGENLYFQGSHMAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRSLE","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5NGU"
"5NGZ",,"X-RAY DIFFRACTION",3.2,61.55,"VAPOR DIFFUSION, SITTING DROP",,"potassium acetate, Tris-HCl pH 8.5",293,"10.1021/acs.jmedchem.7b00147","2BG","5NGZ",22.72,"2.4","2.4","Ube2T in complex with fragment EM04","MQRASRLKRELHMLATEPPPGITCWQDKDQMDDLRAQILGGANTPYEKGVFKLEVIIPERYPFEPPQIRFLTPIYHPNIDSAGRICLDVLKLPPKGAWRPSLNIATVLTSIQLLMSEPNPDDPLMADISSEFKYNKPAFLKNARQWTEKHARQKQKADEEEMLDNLPEAGDSRVHNSTQKRKASQLVGIEKKFHPDV","Homo sapiens","UBE2T, HSPC150, PIG50","Ubiquitin-conjugating enzyme E2 T","1","5NGZ"
"5NH1",,"X-RAY DIFFRACTION",2.56,51.98,"VAPOR DIFFUSION, SITTING DROP",,"1.229 M NaCitrate, HEPES, pH 7.25",303,,,"5NH1",22.17,"2.04","2.04","Structure of the C-terminal domain of human Gasdermin D","PAEGAFTEDFQGLRAEVETISKELELLDRELCQLLLEGLEGVLRDQLALRALEEALEQGQSLGPVEPLDGPAGAVLECLVLSSGMLVPELAIPVVYLLGALTMLSETQHKLLAEALESQTLLGPLELVGSLLEQSAPWQERSTMSLPPGLLGNSWGEGAPAWVLLDECGLELGEDTPHVCWEPQAQGRMCALYASLALLSGLSQEPH","Homo sapiens","GSDMD, DFNA5L, GSDMDC1, FKSG10","Gasdermin-D","1","5NH1"
"5NHF",,"X-RAY DIFFRACTION",2.22,44.68,"VAPOR DIFFUSION, HANGING DROP",,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",298,"10.1021/acs.jmedchem.7b00267","8X5","5NHF",44.48,"2.14","2.14","Human Erk2 with an Erk1/2 inhibitor","MHHHHHHGGGENLYFQGSHMAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRSLE","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5NHF"
"5NHG",,"X-RAY DIFFRACTION",2.28,46.06,"VAPOR DIFFUSION, SITTING DROP",7.45,"0.1 M Bis-Tris (pH 7.45), 0.2 M MgCl2, 25 (w/v)% PEG 3350",293,"10.1016/j.freeradbiomed.2018.06.008",,"5NHG",427.4,"2.27","2.27","Crystal structure of the human dihydrolipoamide dehydrogenase","ASWSHPQFEKGALEVLFQGPGADQPIDADVTVIGSGPGGYVAAIKAAQLGFKTVCIEKNETLGGTCLNVGCIPSKALLNNSHYYHMAHGKDFASRGIEMSEVRLNLDKMMEQKSTAVKALTGGIAHLFKQNKVVHVNGYGKITGKNQVTATKADGGTQVIDTKNILIATGSEVTPFPGITIDEDTIVSSTGALSLKKVPEKMVVIGAGVIGVELGSVWQRLGADVTAVEFLGHVGGVGIDMEISKNFQRILQKQGFKFKLNTKVTGATKKSDGKIDVSIEAASGGKAEVITCDVLLVCIGRRPFTKNLGLEELGIELDPRGRIPVNTRFQTKIPNIYAIGDVVAGPMLAHKAEDEGIICVEGMAGGAVHIDYNCVPSVIYTHPEVAWVGKSEEQLKEEGIEYKVGKFPFAANSRAKTNADTDGMVKILGQKSTDRVLGAHILGPGAGEMVNEAALALEYGASCEDIARVCHAHPTLSEAFREANLAASFGKSINF","Homo sapiens","DLD, GCSL, LAD, PHE3","Dihydrolipoyl dehydrogenase, mitochondrial","1","5NHG"
"5NHH",,"X-RAY DIFFRACTION",2.24,45.03,"VAPOR DIFFUSION, HANGING DROP",,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",298,"10.1021/acs.jmedchem.7b00267","8XH","5NHH",44.57,"1.94","1.94","Human Erk2 with an Erk1/2 inhibitor","MHHHHHHGGGENLYFQGSHMAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRSLE","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5NHH"
"5NHJ",,"X-RAY DIFFRACTION",2.26,45.6,"VAPOR DIFFUSION, HANGING DROP",,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",298,"10.1021/acs.jmedchem.7b00267","8XE","5NHJ",44.47,"2.12","2.12","Human Erk2 with an Erk1/2 inhibitor","MHHHHHHGGGENLYFQGSHMAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRSLE","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5NHJ"
"5NHL",,"X-RAY DIFFRACTION",2.27,45.76,"VAPOR DIFFUSION, HANGING DROP",,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",298,"10.1021/acs.jmedchem.7b00267","8XB","5NHL",44.4,"2.07","2.07","Human Erk2 with an Erk1/2 inhibitor","MHHHHHHGGGENLYFQGSHMAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRSLE","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5NHL"
"5NHO",,"X-RAY DIFFRACTION",2.28,46.05,"VAPOR DIFFUSION, HANGING DROP",,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",298,"10.1021/acs.jmedchem.7b00267","8XN","5NHO",44.4,"2.24","2.24","Human Erk2 with an Erk1/2 inhibitor","MHHHHHHGGGENLYFQGSHMAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRSLE","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5NHO"
"5NHP",,"X-RAY DIFFRACTION",2.52,51.1,"VAPOR DIFFUSION, HANGING DROP",,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",298,"10.1021/acs.jmedchem.7b00267","8XK","5NHP",44.48,"1.99","1.99","Human Erk2 with an Erk1/2 inhibitor","MHHHHHHGGGENLYFQGSHMAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRSLE","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5NHP"
"5NHV",,"X-RAY DIFFRACTION",2.25,45.23,"VAPOR DIFFUSION, HANGING DROP",,"30% PegMME2K, 100mM HEPES pH 7.6, 200mM Ammonium sulfate",298,"10.1021/acs.jmedchem.7b00267","8QB","5NHV",44.32,"2","2","Human Erk2 with an Erk1/2 inhibitor","MHHHHHHGGGENLYFQGSHMAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRSLE","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5NHV"
"5NHW",,"X-RAY DIFFRACTION",2.35,47.61,"VAPOR DIFFUSION",8,"18% PEG 5000 MME, 50mM TRIS",293,"10.1073/pnas.1707925114",,"5NHW",48.19,"1.78","1.78","CRYSTAL STRUCTURE OF THE BIMAGRUMAB Fab","QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSEFDYKDDDDKGAPHHHHHH","Homo sapiens",,"anti-human ActRII Bimagrumab Fab heavy-chain","1","5NHW"
,,,,,,,,,,,,,,,,"QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEA","Homo sapiens",,"anti-human ActRII Bimagrumab Fab light-chain","2","5NHW"
"5NHY",,"X-RAY DIFFRACTION",2.24,45.12,"VAPOR DIFFUSION, SITTING DROP",,"22.7% PEG4000, 0.24 ammonium sulfate, 15% glycerol",277,"10.1021/acschembio.7b00370","8XT","5NHY",38.03,"1.72","1.72","BAY-707 in complex with MTH1","GSHMGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-dihydro-8-oxoguanine triphosphatase","1","5NHY"
"5NI2",,"X-RAY DIFFRACTION",2.8,56.1,"LIQUID DIFFUSION",6.7,"22% (w/v) PEG 8000, 100 mM imidazole pH 6.7, 5 mM YbCl3",277,"10.1073/pnas.1710850114",,"5NI2",70.86,"1.501","1.501","Crystal structure of human LTA4H mutant E271A in complex with LTA4 (crystal form I)","MHHHHHHPEIVDTCSLASPASVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGSPMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIRDGETPDPEDPSRKIYKFIQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFSETESMLKIAEDLGGPYVWGQYDLLVLPPSFPYGGMANPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVYLERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPDVAYSSVPYEKGFALLFYLEQLLGGPEIFLGFLKAYVEKFSYKSITTDDWKDFLYSYFKDKVDVLNQVDWNAWLYSPGLPPIKPNYDMTLTNACIALSQRWITAKEDDLNSFNATDLKDLSSHQLNEFLAQTLQRAPLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKMATEQGRMKFTRPLFKDLAAFDKSHDQAVRTYQEHKASMHPVTAMLVGKDLKVD","Homo sapiens","LTA4H, LTA4","Leukotriene A-4 hydrolase","1","5NI2"
"5NI4",,"X-RAY DIFFRACTION",2.39,48.57,"VAPOR DIFFUSION, HANGING DROP",,"8% (w/v) PEG 20 000, 15% (w/v) PEG MME 550, 100 mM MES/imidazole pH 6.9, 20 mM of each alcohol (1,6-hexanediol, 1-butanol, (RS)-1,2-propanediol, 2-propanol, 1,4-butanediol, 1,3-propanediol)",294,"10.1073/pnas.1710850114",,"5NI4",212.04,"1.895","1.895","Crystal structure of human LTA4H mutant E271A in complex with LTA4 (crystal form II)","MHHHHHHPEIVDTCSLASPASVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGSPMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIRDGETPDPEDPSRKIYKFIQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFSETESMLKIAEDLGGPYVWGQYDLLVLPPSFPYGGMANPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVYLERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPDVAYSSVPYEKGFALLFYLEQLLGGPEIFLGFLKAYVEKFSYKSITTDDWKDFLYSYFKDKVDVLNQVDWNAWLYSPGLPPIKPNYDMTLTNACIALSQRWITAKEDDLNSFNATDLKDLSSHQLNEFLAQTLQRAPLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKMATEQGRMKFTRPLFKDLAAFDKSHDQAVRTYQEHKASMHPVTAMLVGKDLKVD","Homo sapiens","LTA4H, LTA4","Leukotriene A-4 hydrolase","1","5NI4"
"5NI6",,"X-RAY DIFFRACTION",2.46,50,"LIQUID DIFFUSION",7,"22% (w/v) PEG 8000, 100 mM imidazole pH 7.0, 100 mM sodium acetate, 5 mM YbCl3",277,"10.1073/pnas.1710850114",,"5NI6",71.04,"1.54","1.54","Crystal structure of human LTA4H mutant D375N in complex with LTA4","MHHHHHHPEIVDTCSLASPASVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGSPMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIRDGETPDPEDPSRKIYKFIQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFSETESMLKIAEDLGGPYVWGQYDLLVLPPSFPYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVYLERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPNVAYSSVPYEKGFALLFYLEQLLGGPEIFLGFLKAYVEKFSYKSITTDDWKDFLYSYFKDKVDVLNQVDWNAWLYSPGLPPIKPNYDMTLTNACIALSQRWITAKEDDLNSFNATDLKDLSSHQLNEFLAQTLQRAPLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKMATEQGRMKFTRPLFKDLAAFDKSHDQAVRTYQEHKASMHPVTAMLVGKDLKVD","Homo sapiens","LTA4H, LTA4","Leukotriene A-4 hydrolase","1","5NI6"
"5NIA",,"X-RAY DIFFRACTION",2.46,50,"VAPOR DIFFUSION, HANGING DROP",,"8% (w/v) PEG 20 000, 15% (w/v) PEG MME 550, 100 mM Hepes/MOPS pH 7.7-8.0, 15 mM CaCl2, 15 mM MgCl2",294,"10.1073/pnas.1710850114",,"5NIA",70.26,"1.764","1.764","Crystal structure of human LTA4H mutant D375N in open conformation (crystal form I)","MHHHHHHPEIVDTCSLASPASVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGSPMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIRDGETPDPEDPSRKIYKFIQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFSETESMLKIAEDLGGPYVWGQYDLLVLPPSFPYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVYLERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPNVAYSSVPYEKGFALLFYLEQLLGGPEIFLGFLKAYVEKFSYKSITTDDWKDFLYSYFKDKVDVLNQVDWNAWLYSPGLPPIKPNYDMTLTNACIALSQRWITAKEDDLNSFNATDLKDLSSHQLNEFLAQTLQRAPLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKMATEQGRMKFTRPLFKDLAAFDKSHDQAVRTYQEHKASMHPVTAMLVGKDLKVD","Homo sapiens","LTA4H, LTA4","Leukotriene A-4 hydrolase","1","5NIA"
"5NID",,"X-RAY DIFFRACTION",2.56,52,"VAPOR DIFFUSION, HANGING DROP",,"8% (w/v) PEG 20 000, 15% (w/v) PEG MME 550, 100 mM Hepes/MOPS pH 7.7-8.0, 15 mM CaCl2, 15 mM MgCl2",294,"10.1073/pnas.1710850114",,"5NID",70.26,"1.568","1.568","Crystal structure of human LTA4H mutant D375N in open conformation (crystal form II)","MHHHHHHPEIVDTCSLASPASVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGSPMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIRDGETPDPEDPSRKIYKFIQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFSETESMLKIAEDLGGPYVWGQYDLLVLPPSFPYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVYLERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPNVAYSSVPYEKGFALLFYLEQLLGGPEIFLGFLKAYVEKFSYKSITTDDWKDFLYSYFKDKVDVLNQVDWNAWLYSPGLPPIKPNYDMTLTNACIALSQRWITAKEDDLNSFNATDLKDLSSHQLNEFLAQTLQRAPLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKMATEQGRMKFTRPLFKDLAAFDKSHDQAVRTYQEHKASMHPVTAMLVGKDLKVD","Homo sapiens","LTA4H, LTA4","Leukotriene A-4 hydrolase","1","5NID"
"5NIE",,"X-RAY DIFFRACTION",2.69,54.3,"VAPOR DIFFUSION, SITTING DROP",6,"20% (w/v) PEG MME 5000, 100 mM MES monohydrate pH 6.0, 150 mM Ammonium Sulfate",294,"10.1073/pnas.1710850114",,"5NIE",210.52,"2.603","2.603","Crystal structure of human LTA4H mutant R563A in open conformation","MHHHHHHPEIVDTCSLASPASVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGSPMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIRDGETPDPEDPSRKIYKFIQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFSETESMLKIAEDLGGPYVWGQYDLLVLPPSFPYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVYLERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPDVAYSSVPYEKGFALLFYLEQLLGGPEIFLGFLKAYVEKFSYKSITTDDWKDFLYSYFKDKVDVLNQVDWNAWLYSPGLPPIKPNYDMTLTNACIALSQRWITAKEDDLNSFNATDLKDLSSHQLNEFLAQTLQRAPLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKMATEQGAMKFTRPLFKDLAAFDKSHDQAVRTYQEHKASMHPVTAMLVGKDLKVD","Homo sapiens","LTA4H, LTA4","Leukotriene A-4 hydrolase","1","5NIE"
"5NIR",,"X-RAY DIFFRACTION",2.83,56.49,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES, pH 7.5, 40% PEG 200",293,"10.1074/jbc.M117.788992",,"5NIR",18.57,"1.74","1.74","Crystal structure of collagen 2A vWC domain","GSMAQEAGSCVQDGQRYNDKDVWKPEPCRICVCDTGTVLCDDIICEDVKDCLSPEIPFGECCPICPTDLATASG","Homo sapiens","COL2A1","Collagen alpha-1(II) chain","1","5NIR"
"5NIU",,"X-RAY DIFFRACTION",2.39,48.46,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris pH 8.5 containing 0.2 M magnesium chloride and 30% (w/v) PEG 4000",298,"10.18632/oncotarget.20050","8YZ","5NIU",60.03,"2.01","2.01","Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor","AFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYAAALEHHHHHH","Homo sapiens","CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1","Programmed cell death 1 ligand 1","1","5NIU"
"5NJE",,"X-RAY DIFFRACTION",2.03,39.39,"VAPOR DIFFUSION",,"200 mM K/Na Tartrate, 10-20 % PEG3350",298,"10.1038/s41598-019-50702-2",,"5NJE",27.58,"1.978","1.978","The structure of the polo-box domain (PBD) of polo-like kinase 1 (Plk1) in complex with Alpha-Bromo-3-Iodotoluene.","GAHMDCHLSDMLQQLHSVNASKPSERGLVRQEEAEDPACIPIFWVSKWVDYSDKYGLGYQLCDNSVGVLFNDSTRLILYNDGDSLQYIERDGTESYLTVSSHPNSLMKKITLLKYFRNYMSEHLLKAGANITPREGDELARLPYLRTWFRTRSAIILHLSNGSVQINFFQDHTKLILCPLMAAVTYIDEKRDFRTYRLSLLEEYGCCKELASRLRYARTMVDKLLSSRSASNRLKAS","Homo sapiens","PLK1, PLK","Serine/threonine-protein kinase PLK1","1","5NJE"
"5NJZ",,"X-RAY DIFFRACTION",1.95,36.96,"VAPOR DIFFUSION, SITTING DROP",7,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Hepes pH7.0",291,"10.1002/cmdc.201700217","8ZH","5NJZ",34.93,"1.768","1.768","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1g","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NJZ"
"5NK0",,"X-RAY DIFFRACTION",1.92,36.06,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.175 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291,"10.1002/cmdc.201700217",,"5NK0",34.93,"1.597","1.597","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1j","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NK0"
"5NK1",,"X-RAY DIFFRACTION",1.95,36.8,"VAPOR DIFFUSION, SITTING DROP",6,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Bis-Tris pH6.0",291,"10.1002/cmdc.201700217",,"5NK1",34.96,"1.548","1.548","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1k","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NK1"
"5NK2",,"X-RAY DIFFRACTION",1.97,37.68,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.3 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291,"10.1002/cmdc.201700217","8ZZ","5NK2",35.01,"1.649","1.649","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2b","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NK2"
"5NK3",,"X-RAY DIFFRACTION",1.85,33.34,"VAPOR DIFFUSION, SITTING DROP",6,"37.5% MPD/PEG1000/PEG3350 (MD), 0.3 M Amino Acids Mix (MD), 0.1 M MES pH6.0",291,"10.1002/cmdc.201700217","92Q","5NK3",34.98,"1.586","1.586","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1l","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NK3"
"5NK4",,"X-RAY DIFFRACTION",1.97,37.58,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.275 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291,"10.1002/cmdc.201700217","90E","5NK4",35.03,"1.45","1.45","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2c","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NK4"
"5NK5",,"X-RAY DIFFRACTION",1.97,37.59,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.2 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291,"10.1002/cmdc.201700217",,"5NK5",34.94,"1.329","1.329","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 1m","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NK5"
"5NK6",,"X-RAY DIFFRACTION",1.98,37.8,"VAPOR DIFFUSION, SITTING DROP",5.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Bis-Tris pH5.5",291,"10.1002/cmdc.201700217","90W","5NK6",34.95,"1.267","1.267","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2d","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NK6"
"5NK7",,"X-RAY DIFFRACTION",1.97,37.49,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.25 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291,"10.1002/cmdc.201700217","8ZZ","5NK7",34.95,"1.889","1.889","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2a","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NK7"
"5NK8",,"X-RAY DIFFRACTION",1.93,36.23,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.075 M Carboxylic Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291,"10.1002/cmdc.201700217","90Z","5NK8",35,"1.761","1.761","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2f","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NK8"
"5NK9",,"X-RAY DIFFRACTION",1.96,37.36,"VAPOR DIFFUSION, SITTING DROP",6.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Hepes pH6.5",291,"10.1002/cmdc.201700217","912","5NK9",34.96,"1.588","1.588","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2e","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NK9"
"5NKA",,"X-RAY DIFFRACTION",1.99,38.23,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.25 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291,"10.1002/cmdc.201700217","91H","5NKA",35.04,"1.377","1.377","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2g","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NKA"
"5NKB",,"X-RAY DIFFRACTION",1.97,37.43,"VAPOR DIFFUSION, SITTING DROP",6.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Hepes pH6.5",291,"10.1002/cmdc.201700217","8ZT","5NKB",35.1,"1.5","1.5","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 4a","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NKB"
"5NKC",,"X-RAY DIFFRACTION",1.97,37.49,"VAPOR DIFFUSION, SITTING DROP",6,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M MES pH6.0",291,"10.1002/cmdc.201700217","90T","5NKC",35.01,"1.448","1.448","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2h","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NKC"
"5NKD",,"X-RAY DIFFRACTION",1.96,37.22,"VAPOR DIFFUSION, SITTING DROP",6.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Hepes pH6.5",291,"10.1002/cmdc.201700217","91K","5NKD",35.02,"1.408","1.408","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 2i","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NKD"
"5NKE",,"X-RAY DIFFRACTION",1.98,37.72,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.3 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291,"10.1002/cmdc.201700217",,"5NKE",35.01,"1.39","1.39","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3a","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NKE"
"5NKF",,"X-RAY DIFFRACTION",1.96,37.39,"VAPOR DIFFUSION, SITTING DROP",6,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Bis-Tris pH6.0",291,"10.1002/cmdc.201700217",,"5NKF",35,"1.099","1.099","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3b","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NKF"
"5NKG",,"X-RAY DIFFRACTION",1.95,36.96,"VAPOR DIFFUSION, SITTING DROP",6.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Tris pH6.5",291,"10.1002/cmdc.201700217","8ZK","5NKG",34.96,"1.1","1.1","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3d","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NKG"
"5NKH",,"X-RAY DIFFRACTION",1.96,37.29,"VAPOR DIFFUSION, SITTING DROP",8.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Buffer System 3 (MD) pH8.5",291,"10.1002/cmdc.201700217","8ZQ","5NKH",35.02,"1.29","1.29","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 3e","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NKH"
"5NKI",,"X-RAY DIFFRACTION",1.94,36.45,"VAPOR DIFFUSION, SITTING DROP",6.5,"37.5% MPD/PEG1000/PEG3350 (MD), 0.1 M Amino Acids Mix (MD), 0.1 M Hepes pH6.5",291,"10.1002/cmdc.201700217","8ZW","5NKI",34.97,"1.675","1.675","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with Compound 4b","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NKI"
"5NKN",,"X-RAY DIFFRACTION",1.89,34.76,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.2 M (NH4)2SO4, 200 mM Li2SO4, 100 mM Tris/HCl",293,"10.1515/hsz-2018-0342","LOC","5NKN",20.34,"2.2","2.2","Crystal structure of an Anticalin-colchicine complex","SDLIPAPPLSKVPLQQNFQDNQFHGKWYVVGVAGNGFLREDKDPIKMAATIYELKEDKSYNVTFQKFPMKKCQYMTDTLVPGSQPGEFTLGNIKSEPGYTSWLVRVVSTNYNQHAMVFFKAVQQNREDFFITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDG","Homo sapiens","LCN2, HNL, NGAL","Neutrophil gelatinase-associated lipocalin","1","5NKN"
"5NKS",,"X-RAY DIFFRACTION",1.95,36.82,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Bis-tris-propane
0.2 M Sodium fluoride
10% Ethylene glycol
20% PEG3350",277,,,"5NKS",62.04,"1.8","1.8","Human Dihydropyrimidinase-related Protein 4 (DPYSL4, CRMP3, ULIP-4)","SMSFQGKKSIPRITSDRLLIRGGRIVNDDQSFYADVHVEDGLIKQIGENLIVPGGIKTIDAHGLMVLPGGVDVHTRLQMPVLGMTPADDFCQGTKAALAGGTTMILDHVFPDTGVSLLAAYEQWRERADSAACCDYSLHVDITRWHESIKEELEALVKEKGVNSFLVFMAYKDRCQCSDSQMYEIFSIIRDLGALAQVHAENGDIVEEEQKRLLELGITGPEGHVLSHPEEVEAEAVYRAVTIAKQANCPLYVTKVMSKGAADAIAQAKRRGVVVFGEPITASLGTDGSHYWSKNWAKAAAFVTSPPVNPDPTTADHLTCLLSSGDLQVTGSAHCTFTTAQKAVGKDNFALIPEGTNGIEERMSMVWEKCVASGKMDENEFVAVTSTNAAKIFNFYPRKGRVAVGSDADLVIWNPKATKIISAKTHNLNVEYNIFEGVECRGAPAVVISQGRVALEDGKMFVTPGAGRFVPRKTFPDFVYKRIKARNRLAEIHGVPRGLYDGPVHEVMVPAKPGSGAPARASCPGKISVPPVRNLHQSGFSLSGSQADDHIARRTAQKIMAPPGGRSNITSLS","Homo sapiens","DPYSL4, CRMP3, ULIP4","Dihydropyrimidinase-related protein 4","1","5NKS"
"5NL4",,"X-RAY DIFFRACTION",2,39,"VAPOR DIFFUSION, HANGING DROP",,"22-30% (w/v) PEG 1450, 50 mM HEPES pH 6.5-7.0, 35 mM Zn(CH3COO)2",293,"10.1002/chem.201705543",,"5NL4",26.63,"1.32","1.32","Crystal structure of Zn1.3-E16V human ubiquitin (hUb) mutant adduct, from a solution 35 mM zinc acetate/1.3 mM E16V hUb","MQIFVKTLTGKTITLVVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBC","Polyubiquitin-C","1","5NL4"
"5NL5",,"X-RAY DIFFRACTION",2,39,"VAPOR DIFFUSION, HANGING DROP",,"22-30% (w/v) PEG 1450, 50 mM HEPES pH 6.5-7.0, 70 mM Zn(CH3COO)2",293,"10.1002/chem.201705543",,"5NL5",26.39,"1.96","1.96","Crystal structure of Zn1.7-E16V human ubiquitin (hUb) mutant adduct, from a solution 70 mM zinc acetate/1.3 mM E16V hUb","MQIFVKTLTGKTITLVVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBB","Polyubiquitin-B","1","5NL5"
"5NLF",,"X-RAY DIFFRACTION",2,39,"VAPOR DIFFUSION, HANGING DROP",,"22-30% (w/v) PEG 1450, 50 mM HEPES, 100 mM Zn(CH3COO)2",293,"10.1002/chem.201705543",,"5NLF",26.59,"1.5","1.5","Crystal structure of Zn2.7-E16V human ubiquitin (hUb) mutant adduct, from a solution 100 mM zinc acetate/1.3 mM E16V hUb","MQIFVKTLTGKTITLVVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBC","Polyubiquitin-C","1","5NLF"
"5NLI",,"X-RAY DIFFRACTION",2,39,"VAPOR DIFFUSION, HANGING DROP",,"22-30% (w/v) PEG 1450, 50 mM HEPES, 35 mM Zn(CH3COO)2 and 10% v/v TFE",293,"10.1002/chem.201705543",,"5NLI",26.55,"1.53","1.53","Crystal structure of Zn2-E16V human ubiquitin (hUb) mutant adduct, from a solution 35 mM zinc acetate/10% v/v TFE/1.3 mM E16V hUb","MQIFVKTLTGKTITLVVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBC","Polyubiquitin-C","1","5NLI"
"5NLJ",,"X-RAY DIFFRACTION",2,39,"VAPOR DIFFUSION, HANGING DROP",,"22-30% (w/v) PEG 1450, 50 mM HEPES, 70 mM Zn(CH3COO)2 and 20% v/v TFE.",293,"10.1002/chem.201705543",,"5NLJ",26.85,"1.53","1.53","Crystal structure of Zn3-E16V human ubiquitin (hUb) mutant adduct, from a solution 70 mM zinc acetate/20% v/v TFE/1.3 mM E16V hUb","MQIFVKTLTGKTITLVVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBB","Polyubiquitin-B","1","5NLJ"
"5NLK",,"X-RAY DIFFRACTION",2.34,47.52,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Buffer System 3, pH8.5, 37.50% v/v MPD_P1K_P3350, 0.09 M NPS",277,"10.1021/acscentsci.7b00401","92E","5NLK",14.67,"1.8","1.8","Crystal structure of CREBBP bromodomain complexd with US13A","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5NLK"
"5NLV",,"X-RAY DIFFRACTION",3,58.98,"VAPOR DIFFUSION, HANGING DROP",8,"15% PEG3350, 300mM NaCl",298,"10.1073/pnas.1707970114",,"5NLV",47.46,"2.4","2.4","Brag2 Sec7-PH (390-763)","MSYYHHHHHHDYDIPTTENLYFQGAMGAIPMSWDSPAFSNDVIRKRHYRIGLNLFNKKPEKGVQYLIERGFVPDTPVGVAHFLLQRKGLSRQMIGEFLGNRQKQFNRDVLDCVVDEMDFSTMELDEALRKFQAHIRVQGEAQKVERLIEAFSQRYCICNPGVVRQFRNPDTIFILAFAIILLNTDMYSPNVKPERKMKLEDFIKNLRGVDDGEDIPREMLMGIYERIRKRELKTNEDHVSQVQKVEKLIVGKKPIGSLHPGLGCVLSLPHRRLVCYCRLFEVPDPNKPQKLGLHQREIFLFNDLLVVTKIFQKKKNSVTYSFRQSFSLYGMQVLLFENQYYPNGIRLTSSVPGADIKVLINFNAPNPQDRKKFTDDLRESIAEVQEMEKHRIESELEKQKGVVRP","Homo sapiens","IQSEC1, ARFGEP100, BRAG2, KIAA0763","IQ motif and SEC7 domain-containing protein 1","1","5NLV"
"5NLY",,"X-RAY DIFFRACTION",2.62,53.14,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG20000, O.1M Tris pH=8.5",293,"10.1073/pnas.1707970114",,"5NLY",95.57,"2","2","Brag2 Sec7-PH (390-763), P212121","MSYYHHHHHHDYDIPTTENLYFQGAMGSEFMSWDSPAFSNDVIRKRHYRIGLNLFNKKPEKGVQYLIERGFVPDTPVGVAHFLLQRKGLSRQMIGEFLGNRQKQFNRDVLDCVVDEMDFSTMELDEALRKFQAHIRVQGEAQKVERLIEAFSQRYCICNPGVVRQFRNPDTIFILAFAIILLNTDMYSPNVKPERKMKLEDFIKNLRGVDDGEDIPREMLMGIYERIRKRELKTNEDHVSQVQKVEKLIVGKKPIGSLHPGLGCVLSLPHRRLVCYCRLFEVPDPNKPQKLGLHQREIFLFNDLLVVTKIFQKKKNSVTYSFRQSFSLYGMQVLLFENQYYPNGIRLTSSVPGADIKVLINFNAPNPQDRKKFTDDLRESIAEVQEMEKHRIESELEKQKGVVRP","Homo sapiens","IQSEC1, ARFGEP100, BRAG2, KIAA0763","IQ motif and SEC7 domain-containing protein 1","1","5NLY"
,,,,,,,,,,,,,,,,"MSYYHHHHHHDYDIPTTENLYFQGAMGSEFMSWDSPAFSNDVIRKRHYRIGLNLFNKKPEKGVQYLIERGFVPDTPVGVAHFLLQRKGLSRQMIGEFLGNRQKQFNRDVLDCVVDEMDFSTMELDEALRKFQAHIRVQGEAQKVERLIEAFSQRYCICNPGVVRQFRNPDTIFILAFAIILLNTDMYSPNVKPERKMKLEDFIKNLRGVDDGEDIPREMLMGIYERIRKRELKTNEDHVSQVQKVEKLIVGKKPIGSLHPGLGCVLSLPHRRLVCYCRLFEVPDPNKPQKLGLHQREIFLFNDLLVVTKIFQKKKNSVTYSFRQSFSLYGMQVLLFENQYYPNGIRLTSSVPGADIKVLINFNAPNPQDRKKFTDDLRESIAEVQEMEKHRIESELEKQKGVVRP","Homo sapiens","IQSEC1, ARFGEP100, BRAG2, KIAA0763","IQ motif and SEC7 domain-containing protein 1","2","5NLY"
"5NMC",,"X-RAY DIFFRACTION",2,39,"VAPOR DIFFUSION, HANGING DROP",,"22-30% (w/v) PEG 1450, 50 mM HEPES pH 6.5-7.0, 70 mM Zn(CH3COO)2 and 20% v/v TFE",293,"10.1002/chem.201705543",,"5NMC",26.61,"1.7","1.7","Crystal structure of Zn3-hUb(human ubiquitin) adduct from a solution 70 mM zinc acetate/20% v/v TFE/1.3 mM hUb","MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBC","Polyubiquitin-C","1","5NMC"
"5NMD",,"X-RAY DIFFRACTION",2.55,51.72,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Sodium Cacodylate, pH 6.5, 20% PEG 8000",291,"10.3389/fimmu.2017.01503",,"5NMD",100.06,"2.07","2.07","868 TCR Specific for HLA A02 presenting HIV Epitope SLYNTVATL","KEVEQNSGPLSVPEGAIASLNCTYSDRGSQSFFWYRQYSGKSPELIMFIYSNGDKEDGRFTAQLNKASQYISLLIRDSKLSDSATYLCAVRTNSGYALNFGKGTSLLVTPHIQKPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPS","Homo sapiens",,"human T-cell Receptor alpha chain","1","5NMD"
,,,,,,,,,,,,,,,,"DAGVTQSPTHLIKTRGQQVTLRCSPKQGHDTVSWYQQALGQGPQFIFQYYEEEERQRGNFPDRFSGHQFPNYSSELNVNALLLGDSALYLCASSDTVSYEQYFGPGTRLTVTEDLKNVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALSSRLRVSATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRAD","Homo sapiens",,"Human T-cell Receptor, beta chain","2","5NMD"
"5NMM",,"X-RAY DIFFRACTION",2.01,38.81,"VAPOR DIFFUSION",,"200 mM K/Na Tartrate, 20% PEG3350",293,,,"5NMM",27.58,"2.02","2.02","The structure of the polo-box domain (PBD) of Plk1 in complex with Alpha-Bromo-3-Iodotoluene.","GAHMDCHLSDMLQQLHSVNASKPSERGLVRQEEAEDPACIPIFWVSKWVDYSDKYGLGYQLCDNSVGVLFNDSTRLILYNDGDSLQYIERDGTESYLTVSSHPNSLMKKITLLKYFRNYMSEHLLKAGANITPREGDELARLPYLRTWFRTRSAIILHLSNGSVQINFFQDHTKLILCPLMAAVTYIDEKRDFRTYRLSLLEEYGCCKELASRLRYARTMVDKLLSSRSASNRLKAS","Homo sapiens","PLK1, PLK","Serine/threonine-protein kinase PLK1","1","5NMM"
"5NMN",,"X-RAY DIFFRACTION",1.96,37.33,"VAPOR DIFFUSION, SITTING DROP",7,"PEG3350, 100 mM Tris, pH 8",293,"10.1038/s41598-017-14206-1",,"5NMN",4.53,"0.95","0.95","Atomic resolution structure of LL-37 in a monomeric state","LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES","Homo sapiens","CAMP, CAP18, FALL39, HSD26","Cathelicidin antimicrobial peptide","1","5NMN"
"5NMZ",,"X-RAY DIFFRACTION",1.78,30.97,"VAPOR DIFFUSION, HANGING DROP",,"3 M Na formate, 0.1 M Bis Tris pH 6",293,"10.1074/jbc.RA117.000820",,"5NMZ",46.63,"1.6","1.6","human Neurturin (97-197)","RLGARPCGLRELEVRVSELGLGYASDETVLFRYCAGACEAAARVYDLGLRRLRQRRRLRRERVRAQPCCRPTAYEDEVSFLDAHSRYHTVHELSARECACV","Homo sapiens","NRTN","Neurturin","1","5NMZ"
"5NN0",,"X-RAY DIFFRACTION",3.18,61.33,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5
2.3 M Ammonium sulfate",293,"10.1021/acs.jmedchem.7b01086","92H","5NN0",64.49,"2.1","2.1","Crystal structure of huBChE with N-((1-(2,3-dihydro-1H-inden-2-yl)piperidin-3-yl)methyl)-N-(2-(dimethylamino)ethyl)-2-naphthamide.","EDDIIIATKNGKVRGMQLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDQYTKAEEILSRSIVKRWANFAKYGNPQETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKV","Homo sapiens","BCHE, CHE1","Cholinesterase","1","5NN0"
"5NN1",,"X-RAY DIFFRACTION",2.02,39.19,"VAPOR DIFFUSION",,"200 mM Na/K Tartrate, 10-20% PEG3350",298,,,"5NN1",27.29,"1.785","1.785","The structure of the polo-box domain (PBD) of polo-like kinase 1 (Plk1)","GAHMDCHLSDMLQQLHSVNASKPSERGLVRQEEAEDPACIPIFWVSKWVDYSDKYGLGYQLCDNSVGVLFNDSTRLILYNDGDSLQYIERDGTESYLTVSSHPNSLMKKITLLKYFRNYMSEHLLKAGANITPREGDELARLPYLRTWFRTRSAIILHLSNGSVQINFFQDHTKLILCPLMAAVTYIDEKRDFRTYRLSLLEEYGCCKELASRLRYARTMVDKLLSSRSASNRLKAS","Homo sapiens","PLK1, PLK","Serine/threonine-protein kinase PLK1","1","5NN1"
"5NN2",,"X-RAY DIFFRACTION",2.05,40.1,"VAPOR DIFFUSION",,"200 mM K/Na Tartrate, 10-20% PEG3350",293,,,"5NN2",27,"1.81","1.81","The structure of the polo-box domain (PBD) of Plk1 in complex with Z228588490","GPLGSPEFDCHLSDMLQQLHSVNASKPSERGLVRQEEAEDPACIPIFWVSKWVDYSDKYGLGYQLCDNSVGVLFNDSTRLILYNDGDSLQYIERDGTESYLTVSSHPNSLMKKITLLKYFRNYMSEHLLKAGANITPREGDELARLPYLRTWFRTRSAIILHLSNGSVQINFFQDHTKLILCPLMAAVTYIDEKRDFRTYRLSLLEEYGCCKELASRLRYARTMVDKLLSSR","Homo sapiens","PLK1, PLK","Serine/threonine-protein kinase PLK1","1","5NN2"
"5NN3",,"X-RAY DIFFRACTION",3.32,62.94,"VAPOR DIFFUSION, HANGING DROP",7,"1.9 M ammonium sulfate, 0.1 M HEPES pH 7.0, 2% v/v PEG400",293,"10.1038/s41467-017-01263-3",,"5NN3",101.29,"1.9","1.9","Crystal structure of human lysosomal acid-alpha-glucosidase, GAA","QCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPRVHSRAPSPLYSVEFSEEPFGVIVHRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPIEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC","Homo sapiens","GAA","Lysosomal alpha-glucosidase","1","5NN3"
"5NN4",,"X-RAY DIFFRACTION",3.39,63.73,"VAPOR DIFFUSION, HANGING DROP",7,"1.9 M ammonium sulphate, 0.1 M HEPES pH 7.0, 2% v/v PEG400",293,"10.1038/s41467-017-01263-3","SC2","5NN4",102.1,"1.83","1.83","Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with N-acetyl-cysteine","QCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPRVHSRAPSPLYSVEFSEEPFGVIVHRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPIEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC","Homo sapiens","GAA","Lysosomal alpha-glucosidase","1","5NN4"
"5NN5",,"X-RAY DIFFRACTION",3.39,63.73,"VAPOR DIFFUSION, HANGING DROP",7,"1.9 M ammonium sulphate, 0.1 M HEPES pH 7.0, 2% v/v PEG400",293,"10.1038/s41467-017-01263-3","NOJ","5NN5",101.07,"2","2","Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with 1-deoxynojirimycin","QCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPRVHSRAPSPLYSVEFSEEPFGVIVHRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPIEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC","Homo sapiens","GAA","Lysosomal alpha-glucosidase","1","5NN5"
"5NN6",,"X-RAY DIFFRACTION",3.39,63.73,"VAPOR DIFFUSION, HANGING DROP",7,"1.9 M ammonium sulphate, 0.1 M HEPES pH 7.0, 2% v/v PEG400",293,"10.1038/s41467-017-01263-3","MIG","5NN6",101.83,"2","2","Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with N-hydroxyethyl-1-deoxynojirimycin","QCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPRVHSRAPSPLYSVEFSEEPFGVIVHRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPIEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC","Homo sapiens","GAA","Lysosomal alpha-glucosidase","1","5NN6"
"5NN8",,"X-RAY DIFFRACTION",3.39,63.73,"VAPOR DIFFUSION, HANGING DROP",7,"1.9 M ammonium sulphate, 0.1 M HEPES pH 7.0, 2% v/v PEG400",293,"10.1038/s41467-017-01263-3",,"5NN8",102.41,"2.45","2.45","Crystal structure of human lysosomal acid-alpha-glucosidase, GAA, in complex with acarbose","QCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPRVHSRAPSPLYSVEFSEEPFGVIVHRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLDVVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTFNKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPLIGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNNELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPFVISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEELCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQAHVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQTVPIEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTESRQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEGAGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC","Homo sapiens","GAA","Lysosomal alpha-glucosidase","1","5NN8"
"5NNK",,"X-RAY DIFFRACTION",2.86,56.96,"VAPOR DIFFUSION, SITTING DROP",7,"30% Peg400, 100 mM Hepes, pH 7",298,"10.1038/s41598-017-14206-1",,"5NNK",5.19,"1.798","1.798","The structure of LL-37 crystallized in the presence LDAO","LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES","Homo sapiens","CAMP, CAP18, FALL39, HSD26","Cathelicidin antimicrobial peptide","1","5NNK"
"5NNM",,"X-RAY DIFFRACTION",2.8,56.02,"VAPOR DIFFUSION, SITTING DROP",,"15% Peg400, 0.1 M Tris, pH 8",298,"10.1038/s41598-017-14206-1",,"5NNM",9.25,"1.9","1.9","The crystal structure of dimeric LL-37","LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES","Homo sapiens","CAMP, CAP18, FALL39, HSD26","Cathelicidin antimicrobial peptide","1","5NNM"
"5NNT",,"X-RAY DIFFRACTION",2.32,47.05,"VAPOR DIFFUSION, SITTING DROP",,"30% PEGMME 3350, 100 mM Tris, ph 8",298,"10.1038/s41598-017-14206-1",,"5NNT",9.71,"2.209","2.209","The dimeric structure of LL-37 crystallized in DPC","LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES","Homo sapiens","CAMP, CAP18, FALL39, HSD26","Cathelicidin antimicrobial peptide","1","5NNT"
"5NNZ",,"X-RAY DIFFRACTION",2.02,39.09,"EVAPORATION",8,"50mM Tris pH 8 and 50mM NaOxalate",285,"10.1002/pro.3864",,"5NNZ",91.66,"2.651","2.651","Crystal structure of human ODA16","MKLKSLLLRYYPPGIMLEYEKHGELKTKSIDLLDLGPSTDVSALVEEIQKAEPLLTASRTEQVKLLIQRLQEKLGQNSNHTFYLFKVLKAHILPLTNVALNKSGSCFITGSYDRTCKLWDTASGEELNTLEGHRNVVYAIAFNNPYGDKIATGSFDKTCKLWSVETGKCYHTFRGHTAEIVCLSFNPQSTLVATGSMDTTAKLWDIQNGEEVYTLRGHSAEIISLSFNTSGDRIITGSFDHTVVVWDADTGRKVNILIGHCAEISSASFNWDCSLILTGSMDKTCKLWDATNGKCVATLTGHDDEILDSCFDYTGKLIATASADGTARIFSAATRKCIAKLEGHEGEISKISFNPQGNHLLTGSSDKTARIWDAQTGQCLQVLEGHTDEIFSCAFNYKGNIVITGSKDNTCRIWR","Homo sapiens","DAW1, WDR69","Dynein assembly factor with WDR repeat domains 1","1","5NNZ"
"5NO0",,"X-RAY DIFFRACTION",3.04,59.52,"VAPOR DIFFUSION",,"0.2 M sodium chloride, 20% w/v polyethylene glycol 3,350",293.15,"10.1371/journal.pone.0184932",,"5NO0",12.06,"1.57","1.57","Beta domain of human transcobalamin in apo form","GVDHMQTQEIISVTLQVLSLLPPYRQSISVLAGSTVEDVLKKAHELGGFTYETQASLSGPYLTSVMGKAAGEREFWQLLRDPNTPLLQGIADYRPKDGETIELRLVSW","Homo sapiens","TCN2, TC2","Transcobalamin-2","1","5NO0"
"5NOB",,"X-RAY DIFFRACTION",2.25,45.27,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2M TMAO, 0.1M Tris, 20% PEG 2000 MME",277,"10.1021/acs.jmedchem.7b00883","92T","5NOB",55.67,"1.85","1.85","Crystal structure of human tankyrase 2 in complex with OD336","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5NOB"
"5NOI",,"X-RAY DIFFRACTION",3.19,65.26,"VAPOR DIFFUSION, HANGING DROP",,"1.1M NaCl, 11-13% PEG 6000",277,"10.1016/j.jmb.2017.10.002",,"5NOI",21.69,"2.4","2.4","human Robo2 extracellular domains 4-5","RAPPQFVVRPRDQIVAQGRTVTFPCETKGNPQPAVFWQKEGSQNLLFPNQPQQPNSRCSVSPTGDLTITNIQRSDAGYYICQALTVAGSILAKAQLEVTDVLTDRPPPIILQGPAMQTLAVDGTALLKCKATGDPLPVISWLKEGFTFPGRDPRATIQEQGTLQIKNLRISDTGTYTCVATSSSGETSWSAVLDVTESGKL","Homo sapiens","ROBO2, KIAA1568","Roundabout homolog 2","1","5NOI"
"5NOQ",,"X-RAY DIFFRACTION",2.71,54.55,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 8000, Tris-HCl",279.15,"10.1016/j.jmb.2017.06.016",,"5NOQ",18.29,"1.6","1.6","Structure of cyclophilin A in complex with 3-chloropyridin-2-amine","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5NOQ"
"5NOR",,"X-RAY DIFFRACTION",2.75,55.32,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 8000, Tris-HCl",279.15,"10.1016/j.jmb.2017.06.016",,"5NOR",18.25,"1.8","1.8","Structure of cyclophilin A in complex with 3-methylpyridin-2-amine","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5NOR"
"5NOS",,"X-RAY DIFFRACTION",2.73,54.98,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 8000, Tris-HCl",279.15,"10.1016/j.jmb.2017.06.016",,"5NOS",18.15,"1.35","1.35","Structure of cyclophilin A in complex with 3-amino-1H-pyridin-2-one","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5NOS"
"5NOT",,"X-RAY DIFFRACTION",2.76,55.42,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 8000, Tris-HCl",279.15,"10.1016/j.jmb.2017.06.016",,"5NOT",18.3,"1.45","1.45","Structure of cyclophilin A in complex with 4-chloropyrimidin-5-amine","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5NOT"
"5NOU",,"X-RAY DIFFRACTION",2.72,54.72,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 8000, Tris-HCl",279.15,"10.1016/j.jmb.2017.06.016",,"5NOU",18.46,"1.3","1.3","Structure of cyclophilin A in complex with hexahydropyrimidin-2-one","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5NOU"
"5NOV",,"X-RAY DIFFRACTION",2.62,53.12,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 8000, Tris-HCl",279.15,"10.1016/j.jmb.2017.06.016",,"5NOV",18.15,"2","2","Structure of cyclophilin A in complex with hexahydropyrimidine-2-thione","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5NOV"
"5NOW",,"X-RAY DIFFRACTION",2.82,56.36,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 8000, Tris-HCl",279.15,"10.1016/j.jmb.2017.06.016",,"5NOW",18.15,"1.48","1.48","Structure of cyclophilin A in complex with pyridine-3,4-diamine","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5NOW"
"5NOX",,"X-RAY DIFFRACTION",2.82,56.43,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 8000, Tris-HCl",279.15,"10.1016/j.jmb.2017.06.016",,"5NOX",18.17,"1.49","1.49","Structure of cyclophilin A in complex with 2-chloropyridin-3-amine","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5NOX"
"5NOY",,"X-RAY DIFFRACTION",2.83,56.49,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 8000, Tris-HCl",279.15,"10.1016/j.jmb.2017.06.016",,"5NOY",18.19,"1.43","1.43","Structure of cyclophilin A in complex with 3,4-diaminobenzamide","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5NOY"
"5NOZ",,"X-RAY DIFFRACTION",2.8,56.06,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 8000, Tris-HCl",279.15,"10.1016/j.jmb.2017.06.016",,"5NOZ",18.2,"1.61","1.61","Structure of cyclophilin A in complex with 3,4-diaminobenzohydrazide","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5NOZ"
"5NP0","5.7","ELECTRON MICROSCOPY",,,,,,,"10.1126/sciadv.1700933",,"5NP0",704.79,"5.7",,"Closed dimer of human ATM (Ataxia telangiectasia mutated)","MDYKDDDDKHMSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQSTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQSFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV","Homo sapiens","ATM","Serine-protein kinase ATM","1","5NP0"
"5NP1","5.7","ELECTRON MICROSCOPY",,,,,,,"10.1126/sciadv.1700933",,"5NP1",352.39,"5.7",,"Open protomer of human ATM (Ataxia telangiectasia mutated)","MDYKDDDDKHMSLVLNDLLICCRQLEHDRATERKKEVEKFKRLIRDPETIKHLDRHSDSKQGKYLNWDAVFRFLQKYIQKETECLRIAKPNVSASTQASRQKKMQEISSLVKYFIKCANRRAPRLKCQELLNYIMDTVKDSSNGAIYGADCSNILLKDILSVRKYWCEISQQQWLELFSVYFRLYLKPSQDVHRVLVARIIHAVTKGCCSQTDGLNSKFLDFFSKAIQCARQEKSSSGLNHILAALTIFLKTLAVNFRIRVCELGDEILPTLLYIWTQHRLNDSLKEVIIELFQLQIYIHHPKGAKTQEKGAYESTKWRSILYNLYDLLVNEISHIGSRGKYSSGFRNIAVKENLIELMADICHQVFNEDTRSLEISQSYTTTQRESSDYSVPCKRKKIELGWEVIKDHLQKSQNDFDLVPWLQIATQLISKYPASLPNCELSPLLMILSQLLPQQRHGERTPYVLRCLTEVALCQDKRSNLESSQKSDLLKLWNKIWCITFRGISSEQIQAENFGLLGAIIQGSLVEVDREFWKLFTGSACRPSCPAVCCLTLALTTSIVPGTVKMGIEQNMCEVNRSFSLKESIMKWLLFYQLEGDLENSTEVPPILHSNFPHLVLEKILVSLTMKNCKAAMNFFQSVPECEHHQKDKEELSFSEVEELFLQTTFDKMDFLTIVRECGIEKHQSSIGFSVHQNLKESLDRCLLGLSEQLLNNYSSEITNSETLVRCSRLLVGVLGCYCYMGVIAEEEAYKSELFQKAKSLMQCAGESITLFKNKTNEEFRIGSLRNMMQLCTRCLSNCTKKSPNKIASGFFLRLLTSKLMNDIADICKSLASFIKKPFDRGEVESMEDDTNGNLMEVEDQSSMNLFNDYPDSSVSDANEPGESQSTIGAINPLAEEYLSKQDLLFLDMLKFLCLCVTTAQTNTVSFRAADIRRKLLMLIDSSTLEPTKSLHLHMYLMLLKELPGEEYPLPMEDVLELLKPLSNVCSLYRRDQDVCKTILNHVLHVVKNLGQSNMDSENTRDAQGQFLTVIGAFWHLTKERKYIFSVRMALVNCLKTLLEADPYSKWAILNVMGKDFPVNEVFTQFLADNHHQVRMLAAESINRLFQDTKGDSSRLLKALPLKLQQTAFENAYLKAQEGMREMSHSAENPETLDEIYNRKSVLLTLIAVVLSCSPICEKQALFALCKSVKENGLEPHLVKKVLEKVSETFGYRRLEDFMASHLDYLVLEWLNLQDTEYNLSSFPFILLNYTNIEDFYRSCYKVLIPHLVIRSHFDEVKSIANQIQEDWKSLLTDCFPKILVNILPYFAYEGTRDSGMAQQRETATKVYDMLKSENLLGKQIDHLFISNLPEIVVELLMTLHEPANSSASQSTDLCDFSGDLDPAPNPPHFPSHVIKATFAYISNCHKTKLKSILEILSKSPDSYQKILLAICEQAAETNNVYKKHRILKIYHLFVSLLLKDIKSGLGGAWAFVLRDVIYTLIHYINQRPSCIMDVSLRSFSLCCDLLSQVCQTAVTYCKDALENHLHVIVGTLIPLVYEQVEVQKQVLDLLKYLVIDNKDNENLYITIKLLDPFPDHVVFKDLRITQQKIKYSRGPFSLLEEINHFLSVSVYDALPLTRLEGLKDLRRQLELHKDQMVDIMRASQDNPQDGIMVKLVVNLLQLSKMAINHTGEKEVLEAVGSCLGEVGPIDFSTIAIQHSKDASYTKALKLFEDKELQWTFIMLTYLNNTLVEDCVKVRSAAVTCLKNILATKTGHSFWEIYKMTTDPMLAYLQPFRTSRKKFLEVPRFDKENPFEGLDDINLWIPLSENHDIWIKTLTCAFLDSGGTKCEILQLLKPMCEVKTDFCQTVLPYLIHDILLQDTNESWRNLLSTHVQGFFTSCLRHFSQTSRSTTPANLDSESEHFFRCCLDKKSQRTMLAVVDYMRRQKRPSSGTIFNDAFWLDLNYLEVAKVAQSCAAHFTALLYAEIYADKKSMDDQEKRSLAFEEGSQSTTISSLSEKSKEETGISLQDLLLEIYRSIGEPDSLYGCGGGKMLQPITRLRTYEHEAMWGKALVTYDLETAIPSSTRQAGIIQALQNLGLCHILSVYLKGLDYENKDWCPELEELHYQAAWRNMQWDHCTSVSKEVEGTSYHESLYNALQSLRDREFSTFYESLKYARVKEVEEMCKRSLESVYSLYPTLSRLQAIGELESIGELFSRSVTHRQLSEVYIKWQKHSQLLKDSDFSFQEPIMALRTVILEILMEKEMDNSQRECIKDILTKHLVELSILARTFKNTQLPERAIFQIKQYNSVSCGVSEWQLEEAQVFWAKKEQSLALSILKQMIKKLDASCAANNPSLKLTYTECLRVCGNWLAETCLENPAVIMQTYLEKAVEVAGNYDGESSDELRNGKMKAFLSLARFSDTQYQRIENYMKSSEFENKQALLKRAKEEVGLLREHKIQTNRYTVKVQRELELDELALRALKEDRKRFLCKAVENYINCLLSGEEHDMWVFRLCSLWLENSGVSEVNGMMKRDGMKIPTYKFLPLMYQLAARMGTKMMGGLGFHEVLNNLISRISMDHPHHTLFIILALANANRDEFLTKPEVARRSRITKNVPKQSSQLDEDRTEAANRIICTIRSRRPQMVRSVEALCDAYIILANLDATQWKTQRKGINIPADQPITKLKNLEDVVVPTMEIKVDHTGEYGNLVTIQSFKAEFRLAGGVNLPKIIDCVGSDGKERRQLVKGRDDLRQDAVMQQVFQMCNTLLQRNTETRKRKLTICTYKVVPLSQRSGVLEWCTGTVPIGEFLVNNEDGAHKRYRPNDFSAFQCQKKMMEVQKKSFEEKYEVFMDVCQNFQPVFRYFCMEKFLDPAIWFEKRLAYTRSVATSSIVGYILGLGDRHVQNILINEQSAELVHIDLGVAFEQGKILPTPETVPFRLTRDIVDGMGITGVEGVFRRCCEKTMEVMRNSQETLLTIVEVLLYDPLFDWTMNPLKALYLQQRPEDETELHPTLNADDQECKRNLSDIDQSFNKVAERVLMRLQEKLKGVEEGTVLSVGGQVNLLIQQAIDPKNLSRLFPGWKAWV","Homo sapiens","ATM","Serine-protein kinase ATM","1","5NP1"
"5NP2",,"X-RAY DIFFRACTION",2.12,41.91,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.8 M sodium citrate, 0.1 M sodium cacodylate",293,"10.1074/jbc.RA118.004732",,"5NP2",13.82,"1.6","1.6","Abl1 SH3 pTyr89/134","GSHMNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVN","Homo sapiens","ABL1, ABL, JTK7","Tyrosine-protein kinase ABL1","1","5NP2"
"5NP3",,"X-RAY DIFFRACTION",1.86,33.86,"VAPOR DIFFUSION, HANGING DROP",7,"1.8 M di-sodium-DL-malate",293,"10.1074/jbc.RA118.004732",,"5NP3",27.07,"2","2","Abl2 SH3","GSHMNLFVALYDFVASGDNTLSITKGEKLRVLGYNQNGEWSEVRSKNGQGWVPSNYITPVN","Homo sapiens","ABL2, ABLL, ARG","Abelson tyrosine-protein kinase 2","1","5NP3"
"5NP4",,"X-RAY DIFFRACTION",2.74,55.08,"VAPOR DIFFUSION",,"0.15 M Mg formate dihydrate, 22.5% w/v polyethylene glycol 1000",293.15,"10.1371/journal.pone.0184932",,"5NP4",13.42,"1.434","1.434","Beta domain of human transcobalamin bound to cyanocobalamin","GVDHMQTQEIISVTLQVLSLLPPYRQSISVLAGSTVEDVLKKAHELGGFTYETQASLSGPYLTSVMGKAAGEREFWQLLRDPNTPLLQGIADYRPKDGETIELRLVSW","Homo sapiens","TCN2, TC2","Transcobalamin-2","1","5NP4"
"5NP5",,"X-RAY DIFFRACTION",1.71,27.95,"VAPOR DIFFUSION, HANGING DROP",4.6,"1.8 M (NH4)2SO4, 0.1 M sodium acetate",293,"10.1074/jbc.RA118.004732",,"5NP5",13.95,"1.4","1.4","Abl2 SH3 pTyr116/161","GSHMNLFVALYDFVASGDNTLSITKGEKLRVLGYNQNGEWSEVRSKNGQGWVPSNYITPVN","Homo sapiens","ABL2, ABLL, ARG","Abelson tyrosine-protein kinase 2","1","5NP5"
"5NP7","4.2","ELECTRON MICROSCOPY",,,,,,,"10.1093/nar/gkw783",,"5NP7",262.61,"4.2, 4.2",,"CryoEM structure of Human Rad51 on single-stranded DNA to 4.2A resolution.","MAMQMQLEANADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGFHTVEAVAYAPKKELINIKGISEAKADKILAEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKLLQGGIETGSITEMFGEFRTGKTQICHTLAVTCQLPIDRGGGEGKAMYIDTEGTFRPERLLAVAERYGLSGSDVLDNVAYARAFNTDHQTQLLYQASAMMVESRYALLIVDSATALYRTDYSGRGELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAADPKKPIGGNIIAHASTTRLYLRKGRGETRICKIYDSPCLPEAEAMFAINADGVGDAKD","Homo sapiens","RAD51, RAD51A, RECA","DNA repair protein RAD51 homolog 1","1","5NP7"
"5NP8",,"X-RAY DIFFRACTION",2.07,40.67,"VAPOR DIFFUSION, HANGING DROP",,"2.4-2.8M Sodium potassium phosphate, pH 7.4 - 8.2, 10mM DTT",291,"10.1016/j.neo.2019.07.008","3PG","5NP8",45.7,"1.9","1.9","PGK1 in complex with CRT0063465 (3-[2-(4-bromophenyl)-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-6-yl]propanoic acid)","GSHMSLSNKLTLDKLDVKGKRVVMRVDFNVPMKNNQITNNQRIKAAVPSIKFCLDNGAKSVVLMSHLGRPDGVPMPDKYSLEPVAVELKSLLGKDVLFLKDCVGPEVEKACANPAAGSVILLENLRFHVEEEGKGKDASGNKVKAEPAKIEAFRASLSKLGDVYVNDAFGTAHRAHSSMVGVNLPQKAGGFLMKKELNYFAKALESPERPFLAILGGAKVADKIQLINNMLDKVNEMIIGGGMAFTFLKVLNNMEIGTSLFDEEGAKIVKDLMSKAEKNGVKITLPVDFVTADKFDENAKTGQATVASGIPAGWMGLDCGPESSKKYAEAVTRAKQIVWNGPVGVFEWEAFARGTKALMDEVVKATSRGCITIIGGGDTATCCAKWNTEDKVSHVSTGGGASLELLEGKVLPGVDALSNI","Homo sapiens","PGK1, PGKA, MIG10, OK/SW-cl.110","Phosphoglycerate kinase 1","1","5NP8"
"5NPQ",,"X-RAY DIFFRACTION",2.27,45.89,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1M NaCit pH 4.5, 5mM NiCl2, 2.5% glycerol and PEG 4K 18%
Protein concentration: 7.05 mg/ml",293,,,"5NPQ",93.32,"2.372","2.372","Human N-myristoyltransferase 1 (MNT1) with Myristoyl-CoA analogue X10 bound","GPHMEEASKRSYQFWDTQPVPKLGEVVNTHGPVEPDKDNIRQEPYTLPQGFTWDALDLGDRGVLKELYTLLNENYVEDDDNMFRFDYSPEFLLWALRPPGWLPQWHCGVRVVSSRKLVGFISAIPANIHIYDTEKKMVEINFLCVHKKLRSKRVAPVLIREITRRVHLEGIFQAVYTAGVVLPKPVGTCRYWHRSLNPRKLIEVKFSHLSRNMTMQRTMKLYRLPETPKTAGLRPMETKDIPVVHQLLTRYLKQFHLTPVMSQEEVEHWFYPQENIIDTFVVENANGEVTDFLSFYTLPSTIMNHPTHKSLKAAYSFYNVHTQTPLLDLMSDALVLAKMKGFDVFNALDLMENKTFLEKLKFGIGDGNLQYYLYNWKCPSMGAEKVGLVLQ","Homo sapiens","NMT1, NMT","Glycylpeptide N-tetradecanoyltransferase 1","1","5NPQ"
"5NQC",,"X-RAY DIFFRACTION",2.02,39.08,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium tartrate pH 5.6, 2.2 M (NH4)2SO4, 0.2 M NaSCN, 5 mM TCEP, 5 mM NMR154, 5% (v/v) DMSO",292,,,"5NQC",40.43,"2","2","CK2alpha in complex with NMR154","SGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMG","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5NQC"
"5NQE",,"X-RAY DIFFRACTION",3.06,57.8,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.2M Sodium-malonate",277,"10.1016/j.bmcl.2017.04.089",,"5NQE",45.03,"2.71","2.71","Human PARP14 (ARTD8), catalytic fragment in complex with an N-aryl piperazine inhibitor","SMDMKQQNFCVVELLPSDPEYNTVASKFNQTCSHFRIEKIERIQNPDLWNSYQAKKKTMDAKNGQTMNEKQLFHGTDAGSVPHVNRNGFNRSYAGKNAVAYGKGTYFAVNANYSANDTYSRPDANGRKHVYYVRVLTGIYTHGNHSLIVPPSKNPQNPTDLYDTVTDNVHHPSLFVAFYDYQAYPEYLITFRK","Homo sapiens","PARP14, BAL2, KIAA1268","Poly [ADP-ribose] polymerase 14","1","5NQE"
"5NQH",,"X-RAY DIFFRACTION",2.97,58.53,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.08 M sodium acetate,
1.6 M ammonium sulfate,
20 % (v/v) glycerol",291,"10.3389/fnmol.2017.00140",,"5NQH",62.88,"2.6","2.6","Structure of the human Fe65-PTB2 homodimer","APKNELVQKFQVYYLGNVPVAKPVGVDVINGALESVLSSSSREQWTPSHVSVAPATLTILHQQTEAVLGECRVRFLSFLAVGRDVHTFAFIMAAGPASFCCHMFWCEPNAASLSEAVQAACMLRYQKCLDARSQHHHHHH","Homo sapiens","APBB1, FE65, RIR","Amyloid beta A4 precursor protein-binding family B member 1","1","5NQH"
"5NQR",,"X-RAY DIFFRACTION",1.88,34.58,"VAPOR DIFFUSION",,"0.1 M HEPES, pH 7.5, 300 mM NaCl, 10% Glycerol, and 1 mM TCEP",291.15,"10.1038/s41467-017-02293-7","958","5NQR",49.9,"2.2","2.2","Potent inhibitors of NUDT5 silence hormone signaling in breast cancer","MESQEPTESSQNGKQYIISEELISEGKWVKLEKTTYMDPTGKTRTWESVKRTTRKEQTADGVAVIPVLQRTLHYECIVLVKQFRPPMGGYCIEFPAGLIDDGETPEAAALRELEEETGYKGDIAECSPAVCMDPGLSNCTIHIVTVTINGDDAENARPKPKPGDGEFVEVISLPKNDLLQRLDALVAEEHLTVDARVYSYALALKHANAKPFEVPFLKF","Homo sapiens","NUDT5, NUDIX5, HSPC115","ADP-sugar pyrophosphatase","1","5NQR"
"5NR3",,"X-RAY DIFFRACTION",3.71,66.82,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES,0.2 M Li2SO4, 23-33% PEG 3350",298,,,"5NR3",34.09,"2.3","2.3","Human DNMT3B PWWP domain in complex with ethambutol","EADSGDGDSSEYQDGKEFGIGDLVWGKIKGFSWWPAMVVSWKATSKRQAMSGMRWVQWFGDGKFSEVSADKLVALGLFSQHFNLATFNKLVSYRKAMYHALEKARVRAGKTFPSSPGDSLEDQLKPMLEWAHGGFKPTGIEGLKPNNTQP","Homo sapiens","DNMT3B","DNA (cytosine-5)-methyltransferase 3B","1","5NR3"
"5NR4",,"X-RAY DIFFRACTION",2.02,39.03,"VAPOR DIFFUSION, SITTING DROP",8.5,"30mM Sodium fluoride; 30mM Sodium bromide; 30mM Sodium iodide; 100mM Tris(Base)/Bicine pH 8.5; 12.5% v/v MPD; 12.5% PEG1000; 12.5% PEG3350",293,"10.1016/j.devcel.2018.05.032",,"5NR4",51.51,"1.198","1.198","Crystal structure of Clasp2 TOG1 domain","GPMEPRSMEYFCAQVQQKDVGGRLQVGQELLLYLGAPGAISDLEEDLGRLGKTVDALTGWVGSSNYRVSLMGLEILSAFVDRLSTRFKSYVAMVIVALIDRMGDAKDKVRDEAQTLILKLMDQVAPPMYIWEQLASGFKHKNFRSREGVCLCLIETLNIFGAQPLVISKLIPHLCILFGDSNSQVRDAAILAIVEIYRHVGEKVRMDLYKRGIPPARLEMIFAKFDEVQS","Homo sapiens","CLASP2, KIAA0627","CLIP-associating protein 2","1","5NR4"
"5NR8",,"X-RAY DIFFRACTION",2.27,45.88,"VAPOR DIFFUSION, HANGING DROP",,"25% (w/v) polyethylene glycol (PEG) 3350, 200 mM potassium sodium tartrate (PST) at pH 7.2",290,"10.1021/acs.jmedchem.7b01051","95N","5NR8",43.16,"1.349","1.349","Crystal structure of human chitotriosidase-1 (hCHIT) catalytic domain in complex with compound 7a","AKLVCYFTNWAQYRQGEARFLPKDLDPSLCTHLIYAFAGMTNHQLSTTEWNDETLYQEFNGLKKMNPKLKTLLAIGGWNFGTQKFTDMVATANNRQTFVNSAIRFLRKYSFDGLDLDWEYPGSQGSPAVDKERFTTLVQDLANAFQQEAQTSGKERLLLSAAVPAGQTYVDAGYEVDKIAQNLDFVNLMAYDFHGSWEKVTGHNSPLYKRQEESGAAASLNVDAAVQQWLQKGTPASKLILGMPTYGRSFTLASSSDTRVGAPATGSGTPGPFTKEGGMLAYYEVCSWKGATKQRIQDQKVPYIFRDNQWVGFDDVESFKTKVSYLKQKGLGGAMVWALDLDDFAGFSCNQGRYPLIQTLRQELSLVPRGSHHHHHH","Homo sapiens","CHIT1","Chitotriosidase-1","1","5NR8"
"5NRA",,"X-RAY DIFFRACTION",2.25,45.35,"VAPOR DIFFUSION, HANGING DROP",,"25% (w/v) polyethylene glycol (PEG) 3350, 200 mM potassium sodium tartrate (PST) at pH 7.2",290,"10.1021/acs.jmedchem.7b01051","95K","5NRA",42.74,"1.267","1.267","Crystal structure of human chitotriosidase-1 (hCHIT) catalytic domain in complex with compound 7g","AKLVCYFTNWAQYRQGEARFLPKDLDPSLCTHLIYAFAGMTNHQLSTTEWNDETLYQEFNGLKKMNPKLKTLLAIGGWNFGTQKFTDMVATANNRQTFVNSAIRFLRKYSFDGLDLDWEYPGSQGSPAVDKERFTTLVQDLANAFQQEAQTSGKERLLLSAAVPAGQTYVDAGYEVDKIAQNLDFVNLMAYDFHGSWEKVTGHNSPLYKRQEESGAAASLNVDAAVQQWLQKGTPASKLILGMPTYGRSFTLASSSDTRVGAPATGSGTPGPFTKEGGMLAYYEVCSWKGATKQRIQDQKVPYIFRDNQWVGFDDVESFKTKVSYLKQKGLGGAMVWALDLDDFAGFSCNQGRYPLIQTLRQELSLVPRGSHHHHHH","Homo sapiens","CHIT1","Chitotriosidase-1","1","5NRA"
"5NRF",,"X-RAY DIFFRACTION",2.27,45.82,"VAPOR DIFFUSION, HANGING DROP",,"25% (w/v) polyethylene glycol (PEG) 3350, 200 mM potassium sodium tartrate (PST) at pH 7.2",290,"10.1021/acs.jmedchem.7b01051","95Q","5NRF",42.73,"1.447","1.447","Crystal structure of human chitotriosidase-1 (hCHIT) catalytic domain in complex with compound 7i","AKLVCYFTNWAQYRQGEARFLPKDLDPSLCTHLIYAFAGMTNHQLSTTEWNDETLYQEFNGLKKMNPKLKTLLAIGGWNFGTQKFTDMVATANNRQTFVNSAIRFLRKYSFDGLDLDWEYPGSQGSPAVDKERFTTLVQDLANAFQQEAQTSGKERLLLSAAVPAGQTYVDAGYEVDKIAQNLDFVNLMAYDFHGSWEKVTGHNSPLYKRQEESGAAASLNVDAAVQQWLQKGTPASKLILGMPTYGRSFTLASSSDTRVGAPATGSGTPGPFTKEGGMLAYYEVCSWKGATKQRIQDQKVPYIFRDNQWVGFDDVESFKTKVSYLKQKGLGGAMVWALDLDDFAGFSCNQGRYPLIQTLRQELSLVPRGSHHHHHH","Homo sapiens","CHIT1","Chitotriosidase-1","1","5NRF"
"5NRP",,"X-RAY DIFFRACTION",3.03,59.4,"EVAPORATION",,"0.1 M sodium malonate pH 7.0, 12% w/v polyethylene glycol 3,350",293.15,"10.1371/journal.pone.0184932",,"5NRP",13.98,"1.569","1.569","Beta domain of human transcobalamin bound to cobinamide","GVDHMQTQEIISVTLQVLSLLPPYRQSISVLAGSTVEDVLKKAHELGGFTYETQASLSGPYLTSVMGKAAGEREFWQLLRDPNTPLLQGIADYRPKDGETIELRLVSW","Homo sapiens","TCN2, TC2","Transcobalamin-2","1","5NRP"
"5NRR",,"X-RAY DIFFRACTION",3.73,67.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES sodium, 2% v/v Polyethylene glycol 400, 2.0 M Ammonium sulfate",298,,,"5NRR",34.26,"1.7","1.7","Human DNMT3B PWWP domain in complex with 5-[(2-Hydroxyethyl)(propyl)amino]-1-pentanol","EADSGDGDSSEYQDGKEFGIGDLVWGKIKGFSWWPAMVVSWKATSKRQAMSGMRWVQWFGDGKFSEVSADKLVALGLFSQHFNLATFNKLVSYRKAMYHALEKARVRAGKTFPSSPGDSLEDQLKPMLEWAHGGFKPTGIEGLKPNNTQP","Homo sapiens","DNMT3B","DNA (cytosine-5)-methyltransferase 3B","1","5NRR"
"5NRS",,"X-RAY DIFFRACTION",3.82,67.81,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES,0.2 M Li2SO4, 23-33% PEG 3350",298,,,"5NRS",34.23,"2.3","2.3","Human DNMT3B PWWP domain in complex with N,N-bis(2-hydroxypropyl)ethanolamine","EADSGDGDSSEYQDGKEFGIGDLVWGKIKGFSWWPAMVVSWKATSKRQAMSGMRWVQWFGDGKFSEVSADKLVALGLFSQHFNLATFNKLVSYRKAMYHALEKARVRAGKTFPSSPGDSLEDQLKPMLEWAHGGFKPTGIEGLKPNNTQP","Homo sapiens","DNMT3B","DNA (cytosine-5)-methyltransferase 3B","1","5NRS"
"5NRV",,"X-RAY DIFFRACTION",3.63,66.12,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES,0.2 M Li2SO4, 23-33% PEG 3350",298,,,"5NRV",34.76,"2.075","2.075","Human DNMT3B PWWP domain in complex with 6-dipropylamino-1-hexanol","EADSGDGDSSEYQDGKEFGIGDLVWGKIKGFSWWPAMVVSWKATSKRQAMSGMRWVQWFGDGKFSEVSADKLVALGLFSQHFNLATFNKLVSYRKAMYHALEKARVRAGKTFPSSPGDSLEDQLKPMLEWAHGGFKPTGIEGLKPNNTQP","Homo sapiens","DNMT3B","DNA (cytosine-5)-methyltransferase 3B","1","5NRV"
"5NRW",,"X-RAY DIFFRACTION",2.25,45.42,"EVAPORATION",6.5,"LiSO4, PEG 3350, ethylene glycol",277,"10.1002/anie.201705516",,"5NRW",14.81,"1.7","1.7","Crystal structure of the human bromodomain of CREBBP bound to the inhibitor XDM4","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5NRW"
"5NSA",,"X-RAY DIFFRACTION",2.71,54.64,"EVAPORATION",,"0.3 M potassium formate, 17% w/v polyethylene glycol 3,350",293.15,"10.1371/journal.pone.0184932",,"5NSA",13.48,"1.273","1.273","Beta domain of human transcobalamin bound to Co-beta-[2-(2,4-difluorophenyl)ethinyl]cobalamin","GVDHMQTQEIISVTLQVLSLLPPYRQSISVLAGSTVEDVLKKAHELGGFTYETQASLSGPYLTSVMGKAAGEREFWQLLRDPNTPLLQGIADYRPKDGETIELRLVSW","Homo sapiens","TCN2, TC2","Transcobalamin-2","1","5NSA"
"5NSD",,"X-RAY DIFFRACTION",2.54,51.54,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M Sodium Chloride, 0.1 M Tris pH 8.5, 22% w/v PEG 3350",298,"10.1038/s41467-017-02349-8",,"5NSD",115.48,"2.046","2.046","Co-crystal structure of NAMPT dimer with KPT-9274","MNPAAEAEFNILLATDSYKVTHYKQYPPNTSKVYSYFECREKKTENSKLRKVKYEETVFYGLQYILNKYLKGKVVTKEKIQEAKDVYKEHFQDDVFNEKGWNYILEKYDGHLPIEIKAVPEGFVIPRGNVLFTVENTDPECYWLTNWIETILVQSWYPITVATNSREQKKILAKYLLETSGNLDGLEYKLHDFGYRGVSSQETAGIGASAHLVNFKGTDTVAGLALIKKYYGTKDPVPGYSVPAAEHSTITAWGKDHEKDAFEHIVTQFSSVPVSVVSDSYDIYNACEKIWGEDLRHLIVSRSTQAPLIIRPDSGNPLDTVLKVLEILGKKFPVTENSKGYKLLPPYLRVIQGDGVDINTLQEIVEGMKQKMWSIENIAFGSGGGLLQKLTRDLLNCSFKCSYVVTNGLGINVFKDPVADPNKRSKKGRLSLHRTPAGNFVTLEEGKGDLEEYGQDLLHTVFKNGKVTKSYSFDEIRKNAQLNIELEAAHHENLYFQ","Homo sapiens","NAMPT, PBEF, PBEF1","Nicotinamide phosphoribosyltransferase","1","5NSD"
"5NSG",,"X-RAY DIFFRACTION",2.68,54.14,"VAPOR DIFFUSION, HANGING DROP",4.5,"acetate buffer pH 4.5, 0.2 M zinc acetate, 16% w/v PEG 3000",291,"10.1074/jbc.M117.793497",,"5NSG",27.69,"2.22","2.22","Fc DEDE homodimer variant","EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTDPPSREEMTKNQVSLTCEVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK","Homo sapiens","DKFZp686C11235","Putative uncharacterized protein DKFZp686C11235","1","5NSG"
"5NSP",,"X-RAY DIFFRACTION",2.33,47.32,"VAPOR DIFFUSION, SITTING DROP",8.5,"24%/26% PEG3350, 0.2M Lithium sulfate, 0.1M Tris-HCl",277,"10.1021/acs.jmedchem.7b00883","97E","5NSP",55.86,"2.3","2.3","Crystal structure of TNKS2 in complex with OD334","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5NSP"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5NSP"
"5NST",,"X-RAY DIFFRACTION",2.57,52.13,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 4000, 0.1M sodium citrate pH 4.5",291,"10.7554/eLife.27311",,"5NST",126.41,"2.52","2.52","Human monoclonal antibody with a LAIR1 insertion","AIRMTQSPSSLSASPGDKVSITCRASQHINDSLAWFQQRPGKAPKLLIYGASNLHSGVPSRFSGTGSGTDFTLTITGLQSEDFATYFCQQCNCFPPDFGQGTRLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC","Homo sapiens",,"Light Chain of antibody MGD21","1","5NST"
,,,,,,,,,,,,,,,,"EVQLVETGPGLMKTSGTLSLTCAVSGDYVNTNRRWSWVRQAPGKGLEWIGEVHQSGRTNYNPSLKSRVTISVDKSKNQFSLKVDSVTAADTAVYYCARASPLKSQRDTDLPRPSISAEPGTVIPLGSHVTFVCRGPVGVQTFRLERERNYLYSDTEDVSQTSPSESEARFRIDSVNAGNAGLFRCIYYKSRKWSEQSDYLELVVKGEDVTWALSQSQDDPRACPQGELPISTDIYYVDVWGNGTTVTVSSAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGKHHHHHH","Homo sapiens",,"Heavy Chain of antibody MGD21","2","5NST"
"5NSX",,"X-RAY DIFFRACTION",2.42,49.14,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24%          PEG3350, PH 8.5",277,"10.1038/s41598-018-19872-3","97K","5NSX",55.77,"1.8","1.8","Crystal structure of TNKS2 in complex with 2-(1H-indazol-5-yl)-3,4-dihydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5NSX"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5NSX"
"5NT0",,"X-RAY DIFFRACTION",2.41,49,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24% PEG3350",277,"10.1038/s41598-018-19872-3","97H","5NT0",55.81,"1.75","1.75","Crystal structure of TNKS2 in complex with 2-(3-aminophenyl)-3,4-dihydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5NT0"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5NT0"
"5NT4",,"X-RAY DIFFRACTION",2.39,48.64,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24% PEG3350",277,"10.1038/s41598-018-19872-3","97Z","5NT4",55.86,"1.9","1.9","Crystal structure of TNKS2 in complex with 2-[4-(morpholin-4-yl)phenyl]-3,4-dihydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5NT4"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5NT4"
"5NTK",,"X-RAY DIFFRACTION",2.19,43.73,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG 3350, 0.1M MES",298,"10.1002/cmdc.201700278","99N","5NTK",54.95,"1.9","1.9","Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds","GPYASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLSKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHP","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5NTK"
"5NTP",,"X-RAY DIFFRACTION",1.94,36.75,"VAPOR DIFFUSION, HANGING DROP",7,"30% Jeffamine ED-2001, 0.1M HEPES",298,"10.1002/cmdc.201700278","98E","5NTP",28.1,"1.7","1.7","Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds","GPYASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLSKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFP","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5NTP"
"5NTQ",,"X-RAY DIFFRACTION",3.23,61.95,"VAPOR DIFFUSION, HANGING DROP",7,"15% Tacsimate, 4% PEG3350, 0.1M HEPES",298,"10.1002/cmdc.201700278","444","5NTQ",56.22,"2.26","2.26","Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds","GPYASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLSKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFP","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5NTQ"
"5NTT",,"X-RAY DIFFRACTION",3.44,64.26,"VAPOR DIFFUSION, SITTING DROP",7.4,"10.5% (w/v) PEG 350 MME, 10 mM MgCl2, and 100 mM Tris/HCl",291,"10.1074/jbc.M117.783555","SVE","5NTT",34.19,"2.75","2.75","Crystal structure of human Mps1 (TTK) C604Y mutant in complex with NMS-P715","ENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMEYGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHP","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5NTT"
"5NTU",,"X-RAY DIFFRACTION",2.35,47.66,"VAPOR DIFFUSION",7,"10% PEG6000, 0.1M HEPES: cryo-protection: 70% ethylene glycol",292,"10.15252/embj.201797883",,"5NTU",77.14,"2.58","2.58","Crystal Structure of human Pro-myostatin Precursor at 2.6 A Resolution","GSTWRQNTKSSRIEAIKIQILSKLRLETAPNISKDVIRQLLPKAPPLRELIDQYDVQRDDSSDGSLEDDDYHATTETIITMPTESDFLMQVDGKPKCCFFKFSSKIQYNKVVKAQLWIYLRPVETPTTVFVQILRLIKPMKDGTRYTGIRSLKLDMNPGTGIWQSIDVKTVLQNWLAAPASNLGIEIKALDENGHDLAVTFPGPGEDGLNPFLEVKVTDTPKRSRRDFGLDCDEHSTESRCCRYPLTVDFEAFGWDWIIAPKRYKANYCSGECEFVFLAAYPHTHLVHQANPRGSAGPCCTPTKMSPINMLYFNGKEQIIYGKIPAMVVDRCGCS","Homo sapiens","MSTN, GDF8","Growth/differentiation factor 8","1","5NTU"
"5NTY",,"X-RAY DIFFRACTION",3.65,66.31,"MICRODIALYSIS",,"4.5M NaCl, 20mM Na cacodylate, pH 6.8",279,"10.1016/j.bbalip.2018.01.010",,"5NTY",21.28,"2","2","Structure of non-fluorescent human plasma RBP4","ERDCRVSSFRVKENFDKARFSGTWYAMAKKDPEGLFLQDNIVAEFSVDETGQMSATAKGRVRLLNNWDVCADMVGTFTDTEDPAKFKMKYWGVASFLQKGNDDHWIVDTDYDTYAVQYSCRLLNLDGTCADSYSFVFSRDPNGLPPEAQKIVRQRQEELCLARQYRLIVHNGYCDGRSERNL","Homo sapiens","RBP4, PRO2222","Retinol-binding protein 4","1","5NTY"
"5NU2",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, HANGING DROP",,"4.3 M NaCl, 100 mM Hepes,  pH 7.5",293,"10.1016/j.bbalip.2018.01.010",,"5NU2",21.31,"1.5","1.5","Structure of non-fluorescent human urine RBP4","ERDCRVSSFRVKENFDKARFSGTWYAMAKKDPEGLFLQDNIVAEFSVDETGQMSATAKGRVRLLNNWDVCADMVGTFTDTEDPAKFKMKYWGVASFLQKGNDDHWIVDTDYDTYAVQYSCRLLNLDGTCADSYSFVFSRDPNGLPPEAQKIVRQRQEELCLARQYRLIVHNGYCDGRSERNL","Homo sapiens","RBP4, PRO2222","Retinol-binding protein 4","1","5NU2"
"5NU3",,"X-RAY DIFFRACTION",2.5,50.77,"EVAPORATION",6.5,"LiSO4, PEG 3350, ethylene glycol",277,"10.1002/anie.201705516","99E","5NU3",15.05,"1.75","1.75","Crystal structure of the human bromodomain of CREBBP bound to the inhibitor XDM-CBP","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5NU3"
"5NU5",,"X-RAY DIFFRACTION",2.25,45.37,"EVAPORATION",6.5,"KSCN, NaBr, PEG 6000, PEG 8000, PEG 10000",277,"10.1002/anie.201705516","99E","5NU5",28.7,"1.6","1.6","Crystal structure of the human bromodomain of EP300 bound to the inhibitor XDM-CBP","SMIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKSPMDLSTIKRKLDTGQYQEPWQYVDDIWLMFNNAWLYNRKTSRVYKYCSKLSEVFEQEIDPVMQSLG","Homo sapiens","EP300, P300","Histone acetyltransferase p300","1","5NU5"
"5NU6",,"X-RAY DIFFRACTION",3.54,65.22,"VAPOR DIFFUSION, HANGING DROP",,"4.3 M NaCl, 100 mM Hepes, pH 7.5",293,"10.1016/j.bbalip.2018.01.010",,"5NU6",21.31,"1.68","1.68","Structure of non-fluorescent human amniotic fluid RBP4","ERDCRVSSFRVKENFDKARFSGTWYAMAKKDPEGLFLQDNIVAEFSVDETGQMSATAKGRVRLLNNWDVCADMVGTFTDTEDPAKFKMKYWGVASFLQKGNDDHWIVDTDYDTYAVQYSCRLLNLDGTCADSYSFVFSRDPNGLPPEAQKIVRQRQEELCLARQYRLIVHNGYCDGRSERNL","Homo sapiens","RBP4, PRO2222","Retinol-binding protein 4","1","5NU6"
"5NU7",,"X-RAY DIFFRACTION",,,"MICRODIALYSIS",,"4.5 M NaCl, 20 mM Na cacodylate, pH 6.8",277,"10.1016/j.bbalip.2018.01.010",,"5NU7",21.31,"1.5","1.5","Structure of human holo plasma RBP4","ERDCRVSSFRVKENFDKARFSGTWYAMAKKDPEGLFLQDNIVAEFSVDETGQMSATAKGRVRLLNNWDVCADMVGTFTDTEDPAKFKMKYWGVASFLQKGNDDHWIVDTDYDTYAVQYSCRLLNLDGTCADSYSFVFSRDPNGLPPEAQKIVRQRQEELCLARQYRLIVHNGYCDGRSERNL","Homo sapiens","RBP4, PRO2222","Retinol-binding protein 4","1","5NU7"
"5NU8",,"X-RAY DIFFRACTION",3.57,65.52,"VAPOR DIFFUSION, HANGING DROP",,"4.3 M NaCl, 100 mM Hepes, pH 7.5",293,"10.1016/j.bbalip.2018.01.010",,"5NU8",21.31,"1.59","1.59","Structure of human urine RBP4 saturated with palmitate","ERDCRVSSFRVKENFDKARFSGTWYAMAKKDPEGLFLQDNIVAEFSVDETGQMSATAKGRVRLLNNWDVCADMVGTFTDTEDPAKFKMKYWGVASFLQKGNDDHWIVDTDYDTYAVQYSCRLLNLDGTCADSYSFVFSRDPNGLPPEAQKIVRQRQEELCLARQYRLIVHNGYCDGRSERNL","Homo sapiens","RBP4, PRO2222","Retinol-binding protein 4","1","5NU8"
"5NU9",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, HANGING DROP",,"4.3 M NaCl, 100 mM Hepes, pH 7.5",293,"10.1016/j.bbalip.2018.01.010",,"5NU9",21.31,"1.5","1.5","Structure of human amniotic fluid RBP4 saturated with palmitate","ERDCRVSSFRVKENFDKARFSGTWYAMAKKDPEGLFLQDNIVAEFSVDETGQMSATAKGRVRLLNNWDVCADMVGTFTDTEDPAKFKMKYWGVASFLQKGNDDHWIVDTDYDTYAVQYSCRLLNLDGTCADSYSFVFSRDPNGLPPEAQKIVRQRQEELCLARQYRLIVHNGYCDGRSERNL","Homo sapiens","RBP4, PRO2222","Retinol-binding protein 4","1","5NU9"
"5NUA",,"X-RAY DIFFRACTION",3.55,65.37,"VAPOR DIFFUSION, HANGING DROP",,"4.3 M NaCl, 100 mM Hepes, pH 7.5",293,"10.1016/j.bbalip.2018.01.010",,"5NUA",21.26,"1.6","1.6","Structure of human urine RBP4 saturated with laurate","ERDCRVSSFRVKENFDKARFSGTWYAMAKKDPEGLFLQDNIVAEFSVDETGQMSATAKGRVRLLNNWDVCADMVGTFTDTEDPAKFKMKYWGVASFLQKGNDDHWIVDTDYDTYAVQYSCRLLNLDGTCADSYSFVFSRDPNGLPPEAQKIVRQRQEELCLARQYRLIVHNGYCDGRSERNL","Homo sapiens","RBP4, PRO2222","Retinol-binding protein 4","1","5NUA"
"5NUB",,"X-RAY DIFFRACTION",3.53,65.17,"VAPOR DIFFUSION, HANGING DROP",,"4.3 M NaCl, 100 mM Hepes, pH 7.5",293,"10.1016/j.bbalip.2018.01.010",,"5NUB",21.26,"1.6","1.6","Structure of human amniotic fluid RBP4 saturated with laurate","ERDCRVSSFRVKENFDKARFSGTWYAMAKKDPEGLFLQDNIVAEFSVDETGQMSATAKGRVRLLNNWDVCADMVGTFTDTEDPAKFKMKYWGVASFLQKGNDDHWIVDTDYDTYAVQYSCRLLNLDGTCADSYSFVFSRDPNGLPPEAQKIVRQRQEELCLARQYRLIVHNGYCDGRSERNL","Homo sapiens","RBP4, PRO2222","Retinol-binding protein 4","1","5NUB"
"5NUD",,"X-RAY DIFFRACTION",2.39,48.52,"VAPOR DIFFUSION, HANGING DROP",,"1MMEDTA, PH 8.0
                      LIQUID NITROGEN",293,"10.1039/c7md00213k",,"5NUD",69.37,"2.5","2.5","FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527","GPLVSLDLPLDPLWEFPRDRLVLGKPLGEGCFGQVVRAEAFGMDPARPDQASTVAVKMLKDNASDKDLADLVSEMEVMKLIGRHKNIINLLGVCTQEGPLYVIVECAAKGNLREFLRARRPPGPDLSPDGPRSSEGPLSFPVLVSCAYQVARGMQYLESRKCIHRDLAARNVLVTEDNVMKIADFGLARGVHHIDYYKKTSNGRLPVKWMAPEALFDRVYTHQSDVWSFGILLWEIFTLGGSPYPGIPVEELFSLLREGHRMDRPPHCPPELYGLMRECWHAAPSQRPTFKQLVEALDKVLLAVSEE","Homo sapiens","FGFR4, JTK2, TKF","Fibroblast growth factor receptor 4","1","5NUD"
"5NUG","3.8","ELECTRON MICROSCOPY",,,,,,,"10.1016/j.cell.2017.05.025",,"5NUG",1069.79,"3.8, 3.8",,"Motor domains from human cytoplasmic dynein-1 in the phi-particle conformation","MSEPGGGGGEDGSAGLEVSAVQNVADVSVLQKHLRKLVPLLLEDGGEAPAALEAALEEKSALEQMRKFLSDPQVHTVLVERSTLKEDVGDEGEEEKEFISYNINIDIHYGVKSNSLAFIKRTPVIDADKPVSSQLRVLTLSEDSPYETLHSFISNAVAPFFKSYIRESGKADRDGDKMAPSVEKKIAELEMGLLHLQQNIEIPEISLPIHPMITNVAKQCYERGEKPKVTDFGDKVEDPTFLNQLQSGVNRWIREIQKVTKLDRDPASGTALQEISFWLNLERALYRIQEKRESPEVLLTLDILKHGKRFHATVSFDTDTGLKQALETVNDYNPLMKDFPLNDLLSATELDKIRQALVAIFTHLRKIRNTKYPIQRALRLVEAISRDLSSQLLKVLGTRKLMHVAYEEFEKVMVACFEVFQTWDDEYEKLQVLLRDIVKRKREENLKMVWRINPAHRKLQARLDQMRKFRRQHEQLRAVIVRVLRPQVTAVAQQNQGEVPEPQDMKVAEVLFDAADANAIEEVNLAYENVKEVDGLDVSKEGTEAWEAAMKRYDERIDRVETRITARLRDQLGTAKNANEMFRIFSRFNALFVRPHIRGAIREYQTQLIQRVKDDIESLHDKFKVQYPQSQACKMSHVRDLPPVSGSIIWAKQIDRQLTAYMKRVEDVLGKGWENHVEGQKLKQDGDSFRMKLNTQEIFDDWARKVQQRNLGVSGRIFTIESTRVRGRTGNVLKLKVNFLPEIITLSKEVRNLKWLGFRVPLAIVNKAHQANQLYPFAISLIESVRTYERTCEKVEERNTISLLVAGLKKEVQALIAEGIALVWESYKLDPYVQRLAETVFNFQEKVDDLLIIEEKIDLEVRSLETCMYDHKTFSEILNRVQKAVDDLNLHSYSNLPIWVNKLDMEIERILGVRLQAGLRAWTQVLLGQAEDKAEVDMDTDAPQVSHKPGGEPKIKNVVHELRITNQVIYLNPPIEECRYKLYQEMFAWKMVVLSLPRIQSQRYQVGVHYELTEEEKFYRNALTRMPDGPVALEESYSAVMGIVSEVEQYVKVWLQYQCLWDMQAENIYNRLGEDLNKWQALLVQIRKARGTFDNAETKKEFGPVVIDYGKVQSKVNLKYDSWHKEVLSKFGQMLGSNMTEFHSQISKSRQELEQHSVDTASTSDAVTFITYVQSLKRKIKQFEKQVELYRNGQRLLEKQRFQFPPSWLYIDNIEGEWGAFNDIMRRKDSAIQQQVANLQMKIVQEDRAVESRTTDLLTDWEKTKPVTGNLRPEEALQALTIYEGKFGRLKDDREKCAKAKEALELTDTGLLSGSEERVQVALEELQDLKGVWSELSKVWEQIDQMKEQPWVSVQPRKLRQNLDALLNQLKSFPARLRQYASYEFVQRLLKGYMKINMLVIELKSEALKDRHWKQLMKRLHVNWVVSELTLGQIWDVDLQKNEAIVKDVLLVAQGEMALEEFLKQIREVWNTYELDLVNYQNKCRLIRGWDDLFNKVKEHINSVSAMKLSPYYKVFEEDALSWEDKLNRIMALFDVWIDVQRRWVYLEGIFTGSADIKHLLPVETQRFQSISTEFLALMKKVSKSPLVMDVLNIQGVQRSLERLADLLGKIQKALGEYLERERSSFPRFYFVGDEDLLEIIGNSKNVAKLQKHFKKMFAGVSSIILNEDNSVVLGISSREGEEVMFKTPVSITEHPKINEWLTLVEKEMRVTLAKLLAESVTEVEIFGKATSIDPNTYITWIDKYQAQLVVLSAQIAWSENVETALSSMGGGGDAAPLHSVLSNVEVTLNVLADSVLMEQPPLRRRKLEHLITELVHQRDVTRSLIKSKIDNAKSFEWLSQMRFYFDPKQTDVLQQLSIQMANAKFNYGFEYLGVQDKLVQTPLTDRCYLTMTQALEARLGGSPFGPAGTGKTESVKALGHQLGRFVLVFNCDETFDFQAMGRIFVGLCQVGAWGCFDEFNRLEERMLSAVSQQVQCIQEALREHSNPNYDKTSAPITCELLNKQVKVSPDMAIFITMNPGYAGRSNLPDNLKKLFRSLAMTKPDRQLIAQVMLYSQGFRTAEVLANKIVPFFKLCDEQLSSQSHYDFGLRALKSVLVSAGNVKRERIQKIKREKEERGEAVDEGEIAENLPEQEILIQSVCETMVPKLVAEDIPLLFSLLSDVFPGVQYHRGEMTALREELKKVCQEMYLTYGDGEEVGGMWVEKVLQLYQITQINHGLMMVGPSGSGKSMAWRVLLKALERLEGVEGVAHIIDPKAISKDHLYGTLDPNTREWTDGLFTHVLRKIIDSVRGELQKRQWIVFDGDVDPEWVENLNSVLDDNKLLTLPNGERLSLPPNVRIMFEVQDLKYATLATVSRCGMVWFSEDVLSTDMIFNNFLARLRSIPLDEGEDEAQRRRKGKEDEGEEAASPMLQIQRDAATIMQPYFTSNGLVTKALEHAFQLEHIMDLTRLRCLGSLFSMLHQACRNVAQYNANHPDFPMQIEQLERYIQRYLVYAILWSLSGDSRLKMRAELGEYIRRITTVPLPTAPNIPIIDYEVSISGEWSPWQAKVPQIEVETHKVAAPDVVVPTLDTVRHEALLYTWLAEHKPLVLCGPPGSGKTMTLFSALRALPDMEVVGLNFSSATTPELLLKTFDHYCEYRRTPNGVVLAPVQLGKWLVLFCDEINLPDMDKYGTQRVISFIRQMVEHGGFYRTSDQTWVKLERIQFVGACNPPTDPGRKPLSHRFLRHVPVVYVDYPGPASLTQIYGTFNRAMLRLIPSLRTYAEPLTAAMVEFYTMSQERFTQDTQPHYIYSPREMTRWVRGIFEALRPLETLPVEGLIRIWAHEALRLFQDRLVEDEERRWTDENIDTVALKHFPNIDREKAMSRPILYSNWLSKDYIPVDQEELRDYVKARLKVFYEEELDVPLVLFNEVLDHVLRIDRIFRQPQGHLLLIGVSGAGKTTLSRFVAWMNGLSVYQIKVHRKYTGEDFDEDLRTVLRRSGCKNEKIAFIMDESNVLDSGFLERMNTLLANGEVPGLFEGDEYATLMTQCKEGAQKEGLMLDSHEELYKWFTSQVIRNLHVVFTMNPSSEGLKDRAATSPALFNRCVLNWFGDWSTEALYQVGKEFTSKMDLEKPNYIVPDYMPVVYDKLPQPPSHREAIVNSCVFVHQTLHQANARLAKRGGRTMAITPRHYLDFINHYANLFHEKRSELEEQQMHLNVGLRKIKETVDQVEELRRDLRIKSQELEVKNAAANDKLKKMVKDQQEAEKKKVMSQEIQEQLHKQQEVIADKQMSVKEDLDKVEPAVIEAQNAVKSIKKQHLVEVRSMANPPAAVKLALESICLLLGESTTDWKQIRSIIMRENFIPTIVNFSAEEISDAIREKMKKNYMSNPSYNYEIVNRASLACGPMVKWAIAQLNYADMLKRVEPLRNELQKLEDDAKDNQQKANEVEQMIRDLEASIARYKEEYAVLISEAQAIKADLAAVEAKVNRSTALLKSLSAERERWEKTSETFKNQMSTIAGDCLLSAAFIAYAGYFDQQMRQNLFTTWSHHLQQANIQFRTDIARTEYLSNADERLRWQASSLPADDLCTENAIMLKRFNRYPLIIDPSGQATEFIMNEYKDRKITRTSFLDDAFRKNLESALRFGNPLLVQDVESYDPVLNPVLNREVRRTGGRVLITLGDQDIDLSPSFVIFLSTRDPTVEFPPDLCSRVTFVNFTVTRSSLQSQCLNEVLKAERPDVDEKRSDLLKLQGEFQLRLRQLEKSLLQALNEVKGRILDDDTIITTLENLKREAAEVTRKVEETDIVMQEVETVSQQYLPLSTACSSIYFTMESLKQIHFLYQYSLQFFLDIYHNVLYENPNLKGVTDHTQRLSIITKDLFQVAFNRVARGMLHQDHITFAMLLARIKLKGTVGEPTYDAEFQHFLRGNEIVLSAGSTPRIQGLTVEQAEAVVRLSCLPAFKDLIAKVQADEQFGIWLDSSSPEQTVPYLWSEETPATPIGQAIHRLLLIQAFRPDRLLAMAHMFVSTNLGESFMSIMEQPLDLTHIVGTEVKPNTPVLMCSVPGYDASGHVEDLAAEQNTQITSIAIGSAEGFNQADKAINTAVKSGRWVMLKNVHLAPGWLMQLEKKLHSLQPHACFRLFLTMEINPKVPVNLLRAGRIFVFEPPPGVKANMLRTFSSIPVSRICKSPNERARLYFLLAWFHAIIQERLRYAPLGWSKKYEFGESDLRSACDTVDTWLDDTAKGRQNISPDKIPWSALKTLMAQSIYGGRVDNEFDQRLLNTFLERLFTTRSFDSEFKLACKVDGHKDIQMPDGIRREEFVQWVELLPDTQTPSWLGLPNNAERVLLTTQGVDMISKMLKMQMLEDEDDLAYAETEKKTRTDSTSDGRPAWMRTLHTTASNWLHLIPQTLSHLKRTVENIKDPLFRFFEREVKMGAKLLQDVRQDLADVVQVCEGKKKQTNYLRTLINELVKGILPRSWSHYTVPAGMTVIQWVSDFSERIKQLQNISLAAASGGAKELKNIHVCLGGLFVPEAYITATRQYVAQANSWSLEELCLEVNVTTSQGATLDACSFGVTGLKLQGATCNNNKLSLSNAISTALPLTQLRWVKQTNTEKKASVVTLPVYLNFTRADLIFTVDFEIATKEDPRSFYERGVAVLCTE","Homo sapiens","DYNC1H1, DHC1, DNCH1, DNCL, DNECL, DYHC, KIAA0325","Cytoplasmic dynein 1 heavy chain 1","1","5NUG"
"5NUT",,"X-RAY DIFFRACTION",2.42,49.11,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LiSO4, 0.1 M Tris HCl, 24% PEG3350",277,"10.1038/s41598-018-19872-3","9A8","5NUT",55.95,"1.6","1.6","Crystal structure of TNKS2 in complex with 2-[4-(propan-2-yloxy)phenyl]-3,4-dihydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5NUT"
"5NUV",,"X-RAY DIFFRACTION",1.97,37.45,"VAPOR DIFFUSION",6.3,"1.61 M (NH4)2SO4, 0.09 M NaCl, 0.1 M MES pH 6.3",303,"10.1002/pro.3222",,"5NUV",33.58,"1.55","1.55","Structure of the WD40-domain of human ATG16L1","GGGRGSGKEVRVPATALCVFDAHDGEVNAVQFSPGSRLLATGGMDRRVKLWEVFGAACEFKGSLSGSNAGITSIEFDSAGSYLLAASNDFASRIWTVDDYRLRHTLTGHSGKVLSAKFLLDNARIVSGSHDRTLKLWDLRSKVCIKTVFAGSSCNDIVCTEQCVMSGHFDKKIRFWDIRSESIVREMELLGKITALDLNPERTELLSCSRDDLLKVIDLRTNAIKQTFSAPGFKCGSDWTRVVFSPDGSYVAAGSAEGSLYIWSVLTGKVEKVLSKQHSSSINAVAWSPSGSHVVSVDKGCKAVLWAQP","Homo sapiens","ATG16L1, APG16L, UNQ9393/PRO34307","Autophagy-related protein 16-1","1","5NUV"
"5NV0",,"X-RAY DIFFRACTION",3.79,67.56,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES,0.2 M Li2SO4, 23-33% PEG 3350",298,,,"5NV0",34.6,"2.399","2.399","Human DNMT3B PWWP domain in complex with 4-(dipropylamino)butyronitrile","EADSGDGDSSEYQDGKEFGIGDLVWGKIKGFSWWPAMVVSWKATSKRQAMSGMRWVQWFGDGKFSEVSADKLVALGLFSQHFNLATFNKLVSYRKAMYHALEKARVRAGKTFPSSPGDSLEDQLKPMLEWAHGGFKPTGIEGLKPNNTQP","Homo sapiens","DNMT3B","DNA (cytosine-5)-methyltransferase 3B","1","5NV0"
"5NV2",,"X-RAY DIFFRACTION",3.77,67.38,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES,0.2 M Li2SO4, 23-33% PEG 3350",298,,,"5NV2",34.51,"2.029","2.029","Human DNMT3B PWWP domain in complex with N-isopropyl-1,5-dimethylhexylamine (Metron S)","EADSGDGDSSEYQDGKEFGIGDLVWGKIKGFSWWPAMVVSWKATSKRQAMSGMRWVQWFGDGKFSEVSADKLVALGLFSQHFNLATFNKLVSYRKAMYHALEKARVRAGKTFPSSPGDSLEDQLKPMLEWAHGGFKPTGIEGLKPNNTQP","Homo sapiens","DNMT3B","DNA (cytosine-5)-methyltransferase 3B","1","5NV2"
"5NV6",,"X-RAY DIFFRACTION",2.31,46.69,"VAPOR DIFFUSION, HANGING DROP",,"4% polyethylene glycol 4,000
0.1 M sodium acetate, pH 4.6",293,"10.1016/j.str.2017.09.001",,"5NV6",149.6,"2.93","2.93","Structure of human transforming growth factor beta-induced protein (TGFBIp).","MALFVRLLALALALALGPAATLAGPAKSPYQLVLQHSRLRGRQHGPNVCAVQKVIGTNRKYFTNCKQWYQRKICGKSTVISYECCPGYEKVPGEKGCPAALPLSNLYETLGVVGSTTTQLYTDRTEKLRPEMEGPGSFTIFAPSNEAWASLPAEVLDSLVSNVNIELLNALRYHMVGRRVLTDELKHGMTLTSMYQNSNIQIHHYPNGIVTVNCARLLKADHHATNGVVHLIDKVISTITNNIQQIIEIEDTFETLRAAVAASGLNTMLEGNGQYTLLAPTNEAFEKIPSETLNRILGDPEALRDLLNNHILKSAMCAEAIVAGLSVETLEGTTLEVGCSGDMLTINGKAIISNKDILATNGVIHYIDELLIPDSAKTLFELAAESDVSTAIDLFRQAGLGNHLSGSERLTLLAPLNSVFKDGTPPIDAHTRNLLRNHIIKDQLASKYLYHGQTLETLGGKKLRVFVYRNSLCIENSCIAAHDKRGRYGTLFTMDRVLTPPMGTVMDVLKGDNRFSMLVAAIQSAGLTETLNREGVYTVFAPTNEAFRALPPRERSRLLGDAKELANILKYHIGDEILVSGGIGALVRLKSLQGDKLEVSLKNNVVSVNKEPVAEPDIMATNGVVHVITNVLQPPANRPQERGDELADSALEIFKQASAFSRASQRSVRLAPVYQKLLERMKH","Homo sapiens","TGFBI, BIGH3","Transforming growth factor-beta-induced protein ig-h3","1","5NV6"
"5NV7",,"X-RAY DIFFRACTION",3.8,67.62,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES,0.2 M Li2SO4, 23-33% PEG 3350",298,,,"5NV7",34.14,"2.568","2.568","Human DNMT3B PWWP domain in complex with N1-(2-hydroxyethyl)-2-methyl-1,2-propanediamine","EADSGDGDSSEYQDGKEFGIGDLVWGKIKGFSWWPAMVVSWKATSKRQAMSGMRWVQWFGDGKFSEVSADKLVALGLFSQHFNLATFNKLVSYRKAMYHALEKARVRAGKTFPSSPGDSLEDQLKPMLEWAHGGFKPTGIEGLKPNNTQP","Homo sapiens","DNMT3B","DNA (cytosine-5)-methyltransferase 3B","1","5NV7"
"5NVB",,"SOLUTION NMR",,,,,,,,,"5NVB",1.69,,,"Structure of Tau(254-268) bound to F-actin","KNVKSKIGSTENLKH","Homo sapiens","MAPT, MAPTL, MTBT1, TAU","Microtubule-associated protein tau","1","5NVB"
"5NVC",,"X-RAY DIFFRACTION",2.45,49.8,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 %        PEG3350",277,"10.1038/s41598-018-19872-3","9AN","5NVC",55.72,"1.6","1.6","Crystal structure of TNKS2 in complex with 2-(3-hydroxyphenyl)-3,4-dihydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5NVC"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5NVC"
"5NVE",,"X-RAY DIFFRACTION",2.43,49.44,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 %         PEG3350",277,"10.1038/s41598-018-19872-3","9AQ","5NVE",55.87,"1.5","1.5","Crystal structure of TNKS2 in complex with 2-(4-ethoxyphenyl)-3,4-dihydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5NVE"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5NVE"
"5NVF",,"X-RAY DIFFRACTION",2.45,49.86,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 % PEG3350",277,"10.1038/s41598-018-19872-3","9AW","5NVF",55.84,"1.55","1.55","Crystal structure of TNKS2 in complex with 2-[4-(pyridin-2-yl)phenyl]-3,4-dihydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5NVF"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5NVF"
"5NVG",,"X-RAY DIFFRACTION",1.58,22.12,"VAPOR DIFFUSION, SITTING DROP",4.2,"20% (v/v) ethanol, 20% (w/v) PEG-1000, 0.1M Phosphate-citrate pH 4.2",291.15,"10.1038/nmeth.4302",,"5NVG",8.86,"1.07","1.07","Thr12 Phosphorylated Ubiquitin","MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBB","Polyubiquitin-B","1","5NVG"
"5NVH",,"X-RAY DIFFRACTION",2.44,49.5,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 % PEG3350",277,"10.1038/s41598-018-19872-3","9B2","5NVH",56.05,"1.6","1.6","Crystal structure of TNKS2 in complex with 2-[4-(piperidin-1-yl)phenyl]-3,4-dihydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5NVH"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5NVH"
"5NVO",,"X-RAY DIFFRACTION",3.77,67.39,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES,0.2 M Li2SO4, 23-33% PEG 3350",298,,,"5NVO",34.47,"2.4","2.4","Human DNMT3B PWWP domain in complex with choline","EADSGDGDSSEYQDGKEFGIGDLVWGKIKGFSWWPAMVVSWKATSKRQAMSGMRWVQWFGDGKFSEVSADKLVALGLFSQHFNLATFNKLVSYRKAMYHALEKARVRAGKTFPSSPGDSLEDQLKPMLEWAHGGFKPTGIEGLKPNNTQP","Homo sapiens","DNMT3B","DNA (cytosine-5)-methyltransferase 3B","1","5NVO"
"5NVS","8.4","ELECTRON MICROSCOPY",,,,,,,"10.1016/j.cell.2017.05.025",,"5NVS",344.11,"8.4",,"Human cytoplasmic dynein-1 tail in the twisted N-terminus state","XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"dynein heavy chain","1","5NVS"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"Tctex","10","5NVS"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"intermediate chain","11","5NVS"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"intermediate chain","12","5NVS"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"Robl","13","5NVS"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"dynein intermediate chain","2","5NVS"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"dynein heavy chain","3","5NVS"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"dynein light intermediate chain","4","5NVS"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"dynein light intermediate chain","5","5NVS"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"N-terminal dimerization domain","6","5NVS"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"N-terminal dimerization domain","7","5NVS"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"LC8","8","5NVS"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"Tctex","9","5NVS"
"5NVU","15","ELECTRON MICROSCOPY",,,,,,,"10.1016/j.cell.2017.05.025",,"5NVU",883.56,"15",,"Full length human cytoplasmic dynein-1 in the phi-particle conformation","XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"Dynein motor domain","1","5NVU"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"Tctex","10","5NVU"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"Tctex","11","5NVU"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"Intermediate chain N-terminus peptides","12","5NVU"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"Intermediate chain N-terminus peptides","13","5NVU"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"Robl","14","5NVU"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"Dynein tail heavy chain","2","5NVU"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"Dynein intermediate chain","3","5NVU"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"Dynein tail heavy chain","4","5NVU"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"Dynein light intermediate chain","5","5NVU"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"Dynein light intermediate chain","6","5NVU"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"N-terminal dimerization domain","7","5NVU"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"N-terminal dimerization domain","8","5NVU"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"LC8","9","5NVU"
"5NWB",,"X-RAY DIFFRACTION",2.44,49.58,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 %        PEG3350",277,"10.1038/s41598-018-19872-3","9C5","5NWB",56.02,"1.6","1.6","Crystal structure of TNKS2 in complex with 2-{4-[(2-hydroxyethyl)(methyl)amino]phenyl}-3,4-dihydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5NWB"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5NWB"
"5NWC",,"X-RAY DIFFRACTION",2.43,49.46,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 %        PEG3350",277,"10.1038/s41598-018-19872-3","9CE","5NWC",55.81,"1.5","1.5","Crystal structure of TNKS2 in complex with 2-(2-aminophenyl)-3,4-dihydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5NWC"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5NWC"
"5NWD",,"X-RAY DIFFRACTION",2.43,49.46,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 %         
PEG3350",277,"10.1038/s41598-018-19872-3","9C8","5NWD",55.83,"1.45","1.45","Crystal structure of TNKS2 in complex with 2-[4-(diethylamino)phenyl]-3,4-dihydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5NWD"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5NWD"
"5NWG",,"X-RAY DIFFRACTION",2.45,49.81,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 %         PEG3350",277,"10.1038/s41598-018-19872-3","9CB","5NWG",55.81,"1.4","1.4","Crystal structure of TNKS2 in complex with 7-chloro-2-{4-[(2-hydroxyethyl)(methyl)amino]phenyl}-3,4-dihydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5NWG"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5NWG"
"5NWH",,"X-RAY DIFFRACTION",1.98,37.85,"VAPOR DIFFUSION",,"26 mg/ml in 0.1 M HEPES, pH 7.5, 300 mM NaCl, 10% Glycerol, and 1 mM TCEP",291.15,"10.1038/s41467-017-02293-7",,"5NWH",49.69,"2.6","2.6","Potent inhibitors of NUDT5 silence hormone signaling in breast cancer","MESQEPTESSQNGKQYIISEELISEGKWVKLEKTTYMDPTGKTRTWESVKRTTRKEQTADGVAVIPVLQRTLHYECIVLVKQFRPPMGGYCIEFPAGLIDDGETPEAAALRELEEETGYKGDIAECSPAVCMDPGLSNCTIHIVTVTINGDDAENARPKPKPGDGEFVEVISLPKNDLLQRLDALVAEEHLTVDARVYSYALALKHANAKPFEVPFLKF","Homo sapiens","NUDT5, NUDIX5, HSPC115","ADP-sugar pyrophosphatase","1","5NWH"
"5NWL",,"X-RAY DIFFRACTION",3.52,65.02,"VAPOR DIFFUSION, HANGING DROP",,"0.1 MES pH 5.2 
MPD",291,"10.15252/embj.201798162",,"5NWL",525.57,"3.93","3.93","Crystal structure of a human RAD51-ATP filament.","MAMQMQLEANADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGFHTVEAVAYAPKKELINIKGISEAKADKILAEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKLLQGGIETGSITEMFGEFRTGKTQICHTLAVTCQLPIDRGGGEGKAMYIDTEGTFRPERLLAVAERYGLSGSDVLDNVAYARAFNTDHQTQLLYQASAMMVESRYALLIVDSATALYRTDYSGRGELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAADPKKPIGGNIIAHASTTRLYLRKGRGETRICKIYDSPCLPEAEAMFAINADGVGDAKD","Homo sapiens","RAD51, RAD51A, RECA","DNA repair protein RAD51 homolog 1","1","5NWL"
"5NWZ",,"X-RAY DIFFRACTION",2.37,48.12,"VAPOR DIFFUSION, HANGING DROP",,"TRIS, 25% PEG3350.
                      1MM EDTA, PH8.0",293,"10.1039/c7md00213k",,"5NWZ",69.58,"2.37","2.37","FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527","GPLVSLDLPLDPLWEFPRDRLVLGKPLGEGCFGQVVRAEAFGMDPARPDQASTVAVKMLKDNASDKDLADLVSEMEVMKLIGRHKNIINLLGVCTQEGPLYVIVECAAKGNLREFLRARRPPGPDLSPDGPRSSEGPLSFPVLVSCAYQVARGMQYLESRKCIHRDLAARNVLVTEDNVMKIADFGLARGVHHIDYYKKTSNGRLPVKWMAPEALFDRVYTHQSDVWSFGILLWEIFTLGGSPYPGIPVEELFSLLREGHRMDRPPHCPPELYGLMRECWHAAPSQRPTFKQLVEALDKVLLAVSEE","Homo sapiens","FGFR4, JTK2, TKF","Fibroblast growth factor receptor 4","1","5NWZ"
"5NXC",,"X-RAY DIFFRACTION",2.32,46.97,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M HEPES pH 7.0
0.2 M MgCl2
10% PEG8K",277,,,"5NXC",36.41,"2.25","2.25","LIM Domain Kinase 1 (LIMK1) In Complex With PF-00477736","SMPHRIFRPSDLIHGEVLGKGCFGQAIKVTHRETGEVMVMKELIRFDEETQRTFLKEVKVMRCLEHPNVLKFIGVLYKDKRLNFITEYIKGGTLRGIIKSMDSQYPWSQRVSFAKDIASGMAYLHSMNIIHRDLNSHNCLVRENKNVVVADFGLARLMVDEKTQPEGLRSLKKPDRKKRYTVVGNPYWMAPEMINGRSYDEKVDVFSFGIVLCEIIGRVNADPDYLPRTMDFGLNVRGFLDRYCPPNCPPSFFPITVRCCDLDPEKRPSFVKLEHWLETLRMHLAGHLPLGPQLEQLDRGFWETYRRGES","Homo sapiens","LIMK1, LIMK","LIM domain kinase 1","1","5NXC"
"5NXD",,"X-RAY DIFFRACTION",2.3,46.49,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M bis-tris-propane pH 7.5
0.2 M Na2SO4
10% ethylene glycol
17% PEG3.35K",277,,,"5NXD",70.61,"1.9","1.9","LIM Domain Kinase 2 (LIMK2) In Complex With TH-300","SMDLIHGEVLGKGFFGQAIKVTHKATGKVMVMKELIRCDEETQKTFLTEVKVMRSLDHPNVLKFIGVLYKDKKLNLLTEYIEGGTLKDFLRSMDPFPWQQKVRFAKGIASGMAYLHSMCIIHRDLNSHNCLIKLDKTVVVADFGLSRLIVEERKRAPMEKATTKKRTLRKNDRKKRYTVVGNPYWMAPEMLNGKSYDETVDIFSFGIVLCEIIGQVYADPDCLPRTLDFGLNVKLFWEKFVPTDCPPAFFPLAAICCRLEPESRPAFSKLEDSFEALSLYLGELGIPLPAELEELDHTVSMQYGL","Homo sapiens","LIMK2","LIM domain kinase 2","1","5NXD"
"5NXE",,"X-RAY DIFFRACTION",2.43,49.33,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 24/26 % PEG3350",277,"10.1038/s41598-018-19872-3",,"5NXE",55.93,"1.6","1.6","Crystal structure of TNKS2 in complex with 2-{4-[(2-hydroxyethyl)(methyl)amino]phenyl}-1,2,3,4-tetrahydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5NXE"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5NXE"
"5NXG",,"X-RAY DIFFRACTION",2.05,39.86,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris, 1.6 M Natrium Acetate",291.15,"10.1002/cphc.201701104","RA1","5NXG",29.35,"1.2","1.2","Carbonic Anhydrase II Inhibitor RA1","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5NXG"
"5NXI",,"X-RAY DIFFRACTION",2.1,41.47,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris
1.6 M Natrium Citrate",291.15,"10.1002/cphc.201701104","9DE","5NXI",29.79,"1.16","1.16","Carbonic Anhydrase II Inhibitor RA2","AHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5NXI"
"5NXM",,"X-RAY DIFFRACTION",2.09,41.05,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris
1.6 M Natrium Citrate",291.15,"10.1002/cphc.201701104",,"5NXM",29.51,"1.25","1.25","Carbonic Anhydrase II Inhibitor RA1","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5NXM"
"5NXO",,"X-RAY DIFFRACTION",2.11,41.74,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris
1.6 M Natrium Citrate",291,"10.1002/cphc.201701104","9HK","5NXO",29.72,"1.2","1.2","Carbonic Anhydrase II Inhibitor RA6","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5NXO"
"5NXP",,"X-RAY DIFFRACTION",2.05,40,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris
1.6 M Natrium Citrate",291,"10.1002/cphc.201701104","9DH","5NXP",29.46,"1.25","1.25","Carbonic Anhydrase II Inhibitor RA7","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5NXP"
"5NXS",,"X-RAY DIFFRACTION",4.13,70.19,"VAPOR DIFFUSION",4.2,"10 mg/mL protein, reservoir: 0.1M NaAcetate, 1M (NH4)3PO4: cryo-protection: 26% ethylene glycol",292,"10.15252/embj.201797883",,"5NXS",77,"4.19","4.19","Crystal Structure of Human Pro-myostatin Precursor at 4.2 A Resolution with Experimental Phases from SeMet labelling","GSTWRQNTKSSRIEAIKIQILSKLRLETAPNISKDVIRQLLPKAPPLRELIDQYDVQRDDSSDGSLEDDDYHATTETIITMPTESDFLMQVDGKPKCCFFKFSSKIQYNKVVKAQLWIYLRPVETPTTVFVQILRLIKPMKDGTRYTGIRSLKLDMNPGTGIWQSIDVKTVLQNWLKQPESNLGIEIKALDENGHDLAVTFPGPGEDGLNPFLEVKVTDTPKRSRRDFGLDCDEHSTESRCCRYPLTVDFEAFGWDWIIAPKRYKANYCSGECEFVFLQKYPHTHLVHQANPRGSAGPCCTPTKMSPINMLYFNGKEQIIYGKIPAMVVDRCGCS","Homo sapiens","MSTN, GDF8","Growth/differentiation factor 8","1","5NXS"
"5NXV",,"X-RAY DIFFRACTION",2.08,40.72,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris
1.6 M Natrium Citrate",273,"10.1002/cphc.201701104","9E2","5NXV",29.51,"1.1","1.1","Carbonic Anhydrase II Inhibitor RA8","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5NXV"
"5NXW",,"X-RAY DIFFRACTION",2.11,41.65,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris                                               
1.6 M Natrium Citrate",291,"10.1002/cphc.201701104","RA9","5NXW",29.69,"1.1","1.1","Carbonic Anhydrase II Inhibitor RA9","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5NXW"
"5NY1",,"X-RAY DIFFRACTION",2.1,41.54,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris                                               
1.6 M Natrium Citrate",291,"10.1002/cphc.201701104","9E5","5NY1",29.37,"1.1","1.1","Carbonic Anhydrase II Inhibitor RA10","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5NY1"
"5NY3",,"X-RAY DIFFRACTION",2.1,41.31,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris                                               
1.6 M Natrium Citrate",291,"10.1002/cphc.201701104","9E8","5NY3",29.49,"1.4","1.4","Carbonic Anhydrase II Inhibitor RA11","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5NY3"
"5NY6",,"X-RAY DIFFRACTION",2.08,40.73,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris                                               
1.6 M Natrium Citrate",291,"10.1002/cphc.201701104","R92","5NY6",29.85,"1.1","1.1","Carbonic Anhydrase II Inhibitor RA12","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5NY6"
"5NYA",,"X-RAY DIFFRACTION",2.1,41.5,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM Tris                                               
1.6 M Natrium Citrate",291,"10.1002/cphc.201701104","FB2","5NYA",29.29,"1.2","1.2","Carbonic Anhydrase II Inhibitor RA13","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5NYA"
"5NYH",,"X-RAY DIFFRACTION",2.89,57.47,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M sodium fluoride, 0.1 M Bis Tris propane, pH 8.5, 20 % w/v PEG 3350",277.15,"10.1021/acs.jmedchem.8b00080","9EK","5NYH",26.16,"1.65","1.65","Crystal Structure of Hsp90-alpha N-Domain in complex with Indazole derivative","GDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5NYH"
"5NYI",,"X-RAY DIFFRACTION",3.16,61.06,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Bis-Tris buffer pH 8.5, 20% PEG 3,350, 200 mM NaF",277,,"2EQ","5NYI",26.4,"1.44","1.44","Crystal Structure of Hsp90-alpha N-Domain in complex with Resorcinol derivative","GDQPMEEEEVETFAFQAEIAQLMTLIINTFYTNKEIFLRELITNTTDALDKIRYETLTDPTKLDTGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKTGTKAFMEALQAGADITMIGQFGVGFYTAYLVAEKVTVITKHNDDEQYAWETTAGGTFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHTQFIGYPITLFVEEERDKEVTDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5NYI"
"5NYX",,"X-RAY DIFFRACTION",2.26,45.68,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M (NH4)2SO4, 0.1 M Na-Cacodilate pH 6.5, 30 %w/v PEG 8K",293.15,"10.1371/journal.pone.0201922",,"5NYX",154.47,"1.88","1.88","human Fab fragment 5H2 against NHBA from Neisseria meningitidis","QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGSSYWTWIRQTPGKGLEWIGYTSYSGSTKYNPSLKSRVTLSVDMSKNQFSLKLKSVTAADTAVYFCARDRFDVASGSSFDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKGSENLYFQGSWSHPQFEKGGSGGGSGGGSWSHPQFEK","Homo sapiens",,"HEAVY CHAIN","1","5NYX"
,,,,,,,,,,,,,,,,"EIVMTQTPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGTAPKLLTYAASSLGSGVPSRFSGSGSGTDLTLTISSLRPEDFATYYCQQSYGSPTFGQGTKLEIRRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"LIGHT CHAIN","2","5NYX"
"5NZ9",,"SOLUTION NMR",,,,,,,"10.1038/s41598-017-17684-5",,"5NZ9",2.88,,,"NMR structure of an EphA2-Sam fragment","XKRIGVRLPGHQKRIAYSLLGLKDQVX","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5NZ9"
"5NZO",,"X-RAY DIFFRACTION",2.27,45.71,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M PCTP buffer, pH 7 and 23-28 % (w/v) PEG 1500",293,"10.18632/oncotarget.11487","9EZ","5NZO",42.25,"1.29","1.29","Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with 1-methyl-3-phenyl-1H-pyrazol-5-amine","NGNSLSAAELTCGMIMCLARQIPQATASMKDGKWERKKFMGTELNGKTLGILGLGRIGREVATRMQSFGMKTIGYDPIISPEVSASFGVQQLPLEEIWPLCDFITVHTPLLPSTTGLLNDNTFAQCKKGVRVVNCARGGIVDEGALLRALQSGQCAGAALDVFTEEPPRDRALVDHENVISCPHLGASTKEAQSR","Homo sapiens","PHGDH, PGDH3","D-3-phosphoglycerate dehydrogenase","1","5NZO"
"5NZP",,"X-RAY DIFFRACTION",2.17,43.23,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M PCTP, pH 7, 23-25 % PEG 1500",298,"10.18632/oncotarget.11487","9EW","5NZP",44.12,"1.3","1.3","Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with 3-Hydroxybenzisoxazole","MNTPNGNSLSAAELTCGMIMCLARQIPQATASMKDGKWERKKFMGTELNGKTLGILGLGRIGREVATRMQSFGMKTIGYDPIISPEVSASFGVQQLPLEEIWPLCDFITVHTPLLPSTTGLLNDNTFAQCKKGVRVVNCARGGIVDEGALLRALQSGQCAGAALDVFTEEPPRDRALVDHENVISCPHLGASTKEAQSRCGEEI","Homo sapiens","PHGDH, PGDH3","D-3-phosphoglycerate dehydrogenase","1","5NZP"
"5NZQ",,"X-RAY DIFFRACTION",2.02,39.16,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M PCTP pH 7, 23-25 % PEG 1500",293,"10.18632/oncotarget.11487","5AO","5NZQ",48.19,"1.5","1.5","Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with 3-(1,3-oxazol-5-yl)aniline.","MLVMNTPNGNSLSAAELTCGMIMCLARQIPQATASMKDGKWERKKFMGTELNGKTLGILGLGRIGREVATRMQSFGMKTIGYDPIISPEVSASFGVQQLPLEEIWPLCDFITVHTPLLPSTTGLLNDNTFAQCKKGVRVVNCARGGIVDEGALLRALQSGQCAGAALDVFTEEPPRDRALVDHENVISCPHLGASTKEAQSRCGEEIAVQFVDMVKGKSLTGV","Homo sapiens","PHGDH, PGDH3","D-3-phosphoglycerate dehydrogenase","1","5NZQ"
"5NZW",,"X-RAY DIFFRACTION",2.17,43.36,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 1000, 0.1 M MIB buffer pH 6.0",278,,,"5NZW",39.54,"2.7","2.7","Crystal structure of DNA cross-link repair protein 1A in complex with ceftriaxone","KKTCPFYKKIPGTGFTVDAFQYGVVEGCTAYFLTHFHSDHYAGLSKHFTFPVYCSEITGNLLKNKLHVQEQYIHPLPLDTECIVNGVKVVLLDANHCPGAVMILFYLPNGTVILHTGDFRADPSMERSLLADQKVHMLYLDTTYCSPEYTFPSQQEVIRFAINTAFEAVTLNPHALVVCGTYSIGKEKVFLAIADVLGSKVGMSQEKYKTLQCLNIPEINSLITTDMCSSLVHLLPMMQINFKGLQSHLKKCGGKYNQILAFRPTGWTHSNKFTRIADVIPQTKGNISIYGIPYSEHSSYLEMKRFVQWLKPQKIIPTVNVGTWKSRSTMEKYFREWKLEAGY","Homo sapiens","DCLRE1A, KIAA0086, SNM1, SNM1A","DNA cross-link repair 1A protein","1","5NZW"
"5NZX",,"X-RAY DIFFRACTION",2.12,42.02,"VAPOR DIFFUSION, SITTING DROP",6,"30 % PEG 1000, 0.1 M MIB buffer pH 6.0",278,,,"5NZX",39.54,"1.47","1.47","Crystal structure of DNA cross-link repair protein 1A in complex with Ceftriaxone (alternative site)","KKTCPFYKKIPGTGFTVDAFQYGVVEGCTAYFLTHFHSDHYAGLSKHFTFPVYCSEITGNLLKNKLHVQEQYIHPLPLDTECIVNGVKVVLLDANHCPGAVMILFYLPNGTVILHTGDFRADPSMERSLLADQKVHMLYLDTTYCSPEYTFPSQQEVIRFAINTAFEAVTLNPHALVVCGTYSIGKEKVFLAIADVLGSKVGMSQEKYKTLQCLNIPEINSLITTDMCSSLVHLLPMMQINFKGLQSHLKKCGGKYNQILAFRPTGWTHSNKFTRIADVIPQTKGNISIYGIPYSEHSSYLEMKRFVQWLKPQKIIPTVNVGTWKSRSTMEKYFREWKLEAGY","Homo sapiens","DCLRE1A, KIAA0086, SNM1, SNM1A","DNA cross-link repair 1A protein","1","5NZX"
"5NZY",,"X-RAY DIFFRACTION",2.07,40.49,"VAPOR DIFFUSION, SITTING DROP",,"30 % PEG 1000, 0.1 M MIB buffer pH 6.0",278,,,"5NZY",39.89,"1.551","1.551","Crystal structure of DNA cross-link repair protein 1A in complex with Cefotaxime","KKTCPFYKKIPGTGFTVDAFQYGVVEGCTAYFLTHFHSDHYAGLSKHFTFPVYCSEITGNLLKNKLHVQEQYIHPLPLDTECIVNGVKVVLLDANHCPGAVMILFYLPNGTVILHTGDFRADPSMERSLLADQKVHMLYLDTTYCSPEYTFPSQQEVIRFAINTAFEAVTLNPHALVVCGTYSIGKEKVFLAIADVLGSKVGMSQEKYKTLQCLNIPEINSLITTDMCSSLVHLLPMMQINFKGLQSHLKKCGGKYNQILAFRPTGWTHSNKFTRIADVIPQTKGNISIYGIPYSEHSSYLEMKRFVQWLKPQKIIPTVNVGTWKSRSTMEKYFREWKLEAGY","Homo sapiens","DCLRE1A, KIAA0086, SNM1, SNM1A","DNA cross-link repair 1A protein","1","5NZY"
"5O07",,"X-RAY DIFFRACTION",2.09,41.07,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.3 M SODIUM CITRATE, 100 MM TRIS-HCL",293,"10.1080/14756366.2017.1349764","1VQ","5O07",29.6,"1.8","1.8","The crystal structure of the human carbonic anhydrase II in complex with a nitroimidazole sulfamate inhibitor","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5O07"
"5O0Y",,"X-RAY DIFFRACTION",2.47,50.3,"VAPOR DIFFUSION, SITTING DROP",,"20 mM HEPES pH 7, 2M Li2SO4, 10mM MgCl2

1M Na/K tartrate, 0.1M Tris pH7, 200mM LiSO4",277,"10.1038/s41467-018-04941-y",,"5O0Y",67.92,"2.86","2.86","TLK2 kinase domain from human","MGSSHHHHHHSTGSTEHSCSSQKQISIQHRQTQSDLTIEKISALENSKNSDLEKKEGRIDDLLRANCDLRRQIDEQQKMLEKYKERLNRCVTMSKKLLIEKSKQEKMACRDKSMQDRLRLGHFTTVRHGASFTEQWTDGYAFQNLIKQQERINSQREEIERQRKMLAKRKPPAMGQAPPATNEQKQRKSKTNGAENETPSSGNTELKDTAPALGAHSLLRLTLAEYHEQEEIFKLRLGHLKKEEAEIQAELERLERVRNLHIRELKRIHNEDNSQFKDHPTLNDRYLLLHLLGRGGFSEVYKAFDLTEQRYVAVKIHQLNKNWRDEKKENYHKHACREYRIHKELDHPRIVKLYDYFSLDTDSFCTVLEYCEGNDLDFYLKQHKLMSEKEARSIIMQIVNALKYLNEIKPPIIHYDLKPGNILLVNGTACGEIKITDFGLSKIMDDDSYNSVDGMELTSQGAGTYWYLPPECFVVGKEPPKISNKVDVWSVGVIFYQCLYGRKPFGHNQSQQDILQENTILKATEVQFPPKPVVTPEAKAFIRRCLAYRKEDRIDVQQLACDPYLLPHIRKSVSTSSPA","Homo sapiens","TLK2","Serine/threonine-protein kinase tousled-like 2","1","5O0Y"
"5O10",,"X-RAY DIFFRACTION",2.43,49.31,"VAPOR DIFFUSION, SITTING DROP",7.5,"33% PEG 6000
100mM Tris pH 7.5",291,"10.1021/acs.biochem.7b00890",,"5O10",24.47,"1.36","1.36","Y48H mutant of human cytochrome c","GDVEKGKKIFIMKCSQCHTVEKGGKHKTGPNLHGLFGRKTGQAPGYSHTAANKNKGIIWGEDTLMEYLENPKKYIPGTKMIFVGIKKKEERADLIAYLKKATNE","Homo sapiens","CYCS, CYC","Cytochrome c","1","5O10"
"5O11",,"X-RAY DIFFRACTION",3.41,63.91,"VAPOR DIFFUSION, SITTING DROP",8,"Tris, potassium sodium tartrate tetrahydrate",293,"10.1038/s41598-017-13557-z","3NG","5O11",35.17,"2.4","2.4","Crystal structure of PIM1 kinase in complex with small-molecule inhibitor","HHHHHHSQDPNSMKEKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLSPGPSK","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5O11"
"5O12",,"X-RAY DIFFRACTION",3.57,65.54,"VAPOR DIFFUSION, SITTING DROP",8,"Tris, potassium sodium tartrate tetrahydrate",293,"10.1038/s41598-017-13557-z",,"5O12",34.95,"2.4","2.4","Crystal structure of PIM1 kinase in complex with small-molecule inhibitor","HHHHHHSQDPNSMKEKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLSPGPSK","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5O12"
"5O13",,"X-RAY DIFFRACTION",3.5,64.9,"VAPOR DIFFUSION, SITTING DROP",,"Tris, potassium sodium tartrate tetrahydrate",293,"10.1038/s41598-017-13557-z","9G5","5O13",35.04,"2.44","2.44","Crystal structure of PIM1 kinase in complex with small-molecule inhibitor","HHHHHHSQDPNSMKEKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLSPGPSK","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5O13"
"5O1A",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 6 mg/ml protein in 25 mM sodium phosphate, ph 7.2, 150 mm KCl, 5 mm DTT. Reservoir buffer: 100 mm HEPES, pH 7.2, 19% (w/v) polyethylene glycol 4000, 5 mm DTT. Soaking buffer: 30 mM compound in 100 mm HEPES, ph 7.2, 10 mM sodium phosphate, ph 7.2, 19% (w/v) polyethylene glycol 4000, 20 % (v/v) glycerol, 150 mm KCl.",293,"10.1016/j.ejmech.2018.04.035","9H5","5O1A",50.36,"1.44","1.44","p53 cancer mutant Y220C in complex with compound MB240","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","Cellular tumor antigen p53","1","5O1A"
"5O1B",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 6 mg/ml protein in 25 mM sodium phosphate, ph 7.2, 150 mm KCl, 5 mm DTT. Reservoir buffer: 100 mm HEPES, pH 7.2, 19% (w/v) polyethylene glycol 4000, 5 mm DTT. Soaking buffer: 30 mM compound in 100 mm HEPES, ph 7.2, 10 mM sodium phosphate, ph 7.2, 19% (w/v) polyethylene glycol 4000, 20 % (v/v) glycerol, 150 mm KCl.",293,"10.1016/j.ejmech.2018.04.035","9H2","5O1B",50.44,"1.43","1.43","p53 cancer mutant Y220C in complex with compound MB84","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","Cellular tumor antigen p53","1","5O1B"
"5O1C",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 6 mg/ml protein in 25 mM sodium phosphate, ph 7.2, 150 mm KCl, 5 mm DTT. Reservoir buffer: 100 mm HEPES, pH 7.2, 19% (w/v) polyethylene glycol 4000, 5 mm DTT. Soaking buffer: 30 mM compound in 100 mm HEPES, ph 7.2, 10 mM sodium phosphate, ph 7.2, 19% (w/v) polyethylene glycol 4000, 20 % (v/v) glycerol, 150 mm KCl.",293,"10.1016/j.ejmech.2018.04.035","9GZ","5O1C",50.04,"1.32","1.32","p53 cancer mutant Y220C in complex with compound MB184","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","Cellular tumor antigen p53","1","5O1C"
"5O1D",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 6 mg/ml protein in 25 mM sodium phosphate, ph 7.2, 150 mm KCl, 5 mm DTT. Reservoir buffer: 100 mm HEPES, pH 7.2, 19% (w/v) polyethylene glycol 4000, 5 mm DTT. Soaking buffer: 30 mM compound in 100 mm HEPES, ph 7.2, 10 mM sodium phosphate, ph 7.2, 19% (w/v) polyethylene glycol 4000, 20 % (v/v) glycerol, 150 mm KCl.",293,"10.1016/j.ejmech.2018.04.035","9GW","5O1D",50.15,"1.36","1.36","p53 cancer mutant Y220C in complex with compound MB481","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","Cellular tumor antigen p53","1","5O1D"
"5O1E",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 6 mg/ml protein in 25 mM sodium phosphate, ph 7.2, 150 mm KCl, 5 mm DTT. Reservoir buffer: 100 mm HEPES, pH 7.2, 19% (w/v) polyethylene glycol 4000, 5 mm DTT. Soaking buffer: 30 mM compound in 100 mm HEPES, ph 7.2, 10 mM sodium phosphate, ph 7.2, 19% (w/v) polyethylene glycol 4000, 20 % (v/v) glycerol, 150 mm KCl.",293,"10.1016/j.ejmech.2018.04.035","9GT","5O1E",50.15,"1.3","1.3","p53 cancer mutant Y220C im complex with compound MB577","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","Cellular tumor antigen p53","1","5O1E"
"5O1F",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 6 mg/ml protein in 25 mM sodium phosphate, ph 7.2, 150 mm KCl, 5 mm DTT. Reservoir buffer: 100 mm HEPES, pH 7.2, 19% (w/v) polyethylene glycol 4000, 5 mm DTT. Soaking buffer: 30 mM compound in 100 mm HEPES, ph 7.2, 10 mM sodium phosphate, ph 7.2, 19% (w/v) polyethylene glycol 4000, 20 % (v/v) glycerol, 150 mm KCl.",293,"10.1016/j.ejmech.2018.04.035","9GQ","5O1F",49.99,"1.38","1.38","p53 cancer mutant Y220C in complex with compound MB582","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","Cellular tumor antigen p53","1","5O1F"
"5O1G",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 6 mg/ml protein in 25 mM sodium phosphate, ph 7.2, 150 mm KCl, 5 mm DTT. Reservoir buffer: 100 mm HEPES, pH 7.2, 19% (w/v) polyethylene glycol 4000, 5 mm DTT. Soaking buffer: 30 mM compound in 100 mm HEPES, ph 7.2, 10 mM sodium phosphate, ph 7.2, 19% (w/v) polyethylene glycol 4000, 20 % (v/v) glycerol, 150 mm KCl.",293,"10.1016/j.ejmech.2018.04.035","9GK","5O1G",50.18,"1.35","1.35","p53 cancer mutant Y220C in complex with compound MB487","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","Cellular tumor antigen p53","1","5O1G"
"5O1H",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 6 mg/ml protein in 25 mM sodium phosphate, ph 7.2, 150 mm KCl, 5 mm DTT. Reservoir buffer: 100 mm HEPES, pH 7.2, 19% (w/v) polyethylene glycol 4000, 5 mm DTT. Soaking buffer: 30 mM compound in 100 mm HEPES, ph 7.2, 10 mM sodium phosphate, ph 7.2, 19% (w/v) polyethylene glycol 4000, 20 % (v/v) glycerol, 150 mm KCl.",293,"10.1016/j.ejmech.2018.04.035","9GN","5O1H",50.09,"1.32","1.32","p53 cancer mutant Y220C in complex with compound MB539","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","Cellular tumor antigen p53","1","5O1H"
"5O1I",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 6 mg/ml protein in 25 mM sodium phosphate, ph 7.2, 150 mm KCl, 5 mm DTT. Reservoir buffer: 100 mm HEPES, pH 7.2, 19% (w/v) polyethylene glycol 4000, 5 mm DTT. Soaking buffer: Saturated solution of compound in 100 mm HEPES, ph 7.2, 10 mM sodium phosphate, ph 7.2, 19% (w/v) polyethylene glycol 4000, 20 % (v/v) glycerol, 150 mm KCl.",293,"10.1016/j.ejmech.2018.04.035","9GH","5O1I",49.8,"1.4","1.4","p53 cancer mutant Y220C in complex with compound MB710","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","Cellular tumor antigen p53","1","5O1I"
"5O1N",,"X-RAY DIFFRACTION",3.22,61.79,"VAPOR DIFFUSION, HANGING DROP",7.5,"25% PEG3350 -- 0.3M sodium malonate -- 0.1M tris pH 7.5",285,,,"5O1N",55.09,"2.28","2.28","Crystal structure of human aminoadipate semialdehyde synthase, saccharopine dehydrogenase domain with N-[(2S)-2-Pyrrolidinylmethyl]-trifluoromethanesulfonamide bound","MGHHHHHHSSGVDLGTENLYFQSMALPDKYKYIQTLRESRERAQSLSMGTRRKVLVLGSGYISEPVLEYLSRDGNIEITVGSDMKNQIEQLGKKYNINPVSMDICKQEEKLGFLVAKQDLVISLLPYVLHPLVAKACITNKVNMVTASYITPALKELEKSVEDAGITIIGELGLDPGLDHMLAMESIDKAKEVGATIESYISYCGGLPAPEHSNNPLRYKFSWSPVGVLMNVMQSATYLLDGKVVNVAGGISFLDAVTSMDFFPGLNLEGYPNRDSTKYAEIYGISSAHTLLRGTLRYKGYMKALNGFVKLGLINREALPAFRPEANPLTWKQLLCDLVGISPSSEHDVLKEAVLKKLGGDNTQLEAAEWLGLLGDEQVPQAESILDALSKHLVMKLSYGPEEKDMIVMRDSFGIRHPSGHLEHKTIDLVAYGDINGFSAMAKTVGLPTAMAAKMLLDGEIGAKGLMGPFSKEIYGPILERIKAEGIIYTTQSTIKP","Homo sapiens","AASS","Alpha-aminoadipic semialdehyde synthase, mitochondrial","1","5O1N"
"5O1O",,"X-RAY DIFFRACTION",3.22,61.79,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M tris pH 7.5 -- 0.2M sodium malonate -- 20% PEG3350",286,,,"5O1O",109.57,"2.48","2.48","Crystal structure of human aminoadipate semialdehyde synthase, saccharopine dehydrogenase domain with proline bound.","MGHHHHHHSSGVDLGTENLYFQSMALPDKYKYIQTLRESRERAQSLSMGTRRKVLVLGSGYISEPVLEYLSRDGNIEITVGSDMKNQIEQLGKKYNINPVSMDICKQEEKLGFLVAKQDLVISLLPYVLHPLVAKACITNKVNMVTASYITPALKELEKSVEDAGITIIGELGLDPGLDHMLAMESIDKAKEVGATIESYISYCGGLPAPEHSNNPLRYKFSWSPVGVLMNVMQSATYLLDGKVVNVAGGISFLDAVTSMDFFPGLNLEGYPNRDSTKYAEIYGISSAHTLLRGTLRYKGYMKALNGFVKLGLINREALPAFRPEANPLTWKQLLCDLVGISPSSEHDVLKEAVLKKLGGDNTQLEAAEWLGLLGDEQVPQAESILDALSKHLVMKLSYGPEEKDMIVMRDSFGIRHPSGHLEHKTIDLVAYGDINGFSAMAKTVGLPTAMAAKMLLDGEIGAKGLMGPFSKEIYGPILERIKAEGIIYTTQSTIKP","Homo sapiens","AASS","Alpha-aminoadipic semialdehyde synthase, mitochondrial","1","5O1O"
"5O1P",,"X-RAY DIFFRACTION",2.92,57.92,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M tris pH 7.5 -- 0.33M sodium malonate -- 19.5% PEG3350",286,,,"5O1P",54.97,"1.9","1.9","Crystal structure of human aminoadipate semialdehyde synthase, saccharopine dehydrogenase.","MGHHHHHHSSGVDLGTENLYFQSMALPDKYKYIQTLRESRERAQSLSMGTRRKVLVLGSGYISEPVLEYLSRDGNIEITVGSDMKNQIEQLGKKYNINPVSMDICKQEEKLGFLVAKQDLVISLLPYVLHPLVAKACITNKVNMVTASYITPALKELEKSVEDAGITIIGELGLDPGLDHMLAMESIDKAKEVGATIESYISYCGGLPAPEHSNNPLRYKFSWSPVGVLMNVMQSATYLLDGKVVNVAGGISFLDAVTSMDFFPGLNLEGYPNRDSTKYAEIYGISSAHTLLRGTLRYKGYMKALNGFVKLGLINREALPAFRPEANPLTWKQLLCDLVGISPSSEHDVLKEAVLKKLGGDNTQLEAAEWLGLLGDEQVPQAESILDALSKHLVMKLSYGPEEKDMIVMRDSFGIRHPSGHLEHKTIDLVAYGDINGFSAMAKTVGLPTAMAAKMLLDGEIGAKGLMGPFSKEIYGPILERIKAEGIIYTTQSTIKP","Homo sapiens","AASS","Alpha-aminoadipic semialdehyde synthase, mitochondrial","1","5O1P"
"5O1V",,"X-RAY DIFFRACTION",2.42,49.18,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG4000, 10% 2-propanol, 0.1M HEPES pH 7.5. 2:1 protein to reservoir.",277,,,"5O1V",66.46,"1.723","1.723","Crystal structure of WNK3 kinase domain in a monophosphorylated apo state (A-loop swapped)","SMEAEMKAVATSPSGRFLKFDIELGRGAFKTVYKGLDTETWVEVAWCELQDRKLTKAEQQRFKEEAEMLKGLQHPNIVRFYDSWESILKGKKCIVLVTELMTSGTLKTYLKRFKVMKPKVLRSWCRQILKGLQFLHTRTPPIIHRDLKCDNIFITGPTGSVKIGDLGLATLMRTSFAKSVIGTPEFMAPEMYEEHYDESVDVYAFGMCMLEMATSEYPYSECQNAAQIYRKVTSGIKPASFNKVTDPEVKEIIEGCIRQNKSERLSIRDLLNHAFFAEDTGLRVE","Homo sapiens","WNK3, KIAA1566, PRKWNK3","Serine/threonine-protein kinase WNK3","1","5O1V"
"5O21",,"X-RAY DIFFRACTION",2.8,56.02,"VAPOR DIFFUSION, SITTING DROP",,"22.5% PEG Smear Broad, 0.1 M sodium/potassium tartrate, 10% ethylene glycol, 0.1 M cacodylate pH 5.5",277,,,"5O21",66.53,"2.06","2.06","Crystal structure of WNK3 kinase domain in a monophosphorylated state with chloride bound in the active site","SMEAEMKAVATSPSGRFLKFDIELGRGAFKTVYKGLDTETWVEVAWCELQDRKLTKAEQQRFKEEAEMLKGLQHPNIVRFYDSWESILKGKKCIVLVTELMTSGTLKTYLKRFKVMKPKVLRSWCRQILKGLQFLHTRTPPIIHRDLKCDNIFITGPTGSVKIGDLGLATLMRTSFAKSVIGTPEFMAPEMYEEHYDESVDVYAFGMCMLEMATSEYPYSECQNAAQIYRKVTSGIKPASFNKVTDPEVKEIIEGCIRQNKSERLSIRDLLNHAFFAEDTGLRVE","Homo sapiens","WNK3, KIAA1566, PRKWNK3","Serine/threonine-protein kinase WNK3","1","5O21"
"5O23",,"X-RAY DIFFRACTION",3.64,66.22,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG Smear Medium, 0.2 M lithium sulfate, 0.1 M ADA pH 6.5",293,,,"5O23",67.69,"2.25","2.25","Crystal structure of WNK3 kinase domain in a monophosphorylated apo state","SMEAEMKAVATSPSGRFLKFDIELGRGAFKTVYKGLDTETWVEVAWCELQDRKLTKAEQQRFKEEAEMLKGLQHPNIVRFYDSWESILKGKKCIVLVTELMTSGTLKTYLKRFKVMKPKVLRSWCRQILKGLQFLHTRTPPIIHRDLKCDNIFITGPTGSVKIGDLGLATLMRTSFAKSVIGTPEFMAPEMYEEHYDESVDVYAFGMCMLEMATSEYPYSECQNAAQIYRKVTSGIKPASFNKVTDPEVKEIIEGCIRQNKSERLSIRDLLNHAFFAEDTGLRVE","Homo sapiens","WNK3, KIAA1566, PRKWNK3","Serine/threonine-protein kinase WNK3","1","5O23"
"5O26",,"X-RAY DIFFRACTION",2.15,42.85,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 0.1M bis-tris pH 5.5",293,,,"5O26",66.54,"2.379","2.379","Crystal structure of WNK3 kinase domain in a diphosphorylated state and in complex with AMP-PNP/Mg2+","SMAEMKAVATSPSGRFLKFDIELGRGAFKTVYKGLDTETWVEVAWCELQDRKLTKAEQQRFKEEAEMLKGLQHPNIVRFYDSWESILKGKKCIVLVTELMTSGTLKTYLKRFKVMKPKVLRSWCRQILKGLQFLHTRTPPIIHRDLKCDNIFITGPTGSVKIGDLGLATLMRTSFAKSVIGTPEFMAPEMYEEHYDESVDVYAFGMCMLEMATSEYPYSECQNAAQIYRKVTSGIKPASFNKVTDPEVKEIIEGCIRQNKSERLSIRDLLNHAFFAEDTGLRVE","Homo sapiens","WNK3, KIAA1566, PRKWNK3","Serine/threonine-protein kinase WNK3","1","5O26"
"5O2B",,"X-RAY DIFFRACTION",2.16,43.06,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG3350, 0.2M magnesium chloride, 0.1M bis-tris pH 5.5",293,,,"5O2B",65.97,"2.038","2.038","Crystal structure of WNK3 kinase domain in a diphosphorylated state and in a complex with the inhibitor PP-121","SMEAEMKAVATSPSGRFLKFDIELGRGAFKTVYKGLDTETWVEVAWCELQDRKLTKAEQQRFKEEAEMLKGLQHPNIVRFYDSWESILKGKKCIVLVTELMTSGTLKTYLKRFKVMKPKVLRSWCRQILKGLQFLHTRTPPIIHRDLKCDNIFITGPTGSVKIGDLGLATLMRTSFAKSVIGTPEFMAPEMYEEHYDESVDVYAFGMCMLEMATSEYPYSECQNAAQIYRKVTSGIKPASFNKVTDPEVKEIIEGCIRQNKSERLSIRDLLNHAFFAEDTGLRVE","Homo sapiens","WNK3, KIAA1566, PRKWNK3","Serine/threonine-protein kinase WNK3","1","5O2B"
"5O2C",,"X-RAY DIFFRACTION",2.87,57.15,"VAPOR DIFFUSION, SITTING DROP",,"18% PEG3350, 0.1 M Citrate pH 5",277,,,"5O2C",44.09,"2.4","2.4","Crystal structure of WNK3 kinase and CCT1 didomain in a unphosphorylated state","SMEKNEKEMEEEAEMKAVATSPSGRFLKFDIELGRGAFKTVYKGLDTETWVEVAWCELQDRKLTKAEQQRFKEEAEMLKGLQHPNIVRFYDSWESILKGKKCIVLVTELMTSGTLKTYLKRFKVMKPKVLRSWCRQILKGLQFLHTRTPPIIHRDLKCDNIFITGPTGSVKIGDLGLATLMRTSFAKSVIGTPEFMAPEMYEEHYDESVDVYAFGMCMLEMATSEYPYSECQNAAQIYRKVTSGIKPASFNKVTDPEVKEIIEGCIRQNKSERLSIRDLLNHAFFAEDTGLRVELAEEDDCSNSSLALRLWVEDPKKLKGKHKDNEAIEFSFNLETDTPEEVAYEMVKSGFFHESDSKAVAKSIRDRVTPIKKTREKKPA","Homo sapiens","WNK3, KIAA1566, PRKWNK3","Serine/threonine-protein kinase WNK3","1","5O2C"
"5O2D",,"X-RAY DIFFRACTION",2.01,38.89,"VAPOR DIFFUSION",,"0.8M sodium phosphate monobasic, 0.8M potassium phosphate dibasic, 0.1M HEPES pH 7.5",293,"10.1021/acschembio.7b00445","9HH","5O2D",21.93,"1.6","1.6","PARP14 Macrodomain 2 with inhibitor","SMAAAGPGKTSWEKGSLVSPGGLQMLLVKEGVQNAKTDVVVNSVPLDLVLSRGPLSSSLLEKAGPELQEELDTVGQGVAVSMGTVLKTSSWNLDCRYVLHVVAPEWRNGSTSSLKIMEDIIRECMEITESLSLKSIAFPAIGTGNLGFPKNIFAELIISEVFSFSSSNQLSTLQEVHFLLHPSDHENIQAFSDEFARRAN","Homo sapiens","PARP14, BAL2, KIAA1268","Poly [ADP-ribose] polymerase 14","1","5O2D"
"5O2M",,"SOLUTION NMR",,,,,,,"10.1038/s41598-017-08303-4",,"5O2M",9.05,,,"p130Cas SH3 domain","GSMKYLNVLAKALYDNVAESPDELSFRKGDIMTVLERDTQGLDGWWLCSLHGRQGIVPGNRLKILVGMYDKKPAGEFIVTD","Homo sapiens","BCAR1, CAS, CASS1, CRKAS","Breast cancer anti-estrogen resistance 1","1","5O2M"
"5O2Q",,"SOLUTION NMR",,,,,,,"10.1038/s41598-017-08303-4",,"5O2Q",10.62,,,"p130Cas SH3 domain Vinculin peptide chimera","GSMKYLNVLAKALYDNVAESPDELSFRKGDIMTVLERDTQGLDGWWLCSLHGRQGIVPGNRLKILVGMYDKKPAGSGGSGSGLTDELAPPKPPLPEGEV","Homo sapiens","BCAR1","Breast cancer anti-estrogen resistance 1,Vinculin","1","5O2Q"
,,,,,,,,,,,,,,,,,"Homo sapiens","BCAR1"
"5O2V",,"SOLUTION NMR",,,,,,,"10.1002/anie.201702904",,"5O2V",10.28,,,"NMR structure of TIA-1 RRM1 domain","MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAAAALAAMNGRKIMGKEVKVNWATTPSSQKKDTS","Homo sapiens","TIA1","Nucleolysin TIA-1 isoform p40","1","5O2V"
"5O2Z",,"X-RAY DIFFRACTION",2.42,49.24,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.2M ammonium acetate, 0.1M sodium citrate, 30% PEG 4000",293,"10.1093/hmg/ddx383",,"5O2Z",27.25,"1.7","1.7","Domain swap dimer of the G167R variant of gelsolin second domain","GSHHVVPNEVVVQRLFQVKRRRVVRATEVPVSWESFNNGDCFILDLGNNIHQWCGSNSNRYERLKATQVSKGIRDNERSGRARVHVSEEGTEPEAMLQVLGPKPALPAGTEDTAKEDAA","Homo sapiens","GSN","Gelsolin","1","5O2Z"
"5O38",,"X-RAY DIFFRACTION",2.24,45.07,"VAPOR DIFFUSION, SITTING DROP",8,"0.1M Tris pH8.0
50% Pentaerythritol propoxylate (5/4 PO/OH)
0.2M Imidazole",293,"10.1039/c7sc02536j",,"5O38",13.84,"1.2","1.2","Human Brd2(BD2) mutant in free form","SMGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGVHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5O38"
"5O39",,"X-RAY DIFFRACTION",2.26,45.64,"VAPOR DIFFUSION",9,"0.2M Tris pH9
53% Pentaerythritol propoxylate (5/4 PO/OH)",293,"10.1039/c7sc02536j",,"5O39",13.96,"1.74","1.74","Human Brd2(BD2) mutant in complex with ME","SMGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGVHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5O39"
"5O3A",,"X-RAY DIFFRACTION",3.25,62.14,"VAPOR DIFFUSION, SITTING DROP",8.25,"0.1M Tris pH 8.25
55% Pentaerythritol propoxylate (5/4 PO/OH)
0.2M Imidazole",293,"10.1039/c7sc02536j",,"5O3A",13.8,"2.4","2.4","Human Brd2(BD2) mutant in complex with ET","SMGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGVHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5O3A"
"5O3B",,"X-RAY DIFFRACTION",2.59,52.56,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Tris pH 7.5
60% Pentaerythritol propoxylate (5/4 PO/OH)
0.2M Imidazole pH 8.0",293,"10.1039/c7sc02536j",,"5O3B",55.25,"1.95","1.95","Human Brd2(BD2) mutant in complex with AL","SMGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGVHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5O3B"
"5O3C",,"X-RAY DIFFRACTION",2.23,44.8,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2M Tris pH 8.5
60% Pentaerythritol propoxylate (5/4 PO/OH)",293,"10.1039/c7sc02536j",,"5O3C",13.96,"1.6","1.6","Human Brd2(BD2) mutant in complex with 9-Me","SMGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGVHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5O3C"
"5O3D",,"X-RAY DIFFRACTION",2.29,46.26,"VAPOR DIFFUSION, SITTING DROP",8.25,"0.1M Tris pH8.25
55% Pentaerythritol propoxylate (5/4 PO/OH)
0.2M Imidazole",293,"10.1039/c7sc02536j",,"5O3D",13.97,"1.6","1.6","Human Brd2(BD2) mutant in complex with 9-ET","SMGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGVHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5O3D"
"5O3E",,"X-RAY DIFFRACTION",2.33,47.2,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Tris pH 7.75
55% Pentaerythritol propoxylate (5/4 PO/OH)
0.2M Imidazole pH 8",293,"10.1039/c7sc02536j",,"5O3E",13.97,"1.4","1.4","Human Brd2(BD2) mutant in complex with Me-Am1","SMGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGVHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5O3E"
"5O3F",,"X-RAY DIFFRACTION",2.21,44.23,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Tris pH 8.5 
60% Pentaerythritol propoxylate (5/4 PO/OH)",293,"10.1039/c7sc02536j",,"5O3F",13.98,"1.75","1.75","Human Brd2(BD2) mutant in complex with ET-Am1","SMGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGVHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5O3F"
"5O3G",,"X-RAY DIFFRACTION",2.29,46.36,"VAPOR DIFFUSION, SITTING DROP",8.25,"0.1M Tris pH 8.25
55% Pentaerythritol propoxylate (5/4 PO/OH)",293,"10.1039/c7sc02536j",,"5O3G",27.65,"1.85","1.85","Human Brd2(BD2) mutant in complex with AL-Am1","SMGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGVHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5O3G"
"5O3H",,"X-RAY DIFFRACTION",2.24,45.11,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Tris pH 9.0
45% Pentaerythritol propoxylate (5/4 PO/OH)",293,"10.1039/c7sc02536j",,"5O3H",13.97,"1.4","1.4","Human Brd2(BD2) mutant in complex with 9-ME-Am1","SMGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGVHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5O3H"
"5O3I",,"X-RAY DIFFRACTION",2.34,47.49,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Tris pH 7.5
60% Pentaerythritol propoxylate (5/4 PO/OH)",293,"10.1039/c7sc02536j",,"5O3I",14.02,"1.2","1.2","Human Brd2(BD2) mutant in complex with AL-tBu","SMGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGVHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5O3I"
"5O3L","3.4","ELECTRON MICROSCOPY",,,,,,,"10.1038/nature23002",,"5O3L",79.4,"3.4",,"Paired helical filament in Alzheimer's disease brain","VQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTF","Homo sapiens","MAPT, MAPTL, MTBT1, TAU","Microtubule-associated protein tau","1","5O3L"
"5O3O","3.5","ELECTRON MICROSCOPY",,,,,,,"10.1038/nature23002",,"5O3O",79.4,"3.5",,"Pronase-treated paired helical filament in Alzheimer's disease brain","VQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTF","Homo sapiens","MAPT, MAPTL, MTBT1, TAU","Microtubule-associated protein tau","1","5O3O"
"5O3T","3.4","ELECTRON MICROSCOPY",,,,,,,"10.1038/nature23002",,"5O3T",79.4,"3.4",,"Straight filament in Alzheimer's disease brain","VQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTF","Homo sapiens","MAPT, MAPTL, MTBT1, TAU","Microtubule-associated protein tau","1","5O3T"
"5O3Y",,"X-RAY DIFFRACTION",2,38.56,"VAPOR DIFFUSION, HANGING DROP",3.75,"100 mM NaAct pH 3.75, 100 mM NaCl, 2.8 M AmSO4",293,"10.1038/s41467-018-04114-x",,"5O3Y",32.57,"1.3","1.3","SOD1 bound to Ebsulfur","ATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTSAGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVVHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ","Homo sapiens","SOD1","Superoxide dismutase [Cu-Zn]","1","5O3Y"
"5O40",,"X-RAY DIFFRACTION",2,38.48,"VAPOR DIFFUSION, HANGING DROP",4,"100 mM NaACT pH 4, 2.4 M AMSO4, 150 mM NaCl",293,"10.1038/s41467-018-04114-x",,"5O40",32.66,"1.5","1.5","SOD1 bound to Ebselen","ATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTSAGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVVHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ","Homo sapiens","SOD1","Superoxide dismutase [Cu-Zn]","1","5O40"
"5O42",,"X-RAY DIFFRACTION",2.43,49.31,"VAPOR DIFFUSION, SITTING DROP",,"PEG 6000 20% Hepes 0.1M DMSO 5%",291,"10.1016/j.ejmech.2018.05.029","9JW","5O42",29.87,"1.76","1.76","17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal 2,6-pyridinketone inhibitor.","GHMATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRATIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPSGS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5O42"
"5O43",,"X-RAY DIFFRACTION",2.43,49.42,"VAPOR DIFFUSION, SITTING DROP",,"PEG 6000 20% Hepes 0.1M DMSO 5%",291,"10.1016/j.ejmech.2018.05.029","9JQ","5O43",29.88,"1.5","1.5","17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal 2,6-pyridinketone inhibitor.","GHMATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRATIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPSGS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5O43"
"5O49",,"X-RAY DIFFRACTION",2.68,54.19,"VAPOR DIFFUSION, SITTING DROP",,"18-20% (w/v) PEG8000, 200mM ammonium sulphate, 100mM PCTP pH 6.75 and 20% (v/v) ethylene glycol",277,"10.1039/c7ob02028g",,"5O49",71.47,"1.91","1.91","Human FGF in complex with a covalent inhibitor","GAGVSEYELPEDPRWELPRDRLVLGKPLGEGAFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYSYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQE","Homo sapiens","FGFR1, BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR","Fibroblast growth factor receptor 1","1","5O49"
"5O4A",,"X-RAY DIFFRACTION",2.74,55.1,"VAPOR DIFFUSION, HANGING DROP",,"18-20% (w/v) PEG8000, 200mM ammonium sulphate, 100mM PCTP pH 6.75 and 20% (v/v) ethylene glycol",277,"10.1039/c7ob02028g",,"5O4A",71.61,"2.01","2.01","Human FGF in complex with a covalent inhibitor","GAGVSEYELPEDPRWELPRDRLVLGKPLGEGAFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYSYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQE","Homo sapiens","FGFR1, BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR","Fibroblast growth factor receptor 1","1","5O4A"
"5O4S",,"X-RAY DIFFRACTION",2.66,53.79,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-tris propane, pH6.5, 0.15 M Sodium Nitrate, 20% PEG3350",297,"10.1016/j.ejmech.2018.05.037","9KW","5O4S",28.44,"1.75","1.75","Crystal structure of the human BRPF1 bromodomain in complex with BZ135","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5O4S"
"5O4T",,"X-RAY DIFFRACTION",2.46,49.96,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-tris propane, pH6.5, 0.2 M Sodium nitrate, 20% PEG3350",277,"10.1016/j.ejmech.2018.05.037","9KT","5O4T",13.89,"1.5","1.5","Crystal structure of the human BRPF1 bromodomain in complex with BZ061","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5O4T"
"5O55",,"X-RAY DIFFRACTION",2.45,49.8,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-tris propane, pH6.5, 0.15 M Sodium Nitrate, 20% PEG3350",277,"10.1016/j.ejmech.2018.05.037","9L5","5O55",14.12,"1.45","1.45","Crystal structure of the human BRPF1 bromodomain in complex with BZ047","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5O55"
"5O57",,"SOLUTION NMR",,,,,,,"10.1074/jbc.RA118.002918",,"5O57",10.93,,,"Solution Structure of the N-terminal Region of Dkk4","MLVLDFNNIRSSADLHGARKGSQCLSDTDCNTRKFCLQPRDEKPFCATCRGLRRRCQRDAMCCPGTLCVNDVCTTMEDATENLYFQSLEHHHHHH","Homo sapiens","DKK4","Dickkopf-related protein 4","1","5O57"
"5O5A",,"X-RAY DIFFRACTION",2.45,49.71,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-tris propane, pH6.5, 0.2 M Sodium nitrate, 20% PEG3350",277,"10.1016/j.ejmech.2018.05.037","9LN","5O5A",14.17,"1.6","1.6","Crystal structure of the human BRPF1 bromodomain in complex with BZ032","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5O5A"
"5O5E",,"X-RAY DIFFRACTION",3.91,68.59,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M bicine pH 8.5 -- 0.05M sodium chloride -- 36% PEG200",277,"10.1016/j.cell.2018.10.037",,"5O5E",49.22,"3.4","3.4","Crystal structure of human UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1) (V264G mutant) in complex with tunicamycin","SMWAFSELPMPLLINLIVSLLGFVATVTLIPAFRGHFIAARLCGQDLNKTSRQQIPESQGVISGAVFLIILFCFIPFPFLNCFVKEQCKAFPHHEFVALIGALLAICCMIFLGFADDVLNLRWRHKLLLPTAASLPLLMVYFTNFGNTTIVVPKPFRPILGLHLDLGILYYVYMGLLAVFCTNAINILAGINGLEAGQSLVISASIIVFNLVELEGDCRDDHVFSLYFMIPFFFTTLGLLYHNWYPSRVFVGDTFCYFAGMTFAGVGILGHFSKTMLLFFMPQVFNFLYSLPQLLHIIPCPRHRIPRLNIKTGKLEMSYSKFKTKSLSFLGTFILKVAESLQLVTVHQSETEDGEFTECNNMTLINLLLKVLGPIHERNLTLLLLLLQILGSAITFSIRYQLVRLFYDV","Homo sapiens","DPAGT1, DPAGT2","UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase","1","5O5E"
"5O5F",,"X-RAY DIFFRACTION",2.47,50.21,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-tris propane, pH6.5, 0.2 M Sodium Nitrate, 20% PEG3350",277,"10.1016/j.ejmech.2018.05.037","9LT","5O5F",14.25,"1.302","1.302","Crystal structure of the human BRPF1 bromodomain in complex with BZ038","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5O5F"
"5O5G",,"X-RAY DIFFRACTION",2.99,58.8,"VAPOR DIFFUSION, HANGING DROP",4,"6% PEG 4000,
100 mM Sodium citrate,
10 mM Calcium chloride",293,"10.1016/j.str.2017.12.003",,"5O5G",43.05,"3.03","3.03","Robo1 Ig1 to 4 crystal form 1","QEDFPPRIVEHPSDLIVSKGEPATLNCKAEGRPTPTIEWYKGGERVETDKDDPRSHRMLLPSGSLFFLRIVHGRKSRPDEGVYVCVARNYLGEAVSHNASLEVAILRDDFRQNPSDVMVAVGEPAVMECQPPRGHPEPTISWKKDGSPLDDKDERITIRGGKLMITYTRKSDAGKYVCVGTNMVGERESEVAELTVLERPSFVKRPSNLAVTVDDSAEFKCEARGDPVPTVRWRKDDGELPKSRYEIRDDHTLKIRKVTAGDMGSYTCVAENMVGKAEASATLTVQEPPHFVVKPRDQVVALGRTVTFQCEATGNPQPAIFWRREGSQNLLFSYQPPQSSSRFSVSQTGDLTITNVQRSDVGYYICQTLNVAGSIITKAYLEVTG","Homo sapiens","ROBO1, DUTT1","Roundabout homolog 1","1","5O5G"
"5O5H",,"X-RAY DIFFRACTION",2.5,50.84,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris Propane, pH6.5, 0.2 M  Sodium Nitrate, 20% PEG3350",277,"10.1016/j.ejmech.2018.05.037","9LK","5O5H",14.45,"1.85","1.85","Crystal structure of the human BRPF1 bromodomain in complex with BZ053","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5O5H"
"5O5I",,"X-RAY DIFFRACTION",2.65,53.6,"VAPOR DIFFUSION, HANGING DROP",4.5,"25% PEG 3350,
100 mM Sodium acetate,",293,"10.1016/j.str.2017.12.003",,"5O5I",9.81,"3.01","3.01","Robo1 Ig5","PPVIRQGPVNQTVAVDGTFVLSCVATGSPVPTILWRKDGVLVSTQDSRIKQLENGVLQIRYAKLGDTGRYTCIASTPSGEATWSAYIEVQAG","Homo sapiens","ROBO1, DUTT1","Roundabout homolog 1","1","5O5I"
"5O5R",,"X-RAY DIFFRACTION",3.3,62.76,"VAPOR DIFFUSION, HANGING DROP",8,"34 % (v/v) pentaerythritol propoxylate PO/OH 5/4, 
2 % (w/v) PEG 3350, 
100 mM Tris-HCl, pH 8.0.",293.15,,,"5O5R",84.28,"1.65","1.65","X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a urea based inhibitor PSMA 1023","KSSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA","Homo sapiens","FOLH1, FOLH, NAALAD1, PSM, PSMA, GIG27","Glutamate carboxypeptidase 2","1","5O5R"
"5O5T",,"X-RAY DIFFRACTION",3.31,62.8,"VAPOR DIFFUSION, HANGING DROP",8,"34 % (v/v) pentaerythritol propoxylate PO/OH 5/4, 
2 % (w/v) PEG 3350, 
100 mM Tris-HCl, pH 8.0.",293.15,,,"5O5T",83.66,"1.43","1.43","X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a urea based inhibitor PSMA 1007","KSSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA","Homo sapiens","FOLH1, FOLH, NAALAD1, PSM, PSMA, GIG27","Glutamate carboxypeptidase 2","1","5O5T"
"5O5U",,"X-RAY DIFFRACTION",3.32,62.91,"VAPOR DIFFUSION, HANGING DROP",,"33 % (v/v) pentaerythritol propoxylate PO/OH 5/4,
2 % (w/v) PEG 3350, 
100 mM Tris-HCl.",293,,,"5O5U",84.64,"1.53","1.53","X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a urea based inhibitor PSMA 1027","KSSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA","Homo sapiens","FOLH1, FOLH, NAALAD1, PSM, PSMA, GIG27","Glutamate carboxypeptidase 2","1","5O5U"
"5O6C",,"X-RAY DIFFRACTION",3.38,63.63,"VAPOR DIFFUSION, HANGING DROP",6.7,"23.3 mM Na2HPO4
23.3 mM (NH4)2SO4
23.3 mM NaNO3
18 % PEG500 MME
9 % PEG20000",277,"10.1038/s41586-018-0026-1",,"5O6C",30.11,"1.75","1.75","Crystal Structure of a threonine-selective RCR E3 ligase","SATSLKQDADDMCMICFTEALSAAPAIQLDCSHIFHLQCCRRVLENRWLGPRITFGFISCPICKNKINHIVLKDLLDPIKELYEDVRRKALMRLEYEGLHKSEAITTPGVRFYNDPAGYAMNRYAYYVCYKCRKAYFGGEARCDAEAGRGDDYDPRELICGACSDVSRAQMCPKHGTDFLEYKCRYCCSVAVFFCFGTTHFCNACHDDFQRMTSIPKEELPHCPAGPKGKQLEGTECPLHVVHPPTGEEFALGCGVCRNAHTF","Homo sapiens","MYCBP2, KIAA0916, PAM","E3 ubiquitin-protein ligase MYCBP2","1","5O6C"
"5O6H",,"X-RAY DIFFRACTION",2.28,45.95,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.4M Sodium phosphate buffer, 17.5% PEG 3350",291,"10.1038/s41557-018-0039-2","9M2","5O6H",94.87,"1.29","1.29","Human NMT1 in complex with myristoyl-CoA and inhibitor IMP-917","GPHMEEASKRSYQFWDTQPVPKLGEVVNTHGPVEPDKDNIRQEPYTLPQGFTWDALDLGDRGVLKELYTLLNENYVEDDDNMFRFDYSPEFLLWALRPPGWLPQWHCGVRVVSSRKLVGFISAIPANIHIYDTEKKMVEINFLCVHKKLRSKRVAPVLIREITRRVHLEGIFQAVYTAGVVLPKPVGTCRYWHRSLNPRKLIEVKFSHLSRNMTMQRTMKLYRLPETPKTAGLRPMETKDIPVVHQLLTRYLKQFHLTPVMSQEEVEHWFYPQENIIDTFVVENANGEVTDFLSFYTLPSTIMNHPTHKSLKAAYSFYNVHTQTPLLDLMSDALVLAKMKGFDVFNALDLMENKTFLEKLKFGIGDGNLQYYLYNWKCPSMGAEKVGLVLQ","Homo sapiens","NMT1, NMT","Glycylpeptide N-tetradecanoyltransferase 1","1","5O6H"
"5O6J",,"X-RAY DIFFRACTION",2.29,46.35,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.4M Sodium phosphate buffer, 17.5% PEG3350",291,"10.1038/s41557-018-0039-2","9M8","5O6J",94.35,"1.45","1.45","Human NMT1 in complex with myristoyl-CoA and inhibitor IMP-1031","GPHMEEASKRSYQFWDTQPVPKLGEVVNTHGPVEPDKDNIRQEPYTLPQGFTWDALDLGDRGVLKELYTLLNENYVEDDDNMFRFDYSPEFLLWALRPPGWLPQWHCGVRVVSSRKLVGFISAIPANIHIYDTEKKMVEINFLCVHKKLRSKRVAPVLIREITRRVHLEGIFQAVYTAGVVLPKPVGTCRYWHRSLNPRKLIEVKFSHLSRNMTMQRTMKLYRLPETPKTAGLRPMETKDIPVVHQLLTRYLKQFHLTPVMSQEEVEHWFYPQENIIDTFVVENANGEVTDFLSFYTLPSTIMNHPTHKSLKAAYSFYNVHTQTPLLDLMSDALVLAKMKGFDVFNALDLMENKTFLEKLKFGIGDGNLQYYLYNWKCPSMGAEKVGLVLQ","Homo sapiens","NMT1, NMT","Glycylpeptide N-tetradecanoyltransferase 1","1","5O6J"
"5O6O",,"X-RAY DIFFRACTION",2.43,49.35,"VAPOR DIFFUSION, SITTING DROP",,"PEG 6000 20%; HEPES 0.1 M pH 7.00; DMSO 5%",291,"10.1016/j.ejmech.2018.05.029","9MB","5O6O",29.86,"1.45","1.45","17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal 2,6-pyridinketone inhibitor","GHMATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRATIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPSGS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5O6O"
"5O6S",,"X-RAY DIFFRACTION",2,38.46,"VAPOR DIFFUSION, SITTING DROP",7.6,"(0.2 M Zinc acetate, 0.1 M phosphate-citrate pH 4.2, 40 % PEG 300",292,"10.1016/j.molcel.2017.09.027",,"5O6S",55.45,"2.9","2.9","UbV.B4R, a dimeric ubiquitin variant binding to BIRC4 RING","GSGGSMQILVTTISAETIRLEVEPSDTIENVKAKIQDKEGIPPDQQRLFFEGKQLEDGRTLSDYNINKKSTLLLVVKFHRVAS","Homo sapiens","UBB","Polyubiquitin-B","1","5O6S"
"5O6X",,"X-RAY DIFFRACTION",2.42,49.11,"VAPOR DIFFUSION, SITTING DROP",,"PEG 6000 20% HEPES 0.1 M pH 7.00, DMSO 5%",291,"10.1016/j.ejmech.2018.05.029","9MK","5O6X",29.83,"1.35","1.35","17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal quinoline based inhibitor","GHMATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRATIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPSGS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5O6X"
"5O6Z",,"X-RAY DIFFRACTION",2.41,49,"VAPOR DIFFUSION, SITTING DROP",,"PEG 6000 20%, HEPES 0.1 M pH 7.00, DMSO 5%",291,"10.1016/j.ejmech.2018.05.029","9ME","5O6Z",29.82,"1.57","1.57","17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal quinoline based inhibitor","GHMATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRATIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPSGS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5O6Z"
"5O71",,"X-RAY DIFFRACTION",2.86,56.97,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, sodium fluoride",291,"10.1038/s41467-018-07510-5",,"5O71",82.44,"3.283","3.283","Crystal structure of human USP25","GSMTVEQNVLQQSAAQKHQQTFLNQLREITGINDTQILQQALKDSNGNLELAVAFLTAKNAKTPQQEETTYYQTALPGNDRYISVGSQADTNVIDLTGDDKDDLQRAIALSLAESNRAFRETGITDEEQAISRVLEASIAENKACLKRTPTEVWRDSRNPYDRKRQDKAPVGLKNVGNTCWFSAVIQSLFNLLEFRRLVLNYKPPSNAQDLPRNQKEHRNLPFMRELRYLFALLVGTKRKYVDPSRAVEILKDAFKSNDSQQQDVSEFTHKLLDWLEDAFQMKAEEETDEEKPKNPMVELFYGRFLAVGVLEGKKFENTEMFGQYPLQVNGFKDLHECLEAAMIEGEIESLHSENSGKSGQEHWFTELPPVLTFELSRFEFNQALGRPEKIHNKLEFPQVLYLDRYMHRNREITRIKREEIKRLKDYLTVLQQRLERYLSYGSGPKRFPLVDVLQYALEFASSKPVCTSPVDDIDASSPPSGSIPSQTLPSTTEQQGALSSELPSTSPSSVAAISSRSVIHKPFTQSRIPPDLPMHPAPRHITEEELSVLESCLHRWRTEIENDTRDLQESISRIHRTIELMYSDKSMIQVPYRLHAVLVHEGQANAGHYWAYIFDHRESRWMKYNDIAVTKSSWEELVRDSFGGYRNASAYCLMYINDKAQFLIQEEFNKETGQPLVGIETLPPDLRDFVEEDNQRFEKELEEWDAQLAQKALQE","Homo sapiens","USP25, USP21","Ubiquitin carboxyl-terminal hydrolase 25","1","5O71"
"5O72",,"X-RAY DIFFRACTION",2.47,50.17,"VAPOR DIFFUSION, SITTING DROP",,"PEG 6000 20%, HEPES 0.1 M pH 7.00, DMSO 5%",291,"10.1016/j.ejmech.2018.05.029","9MH","5O72",29.71,"1.91","1.91","17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal quinoline based inhibitor","GHMATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRATIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPSGS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5O72"
"5O75",,"X-RAY DIFFRACTION",2.22,44.72,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M citric acid, pH 5.5, 1.9 M ammonium sulphate",293,"10.1016/j.molcel.2017.09.027",,"5O75",9.11,"1.483","1.483","Ube4B U-box domain","GSDAPDEFRDPLMDTLMTDPVRLPSGTIMDRSIILRHLLNSPTDPFNRQTLTESMLEPVPELKEQIQAWMREKQNSDH","Homo sapiens","UBE4B, HDNB1, KIAA0684, UFD2","Ubiquitin conjugation factor E4 B","1","5O75"
"5O7C",,"X-RAY DIFFRACTION",2.39,48.65,"VAPOR DIFFUSION, SITTING DROP",,"PEG 6000 20%, HEPES 0.1 M pH 7.00, DMSO 5%",291,"10.1016/j.ejmech.2018.05.029","9N2","5O7C",29.84,"1.6","1.6","17beta-hydroxysteroid dehydrogenase 14 variant T205 in complex with a non-steroidal quinoline based inhibitor","GHMATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRATIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPSGS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5O7C"
"5O7D",,"X-RAY DIFFRACTION",2.18,43.48,"VAPOR DIFFUSION, HANGING DROP",,"PEG2K-MME 28-34%, bis-tris 0.1M pH 7",293,"10.1371/journal.pone.0199191",,"5O7D",45.07,"1.84","1.84","The X-ray structure of human R38M phosphoglycerate kinase 1 mutant","MSLSNKLTLDKLDVKGKRVVMRVDFNVPMKNNQITNNQMIKAAVPSIKFCLDNGAKSVVLMSHLGRPDGVPMPDKYSLEPVAVELKSLLGKDVLFLKDCVGPEVEKACANPAAGSVILLENLRFHVEEEGKGKDASGNKVKAEPAKIEAFRASLSKLGDVYVNDAFGTAHRAHSSMVGVNLPQKAGGFLMKKELNYFAKALESPERPFLAILGGAKVADKIQLINNMLDKVNEMIIGGGMAFTFLKVLNNMEIGTSLFDEEGAKIVKDLMSKAEKNGVKITLPVDFVTADKFDENAKTGQATVASGIPAGWMGLDCGPESSKKYAEAVTRAKQIVWNGPVGVFEWEAFARGTKALMDEVVKATSRGCITIIGGGDTATCCAKWNTEDKVSHVSTGGGASLELLEGKVLPGVDALSNI","Homo sapiens","PGK1, PGKA, MIG10, OK/SW-cl.110","Phosphoglycerate kinase 1","1","5O7D"
"5O7I",,"X-RAY DIFFRACTION",3.05,59.73,"VAPOR DIFFUSION, SITTING DROP",6.5,"5 % (v/v) PEG 6000, 0.1 M MES (pH 6.0), 5 mM DTT",293,"10.1016/j.ejmech.2019.05.057",,"5O7I",41.52,"2.38","2.38","ERK5 in complex with a pyrrole inhibitor","GDVTFDVGDEYEIIETIGNGAYGVVSSARRRLTGQQVAIKKIPNAFDVVTNAKRTLRELKILKHFKHDNIIAIKDILRPTVPYGEFKSVYVVLDLMESDLHQIIHSSQPLTLEHVRYFLYQLLRGLKYMHSAQVIHRDLKPSNLLVNENCELKIGDFGMARGLCTSPAEHQYFMTEYVATRWYRAPELMLSLHEYTQAIDLWSVGCIFGEMLARRQLFPGKNYVHQLQLIMMVLGTPSPAVIQAVGAERVRAYIQSLPPRQPVPWETVYPGADRQALSLLGRMLRFEPSARISAAAALRHPFLAKYHDPDDEPDCAPPFDFAFDREALTRERIKEAIVAEIEDFHARREGIRQQIRFQ","Homo sapiens","MAPK7, BMK1, ERK5, PRKM7","Mitogen-activated protein kinase 7","1","5O7I"
"5O8I",,"X-RAY DIFFRACTION",2.58,52.35,"VAPOR DIFFUSION, HANGING DROP",8.5,"20% w/v PEG 3350, 0.1 M Bis-Tris Propane pH 8.5, 0.2 M Sodium/Potassium Phosphate",281,,,"5O8I",28.08,"1.27","1.27","Crystal structure of human histidine triad nucleotide-binding protein 1 (hHINT1) crystallized at P212121 space group, and refined to 1.27 A","MADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5O8I"
"5O8U",,"X-RAY DIFFRACTION",2.32,47.03,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2
20-30 % PEG4000",293.15,"10.1002/anie.201706345",,"5O8U",41.77,"2","2","Covalent Inhibitor 4b bound to the Lipid Pocket of p38alpha Mutant S252C","MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISCESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5O8U"
"5O8V",,"X-RAY DIFFRACTION",2.28,46.03,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2
20-30 % PEG4000",293.15,"10.1002/anie.201706345",,"5O8V",41.77,"2","2","Covalent Inhibitor 4a bound to the Lipid Pocket of p38alpha Mutant S251C","MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKICSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5O8V"
"5O91",,"X-RAY DIFFRACTION",3.19,61.43,"VAPOR DIFFUSION, SITTING DROP",7.8,"12.3% (w/v) PEG 350 MME. 1 mM MgCl2, and 100 mM Tris/HCl",291,"10.1074/jbc.M117.783555",,"5O91",36.84,"3.2","3.2","Crystal structure of human Mps1 (TTK) C604W mutant in complex with Cpd-5","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMEWGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5O91"
"5O97",,"X-RAY DIFFRACTION",2.16,42.95,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES, pH8.0, 30% PEG5000MME",277,,"9OE","5O97",15.41,"1.3","1.3","Crystal structure of human BRD4(1) bromodomain in complex with JRMBR4106","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5O97"
"5O9B",,"SOLUTION NMR",,,,,,,,,"5O9B",7.77,,,"Solution NMR structure of human GATA2 C-terminal zinc finger domain","MAHHHHHHSSGLEVLFQGPRRAGTCCANCQTTTTTLWRRNANGDPVCNACGLYYKLHNVNRPLTMKKE","Homo sapiens","GATA2","Endothelial transcription factor GATA-2","1","5O9B"
"5O9H",,"X-RAY DIFFRACTION",3.67,66.51,"LIPIDIC CUBIC PHASE",5.5,"100mM tri-sodium citrate pH 5.5, 200mM Na/K tartrate, 35-45% (v/v) polyethylene glycol 400",295.65,"10.1038/nature25025",,"5O9H",82.31,"2.7","2.7","Crystal structure of thermostabilised human C5a anaphylatoxin chemotactic receptor 1 (C5aR) in complex with NDT9513727","MNTLRVPDILALVIFAVVFLVGVLGNALVVWVTAFEAKRTINAIWFLNLAVADFLACLALPALFTSIVQHHHWPFGGAACSILPSLILLNMYASILLLATISADRFLLVFKPAWCQRFRGAGLAWILCAVAWGLALLLTIPSALYRVVREEYFPPKVLCGVDYSHDKRRERAVAIVRLVLGFLWPLLTLTICYTFILLRTWSARETRSTKTLKVVVAVVASFFIFWLPYQVTGIMMSFLEPSSPTFLLLKKLDSLCVSFAYINCCINPIIYVVAGQGFQGRERKSLPELLREVLTEESVVRESKAAAHHHHHHHHHH","Homo sapiens","C5AR1, C5AR, C5R1","C5a anaphylatoxin chemotactic receptor 1","1","5O9H"
"5O9L",,"X-RAY DIFFRACTION",2.02,39.03,"VAPOR DIFFUSION, SITTING DROP",4,"0.1M MMT pH4.0 and 25% w/v PEG 1500",291,"10.1016/j.molimm.2017.11.022",,"5O9L",41.38,"1.75","1.75","Crystal structure of human Histamine-Releasing Factor (HRF/TCTP)","MIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSRTEGNIDDSLIGGNASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIKGKLEEQRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVALLDYREDGVTPYMIFFKDGLEMEKCLEHHHHHH","Homo sapiens","TPT1","Translationally-controlled tumor protein","1","5O9L"
"5O9M",,"X-RAY DIFFRACTION",2.21,44.42,"VAPOR DIFFUSION, SITTING DROP",6,"0.1M MES pH6.0 and 20% (w/v) PEG MME 2000",291,"10.1016/j.molimm.2017.11.022",,"5O9M",41.49,"1.4","1.4","Crystal structure of human Histamine-Releasing Factor (HRF/TCTP)containing a disulphide-linked dimer","MIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSRTEGNIDDSLIGGNASAEGPEGEGTESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIKGKLEEQRPERVKPFMTGAAEQIKHILANFKNYQFFIGENMNPDGMVALLDYREDGVTPYMIFFKDGLEMEKCLEHHHHHH","Homo sapiens","TPT1","Translationally-controlled tumor protein","1","5O9M"
"5OA9",,"X-RAY DIFFRACTION",2.73,54.89,"VAPOR DIFFUSION, SITTING DROP",7.6,"1:1 mix protein (50 mM HEPES-KOH
pH 7.6, 150 mM KCl, 1 mM TCEP) with reservoir solution (100 mM HEPES-KOH pH 7.6, 25 mM sodium formate,
25 mM ammonium acetate, 25 mM sodium citrate tribasic, 25 mM sodium potassium tartrate,
10.7% PEG3350, 10.7% MPD, 10.7% PEG1000)",292,"10.1016/j.molcel.2017.06.032",,"5OA9",23.28,"1.8","1.8","Human translation re-initiation complex containing eIF2D","SNADIKPLYCVPASMTLLFQESGHKKGSFLEGSEVRTIVINYAKKNDLVDADNKNLVRLDPILCDCILEKNEQHTVMKLPWDSLLTRCLEKLQPAYQVTLPGQEPIVKKGRICPIDITLAQRASNKKVTVVRNLEAYGLDPYSVAAILQQRCQASTTVNPAPGAKDSLQVQIQGNQVHHLGWLLLEEYQLPRKHIQGLEKALKPGKKK","Homo sapiens","EIF2D, HCA56, LGTN","Eukaryotic translation initiation factor 2D","1","5OA9"
"5OAB",,"X-RAY DIFFRACTION",2.45,49.87,"VAPOR DIFFUSION, HANGING DROP",7,"1.3 M SODIUM/POTASSIUM PHOSPHATE",293,"10.1016/j.bbagen.2018.09.021",,"5OAB",15.59,"1.111","1.111","A novel crystal form of human RNase6 at atomic resolution","MWPKRLTKAHWFEIQHIQPSPLQCNRAMSGINNYTQHCKHQNTFLHDSFQNVAAVCDLLSIVCKNRRHNCHQSSKPVNMTDCRLTSGKYPQCRYSAAAQYKFFIVACDPPQKSDPPYKLVPVHLDSIL","Homo sapiens","RNASE6, RNS6","Ribonuclease K6","1","5OAB"
"5OAI",,"X-RAY DIFFRACTION",2.71,54.6,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Bis-Tris pH 6.5, 20% (w/v) PEG 5000 MME",277.15,"10.1111/febs.14774","B5K","5OAI",11.9,"2","2","Structure of MDM2 with low molecular weight inhibitor","MQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQ","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","5OAI"
"5OAX",,"X-RAY DIFFRACTION",2.1,41.43,"VAPOR DIFFUSION",,"19.2 mg/mL GALECTIN-3C, 100mM NaCl, 0.1 M TRIS/HCL, pH 7.5, 30 % PEG 4000, 0.4 M NaSCN, 0.1M MgCl2, 10 mM BETA-MERCAPTOETHANOL, 4.9 mM INHIBITOR COMPOUND",298,"10.1021/acs.jmedchem.7b01626","9Q5","5OAX",16.43,"1.2","1.2","Galectin-3c in complex with thiogalactoside derivate","MLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI","Homo sapiens","LGALS3, MAC2","Galectin-3","1","5OAX"
"5OAZ",,"X-RAY DIFFRACTION",2.47,50.29,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.65 M Ammonium sulphate, 0.1 M Hepes and 6% PEG 300",298,,,"5OAZ",14.34,"1.03","1.03","Crystal structure of the Abl-SH3 domain at pH 7.5","MENDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVNS","Homo sapiens","ABL1, ABL, JTK7","Tyrosine-protein kinase ABL1","1","5OAZ"
"5OB4",,"SOLUTION NMR",,,,,,,"10.1007/s10858-017-0146-1",,"5OB4",9.47,,,"NMR spatial structure of HER2 TM domain dimer in DPC micelles.","GCPAEQRASPLTSIISAVVGILLVVVLGVVFGILIKRRQQKIRK","Homo sapiens","ERBB2, HER2, MLN19, NEU, NGL","Receptor tyrosine-protein kinase erbB-2","1","5OB4"
"5OBJ",,"X-RAY DIFFRACTION",2.75,55.22,"VAPOR DIFFUSION, HANGING DROP",7,"50 MM HEPES, 200 MM MAGNESIUM SULFATE,   20% PEG 3350",292,"10.1039/c7cc05379g",,"5OBJ",32.38,"2.901","2.901","Aurora A kinase in complex with 2-(3-fluorophenyl)quinoline-4-carboxylic acid and ATP","GSMGSKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5OBJ"
"5OBK",,"X-RAY DIFFRACTION",2.32,47.04,"VAPOR DIFFUSION, HANGING DROP",7.5,"30 % PEG-3350, 0.2 M NH4-acetate and 0.1 M HEPES-NaOH pH 7.5",293,"10.1021/acs.jmedchem.8b00137",,"5OBK",14.51,"1","1","The Fk1 domain of FKBP51 in complex with (1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-5-(hydroxymethyl)-3-(pyridin-2-ylmethyl)-3,10-diazabicyclo[4.3.1]decan-2-one","GAPATVTEQGEDITSKKDRGVLKIVKRVGNGEETPMIGDKVYVHYKGKLSNGKKFDSSHDRNEPFVFSLGKGQVIKAWDIGVATMKKGEICHLLCKPEYAYGSAGSLPKIPSNATLFFEIELLDFKGE","Homo sapiens","FKBP5, AIG6, FKBP51","Peptidyl-prolyl cis-trans isomerase FKBP5","1","5OBK"
"5OBN",,"SOLUTION NMR",,,,,,,"10.1261/rna.062844.117",,"5OBN",15.8,,,"NMR solution structure of U11/U12 65K protein's C-terminal RRM domain (381-516)","SDEMPSECISRRELEKGRISREEMETLSVFRSYEPGEPNCRIYVKNLAKHVQEKDLKYIFGRYVDFSSETQRIMFDIRLMKEGRMKGQAFIGLPNEKAAAKALKEANGYVLFGKPMVVQFARSARPKQDPKEGKRK","Homo sapiens","RNPC3, KIAA1839, RBM40, RNP, SNRNP65","RNA-binding protein 40","1","5OBN"
"5OBR",,"X-RAY DIFFRACTION",2.73,54.9,"VAPOR DIFFUSION, HANGING DROP",7,"50 MM HEPES, 200 MM MAGNESIUM SULFATE,   20% PEG 3350",292,"10.1039/c7cc05379g","SKE","5OBR",32.18,"2.62","2.62","Aurora A kinase in complex with 2-(3-chloro-5-fluorophenyl)quinoline-4-carboxylic acid and JNJ-7706621","GSMGSKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5OBR"
"5OC4",,"X-RAY DIFFRACTION",2.84,56.65,"VAPOR DIFFUSION, HANGING DROP",6,"22% PEG 8K
100 mM sodium cacodylate",292,"10.1093/nar/gky1302",,"5OC4",13.78,"1.71","1.71","Crystal structure of human tRNA-dihydrouridine(20) synthase dsRBD R361A-R362A mutant","TSEQTGEPAEDTSGVIKMAVKFDAAAYPAQITPKMCLLEWCRREKLAQPVYETVQRPLDRLFSSIVTVAEQKYQSTLWDKSKKLAEQAAAIVCLRSQGLPEGRLGEESPSLHKHHHHHH","Homo sapiens","DUS2, DUS2L","tRNA-dihydrouridine(20) synthase [NAD(P)+]-like","1","5OC4"
"5OC5",,"X-RAY DIFFRACTION",2.33,47.21,"VAPOR DIFFUSION, HANGING DROP",8.5,"35% PEG 4K
1 M LiCl
100 mM Tris",292,"10.1093/nar/gky1302",,"5OC5",13.96,"1.893","1.893","Crystal structure of human tRNA-dihydrouridine(20) synthase dsRBD K419A-K420A mutant","MTSEQTGEPAEDTSGVIKMAVKFDRRAYPAQITPKMCLLEWCRREKLAQPVYETVQRPLDRLFSSIVTVAEQKYQSTLWDKSAALAEQAAAIVCLRSQGLPEGRLGEESPSLHKHHHHHH","Homo sapiens","DUS2, DUS2L","tRNA-dihydrouridine(20) synthase [NAD(P)+]-like","1","5OC5"
"5OC8",,"X-RAY DIFFRACTION",2.16,43.04,"VAPOR DIFFUSION, HANGING DROP",5,"3M AmSO4, 0.1M citrate",298,"10.1158/0008-5472.CAN-18-0338","9QW","5OC8",11.75,"1.56","1.56","HDM2 (17-111, WILD TYPE) COMPLEXED WITH NVP-HDM201 AT 1.56A","GSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVN","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","5OC8"
"5OC9",,"X-RAY DIFFRACTION",3.22,61.81,"LIPIDIC CUBIC PHASE",6,"0.1M MES pH 6.0 -- 0.1M sodium chloride -- 0.1M calcium chloride -- 30% PEG300",293,"10.1038/s41467-019-11753-1",,"5OC9",160.75,"3.2","3.2","Crystal Structure of human TMEM16K / Anoctamin 10","MKVTLSALDTSESSFTPLVVIELAQDVKEETKEWLKNRIIAKKKDGGAQLLFRPLLNKYEQETLENQNLYLVGASKIRMLLGAEAVGLVKECNDNTMRAFTYRTRQNFKGFDDNNDDFLTMAECQFIIKHELENLRAKDEKMIPGYPQAKLYPGKSLLRRLLTSGIVIQVFPLHDSEALKKLEDTWYTRFALKYQPIDSIRGYFGETIALYFGFLEYFTFALIPMAVIGLPYYLFVWEDYDKYVIFASFNLIWSTVILELWKRGCANMTYRWGTLLMKRKFEEPRPGFHGVLGINSITGKEEPLYPSYKRQLRIYLVSLPFVCLCLYFSLYVMMIYFDMEVWALGLHENSGSEWTSVLLYVPSIIYAIVIEIMNRLYRYAAEFLTSWENHRLESAYQNHLILKVLVFNFLNCFASLFYIAFVLKDMKLLRQSLATLLITSQILNQIMESFLPYWLQRKHGVRVKRKVQALKADIDATLYEQVILEKEMGTYLGTFDDYLELFLQFGYVSLFSCVYPLAAAFAVLNNFTEVNSDALKMCRVFKRPFSEPSANIGVWQLAFETMSVISVVTNCALIGMSPQVNAVFPESKADLILIVVAVEHALLALKFILAFAIPDKPRHIQMKLARLEFESLEALKQQQMKLVTENLKEEPMESGKEKATAENLYFQ","Homo sapiens","ANO10, TMEM16K","Anoctamin-10","1","5OC9"
"5OCG",,"X-RAY DIFFRACTION",2.12,41.87,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M TrisCl pH 8.0, 0.2 M NaOAc and 30-36 % PEG 4000",277,"10.1038/s41467-018-05707-2",,"5OCG",22.5,"1.48","1.48","Discovery of small molecules binding to KRAS via high affinity antibody fragment competition method.","GSTEYKLVVVGADGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQGVDDAFYTLVREIRKHKEKMSKDGKKKKKKSKTKCVIM","Homo sapiens","KRAS, KRAS2, RASK2","GTPase KRas","1","5OCG"
"5OCH",,"X-RAY DIFFRACTION",3.6,65.81,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5 -- 18% PEG3350",293,,,"5OCH",539.52,"3.4","3.4","The crystal structure of human ABCB8 in an outward-facing state","MALCEAEEAPPASSTPHVVGSRFNWKLFWQFLHPHLLVLGVAVVLALGAALVNVQIPLLLGQLVEVVAKYTRDHVGSFMTESQNLSTHLLILYGVQGLLTFGYLVLLSHVGERMAVDMRRALFSSLLRQDITFFDANKTGQLVSRLTTDVQEFKSSFKLVISQGLRSCTQVAGCLVSLSMLSTRLTLLLMVATPALMGVGTLMGSGLRKLSRQCQEQIARAMGVADEALGNVRTVRAFAMEQREEERYGAELEACRCRAEELGRGIALFQGLSNIAFNCMVLGTLFIGGSLVAGQQLTGGDLMSFLVASQTVQRSMANLSVLFGQVVRGLSAGARVFEYMALNPCIPLSGGCCVPKEQLRGSVTFQNVCFSYPCRPGFEVLKDFTLTLPPGKIVALVGQSGGGKTTVASLLERFYDPTAGVVMLDGRDLRTLDPSWLRGQVVGFISQEPVLFGTTIMENIRFGKLEASDEEVYTAAREANAHEFITSFPEGYNTVVGERGTTLSGGQKQRLAIARALIKQPTVLILDEATSALDAESERVVQEALDRASAGRTVLVIAHRLSTVRGAHCIVVMADGRVWEAGTHEELLKKGGLYAELIRRQALDAAENLYFQ","Homo sapiens","ABCB8, MABC1, MITOSUR","ATP-binding cassette sub-family B member 8, mitochondrial","1","5OCH"
,,,,,,,,,,,,,,,,"MALCEAEEAPPASSTPHVVGSRFNWKLFWQFLHPHLLVLGVAVVLALGAALVNVQIPLLLGQLVEVVAKYTRDHVGSFMTESQNLSTHLLILYGVQGLLTFGYLVLLSHVGERMAVDMRRALFSSLLRQDITFFDANKTGQLVSRLTTDVQEFKSSFKLVISQGLRSCTQVAGCLVSLSMLSTRLTLLLMVATPALMGVGTLMGSGLRKLSRQCQEQIARAMGVADEALGNVRTVRAFAMEQREEERYGAELEACRCRAEELGRGIALFQGLSNIAFNCMVLGTLFIGGSLVAGQQLTGGDLMSFLVASQTVQRSMANLSVLFGQVVRGLSAGARVFEYMALNPCIPLSGGCCVPKEQLRGSVTFQNVCFSYPCRPGFEVLKDFTLTLPPGKIVALVGQSGGGKTTVASLLERFYDPTAGVVMLDGRDLRTLDPSWLRGQVVGFISQEPVLFGTTIMENIRFGKLEASDEEVYTAAREANAHEFITSFPEGYNTVVGERGTTLSGGQKQRLAIARALIKQPTVLILDEATSALDAESERVVQEALDRASAGRTVLVIAHRLSTVRGAHCIVVMADGRVWEAGTHEELLKKGGLYAELIRRQALDAAENLYFQ","Homo sapiens","ABCB8, MABC1, MITOSUR","ATP-binding cassette sub-family B member 8, mitochondrial","2","5OCH"
,,,,,,,,,,,,,,,,"MALCEAEEAPPASSTPHVVGSRFNWKLFWQFLHPHLLVLGVAVVLALGAALVNVQIPLLLGQLVEVVAKYTRDHVGSFMTESQNLSTHLLILYGVQGLLTFGYLVLLSHVGERMAVDMRRALFSSLLRQDITFFDANKTGQLVSRLTTDVQEFKSSFKLVISQGLRSCTQVAGCLVSLSMLSTRLTLLLMVATPALMGVGTLMGSGLRKLSRQCQEQIARAMGVADEALGNVRTVRAFAMEQREEERYGAELEACRCRAEELGRGIALFQGLSNIAFNCMVLGTLFIGGSLVAGQQLTGGDLMSFLVASQTVQRSMANLSVLFGQVVRGLSAGARVFEYMALNPCIPLSGGCCVPKEQLRGSVTFQNVCFSYPCRPGFEVLKDFTLTLPPGKIVALVGQSGGGKTTVASLLERFYDPTAGVVMLDGRDLRTLDPSWLRGQVVGFISQEPVLFGTTIMENIRFGKLEASDEEVYTAAREANAHEFITSFPEGYNTVVGERGTTLSGGQKQRLAIARALIKQPTVLILDEATSALDAESERVVQEALDRASAGRTVLVIAHRLSTVRGAHCIVVMADGRVWEAGTHEELLKKGGLYAELIRRQALDAAENLYFQ","Homo sapiens","ABCB8, MABC1, MITOSUR","ATP-binding cassette sub-family B member 8, mitochondrial","3","5OCH"
,,,,,,,,,,,,,,,,"MALCEAEEAPPASSTPHVVGSRFNWKLFWQFLHPHLLVLGVAVVLALGAALVNVQIPLLLGQLVEVVAKYTRDHVGSFMTESQNLSTHLLILYGVQGLLTFGYLVLLSHVGERMAVDMRRALFSSLLRQDITFFDANKTGQLVSRLTTDVQEFKSSFKLVISQGLRSCTQVAGCLVSLSMLSTRLTLLLMVATPALMGVGTLMGSGLRKLSRQCQEQIARAMGVADEALGNVRTVRAFAMEQREEERYGAELEACRCRAEELGRGIALFQGLSNIAFNCMVLGTLFIGGSLVAGQQLTGGDLMSFLVASQTVQRSMANLSVLFGQVVRGLSAGARVFEYMALNPCIPLSGGCCVPKEQLRGSVTFQNVCFSYPCRPGFEVLKDFTLTLPPGKIVALVGQSGGGKTTVASLLERFYDPTAGVVMLDGRDLRTLDPSWLRGQVVGFISQEPVLFGTTIMENIRFGKLEASDEEVYTAAREANAHEFITSFPEGYNTVVGERGTTLSGGQKQRLAIARALIKQPTVLILDEATSALDAESERVVQEALDRASAGRTVLVIAHRLSTVRGAHCIVVMADGRVWEAGTHEELLKKGGLYAELIRRQALDAAENLYFQ","Homo sapiens","ABCB8, MABC1, MITOSUR","ATP-binding cassette sub-family B member 8, mitochondrial","4","5OCH"
,,,,,,,,,,,,,,,,"MALCEAEEAPPASSTPHVVGSRFNWKLFWQFLHPHLLVLGVAVVLALGAALVNVQIPLLLGQLVEVVAKYTRDHVGSFMTESQNLSTHLLILYGVQGLLTFGYLVLLSHVGERMAVDMRRALFSSLLRQDITFFDANKTGQLVSRLTTDVQEFKSSFKLVISQGLRSCTQVAGCLVSLSMLSTRLTLLLMVATPALMGVGTLMGSGLRKLSRQCQEQIARAMGVADEALGNVRTVRAFAMEQREEERYGAELEACRCRAEELGRGIALFQGLSNIAFNCMVLGTLFIGGSLVAGQQLTGGDLMSFLVASQTVQRSMANLSVLFGQVVRGLSAGARVFEYMALNPCIPLSGGCCVPKEQLRGSVTFQNVCFSYPCRPGFEVLKDFTLTLPPGKIVALVGQSGGGKTTVASLLERFYDPTAGVVMLDGRDLRTLDPSWLRGQVVGFISQEPVLFGTTIMENIRFGKLEASDEEVYTAAREANAHEFITSFPEGYNTVVGERGTTLSGGQKQRLAIARALIKQPTVLILDEATSALDAESERVVQEALDRASAGRTVLVIAHRLSTVRGAHCIVVMADGRVWEAGTHEELLKKGGLYAELIRRQALDAAENLYFQ","Homo sapiens","ABCB8, MABC1, MITOSUR","ATP-binding cassette sub-family B member 8, mitochondrial","5","5OCH"
"5OCI",,"X-RAY DIFFRACTION",2.95,58.29,"VAPOR DIFFUSION, HANGING DROP",,"Na-Cacodylate, pH 6.5
28% PEG8000
0,2 M NH4-Sulfate",277,"10.1021/acs.jmedchem.8b00080","9R8","5OCI",26.17,"1.62","1.62","Human Heat Shock Protein 90 bound to 6-Hydroxy-3-(3-methyl-benzyl)-1H-indazole-5-carboxylic acid methyl-(4-morpholin-4-yl-phenyl)-amide","GDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5OCI"
"5OCN",,"X-RAY DIFFRACTION",2.35,47.76,"VAPOR DIFFUSION, SITTING DROP",,"32 % PEG 3350, 0.25 M Potassium Citrate tribasic, 10% Ethylene Glycol",293,,,"5OCN",92.51,"2.7","2.7","Crystal structure of the forkhead domain of human FOXN1","SMPKPIYSYSILIFMALKNSKTGSLPVSEIYNFMTEHFPYFKTAPDGWKNSVRHNLSLNKCFEKVENKSGSSSRKGCLWALNPAKIDKMQEELQKWKRK","Homo sapiens","FOXN1, RONU, WHN","Forkhead box protein N1","1","5OCN"
"5OCO",,"X-RAY DIFFRACTION",2.52,51.14,"VAPOR DIFFUSION, SITTING DROP",5.5,"8-15% w/v Polyethylene Glycol 3350 and 0.2 M lithium citrate",291,"10.1038/s41467-018-05707-2",,"5OCO",134.25,"1.66","1.66","Discovery of small molecules binding to KRAS via high affinity antibody fragment competition method.","MHHHHHHSSGRENLYFQGMTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGHEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQGVDDAFYTLVREIRKHKEK","Homo sapiens","KRAS, KRAS2, RASK2","GTPase KRas","1","5OCO"
"5OCT",,"X-RAY DIFFRACTION",2.47,50.18,"VAPOR DIFFUSION, SITTING DROP",,"8-15% w/v PEG 3350 and 0.2 M lithium citrate",291,"10.1038/s41467-018-05707-2",,"5OCT",134.25,"2.07","2.07","Discovery of small molecules binding to KRAS via high affinity antibody fragment competition method.","MHHHHHHSSGRENLYFQGMTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGHEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQGVDDAFYTLVREIRKHKEK","Homo sapiens","KRAS, KRAS2, RASK2","GTPase KRas","1","5OCT"
"5OD0",,"X-RAY DIFFRACTION",1.99,37.8,"VAPOR DIFFUSION, SITTING DROP",6,"20% (w/v) PEG 6000, 0.1 M MES pH 6.0, 0.2 M ammonium chloride",293,"10.1002/art.40698",,"5OD0",46.97,"1.8","1.8","Crystal structure of ACPA E4","QSVWTQPPSVSAAPGQKVTISCSGDDSILRSAFVSWYQQVPGSAPKLVIFDDRQRPSGIPARFSGSNSGTTATLDIAGLQRGDEADYYCAAWNGRLSAFVFGSGTKLTVLGQPKSSPSVTLFPPSSEELETNKATLVCTITDFYPGVVTVDWKVDGTPVTQGMETTQPSKQSNNKYMASSYLTLTARAWERHSSYSCQVTHEGHTVEKSLSRADCS","Homo sapiens",,"Fab fragment of ACPA E4 - Light chain","1","5OD0"
,,,,,,,,,,,,,,,,"QVQLEESGPGLVRPSETLSLSCTVSGFPMSESYFWGWIRQSPGKGLEWLGSVIHTGTTYYRPSLESRLTIAMDPSKNQVSLSLTSVTVADSAMYYCVRIRGGSSNWLDPWGPGIVVTASSAKTTPPSVYPLAPGCGDTTGSSVTLGCLVKGYFPESVTVTWNSGSLSSSVHTFPALLQSGLYTMSSSVTVPSSTWPSQTVTCSVAHPASSTTVDKKIEPR","Homo sapiens",,"Fab fragment of ACPA E4 - heavy chain","2","5OD0"
"5OD7",,"X-RAY DIFFRACTION",2.95,58.29,"VAPOR DIFFUSION, HANGING DROP",,"Na-Cacodylate, pH 6.5
28% PEG8000
0,2 M NH4-Sulfate",277,"10.1021/acs.jmedchem.8b00080",,"5OD7",26.24,"2","2","Hsp90 inhibitor desolvation as a rationale to steer on-rates and impact residence time","GDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5OD7"
"5OD8",,"X-RAY DIFFRACTION",2.68,53.7,"VAPOR DIFFUSION, HANGING DROP",,"20% (w/v) PEG3350, 0.2 M Na3citrate",293,"10.1002/art.40698",,"5OD8",47.51,"2.2","2.2","Crystal structure of the RA-associated mAb B2 (Fab fragment)","QVQLVQSGAEVKKPGSSVKVSCRASGGTFSNYVISWVRQAPGQGLEWMGGIIPIFGTAHYAQKFQGRVTITADASTSTAYMELSSLRSEDTAVYYCARINTSPILTGYYFPGVHDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"B2 Fab fragment - heavy chain","1","5OD8"
,,,,,,,,,,,,,,,,"AIRMTQSPSSVSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYSASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"B2 Fab fragment - Light chain","2","5OD8"
"5ODB",,"X-RAY DIFFRACTION",2.21,43.8,"VAPOR DIFFUSION, HANGING DROP",4.75,"2.55 M ammonium sulfate, 0.1 M citrate pH 4.75, 0.1 M NDSB-256",293,"10.1002/art.40698",,"5ODB",47.02,"1.53","1.53","Crystal structure of the RA-associated mAb D10 (chimeric Fab fragment)","EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLHMNSLRAEDTAVYYCSKVRGAAATGYYYGMDVWGQGTTVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEP","Homo sapiens",,"D10 Fab fragment - heavy chain","1","5ODB"
,,,,,,,,,,,,,,,,"TSYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQHSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTVVFGGGTKLTVLGQPKSSPSVTLFPPSSEELETNKATLVCTITDFYPGVVTVDWKVDGTPVTQGMETTQPSKQSNNKYMASSYLTLTARAWERHSSYSCQVTHEGHTVEKSLSRADCS","Homo sapiens",,"D10 Fab fragment - light chain","2","5ODB"
"5ODD",,"SOLUTION NMR",,,,,,,"10.1007/s12104-016-9673-z",,"5ODD",10.56,,,"HUMAN MED26 N-TERMINAL DOMAIN (1-92)","MTAAPASPQQIRDRLLQAIDPQSNIRNMVAVLEVISSLEKYPITKEALEETRLGKLINDVRKKTKNEELAKRAKKLLRSWQKLIEPAHQHEA","Homo sapiens","MED26, ARC70, CRSP7","Mediator of RNA polymerase II transcription subunit 26","1","5ODD"
"5ODF",,"SOLUTION NMR",,,,,,,"10.1093/nar/gkx1211",,"5ODF",8.41,,,"NtMe polyamide in complex with 5'CGATGTACATCG3'- hairpin polyamides studies","XGATGTACATCG","Homo sapiens",,"DNA (5'-D(*CP*GP*AP*TP*GP*TP*AP*CP*AP*TP*CP*G)-3')","1","5ODF"
"5ODM",,"SOLUTION NMR",,,,,,,"10.1093/nar/gkx1211",,"5ODM",8.58,,,"NtiPr polyamide in complex with 5'CGATGTACTACG3","XGATGTACATCG","Homo sapiens",,"DNA (5'-D(*CP*GP*AP*TP*GP*TP*AP*CP*AP*TP*CP*G)-3')","1","5ODM"
"5ODX",,"X-RAY DIFFRACTION",2.94,58.22,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M sodium fluoride, 0.1 M Bis Tris propane, pH 8.5, 20 % w/v PEG 3350",277.15,"10.1021/acs.jmedchem.8b00080","9RZ","5ODX",26.36,"1.82","1.82","Crystal Structure of Hsp90-alpha N-Domain in complex with Indazole derivative","GDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5ODX"
"5ODY",,"X-RAY DIFFRACTION",1.9,35.19,"VAPOR DIFFUSION, HANGING DROP",7.5,"30% PEG 4000, 0.1 M Tris/HCl pH 7.5, 0.1 M MgCl2, 0.4 M NaSCN, 7.9 mM beta-mercaptoethanol",298,"10.1021/acs.jmedchem.7b01626","9SK","5ODY",16.43,"1.149","1.149","Galectin-3C in complex with dithiogalactoside derivative","PLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI","Homo sapiens","LGALS3, MAC2","Galectin-3","1","5ODY"
"5OE1",,"SOLUTION NMR",,,,,,,"10.1093/nar/gkx1211",,"5OE1",8.55,,,"Im polyamide in complex with 5'CGATGTACATCG3'- hairpin polyamides studies","XGATGTACATCG","Homo sapiens",,"DNA (5'-D(*CP*GP*AP*TP*GP*TP*AP*CP*AP*TP*CP*G)-3')","1","5OE1"
"5OEG",,"X-RAY DIFFRACTION",3.57,65.55,"VAPOR DIFFUSION",7,"0.1 M Tris/HCl, 10% PEG 8000, 500 mM MgCl2, pH 7",277.15,"10.1038/nchem.1570",,"5OEG",27.25,"3.15","3.15","Molecular tweezers modulate 14-3-3 protein-protein interactions","AMGSMERASLIQKAKLAEQAERYEDMAAFMKGAVEKGEELSCEERNLLSVAYKNVVGGQRAAWRVLSSIEQKSNEEGSEEKGPEVREYREKVETELQGVCDTVLGLLDSHLIKEAGDAESRVFYLKMKGDYYRYLAEVATGDDKKRIIDSARSAYQEAMDISKKEMPPTNPIRLGLALNFSVFHYEIANSPEEAISLAKTTFDEAMADLHTLSEDSYKDSTLIMQLLRDNLTLWT","Homo sapiens","SFN, HME1","14-3-3 protein sigma","1","5OEG"
"5OEH",,"X-RAY DIFFRACTION",3.46,64.41,"VAPOR DIFFUSION",,"0.09 M HEPES sodium salt, 1.26 M Tri-Sodium Citrate, 10 % Glycerol, pH 7.5",277.15,"10.1038/nchem.1570",,"5OEH",27.4,"2.35","2.35","Molecular tweezers modulate 14-3-3 protein-protein interactions.","GAMGSMERASLIQKAKLAEQAERYEDMAAFMKGAVEKGEELSCEERNLLSVAYKNVVGGQRAAWRVLSSIEQKSNEEGSEEKGPEVREYREKVETELQGVCDTVLGLLDSHLIKEAGDAESRVFYLKMKGDYYRYLAEVATGDDKKRIIDSARSAYQEAMDISKKEMPPTNPIRLGLALNFSVFHYEIANSPEEAISLAKTTFDEAMADLHTLSEDSYKDSTLIMQLLRDNLTLWT","Homo sapiens","SFN, HME1","14-3-3 protein sigma","1","5OEH"
"5OEK",,"SOLUTION NMR",,,,,,,"10.1016/j.bbagen.2018.03.022",,"5OEK",10.29,,,"Putative active dimeric state of GHR transmembrane domain","GSMSQFTCEEDFYFPWLLIIIFGIFGLTVMLFVFLFSKQQRIK","Homo sapiens","GHR","Growth hormone receptor","1","5OEK"
"5OF0",,"X-RAY DIFFRACTION",3.32,62.91,"VAPOR DIFFUSION, HANGING DROP",8,"33% (v/v) pentaerythritol propoxylate PO/OH 5/4, 
2 % (w/v) PEG 3350, and 
100 mM Tris-HCl, pH 8.0",293,"10.1021/acsmedchemlett.8b00318","9TB","5OF0",83.64,"1.48","1.48","X-ray structure of human glutamate carboxypeptidase II (GCPII), the E424M inactive mutant, in complex with a inhibitor CFBzOG","KSSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFASWDAMEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA","Homo sapiens","FOLH1, FOLH, NAALAD1, PSM, PSMA, GIG27","Glutamate carboxypeptidase 2","1","5OF0"
"5OF9",,"X-RAY DIFFRACTION",2.38,48.33,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M bicine/Trizma pH 8.5
9% PEG 4000
18% glycerol
0.02 M each of the following: 1,6-hexanediol; 1-butanol; RS-1,2 propanediol; 2-propanol; 1,4-butanediol; 1,3-propanediol
Based on Morpheus crystal screen",291,"10.1038/s41467-018-03045-x",,"5OF9",141.23,"1.807","1.807","Crystal structure of human MORC2 (residues 1-603)","GPRMAFTNYSSLNRAQLTFEYLHTNSTTHEFLFGALAELVDNARDADATRIDIYAERREDLRGGFMLCFLDDGAGMDPSDAASVIQFGKSAKRTPESTQIGQYGNGLKSGSMRIGKDFILFTKKEDTMTCLFLSRTFHEEEGIDEVIVPLPTWNARTREPVTDNVEKFAIETELIYKYSPFRTEEEVMTQFMKIPGDSGTLVIIFNLKLMDNGEPELDIISNPRDIQMAETSPEGTKPERRSFRAYAAVLYIDPRMRIFIHGHKVQTKRLSCCLYKPRMYKYTSSRFKTRAEQEVKKAEHVARIAEEKAREAESKARTLEVRLGGDLTRDSRVMLRQVQNRAITLRREADVKKRIKEAKQRALKEPKELNFVFGVNIEHRDLDGMFIYNCSRLIKMYEKVGPQLEGGMACGGVVGVVDVPYLVLEPTHNKQDFADAKEYRHLLRAMGEHLAQYWKDIAIAQRGIIKFWDEFGYLSANWNQPPSSELRYKRRRAMEIPTTIQCDLCLKWRTLPFQLSSVEKDYPDTWVCSMNPDPEQDRCEASEQKQKVPLGTFRKDMKTQEEKQKQLTEKIRQQQEKLEALQKTTPIRSQADLKKLPLEVTTRPST","Homo sapiens","MORC2, KIAA0852, ZCWCC1","MORC family CW-type zinc finger protein 2","1","5OF9"
"5OFA",,"X-RAY DIFFRACTION",2.4,48,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M bicine/Trizma pH 8.5
10.8% PEG 4k
21.6% glycerol
0.02 M each of the following: 1,6-hexanediol; 1-butanol; RS-1,2 propanediol; 2-propanol; 1,4-butanediol; 1,3-propanediol",291,"10.1038/s41467-018-03045-x",,"5OFA",141.34,"2.57","2.57","Crystal structure of human MORC2 (residues 1-603) with spinal muscular atrophy mutation T424R","GPRMAFTNYSSLNRAQLTFEYLHTNSTTHEFLFGALAELVDNARDADATRIDIYAERREDLRGGFMLCFLDDGAGMDPSDAASVIQFGKSAKRTPESTQIGQYGNGLKSGSMRIGKDFILFTKKEDTMTCLFLSRTFHEEEGIDEVIVPLPTWNARTREPVTDNVEKFAIETELIYKYSPFRTEEEVMTQFMKIPGDSGTLVIIFNLKLMDNGEPELDIISNPRDIQMAETSPEGTKPERRSFRAYAAVLYIDPRMRIFIHGHKVQTKRLSCCLYKPRMYKYTSSRFKTRAEQEVKKAEHVARIAEEKAREAESKARTLEVRLGGDLTRDSRVMLRQVQNRAITLRREADVKKRIKEAKQRALKEPKELNFVFGVNIEHRDLDGMFIYNCSRLIKMYEKVGPQLEGGMACGGVVGVVDVPYLVLEPRHNKQDFADAKEYRHLLRAMGEHLAQYWKDIAIAQRGIIKFWDEFGYLSANWNQPPSSELRYKRRRAMEIPTTIQCDLCLKWRTLPFQLSSVEKDYPDTWVCSMNPDPEQDRCEASEQKQKVPLGTFRKDMKTQEEKQKQLTEKIRQQQEKLEALQKTTPIRSQADLKKLPLEVTTRPST","Homo sapiens","MORC2, KIAA0852, ZCWCC1","MORC family CW-type zinc finger protein 2","1","5OFA"
"5OFB",,"X-RAY DIFFRACTION",2.4,48,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M bicine/Trizma pH 8.5
10.2% PEG 4k
20.4% glycerol
0.02 M each of the following: 1,6-hexanediol; 1-butanol; RS-1,2 propanediol; 2-propanol; 1,4-butanediol; 1,3-propanediol",291,"10.1038/s41467-018-03045-x",,"5OFB",141.31,"2.02","2.02","Crystal structure of human MORC2 (residues 1-603) with spinal muscular atrophy mutation S87L","GPRMAFTNYSSLNRAQLTFEYLHTNSTTHEFLFGALAELVDNARDADATRIDIYAERREDLRGGFMLCFLDDGAGMDPSDAASVIQFGKLAKRTPESTQIGQYGNGLKSGSMRIGKDFILFTKKEDTMTCLFLSRTFHEEEGIDEVIVPLPTWNARTREPVTDNVEKFAIETELIYKYSPFRTEEEVMTQFMKIPGDSGTLVIIFNLKLMDNGEPELDIISNPRDIQMAETSPEGTKPERRSFRAYAAVLYIDPRMRIFIHGHKVQTKRLSCCLYKPRMYKYTSSRFKTRAEQEVKKAEHVARIAEEKAREAESKARTLEVRLGGDLTRDSRVMLRQVQNRAITLRREADVKKRIKEAKQRALKEPKELNFVFGVNIEHRDLDGMFIYNCSRLIKMYEKVGPQLEGGMACGGVVGVVDVPYLVLEPTHNKQDFADAKEYRHLLRAMGEHLAQYWKDIAIAQRGIIKFWDEFGYLSANWNQPPSSELRYKRRRAMEIPTTIQCDLCLKWRTLPFQLSSVEKDYPDTWVCSMNPDPEQDRCEASEQKQKVPLGTFRKDMKTQEEKQKQLTEKIRQQQEKLEALQKTTPIRSQADLKKLPLEVTTRPST","Homo sapiens","MORC2, KIAA0852, ZCWCC1","MORC family CW-type zinc finger protein 2","1","5OFB"
"5OFM",,"X-RAY DIFFRACTION",2.02,39.05,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M PCTP, pH 7, 23-25 % PEG 1500",298,,,"5OFM",48.16,"1.5","1.5","Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with 5-amino-1-methyl-1H-indole","MLVMNTPNGNSLSAAELTCGMIMCLARQIPQATASMKDGKWERKKFMGTELNGKTLGILGLGRIGREVATRMQSFGMKTIGYDPIISPEVSASFGVQQLPLEEIWPLCDFITVHTPLLPSTTGLLNDNTFAQCKKGVRVVNCARGGIVDEGALLRALQSGQCAGAALDVFTEEPPRDRALVDHENVISCPHLGASTKEAQSRCGEEIAVQFVDMVKGKSLTGV","Homo sapiens","PHGDH, PGDH3","D-3-phosphoglycerate dehydrogenase","1","5OFM"
"5OFV",,"X-RAY DIFFRACTION",2.01,38.81,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M PCTP pH 7, 23-25 % PEG 1500",293,"10.18632/oncotarget.11487","9TZ","5OFV",48.18,"1.5","1.5","Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with 5-fluoro-2-methylbenzoic acid","MLVMNTPNGNSLSAAELTCGMIMCLARQIPQATASMKDGKWERKKFMGTELNGKTLGILGLGRIGREVATRMQSFGMKTIGYDPIISPEVSASFGVQQLPLEEIWPLCDFITVHTPLLPSTTGLLNDNTFAQCKKGVRVVNCARGGIVDEGALLRALQSGQCAGAALDVFTEEPPRDRALVDHENVISCPHLGASTKEAQSRCGEEIAVQFVDMVKGKSLTGV","Homo sapiens","PHGDH, PGDH3","D-3-phosphoglycerate dehydrogenase","1","5OFV"
"5OFW",,"X-RAY DIFFRACTION",2.02,39.02,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M PCTP pH 7, 23-25 % PEG 1500",293,"10.18632/oncotarget.11487","9TW","5OFW",48.21,"1.5","1.5","Crystal structure of human 3-phosphoglycerate dehydrogenase in complex with 3-Chloro-4-fluorobenzamide","MLVMNTPNGNSLSAAELTCGMIMCLARQIPQATASMKDGKWERKKFMGTELNGKTLGILGLGRIGREVATRMQSFGMKTIGYDPIISPEVSASFGVQQLPLEEIWPLCDFITVHTPLLPSTTGLLNDNTFAQCKKGVRVVNCARGGIVDEGALLRALQSGQCAGAALDVFTEEPPRDRALVDHENVISCPHLGASTKEAQSRCGEEIAVQFVDMVKGKSLTGV","Homo sapiens","PHGDH, PGDH3","D-3-phosphoglycerate dehydrogenase","1","5OFW"
"5OFY",,"X-RAY DIFFRACTION",3.23,61.86,"VAPOR DIFFUSION, SITTING DROP",9,"protein - 15 mg/ml (165 microM) in
40 mM PhO pH 7.4, 60 mM Hepes pH 7.0, 1.6 molar excess PLP
Reservoir - Hampton Research Crystal Screen solution H12 -  2% dioxane, 0.1M bicine pH 9.0,  10% PEG 20K
Mixing - 0.4 + 0.4 microL",294,"10.1038/s41598-017-11948-w",,"5OFY",43.4,"2.8","2.8","Crystal structure of the D183N variant of human Alanine:Glyoxylate Aminotransferase major allele (AGT-Ma) at pH 9.0. 2.8 Ang; internal aldimine with PLP in the active site","MASHKLLVTPPKALLKPLSIPNQLLLGPGPSNLPPRIMAAGGLQMIGSMSKDMYQIMDEIKEGIQYVFQTRNPLTLVISGSGHCALEAALVNVLEPGDSFLVGANGIWGQRAVDIGERIGARVHPMTKDPGGHYTLQEVEEGLAQHKPVLLFLTHGESSTGVLQPLDGFGELCHRYKCLLLVNSVASLGGTPLYMDRQGIDILYSGSQKALNAPPGTSLISFSDKAKKKMYSRKTKPFSFYLDIKWLANFWGCDDQPRMYHHTIPVISLYSLRESLALIAEQGLENSWRQHREAAAYLHGRLQALGLQLFVKDPALRLPTVTTVAVPAGYDWRDIVSYVIDHFDIEIMGGLGPSTGKVLRIGLLGCNATRENVDRVTEALRAALQHCPKKKL","Homo sapiens","AGXT, AGT1, SPAT","Serine--pyruvate aminotransferase","1","5OFY"
"5OG0",,"X-RAY DIFFRACTION",3.35,63.3,"VAPOR DIFFUSION, HANGING DROP",,"Protein solution; 0.2 M AGT, 18mM potassium phosphate pH7.4, 20mM Hepes pH 7.4, 5% Jeffamine (Hampton), 5mM sodium hydroxylamine. Reservoir; PEG 6k 12%, 100 mM MES pH 5.0. Mixing: 1+1 microL Cryoprotectant; 25% MPD",294,"10.1038/s41598-017-11948-w",,"5OG0",43.31,"2.5","2.5","Crystal structure of human Alanine:Glyoxylate Aminotransferase major allele (AGT-Ma) at 2.5 Angstrom; internal aldimine with PLP in the active site","MASHKLLVTPPKALLKPLSIPNQLLLGPGPSNLPPRIMAAGGLQMIGSMSKDMYQIMDEIKEGIQYVFQTRNPLTLVISGSGHCALEAALVNVLEPGDSFLVGANGIWGQRAVDIGERIGARVHPMTKDPGGHYTLQEVEEGLAQHKPVLLFLTHGESSTGVLQPLDGFGELCHRYKCLLLVDSVASLGGTPLYMDRQGIDILYSGSQKALNAPPGTSLISFSDKAKKKMYSRKTKPFSFYLDIKWLANFWGCDDQPRMYHHTIPVISLYSLRESLALIAEQGLENSWRQHREAAAYLHGRLQALGLQLFVKDPALRLPTVTTVAVPAGYDWRDIVSYVIDHFDIEIMGGLGPSTGKVLRIGLLGCNATRENVDRVTEALRAALQHCPKKKL","Homo sapiens","AGXT, AGT1, SPAT","Serine--pyruvate aminotransferase","1","5OG0"
"5OGB",,"X-RAY DIFFRACTION",1.71,28.22,"VAPOR DIFFUSION, HANGING DROP",,"PEG 4000, Na Acetate",293,"10.1021/acschembio.8b00916",,"5OGB",16.06,"1.8","1.8","Human Cellular Retinoic Acid Binding Protein II (CRABPII) with bound synthetic retinoid DC360.","MPNFSGNWKIIRSENFEELLKVLGVNVMLRKIAVAAASKPAVEIKQEGDTFYIKTSTTVRTTEINFKVGEEFEEQTVDGRPCKSLVKWESENKMVCEQKLLKGEGPKTSWTRELTNDGELILTMTADDVVCTRVYVRE","Homo sapiens","CRABP2","Cellular retinoic acid-binding protein 2","1","5OGB"
"5OGJ",,"X-RAY DIFFRACTION",2.18,43.56,"EVAPORATION",5,"Crystallization buffer: 0.1M ammonium citrate (pH 7), 0.1M  sodium acetate (pH 4.5) and 26% PEG3350",291,,"V90","5OGJ",61.49,"1.06","1.06","Crystal structure of human carbonic anhydrase isozyme XIII with 2-(Cyclooctylamino)-3,5,6-trifluoro-4-[(2-hydroxyethyl)thio]benzenesulfonamide","MMSRLSWGYREHNGPIHWKEFFPIADGDQQSPIEIKTKEVKYDSSLRPLSIKYDPSSAKIISNSGHSFNVDFDDTENKSVLRGGPLTGSYRLRQVHLHWGSADDHGSEHIVDGVSYAAELHVVHWNSDKYPSFVEAAHEPDGLAVLGVFLQIGEPNSQLQKITDTLDSIKEKGKQTRFTNFDLLSLLPPSWDYWTYPGSLTVPPLLESVTWIVLKQPINISSQQLAKFRSLLCTAEGEAAAFLVSNHRPPQPLKGRKVRASFH","Homo sapiens","CA13","Carbonic anhydrase 13","1","5OGJ"
"5OGN",,"X-RAY DIFFRACTION",1.95,36.8,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCl pH 7.8",291,"10.1021/acs.jmedchem.9b00945",,"5OGN",59.29,"1.1","1.1","Metalacarborane inhibitors of Carbonic Anhydrase IX","HHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHSFQVTFDDSQDKAVLKGGPLDGTYRLLQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDVGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTEGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLAECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5OGN"
"5OGO",,"X-RAY DIFFRACTION",2.06,40.4,"EVAPORATION",7,"Crystallization buffer: 0.1M sodium bicine (pH 9.0), 0.2M  ammonium sulfate and 2M sodium malonate (pH 7.0)",291,,"WWO","5OGO",31.04,"0.99","0.99","Crystal structure of chimeric carbonic anhydrase I with 3-(Benzylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNVGHAFHVEFDDSQDKAVLKGGPLDGTYRLFQFHFHWGSLDGQGSEHTVDKKKYAAELHLAHWNTKYGDLGKAAQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTHPPLYECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5OGO"
"5OGP",,"X-RAY DIFFRACTION",2.09,41.03,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate 
50 mM Tris-HCl pH 7.8.",291,"10.1021/acs.jmedchem.9b00945",,"5OGP",29.53,"1.1","1.1","Metalacarborane inhibitors of Carbonic Anhydrase IX","SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHSFQVVFDDSQDKAVLKGGPLDGTYRLLQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDVGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLAECVTWIVLKEPISVSSEQVVKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5OGP"
"5OGS",,"X-RAY DIFFRACTION",2.89,57.43,"VAPOR DIFFUSION, HANGING DROP",,"0.1 MHEPES pH 7.0, 1.1M di-sodium malonate and 0.5 % (v/v) Jeffamine ED-2003, supplemented with 0.36 to 0.42 M sulfobetaine NDSB-195",291,"10.1098/rsob.170217",,"5OGS",56.33,"2.503","2.503","Crystal structure of human AND-1 SepB domain","GSGGGDDMSNAGDFLNDNAVEIPSFSKGIINDDEDDEDLMMASGRPRQRSHILEDDENSVDISMLKTGSSLLKEEEEDGQEGSIHNLPLVTSQRPFYDGPMPTPRQKPFQSGSTPLHLTHRFMVWNSIGIIRCYNDEQDNAIDVEFHDTSIHHATHLSNTLNYTIADLSHEAILLACESTDELASKLHCLHFSSWDSSKEWIIDLPQNEDIEAICLGQGWAAAATSALLLRLFTIGGVQKEVFSLAGPVVSMAGHGEQLFIVYHRGTGFDGDQCLGVQLLELGKKKKQILHGDPLPLTRKSYLAWIGFSAEGTPCYVDSEGIVRMLNRGLGNTWTPICNTREHCKGKSDHYWVVGIHENPQQLRCIPCKGSRFPPTLPRPAVAILSFKLPYCQIATEKGQMEEQFWRSVIFHNHLDYLAKNGYEYEESTKNQATKEQQELLMKMLALSCKLEREFRCVELADLMTQNAVNLAIKYASRSRKLILAQKLSELAVEKAAELTAT","Homo sapiens","WDHD1, AND1","WD repeat and HMG-box DNA-binding protein 1","1","5OGS"
"5OHD",,"SOLUTION NMR",,,,,,,"10.1016/j.bbagen.2018.03.022",,"5OHD",10.29,,,"Putative inactive (dormant) dimeric state of GHR transmembrane domain","GSMSQFTCEEDFYFPWLLIIIFGIFGLTVMLFVFLFSKQQRIK","Homo sapiens","GHR","Growth hormone receptor","1","5OHD"
"5OHH",,"X-RAY DIFFRACTION",2.19,43.83,"EVAPORATION",5,"Crystallization buffer: 0.1M sodium citrate (pH 5.5), 0.1M  sodium acetate (pH 4.5) and 26% PEG4000",291,,,"5OHH",61.61,"1.42","1.42","Crystal structure of human carbonic anhydrase isozyme XIII with 2-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-3,5,6-trifluoro-4-[(2-hydroxyethyl)thio]benzenesulfonamide","MMSRLSWGYREHNGPIHWKEFFPIADGDQQSPIEIKTKEVKYDSSLRPLSIKYDPSSAKIISNSGHSFNVDFDDTENKSVLRGGPLTGSYRLRQVHLHWGSADDHGSEHIVDGVSYAAELHVVHWNSDKYPSFVEAAHEPDGLAVLGVFLQIGEPNSQLQKITDTLDSIKEKGKQTRFTNFDLLSLLPPSWDYWTYPGSLTVPPLLESVTWIVLKQPINISSQQLAKFRSLLCTAEGEAAAFLVSNHRPPQPLKGRKVRASFH","Homo sapiens","CA13","Carbonic anhydrase 13","1","5OHH"
"5OHJ",,"X-RAY DIFFRACTION",1.8,31.5,"VAPOR DIFFUSION, HANGING DROP",4.5,"Drops comprised 2microliters protein solution mixed with reservoir buffer consisting of 100mM sodium acetate pH 4.5, 14% PEG400 and 50mM calcium acetate. After 2 days they were streak seeded with crystals obtained from rolipram complex seed stock. Crystals, up to 100 microns in largest dimension, grew from precipitate after 1-2 weeks. Crystals were transferred to a cryoprotectant solution (100mM sodium acetate pH 4.5, 14% PEG400, 50mM calcium acetate and 20% glycerol) then flash-frozen prior to X-ray data collection.",293,"10.1021/acs.jmedchem.7b01044","9VE","5OHJ",98.52,"1.6","1.6","Human phosphodiesterase 4B catalytic domain in complex with a pyrrolidinyl inhibitor.","MSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEYISNTFLDKQNDVEIPKVTAEEAPQPMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELEDLNKWGLNIFNVAGYSHNRPLTCIMYAIFQERDLLKTFRISSDTFITYMMTLEDHYHSDVAYHNSLHAADVAQSTHVLLSTPALDAVFTDLEILAAIFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEEHCDIFMNLTKKQRQTLRKMVIDMVLATDMSKHMSLLADLKTMVETKKVTSSGVLLLDNYTDRIQVLRNMVHCADLSNPTKSLELYRQWTDRIMEEFFQQGDKERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVQPDAQDILDTLEDNRNWYQSMIPQSHHHHHH","Homo sapiens","PDE4B, DPDE4","cAMP-specific 3',5'-cyclic phosphodiesterase 4B","1","5OHJ"
"5OHO",,"X-RAY DIFFRACTION",1.94,36.51,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M sodium cacodylate pH 6.5, 1.0 M tri-sodium citrate dihydrate",293,"10.1038/nsmb.3465",,"5OHO",26.2,"1.601","1.601","Crystal structure of the KOWx-KOW4 domain of human DSIF","GPWGELVQLDPQTVGVIVRLERETFQVLNMYGKVVTVRHQAVTRKKDNRFAVALDSEQNNIHVKDIVKVIDGPHSGREGEIRHLFRSFAFLHCKKLVENGGMFVCKTRHLVLA","Homo sapiens","SUPT5H, SPT5, SPT5H","Transcription elongation factor SPT5","1","5OHO"
"5OHQ",,"X-RAY DIFFRACTION",2.63,53.22,"VAPOR DIFFUSION, HANGING DROP",7,"0.1 M bis-tris propane pH 7, 3 M sodium formate",293,"10.1038/nsmb.3465",,"5OHQ",12.27,"1.098","1.098","Crystal structure of the KOW6-KOW7 domain of human DSIF","GPWVTTDIQVKVRDTYLDTQVVGQTGVIRSVTGGMCSVYLKDSEKVVSISSEHLEPITPTKNNKVKVILGEDREATGVLLSIDGEDGIVRMDLDEQLKILNLRFLGKLLEA","Homo sapiens","SUPT5H, SPT5, SPT5H","Transcription elongation factor SPT5","1","5OHQ"
"5OI7",,"X-RAY DIFFRACTION",2.17,43.29,"VAPOR DIFFUSION, SITTING DROP",,"100 mM Na-HEPES, pH 7.7
200 mM Na-Citrate
36 % (v/v) MPD",292,"10.1038/s41467-018-04122-x",,"5OI7",20.81,"1.67","1.67","Human CEP85 - coiled coil domain 4","GESWQKRYDSLQKIVEKQQQKMDQLRSQVQSLEQEVAQEEGTSQALREEAQRRDSALQQLRTAVKELSVQNQDLIEKNLTLQEHLRQA","Homo sapiens","CEP85, CCDC21","Centrosomal protein of 85 kDa","1","5OI7"
"5OJ8",,"X-RAY DIFFRACTION",2.44,49.56,"VAPOR DIFFUSION, HANGING DROP",,"20 % PEG400, 
0,15M Phosphate pH7.25
10% PEG10K",291,"10.1371/journal.pone.0186354",,"5OJ8",28.77,"2.247","2.247","Crystal structure of the KLC1-TPR domain ([A1-B5] fragment)","MGSSHHHHHHSSGLVPRGSHMDDPGQGIQQQHSSAAAAAQQGGYEIPARLRTLHNLVIQYASQGRYEVAVPLCKQALEDLEKTSGHDHPDVATMLNILALVYRDQNKYKDAANLLNDALAIREKTLGKDHPAVAATLNNLAVLYGKRGKYKEAEPLCKRALEIREKVLGKDHPDVAKQLNNLALLCQNQGKYEEVEYYYQRALEIYQTKLGPDDPNVAKTKNNLASCYLKQGKFKQAETLYKEILTRAHEREFGS","Homo sapiens","KLC1, KLC, KNS2","Kinesin light chain 1","1","5OJ8"
"5OJJ",,"X-RAY DIFFRACTION",2.29,46.19,"VAPOR DIFFUSION, SITTING DROP",,"10% PEG3350, 0.2 M calcium acetate, 0.1 M Tris pH 8.5",293,"10.1021/acs.jmedchem.7b01071",,"5OJJ",107.24,"1.85","1.85","Crystal structure of the Zn-bound ubiquitin-conjugating enzyme Ube2T","MQRASRLKRELHMLATEPPPGITCWQDKDQMDDLRAQILGGANTPYEKGVFKLEVIIPERYPFEPPQIRFLTPIYHPNIDSAGRICLDVLKLPPKGAWRPSLNIATVLTSIQLLMSEPNPDDPLMADISSEFKYNKPAFLKNARQWTEKHARQK","Homo sapiens","UBE2T, HSPC150, PIG50","Ubiquitin-conjugating enzyme E2 T","1","5OJJ"
"5OJK",,"X-RAY DIFFRACTION",2.39,48.57,"VAPOR DIFFUSION, SITTING DROP",,"0.2M KSCN, 0.1M Bis-tris propane pH 8.5, 20% w/v PEG3350",293,"10.1016/j.neuron.2017.07.040",,"5OJK",132.16,"2.55","2.55","Crystal structure of the human neuroligin 1 cholinesterase domain containing spliced sequence B (SSB) (NL1(-A+B))","ETGQKLDDVDPLVATNFGKIRGIKKELNNEILGPVIQFLGVPYAAPPTGERRFQPPEPPSPWSDIRNATQFAPVCPQNIIDGRLPEVMLPVWFTNNLDVVSSYVQDQSEDCLYLNIYVPTEDDIRDSGGPKPVMVYIHGGSYMEGTGNLYDGSVLASYGNVIVITVNYRLGVLGFLSTGDQAAKGNYGLLDLIQALRWTSENIGFFGGDPLRITVFGSGAGGSCVNLLTLSHYSEGNRWSNSTKGLFQRAIAQSGTALSSWAVSFQPAKYARMLATKVGCNVSDTVELVECLQKKPYKELVDQDIQPARYHIAFGPVIDGDVIPDDPQILMEQGEFLNYDIMLGVNQGEGLKFVENIVDSDDGISASDFDFAVSNFVDNLYGYPEGKDVLRETIKFMYTDWADRHNPETRRKTLLALFTDHQWVAPAVATADLHSNFGSPTYFYAFYHHCQTDQVPAWADAAHGDEVPYVLGIPMIGPTELFPCNFSKNDVMLSAVVMTYWTNFAKTGDPNQPVPQDTKFIHTKPNRFEEVAWTRYSQKDQLYLHIGLKPRVKEHYRANKVNLWLELVPHLHNLNDRTKHHHHHH","Homo sapiens","NLGN1, KIAA1070","Neuroligin-1,Neuroligin-1","1","5OJK"
,,,,,,,,,,,,,,,,,"Homo sapiens","NLGN1, KIAA1070"
"5OJT",,"SOLUTION NMR",,,,,,,"10.1021/acs.jmedchem.7b01062",,"5OJT",1,,,"Structure-Activity Relationships and Biological Characterization of a Novel, Potent and Serum Stable C-X-C chemokine receptor type 4 (CXCR4) Antagonist","XRACRAHX","Homo sapiens",,"ACE-ARG-ALA-(D)CYS-ARG-BNA-HIS-PEN","1","5OJT"
"5OKL",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, HANGING DROP",6,"1.5 uL PEG 1k 30%, CH3COONH4 180mM, 3% 6-aminohexanoic acid plus 1.5 uL 5 mg/ml protein stock 20mM HEPES ph7.5 150 mM NaCl, microseeding",293,"10.1016/j.str.2017.10.006",,"5OKL",137.47,"2.09","2.09","Human afamin monoclinic crystal form","LPTQPRDIENFNSTQKFIEDNIEYITIIAFAQYVQEATFEEMEKLVKDMVEYKDRCMADKTLPECSKLPNNVLQEKICAMEGLPQKHNFSHCCSKVDAQRRLCFFYNKKSDVGFLPPFPTLDPEEKCQAYESNRESLLNHFLYEVARRNPFVFAPTLLTVAVHFEEVAKSCCEEQNKVNCLQTRAIPVTQYLKAFSSYQKHVCGALLKFGTKVVHFIYIAILSQKFPKIEFKELISLVEDVSSNYDGCCEGDVVQCIRDTSKVMNHICSKQDSISSKIKECCEKKIPERGQCIINSNKDDRPKDLSLREGKFTDSENVCQERDADPDTFFAKFTFEYSRRHPDLSIPELLRIVQIYKDLLRNCCNTENPPGCYRYAEDKFNETTEKSLKMVQQECKHFQNLGKDGLKYHYLIRLTKIAPQLSTEELVSLGEKMVTAFTTCCTLSEEFACVDNLADLVFGELCGVNENRTINPAVDHCCKTNFAFRRPCFESLKADKTYVPPPFSQDLFTFHADMCQSQNEELQRKTDRFLVNLVKLKHELTDEELQSLFTNFANVVDKCCKAESPEVCFNEESPKIGNKGENLYFQ","Homo sapiens","AFM, ALB2, ALBA","Afamin","1","5OKL"
"5OKM",,"X-RAY DIFFRACTION",2.54,51.66,"VAPOR DIFFUSION",7,"0.1 M BisTris propane pH 7, 0.2 M NaNO3, 20% PEG 3350, 0.025% CH2Cl2, 2 mM TCEP",293,"10.7554/eLife.26640",,"5OKM",425.41,"1.96","1.96","Crystal structure of human SHIP2 Phosphatase-C2","GPEPDMISVFIGTWNMGSVPPPKNVTSWFTSKGLGKTLDEVTVTIPHDIYVFGTQENSVGDREWLDLLRGGLKELTDLDYRPIAMQSLWNIKVAVLVKPEHENRISHVSTSSVKTGIANTLGNKGAVGVSFMFNGTSFGFVNCHLTSGNEKTARRNQNYLDILRLLSLGDRQLNAFDISLRFTHLFWFGDLNYRLDMDIQEILNYISRKEFEPLLRVDQLNLEREKHKVFLRFSEEEISFPPTYRYERGSRDTYAWHKQKPTGVRTNVPSWCDRILWKSYPETHIICNSYGCTDDIVTSDHSPVFGTFEVGVTSQFISKKGLSKTSDQAYIEFESIEAIVKTASRTKFFIEFYSTCLEEYKKSFENDAQSSDNINFLKVQWSSRQLPTLKPILADIEYLQDQHLLLTVKSMDGYESYGECVVALKSMIGSTAQQFLTFLSHRGEETGNIRGSMKVRVPTER","Homo sapiens","INPPL1, SHIP2","Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2","1","5OKM"
"5OKN",,"X-RAY DIFFRACTION",2.59,52.5,"VAPOR DIFFUSION, HANGING DROP",7,"0.1 M Bis-Tris propane, pH 7.0, 0.4 M KSCN, 20% (w/v) PEG3350",293,"10.7554/eLife.26640",,"5OKN",425.4,"2.65","2.65","Crystal structure of human SHIP2 Phosphatase-C2 D607A mutant","GPEPDMISVFIGTWNMGSVPPPKNVTSWFTSKGLGKTLDEVTVTIPHDIYVFGTQENSVGDREWLDLLRGGLKELTDLDYRPIAMQSLWNIKVAVLVKPEHENRISHVSTSSVKTGIANTLGNKGAVGVSFMFNGTSFGFVNCHLTSGNEKTARRNQNYLDILRLLSLGDRQLNAFDISLRFTHLFWFGALNYRLDMDIQEILNYISRKEFEPLLRVDQLNLEREKHKVFLRFSEEEISFPPTYRYERGSRDTYAWHKQKPTGVRTNVPSWCDRILWKSYPETHIICNSYGCTDDIVTSDHSPVFGTFEVGVTSQFISKKGLSKTSDQAYIEFESIEAIVKTASRTKFFIEFYSTCLEEYKKSFENDAQSSDNINFLKVQWSSRQLPTLKPILADIEYLQDQHLLLTVKSMDGYESYGECVVALKSMIGSTAQQFLTFLSHRGEETGNIRGSMKVRVPTER","Homo sapiens","INPPL1, SHIP2","Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2","1","5OKN"
"5OKO",,"X-RAY DIFFRACTION",2.21,44.35,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M PCB (sodium propionate, sodium cacodylate, and BIS-TRIS propane; 2:1:2 molar ratio) pH 7, 25% PEG 1500",293,"10.7554/eLife.26640",,"5OKO",106.03,"1.94","1.94","Crystal structure of human SHIP2 Phosphatase-C2 double mutant F593D/L597D","GPEPDMISVFIGTWNMGSVPPPKNVTSWFTSKGLGKTLDEVTVTIPHDIYVFGTQENSVGDREWLDLLRGGLKELTDLDYRPIAMQSLWNIKVAVLVKPEHENRISHVSTSSVKTGIANTLGNKGAVGVSFMFNGTSFGFVNCHLTSGNEKTARRNQNYLDILRLLSLGDRQLNADDISDRFTHLFWFGDLNYRLDMDIQEILNYISRKEFEPLLRVDQLNLEREKHKVFLRFSEEEISFPPTYRYERGSRDTYAWHKQKPTGVRTNVPSWCDRILWKSYPETHIICNSYGCTDDIVTSDHSPVFGTFEVGVTSQFISKKGLSKTSDQAYIEFESIEAIVKTASRTKFFIEFYSTCLEEYKKSFENDAQSSDNINFLKVQWSSRQLPTLKPILADIEYLQDQHLLLTVKSMDGYESYGECVVALKSMIGSTAQQFLTFLSHRGEETGNIRGSMKVRVPTER","Homo sapiens","INPPL1, SHIP2","Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2","1","5OKO"
"5OKP",,"X-RAY DIFFRACTION",2.42,49.25,"VAPOR DIFFUSION, SITTING DROP",7.1,"50 mM HEPES pH 7.1, 17.5% PEG 1000",293,"10.7554/eLife.26640",,"5OKP",52.97,"1.85","1.85","Crystal structure of human SHIP2 Phosphatase-C2 double mutant F593D/L597D","GPEPDMISVFIGTWNMGSVPPPKNVTSWFTSKGLGKTLDEVTVTIPHDIYVFGTQENSVGDREWLDLLRGGLKELTDLDYRPIAMQSLWNIKVAVLVKPEHENRISHVSTSSVKTGIANTLGNKGAVGVSFMFNGTSFGFVNCHLTSGNEKTARRNQNYLDILRLLSLGDRQLNADDISDRFTHLFWFGDLNYRLDMDIQEILNYISRKEFEPLLRVDQLNLEREKHKVFLRFSEEEISFPPTYRYERGSRDTYAWHKQKPTGVRTNVPSWCDRILWKSYPETHIICNSYGCTDDIVTSDHSPVFGTFEVGVTSQFISKKGLSKTSDQAYIEFESIEAIVKTASRTKFFIEFYSTCLEEYKKSFENDAQSSDNINFLKVQWSSRQLPTLKPILADIEYLQDQHLLLTVKSMDGYESYGECVVALKSMIGSTAQQFLTFLSHRGEETGNIRGSMKVRVPTER","Homo sapiens","INPPL1, SHIP2","Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2","1","5OKP"
"5OKT",,"X-RAY DIFFRACTION",2.4,48.76,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonium sulfate, 0.1 M sodium acetate pH 5.0 and 5 % (w/v) PEG 2000 MME",294,"10.1021/acs.jmedchem.8b00095","9XK","5OKT",149.85,"2.13","2.13","Crystal structure of human Casein Kinase I delta in complex with IWP-2","MGSSHHHHHHSSGLVPRGSHMELRVGNRYRLGRKIGSGSFGDIYLGTDIAAGEEVAIKLECVKTKHPQLHIESKIYKMMQGGVGIPTIRWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIHSKNFIHRDVKPDNFLMGLGKKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLESLGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFATYLNFCRSLRFDDKPDYSYLRQLFRNLFHRQGFSYDYVFDWNMLK","Homo sapiens","CSNK1D, HCKID","Casein kinase I isoform delta","1","5OKT"
,,,,,,,,,,,,,,,,"MGSSHHHHHHSSGLVPRGSHMELRVGNRYRLGRKIGSGSFGDIYLGTDIAAGEEVAIKLECVKTKHPQLHIESKIYKMMQGGVGIPTIRWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIHSKNFIHRDVKPDNFLMGLGKKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLESLGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFATYLNFCRSLRFDDKPDYSYLRQLFRNLFHRQGFSYDYVFDWNMLK","Homo sapiens","CSNK1D, HCKID","Casein kinase I isoform delta","2","5OKT"
"5OL8",,"X-RAY DIFFRACTION",2.12,42.1,"VAPOR DIFFUSION, HANGING DROP",,"Limited proteolysis with ArgC at RT for 20min. BIS-TRIS pH 5.5-6.5, MgCl2, PEG3350",293,"10.1016/j.cell.2017.09.035",,"5OL8",149.12,"1.9","1.9","Structure of human mitochondrial transcription elongation factor (TEFM) C-terminal domain","MDENAKEPENALDKLFSSEQQASILHVLNTASTKELEAFRLLRGRRSINIVEHRENFGPFQNLESLMNVPLFKYKSTVQVCNSILCPKTGREKRKSPENRFLRKLLKPDIERERLKAVNSIISIVFGTRRIAWAHLDRKLTVLDWQQSDRWSLMRGIYSSSVYLEEISSIISKMPKADFYVLEKTGLSIQNSSLFPILLHFHIMEAMLYALLNKTFAQDGQHQVLSMNRNAVGKHFELMIGDSRTSGKELVKQFLFDSILKADPRVFFPSDKIVHYRQMFLSTELQRVEELYDSLLQAIAFYELAVFDSQPLEHHHHHH","Homo sapiens","TEFM, C17orf42","Transcription elongation factor, mitochondrial","1","5OL8"
"5OL9",,"X-RAY DIFFRACTION",2.13,42.32,"VAPOR DIFFUSION, SITTING DROP",4,"Sodium Acetate, Ammonium Acetate, PEG4000",293,"10.1016/j.cell.2017.09.035",,"5OL9",12.3,"1.302","1.302","Structure of human mitochondrial transcription elongation factor (TEFM) N-terminal domain","MKSTTPKKITPNVTFCDENAKEPENALDKLFSSEQQASILHVLNTASTKELEAFRLLRGRRSINIVEHRENFGPFQNLESLMNVPLFKYKSTVQVCNSILHHHHHH","Homo sapiens","TEFM, C17orf42","Transcription elongation factor, mitochondrial","1","5OL9"
"5OLF",,"SOLUTION NMR",,,,,,,"10.1021/acs.jmedchem.7b01830",,"5OLF",0.91,,,"Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)-Ligand Interactions in Living Cancer Cells","XACRFFC","Homo sapiens",,"GBA-ALA-CYS-ARG-PHE-PHE-CYS","1","5OLF"
"5OLM",,"X-RAY DIFFRACTION",2.37,48.04,"BATCH MODE",,"na",300,"10.7554/eLife.32660",,"5OLM",30.1,"1.95","1.95","TRIM21","GSHMASAARLTMMWEEVTCPICLDPFVEPVSIECGHSFCQECISQVGKGGGSVCPVCRQRFLLKNLRPNRQLANMVNNLKEISQEAREGTQGERCAVHGERLHLFCEKDGKALCWVCAQSRKHRDHAMVPLE","Homo sapiens","TRIM21, RNF81, RO52, SSA1","E3 ubiquitin-protein ligase TRIM21","1","5OLM"
"5OM2",,"X-RAY DIFFRACTION",2.2,44.04,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonium chloride, 
20 % w/v PEG 3350",293,"10.1073/pnas.1716666115",,"5OM2",47.12,"1.47","1.47","Crystal structure of Alpha1-antichymotrypsin variant DBS-I1: a drug-binding serpin for doxycycline","MKHHHHHHMKQNSPLDEENLTQENQDRGTHVDRGLASANVDFAFSLYKQLVLKAPDKNVIFSPLSISTALAFLSLGAHNTTLTEILKGLKFNLTETSEAEIHQSFQHLLRTLNQSSDELQLSMGNAMFVKEQLSLLDRFTEDAKRLYGSEAFATDFQDSAAAKKLINDYVKNGTRGKITDLIKDLDSQTMMVLVNYIFFKAKFEMPFDPQDTHQSRFYLSKKKYVMVPMMSLHHLTIPYFRDEELSCTVVQLNYTGNASALFILPDQDKMEEVEAMLSQETLARFFDSLEFREIGELYLPKFSISRDYNLNDILLQLGIEEAFTSKADLSGITGARNLAVSQVVHKAVLDVFEEGTEASAATALEVLFQ","Homo sapiens","SERPINA3, AACT, GIG24, GIG25","Alpha-1-antichymotrypsin","1","5OM2"
,,,,,,,,,,,,,,,,"GPLVETRTIVRFNRPFLMIIVDHFTWSIFFMSKVTNPKQA","Homo sapiens","SERPINA3, AACT, GIG24, GIG25","Alpha-1-antichymotrypsin","2","5OM2"
"5OM3",,"X-RAY DIFFRACTION",2.16,42.99,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonium sulfate, 0.1 M BIS-TRIS pH 5.5, 25 % w/v PEG 3350",293,"10.1073/pnas.1716666115",,"5OM3",47.26,"2","2","Crystal structure of Alpha1-antichymotrypsin variant DBS-I5: a MMP14-cleavable drug-binding serpin for doxycycline","MKHHHHHHMKQNSPLDEENLTQENQDRGTHVDRGLASANVDFAFSLYKQLVLKAPDKNVIFSPLSISTALAFLSLGAHNTTLTEILKGLKFNLTETSEAEIHQSFQHLLRTLNQSSDELQLSMGNAMFVKEQLSLLDRFTEDAKRLYGSEAFATDFQDSAAAKKLINDYVKNGTRGKITDLIKDLDSQTMMVLVNYIFFKAKFEMPFDPQDTHQSRFYLSKKKYVMVPMMSLHHLTIPYFRDEELSCTVVQLNYTGNASALFILPDQDKMEEVEAMLSQETLSRFFDSLEFREIGELYLPKFSISRDYNLNDILLQLGIEEAFTSKADLSGITGARNLAVSQVVHKAVLDVFEEGTEASAATALFIPLS","Homo sapiens","SERPINA3, AACT, GIG24, GIG25","Alpha-1-antichymotrypsin","1","5OM3"
,,,,,,,,,,,,,,,,"LRMVETRTIVRFNRPFLMIIVDHFTWSIFFMSKVTNPKQA","Homo sapiens","SERPINA3, AACT, GIG24, GIG25","Alpha-1-antichymotrypsin","2","5OM3"
"5OM5",,"X-RAY DIFFRACTION",2.16,42.95,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.0, 30 % v/v
Jeffamine ED-2001 pH 7.0",293,"10.1073/pnas.1716666115",,"5OM5",46.94,"1.595","1.595","Crystal structure of Alpha1-antichymotrypsin variant DBS-I-allo1: an allosterically triggered drug-binding serpin for doxycycline","MKHHHHHHMKQNSPLDEENLTQENQDRGTHVDRGLASANVDFAFSLYKQLVLKAPDKNVIFSPLSISTALAFLSLGAHNTTLTEILKGLKFNLTETSEAEIHQSFQHLLRTLNQSSDELQLSMGNAMFVKEQLSLLDRFTEDAKRLYGSEAFATDFQDSAAAKKLINDYVKNGTRGKITDLIKDLDSQTMMVLVNYIFFKAKFEMPFDPQDTHQSRFYLSKKKYVMVPMMSLHHLTIPYFRDEELSCTVVQLNYTGNASALFILPDQDKMEEVEAMLSQETLSRFFDSLEFREIGELYLPKFSISRDYNLNDILLQLGIEEAFTSKADLSGITGARNLAVSQVVHKAVLDVFEEGTERSAATALEVLFQ","Homo sapiens","SERPINA3, AACT, GIG24, GIG25","Alpha-1-antichymotrypsin","1","5OM5"
,,,,,,,,,,,,,,,,"GPLVETRTIVRFNRPFLMIIVDHFTWSIFFMSKVTNPKQA","Homo sapiens","SERPINA3, AACT, GIG24, GIG25","Alpha-1-antichymotrypsin","2","5OM5"
"5OM6",,"X-RAY DIFFRACTION",2.32,46.9,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M citric acid pH 3.5, 25 % w/v PEG 3350",293,"10.1073/pnas.1716666115",,"5OM6",93.92,"1.849","1.849","Crystal structure of Alpha1-antichymotrypsin variant DBS-I-allo2: a MMP9-cleavable drug-binding serpin for doxycycline","MKHHHHHHMKQNSPLDEENLTQENQDRGTHVDRGLASANVDFAFSLYKQLVLKAPDKNVIFSPLSISTALAFLSLGAHNTTLTEILKGLKFNLTETSEAEIHQSFQHLLRTLNQSSDELQLSMGNAMFVKEQLSLLDRFTEDAKRLYGSEAFATDFQDSAAAKKLINDYVKNGTRGKITDLIKDLDSQTMMVLVNYIFFKAKFEMPFDPQDTHQSRFYLSKKKYVMVPMMSLHHLTIPYFRDEELSCTVVQLNYTGNASALFILPDQDKMEEVEAMLSQETLSRFFDSLEFREIGELYLPKFSISRDYNLNDILLQLGIEEAFTSKADLSGITGARNLAVSQVVHKAVLDVFEEGTERSAATALKGPRQ","Homo sapiens","SERPINA3, AACT, GIG24, GIG25","Alpha-1-antichymotrypsin","1","5OM6"
,,,,,,,,,,,,,,,,"ITAVETRTIVRFNRPFLMIIVDHFTWSIFFMSKVTNPKQA","Homo sapiens","SERPINA3, AACT, GIG24, GIG25","Alpha-1-antichymotrypsin","2","5OM6"
"5OM7",,"X-RAY DIFFRACTION",2.17,43.38,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonium chloride, 20 % w/v
PEG 3350",293,"10.1073/pnas.1716666115",,"5OM7",47.16,"1.727","1.727","Crystal structure of Alpha1-antichymotrypsin variant DBS-II: a drug-binding serpin for doxorubicin","MKHHHHHHMKQNSPLDEENLTQENQDRGTHVDRGLASANVDFAFSLYKQLVLKAPDKNVIFSPLSISTALAFLSLGAHNTTLTEILKGLKFNLTETSEAEIHQSFQHLLRTLNQSSDELQLSMGNAMFVKEQLSLLDRFTEDAKRLYGSEAFATDFQDSAAAKKLINDYVKNGTRGKITDLIKDLDSQTMMVLVNYIFFKAKFEMPFDPQDTHQSRFYLSKKKYVMVPMMSLHHLTIPYFRDEELSCTVVQLNYTGNASALFILPDQDKMEEVEAMLSQETLSRFFESLEFREIGELYLPKFSISRDYNLNDILLQLGIEEAFTSKADLSGITGARNLAVSQVVHKAVLDVFEEGTEASAATALEVLFQ","Homo sapiens","SERPINA3, AACT, GIG24, GIG25","Alpha-1-antichymotrypsin","1","5OM7"
,,,,,,,,,,,,,,,,"GPLVETRTIVRFNRPFLMIIVDNFTWSIFFMSKVTNPKQA","Homo sapiens","SERPINA3, AACT, GIG24, GIG25","Alpha-1-antichymotrypsin","2","5OM7"
"5OM8",,"X-RAY DIFFRACTION",2.15,42.92,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium chloride, 20% w/v 
PEG 3350",293,"10.1073/pnas.1716666115",,"5OM8",46.86,"2.2","2.2","Crystal form 2 of Alpha1-antichymotrypsin variant DBS-II-allo: an allosterically modulated drug-binding serpin for doxorubicin","MKHHHHHHMKQNSPLDEENLTQENQDRGTHVDRGLASANVDFAFSLYKQLVLKAPDKNVIFSPLSISTALAFLSLGAHNTTLTEILKGLKFNLTETSEAEIHQSFQHLLRTLNQSSDELQLSMGNAMFVKEQLSLLDRFTEDAKRLYGSEAFATDFQDSAAAKKLINDYVKNGTRGKITDLIKDLDSQTMMVLVNYIFFKAKFEMPFDPQDTHQSRFYLSKKKYVMVPMMSLHHLTIPYFRDEELSCTVVQLNYTGNASALFILPDQDKMEEVEAMLSQETLSRFFESLEFREIGELYLPKFSISRDYNLNDILLQLGIEEAFTSKADLSGITGARNLAVSQVVHKAVLDVFEEGTERSAATALEVLFQ","Homo sapiens","SERPINA3, AACT, GIG24, GIG25","Alpha-1-antichymotrypsin","1","5OM8"
,,,,,,,,,,,,,,,,"GPLVETRTIVRFNRPFLMIIVDNFTWSIFFMSKVTNPKQA","Homo sapiens","SERPINA3, AACT, GIG24, GIG25","Alpha-1-antichymotrypsin","2","5OM8"
"5OM9",,"X-RAY DIFFRACTION",2,38.6,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 6000, 0.2M MGCL2, 0.1 M TRIS- HCL BUFFER PH 8.0",277,"10.1021/acsmedchemlett.7b00346",,"5OM9",94.93,"1.8","1.8","Crystal structure of the human CARBOXYPEPTIDASE A1 in complex with a thiirane mechanism-based inhibitor","MRGLLVLSVLLGAVFGKEDFVGHQVLRISVADEAQVQKVKELEDLEHLQLDFWRGPAHPGSPIDVRVPFPSIQAVKIFLESHGISYETMIEDVQSLLDEEQEQMFAFRSRARSTDTFNYATYHTLEEIYDFLDLLVAENPHLVSKIQIGNTYEGRPIYVLKFSTGGSKRPAIWIDTGIHSREWVTQASGVWFAKKITQDYGQDAAFTAILDTLDIFLEIVTNPDGFAFTHSTNRMWRKTRSHTAGSLCIGVDPNRNWDAGFGLSGASSNPCSETYHGKFANSEVEVKSIVDFVKDHGNIKAFISIHSYSQLLMYPYGYKTEPVPDQDELDQLSKAAVTALASLYGTKFNYGSIIKAIYQASGSTIDWTYSQGIKYSFTFELRDTGRYGFLLPASQIIPTAKETWLALLTIMEHTLNHPY","Homo sapiens","CPA1, CPA","Carboxypeptidase A1","1","5OM9"
"5OMG",,"X-RAY DIFFRACTION",2.38,48.43,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2, 
20-30 % PEG4000,
50 mM BOG",293.15,"10.1016/j.bbrc.2019.02.063",,"5OMG",41.96,"2","2","p38alpha in complex with pyrazolobenzothiazine inhibitor COXP4M12","MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5OMG"
"5OMH",,"X-RAY DIFFRACTION",2.27,45.81,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES pH 5.6-6.2,
20-30 % PEG4000,
50 mM BOG",293.15,"10.1016/j.bbrc.2019.02.063",,"5OMH",41.69,"2.5","2.5","p38alpha in complex with pyrazolobenzothiazine inhibitor COXH11","MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5OMH"
"5OMP",,"X-RAY DIFFRACTION",3.07,59.94,"VAPOR DIFFUSION, SITTING DROP",6,"20 %w/v PEG MME 5K, 0.2 M NH4SO4, 0.1 M MES 6 pH",277,"10.1038/s41598-017-14731-z",,"5OMP",51.99,"1.88","1.88","Human FKBP5 protein","GPLGSMTTDEGAKNNEESPTATVAEQGEDITSKKDRGVLKIVKRVGNGEETPMIGDKVYVHYKGKLSNGKKFDSSHDRNEPFVFSLGKGQVIKAWDIGVATMKKGEICHLLCKPEYAYGSAGSLPKIPSNATLFFEIELLDFKGEDLFEDGGIIRRTKRKGEGYSNPNEGATVEIHLEGRCGGRMFDCRDVAFTVGEGEDHDIPIGIDKALEKMQREEQCILYLGPRYGFGEAGKPKFGIEPNAELIYEVTLKSFEKAKESWEMDTKEKLEQAAIVKEKGTVYFKGGKYMQAVIQYGKIVSWLEMEYGLSEKESKASESFLLAAFLNLAMCYLKLREYTKAVECCDKALGLDSANEKGLYRRGEAQLLMNEFESAKGDFEKVLEVNPQNKAARLQISMCQKKAKEHNERDRRIYANMFKKFAEQDAKEEANKAMGKKTSEGVTNEKGTDSQAMEEEKPEGHV","Homo sapiens","FKBP5, AIG6, FKBP51","Peptidyl-prolyl cis-trans isomerase FKBP5","1","5OMP"
"5OMY",,"X-RAY DIFFRACTION",1.94,36.66,"VAPOR DIFFUSION, SITTING DROP",,"90 MIKROLITER ENZYME STOCK SOLUTION (6
MG/ML IN 500 MM NACL, 25 MM TRIS/HCL, PH 8.5) WAS MIXED WITH 10
MIKROLITER 4P STOCK SOLUTION (10 MM 4P IN DMSO). THIS
MIXTURE WAS INCUBATED FOR 30 MIN AT ROOM TEMPERATURE. THE
RESERVOIR SOLUTION OF THE CRYSTALLIZATION EXPERIMENT WAS 4.2 M
NACL, 0.1 M CITRIC ACID, PH 5.5. PRIOR TO EQUILIBRATION THE
CRYSTALLIZATION DROP WAS COMPOSED OF 1 MIKROLITER RESERVOIR
SOLUTION PLUS 1 MIKROLITER ENZYME/4P MIXTURE., VAPOR DIFFUSION,
SITTING DROP, TEMPERATURE 293.15K",293.15,"10.3390/ph10040098",,"5OMY",45.75,"1.95","1.95","HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMGSSSMPGGSTPVSSANMMSGISSVPTPSPLGPLAGSPVIAAANPLGMPVPAAAGAQQ","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OMY"
"5ONE",,"X-RAY DIFFRACTION",2.54,51.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"18% PEG 3350, 0.2 M Ammonium citrate, 0.1 M bis-tris, pH 7.5",277.15,"10.1016/j.bmcl.2017.08.016","9YQ","5ONE",33.48,"2.6","2.6","Crystal structure of Aurora-A in complex with FMF-03-145-1 (compound 2)","GAMESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNCQNKESASKQS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5ONE"
"5ONI",,"X-RAY DIFFRACTION",3.2,61.62,"VAPOR DIFFUSION, SITTING DROP",,"90 MICROLITER ENZYME STOCK SOLUTION (6 MG/ML IN 500 MM NACL, 25 MM
TRIS/HCL, PH 8.5) WAS MIXED WITH 10 MIKROLITER 4P STOCK
SOLUTION (10 MM 4P IN DMSO). THIS MIXTURE WAS INCUBATED FOR 30
MIN AT ROOM TEMPERATURE. THE RESERVOIR SOLUTION OF THE
CRYSTALLIZATION EXPERIMENT WAS 25 % (W/V) PEG5000, 0.2 M
AMMONIUM SULPHATE, 0.1 M MES BUFFER, PH 6.5. PRIOR TO
EQUILIBRATION THE CRYSTALLIZATION DROP WAS COMPOSED OF 1
MICROLITER RESERVOIR SOLUTION PLUS 1 MICROLITER ENZYME/4P
MIXTURE., VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293,"10.3390/ph10040098",,"5ONI",92.29,"2","2","LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMGSSSMPGGSTPVSSANMMSGISSVPTPSPLGPLAGSPVIAAANPLGMPVPAAAGAQQ","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5ONI"
"5OO0",,"X-RAY DIFFRACTION",1.99,38.3,"VAPOR DIFFUSION, HANGING DROP",,"15% w/v Jeffamine ED-2003, 50 mM HEPES, 50 mM sodium/potassium phosphate",294,"10.1002/anie.201711825",,"5OO0",34.64,"1.6","1.6","Cdk2(WT) covalent adduct with D28 at C177","GPLGSMENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","Cyclin-dependent kinase 2","1","5OO0"
"5OO1",,"X-RAY DIFFRACTION",1.68,26.89,"VAPOR DIFFUSION, HANGING DROP",,"15% w/v Jeffamine ED-2003, 50 mM HEPES, 50 mM sodium/potassium phosphate",298,,,"5OO1",34.54,"2","2","Cdk2(F80C, C177A) covalent adduct with C37 at F80C","GPLGSMENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVCEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGAKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","Cyclin-dependent kinase 2","1","5OO1"
"5OO3",,"X-RAY DIFFRACTION",1.99,38.16,"VAPOR DIFFUSION, HANGING DROP",,"9 - 15% w/v, 50 mM HEPES, 50 mM sodium/potassium phosphate",298,,,"5OO3",34.53,"1.73","1.73","Cdk2(F80C, C177A) with covalent ligand at F80C","GPLGSMENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVCEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGAKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","Cyclin-dependent kinase 2","1","5OO3"
"5OOG",,"X-RAY DIFFRACTION",2.34,47.5,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 3350, 0.2 M AMMONIUM SULFATE, 0.1 M SODIUM CACODYLATE PH 6.5. NADP ADDED TO A FINAL CONCENTRATION OF 2.5 MM",293,"10.1074/jbc.RA118.001803","A0B","5OOG",23.86,"1.33","1.33","Human biliverdin IX beta reductase: NADP/Phloxine B ternary complex","MAVKKIAIFGATGQTGLTTLAQAVQAGYEVTVLVRDSSRLPSEGPRPAHVVVGDVLQAADVDKTVAGQDAVIVLLGTRNDLSPTTVMSEGARNIVAAMKAHGVDKVVACTSAFLLWDPTKVPPRLQAVTDDHIRMHKVLRESGLKYVAVMPPHIGDQPLTGAYTVTLDGRGPSRVISKHDLGHFMLRCLTTDEYDGHSTYPSHQYQ","Homo sapiens","BLVRB, FLR","Flavin reductase (NADPH)","1","5OOG"
"5OOH",,"X-RAY DIFFRACTION",2.4,48.76,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 3350, 0.2 M AMMONIUM SULFATE, 0.1 M SODIUM CACODYLATE PH 6.5. NADP ADDED TO A FINAL CONCENTRATION OF 2.5 MM",293,"10.1074/jbc.RA118.001803","9ZZ","5OOH",23.82,"1.2","1.2","Human biliverdin IX beta reductase: NADP/Erythrosin extra bluish ternary complex","MAVKKIAIFGATGQTGLTTLAQAVQAGYEVTVLVRDSSRLPSEGPRPAHVVVGDVLQAADVDKTVAGQDAVIVLLGTRNDLSPTTVMSEGARNIVAAMKAHGVDKVVACTSAFLLWDPTKVPPRLQAVTDDHIRMHKVLRESGLKYVAVMPPHIGDQPLTGAYTVTLDGRGPSRVISKHDLGHFMLRCLTTDEYDGHSTYPSHQYQ","Homo sapiens","BLVRB, FLR","Flavin reductase (NADPH)","1","5OOH"
"5OOI",,"X-RAY DIFFRACTION",2.4,48.69,"VAPOR DIFFUSION, SITTING DROP",,"90 MIKROLITER ENZYME STOCK SOLUTION (5
MG/ML IN 500 MM NACL, 25 MM TRIS/HCL, PH 8.5) WAS MIXED WITH 10
MIKROLITER 4P STOCK SOLUTION (10 MM 4P IN DMSO). THIS
MIXTURE WAS INCUBATED FOR 30 MIN AT ROOM TEMPERATURE. THE
RESERVOIR SOLUTION OF THE CRYSTALLIZATION EXPERIMENT WAS 25 % (W/
V) PEG3350, 0.2 M AMMONIUM ACETATE, 0.1 M HEPES BUFFER, PH 8.5.
PRIOR TO EQUILIBRATION THE CRYSTALLIZATION DROP WAS COMPOSED OF
1 MIKROLITER RESERVOIR SOLUTION PLUS 1 MIKROLITER ENZYME/4P
MIXTURE., VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K",293,"10.3390/ph10040098",,"5OOI",86.93,"1.998","1.998","STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA') IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P","MGSSHHHHHHSQDPMPGPAAGSRARVYAEVNSLRSREYWDYEAHVPSWGNQDDYQLVRKLGRGKYSEVFEAINITNNERVVVKILKPVKKKKIKREVKILENLRGGTNIIKLIDTVKDPVSKTPALVFEYINNTDFKQLYQILTDFDIRFYMYELLKALDYCHSKGIMHRDVKPHNVMIDHQQKKLRLIDWGLAEFYHPAQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRREPFFHGQDNYDQLVRIAKVLGTEELYGYLKKYHIDLDPHFNDILGQHSRKRWENFIHSENRHLVSPEALDLLDKLLRYDHQQRLTAKEAMEHPYFYPVVKEQSQPSADNAVLSSGLTAAR","Homo sapiens","CSNK2A2, CK2A2","Casein kinase II subunit alpha'","1","5OOI"
"5OOP",,"X-RAY DIFFRACTION",2.33,47.29,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer, pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186",,"5OOP",34.6,"1.7","1.7","Structure of CHK1 10-pt. mutant complex with AMP-PNP","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADYSLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OOP"
"5OOR",,"X-RAY DIFFRACTION",2.29,46.17,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186",,"5OOR",34.6,"1.9","1.9","Structure of CHK1 10-pt. mutant complex with staurosporine","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADYSLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OOR"
"5OOT",,"X-RAY DIFFRACTION",2.36,47.97,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186","4K4","5OOT",34.66,"2.1","2.1","Structure of CHK1 10-pt. mutant complex with aminopyrimido-benzodiazepinone LRRK2 inhibitor","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADYSLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OOT"
"5OP2",,"X-RAY DIFFRACTION",2.38,48.35,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186","A0Q","5OP2",34.57,"1.9","1.9","Structure of CHK1 10-pt. mutant complex with arylbenzamide LRRK2 inhibitor","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADYSLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OP2"
"5OP4",,"X-RAY DIFFRACTION",2.34,47.55,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186","A0T","5OP4",34.54,"2","2","Structure of CHK1 10-pt. mutant complex with aminopyrimidine LRRK2 inhibitor","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADYSLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OP4"
"5OP5",,"X-RAY DIFFRACTION",2.31,46.7,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186","3FE","5OP5",34.43,"1.9","1.9","Structure of CHK1 10-pt. mutant complex with pyrrolopyrimidine LRRK2 inhibitor","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADYSLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OP5"
"5OP6",,"X-RAY DIFFRACTION",3.37,63.49,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH7.5, 1.1M ammonium sulfate, 2.5% PEG 400",300,"10.1039/c7sc02103h","A0W","5OP6",41.3,"2.45","2.45","Factor Inhibiting HIF (FIH) in complex with zinc and GSK128863","SHMAATAAEAVASGSGEPREEAGALGPAWDESQLRSYSFPTRPIPRLSQSDPRAEELIENEEPVVLTDTNLVYPALKWDLEYLQENIGNGDFSVYSASTHKFLYYDEKKMANFQNFKPRSNREEMKFHEFVEKLQDIQQRGGEERLYLQQTLNDTVGRKIVMDFLGFNWNWINKQQGKRGWGQLTSNLLLIGMEGNVTPAHYDEQQNFFAQIKGYKRCILFPPDQFECLYPYPVHHPCDRQSQVDFDNPDYERFPNFQNVVGYETVVGPGDVLYIPMYWWHHIESLLNGGITITVNFWYKGAPTPKRIEYPLKAHQKVAIMRNIEKMLGEALGNPQEVGPLLNTMIKGRYN","Homo sapiens","HIF1AN, FIH1","Hypoxia-inducible factor 1-alpha inhibitor","1","5OP6"
"5OP7",,"X-RAY DIFFRACTION",2.31,46.68,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186",,"5OP7",34.57,"1.8","1.8","Structure of CHK1 10-pt. mutant complex with pyrrolopyrimidine LRRK2 inhibitor","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADYSLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OP7"
"5OP8",,"X-RAY DIFFRACTION",3.4,63.87,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH7.5, 1.4M ammonium sulfate, 4.5% PEG400",300,"10.1039/c7sc02103h","A1H","5OP8",41.27,"2.3","2.3","Factor Inhibiting HIF (FIH) in complex with zinc and Molidustat","SMAATAAEAVASGSGEPREEAGALGPAWDESQLRSYSFPTRPIPRLSQSDPRAEELIENEEPVVLTDTNLVYPALKWDLEYLQENIGNGDFSVYSASTHKFLYYDEKKMANFQNFKPRSNREEMKFHEFVEKLQDIQQRGGEERLYLQQTLNDTVGRKIVMDFLGFNWNWINKQQGKRGWGQLTSNLLLIGMEGNVTPAHYDEQQNFFAQIKGYKRCILFPPDQFECLYPYPVHHPCDRQSQVDFDNPDYERFPNFQNVVGYETVVGPGDVLYIPMYWWHHIESLLNGGITITVNFWYKGAPTPKRIEYPLKAHQKVAIMRNIEKMLGEALGNPQEVGPLLNTMIKGRYN","Homo sapiens","HIF1AN, FIH1","Hypoxia-inducible factor 1-alpha inhibitor","1","5OP8"
"5OPB",,"X-RAY DIFFRACTION",2.35,47.72,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186","A1N","5OPB",34.54,"1.55","1.55","Structure of CHK1 10-pt. mutant complex with indazole LRRK2 inhibitor","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADYSLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OPB"
"5OPC",,"X-RAY DIFFRACTION",3.48,64.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH7.5, 1.7M ammonium sulfate, 5.5% PEG 400",300,"10.1039/c7sc02103h","A1Z","5OPC",41.73,"2.3","2.3","Factor Inhibiting HIF (FIH) in complex with zinc and Vadadustat","SMAATAAEAVASGSGEPREEAGALGPAWDESQLRSYSFPTRPIPRLSQSDPRAEELIENEEPVVLTDTNLVYPALKWDLEYLQENIGNGDFSVYSASTHKFLYYDEKKMANFQNFKPRSNREEMKFHEFVEKLQDIQQRGGEERLYLQQTLNDTVGRKIVMDFLGFNWNWINKQQGKRGWGQLTSNLLLIGMEGNVTPAHYDEQQNFFAQIKGYKRCILFPPDQFECLYPYPVHHPCDRQSQVDFDNPDYERFPNFQNVVGYETVVGPGDVLYIPMYWWHHIESLLNGGITITVNFWYKGAPTPKRIEYPLKAHQKVAIMRNIEKMLGEALGNPQEVGPLLNTMIKGRYN","Homo sapiens","HIF1AN, FIH1","Hypoxia-inducible factor 1-alpha inhibitor","1","5OPC"
"5OPE",,"X-RAY DIFFRACTION",3.11,60.5,"VAPOR DIFFUSION, HANGING DROP",5.6,"0.5 M ammonium phosphate,
100 mM Na Critrate",293,"10.1016/j.str.2017.12.003",,"5OPE",42.98,"2.54","2.54","Robo1 Ig1-4 crystals form 2","QEDFPPRIVEHPSDLIVSKGEPATLNCKAEGRPTPTIEWYKGGERVETDKDDPRSHRMLLPSGSLFFLRIVHGRKSRPDEGVYVCVARNYLGEAVSHNASLEVAILRDDFRQNPSDVMVAVGEPAVMECQPPRGHPEPTISWKKDGSPLDDKDERITIRGGKLMITYTRKSDAGKYVCVGTNMVGERESEVAELTVLERPSFVKRPSNLAVTVDDSAEFKCEARGDPVPTVRWRKDDGELPKSRYEIRDDHTLKIRKVTAGDMGSYTCVAENMVGKAEASATLTVQEPPHFVVKPRDQVVALGRTVTFQCEATGNPQPAIFWRREGSQNLLFSYQPPQSSSRFSVSQTGDLTITNVQRSDVGYYICQTLNVAGSIITKAYLEVTD","Homo sapiens","ROBO1, DUTT1","Roundabout homolog 1","1","5OPE"
"5OPH",,"SOLUTION NMR",,,,,,,"10.1093/nar/gky886",,"5OPH",7.04,,,"G-quadruplex structure of DNA oligonucleotide containing GGGGCC repeats linked to ALS and FTD","GGGGCCGGGGCCGGGGCCGGGG","Homo sapiens",,"DNA (5'-D(*GP*GP*GP*GP*CP*CP*GP*GP*GP*GP*CP*CP*GP*GP*GP*GP*CP*CP*GP*GP*(BGM)P*G)-3')","1","5OPH"
"5OPK",,"X-RAY DIFFRACTION",3.43,64.13,"VAPOR DIFFUSION",,"0.1 M MES/imidazole pH 6.5; 0.03 M of each divalent cation; 10% w/v PEG 8000, 20% v/v ethylene glycol
(Morpheus condition A2)",293,"10.1038/s41375-018-0073-5",,"5OPK",56.76,"1.74","1.74","Crystal structure of D52N/R367Q cN-II mutant bound to dATP and free phosphate","TSWSDRLQNAADMPANMDKHALKKYRREAYHRVFVNRSLAMEKIKCFGFNMDYTLAVYKSPEYESLGFELTVERLVSIGYPQELLSFAYDSTFPTRGLVFDTLYGNLLKVDAYGNLLVCAHGFNFIRGPETREQYPNKFIQRDDTERFYILNTLFNLPETYLLACLVDFFTNCPRYTSCETGFKDGDLFMSYRSMFQDVRDAVDWVHYKGSLKEKTVENLEKYVVKDGKLPLLLSRMKEVGKVFLATNSDYKYTDKIMTYLFDFPHGPKPGSSHRPWQSYFDLILVDARKPLFFGEGTVLRQVDTKTGKLKIGTYTGPLQHGIVYSGGSSDTICDLLGAKGKDILYIGDHIFGDILKSKKRQGWQTFLVIPELAQELHVWTDKSSLFEELQSLDIFLAELYKHLDSSSIQRRIKKVTHDMDMCYGMMGSLFRSGSRQTLFASQVMRYADLYAASFINLLYYPFSYLFRAAHVLMPHES","Homo sapiens","NT5C2, NT5B, NT5CP, PNT5","Cytosolic purine 5'-nucleotidase","1","5OPK"
"5OPL",,"X-RAY DIFFRACTION",2.98,58.78,"VAPOR DIFFUSION",,"0.1 M MOPS/HEPES-Na pH 7.5; 0.02 M of each carboxylic acid ;  10% w/v PEG 8000, 20% v/v ethylene glycol 

G6 Morpheus condition",293,"10.1038/s41375-018-0073-5",,"5OPL",64.94,"1.8","1.8","Crystal structure of K25E cN-II mutant","MGSSHHHHHHSSGLVPRGSMSTSWSDRLQNAADMPANMDKHALEKYRREAYHRVFVNRSLAMEKIKCFGFDMDYTLAVYKSPEYESLGFELTVERLVSIGYPQELLSFAYDSTFPTRGLVFDTLYGNLLKVDAYGNLLVCAHGFNFIRGPETREQYPNKFIQRDDTERFYILNTLFNLPETYLLACLVDFFTNCPRYTSCETGFKDGDLFMSYRSMFQDVRDAVDWVHYKGSLKEKTVENLEKYVVKDGKLPLLLSRMKEVGKVFLATNSDYKYTDKIMTYLFDFPHGPKPGSSHRPWQSYFDLILVDARKPLFFGEGTVLRQVDTKTGKLKIGTYTGPLQHGIVYSGGSSDTICDLLGAKGKDILYIGDHIFGDILKSKKRQGWRTFLVIPELAQELHVWTDKSSLFEELQSLDIFLAELYKHLDSSSNERPDISSIQRRIKKVTHDMDMCYGMMGSLFRSGSRQTLFASQVMRYADLYAASFINLLYYPFSYLFRAAHVLMPHESTVEHTHVDINEMESPLATRNRTSVDFKDTDYKRHQLTRSISEIKPPNL","Homo sapiens","NT5C2, NT5B, NT5CP, PNT5","Cytosolic purine 5'-nucleotidase","1","5OPL"
"5OPM",,"X-RAY DIFFRACTION",3.47,64.56,"VAPOR DIFFUSION",,"0.1 M bicine/Trizma base pH 8.5; 0.02 M of each amino acid; 10% w/v PEG 4000, 20% v/v glycerol 
H11 Morpheus condition",293,"10.1038/s41375-018-0073-5",,"5OPM",56.36,"1.68","1.68","Crystal structure of D52N/R238W cN-II mutant bound to dATP and free phosphate","TSWSDRLQNAADMPANMDKHALKKYRREAYHRVFVNRSLAMEKIKCFGFNMDYTLAVYKSPEYESLGFELTVERLVSIGYPQELLSFAYDSTFPTRGLVFDTLYGNLLKVDAYGNLLVCAHGFNFIRGPETREQYPNKFIQRDDTERFYILNTLFNLPETYLLACLVDFFTNCPRYTSCETGFKDGDLFMSYRSMFQDVRDAVDWVHYKGSLKEKTVENLEKYVVKDGKLPLLLSWMKEVGKVFLATNSDYKYTDKIMTYLFDFPHGPKPGSSHRPWQSYFDLILVDARKPLFFGEGTVLRQVDTKTGKLKIGTYTGPLQHGIVYSGGSSDTICDLLGAKGKDILYIGDHIFGDILKSKKRQGWRTFLVIPELAQELHVWTDKSSLFEELQSLDIFLAELYKHLDSSSIQRRIKKVTHDMDMCYGMMGSLFRSGSRQTLFASQVMRYADLYAASFINLLYYPFSYLFRAAHVLMPHES","Homo sapiens","NT5C2, NT5B, NT5CP, PNT5","Cytosolic purine 5'-nucleotidase","1","5OPM"
"5OPN",,"X-RAY DIFFRACTION",3.42,64.06,"VAPOR DIFFUSION",,"0.1 M MES/imidazole pH 6.5; 0.02 M of each carboxylic acid;  10% w/v PEG 20 000, 20% v/v PEG MME 550 
G1 Morpheus condition",293,"10.1038/s41375-018-0073-5",,"5OPN",55.85,"1.77","1.77","Crystal structure of R39Q cN-II mutant","TSWSDRLQNAADMPANMDKHALKKYRREAYHRVFVNQSLAMEKIKCFGFDMDYTLAVYKSPEYESLGFELTVERLVSIGYPQELLSFAYDSTFPTRGLVFDTLYGNLLKVDAYGNLLVCAHGFNFIRGPETREQYPNKFIQRDDTERFYILNTLFNLPETYLLACLVDFFTNCPRYTSCETGFKDGDLFMSYRSMFQDVRDAVDWVHYKGSLKEKTVENLEKYVVKDGKLPLLLSRMKEVGKVFLATNSDYKYTDKIMTYLFDFPHGPKPGSSHRPWQSYFDLILVDARKPLFFGEGTVLRQVDTKTGKLKIGTYTGPLQHGIVYSGGSSDTICDLLGAKGKDILYIGDHIFGDILKSKKRQGWRTFLVIPELAQELHVWTDKSSLFEELQSLDIFLAELYKHLDSSSIQRRIKKVTHDMDMCYGMMGSLFRSGSRQTLFASQVMRYADLYAASFINLLYYPFSYLFRAAHVLMPHES","Homo sapiens","NT5C2, NT5B, NT5CP, PNT5","Cytosolic purine 5'-nucleotidase","1","5OPN"
"5OPO",,"X-RAY DIFFRACTION",3.38,63.61,"VAPOR DIFFUSION",,"0.1 M MOPS/HEPES-Na pH 7.5; 0.03 M of each divalent cation ; 10% w/v PEG 4000, 20% v/v glycerol 
A7 Morpheus condition",293,"10.1038/s41375-018-0073-5",,"5OPO",56.79,"2","2","Crystal structure of R238G cN-II mutant","TSWSDRLQNAADMPANMDKHALKKYRREAYHRVFVNRSLAMEKIKCFGFDMDYTLAVYKSPEYESLGFELTVERLVSIGYPQELLSFAYDSTFPTRGLVFDTLYGNLLKVDAYGNLLVCAHGFNFIRGPETREQYPNKFIQRDDTERFYILNTLFNLPETYLLACLVDFFTNCPRYTSCETGFKDGDLFMSYRSMFQDVRDAVDWVHYKGSLKEKTVENLEKYVVKDGKLPLLLSGMKEVGKVFLATNSDYKYTDKIMTYLFDFPHGPKPGSSHRPWQSYFDLILVDARKPLFFGEGTVLRQVDTKTGKLKIGTYTGPLQHGIVYSGGSSDTICDLLGAKGKDILYIGDHIFGDILKSKKRQGWRTFLVIPELAQELHVWTDKSSLFEELQSLDIFLAELYKHLDSSSNERPDISSIQRRIKKVTHDMDMCYGMMGSLFRSGSRQTLFASQVMRYADLYAASFINLLYYPFSYLFRAAHVLMPHES","Homo sapiens","NT5C2, NT5B, NT5CP, PNT5","Cytosolic purine 5'-nucleotidase","1","5OPO"
"5OPP",,"X-RAY DIFFRACTION",3.38,63.58,"VAPOR DIFFUSION",,"0.1 M bicine/Trizma base pH 8.5; 0.03 M of each halide; 10% w/v PEG 8000, 20% v/v ethylene glycol
B10 Morpheus condition",293,"10.1038/s41375-018-0073-5",,"5OPP",56.6,"1.7","1.7","Crystal structure of S408R cN-II mutant","TSWSDRLQNAADMPANMDKHALKKYRREAYHRVFVNRSLAMEKIKCFGFDMDYTLAVYKSPEYESLGFELTVERLVSIGYPQELLSFAYDSTFPTRGLVFDTLYGNLLKVDAYGNLLVCAHGFNFIRGPETREQYPNKFIQRDDTERFYILNTLFNLPETYLLACLVDFFTNCPRYTSCETGFKDGDLFMSYRSMFQDVRDAVDWVHYKGSLKEKTVENLEKYVVKDGKLPLLLSRMKEVGKVFLATNSDYKYTDKIMTYLFDFPHGPKPGSSHRPWQSYFDLILVDARKPLFFGEGTVLRQVDTKTGKLKIGTYTGPLQHGIVYSGGSSDTICDLLGAKGKDILYIGDHIFGDILKSKKRQGWRTFLVIPELAQELHVWTDKSSLFEELQSLDIFLAELYKHLDSSSNERPDISSIQRRIKKVTHDMDMCYGMMGSLFRSGSRQTLFASQVMRYADLYAASFINLLYYPFSYLFRAAHVLMPHES","Homo sapiens","NT5C2, NT5B, NT5CP, PNT5","Cytosolic purine 5'-nucleotidase","1","5OPP"
"5OPR",,"X-RAY DIFFRACTION",2.31,46.65,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186","A3E","5OPR",34.47,"1.95","1.95","Structure of CHK1 10-pt. mutant complex with aminopyridine LRRK2 inhibitor","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADYSLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OPR"
"5OPS",,"X-RAY DIFFRACTION",2.31,46.73,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186","A3Q","5OPS",34.33,"2","2","Structure of CHK1 10-pt. mutant complex with pyrrolopyridine LRRK2 inhibitor","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADYSLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OPS"
"5OPU",,"X-RAY DIFFRACTION",2.31,46.73,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186","A3K","5OPU",34.38,"1.55","1.55","Structure of CHK1 10-pt. mutant complex with pyrrolopyridine LRRK2 inhibitor","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADYSLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OPU"
"5OPV",,"X-RAY DIFFRACTION",2.54,51.66,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186","A3H","5OPV",34.42,"1.9","1.9","Structure of CHK1 10-pt. mutant complex with pyrrolopyridine LRRK2 inhibitor","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADYSLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OPV"
"5OQ0",,"X-RAY DIFFRACTION",2.14,42.54,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium phosphate (pH 7.5), 2.2 M ammonium sulphate",293,"10.1371/journal.pone.0187716",,"5OQ0",13.82,"1.94","1.94","Crystal structure of transthyretin mutant 87-110-117","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPMHEHAEVVFTANDSGPRRYTIAAMLSPYSYETTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5OQ0"
"5OQ4",,"X-RAY DIFFRACTION",2.2,44,"VAPOR DIFFUSION",7.5,"16% PEG 4000, 250mM (NH4)2SO4 and 100mM Tris pH7.5",290.15,"10.1021/acs.jmedchem.7b00930","A3W","5OQ4",111.36,"2.7","2.7","PQR309 - a Potent, Brain-Penetrant, Orally Bioavailable, pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology","MSEESQAFQRQLTALIGYDVTDVSNVHDDELEFTRRGLVTPRMAEVASRDPKLYAMHPWVTSKPLPEYLWKKIANNCIFIVIHRSTTSQTIKVSPDDTPGAILQSFFTKMAKKKSLMDIPESQSEQDFVLRVCGRDEYLVGETPIKNFQWVRHCLKNGEEIHVVLDTPPDPALDEVRKEEWPLVDDCTGVTGYHEQLTIHGKDHESVFTVSLWDCDRKFRVKIRGIDIPVLPRNTDLTVFVEANIQHGQQVLCQRRTSPKPFTEEVLWNVWLEFSIKIKDLPKGALLNLQIYCGKAPALSSKASAESPSSESKGKVRLLYYVNLLLIDHRFLLRRGEYVLHMWQISGKGEDQGSFNADKLTSATNPDKENSMSISILLDNYCHPIALPKHQPTPDPEGDRVRAEMPNQLRKQLEAIIATDPLNPLTAEDKELLWHFRYESLKHPKAYPKLFSSVKWGQQEIVAKTYQLLARREVWDQSALDVGLTMQLLDCNFSDENVRAIAVQKLESLEDDDVLHYLLQLVQAVKFEPYHDSALARFLLKRGLRNKRIGHFLFWFLRSEIAQSRHYQQRFAVILEAYLRGCGTAMLHDFTQQVQVIEMLQKVTLDIKSLSAEKYDVSSQVISQLKQKLENLQNSQLPESFRVPYDPGLKAGALAIEKCKVMASKKKPLWLEFKCADPTALSNETIGIIFKHGDDLRQDMLILQILRIMESIWETESLDLCLLPYGCISTGDKIGMIEIVKDATTIAKIQQSTVGNTGAFKDEVLNHWLKEKSPTEEKFQAAVERFVYSCAGYCVATFVLGIGDRHNDNIMITETGNLFHIDFGHILGNYKSFLGINKERVPFVLTPDFLFVMGTSGKKTSPHFQKFQDICVKAYLALRHHTNLLIILFSMMLMTGMPQLTSKEDIEYIRDALTVGKNEEDAKKYFLDQIEVCRDKGWTVQFNWFLHLVLGIKQGEKHSAHHHHHH","Homo sapiens","PIK3CG","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform","1","5OQ4"
"5OQ5",,"X-RAY DIFFRACTION",2.39,48.64,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186","4K4","5OQ5",34.81,"1.4","1.4","Structure of CHK1 8-pt. mutant complex with aminopyrimido-benzodiazepinone LRRK2 inhibitor","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADFGLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OQ5"
"5OQ6",,"X-RAY DIFFRACTION",2.35,47.65,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186","4K4","5OQ6",34.7,"1.95","1.95","Structure of CHK1 12-pt. mutant complex with aminopyrimido-benzodiazepinone LRRK2 inhibitor","MAVPFVEDWDLVQTLGEGSFGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADYSLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OQ6"
"5OQ7",,"X-RAY DIFFRACTION",2.36,47.92,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186","A0Q","5OQ7",68.9,"2.1","2.1","Structure of CHK1 8-pt. mutant complex with arylbenzamide LRRK2 inhibitor","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADFGLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OQ7"
"5OQ8",,"X-RAY DIFFRACTION",2.35,47.74,"VAPOR DIFFUSION, SITTING DROP",6.5,"7% PEG 8000, 0.1 M MES buffer pH 6.5, 20% ethylene glycol",293,"10.1021/acs.jmedchem.7b01186","A0Q","5OQ8",34.5,"2","2","Structure of CHK1 12-pt. mutant complex with arylbenzamide LRRK2 inhibitor","MAVPFVEDWDLVQTLGEGSFGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICILKMLNHENVIKFYGHRREGNIQYLFMELASGGSLFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPHNLLLDERDNLKIADYSLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5OQ8"
"5OQK",,"SOLUTION NMR",,,,,,,"10.1021/acs.biochem.9b00471",,"5OQK",17.35,,,"Solution NMR structure of truncated, human Hv1/VSOP (Voltage-gated proton channel)","SHMRAPLDFRGMLRKLFSSHRFQVIIICLVVLDALLVLAELILDLKIIQPDKNNYAAMVFHYMSITILVFFMMEIIFKLFVFRLEFFHHKFEILDAVVVVVSFILDIVLLFQEHQFEALGLLILLRLWRVARIINGIIISVKTRSER","Homo sapiens","HVCN1, VSOP, UNQ578/PRO1140","Voltage-gated hydrogen channel 1","1","5OQK"
"5OQU",,"X-RAY DIFFRACTION",2.35,47.63,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k","A4B","5OQU",85.08,"2.324","2.324","The crystal structure of CK2alpha in complex with compound 5","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OQU"
"5OQV","4","ELECTRON MICROSCOPY",,,,,,,"10.1126/science.aao2825",,"5OQV",40.68,"4",,"Near-atomic resolution fibril structure of complete amyloid-beta(1-42) by cryo-EM","DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA","Homo sapiens","APP, A4, AD1","Amyloid beta A4 protein","1","5OQV"
"5OQW",,"X-RAY DIFFRACTION",4.52,72.79,"VAPOR DIFFUSION, SITTING DROP",8,"0.1M HEPES/NaOHpH=8, 2.9M NaCl",293,"10.1158/1535-7163.MCT-17-0848","A4E","5OQW",30.39,"2.31","2.31","XIAP in complex with small molecule","MGSSHHHHHHSSGLVPRGSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5OQW"
"5OR0",,"SOLUTION NMR",,,,,,,"10.1038/s41467-017-01559-4",,"5OR0",6.98,,,"NMR derived model of the 5'-splice site of SMN2 in complex with the 5'-end of U1 snRNA","AUACUUACCUG","Homo sapiens",,"RNA (5'-R(P*AP*UP*AP*CP*(PSU)P*(PSU)P*AP*CP*CP*UP*G)-3')","1","5OR0"
,,,,,,,,,,,,,,,,"GGAGUAAGUCU","Homo sapiens",,"RNA (5'-R(P*GP*GP*AP*GP*UP*AP*AP*GP*UP*CP*U)-3')","2","5OR0"
"5OR8",,"X-RAY DIFFRACTION",3.51,64.93,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 0.2 M MgCl2",277,"10.1021/acs.jcim.7b00336",,"5OR8",12.87,"2.4","2.4","Crystal Structure of BAZ2A bromodomain in complex with 1,3-dimethyl-benzimidazolone compound 1","SMHSDLTFCEIILMEMESHDAAWPFLEPVNPRLVSGYRRIIKNPMDFSTMRERLLRGGYTSSEEFAADALLVFDNCQTFNEDDSEVGKAGHIMRRFFESRWEEFYQ","Homo sapiens","BAZ2A, KIAA0314, TIP5","Bromodomain adjacent to zinc finger domain protein 2A","1","5OR8"
"5OR9",,"X-RAY DIFFRACTION",4.19,70.62,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG500MME, 2% PEG1000, 2% PEG3350, 10% PEG20000, 2% MPD",277,"10.1021/acs.jcim.7b00336","JR5","5OR9",14.07,"2","2","Crystal Structure of BAZ2B bromodomain in complex with 1-methyl-cyclopentapyrazole compound 13","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5OR9"
"5ORB",,"X-RAY DIFFRACTION",4.18,70.59,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG500MME, 2% PEG1000, 2% PEG3350, 10% PEG20000, 2% MPD",277,"10.1021/acs.jcim.7b00336",,"5ORB",14,"2.103","2.103","Crystal Structure of BAZ2B bromodomain in complex with 1-methyl-cyclopentapyrazole compound 30","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5ORB"
"5ORH",,"X-RAY DIFFRACTION",2.2,44.17,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k","A4N","5ORH",84.04,"1.75","1.75","The crystal structure of CK2alpha in complex with compound 2","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5ORH"
"5ORJ",,"X-RAY DIFFRACTION",2.24,44.97,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k","A4Q","5ORJ",85.31,"1.99","1.99","The crystal structure of CK2alpha in complex with compound 3","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5ORJ"
"5ORK",,"X-RAY DIFFRACTION",2.24,44.98,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k","A4T","5ORK",84.2,"2.143","2.143","The crystal structure of CK2alpha in complex with compound 6","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5ORK"
"5ORL",,"X-RAY DIFFRACTION",2.74,55.03,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5; 0.5 M NaCl; 0.2 M MgCl2; 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537",,"5ORL",31.61,"1.69","1.69","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5ORL"
"5ORN",,"X-RAY DIFFRACTION",2.8,56.05,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537",,"5ORN",31.45,"2.19","2.19","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5ORN"
"5ORO",,"X-RAY DIFFRACTION",2.8,55.99,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537",,"5ORO",31.51,"2.12","2.12","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5ORO"
"5ORP",,"X-RAY DIFFRACTION",2.76,55.43,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537",,"5ORP",31.55,"2.19","2.19","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5ORP"
"5ORR",,"X-RAY DIFFRACTION",2.79,55.92,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris, pH 8.5; 0.5 M NaCl; 0.2 M MgCl2; 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537","A5Q","5ORR",31.59,"2.09","2.09","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5ORR"
"5ORS",,"X-RAY DIFFRACTION",2.79,55.9,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537",,"5ORS",31.55,"1.98","1.98","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5ORS"
"5ORT",,"X-RAY DIFFRACTION",2.81,56.16,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537",,"5ORT",31.6,"2.56","2.56","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5ORT"
"5ORV",,"X-RAY DIFFRACTION",2.74,55.06,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537","A65","5ORV",31.55,"1.88","1.88","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5ORV"
"5ORW",,"X-RAY DIFFRACTION",2.8,56.04,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537","A6E","5ORW",31.54,"2","2","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5ORW"
"5ORX",,"X-RAY DIFFRACTION",2.78,55.78,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537","A6H","5ORX",31.53,"1.88","1.88","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5ORX"
"5ORY",,"X-RAY DIFFRACTION",2.79,55.86,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537","AY4","5ORY",31.58,"1.99","1.99","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5ORY"
"5ORZ",,"X-RAY DIFFRACTION",2.76,55.48,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537","A6W","5ORZ",31.62,"1.92","1.92","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5ORZ"
"5OS0",,"X-RAY DIFFRACTION",2.79,55.84,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537","A6Z","5OS0",31.51,"1.74","1.74","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5OS0"
"5OS1",,"X-RAY DIFFRACTION",2.77,55.63,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537","A7H","5OS1",31.57,"1.9","1.9","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5OS1"
"5OS2",,"X-RAY DIFFRACTION",2.78,55.78,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537","A7K","5OS2",31.42,"1.92","1.92","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5OS2"
"5OS3",,"X-RAY DIFFRACTION",2.77,55.61,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537",,"5OS3",31.44,"1.81","1.81","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5OS3"
"5OS4",,"X-RAY DIFFRACTION",2.71,54.61,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537",,"5OS4",31.6,"1.88","1.88","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5OS4"
"5OS5",,"X-RAY DIFFRACTION",2.76,55.46,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537","A8K","5OS5",32,"1.74","1.74","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","KRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSN","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5OS5"
"5OS6",,"X-RAY DIFFRACTION",2.73,54.9,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537",,"5OS6",31.48,"2.2","2.2","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5OS6"
"5OS7",,"X-RAY DIFFRACTION",2.24,45.05,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OS7",84.97,"1.66","1.66","The crystal structure of CK2alpha in complex with compound 4","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OS7"
"5OS8",,"X-RAY DIFFRACTION",1.95,36.96,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OS8",40.49,"1.55","1.55","The crystal structure of CK2alpha in complex with compound 11","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OS8"
"5OSD",,"X-RAY DIFFRACTION",2.73,55.01,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537",,"5OSD",31.9,"1.99","1.99","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","KRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5OSD"
"5OSE",,"X-RAY DIFFRACTION",2.76,55.43,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537","A98","5OSE",31.49,"1.9","1.9","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5OSE"
"5OSF",,"X-RAY DIFFRACTION",2.77,55.66,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris, pH 8.5: 0.5 M NaCl: 0.2 M MgCl2: 32.5 % v/v PEG 3350",298,"10.1021/acschembio.7b00537",,"5OSF",31.52,"1.89","1.89","Crystal structure of Aurora-A kinase in complex with an allosterically binding fragment","QWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5OSF"
"5OSJ",,"X-RAY DIFFRACTION",2.01,38.92,"VAPOR DIFFUSION, HANGING DROP",,"15% w/v Jeffamine ED-2003, 50 mM HEPES, 50 mM sodium/potassium phosphate",298,"10.1002/anie.201711825",,"5OSJ",34.68,"1.83","1.83","Cdk2(WT) with covalent adduct at C177","GPLGSMENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","Cyclin-dependent kinase 2","1","5OSJ"
"5OSL",,"X-RAY DIFFRACTION",1.94,36.54,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OSL",41.94,"1.95","1.95","The crystal structure of CK2alpha in complex with compound 7","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OSL"
"5OSM",,"X-RAY DIFFRACTION",1.98,37.82,"VAPOR DIFFUSION, HANGING DROP",,"15% w/v Jeffamine ED-2003, 50 mM HEPES, 50 mM sodium/potassium phosphate",298,"10.1002/anie.201711825",,"5OSM",34.56,"1.77","1.77","Cdk2(F80C, C177A) with covalent adduct at C80","GPLGSMENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVCEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGAKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","Cyclin-dependent kinase 2","1","5OSM"
"5OSP",,"X-RAY DIFFRACTION",1.92,35.95,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OSP",41.78,"1.91","1.91","The crystal structure of CK2alpha in complex with an analogue of compound 1","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OSP"
"5OSR",,"X-RAY DIFFRACTION",1.93,36.31,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OSR",41.67,"1.57","1.57","The crystal structure of CK2alpha in complex with an analogue of compound 1","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OSR"
"5OSU",,"X-RAY DIFFRACTION",1.92,36.02,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OSU",41.16,"1.63","1.63","The crystal structure of CK2alpha in complex with analogues of compound 1","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OSU"
"5OSY",,"X-RAY DIFFRACTION",2.21,44.41,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Tris-HCl pH 7.6, 31% w/v PEG 4000",291,"10.1021/jacs.8b02597","AJQ","5OSY",71.95,"2.06","2.06","Human Decapping Scavenger enzyme (hDcpS) in complex with m7G(5'S)ppSp(5'S)G mRNA 5' cap analog","SAPVRLPFSGFRLQKVLRESARDKIIFLHGKVNEASGDGDGEDAVVILEKTPFQVEQVAQLLTGSPELQLQFSNDIYSTYHLFPPRQLNDVKTTVVYPATEKHLQKYLRQDLRLIRETGDDYRNITLPHLESQSLSIQWVYNILDKKAEADRIVFENPDPSDGFVLIPDLKWNQQQLDDLYLIAICHRRGIRSLRDLTPEHLPLLRNILHQGQEAILQRYRMKGDHLRVYLHYLPSYYHLHVHFTALGFEAPGSGVERAHLLAEVIENLECDPRHYQQRTLTFALRADDPLLKLLQEAQQS","Homo sapiens","DCPS, DCS1, HINT5, HSPC015","m7GpppX diphosphatase","1","5OSY"
"5OSZ",,"X-RAY DIFFRACTION",1.98,37.85,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OSZ",42.08,"2","2","The crystal structure of CK2alpha in complex with compound 23","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OSZ"
"5OT5",,"X-RAY DIFFRACTION",2.22,44.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OT5",84.39,"1.63","1.63","The crystal structure of CK2alpha in complex with compound 24","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OT5"
"5OT6",,"X-RAY DIFFRACTION",2.23,44.87,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OT6",83.75,"1.94","1.94","The crystal structure of CK2alpha in complex with compound 19","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OT6"
"5OTD",,"X-RAY DIFFRACTION",2.31,46.76,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OTD",84.34,"1.57","1.57","The crystal structure of CK2alpha in complex with compound 25","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OTD"
"5OTE",,"X-RAY DIFFRACTION",2.37,47.99,"VAPOR DIFFUSION, SITTING DROP",5.6,"12-18% PEG 3350, 100mM ammonium sulphate, 100mM sodium potassium tartrate, 100mM bis-tris pH 5.6",277,"10.1158/0008-5472.CAN-17-2870",,"5OTE",48.47,"1.68","1.68","MRCK beta in complex with BDP-00008900","GGSSAKVRLKKLEQLLLDGPWRNESALSVETLLDVLVCLYTECSHSALRRDKYVAEFLEWAKPFTQLVKEMQLHREDFEIIKVIGRGAFGEVAVVKMKNTERIYAMKILNKWEMLKRAETACFREERDVLVNGDCQWITALHYAFQDENHLYLVMDYYVGGDLLTLLSKFEDKLPEDMARFYIGEMVLAIDSIHQLHYVHRDIKPDNVLLDVNGHIRLADFGSCLKMNDDGTVQSSVAVGTPDYISPEILQAMEDGMGKYGPECDWWSLGVCMYEMLYGETPFYAESLVETYGKIMNHEERFQFPSHVTDVSEEAKDLIQRLICSRERRLGQNGIEDFKKHAFFEGLNWENIRNLEAPYIPDVSSPSDTSNFDVDDDVLRNTEILPPGSHTGFSGLHLPFIGFTFTTESCFSDRGSLKS","Homo sapiens","CDC42BPB, KIAA1124","Serine/threonine-protein kinase MRCK beta","1","5OTE"
"5OTF",,"X-RAY DIFFRACTION",2.36,47.85,"VAPOR DIFFUSION",5.6,"12-18% PEG 3350, 100mM ammonium sulphate, 100mM sodium potassium tartrate, 100mM bis-tris pH 5.6",277,"10.1158/0008-5472.CAN-17-2870",,"5OTF",48.53,"2","2","MRCK beta in complex with BDP-00009066","GGSSAKVRLKKLEQLLLDGPWRNESALSVETLLDVLVCLYTECSHSALRRDKYVAEFLEWAKPFTQLVKEMQLHREDFEIIKVIGRGAFGEVAVVKMKNTERIYAMKILNKWEMLKRAETACFREERDVLVNGDCQWITALHYAFQDENHLYLVMDYYVGGDLLTLLSKFEDKLPEDMARFYIGEMVLAIDSIHQLHYVHRDIKPDNVLLDVNGHIRLADFGSCLKMNDDGTVQSSVAVGTPDYISPEILQAMEDGMGKYGPECDWWSLGVCMYEMLYGETPFYAESLVETYGKIMNHEERFQFPSHVTDVSEEAKDLIQRLICSRERRLGQNGIEDFKKHAFFEGLNWENIRNLEAPYIPDVSSPSDTSNFDVDDDVLRNTEILPPGSHTGFSGLHLPFIGFTFTTESCFSDRGSLKS","Homo sapiens","CDC42BPB, KIAA1124","Serine/threonine-protein kinase MRCK beta","1","5OTF"
"5OTH",,"X-RAY DIFFRACTION",2.2,44.03,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OTH",84.28,"1.69","1.69","The crystal structure of CK2alpha in complex with compound 26","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OTH"
"5OTI",,"X-RAY DIFFRACTION",1.91,35.68,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OTI",41.37,"1.59","1.59","The crystal structure of CK2alpha in complex with compound 27","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OTI"
"5OTL",,"X-RAY DIFFRACTION",2.2,44.1,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OTL",84.48,"1.57","1.57","The crystal structure of CK2alpha in complex with compound 29","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OTL"
"5OTM",,"X-RAY DIFFRACTION",2.17,43.26,"VAPOR DIFFUSION",3.7,"26% w/v PEG6000, 0.1 M Sodium acetate trihydrate pH 3.7, 0.2 M LiSO4, 3 mM O6-methyl-2'-dGTP, 2 mM TCEP",293,"10.1093/nar/gky896",,"5OTM",38.06,"1.8","1.8","Crystal structure of human MTH1 in complex with O6-methyl-dGMP","GSHMGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-dihydro-8-oxoguanine triphosphatase","1","5OTM"
"5OTO",,"X-RAY DIFFRACTION",2.31,46.85,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OTO",84.39,"1.51","1.51","The crystal structure of CK2alpha in complex with compound 30","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OTO"
"5OTP",,"X-RAY DIFFRACTION",2.25,45.25,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OTP",83.83,"1.57","1.57","The crystal structure of CK2alpha in complex with an analogue of compound 22","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OTP"
"5OTQ",,"X-RAY DIFFRACTION",1.95,36.93,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OTQ",41.68,"1.38","1.38","The crystal structure of CK2alpha in complex with compound 33","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OTQ"
"5OTR",,"X-RAY DIFFRACTION",1.94,36.71,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OTR",42.17,"1.52","1.52","The crystal structure of CK2alpha in complex with compound 14","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OTR"
"5OTS",,"X-RAY DIFFRACTION",1.99,38.33,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OTS",41.98,"1.9","1.9","The crystal structure of CK2alpha in complex with an analogue of compound 22","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OTS"
"5OTY",,"X-RAY DIFFRACTION",1.94,36.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OTY",41.5,"1.48","1.48","The crystal structure of CK2alpha in complex with CAM4712","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OTY"
"5OTZ",,"X-RAY DIFFRACTION",1.95,36.78,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k","AUT","5OTZ",41.58,"1.46","1.46","The crystal structure of CK2alpha in complex with compound 1","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OTZ"
"5OU0",,"X-RAY DIFFRACTION",2.18,43.57,"VAPOR DIFFUSION, HANGING DROP",5.5,"20% PEG 6000, 50 mM MES, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 297K",297,"10.1016/j.ejmech.2018.04.015","AV5","5OU0",37.02,"0.94","0.94","Crystal structure of human AKR1B1 complexed with NADP+ and compound 37","MASRILLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEVGVAIQEKLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIHWPTGFKPGKEFFPLDESGNVVPSDTNILDTWAAMEELVDEGLVKAIGISNFNHLQVEMILNKPGLKYKPAVNQIECHPYLTQEKLIQYCQSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIAAKHNKTTAQVLIRFPMQRNLVVIPKSVTPERIAENFKVFDFELSSQDMTTLLSYNRNWRVCALLSCTSHKDYPFHEEF","Homo sapiens","AKR1B1, ALDR1, ALR2","Aldose reductase","1","5OU0"
"5OU7",,"X-RAY DIFFRACTION",2.5,50.87,"VAPOR DIFFUSION, SITTING DROP",4,"0.1 M phosphate-citrate buffer pH 4.0
40% (v/v) PEG-300",293,,,"5OU7",80.98,"1.9","1.9","Crystal structure of the Glycoprotein VI loop truncation mutant PAVS-PAPYKN","GSQSGPLPKPSLQALPSSLVPLEKPVTLRCQGPPGVDLYRLEKLSSSRYQDQAVLFIPAMKRSLAGRYRCSYQNGSLWSLPSDQLELVATGVFAKPSLSAQPGSGGDVTLQCQTRYGFDQFALYKEGDPERWYRASFPIITVTAAHSGTYRCYSFSSRDPYLWSAPSDPLELVVTGTSAAA","Homo sapiens","GP6","Platelet glycoprotein VI","1","5OU7"
"5OUE",,"X-RAY DIFFRACTION",2.21,44.36,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OUE",83.83,"2.01","2.01","The crystal structure of CK2alpha in complex with compound 20","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OUE"
"5OUG",,"X-RAY DIFFRACTION",2.81,56.2,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.5, 8% ethylene glycol and 10% PEG8000.",293.15,"10.1074/jbc.M117.815316",,"5OUG",127.2,"2.57","2.57","Humanized alpha-AChBP (acetylcholine binding protein) in complex with lobeline and allosteric binder fragment 4.","GEFQRKLYKELVKNYNPDVIPTQRDRPVTVYFSLSLLQIMDVDEKNQVVDVVIWLQMSWTDHYLQWNVSEYPGVKQVSVPISSLWKPDILLYNAIERPEVLTPQLALVNSSGHVQYLPSIRQRFSCDVSGVDTESGATCKLKFGSWTHHSRELDLQMQEADISGYIPYSRFELVGVTQKRSERFYECCKEPYPDVTFTVTFRKKG","Homo sapiens","CHRNA7, NACHRA7","Humanized alpha-AChBP","1","5OUG"
"5OUH",,"X-RAY DIFFRACTION",3.07,59.87,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES pH 7.5, 8% ethylene glycol and 10% PEG8000.",293,"10.1074/jbc.M117.815316",,"5OUH",123.69,"2.5","2.5","Humanized alpha-AChBP (acetylcholine binding protein) in complex with lobeline.","GEFQRKLYKELVKNYNPDVIPTQRDRPVTVYFSLSLLQIMDVDEKNQVVDVVIWLQMSWTDHYLQWNVSEYPGVKQVSVPISSLWKPDILLYNAIERPEVLTPQLALVNSSGHVQYLPSIRQRFSCDVSGVDTESGATCKLKFGSWTHHSRELDLQMQEADISGYIPYSRFELVGVTQKRSERFYECCKEPYPDVTFTVTFRKKG","Homo sapiens",,"Acetylcholine binding protein","1","5OUH"
"5OUJ",,"X-RAY DIFFRACTION",2.2,44.18,"VAPOR DIFFUSION, HANGING DROP",5.5,"20% PEG 6000, 50 mM MES, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 297K",297,"10.1016/j.ejmech.2018.04.015","AW8","5OUJ",37.04,"0.96","0.96","Crystal structure of human AKR1B1 complexed with NADP+ and compound 39","MASRILLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEVGVAIQEKLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIHWPTGFKPGKEFFPLDESGNVVPSDTNILDTWAAMEELVDEGLVKAIGISNFNHLQVEMILNKPGLKYKPAVNQIECHPYLTQEKLIQYCQSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIAAKHNKTTAQVLIRFPMQRNLVVIPKSVTPERIAENFKVFDFELSSQDMTTLLSYNRNWRVCALLSCTSHKDYPFHEEF","Homo sapiens","AKR1B1, ALDR1, ALR2","Aldose reductase","1","5OUJ"
"5OUK",,"X-RAY DIFFRACTION",2.22,44.52,"VAPOR DIFFUSION, HANGING DROP",5.5,"20% PEG 6000, 50 mM MES, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 297K",297,"10.1016/j.ejmech.2018.04.015","AVT","5OUK",37.04,"0.959","0.959","Crystal structure of human AKR1B1 complexed with NADP+ and compound 41","MASRILLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEVGVAIQEKLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIHWPTGFKPGKEFFPLDESGNVVPSDTNILDTWAAMEELVDEGLVKAIGISNFNHLQVEMILNKPGLKYKPAVNQIECHPYLTQEKLIQYCQSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIAAKHNKTTAQVLIRFPMQRNLVVIPKSVTPERIAENFKVFDFELSSQDMTTLLSYNRNWRVCALLSCTSHKDYPFHEEF","Homo sapiens","AKR1B1, ALDR1, ALR2","Aldose reductase","1","5OUK"
"5OUL",,"X-RAY DIFFRACTION",1.94,36.69,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OUL",42.43,"1.34","1.34","The crystal structure of CK2alpha in complex with compound 9","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OUL"
"5OUM",,"X-RAY DIFFRACTION",2.17,43.43,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OUM",83.42,"2.05","2.05","The crystal structure of CK2alpha in complex with compound 21","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OUM"
"5OUU",,"X-RAY DIFFRACTION",2.2,44.2,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OUU",84.12,"1.81","1.81","The crystal structure of CK2alpha in complex with compound 22","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OUU"
"5OV8",,"X-RAY DIFFRACTION",2.36,47.86,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris Propane pH9, 10% EG, 0.15M NaNO3, 25% PEG3350",277,"10.1016/j.ejmech.2018.05.037","AXN","5OV8",28.41,"1.8","1.8","Crystal structure of the human BRPF1 bromodomain in complex with BZ097","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5OV8"
"5OVB",,"X-RAY DIFFRACTION",2.48,50.49,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M TRIS, pH 8.5, 0.2 M Ca Acet, 25% PEG 2K MME",277,"10.1021/acscentsci.7b00401",,"5OVB",31.06,"1.95","1.95","Crystal structure of human BRD4(1) bromodomain in complex with DR46","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5OVB"
"5OVD",,"X-RAY DIFFRACTION",2.68,54.14,"VAPOR DIFFUSION, HANGING DROP",7.5,"Protein concentration 30.7 mg/ml. Protein buffer 25 Millimolar TRIS-HCL PH 7.5, 50 millimolar NaCl, 1 millimolar DTT. Reservoir 23% (v/v) ethylenglycol. No cryo required as grown from ethylenglycol as precipitant",293,"10.1073/pnas.1812963116",,"5OVD",57.69,"1.9","1.9","Ras guanine nucleotide exchange factor SOS1 (Rem-cdc25) in new crystal form","GAMAEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGT","Homo sapiens","SOS1","Son of sevenless homolog 1","1","5OVD"
"5OVE",,"X-RAY DIFFRACTION",2.72,54.74,"VAPOR DIFFUSION, HANGING DROP",,"Protein concentration 30.7 mg/ml. Protein buffer 25 Millimolar TRIS-HCL PH 7.5, 50 millimolar NaCl, 1 millimolar DTT. Reservoir 25% (v/v) ethylenglycol. Protein incubated with 2 MILLIMOLAR LIGAND prior to crystallization.",293,"10.1073/pnas.1812963116","AXE","5OVE",57.92,"1.85","1.85","Ras guanine nucleotide exchange factor SOS1 (Rem-cdc25) in complex with small molecule inhibitor compound 1","GAMAEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGT","Homo sapiens","SOS1","Son of sevenless homolog 1","1","5OVE"
"5OVF",,"X-RAY DIFFRACTION",2.61,52.93,"VAPOR DIFFUSION, HANGING DROP",7.5,"Protein concentration 30.7 mg/ml. Protein buffer 25 Millimolar TRIS-HCL PH 7.5, 50 millimolar NaCl, 1 millimolar DTT. Reservoir 27% (v/v) ethylenglycol. Protein incubated with 2 MILLIMOLAR LIGAND prior to crystallization.",293,"10.1073/pnas.1812963116","AWT","5OVF",57.83,"2.01","2.01","Ras guanine nucleotide exchange factor SOS1 (Rem-cdc25) in complex with small molecule inhibitor compound 17","GAMAEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGT","Homo sapiens","SOS1","Son of sevenless homolog 1","1","5OVF"
"5OVG",,"X-RAY DIFFRACTION",2.7,54.52,"VAPOR DIFFUSION, SITTING DROP",7.5,"Protein concentration 30.7 mg/ml. Protein buffer 25 Millimolar TRIS-HCL PH 7.5, 50 millimolar NaCl, 1 millimolar DTT. Reservoir 27% (v/v) ethylenglycol. Protein incubated with 2 MILLIMOLAR LIGAND prior to crystallization.",293,"10.1073/pnas.1812963116","AWZ","5OVG",57.94,"2.3","2.3","Ras guanine nucleotide exchange factor SOS1 (Rem-cdc25) in complex with small molecule inhibitor compound 18","GAMAEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGT","Homo sapiens","SOS1","Son of sevenless homolog 1","1","5OVG"
"5OVH",,"X-RAY DIFFRACTION",2.71,54.69,"VAPOR DIFFUSION, HANGING DROP",7.5,"Protein concentration 30.7 mg/ml. Protein buffer 25 Millimolar TRIS-HCL PH 7.5, 50 millimolar NaCl, 1 millimolar DTT. Reservoir 23% (v/v) ethylenglycol. Protein incubated with 5 MILLIMOLAR LIGAND overnight at 277K prior to crystallization.",293,"10.1073/pnas.1812963116","AWW","5OVH",57.94,"2.3","2.3","Ras guanine nucleotide exchange factor SOS1 (Rem-cdc25) in complex with small molecule inhibitor compound 21","GAMAEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGT","Homo sapiens","SOS1","Son of sevenless homolog 1","1","5OVH"
"5OVI",,"X-RAY DIFFRACTION",2.54,51.59,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein concentration 30.7 mg/ml. Protein buffer 25 Millimolar TRIS-HCL PH 7.5, 50 millimolar NaCl, 1 millimolar DTT. Reservoir 0.1 M TRIS pH 8.5, 25 % (w/v) PEG 3350. CRYO BUFFER WAS RESERVOIR SUPPLEMENTED WITH 2 MILLIMOLAR INHIBITOR (FROM 100 MILLIMOLAR DMSO STOCK) AND 15 % (v/v) ETHYLENE GLYCOL",293,"10.1073/pnas.1812963116","AXH","5OVI",58.01,"2.2","2.2","Ras guanine nucleotide exchange factor SOS1 (Rem-cdc25) in complex with small molecule inhibitor BAY-293 (compound 23)","GAMAEEQMRLPSADVYRFAEPDSEENIIFEENMQPKAGIPIIKAGTVIKLIERLTYHMYADPNFVRTFLTTYRSFCKPQELLSLIIERFEIPEPEPTEADRIAIENGDQPLSAELKRFRKEYIQPVQLRVLNVCRHWVEHHFYDFERDAYLLQRMEEFIGTVRGKAMKKWVESITKIIQRKKIARDNGPGHNITFQSSPPTVEWHISRPGHIETFDLLTLHPIEIARQLTLLESDLYRAVQPSELVGSVWTKEDKEINSPNLLKMIRHTTNLTLWFEKCIVETENLEERVAVVSRIIEILQVFQELNNFNGVLEVVSAMNSSPVYRLDHTFEQIPSRQKKILEEAHELSEDHYKKYLAKLRSINPPCVPFFGIYLTNILKTEEGNPEVLKRHGKELINFSKRRKVAEITGEIQQYQNQPYCLRVESDIKRFFENLNPMGNSMEKEFTDYLFNKSLEIEPRNPKPLPRFPKKYSYPLKSPGVRPSNPRPGT","Homo sapiens","SOS1","Son of sevenless homolog 1","1","5OVI"
"5OVR",,"X-RAY DIFFRACTION",2.55,51.84,"VAPOR DIFFUSION, HANGING DROP",,"26-28% PEG3350, 0.1M Bis-Tris pH5.5, 0.2M Lithium sulfate",277,"10.1021/acs.jmedchem.7b01292","AXK","5OVR",35.66,"2.15","2.15","X-Ray Characterization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors","MHHHHHHSSGVDLGTENLYFQSMSRVLQAEELHEKALDPFLLQAEFFEIPMNFVDPKEYDIPGLVRKNRYKTILPNPHSRVCLTSPDPDDPLSSYINANYIRGYGGEEKVYIATQGPIVSTVADFWRMVWQEHTPIIVMITNIEEMNEKCTEYWPEEQVAYDGVEITVQKVIHTEDYRLRLISLKSGTEERGLKHYWFTSWPDQKTPDRAPPLLHLVREVEEAAQQEGPHCAPIIVHCSAGIGRTGCFIATSICCQQLRQEGVVDILKTTCQLRQDRGGMIQTCEQYQFVHHVMSLYEKQLSHQS","Homo sapiens","PTPN5","Tyrosine-protein phosphatase non-receptor type 5","1","5OVR"
"5OVX",,"X-RAY DIFFRACTION",2.53,51.29,"VAPOR DIFFUSION, HANGING DROP",,"26-28% PEG3350, 0.1M Bis-Tris pH5.5, 0.2M Lithium sulfate",277,"10.1021/acs.jmedchem.7b01292","AY5","5OVX",35.66,"2.1","2.1","X-Ray Characterization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors","MHHHHHHSSGVDLGTENLYFQSMSRVLQAEELHEKALDPFLLQAEFFEIPMNFVDPKEYDIPGLVRKNRYKTILPNPHSRVCLTSPDPDDPLSSYINANYIRGYGGEEKVYIATQGPIVSTVADFWRMVWQEHTPIIVMITNIEEMNEKCTEYWPEEQVAYDGVEITVQKVIHTEDYRLRLISLKSGTEERGLKHYWFTSWPDQKTPDRAPPLLHLVREVEEAAQQEGPHCAPIIVHCSAGIGRTGCFIATSICCQQLRQEGVVDILKTTCQLRQDRGGMIQTCEQYQFVHHVMSLYEKQLSHQS","Homo sapiens","PTPN5","Tyrosine-protein phosphatase non-receptor type 5","1","5OVX"
"5OW1",,"X-RAY DIFFRACTION",2.59,52.54,"VAPOR DIFFUSION, HANGING DROP",,"26-28% PEG3350, 0.1M Bis-Tris pH5.5, 0.2M Lithium sulfate",277,"10.1021/acs.jmedchem.7b01292","AY8","5OW1",35.62,"2.05","2.05","X-Ray Characterization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors","MHHHHHHSSGVDLGTENLYFQSMSRVLQAEELHEKALDPFLLQAEFFEIPMNFVDPKEYDIPGLVRKNRYKTILPNPHSRVCLTSPDPDDPLSSYINANYIRGYGGEEKVYIATQGPIVSTVADFWRMVWQEHTPIIVMITNIEEMNEKCTEYWPEEQVAYDGVEITVQKVIHTEDYRLRLISLKSGTEERGLKHYWFTSWPDQKTPDRAPPLLHLVREVEEAAQQEGPHCAPIIVHCSAGIGRTGCFIATSICCQQLRQEGVVDILKTTCQLRQDRGGMIQTCEQYQFVHHVMSLYEKQLSHQS","Homo sapiens","PTPN5","Tyrosine-protein phosphatase non-receptor type 5","1","5OW1"
"5OW8",,"X-RAY DIFFRACTION",2.23,44.75,"VAPOR DIFFUSION, HANGING DROP",,"37-45% PEG400
0.1M bis-Tris pH 5.6-5.9",293,"10.1021/acsmedchemlett.7b00505","AYN","5OW8",29.28,"1.9","1.9","Indole-2 carboxamides as selective secreted phospholipase A2 type X (sPLA2-X) inhibitors","GILELAGTVGCVGPRTPIAYMKYGCFCGLGGHGQPRDAIDWCCHGHDCCYTRAEEAGCSPKTERYSWQCVNQSVLCGPAENKCQELLCKCDQEIANCLAQTEYNLKYLFYPQFLCEPDSPKCD","Homo sapiens","PLA2G10","Group 10 secretory phospholipase A2","1","5OW8"
"5OWA",,"X-RAY DIFFRACTION",2.34,47.44,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M MgCl2, 20% PEG3350",277,"10.1016/j.ejmech.2018.05.037","B0H","5OWA",55.86,"1.95","1.95","Crystal structure of the human BRPF1 bromodomain in complex with BZ054","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5OWA"
"5OWB",,"X-RAY DIFFRACTION",2.44,49.61,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Sodium Acetate, pH5.5, 0.15 M Sodium Nitrate, 20% PEG3350",277,,,"5OWB",13.93,"1.65","1.65","Crystal structure of the human BRPF1 bromodomain in complex with DSPBP1004","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5OWB"
"5OWC",,"X-RAY DIFFRACTION",2.3,46.58,"VAPOR DIFFUSION, HANGING DROP",,"37-45% PEG400
0.1M bis-Tris pH 5.6-5.9",293,"10.1021/acsmedchemlett.7b00505","AYZ","5OWC",28.87,"1.75","1.75","Indole-2 carboxamides as selective secreted phospholipase A2 type X (sPLA2-X) inhibitors","GILELAGTVGCVGPRTPIAYMKYGCFCGLGGHGQPRDAIDWCCHGHDCCYTRAEEAGCSPKTERYSWQCVNQSVLCGPAENKCQELLCKCDQEIANCLAQTEYNLKYLFYPQFLCEPDSPKC","Homo sapiens","PLA2G10","Group 10 secretory phospholipase A2","1","5OWC"
"5OWE",,"X-RAY DIFFRACTION",2.46,49.95,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-tris propane, pH6.5, 0.2 M Sodium nitrate, 20% PEG3350",277,,,"5OWE",13.98,"1.7","1.7","Crystal structure of the human BRPF1 bromodomain in complex with DSPBP1010","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5OWE"
"5OWH",,"X-RAY DIFFRACTION",2.13,42.32,"VAPOR DIFFUSION, SITTING DROP",,"1 MIKROLITER OF A CK2ALPHA/INHIBITOR MIXTURE (COMPOSITION: 7 MG/ML CK2ALPHA ENZYME, 1 MILLIMOLAR         
INHIBITOR, 10 % DIMETHYL SULFOXIDE, 450 MM NACL, 22.5 MM TRIS/HCL, PH 8.5) WAS MIXED WITH 1 MIKROLITER RESERVOIR SOLUTION (COMPOSITION: 4.4 M sodium chloride, 0.1 M SODIUM Acetate, PH 5.5) FOLLOWED BY VAPOUR DIFFUSION EQUILIBRATION AGAINST MICROLITER OF THE RESERVOIR SOLUTION.",293.15,"10.1016/j.bioorg.2018.06.022",,"5OWH",40.59,"2.3","2.3","High salt structure of human protein kinase CK2alpha in complex with 3-aminopropyl-4,5,6,7-tetrabromobenzimidazol","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMG","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OWH"
"5OWK",,"X-RAY DIFFRACTION",2.15,42.73,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES, pH6.5, 0.1 M MgCl2, 20% PEG6K, 10% EG",277,"10.1021/acsmedchemlett.8b00286",,"5OWK",14.65,"1.25","1.25","Crystal structure of CREBBP bromodomain complexed with DSPB2A002","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5OWK"
"5OWL",,"X-RAY DIFFRACTION",3.12,60.58,"VAPOR DIFFUSION, SITTING DROP",,"1 MIKROLITER OF THE CK2ALPHA/INHIBITOR MIXTURE (COMPOSITION: 7 MG/ML CK2ALPHA ENZYME, 1 MILLIMOLAR INHIBITOR, 10 % DIMETHYL SULFOXIDE, 450 MM NACL, 22.5 MM TRIS/HCL, PH 8.5) WAS MIXED WITH 1 MIKROLITER RESERVOIR SOLUTION (COMPOSITION: 25 % PEG3350, 0.2 M AMMONIUM SULPHATE, 0.1 M BIS-TRIS BUFFER, PH 5.5) FOLLOWED BY VAPOUR DIFFUSION EQUILIBRATION  AGAINST THE RESERVOIR SOLUTION.",293.15,"10.1016/j.bioorg.2018.06.022",,"5OWL",81.69,"2.23","2.23","Low salt structure of human protein kinase CK2alpha in complex with 3-aminopropyl-4,5,6,7-tetrabromobenzimidazol","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMG","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OWL"
"5OWM",,"X-RAY DIFFRACTION",1.99,38.26,"VAPOR DIFFUSION, SITTING DROP",,"HEPES, Sodium chloride",277,"10.1021/acscentsci.7b00401",,"5OWM",15.35,"1.5","1.5","Crystal structure of human BRD4(1) bromodomain in complex with UT48","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5OWM"
"5OWO",,"X-RAY DIFFRACTION",2.55,51.8,"VAPOR DIFFUSION, HANGING DROP",5.5,"100mM Sodium acetate, pH 5.5, 10% Glycerol, 50mM Calcium acetate, 20% PEG 2,000 MME",291.15,"10.1038/nature25462",,"5OWO",90.19,"1.79","1.79","Human cytoplasmic Dynein N-Terminus dimerization domain at 1.8 Angstrom resolution","MSEPGGGGGEDGSAGLEVSAVQNVADVSVLQKHLRKLVPLLLEDGGEAPAALEAALEEKSALEQMRKFLSDPQVHTVLVERSTLKEDVGDEGEEEKEFISYNINIDIHYGVKSNSLAFIKRTPVIDADKPVSSQLRVLTLSEDSPYETLHSFISNAVAPFFKSYIRESGKADRDGDKMAPSVEKKIAELEMGLLHLQQNIE","Homo sapiens","DYNC1H1, DHC1, DNCH1, DNCL, DNECL, DYHC, KIAA0325","Cytoplasmic dynein 1 heavy chain 1","1","5OWO"
"5OWQ",,"X-RAY DIFFRACTION",2.41,48.91,"VAPOR DIFFUSION, SITTING DROP",,"0.1M sodium formate, 15%(w/v) PEG 3350",277,,,"5OWQ",69.38,"2.7","2.7","Human STK10 bound to dovitinib","SMRKSREYEHVRRDLDPNEVWEIVGELGDGAFGKVYKAKNKETGALAAAKVIETKSEEELEDYIVEIEILATCDHPYIVKLLGAYYHDGKLWIMIEFCPGGAVDAIMLELDRGLTEPQIQVVCRQMLEALNFLHSKRIIHRDLKAGNVLMTLEGDIRLADFGVSAKNLKTLQKRDSFIGTPYWMAPEVVMCETMKDTPYDYKADIWSLGITLIEMAQIEPPHHELNPMRVLLKIAKSDPPTLLTPSKWSVEFRDFLKIALDKNPETRPSAAQLLEHPFVSSITSNKALRELVAEAKAEVMEE","Homo sapiens","STK10, LOK","Serine/threonine-protein kinase 10","1","5OWQ"
"5OWR",,"X-RAY DIFFRACTION",2.7,54.48,"VAPOR DIFFUSION, SITTING DROP",,"40% PEG 300, 0.20M Ca(ac)2, 0.1M cacodylate pH 6.5",277,,"1N1","5OWR",34.83,"2.3","2.3","Human STK10 bound to dasatinib","SMRKSREYEHVRRDLDPNEVWEIVGELGDGAFGKVYKAKNKETGALAAAKVIETKSEEELEDYIVEIEILATCDHPYIVKLLGAYYHDGKLWIMIEFCPGGAVDAIMLELDRGLTEPQIQVVCRQMLEALNFLHSKRIIHRDLKAGNVLMTLEGDIRLADFGVSAKNLKTLQKRDSFIGTPYWMAPEVVMCETMKDTPYDYKADIWSLGITLIEMAQIEPPHHELNPMRVLLKIAKSDPPTLLTPSKWSVEFRDFLKIALDKNPETRPSAAQLLEHPFVSSITSNKALRELVAEAKAEVMEE","Homo sapiens","STK10, LOK","Serine/threonine-protein kinase 10","1","5OWR"
"5OWS",,"X-RAY DIFFRACTION",2.44,49.65,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350",277,"10.1038/s41598-018-19872-3",,"5OWS",55.94,"1.8","1.8","Crystal structure of TNKS2 in complex with 2-[4-(4-methyl-2-oxoimidazolidin-4-yl)phenyl]-3,4-dihydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5OWS"
"5OWT",,"X-RAY DIFFRACTION",2.27,45.8,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350",277,"10.1038/s41598-018-19872-3",,"5OWT",55.78,"2.2","2.2","Crystal structure of TNKS2 in complex with (5S)-5-methyl-5-[4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]imidazolidine-2,4-dione","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5OWT"
"5OWW",,"X-RAY DIFFRACTION",2.27,45.87,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES sodium pH 7.5, 10% v/v 2-Propanol, 20% w/v Polyethylene glycol 4,000",277,"10.1021/acscentsci.7b00401",,"5OWW",61.73,"1.5","1.5","Crystal structure of human BRD4(1) bromodomain in complex with UT22B","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5OWW"
"5OX5",,"X-RAY DIFFRACTION",2.77,55.68,"VAPOR DIFFUSION, SITTING DROP",6.5,"1.5 M sodium citrate tribasic dehydrate pH 6.5, Sitting drop (300 nl), protein-to-well ratio, 1:1.",293,"10.1039/c7sc02103h","B2E","5OX5",28.47,"2.251","2.251","HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with CCT6, a GSK1278863-related compound","GSHMASPNGQTKPLPALKLALEYIVPCMNKHGICVVDDFLGKETGQQIGDEVRALHDTGKFTDGQLVSQKSDSSKDIRGDKITWIEGKEPGCETIGLLMSSMDDLIRHCNGKLGSYKINGRTKAMVACYPGNGTGYVRHVDNPNGDGRCVTCIYYLNKDWDAKVSGGILRIFPEGKAQFADIEPKFDRLLFFWSDRRNPHEVQPAYATRYAITVWYFDADERARAKVKYLTGEKGVRVELNKPSDSVGKDVF","Homo sapiens","EGLN1, C1orf12, PNAS-118, PNAS-137","Egl nine homolog 1","1","5OX5"
"5OX6",,"X-RAY DIFFRACTION",2.86,56.99,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.2 M Ammonium sulfate, 0.1 M Sodium acetate trihydrate pH 4.6, 25% w/v Polyethylene glycol 4000, Sitting drop (300 nl), protein-to-well ratio, 2:1",293,"10.1039/c7sc02103h","A1Z","5OX6",28.83,"1.99","1.99","HIF prolyl hydroxylase 2 (PHD2/ EGLN1) in complex with Vadadustat","GSHMASPNGQTKPLPALKLALEYIVPCMNKHGICVVDDFLGKETGQQIGDEVRALHDTGKFTDGQLVSQKSDSSKDIRGDKITWIEGKEPGCETIGLLMSSMDDLIRHCNGKLGSYKINGRTKAMVACYPGNGTGYVRHVDNPNGDGRCVTCIYYLNKDWDAKVSGGILRIFPEGKAQFADIEPKFDRLLFFWSDRRNPHEVQPAYATRYAITVWYFDADERARAKVKYLTGEKGVRVELNKPSDSVGKDVF","Homo sapiens","EGLN1, C1orf12, PNAS-118, PNAS-137","Egl nine homolog 1","1","5OX6"
"5OXG",,"X-RAY DIFFRACTION",2.81,56.29,"VAPOR DIFFUSION, SITTING DROP",6.5,"18% PEG8000 -- 0.2M calcium acetate -- 0.1M cacodylate pH 6.5",277,"10.1016/j.bone.2017.09.004","B4B","5OXG",140.08,"2.13","2.13","Crystal structure of the ACVR1 (ALK2) kinase in complex with LDN-212854","SMQRTVARDITLLECVGKGRYGEVWRGSWQGENVAVKIFSSRDEKSWFRETELYNTVMLRHENILGFIASDMTSRHSSTQLWLITHYHEMGSLYDYLQLTTLDTVSCLRIVLSIASGLAHLHIEIFGTQGKPAIAHRDLKSKNILVKKNGQCCIADLGLAVMHSQSTNQLDVGNNPRVGTKRYMAPEVLDETIQVDCFDSYKRVDIWAFGLVLWEVARRMVSNGIVEDYKPPFYDVVPNDPSFEDMRKVVCVDQQRPNIPNRWFSDPTLTSLAKLMKECWYQNPSARLTALRIKKTLTKID","Homo sapiens","ACVR1, ACVRLK2","Activin receptor type-1","1","5OXG"
"5OXH",,"X-RAY DIFFRACTION",3.73,67.01,"VAPOR DIFFUSION, SITTING DROP",9,"3.2 M ammonium sulfate, 0.1 M bicine (pH 9.0); 1:1 protein to reservoir ratio",291,"10.15252/embj.201797876",,"5OXH",9.42,"1.601","1.601","C-terminally retracted ubiquitin T66V/L67N mutant","MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESVNHLVLRLRGG","Homo sapiens","UBC","Ubiquitin T66V/L67N mutant","1","5OXH"
"5OXI",,"X-RAY DIFFRACTION",2.18,43.68,"VAPOR DIFFUSION, SITTING DROP",6,"3 M ammonium sulfate, 0.1 M MES (pH 6.0); 2:1 protein to reservoir ratio",291,"10.15252/embj.201797876",,"5OXI",17.68,"1.63","1.63","C-terminally retracted ubiquitin L67S mutant","MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTSHLVLRLRGG","Homo sapiens","UBC","Ubiquitin L67S mutant","1","5OXI"
"5OXR",,"X-RAY DIFFRACTION",2.95,58.25,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M Tris pH 7.0, 16% PEG 10000",293,"10.1371/journal.pone.0199175",,"5OXR",58.07,"1.75","1.75","Crystal structure of human lung surfactant protein D trimeric fragment with bound ligand Salmonella enterica Minnesota R7 oligosaccharide","GSPGLKGDKGIPGDKGAKGESGLPDVASLRQQVEALQGQVQHLQAAFSQYKKVELFPNGQSVGEKIFKTAGFVKPFTEAQLLCTQAGGQLASPRSAAENAALQQLVVAKNEAAFLSMTDSKTEGKFTYPTGESLVYSNWAPGEPNDDGGSEDCVEIFTNGKWNDRACGEKRLVVCEF","Homo sapiens","SFTPD, COLEC7, PSPD, SFTP4","Pulmonary surfactant-associated protein D","1","5OXR"
"5OXS",,"X-RAY DIFFRACTION",3,58.99,"VAPOR DIFFUSION, SITTING DROP",8,"0.1M Tris pH 8.0, 16% PEG 6000",293,"10.1371/journal.pone.0199175",,"5OXS",59.01,"1.65","1.65","Crystal structure of human lung surfactant protein D trimeric fragment with bound ligand Salmonella enterica Minnesota R5 oligosaccharide","GSPGLKGDKGIPGDKGAKGESGLPDVASLRQQVEALQGQVQHLQAAFSQYKKVELFPNGQSVGEKIFKTAGFVKPFTEAQLLCTQAGGQLASPRSAAENAALQQLVVAKNEAAFLSMTDSKTEGKFTYPTGESLVYSNWAPGEPNDDGGSEDCVEIFTNGKWNDRACGEKRLVVCEF","Homo sapiens","SFTPD, COLEC7, PSPD, SFTP4","Pulmonary surfactant-associated protein D","1","5OXS"
"5OY6",,"X-RAY DIFFRACTION",2.4,48.78,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.3M magnesium formate, 0.1M bis-tris pH 5.5",277,,,"5OY6",139.6,"2.56","2.56","Crystal structure of the ACVR1 (ALK2) kinase in complex with cyclical inhibitor OD36.","SMQRTVARDITLLECVGKGRYGEVWRGSWQGENVAVKIFSSRDEKSWFRETELYNTVMLRHENILGFIASDMTSRHSSTQLWLITHYHEMGSLYDYLQLTTLDTVSCLRIVLSIASGLAHLHIEIFGTQGKPAIAHRDLKSKNILVKKNGQCCIADLGLAVMHSQSTNQLDVGNNPRVGTKRYMAPEVLDETIQVDCFDSYKRVDIWAFGLVLWEVARRMVSNGIVEDYKPPFYDVVPNDPSFEDMRKVVCVDQQRPNIPNRWFSDPTLTSLAKLMKECWYQNPSARLTALRIKKTLTKID","Homo sapiens","ACVR1, ACVRLK2","Activin receptor type-1","1","5OY6"
"5OYF",,"X-RAY DIFFRACTION",1.98,37.81,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c7sc05122k",,"5OYF",41.64,"1.54","1.54","The crystal structure of CK2alpha in complex with compound 31","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5OYF"
"5OYM",,"X-RAY DIFFRACTION",2.42,49.13,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M Sodium Fluoride, 0.1 M bis-Tris propane, pH 8.5 and 20 % w/v PEG 3350",293,"10.1107/S2053230X18001553",,"5OYM",95.18,"2.05","2.05","HIV Integrase Binding Domain of Lens Epithelium-Derived Growth Factor","GGSMGSGGGGSGGGGSGGGGAAAMETSMDSRLQRIHAEIKNSLKIDNLDVNRCIEALDELASLQVTMQQAQKHTEMITTLKKIRRFKVSQVIMEKSTMLYNKFKNMFLVGE","Homo sapiens","PSIP1, DFS70, LEDGF, PSIP2","PC4 and SFRS1-interacting protein","1","5OYM"
"5P21",,"X-RAY DIFFRACTION",2.01,38.93,,,,,"10.1002/j.1460-2075.1990.tb07409.x",,"5P21",19.42,"1.35","1.35","REFINED CRYSTAL STRUCTURE OF THE TRIPHOSPHATE CONFORMATION OF H-RAS P21 AT 1.35 ANGSTROMS RESOLUTION: IMPLICATIONS FOR THE MECHANISM OF GTP HYDROLYSIS","MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNKCDLAARTVESRQAQDLARSYGIPYIETSAKTRQGVEDAFYTLVREIRQH","Homo sapiens","HRAS, HRAS1","C-H-RAS P21 PROTEIN","1","5P21"
"5P9F",,"X-RAY DIFFRACTION",2.26,45.64,"VAPOR DIFFUSION",7,"PEG 3350, sodium actate, BisTrisPropane",298,"10.1124/mol.116.107037","2VL","5P9F",33.26,"1.71","1.71","BTK IN COMPLEX WITH GDC-0834","GKNAPSTAGLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","5P9F"
"5P9G",,"X-RAY DIFFRACTION",2.23,44.95,"VAPOR DIFFUSION",7,"PEG 3350, sodium actate, BisTrisPropane",298,"10.1124/mol.116.107037","7G6","5P9G",32.93,"1.75","1.75","Structure of BTK with RN486","GKNAPSTAGLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","5P9G"
"5P9H",,"X-RAY DIFFRACTION",1.88,34.41,"VAPOR DIFFUSION",7,"PEG 3350, sodium actate, BisTrisPropane",298,"10.1124/mol.116.107037",,"5P9H",32.95,"1.95","1.95","BTK1 COCRYSTALLIZED WITH RN983","GKNAPSTAGLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","5P9H"
"5P9I",,"X-RAY DIFFRACTION",2.2,44.14,"VAPOR DIFFUSION",7,"PEG 3350, sodium actate, BisTrisPropane",298,"10.1124/mol.116.107037","1E8","5P9I",32.92,"1.11","1.11","BTK1 SOAKED WITH IBRUTINIB-Rev","GKNAPSTAGLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","5P9I"
"5P9J",,"X-RAY DIFFRACTION",2.23,44.77,"VAPOR DIFFUSION",7,"PEG 3350, sodium actate, BisTrisPropane",298,"10.1124/mol.116.107037",,"5P9J",32.77,"1.08","1.08","BTK1 COCRYSTALLIZED WITH IBRUTINIB","GKNAPSTAGLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","5P9J"
"5P9K",,"X-RAY DIFFRACTION",2.2,44.14,"VAPOR DIFFUSION",7,"PEG 3350, sodium actate, BisTrisPropane",298,"10.1124/mol.116.107037",,"5P9K",32.83,"1.28","1.28","CRYSTAL STRUCTURE OF BTK with CNX 774","GKNAPSTAGLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","5P9K"
"5P9L",,"X-RAY DIFFRACTION",2.23,44.94,"VAPOR DIFFUSION",7,"PEG 3350, sodium actate, BisTrisPropane",298,"10.1124/mol.116.107037",,"5P9L",32.75,"1.25","1.25","BTK1 IN COMPLEX WITH CC 292","GKNAPSTAGLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","5P9L"
"5P9M",,"X-RAY DIFFRACTION",2.18,43.65,"VAPOR DIFFUSION",7,"PEG 3350, sodium actate, BisTrisPropane",298,"10.1124/mol.116.107037",,"5P9M",32.86,"1.41","1.41","BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059","GKNAPSTAGLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","5P9M"
"5PA8",,"X-RAY DIFFRACTION",3.77,67.36,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PA8",35.77,"1.98","1.98","Crystal Structure of Factor VIIa in complex with cyclohexanamine","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PA8"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PA8"
"5PA9",,"X-RAY DIFFRACTION",3.76,67.26,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PA9",35.68,"1.55","1.55","Crystal Structure of Factor VIIa in complex with phenylmethanamine;hydrochloride","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PA9"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PA9"
"5PAA",,"X-RAY DIFFRACTION",3.76,67.25,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAA",35.86,"1.98","1.98","Crystal Structure of Factor VIIa in complex with cyclohexylmethanamine","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAA"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAA"
"5PAB",,"X-RAY DIFFRACTION",3.75,67.21,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,"7XD","5PAB",36.25,"1.99","1.99","Crystal Structure of Factor VIIa in complex with 1-[[3-[2-hydroxy-3-(1H-pyrrolo[3,2-c]pyridin-2-yl)phenyl]phenyl]methyl]-3-phenylurea","IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","1","5PAB"
,,,,,,,,,,,,,,,,"LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","2","5PAB"
"5PAC",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAC",36.04,"1.5","1.5","human factor VIIa in complex with 5-hydroxy-N-(4-oxo-3H-quinazolin-6-yl)-1-[3-[(phenylcarbamoylamino)methyl]phenyl]pyrazole-4-carboxamide at 1.50A","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAC"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAC"
"5PAE",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAE",36.17,"1.45","1.45","Crystal Structure of Factor VIIa in complex with (2S)-2-hydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]propanamide","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAE"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAE"
"5PAF",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAF",36.39,"1.5","1.5","Crystal Structure of Factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-2-[3-[(2-amino-2-oxoethyl)-methylsulfonylamino]-5-chlorophenyl]acetamide;2,2,2-trifluoroacetic acid","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAF"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAF"
"5PAG",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAG",35.88,"1.36","1.36","Crystal Structure of Factor VIIa in complex with (2R)-2-hydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-methylbutanamide;hydrobromide","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAG"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAG"
"5PAH",,"X-RAY DIFFRACTION",3.22,62,,6.8,"pH 6.8",,"10.1021/bi9815290",,"5PAH",35.91,"2.1","2.1","HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND DOPAMINE INHIBITOR","TVPWFPRTIQELDRFANQILSYGAELDADHPGFKDPVYRARRKQFADIAYNYRHGQPIPRVEYMEEEKKTWGTVFKTLKSLYKTHACYEYNHIFPLLEKYCGFHEDNIPQLEDVSQFLQTCTGFRLRPVAGLLSSRDFLGGLAFRVFHCTQYIRHGSKPMYTPEPDICHELLGHVPLFSDRSFAQFSQEIGLASLGAPDEYIEKLATIYWFTVEFGLCKQGDSIKAYGAGLLSSFGELQYCLSEKPKLLPLELEKTAIQNYTVTEFQPLYYVAESFNDAKEKVRNFAATIPRPFSVRYDPYTQRIEVL","Homo sapiens","PAH","PHENYLALANINE 4-MONOOXYGENASE","1","5PAH"
"5PAI",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAI",35.95,"1.73","1.73","human factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-1-[3-[[(3,5-dimethyl-1,2-oxazol-4-yl)carbamoylamino]methyl]phenyl]-5-hydroxypyrazole-4-carboxamide at 1.73A","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAI"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAI"
"5PAJ",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAJ",35.88,"1.7","1.7","Crystal Structure of Factor VIIa in complex with 1-(1-aminoisoquinolin-6-yl)-3-benzylurea","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAJ"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAJ"
"5PAK",,"X-RAY DIFFRACTION",3.77,67.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAK",35.69,"1.56","1.56","Crystal Structure of Factor VIIa in complex with N-[[4-(aminomethyl)-2-(2-amino-2-oxoethoxy)phenyl]methyl]-2-(4-hydroxyphenyl)-2-methoxyacetamide;hydrochloride","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAK"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAK"
"5PAM",,"X-RAY DIFFRACTION",3.73,67.01,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAM",36,"1.6","1.6","Crystal Structure of Factor VIIa in complex with 2-[(1-aminoisoquinolin-6-yl)amino]-2-(5-ethoxy-2-fluorophenyl)-1-(2-phenylpyrrolidin-1-yl)ethanone","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAM"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAM"
"5PAN",,"X-RAY DIFFRACTION",3.77,67.39,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAN",36.12,"1.62","1.62","Crystal Structure of Factor VIIa in complex with 5-hydroxy-N-(3-oxo-1,2-dihydroisoindol-5-yl)-1-[3-[(phenylcarbamoylamino)methyl]phenyl]pyrazole-4-carboxamide","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAN"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAN"
"5PAO",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAO",36.22,"1.4","1.4","Crystal Structure of Factor VIIa in complex with (2S)-2,3-dihydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]propanamide;hydrobromide","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAO"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAO"
"5PAQ",,"X-RAY DIFFRACTION",3.82,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAQ",36.04,"1.59","1.59","Crystal Structure of Factor VIIa in complex with 2-[(1-aminoisoquinolin-6-yl)amino]-2-(3-ethoxy-4-propan-2-yloxyphenyl)-1-(2-phenylpyrrolidin-1-yl)ethanone","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAQ"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAQ"
"5PAR",,"X-RAY DIFFRACTION",3.78,67.46,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAR",36.11,"2.1","2.1","Crystal Structure of Factor VIIa in complex with 1H-benzimidazol-2-amine","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAR"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAR"
"5PAS",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAS",35.9,"1.48","1.48","Crystal Structure of Factor VIIa in complex with (2S)-2-hydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylpropanamide","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAS"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAS"
"5PAT",,"X-RAY DIFFRACTION",3.75,67.18,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAT",35.58,"1.6","1.6","Crystal Structure of Factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-2-(3-chlorophenyl)acetamide","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAT"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAT"
"5PAU",,"X-RAY DIFFRACTION",3.77,67.38,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAU",36.08,"1.55","1.55","Crystal Structure of Factor VIIa in complex with N-(2-amino-1H-benzimidazol-5-yl)-2-[3-[(2-amino-2-oxoethyl)-methylsulfonylamino]phenyl]acetamide;2,2,2-trifluoroacetic acid","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAU"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAU"
"5PAV",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAV",36.18,"1.4","1.4","Crystal Structure of Factor VIIa in complex with N-(6-aminopyridin-3-yl)-5-hydroxy-1-phenylpyrazole-4-carboxamide","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAV"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAV"
"5PAW",,"X-RAY DIFFRACTION",3.77,67.39,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAW",35.59,"2.2","2.2","Crystal Structure of Factor VIIa in complex with isoquinoline-1,6-diamine","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAW"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAW"
"5PAX",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAX",36,"1.36","1.36","Crystal Structure of Factor VIIa in complex with 1-(2,6-difluorophenyl)-3-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]urea","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAX"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAX"
"5PAY",,"X-RAY DIFFRACTION",3.76,67.24,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PAY",36.09,"1.66","1.66","Crystal Structure of Factor VIIa in complex with 1-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylurea","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PAY"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PAY"
"5PB0",,"X-RAY DIFFRACTION",3.76,67.24,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PB0",36.16,"1.98","1.98","Crystal Structure of Factor VIIa in complex with 2-(4-ethoxy-3-methoxyphenyl)-2-(isoquinolin-6-ylamino)acetic acid","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PB0"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PB0"
"5PB1",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PB1",36.21,"1.9","1.9","Crystal Structure of Factor VIIa in complex with benzenecarboximidamide","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PB1"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PB1"
"5PB2",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PB2",35.76,"1.45","1.45","Crystal Structure of Factor VIIa in complex with 2-phenyl-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-3-ol","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PB2"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PB2"
"5PB3",,"X-RAY DIFFRACTION",3.75,67.19,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PB3",36.14,"1.9","1.9","Crystal Structure of Factor VIIa in complex with 1-[[3-[4-(5-amino-1H-pyrrolo[3,2-b]pyridin-2-yl)-5-hydroxypyrazol-1-yl]phenyl]methyl]-3-phenylurea","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PB3"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PB3"
"5PB4",,"X-RAY DIFFRACTION",3.81,67.72,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PB4",35.92,"2.43","2.43","human factor VIIa in complex with 1-[[3-[5-hydroxy-3-methyl-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylurea at 2.43A","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PB4"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PB4"
"5PB5",,"X-RAY DIFFRACTION",3.75,,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PB5",35.87,"1.84","1.84","human factor VIIa in complex with 1-[[3-[5-hydroxy-4-(7H-pyrrolo[2,3-d]pyrimidin-6-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylurea at 1.84A","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PB5"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PB5"
"5PB6",,"X-RAY DIFFRACTION",3.76,67.27,"VAPOR DIFFUSION, SITTING DROP",8.5,"16 mg/ml protein in 20mM Tris/HCl pH 8.4, 5 mM benzamidine, 0.1 M NaCl, 50 mM CaCl2 mixed 1+1 with 32-35% AMMONIUM SULPHATE, 2% PEG 4000, 0.1 M Bicine-NaOH pH 8.5, 15% glycerol",277,,,"5PB6",36.09,"1.9","1.9","Crystal Structure of Factor VIIa in complex with N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]pentanamide","LICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGR","Homo sapiens","F7","Coagulation factor VII light chain","1","5PB6"
,,,,,,,,,,,,,,,,"IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII heavy chain","2","5PB6"
"5PB7",,"X-RAY DIFFRACTION",3.54,65.24,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PB7",16.41,"1.655","1.655","PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09440a","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PB7"
"5PB8",,"X-RAY DIFFRACTION",3.59,65.74,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PB8",16.47,"1.649","1.649","PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09522a","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PB8"
"5PB9",,"X-RAY DIFFRACTION",3.55,65.33,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PB9",16.41,"1.782","1.782","PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09521a","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PB9"
"5PBA",,"X-RAY DIFFRACTION",3.53,65.18,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBA",16.49,"1.925","1.925","PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09460a","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBA"
"5PBB",,"X-RAY DIFFRACTION",3.59,65.71,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBB",16.42,"1.783","1.783","PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09496a","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBB"
"5PBC",,"X-RAY DIFFRACTION",3.58,65.64,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBC",16.36,"1.771","1.771","PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09724a","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBC"
"5PBD",,"X-RAY DIFFRACTION",3.6,65.84,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBD",16.39,"1.776","1.776","PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09682a","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBD"
"5PBE",,"X-RAY DIFFRACTION",3.66,66.4,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBE",16.37,"1.835","1.835","PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09428a","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBE"
"5PBF",,"X-RAY DIFFRACTION",3.54,65.26,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBF",16.38,"1.801","1.801","PanDDA analysis group deposition -- Crystal Structure of BAZ2B in complex with N09645a","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBF"
"5PBG",,"X-RAY DIFFRACTION",3.61,65.96,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBG",16.15,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 1)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBG"
"5PBH",,"X-RAY DIFFRACTION",3.59,65.76,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBH",16.15,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 2)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBH"
"5PBI",,"X-RAY DIFFRACTION",3.6,65.8,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBI",16.15,"1.78","1.78","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 3)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBI"
"5PBJ",,"X-RAY DIFFRACTION",3.58,65.62,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBJ",16.15,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 4)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBJ"
"5PBK",,"X-RAY DIFFRACTION",3.56,65.46,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBK",16.15,"1.77","1.77","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 5)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBK"
"5PBL",,"X-RAY DIFFRACTION",3.56,65.46,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBL",16.15,"1.84","1.84","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 6)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBL"
"5PBM",,"X-RAY DIFFRACTION",3.57,65.52,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBM",16.15,"1.67","1.67","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 7)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBM"
"5PBN",,"X-RAY DIFFRACTION",3.6,65.82,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBN",16.15,"1.86","1.86","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 8)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBN"
"5PBO",,"X-RAY DIFFRACTION",3.59,65.71,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBO",16.15,"1.95","1.95","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 9)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBO"
"5PBP",,"X-RAY DIFFRACTION",3.56,65.43,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBP",16.15,"1.88","1.88","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 10)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBP"
"5PBQ",,"X-RAY DIFFRACTION",3.57,65.55,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBQ",16.15,"1.93","1.93","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 11)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBQ"
"5PBR",,"X-RAY DIFFRACTION",3.58,65.65,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBR",16.15,"1.81","1.81","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 12)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBR"
"5PBS",,"X-RAY DIFFRACTION",3.57,65.59,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBS",16.15,"1.77","1.77","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 13)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBS"
"5PBT",,"X-RAY DIFFRACTION",3.59,65.71,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBT",16.15,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 14)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBT"
"5PBU",,"X-RAY DIFFRACTION",3.63,66.08,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBU",16.15,"1.88","1.88","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 15)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBU"
"5PBV",,"X-RAY DIFFRACTION",3.71,66.85,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBV",16.15,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 16)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBV"
"5PBW",,"X-RAY DIFFRACTION",3.6,65.88,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBW",16.15,"1.84","1.84","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 17)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBW"
"5PBX",,"X-RAY DIFFRACTION",3.6,65.83,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBX",16.15,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 18)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBX"
"5PBY",,"X-RAY DIFFRACTION",3.59,65.79,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBY",16.15,"1.75","1.75","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 19)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBY"
"5PBZ",,"X-RAY DIFFRACTION",3.56,65.46,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PBZ",16.15,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 20)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PBZ"
"5PC0",,"X-RAY DIFFRACTION",3.61,65.91,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PC0",16.15,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 21)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PC0"
"5PC1",,"X-RAY DIFFRACTION",3.56,65.48,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PC1",16.15,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 22)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PC1"
"5PC2",,"X-RAY DIFFRACTION",3.58,65.65,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PC2",16.15,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 23)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PC2"
"5PC3",,"X-RAY DIFFRACTION",3.59,65.7,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PC3",16.15,"1.8","1.8","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 24)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PC3"
"5PC4",,"X-RAY DIFFRACTION",3.56,65.49,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PC4",16.15,"1.86","1.86","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 25)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PC4"
"5PC5",,"X-RAY DIFFRACTION",3.53,65.16,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PC5",16.15,"1.85","1.85","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 26)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PC5"
"5PC6",,"X-RAY DIFFRACTION",3.66,66.38,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PC6",16.15,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 27)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PC6"
"5PC7",,"X-RAY DIFFRACTION",3.55,65.38,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PC7",16.15,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 28)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PC7"
"5PC8",,"X-RAY DIFFRACTION",3.62,66.03,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PC8",16.15,"1.85","1.85","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 29)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PC8"
"5PC9",,"X-RAY DIFFRACTION",3.51,65,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PC9",16.15,"1.76","1.76","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 30)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PC9"
"5PCA",,"X-RAY DIFFRACTION",3.54,65.28,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCA",16.15,"1.84","1.84","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 31)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCA"
"5PCB",,"X-RAY DIFFRACTION",3.59,65.71,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCB",16.15,"1.8","1.8","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 32)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCB"
"5PCC",,"X-RAY DIFFRACTION",3.6,65.81,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCC",16.15,"1.83","1.83","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 33)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCC"
"5PCD",,"X-RAY DIFFRACTION",3.58,65.6,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCD",16.15,"1.76","1.76","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 34)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCD"
"5PCE",,"X-RAY DIFFRACTION",3.55,65.32,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCE",16.15,"2.16","2.16","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 35)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCE"
"5PCF",,"X-RAY DIFFRACTION",3.55,65.35,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCF",16.15,"2.02","2.02","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 36)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCF"
"5PCG",,"X-RAY DIFFRACTION",3.62,66.06,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCG",16.15,"1.98","1.98","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 37)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCG"
"5PCH",,"X-RAY DIFFRACTION",3.6,65.83,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCH",16.15,"1.75","1.75","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 38)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCH"
"5PCI",,"X-RAY DIFFRACTION",3.53,65.11,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCI",16.15,"1.88","1.88","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 39)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCI"
"5PCJ",,"X-RAY DIFFRACTION",3.52,65.03,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCJ",16.15,"1.97","1.97","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 40)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCJ"
"5PCK",,"X-RAY DIFFRACTION",3.56,65.49,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCK",16.15,"1.75","1.75","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 41)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCK"
"5PCL",,"X-RAY DIFFRACTION",3.56,65.46,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCL",16.15,"2.19","2.19","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 42)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCL"
"5PCM",,"X-RAY DIFFRACTION",3.56,65.43,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCM",16.15,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 43)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCM"
"5PCN",,"X-RAY DIFFRACTION",3.56,65.5,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCN",16.15,"1.84","1.84","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 44)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCN"
"5PCO",,"X-RAY DIFFRACTION",3.57,65.5,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCO",16.15,"1.77","1.77","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 45)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCO"
"5PCP",,"X-RAY DIFFRACTION",3.62,66,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCP",16.15,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 46)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCP"
"5PCQ",,"X-RAY DIFFRACTION",3.64,66.21,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCQ",16.15,"2.29","2.29","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 47)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCQ"
"5PCR",,"X-RAY DIFFRACTION",3.57,65.58,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCR",16.15,"1.9","1.9","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 48)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCR"
"5PCS",,"X-RAY DIFFRACTION",3.61,65.9,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCS",16.15,"1.83","1.83","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 49)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCS"
"5PCT",,"X-RAY DIFFRACTION",3.61,65.89,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCT",16.15,"1.78","1.78","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 50)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCT"
"5PCU",,"X-RAY DIFFRACTION",3.54,65.24,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCU",16.15,"1.75","1.75","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 51)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCU"
"5PCV",,"X-RAY DIFFRACTION",3.59,65.71,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCV",16.15,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 52)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCV"
"5PCW",,"X-RAY DIFFRACTION",3.57,65.5,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCW",16.15,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 53)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCW"
"5PCX",,"X-RAY DIFFRACTION",3.61,65.89,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCX",16.15,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 54)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCX"
"5PCZ",,"X-RAY DIFFRACTION",3.58,65.61,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PCZ",16.15,"1.84","1.84","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 55)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PCZ"
"5PD0",,"X-RAY DIFFRACTION",3.54,65.21,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PD0",16.15,"1.84","1.84","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 56)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PD0"
"5PD1",,"X-RAY DIFFRACTION",3.55,65.35,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PD1",16.15,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 57)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PD1"
"5PD2",,"X-RAY DIFFRACTION",3.61,65.94,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PD2",16.15,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 58)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PD2"
"5PD3",,"X-RAY DIFFRACTION",3.56,65.45,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PD3",16.15,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 59)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PD3"
"5PD4",,"X-RAY DIFFRACTION",3.55,65.34,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PD4",16.15,"1.8","1.8","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 60)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PD4"
"5PD5",,"X-RAY DIFFRACTION",3.65,66.3,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PD5",16.15,"1.89","1.89","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 61)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PD5"
"5PD6",,"X-RAY DIFFRACTION",3.6,65.82,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PD6",16.15,"2.01","2.01","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 62)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PD6"
"5PD7",,"X-RAY DIFFRACTION",3.58,65.66,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PD7",16.15,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 63)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PD7"
"5PD8",,"X-RAY DIFFRACTION",3.56,65.42,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PD8",16.15,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 64)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PD8"
"5PD9",,"X-RAY DIFFRACTION",3.62,65.98,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PD9",16.15,"1.86","1.86","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 65)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PD9"
"5PDA",,"X-RAY DIFFRACTION",3.54,65.23,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDA",16.15,"1.77","1.77","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 66)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDA"
"5PDB",,"X-RAY DIFFRACTION",3.65,66.28,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDB",16.15,"1.8","1.8","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 67)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDB"
"5PDC",,"X-RAY DIFFRACTION",3.62,65.98,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDC",16.15,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 68)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDC"
"5PDD",,"X-RAY DIFFRACTION",3.58,65.64,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDD",16.15,"1.77","1.77","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 69)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDD"
"5PDE",,"X-RAY DIFFRACTION",3.63,66.09,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDE",16.15,"1.88","1.88","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 70)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDE"
"5PDF",,"X-RAY DIFFRACTION",3.61,65.89,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDF",16.15,"1.68","1.68","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 71)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDF"
"5PDG",,"X-RAY DIFFRACTION",3.55,65.31,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDG",16.15,"1.63","1.63","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 72)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDG"
"5PDH",,"X-RAY DIFFRACTION",3.61,65.94,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDH",16.15,"1.78","1.78","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 73)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDH"
"5PDI",,"X-RAY DIFFRACTION",3.62,66.04,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDI",16.15,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 74)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDI"
"5PDJ",,"X-RAY DIFFRACTION",3.59,65.74,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDJ",16.15,"1.84","1.84","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 76)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDJ"
"5PDK",,"X-RAY DIFFRACTION",3.59,65.74,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDK",16.15,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 77)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDK"
"5PDL",,"X-RAY DIFFRACTION",3.56,65.43,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDL",16.15,"1.8","1.8","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 78)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDL"
"5PDM",,"X-RAY DIFFRACTION",3.59,65.7,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDM",16.15,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 79)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDM"
"5PDN",,"X-RAY DIFFRACTION",3.58,65.68,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDN",16.15,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 80)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDN"
"5PDO",,"X-RAY DIFFRACTION",3.59,65.77,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDO",16.15,"1.78","1.78","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 81)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDO"
"5PDP",,"X-RAY DIFFRACTION",3.58,65.67,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDP",16.15,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 82)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDP"
"5PDQ",,"X-RAY DIFFRACTION",3.63,66.12,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDQ",16.15,"2.26","2.26","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 83)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDQ"
"5PDR",,"X-RAY DIFFRACTION",3.59,65.78,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDR",16.15,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 84)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDR"
"5PDS",,"X-RAY DIFFRACTION",3.62,66.03,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDS",16.15,"1.78","1.78","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 85)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDS"
"5PDT",,"X-RAY DIFFRACTION",3.63,66.09,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDT",16.15,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 86)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDT"
"5PDU",,"X-RAY DIFFRACTION",3.57,65.56,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDU",16.15,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 87)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDU"
"5PDV",,"X-RAY DIFFRACTION",3.56,65.41,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDV",16.15,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 88)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDV"
"5PDW",,"X-RAY DIFFRACTION",3.52,65.09,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDW",16.15,"1.88","1.88","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 89)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDW"
"5PDX",,"X-RAY DIFFRACTION",3.61,65.93,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDX",16.15,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 90)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDX"
"5PDY",,"X-RAY DIFFRACTION",3.57,65.58,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDY",16.15,"1.93","1.93","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 91)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDY"
"5PDZ",,"X-RAY DIFFRACTION",3.55,65.38,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PDZ",16.15,"1.9","1.9","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 92)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PDZ"
"5PE0",,"X-RAY DIFFRACTION",3.59,65.76,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PE0",16.15,"1.76","1.76","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 93)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PE0"
"5PE1",,"X-RAY DIFFRACTION",3.58,65.64,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PE1",16.15,"1.91","1.91","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 94)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PE1"
"5PE2",,"X-RAY DIFFRACTION",3.57,65.57,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PE2",16.15,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 95)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PE2"
"5PE3",,"X-RAY DIFFRACTION",3.59,65.69,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PE3",16.15,"1.76","1.76","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 96)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PE3"
"5PE4",,"X-RAY DIFFRACTION",3.61,65.9,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PE4",16.15,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 97)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PE4"
"5PE5",,"X-RAY DIFFRACTION",3.63,66.08,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PE5",16.15,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 98)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PE5"
"5PE6",,"X-RAY DIFFRACTION",3.56,65.44,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PE6",16.15,"1.67","1.67","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 99)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PE6"
"5PE7",,"X-RAY DIFFRACTION",3.51,64.94,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PE7",16.15,"1.81","1.81","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 100)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PE7"
"5PE8",,"X-RAY DIFFRACTION",3.56,65.48,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PE8",16.15,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 101)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PE8"
"5PE9",,"X-RAY DIFFRACTION",3.58,65.66,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PE9",16.15,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 102)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PE9"
"5PEA",,"X-RAY DIFFRACTION",3.63,66.07,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEA",16.15,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 103)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEA"
"5PEB",,"X-RAY DIFFRACTION",3.73,67,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEB",16.15,"2.11","2.11","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 104)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEB"
"5PEC",,"X-RAY DIFFRACTION",3.58,65.63,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEC",16.15,"1.85","1.85","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 105)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEC"
"5PED",,"X-RAY DIFFRACTION",3.57,65.51,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PED",16.15,"1.8","1.8","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 106)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PED"
"5PEE",,"X-RAY DIFFRACTION",3.6,65.79,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEE",16.15,"1.75","1.75","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 107)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEE"
"5PEF",,"X-RAY DIFFRACTION",3.61,65.97,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEF",16.15,"1.73","1.73","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 108)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEF"
"5PEG",,"X-RAY DIFFRACTION",3.63,66.09,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEG",16.15,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 109)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEG"
"5PEH",,"X-RAY DIFFRACTION",3.6,65.83,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEH",16.15,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 110)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEH"
"5PEI",,"X-RAY DIFFRACTION",3.6,65.87,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEI",16.15,"1.66","1.66","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 111)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEI"
"5PEJ",,"X-RAY DIFFRACTION",3.6,65.87,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEJ",16.15,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 112)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEJ"
"5PEK",,"X-RAY DIFFRACTION",3.59,65.74,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEK",16.15,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 113)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEK"
"5PEL",,"X-RAY DIFFRACTION",3.59,65.76,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEL",16.15,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 114)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEL"
"5PEM",,"X-RAY DIFFRACTION",3.54,65.25,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEM",16.15,"1.97","1.97","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 115)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEM"
"5PEN",,"X-RAY DIFFRACTION",3.57,65.56,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEN",16.15,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 116)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEN"
"5PEO",,"X-RAY DIFFRACTION",3.59,65.75,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEO",16.15,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 118)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEO"
"5PEQ",,"X-RAY DIFFRACTION",3.61,65.9,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEQ",16.15,"1.75","1.75","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 119)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEQ"
"5PER",,"X-RAY DIFFRACTION",3.56,65.43,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PER",16.15,"2","2","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 120)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PER"
"5PES",,"X-RAY DIFFRACTION",3.59,65.75,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PES",16.15,"1.8","1.8","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 121)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PES"
"5PET",,"X-RAY DIFFRACTION",3.62,66,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PET",16.15,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 122)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PET"
"5PEU",,"X-RAY DIFFRACTION",3.57,65.54,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEU",16.15,"1.9","1.9","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 123)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEU"
"5PEV",,"X-RAY DIFFRACTION",3.64,66.24,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEV",16.15,"1.81","1.81","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 124)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEV"
"5PEW",,"X-RAY DIFFRACTION",3.58,65.64,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEW",16.15,"1.77","1.77","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 125)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEW"
"5PEX",,"X-RAY DIFFRACTION",3.64,66.19,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEX",16.15,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 126)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEX"
"5PEY",,"X-RAY DIFFRACTION",3.61,65.93,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEY",16.15,"1.8","1.8","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 127)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEY"
"5PEZ",,"X-RAY DIFFRACTION",3.63,66.15,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PEZ",16.15,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 128)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PEZ"
"5PF0",,"X-RAY DIFFRACTION",3.59,65.78,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PF0",16.15,"1.95","1.95","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 129)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PF0"
"5PF1",,"X-RAY DIFFRACTION",3.67,66.52,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PF1",16.15,"1.78","1.78","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 130)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PF1"
"5PF2",,"X-RAY DIFFRACTION",3.62,66.05,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PF2",16.15,"1.89","1.89","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 131)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PF2"
"5PF3",,"X-RAY DIFFRACTION",3.64,66.19,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PF3",16.15,"1.83","1.83","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 132)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PF3"
"5PF4",,"X-RAY DIFFRACTION",3.56,65.42,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PF4",16.15,"2.01","2.01","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 133)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PF4"
"5PF5",,"X-RAY DIFFRACTION",3.63,66.14,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PF5",16.15,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 134)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PF5"
"5PF6",,"X-RAY DIFFRACTION",3.62,65.99,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PF6",16.15,"1.75","1.75","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 135)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PF6"
"5PF7",,"X-RAY DIFFRACTION",3.63,66.08,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PF7",16.15,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 136)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PF7"
"5PF8",,"X-RAY DIFFRACTION",3.6,65.81,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PF8",16.15,"1.78","1.78","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 137)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PF8"
"5PF9",,"X-RAY DIFFRACTION",3.59,65.7,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PF9",16.15,"1.91","1.91","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 138)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PF9"
"5PFA",,"X-RAY DIFFRACTION",3.62,65.98,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFA",16.15,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 139)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFA"
"5PFB",,"X-RAY DIFFRACTION",3.57,65.52,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFB",16.15,"1.8","1.8","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 140)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFB"
"5PFC",,"X-RAY DIFFRACTION",3.58,65.61,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFC",16.15,"1.75","1.75","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 141)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFC"
"5PFD",,"X-RAY DIFFRACTION",3.6,65.82,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFD",16.15,"1.88","1.88","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 142)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFD"
"5PFE",,"X-RAY DIFFRACTION",3.63,66.08,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFE",16.15,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 143)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFE"
"5PFF",,"X-RAY DIFFRACTION",3.6,65.8,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFF",16.15,"1.96","1.96","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 144)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFF"
"5PFG",,"X-RAY DIFFRACTION",3.59,65.74,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFG",16.15,"1.68","1.68","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 145)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFG"
"5PFH",,"X-RAY DIFFRACTION",3.58,65.64,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFH",16.15,"1.66","1.66","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 146)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFH"
"5PFI",,"X-RAY DIFFRACTION",3.64,66.16,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFI",16.15,"1.66","1.66","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 147)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFI"
"5PFJ",,"X-RAY DIFFRACTION",3.53,65.16,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFJ",16.15,"2.07","2.07","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 148)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFJ"
"5PFL",,"X-RAY DIFFRACTION",3.54,65.26,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFL",16.15,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 149)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFL"
"5PFM",,"X-RAY DIFFRACTION",3.57,65.54,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFM",16.15,"1.54","1.54","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 150)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFM"
"5PFN",,"X-RAY DIFFRACTION",3.56,65.45,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFN",16.15,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 151)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFN"
"5PFO",,"X-RAY DIFFRACTION",3.52,65.1,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFO",16.15,"1.82","1.82","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 152)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFO"
"5PFP",,"X-RAY DIFFRACTION",3.54,65.29,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFP",16.15,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 153)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFP"
"5PFQ",,"X-RAY DIFFRACTION",3.65,66.27,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFQ",16.15,"1.78","1.78","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 154)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFQ"
"5PFR",,"X-RAY DIFFRACTION",3.55,65.38,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFR",16.15,"1.89","1.89","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 155)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFR"
"5PFS",,"X-RAY DIFFRACTION",3.58,65.62,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFS",16.15,"2","2","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 156)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFS"
"5PFT",,"X-RAY DIFFRACTION",3.64,66.24,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFT",16.15,"2.02","2.02","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 157)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFT"
"5PFU",,"X-RAY DIFFRACTION",3.56,65.46,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFU",16.15,"1.75","1.75","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 158)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFU"
"5PFV",,"X-RAY DIFFRACTION",3.52,65.09,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFV",16.15,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 159)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFV"
"5PFW",,"X-RAY DIFFRACTION",3.55,65.32,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFW",16.15,"1.64","1.64","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 160)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFW"
"5PFX",,"X-RAY DIFFRACTION",3.62,66.05,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFX",16.15,"1.9","1.9","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 161)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFX"
"5PFY",,"X-RAY DIFFRACTION",3.59,65.72,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFY",16.15,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 162)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFY"
"5PFZ",,"X-RAY DIFFRACTION",3.6,65.82,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PFZ",16.15,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 163)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PFZ"
"5PG0",,"X-RAY DIFFRACTION",3.59,65.73,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PG0",16.15,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 164)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PG0"
"5PG1",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PG1",16.15,"1.49","1.49","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 165)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PG1"
"5PG2",,"X-RAY DIFFRACTION",3.61,65.88,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PG2",16.15,"1.68","1.68","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 166)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PG2"
"5PG3",,"X-RAY DIFFRACTION",3.58,65.6,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PG3",16.15,"1.66","1.66","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 167)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PG3"
"5PG4",,"X-RAY DIFFRACTION",3.59,65.73,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PG4",16.15,"2.49","2.49","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 168)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PG4"
"5PG5",,"X-RAY DIFFRACTION",3.59,65.71,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PG5",16.15,"1.75","1.75","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 169)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PG5"
"5PG6",,"X-RAY DIFFRACTION",3.59,65.74,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PG6",16.15,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 170)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PG6"
"5PG7",,"X-RAY DIFFRACTION",3.58,65.65,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PG7",16.15,"1.96","1.96","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 171)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PG7"
"5PG8",,"X-RAY DIFFRACTION",3.54,65.23,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PG8",16.15,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 172)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PG8"
"5PG9",,"X-RAY DIFFRACTION",3.59,65.7,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PG9",16.15,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 173)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PG9"
"5PGA",,"X-RAY DIFFRACTION",3.58,65.6,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGA",16.15,"1.59","1.59","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 174)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGA"
"5PGB",,"X-RAY DIFFRACTION",3.54,65.28,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGB",16.15,"1.57","1.57","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 175)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGB"
"5PGC",,"X-RAY DIFFRACTION",3.56,65.43,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGC",16.15,"1.61","1.61","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 176)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGC"
"5PGD",,"X-RAY DIFFRACTION",3.65,66.33,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGD",16.15,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 177)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGD"
"5PGE",,"X-RAY DIFFRACTION",3.54,65.29,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGE",16.15,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 178)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGE"
"5PGF",,"X-RAY DIFFRACTION",3.55,65.33,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGF",16.15,"1.82","1.82","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 179)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGF"
"5PGG",,"X-RAY DIFFRACTION",3.53,65.18,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGG",16.15,"1.68","1.68","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 180)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGG"
"5PGH",,"X-RAY DIFFRACTION",3.57,65.55,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGH",16.15,"1.93","1.93","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 181)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGH"
"5PGI",,"X-RAY DIFFRACTION",3.61,65.91,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGI",16.15,"1.88","1.88","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 182)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGI"
"5PGJ",,"X-RAY DIFFRACTION",3.57,65.57,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGJ",16.15,"1.58","1.58","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 183)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGJ"
"5PGK",,"X-RAY DIFFRACTION",3.56,65.41,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGK",16.15,"1.83","1.83","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 184)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGK"
"5PGL",,"X-RAY DIFFRACTION",3.5,64.88,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGL",16.15,"2.23","2.23","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 185)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGL"
"5PGN",,"X-RAY DIFFRACTION",3.56,65.49,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGN",16.15,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 186)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGN"
"5PGO",,"X-RAY DIFFRACTION",3.55,65.31,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGO",16.15,"1.88","1.88","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 187)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGO"
"5PGP",,"X-RAY DIFFRACTION",3.6,65.8,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGP",16.15,"1.76","1.76","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 188)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGP"
"5PGQ",,"X-RAY DIFFRACTION",3.56,65.47,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGQ",16.15,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 189)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGQ"
"5PGR",,"X-RAY DIFFRACTION",3.54,65.26,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGR",16.15,"2","2","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 190)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGR"
"5PGS",,"X-RAY DIFFRACTION",3.5,64.9,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGS",16.15,"1.64","1.64","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 191)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGS"
"5PGT",,"X-RAY DIFFRACTION",3.58,65.62,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG600 -- 0.1M MES pH 6.0",277,"10.1038/ncomms15123",,"5PGT",16.15,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of BAZ2B after initial refinement with no ligand modelled (structure 192)","MHHHHHHSSGVDLGTENLYFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5PGT"
"5PGU",,"X-RAY DIFFRACTION",2.34,47.34,"VAPOR DIFFUSION, HANGING DROP",7.3,"200 mM potassium formate, pH 7.3, 22% (W/V) PEG3350, 1.5 mM Zwittergent 3-12",277,"10.1021/acs.jmedchem.7b00211","8K4","5PGU",129.79,"2.35","2.35","CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 2-[2-(4-fluorophenyl)-2-adamantyl]-1-(3-methoxyazetidin-1-yl)ethanone","GSHMASMTGGQQMGRGSNEEFRPEMLQGKKVIVTGASKGIGREMAYHLAKMGAHVVVTARSKETLQKVVSHCLELGAASAHYIAGTMEDMTFAEQFVAQAGKLMGGLDMLILNHITNTSLNLFHDDIHHVRKSMEVNFLSYVVLTVAALPMLKQSNGSIVVVSSLAGKVAYPMVAAYSASKFALDGFFSSIRKEYSVSRVNVSITLCVLGLIDTETAMKAVSGIVHMQAAPKEECALEIIKGGALRQEEVYYDSSRWTTLLIRNPCRKILEELYSTSYNMDRFINK","Homo sapiens","HSD11B1, HSD11, HSD11L, SDR26C1","Corticosteroid 11-beta-dehydrogenase isozyme 1","1","5PGU"
"5PGV",,"X-RAY DIFFRACTION",2.23,44.76,"VAPOR DIFFUSION, HANGING DROP",7.3,"200 mM potassium formate, pH 7.3, 22% (W/V) PEG3350, 1.5 mM Zwittergent 3-12",277,"10.1021/acs.jmedchem.7b00211","8K7","5PGV",129.85,"2.35","2.35","CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 1-(3-HYDROXYAZETIDIN-1-YL)-2-[(2S,5R)-2-(4-FLUOROPHENYL)-5-METHOXYADAMANTAN-2-YL]ETHAN-1-ONE","GSHMASMTGGQQMGRGSNEEFRPEMLQGKKVIVTGASKGIGREMAYHLAKMGAHVVVTARSKETLQKVVSHCLELGAASAHYIAGTMEDMTFAEQFVAQAGKLMGGLDMLILNHITNTSLNLFHDDIHHVRKSMEVNFLSYVVLTVAALPMLKQSNGSIVVVSSLAGKVAYPMVAAYSASKFALDGFFSSIRKEYSVSRVNVSITLCVLGLIDTETAMKAVSGIVHMQAAPKEECALEIIKGGALRQEEVYYDSSRWTTLLIRNPCRKILEELYSTSYNMDRFINK","Homo sapiens","HSD11B1, HSD11, HSD11L, SDR26C1","Corticosteroid 11-beta-dehydrogenase isozyme 1","1","5PGV"
"5PGW",,"X-RAY DIFFRACTION",2.23,44.77,"VAPOR DIFFUSION, HANGING DROP",7.3,"200 mM potassium formate, pH 7.3, 22% (W/V) PEG3350, 1.5 mM Zwittergent 3-12",277,"10.1021/acs.jmedchem.7b00211","8KA","5PGW",130.1,"2.37","2.37","CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 2-[(1R,3S,5R,7S)-2-[4-(4-FLUOROPHENYL)PHENYL]-6-HYDROXYADAMANTAN-2-YL]-1-(3- HYDROXYAZETIDIN-1-YL)ETHAN-1-ONE","GSHMASMTGGQQMGRGSNEEFRPEMLQGKKVIVTGASKGIGREMAYHLAKMGAHVVVTARSKETLQKVVSHCLELGAASAHYIAGTMEDMTFAEQFVAQAGKLMGGLDMLILNHITNTSLNLFHDDIHHVRKSMEVNFLSYVVLTVAALPMLKQSNGSIVVVSSLAGKVAYPMVAAYSASKFALDGFFSSIRKEYSVSRVNVSITLCVLGLIDTETAMKAVSGIVHMQAAPKEECALEIIKGGALRQEEVYYDSSRWTTLLIRNPCRKILEELYSTSYNMDRFINK","Homo sapiens","HSD11B1, HSD11, HSD11L, SDR26C1","Corticosteroid 11-beta-dehydrogenase isozyme 1","1","5PGW"
"5PGX",,"X-RAY DIFFRACTION",2.34,47.4,"VAPOR DIFFUSION, HANGING DROP",7.3,"200 mM potassium formate, pH 7.3, 22% (W/V) PEG3350, 1.5 mM Zwittergent 3-12",277,"10.1021/acs.jmedchem.7b00211","8KD","5PGX",129.78,"2.5","2.5","CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 2-(2-BENZYL-6-HYDROXYADAMANTAN-2-YL)-1-(3-HYDROXYAZETIDIN-1-YL)ETHAN-1-ONE","GSHMASMTGGQQMGRGSNEEFRPEMLQGKKVIVTGASKGIGREMAYHLAKMGAHVVVTARSKETLQKVVSHCLELGAASAHYIAGTMEDMTFAEQFVAQAGKLMGGLDMLILNHITNTSLNLFHDDIHHVRKSMEVNFLSYVVLTVAALPMLKQSNGSIVVVSSLAGKVAYPMVAAYSASKFALDGFFSSIRKEYSVSRVNVSITLCVLGLIDTETAMKAVSGIVHMQAAPKEECALEIIKGGALRQEEVYYDSSRWTTLLIRNPCRKILEELYSTSYNMDRFINK","Homo sapiens","HSD11B1, HSD11, HSD11L, SDR26C1","Corticosteroid 11-beta-dehydrogenase isozyme 1","1","5PGX"
"5PGY",,"X-RAY DIFFRACTION",2.23,44.76,"VAPOR DIFFUSION, HANGING DROP",7.3,"200 mM potassium formate, pH 7.3, 22% (W/V) PEG3350, 1.5 mM Zwittergent 3-12",277,"10.1021/acs.jmedchem.7b00211","8KG","5PGY",129.72,"2.07","2.07","CRYSTAL STRUCTURE OF 11BETA-HSD1 DOUBLE MUTANT (L262R, F278E) COMPLEXED WITH 2-[(5R,7S)-6-HYDROXY-2-PHENYLADAMANTAN-2-YL]-1-(3-HYDROXYAZETIDIN-1-YL)ETHAN-1-ONE (BMS-816336)","GSHMASMTGGQQMGRGSNEEFRPEMLQGKKVIVTGASKGIGREMAYHLAKMGAHVVVTARSKETLQKVVSHCLELGAASAHYIAGTMEDMTFAEQFVAQAGKLMGGLDMLILNHITNTSLNLFHDDIHHVRKSMEVNFLSYVVLTVAALPMLKQSNGSIVVVSSLAGKVAYPMVAAYSASKFALDGFFSSIRKEYSVSRVNVSITLCVLGLIDTETAMKAVSGIVHMQAAPKEECALEIIKGGALRQEEVYYDSSRWTTLLIRNPCRKILEELYSTSYNMDRFINK","Homo sapiens","HSD11B1, HSD11, HSD11L, SDR26C1","Corticosteroid 11-beta-dehydrogenase isozyme 1","1","5PGY"
"5PH0",,"X-RAY DIFFRACTION",2.28,46.09,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PH0",43.43,"1.341","1.341","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09484a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PH0"
"5PH1",,"X-RAY DIFFRACTION",2.27,45.79,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PH1",43.31,"1.249","1.249","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09449a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PH1"
"5PH2",,"X-RAY DIFFRACTION",2.26,45.6,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PH2",43.21,"1.454","1.454","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09597a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PH2"
"5PH3",,"X-RAY DIFFRACTION",2.27,45.7,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PH3",43.35,"1.24","1.24","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09575a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PH3"
"5PH4",,"X-RAY DIFFRACTION",2.29,46.19,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PH4",43.28,"1.269","1.269","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09597a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PH4"
"5PH5",,"X-RAY DIFFRACTION",2.27,45.88,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PH5",43.29,"1.349","1.349","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09724a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PH5"
"5PH6",,"X-RAY DIFFRACTION",2.26,45.64,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PH6",43.4,"1.742","1.742","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09736a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PH6"
"5PH7",,"X-RAY DIFFRACTION",2.26,45.58,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PH7",43.3,"1.431","1.431","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09504a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PH7"
"5PH8",,"X-RAY DIFFRACTION",2.26,45.64,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PH8",43.39,"1.396","1.396","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09552a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PH8"
"5PH9",,"X-RAY DIFFRACTION",2.27,45.85,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PH9",43.37,"1.48","1.48","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09701a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PH9"
"5PHA",,"X-RAY DIFFRACTION",2.26,45.46,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHA",43.52,"1.45","1.45","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09398a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHA"
"5PHB",,"X-RAY DIFFRACTION",2.28,46.09,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHB",43.52,"1.338","1.338","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09447a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHB"
"5PHC",,"X-RAY DIFFRACTION",2.3,46.54,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHC",43.39,"1.29","1.29","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09649a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHC"
"5PHD",,"X-RAY DIFFRACTION",2.28,46.12,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHD",43.73,"1.359","1.359","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09419a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHD"
"5PHE",,"X-RAY DIFFRACTION",2.29,46.21,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHE",43.41,"1.351","1.351","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09453a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHE"
"5PHF",,"X-RAY DIFFRACTION",2.3,46.44,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHF",43.72,"1.389","1.389","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09688a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHF"
"5PHG",,"X-RAY DIFFRACTION",2.29,46.34,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHG",43.37,"1.398","1.398","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09689a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHG"
"5PHH",,"X-RAY DIFFRACTION",2.28,46.15,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHH",43.23,"1.604","1.604","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09457a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHH"
"5PHI",,"X-RAY DIFFRACTION",2.29,46.37,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHI",43.37,"1.971","1.971","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09480a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHI"
"5PHJ",,"X-RAY DIFFRACTION",2.3,46.62,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHJ",43.34,"1.15","1.15","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09400a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHJ"
"5PHK",,"X-RAY DIFFRACTION",2.29,46.36,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHK",43.32,"1.25","1.25","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09720a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHK"
"5PHL",,"X-RAY DIFFRACTION",2.29,46.21,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHL",43.45,"1.141","1.141","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09506a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHL"
"5PHM",,"X-RAY DIFFRACTION",2.29,46.21,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHM",43.95,"1.398","1.398","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09455a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHM"
"5PHN",,"X-RAY DIFFRACTION",2.3,46.53,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHN",43.47,"1.29","1.29","PanDDA analysis group deposition -- Crystal Structure of JMJD2D in complex with N09522a","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHN"
"5PHO",,"X-RAY DIFFRACTION",2.31,46.84,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHO",43.13,"1.4","1.4","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 1)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHO"
"5PHP",,"X-RAY DIFFRACTION",2.25,45.24,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHP",43.13,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 2)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHP"
"5PHQ",,"X-RAY DIFFRACTION",2.3,46.47,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHQ",43.13,"2.23","2.23","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 3)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHQ"
"5PHR",,"X-RAY DIFFRACTION",2.29,46.23,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHR",43.13,"1.66","1.66","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 4)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHR"
"5PHS",,"X-RAY DIFFRACTION",2.26,45.66,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHS",43.13,"2.54","2.54","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 5)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHS"
"5PHT",,"X-RAY DIFFRACTION",2.27,45.8,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHT",43.13,"1.83","1.83","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 6)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHT"
"5PHU",,"X-RAY DIFFRACTION",2.27,45.83,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHU",43.13,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 7)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHU"
"5PHV",,"X-RAY DIFFRACTION",2.29,46.19,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHV",43.13,"1.83","1.83","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 8)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHV"
"5PHW",,"X-RAY DIFFRACTION",2.27,45.87,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHW",43.13,"1.31","1.31","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 9)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHW"
"5PHX",,"X-RAY DIFFRACTION",2.28,45.98,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHX",43.13,"1.27","1.27","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 10)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHX"
"5PHY",,"X-RAY DIFFRACTION",2.28,46.15,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHY",43.13,"1.34","1.34","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 11)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHY"
"5PHZ",,"X-RAY DIFFRACTION",2.28,46.02,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PHZ",43.13,"1.47","1.47","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 12)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PHZ"
"5PI0",,"X-RAY DIFFRACTION",2.27,45.87,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PI0",43.13,"1.5","1.5","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 13)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PI0"
"5PI1",,"X-RAY DIFFRACTION",2.29,46.31,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PI1",43.13,"1.34","1.34","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 14)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PI1"
"5PI2",,"X-RAY DIFFRACTION",2.23,44.96,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PI2",43.13,"1.52","1.52","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 15)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PI2"
"5PI3",,"X-RAY DIFFRACTION",2.28,46.04,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PI3",43.13,"1.29","1.29","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 16)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PI3"
"5PI4",,"X-RAY DIFFRACTION",2.26,45.48,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PI4",43.13,"1.35","1.35","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 17)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PI4"
"5PI5",,"X-RAY DIFFRACTION",2.27,45.93,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PI5",43.13,"1.42","1.42","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 18)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PI5"
"5PI6",,"X-RAY DIFFRACTION",2.29,46.38,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PI6",43.13,"1.29","1.29","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 19)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PI6"
"5PI7",,"X-RAY DIFFRACTION",2.25,45.36,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PI7",43.13,"1.61","1.61","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 20)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PI7"
"5PI8",,"X-RAY DIFFRACTION",2.28,46.14,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PI8",43.13,"1.27","1.27","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 21)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PI8"
"5PI9",,"X-RAY DIFFRACTION",2.25,45.36,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PI9",43.13,"1.45","1.45","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 22)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PI9"
"5PIA",,"X-RAY DIFFRACTION",2.27,45.86,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIA",43.13,"1.18","1.18","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 23)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIA"
"5PIB",,"X-RAY DIFFRACTION",2.24,45.11,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIB",43.13,"1.64","1.64","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 24)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIB"
"5PIC",,"X-RAY DIFFRACTION",2.26,45.51,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIC",43.13,"1.29","1.29","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 25)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIC"
"5PID",,"X-RAY DIFFRACTION",2.27,45.9,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PID",43.13,"1.5","1.5","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 26)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PID"
"5PIE",,"X-RAY DIFFRACTION",2.27,45.78,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIE",43.13,"1.42","1.42","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 27)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIE"
"5PIF",,"X-RAY DIFFRACTION",2.28,46.03,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIF",43.13,"1.37","1.37","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 28)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIF"
"5PIG",,"X-RAY DIFFRACTION",2.29,46.19,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIG",43.13,"1.44","1.44","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 29)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIG"
"5PIH",,"X-RAY DIFFRACTION",2.24,45.12,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIH",43.13,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 30)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIH"
"5PII",,"X-RAY DIFFRACTION",2.27,45.81,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PII",43.13,"1.45","1.45","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 31)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PII"
"5PIJ",,"X-RAY DIFFRACTION",2.28,46.09,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIJ",43.13,"1.45","1.45","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 32)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIJ"
"5PIK",,"X-RAY DIFFRACTION",2.29,46.22,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIK",43.13,"1.8","1.8","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 33)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIK"
"5PIL",,"X-RAY DIFFRACTION",2.29,46.26,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIL",43.13,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 34)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIL"
"5PIM",,"X-RAY DIFFRACTION",2.28,46.16,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIM",43.13,"1.25","1.25","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 35)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIM"
"5PIN",,"X-RAY DIFFRACTION",2.28,46.04,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIN",43.13,"1.5","1.5","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 36)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIN"
"5PIO",,"X-RAY DIFFRACTION",2.29,46.24,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIO",43.13,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 37)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIO"
"5PIP",,"X-RAY DIFFRACTION",2.26,45.6,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIP",43.13,"1.42","1.42","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 38)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIP"
"5PIQ",,"X-RAY DIFFRACTION",2.28,45.94,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIQ",43.13,"1.5","1.5","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 39)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIQ"
"5PIR",,"X-RAY DIFFRACTION",2.26,45.65,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIR",43.13,"1.45","1.45","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 40)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIR"
"5PIS",,"X-RAY DIFFRACTION",2.27,45.9,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIS",43.13,"1.3","1.3","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 41)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIS"
"5PIT",,"X-RAY DIFFRACTION",2.24,45.19,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIT",43.13,"1.79","1.79","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 42)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIT"
"5PIU",,"X-RAY DIFFRACTION",2.26,45.67,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIU",43.13,"1.48","1.48","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 43)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIU"
"5PIV",,"X-RAY DIFFRACTION",2.26,45.63,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIV",43.13,"1.43","1.43","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 44)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIV"
"5PIW",,"X-RAY DIFFRACTION",2.26,45.61,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIW",43.13,"1.23","1.23","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 45)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIW"
"5PIX",,"X-RAY DIFFRACTION",2.28,46.05,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIX",43.13,"1.35","1.35","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 46)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIX"
"5PIY",,"X-RAY DIFFRACTION",2.26,45.59,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIY",43.13,"1.31","1.31","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 47)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIY"
"5PIZ",,"X-RAY DIFFRACTION",2.26,45.49,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PIZ",43.13,"1.38","1.38","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 48)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PIZ"
"5PJ0",,"X-RAY DIFFRACTION",2.28,45.94,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJ0",43.13,"1.31","1.31","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 49)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJ0"
"5PJ1",,"X-RAY DIFFRACTION",2.29,46.26,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJ1",43.13,"1.35","1.35","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 50)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJ1"
"5PJ2",,"X-RAY DIFFRACTION",2.27,45.8,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJ2",43.13,"1.44","1.44","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 51)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJ2"
"5PJ3",,"X-RAY DIFFRACTION",2.27,45.87,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJ3",43.13,"1.3","1.3","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 52)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJ3"
"5PJ4",,"X-RAY DIFFRACTION",2.28,45.95,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJ4",43.13,"1.52","1.52","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 53)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJ4"
"5PJ5",,"X-RAY DIFFRACTION",2.26,45.66,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJ5",43.13,"1.24","1.24","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 54)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJ5"
"5PJ6",,"X-RAY DIFFRACTION",2.26,45.69,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJ6",43.13,"1.35","1.35","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 55)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJ6"
"5PJ7",,"X-RAY DIFFRACTION",2.27,45.82,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJ7",43.13,"1.39","1.39","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 56)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJ7"
"5PJ8",,"X-RAY DIFFRACTION",2.27,45.83,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJ8",43.13,"1.4","1.4","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 57)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJ8"
"5PJ9",,"X-RAY DIFFRACTION",2.25,45.43,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJ9",43.13,"1.5","1.5","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 58)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJ9"
"5PJA",,"X-RAY DIFFRACTION",2.24,45.07,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJA",43.13,"1.89","1.89","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 59)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJA"
"5PJB",,"X-RAY DIFFRACTION",2.26,45.58,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJB",43.13,"1.58","1.58","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 60)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJB"
"5PJC",,"X-RAY DIFFRACTION",2.27,45.78,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJC",43.13,"1.4","1.4","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 61)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJC"
"5PJD",,"X-RAY DIFFRACTION",2.26,45.6,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJD",43.13,"1.43","1.43","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 62)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJD"
"5PJE",,"X-RAY DIFFRACTION",2.25,45.45,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJE",43.13,"1.37","1.37","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 63)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJE"
"5PJF",,"X-RAY DIFFRACTION",2.26,45.56,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJF",43.13,"1.47","1.47","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 64)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJF"
"5PJG",,"X-RAY DIFFRACTION",2.27,45.78,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJG",43.13,"1.4","1.4","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 65)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJG"
"5PJH",,"X-RAY DIFFRACTION",2.26,45.56,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJH",43.13,"1.18","1.18","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 66)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJH"
"5PJI",,"X-RAY DIFFRACTION",2.26,45.49,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJI",43.13,"1.34","1.34","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 67)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJI"
"5PJJ",,"X-RAY DIFFRACTION",2.28,45.95,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJJ",43.13,"1.67","1.67","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 68)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJJ"
"5PJK",,"X-RAY DIFFRACTION",2.24,45.07,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJK",43.13,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 69)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJK"
"5PJL",,"X-RAY DIFFRACTION",2.25,45.41,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJL",43.13,"1.52","1.52","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 70)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJL"
"5PJM",,"X-RAY DIFFRACTION",2.26,45.68,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJM",43.13,"1.43","1.43","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 71)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJM"
"5PJN",,"X-RAY DIFFRACTION",2.26,45.47,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJN",43.13,"1.48","1.48","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 72)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJN"
"5PJO",,"X-RAY DIFFRACTION",2.28,46.07,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJO",43.13,"1.35","1.35","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 73)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJO"
"5PJP",,"X-RAY DIFFRACTION",2.27,45.73,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJP",43.13,"1.39","1.39","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 74)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJP"
"5PJQ",,"X-RAY DIFFRACTION",2.25,45.44,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJQ",43.13,"1.38","1.38","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 75)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJQ"
"5PJR",,"X-RAY DIFFRACTION",2.25,45.3,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJR",43.13,"1.29","1.29","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 76)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJR"
"5PJS",,"X-RAY DIFFRACTION",2.24,45.03,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJS",43.13,"1.64","1.64","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 77)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJS"
"5PJT",,"X-RAY DIFFRACTION",2.27,45.84,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJT",43.13,"1.54","1.54","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 78)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJT"
"5PJU",,"X-RAY DIFFRACTION",2.27,45.81,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJU",43.13,"1.27","1.27","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 79)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJU"
"5PJV",,"X-RAY DIFFRACTION",2.29,46.26,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJV",43.13,"1.34","1.34","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 80)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJV"
"5PJW",,"X-RAY DIFFRACTION",2.25,45.38,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJW",43.13,"1.56","1.56","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 81)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJW"
"5PJX",,"X-RAY DIFFRACTION",2.28,46.12,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJX",43.13,"1.35","1.35","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 82)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJX"
"5PJY",,"X-RAY DIFFRACTION",2.28,46.05,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJY",43.13,"1.34","1.34","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 83)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJY"
"5PJZ",,"X-RAY DIFFRACTION",2.27,45.84,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PJZ",43.13,"1.29","1.29","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 84)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PJZ"
"5PK0",,"X-RAY DIFFRACTION",2.27,45.79,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PK0",43.13,"1.28","1.28","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 85)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PK0"
"5PK1",,"X-RAY DIFFRACTION",2.26,45.63,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PK1",43.13,"1.35","1.35","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 86)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PK1"
"5PK2",,"X-RAY DIFFRACTION",2.26,45.6,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PK2",43.13,"1.42","1.42","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 87)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PK2"
"5PK3",,"X-RAY DIFFRACTION",2.27,45.77,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PK3",43.13,"1.42","1.42","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 88)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PK3"
"5PK4",,"X-RAY DIFFRACTION",2.3,46.53,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PK4",43.13,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 89)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PK4"
"5PK5",,"X-RAY DIFFRACTION",2.28,45.99,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PK5",43.13,"1.39","1.39","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 90)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PK5"
"5PK6",,"X-RAY DIFFRACTION",2.27,45.76,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PK6",43.13,"2.38","2.38","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 91)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PK6"
"5PK7",,"X-RAY DIFFRACTION",2.29,46.25,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PK7",43.13,"1.29","1.29","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 92)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PK7"
"5PK8",,"X-RAY DIFFRACTION",2.27,45.82,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PK8",43.13,"1.44","1.44","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 93)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PK8"
"5PK9",,"X-RAY DIFFRACTION",2.28,46.11,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PK9",43.13,"1.34","1.34","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 94)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PK9"
"5PKA",,"X-RAY DIFFRACTION",2.28,46.03,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKA",43.13,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 95)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKA"
"5PKB",,"X-RAY DIFFRACTION",2.25,45.43,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKB",43.13,"1.4","1.4","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 96)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKB"
"5PKC",,"X-RAY DIFFRACTION",2.28,46.05,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKC",43.13,"1.29","1.29","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 97)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKC"
"5PKD",,"X-RAY DIFFRACTION",2.27,45.87,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKD",43.13,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 98)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKD"
"5PKE",,"X-RAY DIFFRACTION",2.27,45.87,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKE",43.13,"1.44","1.44","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 99)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKE"
"5PKF",,"X-RAY DIFFRACTION",2.27,45.86,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKF",43.13,"1.34","1.34","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 100)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKF"
"5PKG",,"X-RAY DIFFRACTION",2.29,46.29,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKG",43.13,"1.54","1.54","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 101)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKG"
"5PKH",,"X-RAY DIFFRACTION",2.28,46.05,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKH",43.13,"1.19","1.19","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 102)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKH"
"5PKI",,"X-RAY DIFFRACTION",2.28,46.1,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKI",43.13,"1.19","1.19","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 103)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKI"
"5PKJ",,"X-RAY DIFFRACTION",2.27,45.93,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKJ",43.13,"1.22","1.22","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 104)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKJ"
"5PKK",,"X-RAY DIFFRACTION",2.26,45.62,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKK",43.13,"1.5","1.5","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 105)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKK"
"5PKL",,"X-RAY DIFFRACTION",2.3,46.41,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKL",43.13,"1.35","1.35","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 106)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKL"
"5PKM",,"X-RAY DIFFRACTION",2.27,45.76,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKM",43.13,"1.37","1.37","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 107)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKM"
"5PKN",,"X-RAY DIFFRACTION",2.28,46.16,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKN",43.13,"1.3","1.3","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 108)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKN"
"5PKO",,"X-RAY DIFFRACTION",2.23,44.84,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKO",43.13,"2.38","2.38","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 109)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKO"
"5PKP",,"X-RAY DIFFRACTION",2.28,46.02,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKP",43.13,"1.3","1.3","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 110)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKP"
"5PKQ",,"X-RAY DIFFRACTION",2.29,46.39,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKQ",43.13,"1.28","1.28","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 111)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKQ"
"5PKR",,"X-RAY DIFFRACTION",2.27,45.84,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKR",43.13,"1.31","1.31","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 112)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKR"
"5PKS",,"X-RAY DIFFRACTION",2.29,46.37,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKS",43.13,"1.5","1.5","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 113)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKS"
"5PKT",,"X-RAY DIFFRACTION",2.27,45.84,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKT",43.13,"1.5","1.5","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 114)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKT"
"5PKU",,"X-RAY DIFFRACTION",2.27,45.75,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKU",43.13,"1.47","1.47","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 115)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKU"
"5PKV",,"X-RAY DIFFRACTION",2.31,46.69,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKV",43.13,"1.35","1.35","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 116)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKV"
"5PKW",,"X-RAY DIFFRACTION",2.26,45.66,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKW",43.13,"1.35","1.35","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 117)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKW"
"5PKX",,"X-RAY DIFFRACTION",2.27,45.81,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKX",43.13,"1.45","1.45","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 118)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKX"
"5PKY",,"X-RAY DIFFRACTION",2.28,46.02,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKY",43.13,"1.25","1.25","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 119)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKY"
"5PKZ",,"X-RAY DIFFRACTION",2.27,45.82,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PKZ",43.13,"1.5","1.5","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 120)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PKZ"
"5PL0",,"X-RAY DIFFRACTION",2.27,45.85,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PL0",43.13,"1.27","1.27","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 121)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PL0"
"5PL1",,"X-RAY DIFFRACTION",2.27,45.83,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PL1",43.13,"1.42","1.42","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 122)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PL1"
"5PL2",,"X-RAY DIFFRACTION",2.27,45.84,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PL2",43.13,"1.34","1.34","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 123)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PL2"
"5PL3",,"X-RAY DIFFRACTION",2.27,45.75,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PL3",43.13,"1.27","1.27","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 124)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PL3"
"5PL4",,"X-RAY DIFFRACTION",2.29,46.25,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PL4",43.13,"1.21","1.21","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 125)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PL4"
"5PL5",,"X-RAY DIFFRACTION",2.27,45.82,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PL5",43.13,"1.57","1.57","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 126)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PL5"
"5PL6",,"X-RAY DIFFRACTION",2.27,45.89,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PL6",43.13,"1.29","1.29","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 127)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PL6"
"5PL7",,"X-RAY DIFFRACTION",2.3,46.48,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PL7",43.13,"1.3","1.3","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 128)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PL7"
"5PL8",,"X-RAY DIFFRACTION",2.29,46.24,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PL8",43.13,"1.54","1.54","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 129)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PL8"
"5PL9",,"X-RAY DIFFRACTION",2.27,45.83,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PL9",43.13,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 130)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PL9"
"5PLA",,"X-RAY DIFFRACTION",2.27,45.87,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLA",43.13,"1.37","1.37","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 131)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLA"
"5PLB",,"X-RAY DIFFRACTION",2.3,46.56,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLB",43.13,"1.49","1.49","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 132)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLB"
"5PLC",,"X-RAY DIFFRACTION",2.29,46.34,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLC",43.13,"1.49","1.49","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 133)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLC"
"5PLD",,"X-RAY DIFFRACTION",2.29,46.24,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLD",43.13,"1.46","1.46","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 134)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLD"
"5PLE",,"X-RAY DIFFRACTION",2.28,46.09,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLE",43.13,"1.45","1.45","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 135)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLE"
"5PLF",,"X-RAY DIFFRACTION",2.3,46.52,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLF",43.13,"1.33","1.33","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 136)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLF"
"5PLG",,"X-RAY DIFFRACTION",2.29,46.25,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLG",43.13,"1.31","1.31","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 137)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLG"
"5PLH",,"X-RAY DIFFRACTION",2.28,46.03,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLH",43.13,"1.46","1.46","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 138)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLH"
"5PLI",,"X-RAY DIFFRACTION",2.29,46.37,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLI",43.13,"1.39","1.39","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 139)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLI"
"5PLJ",,"X-RAY DIFFRACTION",2.29,46.2,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLJ",43.13,"1.49","1.49","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 140)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLJ"
"5PLK",,"X-RAY DIFFRACTION",2.29,46.38,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLK",43.13,"1.14","1.14","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 141)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLK"
"5PLL",,"X-RAY DIFFRACTION",2.3,46.49,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLL",43.13,"1.28","1.28","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 142)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLL"
"5PLM",,"X-RAY DIFFRACTION",2.29,46.35,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLM",43.13,"1.14","1.14","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 143)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLM"
"5PLN",,"X-RAY DIFFRACTION",2.29,46.3,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLN",43.13,"1.14","1.14","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 144)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLN"
"5PLO",,"X-RAY DIFFRACTION",2.29,46.25,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLO",43.13,"1.14","1.14","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 145)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLO"
"5PLP",,"X-RAY DIFFRACTION",2.3,46.51,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLP",43.13,"1.46","1.46","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 146)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLP"
"5PLQ",,"X-RAY DIFFRACTION",2.31,46.65,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLQ",43.13,"1.36","1.36","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 147)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLQ"
"5PLR",,"X-RAY DIFFRACTION",2.28,46.16,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLR",43.13,"1.53","1.53","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 148)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLR"
"5PLS",,"X-RAY DIFFRACTION",2.28,46.14,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLS",43.13,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 149)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLS"
"5PLT",,"X-RAY DIFFRACTION",2.28,45.96,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLT",43.13,"1.53","1.53","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 150)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLT"
"5PLU",,"X-RAY DIFFRACTION",2.28,46.13,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLU",43.13,"1.47","1.47","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 151)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLU"
"5PLV",,"X-RAY DIFFRACTION",2.3,46.47,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLV",43.13,"1.14","1.14","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 152)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLV"
"5PLW",,"X-RAY DIFFRACTION",2.31,46.82,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLW",43.13,"1.31","1.31","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 153)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLW"
"5PLX",,"X-RAY DIFFRACTION",2.33,47.15,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLX",43.13,"1.29","1.29","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 155)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLX"
"5PLY",,"X-RAY DIFFRACTION",2.28,46.12,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLY",43.13,"1.38","1.38","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 156)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLY"
"5PLZ",,"X-RAY DIFFRACTION",2.28,46.11,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PLZ",43.13,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 157)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PLZ"
"5PM0",,"X-RAY DIFFRACTION",2.29,46.27,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PM0",43.13,"2.14","2.14","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 158)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PM0"
"5PM1",,"X-RAY DIFFRACTION",2.3,46.62,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PM1",43.13,"1.54","1.54","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 159)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PM1"
"5PM2",,"X-RAY DIFFRACTION",2.3,46.5,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PM2",43.13,"1.52","1.52","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 160)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PM2"
"5PM3",,"X-RAY DIFFRACTION",2.3,46.41,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PM3",43.13,"1.46","1.46","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 161)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PM3"
"5PM4",,"X-RAY DIFFRACTION",2.32,46.91,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PM4",43.13,"1.44","1.44","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 162)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PM4"
"5PM5",,"X-RAY DIFFRACTION",2.26,45.69,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PM5",43.13,"1.76","1.76","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 163)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PM5"
"5PM6",,"X-RAY DIFFRACTION",2.31,46.81,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PM6",43.13,"1.78","1.78","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 164)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PM6"
"5PM7",,"X-RAY DIFFRACTION",2.28,46.01,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PM7",43.13,"1.43","1.43","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 165)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PM7"
"5PM8",,"X-RAY DIFFRACTION",2.3,46.44,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PM8",43.13,"1.54","1.54","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 166)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PM8"
"5PM9",,"X-RAY DIFFRACTION",2.29,46.23,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PM9",43.13,"1.5","1.5","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 167)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PM9"
"5PMA",,"X-RAY DIFFRACTION",2.32,46.91,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMA",43.13,"1.29","1.29","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 168)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMA"
"5PMB",,"X-RAY DIFFRACTION",2.31,46.83,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMB",43.13,"1.63","1.63","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 169)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMB"
"5PMC",,"X-RAY DIFFRACTION",2.29,46.36,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMC",43.13,"1.58","1.58","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 170)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMC"
"5PMD",,"X-RAY DIFFRACTION",2.32,46.9,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMD",43.13,"1.63","1.63","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 171)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMD"
"5PME",,"X-RAY DIFFRACTION",2.32,46.91,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PME",43.13,"1.39","1.39","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 172)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PME"
"5PMF",,"X-RAY DIFFRACTION",2.29,46.24,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMF",43.13,"1.36","1.36","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 173)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMF"
"5PMG",,"X-RAY DIFFRACTION",2.27,45.93,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMG",43.13,"1.51","1.51","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 174)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMG"
"5PMH",,"X-RAY DIFFRACTION",2.29,46.25,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMH",43.13,"1.52","1.52","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 175)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMH"
"5PMI",,"X-RAY DIFFRACTION",2.29,46.37,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMI",43.13,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 176)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMI"
"5PMJ",,"X-RAY DIFFRACTION",2.3,46.58,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMJ",43.13,"1.37","1.37","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 177)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMJ"
"5PMK",,"X-RAY DIFFRACTION",2.29,46.33,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMK",43.13,"1.44","1.44","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 178)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMK"
"5PML",,"X-RAY DIFFRACTION",2.28,45.96,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PML",43.13,"1.58","1.58","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 179)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PML"
"5PMM",,"X-RAY DIFFRACTION",2.3,46.47,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMM",43.13,"1.39","1.39","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 180)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMM"
"5PMN",,"X-RAY DIFFRACTION",2.3,46.42,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMN",43.13,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 181)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMN"
"5PMO",,"X-RAY DIFFRACTION",2.3,46.64,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMO",43.13,"1.53","1.53","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 182)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMO"
"5PMP",,"X-RAY DIFFRACTION",2.3,46.47,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMP",43.13,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 183)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMP"
"5PMQ",,"X-RAY DIFFRACTION",2.3,46.48,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMQ",43.13,"1.46","1.46","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 184)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMQ"
"5PMR",,"X-RAY DIFFRACTION",2.32,47.05,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMR",43.13,"1.51","1.51","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 185)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMR"
"5PMS",,"X-RAY DIFFRACTION",2.31,46.65,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMS",43.13,"1.24","1.24","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 186)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMS"
"5PMT",,"X-RAY DIFFRACTION",2.31,46.81,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMT",43.13,"1.22","1.22","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 187)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMT"
"5PMU",,"X-RAY DIFFRACTION",2.28,46.17,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMU",43.13,"1.48","1.48","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 188)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMU"
"5PMV",,"X-RAY DIFFRACTION",2.3,46.51,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMV",43.13,"1.34","1.34","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 189)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMV"
"5PMW",,"X-RAY DIFFRACTION",2.31,46.72,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMW",43.13,"1.19","1.19","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 190)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMW"
"5PMX",,"X-RAY DIFFRACTION",2.3,46.63,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMX",43.13,"1.14","1.14","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 191)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMX"
"5PMY",,"X-RAY DIFFRACTION",2.29,46.19,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMY",43.13,"1.29","1.29","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 192)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMY"
"5PMZ",,"X-RAY DIFFRACTION",2.29,46.3,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PMZ",43.13,"1.15","1.15","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 193)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PMZ"
"5PN0",,"X-RAY DIFFRACTION",2.28,46.14,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PN0",43.13,"1.14","1.14","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 194)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PN0"
"5PN1",,"X-RAY DIFFRACTION",2.3,46.47,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PN1",43.13,"1.41","1.41","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 195)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PN1"
"5PN2",,"X-RAY DIFFRACTION",2.3,46.53,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PN2",43.13,"1.41","1.41","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 196)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PN2"
"5PN3",,"X-RAY DIFFRACTION",2.3,46.51,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PN3",43.13,"1.6","1.6","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 197)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PN3"
"5PN4",,"X-RAY DIFFRACTION",2.3,46.43,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PN4",43.13,"1.37","1.37","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 198)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PN4"
"5PN5",,"X-RAY DIFFRACTION",2.3,46.61,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PN5",43.13,"1.3","1.3","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 199)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PN5"
"5PN6",,"X-RAY DIFFRACTION",2.3,46.47,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PN6",43.13,"1.42","1.42","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 200)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PN6"
"5PN7",,"X-RAY DIFFRACTION",2.32,46.96,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PN7",43.13,"1.25","1.25","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 201)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PN7"
"5PN8",,"X-RAY DIFFRACTION",2.31,46.77,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PN8",43.13,"1.34","1.34","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 202)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PN8"
"5PN9",,"X-RAY DIFFRACTION",2.31,46.76,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PN9",43.13,"1.48","1.48","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 203)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PN9"
"5PNA",,"X-RAY DIFFRACTION",2.29,46.36,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNA",43.13,"1.78","1.78","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 204)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNA"
"5PNB",,"X-RAY DIFFRACTION",2.29,46.29,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNB",43.13,"1.23","1.23","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 205)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNB"
"5PNC",,"X-RAY DIFFRACTION",2.29,46.39,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNC",43.13,"1.35","1.35","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 206)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNC"
"5PND",,"X-RAY DIFFRACTION",2.3,46.49,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PND",43.13,"1.49","1.49","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 207)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PND"
"5PNE",,"X-RAY DIFFRACTION",2.3,46.5,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNE",43.13,"1.29","1.29","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 208)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNE"
"5PNF",,"X-RAY DIFFRACTION",2.31,46.74,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNF",43.13,"1.24","1.24","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 209)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNF"
"5PNG",,"X-RAY DIFFRACTION",2.29,46.25,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNG",43.13,"1.38","1.38","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 210)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNG"
"5PNH",,"X-RAY DIFFRACTION",2.28,46.1,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNH",43.13,"1.14","1.14","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 211)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNH"
"5PNI",,"X-RAY DIFFRACTION",2.3,46.56,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNI",43.13,"1.45","1.45","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 212)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNI"
"5PNJ",,"X-RAY DIFFRACTION",2.27,45.85,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNJ",43.13,"1.4","1.4","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 213)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNJ"
"5PNK",,"X-RAY DIFFRACTION",2.29,46.18,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNK",43.13,"1.27","1.27","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 214)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNK"
"5PNL",,"X-RAY DIFFRACTION",2.31,46.71,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNL",43.13,"1.44","1.44","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 215)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNL"
"5PNM",,"X-RAY DIFFRACTION",2.3,46.54,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNM",43.13,"1.25","1.25","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 216)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNM"
"5PNN",,"X-RAY DIFFRACTION",2.29,46.37,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNN",43.13,"1.21","1.21","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 217)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNN"
"5PNO",,"X-RAY DIFFRACTION",2.27,45.8,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNO",43.13,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 218)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNO"
"5PNP",,"X-RAY DIFFRACTION",2.28,46.1,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNP",43.13,"1.47","1.47","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 219)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNP"
"5PNQ",,"X-RAY DIFFRACTION",2.3,46.56,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNQ",43.13,"1.47","1.47","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 220)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNQ"
"5PNR",,"X-RAY DIFFRACTION",2.28,46.17,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNR",43.13,"1.14","1.14","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 221)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNR"
"5PNS",,"X-RAY DIFFRACTION",2.32,47.05,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNS",43.13,"1.36","1.36","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 222)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNS"
"5PNT",,"X-RAY DIFFRACTION",2.61,50,,6.5,"PROTEIN WAS CRYSTALLIZED FROM 30% PEGMME 5000, 200 MM AMMONIUM SULFATE, 100 MM MES, PH 6.5",,"10.1074/jbc.273.34.21714",,"5PNT",18.13,"2.2","2.2","CRYSTAL STRUCTURE OF A HUMAN LOW MOLECULAR WEIGHT PHOSPHOTYROSYL PHOSPHATASE. IMPLICATIONS FOR SUBSTRATE SPECIFICITY","AEQATKSVLFVCLGNICRSPIAEAVFRKLVTDQNISENWRVDSAATSGYEIGNPPDYRGQSCMKRHGIPMSHVARQITKEDFATFDYILCMDESNLRDLNRKSNQVKTCKAKIELLGSYDPQKQLIIEDPYYGNDSDFETVYQQCVRCCRAFLEKAH","Homo sapiens","ACP1","LOW MOLECULAR WEIGHT PHOSPHOTYROSYL PHOSPHATASE","1","5PNT"
"5PNU",,"X-RAY DIFFRACTION",2.3,46.52,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNU",43.13,"1.14","1.14","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 223)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNU"
"5PNV",,"X-RAY DIFFRACTION",2.3,46.5,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNV",43.13,"1.6","1.6","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 224)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNV"
"5PNW",,"X-RAY DIFFRACTION",2.3,46.44,"VAPOR DIFFUSION, SITTING DROP",7,"28% PEG3350 -- 0.1M HEPES pH 7.0 -- 0.25M ammonium sulfate",298,"10.1038/ncomms15123",,"5PNW",43.13,"1.4","1.4","PanDDA analysis group deposition -- Crystal Structure of JMJD2D after initial refinement with no ligand modelled (structure 225)","MHHHHHHSSGVDLGTENLYFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5PNW"
"5PNX",,"X-RAY DIFFRACTION",2.18,43.62,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PNX",36.82,"1.47","1.47","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10128a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PNX"
"5PNY",,"X-RAY DIFFRACTION",2.19,43.71,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PNY",36.94,"1.479","1.479","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10174a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PNY"
"5PNZ",,"X-RAY DIFFRACTION",2.17,43.37,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PNZ",36.97,"1.557","1.557","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10162a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PNZ"
"5PO0",,"X-RAY DIFFRACTION",2.19,43.72,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PO0",36.95,"1.458","1.458","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10146a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PO0"
"5PO1",,"X-RAY DIFFRACTION",2.19,43.72,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PO1",36.91,"1.517","1.517","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10152a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PO1"
"5PO2",,"X-RAY DIFFRACTION",2.2,44.02,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PO2",36.87,"1.67","1.67","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10132a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PO2"
"5PO3",,"X-RAY DIFFRACTION",2.16,43.14,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PO3",36.91,"1.699","1.699","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10164a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PO3"
"5PO4",,"X-RAY DIFFRACTION",2.17,43.31,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PO4",36.93,"1.487","1.487","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10170a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PO4"
"5PO5",,"X-RAY DIFFRACTION",2.18,43.49,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PO5",36.94,"1.439","1.439","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10192a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PO5"
"5PO6",,"X-RAY DIFFRACTION",2.18,43.49,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PO6",36.96,"1.61","1.61","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10157a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PO6"
"5PO7",,"X-RAY DIFFRACTION",2.18,43.69,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PO7",37.07,"1.5","1.5","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11083a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PO7"
"5PO8",,"X-RAY DIFFRACTION",2.16,43,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PO8",37.13,"1.5","1.5","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N07808b","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PO8"
"5PO9",,"X-RAY DIFFRACTION",2.13,42.35,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PO9",37.02,"2.116","2.116","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N07950b","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PO9"
"5POA",,"X-RAY DIFFRACTION",2.17,43.37,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POA",36.93,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10186a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POA"
"5POB",,"X-RAY DIFFRACTION",2.19,43.86,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POB",36.89,"1.779","1.779","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with E13683b","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POB"
"5POC",,"X-RAY DIFFRACTION",2.19,43.72,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POC",37,"1.478","1.478","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11081a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POC"
"5POD",,"X-RAY DIFFRACTION",2.16,43.08,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POD",36.88,"1.56","1.56","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N07807b","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POD"
"5POE",,"X-RAY DIFFRACTION",2.16,43.12,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POE",37.29,"1.518","1.518","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10188a and N07807b","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POE"
"5POF",,"X-RAY DIFFRACTION",2.2,44.16,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POF",37,"2.27","2.27","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10941a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POF"
"5POG",,"X-RAY DIFFRACTION",2.2,44.15,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POG",37.11,"1.77","1.77","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11063a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POG"
"5POH",,"X-RAY DIFFRACTION",2.2,44.14,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POH",37.08,"1.61","1.61","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11029a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POH"
"5POI",,"X-RAY DIFFRACTION",2.21,44.43,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POI",36.99,"2.365","2.365","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11016a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POI"
"5POJ",,"X-RAY DIFFRACTION",2.19,43.86,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POJ",37.12,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10941a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POJ"
"5POK",,"X-RAY DIFFRACTION",2.19,43.72,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POK",37.13,"1.56","1.56","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10908a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POK"
"5POL",,"X-RAY DIFFRACTION",2.18,43.46,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POL",37.07,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10971a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POL"
"5POM",,"X-RAY DIFFRACTION",2.18,43.67,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POM",36.91,"1.54","1.54","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10958a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POM"
"5PON",,"X-RAY DIFFRACTION",2.22,44.48,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PON",36.94,"1.519","1.519","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10980a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PON"
"5POO",,"X-RAY DIFFRACTION",2.2,43.98,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POO",36.99,"1.499","1.499","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10966a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POO"
"5POP",,"X-RAY DIFFRACTION",2.2,43.97,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POP",37.07,"1.579","1.579","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10987a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POP"
"5POQ",,"X-RAY DIFFRACTION",2.23,44.85,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POQ",37.13,"1.97","1.97","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10974a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POQ"
"5POR",,"X-RAY DIFFRACTION",2.19,43.82,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POR",37,"1.578","1.578","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10982a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POR"
"5POS",,"X-RAY DIFFRACTION",2.19,43.88,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POS",37.14,"1.75","1.75","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10919a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POS"
"5POT",,"X-RAY DIFFRACTION",2.19,43.89,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POT",36.9,"1.628","1.628","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10931a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POT"
"5POU",,"X-RAY DIFFRACTION",2.19,43.82,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POU",36.91,"1.43","1.43","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10954a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POU"
"5POV",,"X-RAY DIFFRACTION",2.21,44.25,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POV",36.92,"1.57","1.57","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11063a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POV"
"5POW",,"X-RAY DIFFRACTION",2.19,43.83,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POW",37.08,"1.768","1.768","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N10894b","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POW"
"5POX",,"X-RAY DIFFRACTION",2.18,43.64,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POX",36.91,"1.75","1.75","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11075a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POX"
"5POY",,"X-RAY DIFFRACTION",2.21,44.38,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POY",37.08,"1.758","1.758","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11029a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POY"
"5POZ",,"X-RAY DIFFRACTION",2.18,43.67,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5POZ",36.98,"1.5","1.5","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11039a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5POZ"
"5PP0",,"X-RAY DIFFRACTION",2.2,44,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PP0",36.75,"1.61","1.61","PanDDA analysis group deposition -- Crystal Structure of BRD1 in complex with N11009a","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PP0"
"5PP1",,"X-RAY DIFFRACTION",2.23,44.73,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PP1",36.72,"2.35","2.35","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 1)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PP1"
"5PP2",,"X-RAY DIFFRACTION",2.14,42.51,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PP2",36.72,"1.61","1.61","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 2)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PP2"
"5PP3",,"X-RAY DIFFRACTION",2,38.51,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PP3",36.72,"2.58","2.58","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 3)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PP3"
"5PP4",,"X-RAY DIFFRACTION",2.17,43.25,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PP4",36.72,"1.92","1.92","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 4)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PP4"
"5PP5",,"X-RAY DIFFRACTION",2.17,43.21,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PP5",36.72,"1.87","1.87","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 5)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PP5"
"5PP6",,"X-RAY DIFFRACTION",2.18,43.51,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PP6",36.72,"1.52","1.52","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 6)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PP6"
"5PP7",,"X-RAY DIFFRACTION",2.19,43.71,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PP7",36.72,"1.52","1.52","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 7)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PP7"
"5PP8",,"X-RAY DIFFRACTION",2.15,42.8,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PP8",36.72,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 8)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PP8"
"5PP9",,"X-RAY DIFFRACTION",2.14,42.64,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PP9",36.72,"1.82","1.82","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 9)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PP9"
"5PPA",,"X-RAY DIFFRACTION",2.13,42.38,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPA",36.72,"1.91","1.91","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 10)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPA"
"5PPB",,"X-RAY DIFFRACTION",2.17,43.43,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPB",36.72,"1.48","1.48","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 11)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPB"
"5PPC",,"X-RAY DIFFRACTION",2.14,42.54,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPC",36.72,"1.61","1.61","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 12)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPC"
"5PPD",,"X-RAY DIFFRACTION",2.16,42.99,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPD",36.72,"1.67","1.67","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 13)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPD"
"5PPE",,"X-RAY DIFFRACTION",2.18,43.56,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPE",36.72,"1.46","1.46","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 14)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPE"
"5PPF",,"X-RAY DIFFRACTION",2.2,44.16,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPF",36.72,"1.64","1.64","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 16)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPF"
"5PPG",,"X-RAY DIFFRACTION",2.19,43.77,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPG",36.72,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 17)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPG"
"5PPH",,"X-RAY DIFFRACTION",2.18,43.46,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPH",36.72,"1.89","1.89","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 18)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPH"
"5PPI",,"X-RAY DIFFRACTION",2.16,43.17,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPI",36.72,"1.56","1.56","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 19)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPI"
"5PPJ",,"X-RAY DIFFRACTION",2.17,43.28,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPJ",36.72,"1.61","1.61","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 20)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPJ"
"5PPK",,"X-RAY DIFFRACTION",2.17,43.33,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPK",36.72,"1.87","1.87","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 21)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPK"
"5PPL",,"X-RAY DIFFRACTION",2.18,43.54,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPL",36.72,"1.63","1.63","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 22)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPL"
"5PPM",,"X-RAY DIFFRACTION",2.18,43.57,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPM",36.72,"1.87","1.87","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 23)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPM"
"5PPN",,"X-RAY DIFFRACTION",2.17,43.38,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPN",36.72,"1.8","1.8","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 24)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPN"
"5PPO",,"X-RAY DIFFRACTION",2.18,43.53,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPO",36.72,"1.84","1.84","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 25)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPO"
"5PPP",,"X-RAY DIFFRACTION",2.17,43.36,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPP",36.72,"1.68","1.68","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 26)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPP"
"5PPQ",,"X-RAY DIFFRACTION",2.17,43.43,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPQ",36.72,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 27)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPQ"
"5PPR",,"X-RAY DIFFRACTION",2.21,44.26,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPR",36.72,"2.69","2.69","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 28)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPR"
"5PPS",,"X-RAY DIFFRACTION",2.19,43.75,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPS",36.72,"1.53","1.53","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 29)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPS"
"5PPT",,"X-RAY DIFFRACTION",2.17,43.4,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPT",36.72,"1.61","1.61","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 30)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPT"
"5PPU",,"X-RAY DIFFRACTION",2.15,42.8,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPU",36.72,"1.63","1.63","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 31)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPU"
"5PPV",,"X-RAY DIFFRACTION",2.18,43.49,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPV",36.72,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 32)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPV"
"5PPW",,"X-RAY DIFFRACTION",2.16,43.18,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPW",36.72,"1.45","1.45","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 33)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPW"
"5PPX",,"X-RAY DIFFRACTION",2.16,42.98,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPX",36.72,"1.44","1.44","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 34)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPX"
"5PPY",,"X-RAY DIFFRACTION",2.17,43.36,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPY",36.72,"1.45","1.45","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 35)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPY"
"5PPZ",,"X-RAY DIFFRACTION",2.19,43.92,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PPZ",36.72,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 36)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PPZ"
"5PQ0",,"X-RAY DIFFRACTION",2.12,42.09,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQ0",36.72,"1.81","1.81","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 37)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQ0"
"5PQ1",,"X-RAY DIFFRACTION",2.18,43.46,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQ1",36.72,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 38)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQ1"
"5PQ2",,"X-RAY DIFFRACTION",2.17,43.29,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQ2",36.72,"1.47","1.47","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 39)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQ2"
"5PQ3",,"X-RAY DIFFRACTION",2.14,42.48,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQ3",36.72,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 40)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQ3"
"5PQ4",,"X-RAY DIFFRACTION",2.16,43.15,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQ4",36.72,"1.63","1.63","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 41)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQ4"
"5PQ5",,"X-RAY DIFFRACTION",2.16,43.14,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQ5",36.72,"1.6","1.6","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 42)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQ5"
"5PQ6",,"X-RAY DIFFRACTION",2.17,43.3,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQ6",36.72,"1.64","1.64","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 43)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQ6"
"5PQ7",,"X-RAY DIFFRACTION",2.17,43.35,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQ7",36.72,"1.56","1.56","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 44)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQ7"
"5PQ8",,"X-RAY DIFFRACTION",2.17,43.24,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQ8",36.72,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 45)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQ8"
"5PQ9",,"X-RAY DIFFRACTION",2.16,42.99,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQ9",36.72,"1.6","1.6","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 46)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQ9"
"5PQA",,"X-RAY DIFFRACTION",2.19,43.77,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQA",36.72,"1.78","1.78","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 47)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQA"
"5PQB",,"X-RAY DIFFRACTION",2.17,43.33,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQB",36.72,"1.58","1.58","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 48)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQB"
"5PQC",,"X-RAY DIFFRACTION",2.2,44.03,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQC",36.72,"1.45","1.45","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 49)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQC"
"5PQD",,"X-RAY DIFFRACTION",2.18,43.59,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQD",36.72,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 50)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQD"
"5PQE",,"X-RAY DIFFRACTION",2.17,43.29,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQE",36.72,"1.53","1.53","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 51)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQE"
"5PQF",,"X-RAY DIFFRACTION",2.15,42.69,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQF",36.72,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 52)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQF"
"5PQG",,"X-RAY DIFFRACTION",2.19,43.78,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQG",36.72,"1.82","1.82","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 53)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQG"
"5PQH",,"X-RAY DIFFRACTION",2.17,43.29,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQH",36.72,"1.52","1.52","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 54)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQH"
"5PQI",,"X-RAY DIFFRACTION",2.18,43.5,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQI",36.72,"1.33","1.33","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 55)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQI"
"5PQJ",,"X-RAY DIFFRACTION",2.16,43.01,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQJ",36.72,"1.59","1.59","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 56)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQJ"
"5PQK",,"X-RAY DIFFRACTION",2.16,43.11,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQK",36.72,"1.58","1.58","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 57)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQK"
"5PQL",,"X-RAY DIFFRACTION",2.17,43.27,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQL",36.72,"1.52","1.52","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 58)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQL"
"5PQM",,"X-RAY DIFFRACTION",2.18,43.59,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQM",36.72,"2.56","2.56","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 59)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQM"
"5PQN",,"X-RAY DIFFRACTION",2.16,43.18,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQN",36.72,"2","2","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 60)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQN"
"5PQO",,"X-RAY DIFFRACTION",2.17,43.37,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQO",36.72,"1.75","1.75","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 61)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQO"
"5PQP",,"X-RAY DIFFRACTION",2.18,43.47,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQP",36.72,"1.97","1.97","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 62)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQP"
"5PQQ",,"X-RAY DIFFRACTION",2.15,42.7,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQQ",36.72,"2.3","2.3","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 63)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQQ"
"5PQR",,"X-RAY DIFFRACTION",2.19,43.72,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQR",36.72,"2.43","2.43","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 64)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQR"
"5PQS",,"X-RAY DIFFRACTION",2.16,43.13,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQS",36.72,"1.82","1.82","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 65)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQS"
"5PQT",,"X-RAY DIFFRACTION",2.18,43.62,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQT",36.72,"1.89","1.89","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 66)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQT"
"5PQU",,"X-RAY DIFFRACTION",2.16,43.16,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQU",36.72,"2","2","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 67)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQU"
"5PQV",,"X-RAY DIFFRACTION",2.17,43.25,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQV",36.72,"1.97","1.97","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 68)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQV"
"5PQW",,"X-RAY DIFFRACTION",2.16,43.11,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQW",36.72,"2","2","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 69)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQW"
"5PQX",,"X-RAY DIFFRACTION",2.16,42.94,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQX",36.72,"1.95","1.95","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 70)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQX"
"5PQY",,"X-RAY DIFFRACTION",2.18,43.66,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQY",36.72,"1.89","1.89","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 71)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQY"
"5PQZ",,"X-RAY DIFFRACTION",2.16,43.16,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PQZ",36.72,"2.58","2.58","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 72)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PQZ"
"5PR0",,"X-RAY DIFFRACTION",2.16,43.11,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PR0",36.72,"2.23","2.23","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 73)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PR0"
"5PR1",,"X-RAY DIFFRACTION",2.19,43.75,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PR1",36.72,"2.1","2.1","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 74)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PR1"
"5PR2",,"X-RAY DIFFRACTION",2.2,44.06,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PR2",36.72,"2.1","2.1","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 75)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PR2"
"5PR4",,"X-RAY DIFFRACTION",2.18,43.68,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PR4",36.72,"1.82","1.82","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 77)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PR4"
"5PR5",,"X-RAY DIFFRACTION",2.19,43.91,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PR5",36.72,"1.95","1.95","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 78)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PR5"
"5PR6",,"X-RAY DIFFRACTION",2.17,43.33,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PR6",36.72,"1.8","1.8","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 79)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PR6"
"5PR7",,"X-RAY DIFFRACTION",2.18,43.65,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PR7",36.72,"1.8","1.8","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 80)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PR7"
"5PR8",,"X-RAY DIFFRACTION",2.18,43.64,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PR8",36.72,"1.92","1.92","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 81)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PR8"
"5PR9",,"X-RAY DIFFRACTION",2.19,43.85,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PR9",36.72,"1.82","1.82","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 82)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PR9"
"5PRA",,"X-RAY DIFFRACTION",2.17,43.27,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRA",36.72,"1.87","1.87","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 83)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRA"
"5PRB",,"X-RAY DIFFRACTION",2.2,43.99,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRB",36.72,"2.23","2.23","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 84)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRB"
"5PRD",,"X-RAY DIFFRACTION",2.19,43.75,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRD",36.72,"1.9","1.9","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 85)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRD"
"5PRE",,"X-RAY DIFFRACTION",2.19,43.8,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRE",36.72,"1.73","1.73","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 86)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRE"
"5PRF",,"X-RAY DIFFRACTION",2.18,43.6,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRF",36.72,"1.82","1.82","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 87)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRF"
"5PRG",,"X-RAY DIFFRACTION",2.18,43.68,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRG",36.72,"2.68","2.68","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 88)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRG"
"5PRH",,"X-RAY DIFFRACTION",2.2,44.13,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRH",36.72,"1.95","1.95","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 89)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRH"
"5PRI",,"X-RAY DIFFRACTION",2.2,44.22,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRI",36.72,"1.9","1.9","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 90)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRI"
"5PRJ",,"X-RAY DIFFRACTION",2.2,44.16,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRJ",36.72,"2.17","2.17","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 91)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRJ"
"5PRK",,"X-RAY DIFFRACTION",2.08,40.85,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRK",36.72,"2.23","2.23","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 92)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRK"
"5PRL",,"X-RAY DIFFRACTION",2.2,43.97,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRL",36.72,"1.75","1.75","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 93)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRL"
"5PRM",,"X-RAY DIFFRACTION",2.21,44.32,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRM",36.72,"3.58","3.58","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 94)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRM"
"5PRO",,"X-RAY DIFFRACTION",2.19,43.84,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRO",36.72,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 95)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRO"
"5PRP",,"X-RAY DIFFRACTION",2.19,43.94,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRP",36.72,"1.45","1.45","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 96)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRP"
"5PRQ",,"X-RAY DIFFRACTION",2.2,44.18,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRQ",36.72,"1.68","1.68","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 97)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRQ"
"5PRR",,"X-RAY DIFFRACTION",2.21,44.23,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRR",36.72,"1.63","1.63","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 98)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRR"
"5PRS",,"X-RAY DIFFRACTION",2.2,44.08,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRS",36.72,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 99)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRS"
"5PRT",,"X-RAY DIFFRACTION",2.2,44.08,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRT",36.72,"1.89","1.89","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 100)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRT"
"5PRU",,"X-RAY DIFFRACTION",2.2,44.16,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRU",36.72,"1.58","1.58","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 101)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRU"
"5PRV",,"X-RAY DIFFRACTION",2.2,44.06,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRV",36.72,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 102)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRV"
"5PRW",,"X-RAY DIFFRACTION",2.2,44.11,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRW",36.72,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 103)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRW"
"5PRX",,"X-RAY DIFFRACTION",2.22,44.58,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRX",36.72,"1.87","1.87","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 104)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRX"
"5PRY",,"X-RAY DIFFRACTION",2.22,44.7,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRY",36.72,"1.8","1.8","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 105)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRY"
"5PRZ",,"X-RAY DIFFRACTION",2.2,44.21,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PRZ",36.72,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 106)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PRZ"
"5PS0",,"X-RAY DIFFRACTION",2.2,44.17,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PS0",36.72,"1.68","1.68","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 107)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PS0"
"5PS1",,"X-RAY DIFFRACTION",2.21,44.26,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PS1",36.72,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 108)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PS1"
"5PS2",,"X-RAY DIFFRACTION",2.2,44.13,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PS2",36.72,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 109)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PS2"
"5PS3",,"X-RAY DIFFRACTION",2.22,44.63,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PS3",36.72,"1.93","1.93","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 110)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PS3"
"5PS4",,"X-RAY DIFFRACTION",2.19,43.96,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PS4",36.72,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 111)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PS4"
"5PS5",,"X-RAY DIFFRACTION",2.22,44.57,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PS5",36.72,"2.15","2.15","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 113)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PS5"
"5PS6",,"X-RAY DIFFRACTION",2.2,44.11,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PS6",36.72,"1.52","1.52","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 114)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PS6"
"5PS7",,"X-RAY DIFFRACTION",2.2,44.08,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PS7",36.72,"2.21","2.21","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 115)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PS7"
"5PS8",,"X-RAY DIFFRACTION",2.21,44.33,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PS8",36.72,"1.93","1.93","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 116)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PS8"
"5PS9",,"X-RAY DIFFRACTION",2.21,44.25,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PS9",36.72,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 117)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PS9"
"5PSA",,"X-RAY DIFFRACTION",2.21,44.27,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSA",36.72,"1.64","1.64","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 118)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSA"
"5PSB",,"X-RAY DIFFRACTION",2.21,44.31,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSB",36.72,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 119)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSB"
"5PSC",,"X-RAY DIFFRACTION",2.2,44.1,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSC",36.72,"1.68","1.68","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 120)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSC"
"5PSD",,"X-RAY DIFFRACTION",2.21,44.24,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSD",36.72,"1.63","1.63","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 121)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSD"
"5PSE",,"X-RAY DIFFRACTION",2.22,44.71,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSE",36.72,"2.19","2.19","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 122)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSE"
"5PSF",,"X-RAY DIFFRACTION",2.21,44.33,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSF",36.72,"2.31","2.31","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 123)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSF"
"5PSG",,"X-RAY DIFFRACTION",2.2,44.13,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSG",36.72,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 124)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSG"
"5PSH",,"X-RAY DIFFRACTION",2.18,43.51,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSH",36.72,"3.43","3.43","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 125)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSH"
"5PSI",,"X-RAY DIFFRACTION",2.17,43.24,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSI",36.72,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 126)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSI"
"5PSJ",,"X-RAY DIFFRACTION",2.17,43.43,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSJ",36.72,"1.38","1.38","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 127)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSJ"
"5PSK",,"X-RAY DIFFRACTION",2.18,43.53,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSK",36.72,"1.38","1.38","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 128)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSK"
"5PSL",,"X-RAY DIFFRACTION",2.18,43.45,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSL",36.72,"1.39","1.39","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 129)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSL"
"5PSM",,"X-RAY DIFFRACTION",2.18,43.62,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSM",36.72,"1.53","1.53","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 130)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSM"
"5PSN",,"X-RAY DIFFRACTION",2.18,43.52,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSN",36.72,"1.48","1.48","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 131)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSN"
"5PSO",,"X-RAY DIFFRACTION",2.18,43.64,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSO",36.72,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 132)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSO"
"5PSP",,"X-RAY DIFFRACTION",2.18,43.62,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSP",36.72,"1.58","1.58","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 133)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSP"
"5PSQ",,"X-RAY DIFFRACTION",2.18,43.52,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSQ",36.72,"1.43","1.43","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 134)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSQ"
"5PSR",,"X-RAY DIFFRACTION",2.18,43.53,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSR",36.72,"1.59","1.59","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 135)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSR"
"5PSS",,"X-RAY DIFFRACTION",2.18,43.5,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSS",36.72,"1.59","1.59","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 136)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSS"
"5PST",,"X-RAY DIFFRACTION",2.18,43.53,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PST",36.72,"1.39","1.39","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 137)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PST"
"5PSU",,"X-RAY DIFFRACTION",2.17,43.44,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSU",36.72,"1.56","1.56","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 138)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSU"
"5PSV",,"X-RAY DIFFRACTION",2.18,43.69,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSV",36.72,"1.53","1.53","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 139)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSV"
"5PSW",,"X-RAY DIFFRACTION",2.19,43.74,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSW",36.72,"1.53","1.53","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 140)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSW"
"5PSX",,"X-RAY DIFFRACTION",2.19,43.92,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSX",36.72,"1.59","1.59","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 141)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSX"
"5PSY",,"X-RAY DIFFRACTION",2.19,43.95,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSY",36.72,"1.82","1.82","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 142)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSY"
"5PSZ",,"X-RAY DIFFRACTION",2.18,43.65,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PSZ",36.72,"1.53","1.53","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 143)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PSZ"
"5PT0",,"X-RAY DIFFRACTION",2.19,43.76,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PT0",36.72,"1.43","1.43","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 144)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PT0"
"5PT1",,"X-RAY DIFFRACTION",2.19,43.91,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PT1",36.72,"1.54","1.54","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 145)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PT1"
"5PT2",,"X-RAY DIFFRACTION",2.19,43.89,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PT2",36.72,"1.52","1.52","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 146)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PT2"
"5PT3",,"X-RAY DIFFRACTION",2.18,43.57,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PT3",36.72,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 147)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PT3"
"5PT4",,"X-RAY DIFFRACTION",2.19,43.79,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PT4",36.72,"1.54","1.54","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 148)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PT4"
"5PT5",,"X-RAY DIFFRACTION",2.2,43.99,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PT5",36.72,"1.76","1.76","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 149)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PT5"
"5PT6",,"X-RAY DIFFRACTION",2.19,43.81,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PT6",36.72,"1.53","1.53","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 150)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PT6"
"5PT7",,"X-RAY DIFFRACTION",2.18,43.65,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PT7",36.72,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 151)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PT7"
"5PT8",,"X-RAY DIFFRACTION",2.19,43.94,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PT8",36.72,"1.66","1.66","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 152)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PT8"
"5PT9",,"X-RAY DIFFRACTION",2.17,43.29,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PT9",36.72,"1.47","1.47","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 153)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PT9"
"5PTA",,"X-RAY DIFFRACTION",2.21,44.26,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTA",36.72,"2.19","2.19","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 154)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTA"
"5PTB",,"X-RAY DIFFRACTION",2.16,43.1,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTB",36.72,"1.88","1.88","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 155)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTB"
"5PTC",,"X-RAY DIFFRACTION",2.18,43.5,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTC",36.72,"1.78","1.78","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 156)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTC"
"5PTE",,"X-RAY DIFFRACTION",2.17,43.34,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTE",36.72,"1.63","1.63","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 157)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTE"
"5PTF",,"X-RAY DIFFRACTION",2.18,43.58,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTF",36.72,"1.49","1.49","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 158)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTF"
"5PTG",,"X-RAY DIFFRACTION",2.17,43.44,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTG",36.72,"1.46","1.46","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 159)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTG"
"5PTH",,"X-RAY DIFFRACTION",2.18,43.58,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTH",36.72,"1.56","1.56","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 160)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTH"
"5PTJ",,"X-RAY DIFFRACTION",2.18,43.57,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTJ",36.72,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 161)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTJ"
"5PTK",,"X-RAY DIFFRACTION",2.18,43.54,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTK",36.72,"1.48","1.48","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 162)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTK"
"5PTL",,"X-RAY DIFFRACTION",2.18,43.64,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTL",36.72,"1.53","1.53","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 163)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTL"
"5PTM",,"X-RAY DIFFRACTION",2.18,43.7,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTM",36.72,"1.41","1.41","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 164)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTM"
"5PTN",,"X-RAY DIFFRACTION",2.19,43.87,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTN",36.72,"1.47","1.47","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 165)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTN"
"5PTO",,"X-RAY DIFFRACTION",2.19,43.74,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTO",36.72,"1.67","1.67","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 167)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTO"
"5PTQ",,"X-RAY DIFFRACTION",2.18,43.48,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTQ",36.72,"1.49","1.49","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 168)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTQ"
"5PTR",,"X-RAY DIFFRACTION",2.2,44.03,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTR",36.72,"1.52","1.52","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 169)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTR"
"5PTS",,"X-RAY DIFFRACTION",2.19,43.82,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTS",36.72,"1.45","1.45","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 170)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTS"
"5PTT",,"X-RAY DIFFRACTION",2.19,43.79,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTT",36.72,"1.47","1.47","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 171)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTT"
"5PTU",,"X-RAY DIFFRACTION",2.19,43.85,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTU",36.72,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 172)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTU"
"5PTV",,"X-RAY DIFFRACTION",2.19,43.92,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTV",36.72,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 173)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTV"
"5PTW",,"X-RAY DIFFRACTION",2.19,43.78,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTW",36.72,"1.82","1.82","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 174)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTW"
"5PTX",,"X-RAY DIFFRACTION",2.19,43.89,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTX",36.72,"1.6","1.6","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 175)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTX"
"5PTY",,"X-RAY DIFFRACTION",2.19,43.72,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTY",36.72,"2.1","2.1","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 176)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTY"
"5PTZ",,"X-RAY DIFFRACTION",2.18,43.65,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PTZ",36.72,"1.51","1.51","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 177)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PTZ"
"5PU0",,"X-RAY DIFFRACTION",2.22,44.51,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PU0",36.72,"1.89","1.89","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 178)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PU0"
"5PU1",,"X-RAY DIFFRACTION",2.18,43.59,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PU1",36.72,"1.73","1.73","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 179)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PU1"
"5PU2",,"X-RAY DIFFRACTION",2.19,43.82,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PU2",36.72,"1.59","1.59","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 180)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PU2"
"5PU3",,"X-RAY DIFFRACTION",2.19,43.92,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PU3",36.72,"2.37","2.37","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 181)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PU3"
"5PU4",,"X-RAY DIFFRACTION",2.2,44.04,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PU4",36.72,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 182)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PU4"
"5PU5",,"X-RAY DIFFRACTION",2.19,43.86,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PU5",36.72,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 183)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PU5"
"5PU6",,"X-RAY DIFFRACTION",2.19,43.84,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PU6",36.72,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 184)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PU6"
"5PU7",,"X-RAY DIFFRACTION",2.19,43.92,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PU7",36.72,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 185)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PU7"
"5PU8",,"X-RAY DIFFRACTION",2.19,43.77,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PU8",36.72,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 186)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PU8"
"5PU9",,"X-RAY DIFFRACTION",2.2,44.06,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PU9",36.72,"1.56","1.56","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 187)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PU9"
"5PUA",,"X-RAY DIFFRACTION",2.2,43.97,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUA",36.72,"1.63","1.63","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 188)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUA"
"5PUB",,"X-RAY DIFFRACTION",2.21,44.24,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUB",36.72,"2.23","2.23","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 189)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUB"
"5PUC",,"X-RAY DIFFRACTION",2.2,44.08,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUC",36.72,"1.64","1.64","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 190)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUC"
"5PUD",,"X-RAY DIFFRACTION",2.18,43.64,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUD",36.72,"2.01","2.01","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 191)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUD"
"5PUE",,"X-RAY DIFFRACTION",2.18,43.63,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUE",36.72,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 192)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUE"
"5PUF",,"X-RAY DIFFRACTION",2.12,41.99,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUF",36.72,"1.82","1.82","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 193)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUF"
"5PUG",,"X-RAY DIFFRACTION",2.17,43.43,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUG",36.72,"2","2","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 194)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUG"
"5PUH",,"X-RAY DIFFRACTION",2.16,43.08,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUH",36.72,"1.92","1.92","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 195)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUH"
"5PUI",,"X-RAY DIFFRACTION",2.17,43.19,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUI",36.72,"1.51","1.51","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 196)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUI"
"5PUJ",,"X-RAY DIFFRACTION",2.17,43.32,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUJ",36.72,"1.9","1.9","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 197)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUJ"
"5PUK",,"X-RAY DIFFRACTION",2.19,43.95,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUK",36.72,"1.64","1.64","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 198)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUK"
"5PUL",,"X-RAY DIFFRACTION",2.16,43.12,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUL",36.72,"1.95","1.95","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 199)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUL"
"5PUM",,"X-RAY DIFFRACTION",2.14,42.39,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUM",36.72,"2.15","2.15","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 200)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUM"
"5PUN",,"X-RAY DIFFRACTION",2.15,42.78,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUN",36.72,"1.84","1.84","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 201)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUN"
"5PUO",,"X-RAY DIFFRACTION",2.09,41.17,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUO",36.72,"2.06","2.06","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 202)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUO"
"5PUP",,"X-RAY DIFFRACTION",2.21,44.43,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUP",36.72,"1.6","1.6","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 203)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUP"
"5PUQ",,"X-RAY DIFFRACTION",2.19,43.88,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUQ",36.72,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 204)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUQ"
"5PUR",,"X-RAY DIFFRACTION",2.16,43.16,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUR",36.72,"1.73","1.73","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 205)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUR"
"5PUS",,"X-RAY DIFFRACTION",2.2,44.04,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUS",36.72,"1.67","1.67","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 206)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUS"
"5PUT",,"X-RAY DIFFRACTION",2.21,44.33,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUT",36.72,"2.32","2.32","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 207)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUT"
"5PUU",,"X-RAY DIFFRACTION",2.21,44.27,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUU",36.72,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 208)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUU"
"5PUV",,"X-RAY DIFFRACTION",2.21,44.35,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUV",36.72,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 209)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUV"
"5PUW",,"X-RAY DIFFRACTION",2.21,44.28,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUW",36.72,"1.82","1.82","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 210)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUW"
"5PUX",,"X-RAY DIFFRACTION",2.2,44.14,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUX",36.72,"1.51","1.51","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 211)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUX"
"5PUY",,"X-RAY DIFFRACTION",2.2,44.07,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUY",36.72,"2.01","2.01","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 212)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUY"
"5PUZ",,"X-RAY DIFFRACTION",2.2,44.07,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PUZ",36.72,"1.49","1.49","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 213)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PUZ"
"5PV0",,"X-RAY DIFFRACTION",2.19,43.83,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PV0",36.72,"1.76","1.76","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 214)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PV0"
"5PV1",,"X-RAY DIFFRACTION",2.2,44.11,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PV1",36.72,"1.73","1.73","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 215)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PV1"
"5PV2",,"X-RAY DIFFRACTION",2.21,44.28,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PV2",36.72,"1.63","1.63","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 216)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PV2"
"5PV3",,"X-RAY DIFFRACTION",2.2,44.11,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PV3",36.72,"1.48","1.48","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 217)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PV3"
"5PV4",,"X-RAY DIFFRACTION",2.19,43.74,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PV4",36.72,"1.58","1.58","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 218)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PV4"
"5PV5",,"X-RAY DIFFRACTION",2.18,43.53,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PV5",36.72,"1.68","1.68","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 219)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PV5"
"5PV6",,"X-RAY DIFFRACTION",2.2,44.15,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PV6",36.72,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 220)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PV6"
"5PV7",,"X-RAY DIFFRACTION",2.19,43.87,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PV7",36.72,"1.58","1.58","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 221)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PV7"
"5PV8",,"X-RAY DIFFRACTION",2.18,43.67,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PV8",36.72,"1.49","1.49","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 222)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PV8"
"5PV9",,"X-RAY DIFFRACTION",2.18,43.59,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PV9",36.72,"1.67","1.67","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 223)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PV9"
"5PVA",,"X-RAY DIFFRACTION",2.18,43.7,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVA",36.72,"1.98","1.98","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 224)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVA"
"5PVB",,"X-RAY DIFFRACTION",2.2,44.01,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVB",36.72,"1.53","1.53","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 225)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVB"
"5PVC",,"X-RAY DIFFRACTION",2.19,43.74,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVC",36.72,"1.56","1.56","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 226)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVC"
"5PVD",,"X-RAY DIFFRACTION",2.19,43.76,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVD",36.72,"1.53","1.53","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 227)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVD"
"5PVE",,"X-RAY DIFFRACTION",2.21,44.31,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVE",36.72,"2.29","2.29","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 228)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVE"
"5PVF",,"X-RAY DIFFRACTION",2.19,43.84,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVF",36.72,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 229)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVF"
"5PVG",,"X-RAY DIFFRACTION",2.19,43.83,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVG",36.72,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 230)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVG"
"5PVH",,"X-RAY DIFFRACTION",2.2,44.07,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVH",36.72,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 232)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVH"
"5PVI",,"X-RAY DIFFRACTION",2.18,43.67,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVI",36.72,"2.19","2.19","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 233)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVI"
"5PVJ",,"X-RAY DIFFRACTION",2.2,43.97,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVJ",36.72,"1.57","1.57","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 234)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVJ"
"5PVK",,"X-RAY DIFFRACTION",2.16,43.13,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVK",36.72,"1.58","1.58","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 235)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVK"
"5PVL",,"X-RAY DIFFRACTION",2.17,43.45,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVL",36.72,"1.53","1.53","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 236)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVL"
"5PVM",,"X-RAY DIFFRACTION",2.16,43.01,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVM",36.72,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 237)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVM"
"5PVN",,"X-RAY DIFFRACTION",2.19,43.86,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVN",36.72,"1.63","1.63","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 238)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVN"
"5PVO",,"X-RAY DIFFRACTION",2.19,43.8,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVO",36.72,"1.96","1.96","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 239)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVO"
"5PVP",,"X-RAY DIFFRACTION",2.19,43.74,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVP",36.72,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 240)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVP"
"5PVQ",,"X-RAY DIFFRACTION",2.2,44.03,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVQ",36.72,"1.61","1.61","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 241)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVQ"
"5PVR",,"X-RAY DIFFRACTION",2.19,43.71,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVR",36.72,"1.57","1.57","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 242)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVR"
"5PVS",,"X-RAY DIFFRACTION",2.17,43.25,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVS",36.72,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 243)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVS"
"5PVT",,"X-RAY DIFFRACTION",2.18,43.63,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVT",36.72,"1.48","1.48","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 244)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVT"
"5PVU",,"X-RAY DIFFRACTION",2.19,43.74,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVU",36.72,"3.01","3.01","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 245)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVU"
"5PVV",,"X-RAY DIFFRACTION",2.15,42.88,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVV",36.72,"1.8","1.8","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 246)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVV"
"5PVW",,"X-RAY DIFFRACTION",2.2,43.98,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVW",36.72,"2.18","2.18","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 247)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVW"
"5PVX",,"X-RAY DIFFRACTION",2.19,43.85,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVX",36.72,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 248)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVX"
"5PVY",,"X-RAY DIFFRACTION",2.2,44.11,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVY",36.72,"2.49","2.49","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 249)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVY"
"5PVZ",,"X-RAY DIFFRACTION",2.19,43.89,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PVZ",36.72,"1.64","1.64","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 250)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PVZ"
"5PW0",,"X-RAY DIFFRACTION",2.21,44.26,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PW0",36.72,"2.13","2.13","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 251)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PW0"
"5PW1",,"X-RAY DIFFRACTION",2.2,44.05,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PW1",36.72,"1.57","1.57","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 252)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PW1"
"5PW2",,"X-RAY DIFFRACTION",2.21,44.4,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PW2",36.72,"2.32","2.32","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 253)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PW2"
"5PW3",,"X-RAY DIFFRACTION",2.2,44.21,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PW3",36.72,"2.21","2.21","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 254)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PW3"
"5PW4",,"X-RAY DIFFRACTION",2.19,43.75,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PW4",36.72,"1.91","1.91","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 255)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PW4"
"5PW5",,"X-RAY DIFFRACTION",2.21,44.47,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PW5",36.72,"2.09","2.09","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 256)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PW5"
"5PW6",,"X-RAY DIFFRACTION",2.22,44.61,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PW6",36.72,"2.75","2.75","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 257)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PW6"
"5PW7",,"X-RAY DIFFRACTION",2.23,44.86,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PW7",36.72,"1.85","1.85","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 258)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PW7"
"5PW8",,"X-RAY DIFFRACTION",2.21,44.31,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PW8",36.72,"2.08","2.08","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 259)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PW8"
"5PW9",,"X-RAY DIFFRACTION",2.22,44.59,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PW9",36.72,"3.44","3.44","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 260)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PW9"
"5PWA",,"X-RAY DIFFRACTION",2.21,44.47,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PWA",36.72,"1.86","1.86","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 261)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PWA"
"5PWB",,"X-RAY DIFFRACTION",2.21,44.42,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M bis-tris pH 7.0 -- 30% PEG3350",293,"10.1038/ncomms15123",,"5PWB",36.72,"2.09","2.09","PanDDA analysis group deposition -- Crystal Structure of BRD1 after initial refinement with no ligand modelled (structure 262)","MHHHHHHSSGVDLGTENLYFQSMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5PWB"
"5PWC",,"X-RAY DIFFRACTION",2.75,55.2,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWC",44.21,"1.549","1.549","PanDDA analysis group deposition -- Crystal Structure of SP100 in complex with E48115b","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWC"
"5PWD",,"X-RAY DIFFRACTION",2.75,55.24,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWD",43.8,"1.569","1.569","PanDDA analysis group deposition -- Crystal Structure of SP100 in complex with N09600b","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWD"
"5PWE",,"X-RAY DIFFRACTION",2.74,55.18,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWE",43.64,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 1)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWE"
"5PWF",,"X-RAY DIFFRACTION",2.73,55.01,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWF",43.64,"1.48","1.48","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 2)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWF"
"5PWG",,"X-RAY DIFFRACTION",2.74,55.12,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWG",43.64,"1.46","1.46","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 3)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWG"
"5PWH",,"X-RAY DIFFRACTION",2.74,55.06,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWH",43.64,"1.5","1.5","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 4)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWH"
"5PWI",,"X-RAY DIFFRACTION",2.74,55.1,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWI",43.64,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 5)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWI"
"5PWJ",,"X-RAY DIFFRACTION",2.73,54.99,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWJ",43.64,"1.89","1.89","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 6)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWJ"
"5PWK",,"X-RAY DIFFRACTION",2.73,54.87,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWK",43.64,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 7)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWK"
"5PWL",,"X-RAY DIFFRACTION",2.72,54.84,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWL",43.64,"1.83","1.83","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 8)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWL"
"5PWM",,"X-RAY DIFFRACTION",2.73,54.89,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWM",43.64,"1.54","1.54","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 9)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWM"
"5PWN",,"X-RAY DIFFRACTION",2.73,54.89,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWN",43.64,"1.64","1.64","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 10)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWN"
"5PWO",,"X-RAY DIFFRACTION",2.72,54.77,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWO",43.64,"1.85","1.85","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 11)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWO"
"5PWP",,"X-RAY DIFFRACTION",2.75,55.21,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWP",43.64,"1.51","1.51","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 13)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWP"
"5PWQ",,"X-RAY DIFFRACTION",2.74,55.19,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWQ",43.64,"1.52","1.52","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 14)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWQ"
"5PWR",,"X-RAY DIFFRACTION",2.74,55.15,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWR",43.64,"1.46","1.46","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 15)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWR"
"5PWS",,"X-RAY DIFFRACTION",2.74,55.13,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWS",43.64,"1.4","1.4","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 16)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWS"
"5PWT",,"X-RAY DIFFRACTION",2.76,55.38,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWT",43.64,"1.58","1.58","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 17)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWT"
"5PWU",,"X-RAY DIFFRACTION",2.74,55.13,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWU",43.64,"1.44","1.44","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 18)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWU"
"5PWV",,"X-RAY DIFFRACTION",2.74,55.07,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWV",43.64,"1.58","1.58","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 19)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWV"
"5PWW",,"X-RAY DIFFRACTION",2.74,55.17,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWW",43.64,"1.59","1.59","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 20)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWW"
"5PWX",,"X-RAY DIFFRACTION",2.74,55.15,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWX",43.64,"1.69","1.69","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 21)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWX"
"5PWY",,"X-RAY DIFFRACTION",2.74,55.05,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWY",43.64,"1.98","1.98","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 22)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWY"
"5PWZ",,"X-RAY DIFFRACTION",2.74,55.06,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PWZ",43.64,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 23)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PWZ"
"5PX0",,"X-RAY DIFFRACTION",2.74,55.16,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PX0",43.64,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 24)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PX0"
"5PX1",,"X-RAY DIFFRACTION",2.75,55.22,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PX1",43.64,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 25)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PX1"
"5PX2",,"X-RAY DIFFRACTION",2.75,55.24,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PX2",43.64,"1.43","1.43","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 26)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PX2"
"5PX3",,"X-RAY DIFFRACTION",2.75,55.32,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PX3",43.64,"1.57","1.57","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 27)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PX3"
"5PX4",,"X-RAY DIFFRACTION",2.75,55.21,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PX4",43.64,"1.45","1.45","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 28)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PX4"
"5PX5",,"X-RAY DIFFRACTION",2.74,55.04,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PX5",43.64,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 29)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PX5"
"5PX6",,"X-RAY DIFFRACTION",2.73,54.88,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PX6",43.64,"1.43","1.43","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 30)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PX6"
"5PX7",,"X-RAY DIFFRACTION",2.74,55.05,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PX7",43.64,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 31)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PX7"
"5PX8",,"X-RAY DIFFRACTION",2.73,54.9,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PX8",43.64,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 32)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PX8"
"5PX9",,"X-RAY DIFFRACTION",2.73,54.92,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PX9",43.64,"1.89","1.89","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 33)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PX9"
"5PXA",,"X-RAY DIFFRACTION",2.74,55.16,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXA",43.64,"1.43","1.43","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 34)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXA"
"5PXB",,"X-RAY DIFFRACTION",2.74,55.1,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXB",43.64,"1.46","1.46","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 35)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXB"
"5PXC",,"X-RAY DIFFRACTION",2.74,55.17,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXC",43.64,"1.52","1.52","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 36)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXC"
"5PXD",,"X-RAY DIFFRACTION",2.73,55.01,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXD",43.64,"1.64","1.64","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 37)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXD"
"5PXE",,"X-RAY DIFFRACTION",2.74,55.13,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXE",43.64,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 38)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXE"
"5PXF",,"X-RAY DIFFRACTION",2.73,54.91,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXF",43.64,"1.71","1.71","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 39)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXF"
"5PXG",,"X-RAY DIFFRACTION",2.73,54.97,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXG",43.64,"1.98","1.98","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 40)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXG"
"5PXH",,"X-RAY DIFFRACTION",2.74,55.03,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXH",43.64,"2.25","2.25","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 41)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXH"
"5PXI",,"X-RAY DIFFRACTION",2.73,54.99,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXI",43.64,"1.76","1.76","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 42)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXI"
"5PXJ",,"X-RAY DIFFRACTION",2.73,54.99,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXJ",43.64,"1.68","1.68","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 43)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXJ"
"5PXK",,"X-RAY DIFFRACTION",2.72,54.78,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXK",43.64,"1.98","1.98","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 44)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXK"
"5PXL",,"X-RAY DIFFRACTION",2.75,55.2,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXL",43.64,"1.35","1.35","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 45)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXL"
"5PXM",,"X-RAY DIFFRACTION",2.75,55.29,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXM",43.64,"1.59","1.59","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 46)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXM"
"5PXN",,"X-RAY DIFFRACTION",2.75,55.26,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXN",43.64,"1.43","1.43","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 47)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXN"
"5PXO",,"X-RAY DIFFRACTION",2.72,54.83,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXO",43.64,"1.78","1.78","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 48)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXO"
"5PXP",,"X-RAY DIFFRACTION",2.74,55.15,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXP",43.64,"1.86","1.86","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 49)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXP"
"5PXQ",,"X-RAY DIFFRACTION",2.74,55.15,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXQ",43.64,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 50)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXQ"
"5PXR",,"X-RAY DIFFRACTION",2.74,55.13,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXR",43.64,"1.81","1.81","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 51)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXR"
"5PXS",,"X-RAY DIFFRACTION",2.75,55.19,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXS",43.64,"1.49","1.49","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 52)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXS"
"5PXT",,"X-RAY DIFFRACTION",2.75,55.25,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXT",43.64,"1.4","1.4","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 53)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXT"
"5PXU",,"X-RAY DIFFRACTION",2.74,55.19,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXU",43.64,"1.76","1.76","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 54)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXU"
"5PXV",,"X-RAY DIFFRACTION",2.74,55.17,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXV",43.64,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 55)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXV"
"5PXW",,"X-RAY DIFFRACTION",2.74,55.15,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXW",43.64,"2.01","2.01","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 56)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXW"
"5PXX",,"X-RAY DIFFRACTION",2.73,55,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXX",43.64,"1.57","1.57","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 57)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXX"
"5PXY",,"X-RAY DIFFRACTION",2.74,55.06,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXY",43.64,"2.14","2.14","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 58)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXY"
"5PXZ",,"X-RAY DIFFRACTION",2.74,55.05,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PXZ",43.64,"1.65","1.65","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 59)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PXZ"
"5PY0",,"X-RAY DIFFRACTION",2.73,54.91,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PY0",43.64,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 60)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PY0"
"5PY1",,"X-RAY DIFFRACTION",2.73,54.98,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PY1",43.64,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 61)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PY1"
"5PY2",,"X-RAY DIFFRACTION",2.74,55.09,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PY2",43.64,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 62)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PY2"
"5PY3",,"X-RAY DIFFRACTION",2.73,54.88,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PY3",43.64,"1.78","1.78","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 63)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PY3"
"5PY4",,"X-RAY DIFFRACTION",2.73,54.92,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PY4",43.64,"1.67","1.67","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 64)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PY4"
"5PY5",,"X-RAY DIFFRACTION",2.72,54.85,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PY5",43.64,"1.44","1.44","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 65)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PY5"
"5PY6",,"X-RAY DIFFRACTION",2.73,54.93,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PY6",43.64,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 66)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PY6"
"5PY7",,"X-RAY DIFFRACTION",2.74,55.04,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PY7",43.64,"1.68","1.68","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 67)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PY7"
"5PY8",,"X-RAY DIFFRACTION",2.74,55.12,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PY8",43.64,"1.66","1.66","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 68)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PY8"
"5PY9",,"X-RAY DIFFRACTION",2.75,55.22,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PY9",43.64,"1.73","1.73","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 69)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PY9"
"5PYA",,"X-RAY DIFFRACTION",2.76,55.38,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYA",43.64,"1.55","1.55","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 70)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYA"
"5PYB",,"X-RAY DIFFRACTION",2.75,55.22,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYB",43.64,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 71)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYB"
"5PYC",,"X-RAY DIFFRACTION",2.75,55.28,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYC",43.64,"1.87","1.87","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 72)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYC"
"5PYD",,"X-RAY DIFFRACTION",2.74,55.13,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYD",43.64,"2.02","2.02","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 73)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYD"
"5PYE",,"X-RAY DIFFRACTION",2.74,55.09,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYE",43.64,"1.81","1.81","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 74)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYE"
"5PYF",,"X-RAY DIFFRACTION",2.74,55.12,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYF",43.64,"1.83","1.83","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 75)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYF"
"5PYG",,"X-RAY DIFFRACTION",2.75,55.35,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYG",43.64,"1.95","1.95","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 76)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYG"
"5PYH",,"X-RAY DIFFRACTION",2.75,55.29,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYH",43.64,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 77)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYH"
"5PYI",,"X-RAY DIFFRACTION",2.77,55.53,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYI",43.64,"2.29","2.29","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 78)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYI"
"5PYJ",,"X-RAY DIFFRACTION",2.77,55.54,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYJ",43.64,"1.97","1.97","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 79)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYJ"
"5PYK",,"X-RAY DIFFRACTION",2.76,55.44,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYK",43.64,"1.88","1.88","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 80)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYK"
"5PYL",,"X-RAY DIFFRACTION",2.75,55.28,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYL",43.64,"1.53","1.53","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 81)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYL"
"5PYM",,"X-RAY DIFFRACTION",2.78,55.72,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYM",43.64,"1.7","1.7","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 82)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYM"
"5PYN",,"X-RAY DIFFRACTION",2.76,55.48,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYN",43.64,"1.89","1.89","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 83)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYN"
"5PYO",,"X-RAY DIFFRACTION",2.74,55.08,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYO",43.64,"1.67","1.67","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 84)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYO"
"5PYP",,"X-RAY DIFFRACTION",2.75,55.29,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYP",43.64,"1.63","1.63","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 85)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYP"
"5PYQ",,"X-RAY DIFFRACTION",2.73,54.91,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYQ",43.64,"1.97","1.97","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 86)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYQ"
"5PYR",,"X-RAY DIFFRACTION",2.74,55.1,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYR",43.64,"1.94","1.94","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 87)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYR"
"5PYS",,"X-RAY DIFFRACTION",2.78,55.7,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYS",43.64,"2.09","2.09","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 88)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYS"
"5PYT",,"X-RAY DIFFRACTION",2.75,55.31,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYT",43.64,"2.13","2.13","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 89)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYT"
"5PYU",,"X-RAY DIFFRACTION",2.75,55.31,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYU",43.64,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 90)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYU"
"5PYV",,"X-RAY DIFFRACTION",2.74,55.16,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYV",43.64,"1.94","1.94","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 91)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYV"
"5PYW",,"X-RAY DIFFRACTION",2.75,55.32,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYW",43.64,"1.45","1.45","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 92)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYW"
"5PYX",,"X-RAY DIFFRACTION",2.77,55.61,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYX",43.64,"1.57","1.57","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 93)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYX"
"5PYY",,"X-RAY DIFFRACTION",2.76,55.41,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYY",43.64,"1.64","1.64","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 94)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYY"
"5PYZ",,"X-RAY DIFFRACTION",2.77,55.54,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PYZ",43.64,"1.59","1.59","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 95)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PYZ"
"5PZ0",,"X-RAY DIFFRACTION",2.77,55.53,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZ0",43.64,"2.13","2.13","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 96)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZ0"
"5PZ1",,"X-RAY DIFFRACTION",2.77,55.56,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZ1",43.64,"2.13","2.13","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 97)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZ1"
"5PZ2",,"X-RAY DIFFRACTION",2.77,55.54,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZ2",43.64,"1.88","1.88","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 98)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZ2"
"5PZ3",,"X-RAY DIFFRACTION",2.76,55.38,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZ3",43.64,"1.93","1.93","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 99)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZ3"
"5PZ4",,"X-RAY DIFFRACTION",2.78,55.7,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZ4",43.64,"1.94","1.94","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 100)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZ4"
"5PZ5",,"X-RAY DIFFRACTION",2.76,55.49,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZ5",43.64,"2.64","2.64","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 101)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZ5"
"5PZ6",,"X-RAY DIFFRACTION",2.76,55.46,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZ6",43.64,"1.87","1.87","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 102)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZ6"
"5PZ7",,"X-RAY DIFFRACTION",2.76,55.47,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZ7",43.64,"1.54","1.54","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 103)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZ7"
"5PZ8",,"X-RAY DIFFRACTION",2.77,55.68,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZ8",43.64,"1.52","1.52","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 104)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZ8"
"5PZ9",,"X-RAY DIFFRACTION",2.77,55.59,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZ9",43.64,"2.01","2.01","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 105)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZ9"
"5PZA",,"X-RAY DIFFRACTION",2.77,55.67,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZA",43.64,"1.59","1.59","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 106)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZA"
"5PZB",,"X-RAY DIFFRACTION",2.75,55.31,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZB",43.64,"2.05","2.05","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 107)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZB"
"5PZC",,"X-RAY DIFFRACTION",2.76,55.39,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZC",43.64,"1.61","1.61","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 108)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZC"
"5PZD",,"X-RAY DIFFRACTION",2.75,55.29,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZD",43.64,"1.74","1.74","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 109)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZD"
"5PZE",,"X-RAY DIFFRACTION",2.75,55.31,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZE",43.64,"1.82","1.82","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 110)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZE"
"5PZF",,"X-RAY DIFFRACTION",2.75,55.21,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZF",43.64,"1.84","1.84","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 111)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZF"
"5PZG",,"X-RAY DIFFRACTION",2.76,55.47,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZG",43.64,"1.88","1.88","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 112)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZG"
"5PZH",,"X-RAY DIFFRACTION",2.77,55.52,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZH",43.64,"1.63","1.63","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 113)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZH"
"5PZI",,"X-RAY DIFFRACTION",2.75,55.31,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZI",43.64,"1.62","1.62","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 114)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZI"
"5PZJ",,"X-RAY DIFFRACTION",2.76,55.5,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M MES pH 6.1 -- 20% PEG20K",277,"10.1038/ncomms15123",,"5PZJ",43.64,"1.72","1.72","PanDDA analysis group deposition -- Crystal Structure of SP100 after initial refinement with no ligand modelled (structure 115)","ENSNICEVCNKWGRLFCCDTCPRSFHEHCHIPSVEANKNPWSCIFCRIKTIQERCPESQSGHQESEVLMRQMLPEEQLKCEFLLLKVYCDSKSCFFASEPYYNREGSQGPQKPMWLNKVKTSLNEQMYTRVEGFVQDMRLIFHNHKEFYREDKFTRLGIQVQDIFEKNFRNIFAIQETSK","Homo sapiens","SP100","Nuclear autoantigen Sp-100","1","5PZJ"
"5PZQ",,"X-RAY DIFFRACTION",2.37,48.14,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12%-25% PEG 3350",300,,,"5PZQ",148.49,"2.7","2.7","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 2-(4-methoxyphenyl)furan-3,4-dicarboxylic acid","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5PZQ"
"5PZR",,"X-RAY DIFFRACTION",2.72,54.81,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12% PEG 3350",300,,"93S","5PZR",148.57,"1.9","1.9","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(3-chlorophenyl)sulfonyl-3-[3-[3-[(3-chlorophenyl)sulfonylcarbamoylamino]propoxy]propyl]urea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5PZR"
"5PZS",,"X-RAY DIFFRACTION",2.74,55.12,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12% PEG 3350",300,,"93Y","5PZS",148.54,"2.368","2.368","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(3-chlorophenyl)sulfonyl-3-[6-[(3-chlorophenyl)sulfonylcarbamoylamino]hexyl]urea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5PZS"
"5PZT",,"X-RAY DIFFRACTION",2.84,56.63,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12%-25% PEG 3350",300,,"947","5PZT",298.61,"2.8","2.8","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-(3-ethyl-4-phenylphenyl)sulfonylurea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5PZT"
"5PZU",,"X-RAY DIFFRACTION",2.74,55.12,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12% PEG 3350",300,,"94D","5PZU",148.65,"1.901","1.901","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor [5-[2-amino-5-(2-methylpropyl)-1,3-thiazol-4-yl]furan-2-yl]phosphonic acid","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5PZU"
"5PZV",,"X-RAY DIFFRACTION",2.74,55.06,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12% PEG 3350",300,,,"5PZV",149,"2","2","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(4-bromopyridin-2-yl)-3-(4-chlorophenyl)sulfonylurea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5PZV"
"5PZW",,"X-RAY DIFFRACTION",2.74,55.18,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12% PEG 3350",300,,"94J","5PZW",149.19,"2","2","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(3-chlorophenyl)sulfonyl-3-[5-[(3-chlorophenyl)sulfonylcarbamoylamino]pentyl]urea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5PZW"
"5PZX",,"X-RAY DIFFRACTION",2.73,54.96,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12%-25% PEG 3350",300,,,"5PZX",298.46,"2.75","2.75","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[4-methoxy-3-(2-methylpropyl)phenyl]sulfonylurea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5PZX"
"5PZY",,"X-RAY DIFFRACTION",2.72,54.8,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12%-25% PEG 3350",300,,,"5PZY",298.05,"2.21","2.21","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-(2-chlorophenyl)sulfonylurea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5PZY"
"5PZZ",,"X-RAY DIFFRACTION",2.71,54.68,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12%-25% PEG 3350",300,,,"5PZZ",298.32,"2.5","2.5","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-(3,4-dichlorophenyl)sulfonylurea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5PZZ"
"5Q00",,"X-RAY DIFFRACTION",2.74,55.19,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12%-25% PEG 3350",300,,,"5Q00",298.78,"2.6","2.6","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 2-[3-[(5-bromo-1,3-thiazol-2-yl)carbamoylsulfamoyl]-1-methylindol-7-yl]oxyacetamide","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5Q00"
"5Q01",,"X-RAY DIFFRACTION",2.84,56.63,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12%-25% PEG 3350",300,,,"5Q01",299.09,"2.603","2.603","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[4-(4,5-dichloro-2-methylpyrazol-3-yl)oxyphenyl]sulfonylurea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5Q01"
"5Q02",,"X-RAY DIFFRACTION",2.73,54.88,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12% PEG 3350",300,,,"5Q02",149.18,"2.095","2.095","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[5-(1,2-oxazol-3-yl)thiophen-2-yl]sulfonylurea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5Q02"
"5Q03",,"X-RAY DIFFRACTION",2.84,56.63,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12%-25% PEG 3350",300,,,"5Q03",298.27,"2.31","2.31","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[5-(2-methylpropyl)thiophen-2-yl]sulfonylurea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5Q03"
"5Q04",,"X-RAY DIFFRACTION",2.75,55.22,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12%-25% PEG 3350",300,,"95P","5Q04",298.73,"2.502","2.502","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(4-bromo-5-chlorothiophen-2-yl)sulfonyl-3-(5-bromo-1,3-thiazol-2-yl)urea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5Q04"
"5Q05",,"X-RAY DIFFRACTION",2.78,55.68,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12%-25% PEG 3350",300,,"95S","5Q05",298.4,"2.2","2.2","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[5-(2-methoxyethyl)-4-methylthiophen-2-yl]sulfonylurea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5Q05"
"5Q06",,"X-RAY DIFFRACTION",2.76,55.43,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12% PEG 3350",300,,,"5Q06",149.28,"2.4","2.4","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[4-(2-methyl-1,3-thiazol-4-yl)phenyl]sulfonylurea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5Q06"
"5Q07",,"X-RAY DIFFRACTION",2.72,54.79,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12%-25% PEG 3350",300,,,"5Q07",299.03,"2.424","2.424","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(4-bromo-6-morpholin-4-ylpyridin-2-yl)-3-[5-(2-methoxyethyl)-4-methylthiophen-2-yl]sulfonylurea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5Q07"
"5Q08",,"X-RAY DIFFRACTION",2.73,54.99,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12%-25% PEG 3350",300,,,"5Q08",298.22,"2.2","2.2","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(1-benzothiophen-3-ylsulfonyl)-3-(5-bromo-1,3-thiazol-2-yl)urea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5Q08"
"5Q09",,"X-RAY DIFFRACTION",2.77,55.61,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12%-25% PEG 3350",300,,,"5Q09",298.81,"1.9","1.9","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-[4-bromo-6-(carbamoylamino)pyridin-2-yl]-3-[5-(2-methoxyethyl)-4-methylthiophen-2-yl]sulfonylurea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5Q09"
"5Q0A",,"X-RAY DIFFRACTION",2.83,56.58,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12% PEG 3350",300,,,"5Q0A",148.91,"2.3","2.3","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-cyanopyrazin-2-yl)-3-[3-(difluoromethoxy)phenyl]sulfonylurea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5Q0A"
"5Q0B",,"X-RAY DIFFRACTION",2.71,54.68,"VAPOR DIFFUSION, SITTING DROP",7,"0.1M HEPES pH 7.0, 0.1M AMMONIUM ACETATE, 12% PEG 3350",300,,,"5Q0B",149,"2.3","2.3","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(4-bromo-3-methyl-1,2-thiazol-5-yl)-3-(3-methylphenyl)sulfonylurea","MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGIAGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDCGVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYAKDFDPAVTEYIQRKKFPPDNSAPYGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGKEAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ","Homo sapiens","FBP1, hCG_1640493, FBP","Fructose-1,6-bisphosphatase 1","1","5Q0B"
"5Q0C",,"X-RAY DIFFRACTION",3.26,62.3,"VAPOR DIFFUSION, SITTING DROP",,"entry deposited much later from experimental date, thus exact crystallization details not known",,,,"5Q0C",300.9,"2.4","2.4","Human liver fructose-1,6-bisphosphatase 1 (fructose 1,6-bisphosphate 1-phosphatase, E.C.3.1.3.11) complexed with the allosteric inhibitor 1-(5-bromo-1,3-thiazol-2-yl)-3-[5-(4-methoxyphenyl)thiophen-2-yl]sulfonylurea and with fructose-2,6-diphosphate","MTDRSPFETDMLTLTRYVMEKGRQAKGTGELTQLLNSMLTAIKAISSAVRKAGLAHLYGIAGSVNVTGDEVKKLDVLSNSLVINMLQSSYSTCVLVSEENKDAIITAKEKRGKYVVCFDPLDGSSNIDCLASIGTIFAIYRKTSEDEPSEKDALQCGRNIVAAGYALYGSATLVALSTGQGVDLFMLDPALGEFVLVEKDVKIKKKGKIYSLNEGYAKYFDAATTEYVQKKKFPEDGSAPYGARYVGSMVADVHRTLVYGGIFLYPANQKSPKGKLRLLYECNPVAYIIEQAGGLATTGTQPVLDVKPEAIHQRVPLILGSPEDVQEYLTCVQKNQAGS","Homo sapiens","FBP2","Fructose-1,6-bisphosphatase isozyme 2","1","5Q0C"
"5Q0D",,"X-RAY DIFFRACTION",3.44,64.23,"VAPOR DIFFUSION, HANGING DROP",7,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277,"10.1016/j.bmcl.2017.06.058","9EY","5Q0D",29.18,"2.12","2.12","FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-2-oxo-1,2,3,4,5,6,7,9-octahydro-11,8-(azeno)-1,9-benzodiazacyclotridecin-14-yl]carbamate","IVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVGYGDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAVHHHHHH","Homo sapiens","F11","Coagulation factor XI","1","5Q0D"
"5Q0E",,"X-RAY DIFFRACTION",3.44,64.27,"VAPOR DIFFUSION, HANGING DROP",7,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277,"10.1016/j.bmcl.2017.06.058","9FD","5Q0E",29.33,"2.12","2.12","FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(4S,8S)-8-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-4-methyl-2-oxo-1,3,4,5,6,7,8,10-octahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate","IVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVGYGDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAVHHHHHH","Homo sapiens","F11","Coagulation factor XI","1","5Q0E"
"5Q0G",,"X-RAY DIFFRACTION",3.45,64.32,"VAPOR DIFFUSION, HANGING DROP",7,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277,"10.1016/j.bmcl.2017.06.058","9F7","5Q0G",28.61,"2.6","2.6","FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}amino)-3-ethyl-2-oxo-1,2,3,4,5,6,7,9-octahydro-11,8-(azeno)-1,9-benzodiazacyclotridecin-14-yl]carbamate","IVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVGYGDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAVHHHHHH","Homo sapiens","F11","Coagulation factor XI","1","5Q0G"
"5Q0H",,"X-RAY DIFFRACTION",3.43,64.16,"VAPOR DIFFUSION, HANGING DROP",7,"100 mM sodium acetate, pH 4.6, 25% (w/v) MePEG2000, 200 mM ammonium sulfate, then transferred to 100 mM Tris-HCl, pH 7.0, 25% (w/v) MePEG2000, 200 MM ammonium sulfate",277,"10.1016/j.bmcl.2017.06.058","9F1","5Q0H",28.85,"2.5","2.5","FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(4R,5E,8S)-11-chloro-8-[(2,6-difluoro-4-methylbenzene-1-carbonyl)amino]-4-methyl-2-oxo-1,3,4,7,8,10-hexahydro-2H-12,9-(azeno)-1,10-benzodiazacyclotetradecin-15-yl]carbamate","IVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVGYGDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAVHHHHHH","Homo sapiens","F11","Coagulation factor XI","1","5Q0H"
"5Q1J",,"X-RAY DIFFRACTION",2.21,44.44,"VAPOR DIFFUSION, SITTING DROP",6,"30% PEG1000, 0.1 M MIB buffer",298,,,"5Q1J",39.23,"1.42","1.42","PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMSOA000341b","KKTCPFYKKIPGTGFTVDAFQYGVVEGCTAYFLTHFHSDHYAGLSKHFTFPVYCSEITGNLLKNKLHVQEQYIHPLPLDTECIVNGVKVVLLDANHCPGAVMILFYLPNGTVILHTGDFRADPSMERSLLADQKVHMLYLDTTYCSPEYTFPSQQEVIRFAINTAFEAVTLNPHALVVCGTYSIGKEKVFLAIADVLGSKVGMSQEKYKTLQCLNIPEINSLITTDMCSSLVHLLPMMQINFKGLQSHLKKCGGKYNQILAFRPTGWTHSNKFTRIADVIPQTKGNISIYGIPYSEHSSYLEMKRFVQWLKPQKIIPTVNVGTWKSRSTMEKYFREWKLEAGY","Homo sapiens","DCLRE1A, KIAA0086, SNM1, SNM1A","DNA cross-link repair 1A protein","1","5Q1J"
"5Q1K",,"X-RAY DIFFRACTION",2.2,44.22,"VAPOR DIFFUSION, SITTING DROP",6,"30% PEG1000, 0.1 M MIB buffer",298,,,"5Q1K",39.32,"1.42","1.42","PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000074a","KKTCPFYKKIPGTGFTVDAFQYGVVEGCTAYFLTHFHSDHYAGLSKHFTFPVYCSEITGNLLKNKLHVQEQYIHPLPLDTECIVNGVKVVLLDANHCPGAVMILFYLPNGTVILHTGDFRADPSMERSLLADQKVHMLYLDTTYCSPEYTFPSQQEVIRFAINTAFEAVTLNPHALVVCGTYSIGKEKVFLAIADVLGSKVGMSQEKYKTLQCLNIPEINSLITTDMCSSLVHLLPMMQINFKGLQSHLKKCGGKYNQILAFRPTGWTHSNKFTRIADVIPQTKGNISIYGIPYSEHSSYLEMKRFVQWLKPQKIIPTVNVGTWKSRSTMEKYFREWKLEAGY","Homo sapiens","DCLRE1A, KIAA0086, SNM1, SNM1A","DNA cross-link repair 1A protein","1","5Q1K"
"5Q1L",,"X-RAY DIFFRACTION",2.22,44.58,"VAPOR DIFFUSION, SITTING DROP",6,"30% PEG1000, 0.1 M MIB buffer",298,,,"5Q1L",39.33,"1.76","1.76","PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000073a","KKTCPFYKKIPGTGFTVDAFQYGVVEGCTAYFLTHFHSDHYAGLSKHFTFPVYCSEITGNLLKNKLHVQEQYIHPLPLDTECIVNGVKVVLLDANHCPGAVMILFYLPNGTVILHTGDFRADPSMERSLLADQKVHMLYLDTTYCSPEYTFPSQQEVIRFAINTAFEAVTLNPHALVVCGTYSIGKEKVFLAIADVLGSKVGMSQEKYKTLQCLNIPEINSLITTDMCSSLVHLLPMMQINFKGLQSHLKKCGGKYNQILAFRPTGWTHSNKFTRIADVIPQTKGNISIYGIPYSEHSSYLEMKRFVQWLKPQKIIPTVNVGTWKSRSTMEKYFREWKLEAGY","Homo sapiens","DCLRE1A, KIAA0086, SNM1, SNM1A","DNA cross-link repair 1A protein","1","5Q1L"
"5Q1M",,"X-RAY DIFFRACTION",2.19,43.84,"VAPOR DIFFUSION, SITTING DROP",6,"30% PEG1000, 0.1 M MIB buffer",298,,,"5Q1M",39.32,"1.56","1.56","PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000740a","KKTCPFYKKIPGTGFTVDAFQYGVVEGCTAYFLTHFHSDHYAGLSKHFTFPVYCSEITGNLLKNKLHVQEQYIHPLPLDTECIVNGVKVVLLDANHCPGAVMILFYLPNGTVILHTGDFRADPSMERSLLADQKVHMLYLDTTYCSPEYTFPSQQEVIRFAINTAFEAVTLNPHALVVCGTYSIGKEKVFLAIADVLGSKVGMSQEKYKTLQCLNIPEINSLITTDMCSSLVHLLPMMQINFKGLQSHLKKCGGKYNQILAFRPTGWTHSNKFTRIADVIPQTKGNISIYGIPYSEHSSYLEMKRFVQWLKPQKIIPTVNVGTWKSRSTMEKYFREWKLEAGY","Homo sapiens","DCLRE1A, KIAA0086, SNM1, SNM1A","DNA cross-link repair 1A protein","1","5Q1M"
"5Q1N",,"X-RAY DIFFRACTION",2.2,44,"VAPOR DIFFUSION, SITTING DROP",6,"30% PEG1000, 0.1 M MIB buffer",298,,,"5Q1N",39.31,"1.38","1.38","PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000295a","KKTCPFYKKIPGTGFTVDAFQYGVVEGCTAYFLTHFHSDHYAGLSKHFTFPVYCSEITGNLLKNKLHVQEQYIHPLPLDTECIVNGVKVVLLDANHCPGAVMILFYLPNGTVILHTGDFRADPSMERSLLADQKVHMLYLDTTYCSPEYTFPSQQEVIRFAINTAFEAVTLNPHALVVCGTYSIGKEKVFLAIADVLGSKVGMSQEKYKTLQCLNIPEINSLITTDMCSSLVHLLPMMQINFKGLQSHLKKCGGKYNQILAFRPTGWTHSNKFTRIADVIPQTKGNISIYGIPYSEHSSYLEMKRFVQWLKPQKIIPTVNVGTWKSRSTMEKYFREWKLEAGY","Homo sapiens","DCLRE1A, KIAA0086, SNM1, SNM1A","DNA cross-link repair 1A protein","1","5Q1N"
"5Q1O",,"X-RAY DIFFRACTION",2.19,43.94,"VAPOR DIFFUSION, SITTING DROP",6,"30% PEG1000, 0.1 M MIB buffer",298,,,"5Q1O",39.32,"1.25","1.25","PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000478a","KKTCPFYKKIPGTGFTVDAFQYGVVEGCTAYFLTHFHSDHYAGLSKHFTFPVYCSEITGNLLKNKLHVQEQYIHPLPLDTECIVNGVKVVLLDANHCPGAVMILFYLPNGTVILHTGDFRADPSMERSLLADQKVHMLYLDTTYCSPEYTFPSQQEVIRFAINTAFEAVTLNPHALVVCGTYSIGKEKVFLAIADVLGSKVGMSQEKYKTLQCLNIPEINSLITTDMCSSLVHLLPMMQINFKGLQSHLKKCGGKYNQILAFRPTGWTHSNKFTRIADVIPQTKGNISIYGIPYSEHSSYLEMKRFVQWLKPQKIIPTVNVGTWKSRSTMEKYFREWKLEAGY","Homo sapiens","DCLRE1A, KIAA0086, SNM1, SNM1A","DNA cross-link repair 1A protein","1","5Q1O"
"5Q1P",,"X-RAY DIFFRACTION",2.18,43.69,"VAPOR DIFFUSION, SITTING DROP",6,"30% PEG1000, 0.1 M MIB buffer",298,,,"5Q1P",39.33,"1.56","1.56","PanDDA analysis group deposition -- Crystal Structure of DCLRE1A in complex with FMOPL000299a","KKTCPFYKKIPGTGFTVDAFQYGVVEGCTAYFLTHFHSDHYAGLSKHFTFPVYCSEITGNLLKNKLHVQEQYIHPLPLDTECIVNGVKVVLLDANHCPGAVMILFYLPNGTVILHTGDFRADPSMERSLLADQKVHMLYLDTTYCSPEYTFPSQQEVIRFAINTAFEAVTLNPHALVVCGTYSIGKEKVFLAIADVLGSKVGMSQEKYKTLQCLNIPEINSLITTDMCSSLVHLLPMMQINFKGLQSHLKKCGGKYNQILAFRPTGWTHSNKFTRIADVIPQTKGNISIYGIPYSEHSSYLEMKRFVQWLKPQKIIPTVNVGTWKSRSTMEKYFREWKLEAGY","Homo sapiens","DCLRE1A, KIAA0086, SNM1, SNM1A","DNA cross-link repair 1A protein","1","5Q1P"
